Für einen individuellen Ausdruck passen Sie bitte die Einstellungen in der Druckvorschau Ihres Browsers an. |
VO (EG) 1272/2008, Anhang VI, Teil 3
Tabelle 3 Die Liste der harmonisierten Einstufung und Kennzeichnung gefährlicher Stoffe 17
gültig ab 01.12.2019
Stand: VO"en (EU) 2024/2564; (EU) 2024/197; (EU) 2023/1435; (EU) 2022/692; (EU) 2021/849; (EU) 2020/1182; (EU) 2020/217
Index-Nr. | Chemische Bezeichnung | EG-Nr. | CAS-Nr. | Einstufung | Kennzeichnung | Spezifische Konzentra- tionsgrenzen, M-Faktoren und ATE * |
Anm. | |||
---|---|---|---|---|---|---|---|---|---|---|
Kodierung der Gefahrenklassen und -kategorien | Kodierung der Gef.- hinweise |
Piktogr., Kodierung der Signal-worte |
Kodierung der Gef.- hinweise |
Kodierung der erg. Gef.- merkm. | ||||||
(1) |
(2) |
(3) |
(4) |
(5) |
(6) |
(7) |
(8) |
(9) |
(10) |
(11) |
001-001-00-9 | Wasserstoff | 215-605-7 | 1333-74-0 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
001-002-00-4 | Lithiumaluminiumhydrid | 240-877-9 | 16853-85-3 | Water-react. 1 Skin Corr. 1A | H260 H314 | GHS02 GHS05 Gef. | H260 H314 | |||
001-003-00-X | Natriumhydrid | 231-587-3 | 7646-69-7 | Water-react. 1 | H260 | GHS02 Gef. | H260 | |||
001-004-00-5 | Calciumhydrid | 232-189-2 | 7789-78-8 | Water-react. 1 | H260 | GHS02 Gef. | H260 | |||
003-001-00-4 | Lithium | 231-102-5 | 7439-93-2 | Water-react. 1 Skin Corr. 1B | H260 H314 | GHS02 GHS05 Gef. | H260 H314 | EUH014 | ||
003-002-00-X | n-Hexyllithium | 404-950-0 | 21369-64-2 | Water-react. 1 Pyr. Sol. 1 Skin Corr. 1A | H260 H250 H314 | GHS02 GHS05 Gef. | H260 H250 H314 | EUH014 | ||
003-003-00-5 | (2-Methylpropyl)lithium; Isobutyllithium | 440-620-2 | 920-36-5 | Water-react. 1 Pyr. Liq. 1 Skin Corr. 1A STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H260 H250 H314 H336 H400 H410 | GHS02 GHS05 GHS07 GHS09 Gef. | H260 H250 H314 H336 H410 | EUH014 | ||
004-001-00-7 | Beryllium | 231-150-7 | 7440-41-7 | Carc. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H350i H330 H301 H372 ** H319 H335 H315 H317 | GHS06 GHS08 Gef. | H350i H330 H301 H372 ** H319 H335 H315 H317 | |||
004-002-00-2 | Berylliumverbindungen, ausgenommen Beryllium-Tonerdesilikate, und soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Carc. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H350i H330 H301 H372 ** H319 H335 H315 H317 H411 | GHS06 GHS08 GHS09 Gef. | H350i H330 H301 H372 ** H319 H335 H315 H317 H411 | A | ||
004-003-00-8 | Berylliumoxid | 215-133-1 | 1304-56-9 | Carc. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H350i H330 H301 H372 ** H319 H335 H315 H317 | GHS06 GHS08 Gef. | H350i H330 H301 H372 ** H319 H335 H315 H317 | |||
005-001-00-X | Bortrifluorid | 231-569-5 | 7637-07-2 | Press. Gas Acute Tox. 2 * Skin Corr. 1A | H330 H314 | GHS04 GHS06 GHS05 Gef. | H330 H314 | EUH014 | U | |
005-002-00-5 | Bortrichlorid | 233-658-4 | 10294-34-5 | Press. Gas Acute Tox. 2 * Acute Tox. 2 * Skin Corr. 1B | H330 H300 H314 | GHS04 GHS06 GHS05 Gef. | H330 H300 H314 | EUH014 | U | |
005-003-00-0 | Bortribromid | 233-657-9 | 10294-33-4 | Acute Tox. 2 * Acute Tox. 2 * Skin Corr. 1A | H330 H300 H314 | GHS06 GHS05 Gef. | H330 H300 H314 | EUH014 | ||
005-004-00-6 | Trialkylborane, fest | - | - | Pyr. Sol. 1 Skin Corr. 1B | H250 H314 | GHS02 GHS05 Gef. | H250 H314 | A | ||
005-004-01-3 | Trialkylborane, flüssig | - | - | Pyr. Liq. 1 Skin Corr. 1B | H250 H314 | GHS02 GHS05 Gef. | H250 H314 | A | ||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-005-00-1 | Trimethylborat | 204-468-9 | 121-43-7 | Flam. Liq. 3 Acute Tox. 4 * | H226 H312 | GHS02 GHS07 Achtg. | H226 H312 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-005-00-1 | Trimethylborat | 204-468-9 | 121-43-7 | Flam. Liq. 3 Repr. 1B Acute Tox. 4* | H226 H360FD H312 | GHS02 GHS08 GHS07 Dgr | H226 H360FD H312 | 11) | ||
005-006-00-7 | Dibutylzinnhydrogenborat | 401-040-5 | 75113-37-0 | Repr. 1B Muta. 2 STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360FD H341 H372** H312 H302 H318 H317 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H360FD H341 H372** H312 H302 H318 H317 H410 | |||
(Gültig bis 31.01.2025 gem. VO (EU) 2023/1435 | ||||||||||
005-007-00-2 | Borsäure [1] Borsäure [2] | 233-139-2 [1] 234-343-4 [2] | 10043-35-3 [1] 11113-50-1 [2] | Repr. 1B | H360FD | GHS08 Dgr | H360FD | ) | ||
(Gültig ab 01.02.2025 gem. VO (EU) 2023/1435 | ||||||||||
005-007-00-2 | Borsäure [1] Borsäure [2] | 233-139-2 [1] 234-343-4 [2] | 10043-35-3 [1] 11113-50-1 [2] | Repr. 1B | H360FD | GHS08 Dgr | H360FD | 11 ) | ||
(Gültig bis 31.01.2025 gem. VO (EU) 2023/1435 | ||||||||||
005-008-00-8 | Dibortrioxid | 215-125-8 | 1303-86-2 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | ) | ||
(Gültig ab 01.02.2025 gem. VO (EU) 2023/1435 | ||||||||||
005-008-00-8 | Dibortrioxid | 215-125-8 | 1303-86-2 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | 11 ) | ||
005-009-00-3 | Tetrabutylammoniumbutyltriphenylborat | 418-080-4 | 120307-06-4 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
005-010-00-9 | N, N-Dimethylanilintetrakis-(pentafluorphenyl)borat | 422-050-6 | 118612-00-3 | Carc. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 | H351 H302 H315 H318 | GHS08 GHS05 GHS07 Gef. | H351 H302 H315 H318 | |||
(Gültig bis 31.01.2025 gem. VO (EU) 2023/1435 | ||||||||||
005-011-00-4 | Tetrabordinatriumheptaoxid, Hydrat; [1] Dinatriumtetraborat, wasserfrei; [2] Orthoborsäure, Natriumsalz [3] Dinatriumtetraboratdecahydrat [4] Dinatriumtetraboratpentahydrat [5] | 235-541-3 [1] 215-540-4 [2] 237-560-2 [3] 215-540-4 [4] 215-540-4 [5] | 12267-73-1 [1] 1330-43-4 [2] 13840-56-7 [3] 1303-96-4 [4] 12179-04-3 [5] | Repr. 1B | H360FD | GHS08 Dgr | H360FD | ) | ||
(Gültig ab 01.02.2025 gem. VO (EU) 2023/1435 | ||||||||||
005-011-00-4 | Tetrabordinatriumheptaoxid, Hydrat; [1] Dinatriumtetraborat, wasserfrei; [2] Orthoborsäure, Natriumsalz; [3] Dinatriumtetraborat-Decahydrat; [4] Dinatriumtetraborat-Pentahydrat; [5] | 235-541-3 [1] 215-540-4 [2] 237-560-2 [3] 215-540-4 [4] 215-540-4 [5] | 12267-73-1 [1] 1330-43-4 [2] 13840-56-7 [3] 1303-96-4 [4] 12179-04-3 [5] | Repr. 1B | H360FD | GHS08 Dgr | H360FD | 11 ) | ||
005-011-01-1 | Dinatriumtetraborat-Decahydrat; Boraxdecahydrat | 215-540-4 | 1303-96-4 | Repr. 1B | H360FD | GHS08 Gef. | H360FD | Repr.1B; H360FD: C ≥ 8,5 % | ||
005-011-02-9 | Dinatriumtetraborat-Pentahydrat; Boraxpentahydrat | 215-540-4 | 12179-04-3 | Repr. 1B | H360FD | GHS08 Gef. | H360FD | Repr.B; H360FD: C ≥ 6,5 % | ||
005-012-00-X | Diethyl{4-[1,5,5-tris(4-diethylaminophenyl)penta-2,4-dienyliden]cyclohexa-2,5-dienyliden}ammoniumbutyltriphenylborat | 418-070-1 | 141714-54-7 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
005-013-00-5 | Diethylmethoxyboran | 425-380-9 | 7397-46-8 | Pyr. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 4 | H250 H332 H312 H302 H373** H314 H317 H413 | GHS02 GHS05 GHS08 GHS07 Gef. | H250 H332 H312 H302 H373** H314 H317 H413 | |||
005-014-00-0 | 4-Formylphenylboronsäure | 438-670-5 | 87199-17-5 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
005-015-00-6 | 1-Chlormethyl-4-fluor-1,4-diazoniabicyclo[2.2.2]octan-bis(tetrafluorborat) | 414-380-4 | 140681-55-6 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H302 H318 H317 H412 | GHS05 GHS07 Gef. | H302 H318 H317 H412 | |||
005-016-00-1 | Tetrabutylammoniumbutyl-tris(4- tert-butylphenyl)borat | 431-370-5 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-017-00-7 | Natriumperborat [1]; Natriumperoxometaborat [2] Natriumperoxoborat [Gehalt an Partikeln mit aerodynamischem Durchmesser unter 50 μm < 0,1 Gewichtsprozent] | 239-172-9 [1] 231-556-4 [2] | 15120-21-5 [1] 7632-04-4 [2] | Ox. Sol. 2 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 | H272 H360Df H302 H335 H318 | GHS03 GHS05 GHS08 GHS07 Gef. | H272 H360Df H302 H335 H318 | Repr.1B; H360Df: C ≥9 % Repr.1B; H360 D: 6,5 % ≤ C <9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % | ) | |
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-017-01-4 | Natriumperborat [1]; Natriumperoxometaborat [2] Natriumperoxoborat [Gehalt an Partikeln mit aerodynamischem Durchmesser unter 50 μm > 0,1 Gewichtsprozent] | 239-172-9 [1] 231-556-4 [2] | 15120-21-5 [1] 7632-04-4 [2] | Ox. Sol. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Eye Dam. 1 | H272 H360Df H331 H302 H335 H318 | GHS03 GHS06 GHS05 GHS08 Gef. | H272 H360Df H331 H302 H335 H318 | Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % | ) | |
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-018-00-2 | Perborsäure (H3BO2(O2)), Mononatriumsalz-Trihydrat [1]; Perborsäure, Natriumsalz-Tetrahydrat [2]; Perborsäure (HBO(O2)), Natriumsalz-Tetrahydrat [3] Natriumperoxoborat-Hexahydrat [Gehalt an Partikeln mit aerodynamischem Durchmesser unter 50 μm < 0,1 Gewichtsprozent] | 239-172-9 [1] 234-390-0 [2] 231-556-4 [3] | 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] | Repr. 1B STOT SE 3 Eye Dam. 1 | H360Df H335 H318 | GHS05 GHS08 GHS07 Gef. | H360Df H335 H318 | Repr. 1B; H360Df: C ≥ 14 % Repr. 1B; H360D: 10 % ≤ C < 14 % Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % | ) | |
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-018-01-X | Perborsäure (H3BO2(O2)), Mononatriumsalz-Trihydrat [1]; Perborsäure, Natriumsalz-Tetrahydrat [2]; Perborsäure (HBO(O2)), Natriumsalz-Tetrahydrat [3] Natriumperoxoborat-Hexahydrat [Gehalt an Partikeln mit aerodynamischem Durchmesser unter 50 μm > 0,1 Gewichtsprozent] | 239-172-9 [1] 234-390-0 [2] 231-556-4 [3] | 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] | Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 | H360Df H332 H335 H318 | GHS05 GHS08 GHS07 Gef. | H360Df H332 H335 H318 | Repr. 1B; H360 Df: C ≥ 14 % Repr. 1B; H360D: 10 % ≤ C < 14 % Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % | ) | |
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-019-00-8 | Perborsäure, Natriumsalz [1]; Perborsäure, Natriumsalz- Monohydrat [2]; Perborsäure (HBO(O2)), Natriumsalz-Monohydrat [3] Natriumperoxoborat [Gehalt an Partikeln mit aerodynamischem Durchmesser unter 50 μm < 0,1 Gewichtsprozent] | 234-390-0 [1] 234-390-0 [2] 231-556-4 [3] | 11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] | Ox. Sol. 3 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 | H272 H360Df H302 H335 H318 | GHS03 GHS05 GHS08 GHS07 Gef. | H272 H360Df H302 H335 H318 | Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % | ) | |
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-019-01-5 | Perborsäure, Natriumsalz [1]; Perborsäure, Natriumsalz-Monohydrat [2]; Perborsäure (HBO(O2)), Natriumsalz-Monohydrat [3] Natriumperoxoborat [Gehalt an Partikeln mit aerodynamischem Durchmesser unter 50 μm > 0,1 Gewichtsprozent] | 234-390-0 [1] 234-390-0 [2] 231-556-4 [3] | 11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] | Ox. Sol. 3 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Eye Dam. 1 | H272 H360Df H331 H302 H335 H318 | GHS03 GHS06 GHS05 GHS08 Gef. | H272 H360Df H331 H302 H335 H318 | Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % | ) | |
005-020-00-3 | Dinatriumoctaborat wasserfrei; [1] Dinatriumoctaborat Tetrahydrat [2] | 234-541-0 [1] 234-541-0 [2] | 12008-41-2 [1] 12280-03-4 [2] | Repr. 1B | H360FD | GHS08 Gef. | H360FD | |||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-022-00-4 | Perborsäure, Natriumsalz [1] Perborsäure, Natriumsalz-Monohydrat [2] Perborsäure (HBO(O2)), Natriumsalz-Monohydrat [3] Natriumperoxoborat [4] Natriumperborat [5] | 234-390-0 [1] 234-390-0 [2] - [3] - [4] 239-172-9 [5] | 11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] - [4] 15120-21-5 [5] | Ox. Sol. 3 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 | H272 H360FD H331 H302 H335 H318 | GHS03 GHS08 GHS06 GHS05 Dgr | H272 H360FD H331 H302 H335 H318 | Einatmung:
ATE = 0,75 mg/L (Stäube oder Nebel) Oral: ATE = 890 mg/kg KG Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % | 11 ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-023-00-X | Perborsäure (H3BO2(O2)), Mononatriumsalz-Trihydrat [1] Perborsäure, Natriumsalz-Tetrahydrat [2] Perborsäure (HBO(O2)), Natriumsalz-Tetrahydrat [3] Natriumperoxoborat-Hexyhydrat [4] | 239-172-9 [1] 234-390-0 [2] - [3] - [4] | 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] - [4] | Repr. 1B Acute Tox. 4 STOT SE 3 Eye Dam. 1 | H360FD H332 H335 H318 | GHS08 GHS05 GHS07 Dgr | H360FD H332 H335 H318 | Einatmung:
ATE = 1,2 mg/L (Stäube oder Nebel) Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % | 11 ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
005-024-00-5 | Natriumperoxometaborat | 231-556-4 | 7632-04-4 | Ox. Sol. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 | H272 H360FD H331 H302 H335 H318 | GHS03 GHS08 GHS06 GHS05 Dgr | H272 H360FD H331 H302 H335 H318 | Einatmung:
ATE = 0,62 mg/L (Stäube oder Nebel) Oral: ATE = 730 mg/kg KG Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % | 11 ) | |
006-001-00-2 | Kohlenstoffmonoxid; Kohlenmonoxid; Kohlenoxid | 211-128-3 | 630-08-0 | Flam. Gas 1 Press. Gas Repr. 1A Acute Tox. 3 * STOT RE 1 | H220 H360D *** H331 H372 ** | GHS02 GHS04 GHS06 GHS08 Gef. | H220 H360D *** H331 H372 ** | U | ||
006-002-00-8 | Phosgen; Carbonylchlorid | 200-870-3 | 75-44-5 | Press.
Gas Acute Tox. 2 * Skin Corr. 1B | H330 H314 | GHS04 GHS06 GHS05 Gef. | H330 H314 | U | ||
006-003-00-3 | Kohlenstoffdisulfid; Schwefelkohlenstoff | 200-843-6 | 75-15-0 | Flam. Liq. 2 Repr. 2 STOT RE 1 Eye Irrit. 2 Skin Irrit. 2 | H225 H361fd H372 ** H319 H315 | GHS02 GHS08 GHS07 Gef. | H225 H361fd H372 ** H319 H315 | Repr. 2; H361fd: C ≥ 1 % STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,2 % ≤ C < 1 % | ||
006-004-00-9 | Calciumcarbid | 200-848-3 | 75-20-7 | Water-react. 1 | H260 | GHS02 Gef. | H260 | T | ||
006-005-00-4 | Thiram (ISO); Tetramethylthiuramdisulfid; Bis(dimethyl-thiocarbamoyl)-disulfid | 205-286-2 | 137-26-8 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H373 ** H319 H315 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H332 H302 H373 ** H319 H315 H317 H410 | M = 10 | ||
006-006-00-X | Cyanwasserstoff; Cyanwasserstoffsäure; Blausäuregas | 200-821-6 | 74-90-8 | Flam. Liq. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H224 H330 H400 H410 | GHS02 GHS06 GHS09 Gef. | H224 H330 H410 | |||
006-006-01-7 | Cyanwasserstoff ... %; Cyanwasserstoffsäure ... %; Blausäure ...% | 200-821-6 | 74-90-8 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H300 H410 | B | ||
006-007-00-5 | Salze der Blausäure, ausgenommen komplexe Cyanide, z.B. Cyanoferrate (II) und (III) und Quecksilberoxidcyanid, und soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H300 H410 | EUH032 | A | |
006-008-00-0 | Antu (ISO); 1-(1-Naphthyl)-2-thioharnstoff | 201-706-3 | 86-88-4 | Acute Tox. 2 * Carc. 2 | H300 H351 | GHS06 GHS08 Gef. | H300 H351 | |||
006-009-00-6 | 1-Isopropyl-3-methylpyrazol-5-yldimethylcarbamat; Isolan | 204-318-2 | 119-38-0 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
006-010-00-1 | 5,5-Dimethyl-3-oxocyclohex-1-enyldimethylcarbamat; 5,5-Dimethyldihydroresorcindimethylcarbamat; Dimetan | 204-525-8 | 122-15-6 | Acute Tox. 3 * | H301 | GHS06 Gef. | H301 | |||
006-011-00-7 | Carbaryl (ISO); 1-Naphthylmethylcarbamat | 200-555-0 | 63-25-2 | Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 | H351 H332 H302 H400 | GHS08 GHS07 GHS09 Achtg. | H351 H332 H302 H400 | M=100 | ||
006-012-00-2 | Ziram (ISO); Zinkbis(dimethyl-dithiocarbamat) | 205-288-3 | 137-30-4 | Acute Tox. 2 * Acute Tox. 4 * STOT RE 2 * STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H373 ** H335 H318 H317 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H330 H302 H373 ** H335 H318 H317 H410 | M = 100 | ||
006-013-00-8 | Metam-Natrium (ISO); Natriummethyldithiocarbamat | 205-293-0 | 137-42-8 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H314 H317 H410 | EUH031 | ||
006-014-00-3 | Nabam (ISO); Dinatriumethylenbis( N, N"-dithiocarbamat) | 205-547-0 | 142-59-6 | Acute Tox. 4 * STOT SE 3 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H335 H317 H410 | GHS07 GHS09 Achtg. | H302 H335 H317 H410 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
006-015-00-9 | Diuron (ISO); 3-(3,4-Dichlorphenyl)-1,1-dimethylharnstoff | 206-354-4 | 330-54-1 | Carc. 2 Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H373** H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H373** H410 | M = 10 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
006-015-00-9 | Diuron (ISO); 3-(3,4-Dichlorphenyl)-1,1-dimethylharnstoff | 206-354-4 | 330-54-1 | Carc. 1B STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H350 H373 (Blutkreislauf) H400 H410 | GHS08 GHS09 Dgr | H350 H373 (Blutkreislauf) H410 | M = 100 M = 100 | ) | |
006-016-00-4 | Propoxur (ISO); 2-Isopropoxyphenyl- N-methylcarbamat; 2-Isopropoxyphenylmethylcarbamat | 204-043-8 | 114-26-1 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H410 | |||
006-017-00-X | Aldicarb (ISO); 2-Methyl-2-(methylthio) propanal- O-( N-methylcarbamoyl)oxim | 204-123-2 | 116-06-3 | Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H311 H400 H410 | GHS06 GHS09 Gef. | H330 H300 H311 H410 | |||
006-018-00-5 | Aminocarb (ISO); 4-Dimethylamino-3-tolylmethylcarbamat | 217-990-7 | 2032-59-9 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H410 | |||
006-019-00-0 | Diallat (ISO); S-(2,3-Dichlorallyl)- N, N-diisopropylthiocarbamat | 218-961-1 | 2303-16-4 | Carc. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H410 | |||
006-020-00-6 | Barban (ISO); 4-Chlor-2-butinyl(3-chlorphenyl)carbamat | 202-930-4 | 101-27-9 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
006-021-00-1 | Linuron (ISO); 3-(3,4-Dichlorphenyl)-1-methoxy-1-methylharnstoff | 206-356-5 | 330-55-2 | Repr. 1B Carc. 2 Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H360Df H351 H302 H373 ** H400 H410 | GHS08 GHS07 GHS09 Gef. | H360Df H351 H302 H373 ** H410 | |||
006-022-00-7 | Decarbofuran (ISO); 2,3-Dihydro-2-methylbenzofuran-7-ylmethylcarbamat | - | 1563-67-3 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | |||
006-023-00-2 | Mercaptodimethur (ISO); Methiocarb (ISO); xylylmethylcarbamat; 3,5-Dimethyl-4- methylthiophenyl- N-methylcarbamat | 217-991-2 | 2032-65-7 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H410 | |||
006-024-00-8 | Proxan-Natrium (ISO); Natrium- O-isopropyldithiocarbonat; Natrium-isopropyl-xanthogenat | 205-443-5 | 140-93-2 | Acute Tox. 4 * Skin Irrit. 2 Aquatic Chronic 2 | H302 H315 H411 | GHS07 GHS09 Achtg. | H302 H315 H411 | |||
006-025-00-3 | Allethrin; (RS)-3-Allyl-2-methyl-4-oxocyclopent-2-enyl(1 RS,3 RS;1 RS,3 SR)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropancarboxylat; Bioallethrin; (RS)-3-Allyl-2-methyl-4-oxocyclopent-2-enyl(1 R,3 R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropancarboxylat [1]; S-Bioallethrin [3]; (S)-3-Allyl-2-methyl-4-oxocyclopent-2-enyl(1 R,3 R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropancarboxylat [2] Esbiothrin; (RS)-3-Allyl-2-methyl-4-oxocyclopent-2-enyl(1 R,3 R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropancarboxylat | 209-542-4 [1] 249-013-5 [2]- [3] | 584-79-2 [1] 28434-00-6 [2] 84030-86-4 [3] | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H302 H410 | C | ||
006-026-00-9 | Carbofuran (ISO); 2,3-Dihydro-2,2-dimethylbenzofuran-7-ylmethylcarbamat | 216-353-0 | 1563-66-2 | Acute Tox. 2 * Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H300 H410 | |||
006-028-00-X | Dinobuton (ISO); 2- sec-Butyl-4,6-dinitrophenylisopropylcarbonat | 213-546-1 | 973-21-7 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H410 | |||
006-029-00-5 | Dioxacarb (ISO); 2-(1,3-Dioxolan-2-yl)phenyl- N-methylcarbamat | 230-253-4 | 6988-21-2 | Acute Tox. 3 * Aquatic Chronic 2 | H301 H411 | GHS06 GHS09 Gef. | H301 H411 | |||
006-030-00-0 | EPTC (ISO); S-Ethyldipropylthiocarbamat | 212-073-8 | 759-94-4 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
006-031-00-6 | Formetanat (ISO); 3-[( EZ)-Dimethylaminomethylenamino]phenylmethylcarbamat | 244-879-0 | 22259-30-9 | Acute Tox. 2 * Acute Tox. 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H317 H400 H410 | GHS06 GHS09 Gef. | H330 H300 H317 H410 | |||
006-032-00-1 | Monolinuron (ISO); 3-(4-Chlorphenyl)-1-methoxy-1-methylharnstoff | 217-129-5 | 1746-81-2 | Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H410 | |||
006-033-00-7 | Metoxuron (ISO); 3-(3-Chlor-4-methoxyphenyl)-1,1-dimethylharnstoff | 243-433-2 | 19937-59-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
006-034-00-2 | Pebulat (ISO); N-Butyl- N-ethyl-S-propylthiocarbamat; N-Butyl-N-ethyl-S-propylthiocarbamat | 214-215-4 | 1114-71-2 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
006-035-00-8 | Pirimicarb (ISO); 2-(Dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamat | 245-430-1 | 23103-98-2 | Carc. 2 Acute Tox. 3 Acute Tox. 3 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H331 H301 H317 H400 H410 | GHS08 GHS06 GHS09 Gef. | H351 H331 H301 H317 H410 | M = 10 M = 100 | ||
006-036-00-3 | Benzthiazuron (ISO); 1-Benzothiazol-2-yl-3-methylharnstoff | 217-685-9 | 1929-88-0 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
006-037-00-9 | Promecarb (ISO); 3-Isopropyl-5- methylphenyl- N-methylcarbamat 3-Isopropyl-5-methylphenyl- N-methylcarbamat | 220-113-0 | 2631-37-0 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H410 | |||
006-038-00-4 | Sulfallat (ISO); 2-Chlorallyl-N, N-dimethyldithiocarbamat | 202-388-9 | 95-06-7 | Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H410 | |||
006-039-00-X | Triallat (ISO); S-2,3,3-Trichlorallyldiisopropylthiocarbamat | 218-962-7 | 2303-17-5 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H317 H410 | |||
006-040-00-5 | 3-Methylpyrazol-5-yl- dimethylcarbamat; Monometilan | - | 2532-43-6 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | |||
006-041-00-0 | Dimethylcarbamoylchlorid; Dimethylcarbamidsäurechlorid | 201-208-6 | 79-44-7 | Carc. 1B Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H350 H331 H302 H319 H335 H315 | GHS06 GHS08 Gef. | H350 H331 H302 H319 H335 H315 | Carc. 1B; H350: C ≥ 0,001 % | ||
006-042-00-6 | Monuron (ISO); 3-(4-Chlorphenyl)-1,1-dimethylharnstoff | 205-766-1 | 150-68-5 | Carc. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H410 | |||
006-043-00-1 | 3-(4-Chlorphenyl)-1,1-dimethyluroniumtrichloracetat Monuron-TCA | - | 140-41-0 | Carc. 2 Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H319 H315 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H319 H315 H410 | |||
06-044-00-7 | Isoproturon (ISO); 3-(4-Isopropylphenyl)-1,1-dimethylharnstoff | 251-835-4 | 34123-59-6 | Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H373 (Blut) H400 H410 | GHS08 GHS09 Wng | H351 H373 (Blut) H410 | M = 10 M = 10 | ||
006-045-00-2 | Methomyl (ISO); 1-(Methylthio)ethylidenamino- N-methylcarbamat | 240-815-0 | 16752-77-5 | Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H400 H410 | GHS06 GHS09 Gef. | H300 H410 | M=100 | ||
006-046-00-8 | Bendiocarb (ISO); 2,2-Dimethyl-1,3-benzodioxol-4-yl-N-methylcarbamat; 2,2-Dimethyl-1,3-benzodioxol-4-yl-methylcarbamat | 245-216-8 | 22781-23-3 | Acute Tox. 3 Acute Tox. 3 Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H300 H400 H410 | GHS06 GHS09 grgr | H331 H311 H300 H410 | M = 10 M = 100 | ||
006-047-00-3 | Bufencarb (ISO); Reaktionsmasse aus 3-(1-Methylbutyl)phenyl- N-methylcarbamat und 3-(1-Ethylpropyl)phenyl- N-methylcarbamat | - | 8065-36-9 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H410 | |||
006-048-00-9 | Ethiofencarb (ISO); 2-(Ethylthiomethyl)phenyl- N-methylcarbamat | 249-981-9 | 29973-13-5 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
006-049-00-4 | Dixanthogen; O, O-Diethyldithiobis(thioformiat) | 207-944-4 | 502-55-6 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
006-050-00-X | 1,1-Dimethyl-3-phenyluroniumtrichloracetat; Fenuron-TCA | - | 4482-55-7 | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
006-051-00-5 | Ferbam (ISO); Eisentris(dimethyldithiocarbamat) | 238-484-2 | 14484-64-1 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H335 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H335 H315 H410 | |||
006-052-00-0 | Formetanathydrochlorid; 3-( N, N-dimethylaminomethylenamino)phenyl- N-methylcarbamat | 245-656-0 | 23422-53-9 | Acute Tox. 2 * Acute Tox. 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H317 H400 H410 | GHS06 GHS09 Gef. | H330 H300 H317 H410 | |||
006-053-00-6 | Isoprocarb (ISO); (2-Isopropylphenyl)- N-methylcarbamat; o-Cumenylmethylcarbamat | 220-114-6 | 2631-40-5 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
006-054-00-1 | Mexacarbat (ISO); 3,5-Dimethyl-4-dimethylaminophenyl- N-methylcarbamat | 206-249-3 | 315-18-4 | Acute Tox. 2 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H312 H400 H410 | GHS06 GHS09 Gef. | H300 H312 H410 | |||
006-055-00-7 | Xylylcarb (ISO); 3,4-Dimethylphenyl- N-methylcarbamat; 3,4-Xylylmethylcarbamat; MPMC | 219-364-9 | 2425-10-7 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
006-056-00-2 | Metolcarb (ISO); m-Tolylmethylcarbamat; MTMC | 214-446-0 | 1129-41-5 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
006-057-00-8 | Nitrapyrin (ISO); 2-Chlor-6-trichlormethylpyridin | 217-682-2 | 1929-82-4 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
006-058-00-3 | Noruron (ISO); 1,1-Dimethyl-3-(perhydro-4,7-methanoinden-5-yl)harnstoff | - | 2163-79-3 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
006-059-00-9 | Oxamyl (ISO); N",N"-Dimethylcarbamoyl(methylthio)methylenamin- N-methylcarbamat | 245-445-3 | 23135-22-0 | Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 4 * Aquatic Chronic 2 | H330 H300 H312 H411 | GHS06 GHS09 Gef. | H330 H300 H312 H411 | |||
006-060-00-4 | Oxycarboxin (ISO); 2,3-Dihydro-6-methyl-5-( N-phenylcarbamoyl-1,4-oxathiin-4,4-dioxid | 226-066-2 | 5259-88-1 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
006-061-00-X | S-Ethyl- N-(dimethylaminopropyl)thiocarbamathydrochlorid; Prothiocarb-Hydrochlorid | 243-193-9 | 19622-19-6 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
006-062-00-5 | Methyl-3,4-dichlorphenylcarbanilat; SWEP | - | 1918-18-9 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
006-063-00-0 | Thiobencarb (ISO); S-4-Chlorbenzyldiethylthiocarbamat | 248-924-5 | 28249-77-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
006-064-00-6 | Thiofanox (ISO); 3,3-Dimethyl-1-(methylthio)butanon- O-( N-methylcarbamoyl)oxim | 254-346-4 | 39196-18-4 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | |||
006-065-00-1 | 3-Chlor-6-cyanobicyclo[2,2,1]heptan-2-on- O-( N-methylcarbamoyl)oxim; Triamid | - | 15271-41-7 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Chronic 2 | H300 H311 H411 | GHS06 GHS09 Gef. | H300 H311 H411 | |||
006-066-00-7 | Vernolat (ISO); S-Propyldipropylthiocarbamat | 217-681-7 | 1929-77-7 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
006-067-00-2 | XMC; 3,5-Xylylmethylcarbamat | - | 2655-14-3 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
006-068-00-8 | Diazomethan | 206-382-7 | 334-88-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
006-069-00-3 | Thiophanat-methyl (ISO); Dimethyl-(1,2-phenylendicarbamothioyl)biscarbamat; Dimethyl-4,4"-( o-phenylen)bis(3-thioallophanat) | 245-740-7 | 23564-05-8 | Carc. 2 Muta. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H341 H332 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H341 H332 H317 H410 | Einatmen:
ATE = 1,7 mg/L (Stäube und Nebel) M = 10 M = 10 | ||
006-070-00-9 | Furmecyclox (ISO); N-Cyclohexyl- N-methoxy-2,5-dimethyl-3-furamid | 262-302-0 | 60568-05-0 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
006-071-00-4 | Cyclooct-4-en-1-ylmethylcarbonat | 401-620-8 | 87731-18-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
006-072-00-X | Prosulfocarb (ISO); S-Benzyl- N, N-dipropylthiocarbamat | 401-730-6 | 52888-80-9 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
006-073-00-5 | 3-(Dimethylamino)propylharnstoff | 401-950-2 | 31506-43-1 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
006-074-00-0 | 2-(3-(Prop-1-en-2-yl)phenyl)prop-2-ylisocyanat | 402-440-2 | 2094-99-7 | Acute Tox. 2 * Skin Corr. 1B STOT RE 2 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H314 H373 ** H334 H317 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H330 H314 H373 ** H334 H317 H410 | |||
006-076-00-1 | Mancozeb (ISO); Manganethylen-bis(dithiocarbamat) (polymer), Komplex mit Zinksalz | - | 8018-01-7 | Carc. 2 Repr. 1B STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H360D H373 (Schilddrüse, Nervensystem) H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H351 H360D H373 (Schilddrüse, Nervensystem) H317 H410 | M = 10 M = 10 | ||
006-077-00-7 | Maneb (ISO); Manganethylenbis(dithiocarbamat) (Polymer) | 235-654-8 | 12427-38-2 | Repr. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d*** H332 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361d*** H332 H319 H317 H410 | M=10 | ||
006-078-00-2 | Zineb (ISO); Zinkethylenbis(dithiocarbamat) (Polymer) | 235-180-1 | 12122-67-7 | STOT SE 3 Skin Sens. 1 | H335 H317 | GHS07 Achtg. | H335 H317 | |||
006-079-00-8 | Disulfiram; Tetraethylthiuramdisulfid | 202-607-8 | 97-77-8 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H317 H410 | |||
006-080-00-3 | Tetramethylthiurammonosulfid | 202-605-7 | 97-74-5 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
006-081-00-9 | Zinkbis(dibutyldithiocarbamat) | 205-232-8 | 136-23-2 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H319 H335 H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H319 H335 H315 H317 H410 | |||
006-082-00-4 | Zinkbis(diethyldithiocarbamat) | 238-270-9 | 14324-55-1 | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H335 H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H335 H315 H317 H410 | |||
006-083-00-X | Butocarboxim (ISO); 3-(Methylthio)-2-butanon- O-[(methylamino)carbonyl]oxim | 252-139-3 | 34681-10-2 | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H226 H331 H311 H301 H319 H400 H410 | GHS02 GHS06 GHS09 Gef. | H226 H331 H311 H301 H319 H410 | |||
006-084-00-5 | Carbosulfan (ISO); 2,3-Dihydro-2,2-dimethyl-7-benzofuryl[(dibutylamino)thio]methylcarbamat | 259-565-9 | 55285-14-8 | Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H301 H317 H400 H410 | GHS06 GHS09 Gef. | H330 H301 H317 H410 | |||
006-085-00-0 | Fenobucarb (ISO); 2-Butylphenylmethylcarbamat | 223-188-8 | 3766-81-2 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
006-086-00-6 | Fenoxycarb (ISO); Ethyl-[2-(4-phenoxyphenoxy)ethyl]carbamat | 276-696-7 | 72490-01-8 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | M = 1 M = 10 000 | ||
006-087-00-1 | Furathiocarb (ISO); 2,3-Dihydro-2,2-dimethyl-7-benzofuryl-2,4-dimethyl-6-oxa-5-oxo-3-thia-2,4-diazadecanoat | 265-974-3 | 65907-30-4 | Acute Tox. 2 * Acute Tox. 3 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H301 H373** H319 H315 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H301 H373** H319 H315 H317 H410 | M = 100 | ||
006-088-00-7 | Benfuracarb (ISO); Ethyl- N-[2,3-dihydro-2,2-dimethylbenzofuran-7-yloxycarbonyl(methyl)aminothio]- N-isopropyl-β-alaninat | - | 82560-54-1 | Repr. 2 Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H361f*** H331 H302 H400 H410 | GHS06 GHS08 GHS09 Gef. | H361f*** H331 H302 H410 | |||
006-090-00-8 | 2-(3-Iodprop-2-in-1-yloxy)ethylphenylcarbamat | 408-010-0 | 88558-41-2 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H332 H318 H412 | GHS05 GHS07 Gef. | H332 H318 H412 | |||
006-091-00-3 | Propineb (ISO); Zinkpropylenbis(dithiocarbamat) (Polymer) | - | 9016-72-2 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 | H332 H373** H317 H400 | GHS08 GHS07 GHS09 Achtg. | H332 H373** H317 H400 | |||
006-092-00-9 | tert-Butyl-(1 S)- N-[1-((2 S)-2-oxiranyl)-2-phenylethyl]carbamat | 425-420-5 | 98737-29-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
006-093-00-4 | 2,2"-Dithiodi(ethylammonium)-bis(dibenzyldithiocarbamat) | 427-180-7 | - | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
006-094-00-X | O-Isobutyl- N-ethoxycarbonylthiocarbamat | 434-350-4 | 103122-66-3 | Flam. Liq. 3 Carc. 1B Muta. 1B Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H226 H350 H340 H302 H373** H317 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H226 H350 H340 H302 H373** H317 H411 | |||
006-095-00-5 | Fosetyl-Aluminium (ISO); Aluminiumtriethyltriphosphonat | 254-320-2 | 39148-24-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
006-096-00-0 | Chlorpropham (ISO); Isopropyl-3-chlorcarbanilat | 202-925-7 | 101-21-3 | Carc. 2 STOT RE 2 * Aquatic Chronic 2 | H351 H373** H411 | GHS08 GHS09 Achtg. | H351 H373** H411 | |||
006-097-00-6 | 1-Phenyl-3-( p-toluolsulfonyl)harnstoff | 424-620-1 | 13909-63-2 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 | H302 H373** H412 | GHS08 GHS07 Achtg. | H302 H373** H412 | |||
006-098-00-1 | tert-Butyl-(1 R,5 S)-3-azabicyclo[3.1.0]hex-6-ylcarbamat | 429-170-8 | 134575-17-0 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H302 H373** H318 H317 | GHS05 GHS08 GHS07 Gef. | H302 H373** H318 H317 | |||
006-099-00-7 | N-( p-Toluolsulfonyl)- N"-(3-( p-toluolsulfonyloxy)phenyl)harnstoff; 3-({[(4-Methylphenyl)sulfonyl]carbamoyl}amino)phenyl-4- methylbenzolsulfonat | 432-520-2 | 232938-43-1 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
006-101-00-6 | Reaktionsmasse aus N, N""-(Methylendi-4,1-phenylen)bis[ N"-phenylharnstoff]; N-(4-[[4-[[(Phenylamino)carbonyl]amino]phenylmethyl]phenyl]- N"-cyclohexylharnstoff und N, N""-(Methylendi-4,1-phenylen)bis[ N"-cyclohexylharnstoff] | 423-070-8 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
006-102-00-1 | O-Hexyl- N-ethoxycarbonylthiocarbamat | 432-750-3 | - | Carc. 1B Muta. 1B Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H350 H340 H302 H373** H317 H411 | GHS08 GHS07 GHS09 Gef. | H350 H340 H302 H373** H317 H411 | |||
006-103-00-7 | N, N""-(Methylendi-4,1-phenylen)bis[ N"-octyl]harnstoff | 445-760-8 | - | Eye Dam. 1 Resp. Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H334 H400 H410 | GHS05 GHS08 GHS09 Gef. | H318 H334 H410 | M=100 | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
006-104-00-2 | mehrwandige Kohlenstoffröhren (röhrenförmiger synthetischer Graphit) mit einem geometrischen Durchmesser der Röhren von ≥ 30 nm bis < 3 μm und einer Länge von ≥ 5 μm und einem Aspektverhältnis von > 3:1, einschließlich mehrwandiger Kohlenstoffnanoröhren, MWC(N)T; | - | - | Carc. 1B STOT RE 1 | H350i H372 (Lunge) (Einatmen) | GHS08 Dgr | H350i H372 (Lunge) (Einatmen) | STOT RE 1; H372: C ≥ 1 %; STOT RE 2; H373: 0,1 % ≤ C < 1 %" | ) | |
007-001-00-5 | Ammoniak, wasserfrei | 231-635-3 | 7664-41-7 | Flam. Gas 2 Press. Gas Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 | H221 H331 H314 H400 | GHS04 GHS06 GHS05 GHS09 Gef. | H221 H331 H314 H400 | U | ||
007-001-01-2 | Ammoniak ....%; Ammoniaklösung ... % | 215-647-6 | 1336-21-6 | Skin Corr. 1B Aquatic Acute 1 | H314 H400 | GHS05 GHS09 Gef. | H314 H400 | STOT SE 3; H335: C ≥ 5 % | B | |
007-002-00-0 | Stickstoffdioxid [1]; Distickstofftetraoxid [2] | 233-272-6 [1] 234-126-4 [2] | 10102-44-0 [1] 10544-72-6 [2] | Press.
Gas Ox. Gas 1 Acute Tox. 2 * Skin Corr. 1B | H270 H330 H314 | GHS04 GHS03 GHS06 GHS05 Gef. | H270 H330 H314 | * STOT SE 3; H335: C ≥0,5 % | 5 | |
007-003-00-6 | Chlormequatchlorid (ISO); 2-Chlorethyltrimethylammoniumchlorid | 213-666-4 | 999-81-5 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
007-004-00-1 | Salpetersäure ... % [C > 70 %] | 231-714-2 | 7697-37-2 | Ox. Liq. 2 Acute Tox. 1 Skin Corr. 1A | H272 H330 H314 | GHS03 GHS06 GHS05 Dgr | H272 H330 H314 | EUH071 | Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 % | B |
007-006-00-2 | Ethylnitrit | 203-722-6 | 109-95-5 | Flam. Gas 1 Press. Gas Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H220 H332 H312 H302 | GHS02 GHS04 GHS07 Gef. | H220 H332 H312 H302 | U | ||
007-007-00-8 | Ethylnitrat | 210-903-3 | 625-58-1 | Unst. Expl. | H200 | GHS01 Gef. | H200 | |||
007-008-00-3 | Hydrazin | 206-114-9 | 302-01-2 | Flam. Liq. 3 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H226 H350 H331 H311 H301 H314 H317 H400 H410 | GHS02 GHS06 GHS08 GHS05 GHS09 Gef. | H226 H350 H331 H311 H301 H314 H317 H410 | Skin Corr. 1B; H314: C ≥ 10 % Skin Irrit. 2; H315: 3 % ≤ C < 10 % Eye Irrit. 2; H319: 3 % ≤ C < 10 % | ||
007-009-00-9 | Dicyclohexylammoniumnitrit | 221-515-9 | 3129-91-7 | Acute Tox. 4 * Acute Tox. 4 * | H332 H302 | GHS07 Achtg. | H332 H302 | * | ||
007-010-00-4 | Natriumnitrit | 231-555-9 | 7632-00-0 | Ox. Sol. 3 Acute Tox. 3 * Aquatic Acute 1 | H272 H301 H400 | GHS03 GHS06 GHS09 Gef. | H272 H301 H400 | * | ||
007-011-00-X | Kaliumnitrit | 231-832-4 | 7758-09-0 | Ox. Sol. 2 Acute Tox. 3 * Aquatic Acute 1 | H272 H301 H400 | GHS03 GHS06 GHS09 Gef. | H272 H301 H400 | * | ||
007-012-00-5 | N, N-Dimethylhydrazin | 200-316-0 | 57-14-7 | Flam. Liq. 2 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Chronic 2 | H225 H350 H331 H301 H314 H411 | GHS02 GHS06 GHS08 GHS05 GHS09 Gef. | H225 H350 H331 H301 H314 H411 | |||
007-013-00-0 | 1,2-Dimethylhydrazin | - | 540-73-8 | Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H350 H331 H311 H301 H411 | GHS06 GHS08 GHS09 Gef. | H350 H331 H311 H301 H411 | Carc. 1B; H350: C ≥ 0,01 % | ||
007-014-00-6 | Salze von Hydrazin | - | - | Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H331 H311 H301 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H331 H311 H301 H317 H410 | A | ||
007-015-00-1 | O-Ethylhydroxylamin | 402-030-3 | 624-86-2 | Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H225 H331 H311 H301 H372 ** H319 H317 H400 | GHS02 GHS06 GHS08 GHS09 Gef. | H225 H331 H311 H301 H372 ** H319 H317 H400 | |||
007-016-00-7 | Butylnitrit; n-Butylnitrit | 208-862-1 | 544-16-1 | Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * | H225 H331 H301 | GHS02 GHS06 Gef. | H225 H331 H301 | |||
007-017-00-2 | Isobutylnitrit; 2-Methyl-propylnitrit-1 | 208-819-7 | 542-56-3 | Flam. Liq. 2 Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * | H225 H350 H341 H332 H302 | GHS02 GHS08 GHS07 Gef. | H225 H350 H341 H332 H302 | |||
007-018-00-8 | sec-Butylnitrit; 1-Methyl-propylnitrit-1 | 213-104-8 | 924-43-6 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * | H225 H332 H302 | GHS02 GHS07 Gef. | H225 H332 H302 | |||
007-019-00-3 | tert-Butylnitrit 1,1-Dimethyl-ethylnitrit-1 | 208-757-0 | 540-80-7 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * | H225 H332 H302 | GHS02 GHS07 Gef. | H225 H332 H302 | |||
007-020-00-9 | Pentylnitrit [1]; "Amylnitrit", Isomerengemisch [2] | 207-332-7 [1] 203-770-8 [2] | 463-04-7 [1] 110-46-3 [2] | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * | H225 H332 H302 | GHS02 GHS07 Gef. | H225 H332 H302 | |||
007-021-00-4 | Hydrazobenzol; 1,2-Diphenylhydrazin | 204-563-5 | 122-66-7 | Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H410 | |||
007-022-00-X | Hydrazinbis(3-carboxy-4-hydroxybenzolsulfonat) | 405-030-1 | - | Carc. 1B Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 | H350 H302 H314 H317 H412 | GHS08 GHS05 GHS07 Gef. | H350 H302 H314 H317 H412 | |||
007-023-00-5 | Natrium-3,5-bis(3-(2,4-di- tert-pentylphenoxy)propylcarbamoyl)benzolsulfonat | 405-510-0 | - | Skin Irrit. 2 Skin Sens. 1 | H315 H317 | GHS07 Achtg. | H315 H317 | |||
007-024-00-0 | 2-(Decylthio)ethylammoniumchlorid | 405-640-8 | 36362-09-1 | STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H315 H318 H400 H410 | GHS08 GHS05 GHS09 Gef. | H373 ** H315 H318 H410 | |||
007-025-00-6 | (4-Hydrazinphenyl)- N-methylmethansulfonamidhydrochlorid | 406-090-1 | 81880-96-8 | Muta. 2 Acute Tox. 3 * STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H341 H301 H372 ** H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H341 H301 H372 ** H317 H410 | |||
007-026-00-1 | Oxo-((2,2,6,6-tetramethylpiperidin-4-yl)amino)carbonylacetohydrazid | 413-230-5 | 122035-71-6 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
007-027-00-7 | 1,6-Bis(3,3-bis((1-methylpentylidenimino)propyl)ureido)hexan | 420-190-2 | 771478-66-1 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H373 ** H314 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H312 H302 H373 ** H314 H317 H410 | |||
007-028-00-2 | Hydroxylammoniumnitrat | 236-691-2 | 13465-08-2 | Expl. 1.1 **** Carc. 2 Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H201 H351 H311 H302 H373** H319 H315 H317 H400 | GHS01 GHS06 GHS08 GHS09 Gef. | H201 H351 H311 H302 H373** H319 H315 H317 H400 | |||
007-029-00-8 | Diethyldimethylammoniumhydroxid | 419-400-5 | 95500-19-9 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | |||
007-030-00-3 | Salpetersäure ... % [C ≤ 70 %] | 231-714-2 | 7697-37-2 | Ox. Liq. 3 Acute Tox 3 Skin Corr. 1A | H272 H331 H314 | GHS03 GHS06 GHS05 Dgr | H272 H331 H314 | EUH071 | Ox. Liq. 3; H272: C ≥ 65 % Einatmen: ATE = 2,65 mg/L (Dämpfe) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % | B |
008-001-00-8 | Sauerstoff | 231-956-9 | 7782-44-7 | Ox. Gas 1 Press. Gas | H270 | GHS03 GHS04 Gef. | H270 | U | ||
008-003-00-9 | Wasserstoffperoxid-Lösung ... % | 231-765-0 | 7722-84-1 | Ox. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H271 H332 H302 H314 | GHS03 GHS05 GHS07 Gef. | H271 H332 H302 H314 | Ox. Liq. 1; H271: C ≥ 70 %**** Ox. Liq. 2; H272: 50 % ≤ C < 70 % **** * Skin Corr. 1A; H314: C ≥ 70 % Skin Corr. 1B; H314: 50 % ≤ C < 70 % Skin Irrit. 2; H315: 35 % ≤ C < 50 % Eye Dam. 1; H318: 8 % ≤ C < 50 % Eye Irrit. 2; H319: 5 % ≤ C < 8 % STOT SE 3; H335; C ≥ 35 % | B | |
009-001-00-0 | Fluor | 231-954-8 | 7782-41-4 | Press.
Gas Ox. Gas 1 Acute Tox. 2 * Skin Corr. 1A | H270 H330 H314 | GHS04 GHS03 GHS06 GHS05 Gef. | H270 H330 H314 | |||
009-002-00-6 | Fluorwasserstoff; Hydrogenfluorid | 231-634-8 | 7664-39-3 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Corr. 1A | H330 H310 H300 H314 | GHS06 GHS05 Gef. | H330 H310 H300 H314 | |||
009-003-00-1 | Fluorwasserstoffsäure ... % Flusssäure ... % | 231-634-8 | 7664-39-3 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Corr. 1A | H330 H310 H300 H314 | GHS06 GHS05 Gef. | H330 H310 H300 H314 | Skin Corr. 1A; H314: C ≥ 7 % Skin Corr. 1B; H314: 1 % ≤ C < 7 % Eye Irrit. 2; H319: 0,1 % ≤ C < 1 % | B | |
009-004-00-7 | Natriumfluorid | 231-667-8 | 7681-49-4 | Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 | H301 H319 H315 | GHS06 Gef. | H301 H319 H315 | EUH032 | ||
009-005-00-2 | Kaliumfluorid | 232-151-5 | 7789-23-3 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | |||
009-006-00-8 | Ammoniumfluorid | 235-185-9 | 12125-01-8 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | |||
009-007-00-3 | Natriumbifluorid; Natriumhydrogendifluorid | 215-608-3 | 1333-83-1 | Acute Tox. 3 * Skin Corr. 1B | H301 H314 | GHS06 GHS05 Gef. | H301 H314 | * Skin Corr. 1B; H314: C ≥ 1 % Skin Irrit. 2; H315: 0,1 % ≤ C < 1 % Eye Irrit. 2; H319: 0,1 % ≤ C < 1 % | ||
009-008-00-9 | Kaliumbifluorid; Kaliumhydrogendifluorid | 232-156-2 | 7789-29-9 | Acute Tox. 3 * Skin Corr. 1B | H301 H314 | GHS06 GHS05 Gef. | H301 H314 | * Skin Corr. 1B; H314: C ≥ 1 % Skin Irrit. 2; H315: 0,1 % ≤ C < 1 % Eye Irrit. 2; H319: 0,1 % ≤ C < 1 % | ||
009-009-00-4 | Ammoniumbifluorid; Ammoniumhydrogendifluorid | 215-676-4 | 1341-49-7 | Acute Tox. 3 * Skin Corr. 1B | H301 H314 | GHS06 GHS05 Gef. | H301 H314 | * Skin Corr. 1B; H314: C ≥ 1 % Skin Irrit. 2; H315: 0,1 % ≤ C < 1 % Eye Irrit. 2; H319: 0,1 % ≤ C < 1 % | ||
009-010-00-X | Borfluorwasserstoffsäure ... % Tetrafluorborsäure ... % | 240-898-3 | 16872-11-0 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % | B | |
009-011-00-5 | Hexafluorokieselsäure ... % Kieselfluorwasserstoffsäure ... % | 241-034-8 | 16961-83-4 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | B | ||
009-012-00-0 | Alkalihexafluorsilicate(Na) [1];Alkalihexafluorsilicate(K) [2];Alkalihexafluorsilicate(NH4) [3] | 240-934-8 [1] 240-896-2 [2] 240-968-3 [3] | 16893-85-9 [1] 16871-90-2 [2] 16919-19-0 [3] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | * | A | |
009-013-00-6 | Fluorsilicate, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | * | A | |
009-014-00-1 | Bleihexafluorsilikat; Blei(II)-hexafluorsilikat | 247-278-1 | 25808-74-6 | Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H360Df H332 H302 H373 ** H400 H410 | GHS08 GHS07 GHS09 Gef. | H360Df H332 H302 H373 ** H410 | 1 | ||
009-015-00-7 | Sulfuryldifluorid | 220-281-5 | 2699-79-8 | Press.
Gas Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 | H331 H373 ** H400 | GHS04 GHS06 GHS08 GHS09 Gef. | H331 H373 ** H400 | U | ||
009-016-00-2 | Trinatriumhexafluoraluminat [1]; Aluminiumtrinatriumhexafluorid Trinatriumhexafluoraluminat (Kryolit) [2] | 237-410-6 [1] 239-148-8 [2] | 13775-53-6 [1] 15096-52-3 [2] | STOT RE 1 Acute Tox. 4 Aquatic Chronic 2 | H372 H332 H411 | GHS07 GHS08 GHS09 Gef. | H372 H332 H411 | |||
009-017-00-8 | Kalium-μ-fluorbis(triethylaluminium) | 400-040-2 | 12091-08-6 | Flam. Sol. 1 Water-react. 1 Skin Corr. 1A Acute Tox. 4 * | H228 H270 H314 H332 | GHS02 GHS05 GHS07 Gef. | H228 H270 H314 H332 | EUH014 | T | |
009-018-00-3 | Magnesiumhexafluorsilicat | 241-022-2 | 16949-65-8 | Acute Tox. 3 * | H301 | GHS06 Gef. | H301 | * | ||
011-001-00-0 | Natrium | 231-132-9 | 7440-23-5 | Water-react. 1 Skin Corr. 1B | H260 H314 | GHS02 GHS05 Gef. | H260 H314 | EUH014 | ||
011-002-00-6 | Natriumhydroxid; Ätznatron; Natronlauge | 215-185-5 | 1310-73-2 | Skin Corr. 1A | H314 | GHS05 Gef. | H314 | Skin Corr. 1A; H314: C ≥ 5 % Skin Corr. 1B; H314 2 % ≤ C < 5 % Skin Irrit. 2; H315: 0,5 % ≤ C < 2 % Eye Irrit.2; H319: 0,5 % ≤ C < 2 % | ||
011-003-00-1 | Natriumperoxid | 215-209-4 | 1313-60-6 | Ox. Sol. 1 Skin Corr. 1A | H271 H314 | GHS03 GHS05 Gef. | H271 H314 | |||
011-004-00-7 | Natriumazid | 247-852-1 | 26628-22-8 | Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H400 H410 | GHS06 GHS09 Gef. | H300 H400 H410 | EUH032 | ||
011-005-00-2 | Natriumcarbonat | 207-838-8 | 497-19-8 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
011-006-00-8 | Natriumcyanat | 213-030-6 | 917-61-3 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
011-007-00-3 |
Propoxycarbazon-Natrium; | - | 181274-15-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 10 | ||
012-001-00-3 | Magnesiumpulver (pyrophor) | 231-104-6 | 7439-95-4 | Water-react. 1 Pyr. Sol. 1 | H260 H250 | GHS02 Gef. | H260 H250 | T | ||
012-002-00-9 | Magnesium, Pulver oder Späne | 231-104-6 | - | Flam. Sol. 1 Water-react. 2 Self-heat. 1 | H228 H261 H252 | GHS02 Gef. | H228 H261 H252 | T | ||
012-003-00-4 | Magnesiumalkyle | - | - | Pyr. Liq. 1 Water-react. 1 Skin Corr. 1B | H250 H260 H314 | GHS02 GHS05 Gef. | H250 H260 H314 | EUH014 | A | |
012-004-00-X | Aluminium-Magnesium-Carbonat-Hydroxid-Perchlorat-Hydrat | 422-150-1 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
013-001-00-6 | Aluminiumpulver (pyrophor) | 231-072-3 | 7429-90-5 | Water-react. 2 Pyr. Sol. 1 | H261 H250 | GHS02 Gef. | H261 H250 | T | ||
013-002-00-1 | Aluminiumpulver (stabilisiert) | 231-072-3 | 7429-90-5 | Water-react. 2 Flam. Sol. 1 | H261 H228 | GHS02 Gef. | H261 H228 | T | ||
013-003-00-7 | Aluminiumchlorid, wasserfrei | 231-208-1 | 7446-70-0 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
013-004-00-2 | Aluminiumalkyle | - | - | Pyr. Liq. 1 Water-react. 1 Skin Corr. 1B | H250 H260 H314 | GHS02 GHS05 Gef. | H250 H260 H314 | EUH014 | A | |
013-005-00-8 | Diethyl(ethyldimethylsilanolato)aluminium | 401-160-8 | 55426-95-4 | Water-react. 1 Pyr. Liq. 1 Skin Corr. 1A | H260 H250 H314 | GHS02 GHS05 Gef. | H260 H250 H314 | EUH014 | ||
013-006-00-3 | (Ethyl-3-oxobutanoato- O"1, O"3)(2-dimethylaminoethanolato)(1-methoxy-2-propanolato)aluminium(III), dimerisiert | 402-370-2 | - | Flam. Liq. 3 Eye Dam. 1 | H226 H318 | GHS02 GHS05 Gef. | H226 H318 | |||
013-007-00-9 | Poly(oxo(2-butoxyethyl-3-oxobutanoato- O"1, O"3)aluminium) | 403-430-0 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
013-008-00-4 | Di- n-octylaluminiumiodid | 408-190-0 | 7585-14-0 | Pyr. Liq. 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H250 H314 H400 H410 | GHS02 GHS05 GHS09 Gef. | H250 H314 H410 | EUH014 | ||
013-009-00-X | Natrium( n-butyl)x(ethyl)y-1,5-dihydro)aluminat, x = 0,5; y = 1,5 | 418-720-2 | - | Flam. Sol. 1 Water-react. 1 Pyr. Sol. 1 Acute Tox. 4 * Skin Corr. 1A | H228 H260 H250 H332 H314 | GHS02 GHS05 GHS07 Gef. | H228 H260 H250 H332 H314 | EUH014 | T | |
013-010-00-5 | Hydroxylaluminiumbis(2,4,8,10-tetra- tert-butyl-6-hydroxy-12 H-dibenzo[ d, g][1.3.2]dioxaphosphocin-6-oxid) | 430-650-4 | 151841-65-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
014-001-00-9 | Trichlorsilan | 233-042-5 | 10025-78-2 | Flam. Liq. 1 Waterreact. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 | H224 H260 H331 H302 H314 H318 | GHS02 GHS06 GHS05 Dgr | H224 H260 H331 H302 H314 | EUH014 EUH029 EUH071 | Einatmung: ATE = 7,6 mg/L (Dämpfe) Oral: ATE = 1.000 mg/kg KG | |
014-002-00-4 | Siliciumtetrachlorid | 233-054-0 | 10026-04-7 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | EUH014 | ||
014-003-00-X | Dimethyldichlorsilan | 200-901-0 | 75-78-5 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H225 H319 H335 H315 | GHS02 GHS07 Gef. | H225 H319 H335 H315 | |||
014-004-00-5 | Trichlor(methyl)silan; Methyltrichlorsilan | 200-902-6 | 75-79-6 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H225 H319 H335 H315 | GHS02 GHS07 Gef. | H225 H319 H335 H315 | EUH014 | Skin Irrit.2; H315: C ≥ 1 % Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % | |
014-005-00-0 | Tetraethylsilicat; Ethylsilicat; Tetraethoxysilan | 201-083-8 | 78-10-4 | Flam. Liq. 3 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 | H226 H332 H319 H335 | GHS02 GHS07 Achtg. | H226 H332 H319 H335 | |||
014-006-00-6 | Bis(4-fluorphenyl)-methyl-(1,2,4-triazol-4-ylmethyl)silanhydrochlorid | 401-380-4 | - | Eye Irrit. 2 Aquatic Chronic 2 | H319 H411 | GHS07 GHS09 Achtg. | H319 H411 | |||
014-007-00-1 | Triethoxyisobutylsilan | 402-810-3 | 17980-47-1 | Skin Irrit. 2 | H315 | GHS07 Achtg. | H315 | |||
014-008-00-7 | (Chlormethyl)bis(4-fluorphenyl)methylsilan | 401-200-4 | 85491-26-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
014-009-00-2 | Isobutylisopropyldimethoxysilan | 402-580-4 | 111439-76-0 | Flam. Liq. 3 Acute Tox. 4 * Skin Irrit. 2 | H226 H332 H315 | GHS02 GHS07 Achtg. | H226 H332 H315 | |||
014-010-00-8 | Dinatriummetasilicat | 229-912-9 | 6834-92-0 | Skin Corr. 1B STOT SE 3 | H314 H335 | GHS05 GHS07 Gef. | H314 H335 | |||
014-011-00-3 | Cyclohexyldimethoxymethylsilan | 402-140-1 | 17865-32-6 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
014-012-00-9 | Bis(3-(trimethoxysilyl)propyl)amin | 403-480-3 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
014-013-00-4 | α-Hydroxypoly(methyl-(3-(2,2,6,6-tetramethylpiperidin-4-yloxy)propyl)siloxan) | 404-920-7 | - | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 | H312 H302 H314 H411 | GHS05 GHS07 GHS09 Gef. | H312 H302 H314 H411 | |||
014-014-00-X | Etacelasil (ISO); 6-(2-Chlorethyl)-6-(2-methoxyethoxy)-2,5,7,10-tetraoxa-6-silaundecan | 253-704-7 | 37894-46-5 | Repr. 1B Acute Tox. 4 * STOT RE 2 * | H360D *** H302 H373 ** | GHS08 GHS07 Gef. | H360D *** H302 H373 ** | |||
014-015-00-5 | α-Trimethylsilanyl-ω-trimethylsiloxypoly[oxy(methyl-3-(2-(2-methoxypropoxy)propoxy)propylsilandiyl]-co-oxy(dimethylsilan)) | 406-420-4 | 69430-40-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
014-016-00-0 | Reaktionsmasse aus: 1,3-Dihex-5-en-1-yl-1,1,3,3-tetramethyldisiloxan und 1,3-Dihex-n-en-1-yl-1,1,3,3-tetramethyldisiloxan | 406-490-6 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
014-017-00-6 | Flusilazol (ISO); Bis(4-fluorphenyl)(methyl)(1 H-1,2,4-triazol-1-ylmethyl)silan | - | 85509-19-9 | Carc. 2 Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 | H351 H360D *** H302 H411 | GHS08 GHS07 GHS09 Gef. | H351 H360D *** H302 H411 | |||
014-018-00-1 | Octamethylcyclotetrasiloxan; [D4] | 209-136-7 | 556-67-2 | Repr. 2 Aquatic Chronic 1 | H361f *** H410 | GHS08 GHS09 Wng | H361f *** H410 | M = 10 | ||
014-019-00-7 | Reaktionsmasse aus 4-[[Bis(4-fluorphenyl)methylsilyl]methyl]-4 H-1,2,4-triazol und 1-[[Bis(4-fluorphenyl)methylsilyl]methyl]-1 H-1,2,4-triazol | 403-250-2 | - | Carc. 2 Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 | H351 H360D *** H302 H411 | GHS08 GHS07 GHS09 Gef. | H351 H360D *** H302 H411 | |||
014-020-00-2 | Bis(1,1-dimethyl-2-propynyloxy)dimethylsilan | 414-960-7 | 53863-99-3 | Acute Tox. 4 * | H332 | GHS07 Achtg. | H332 | |||
014-021-00-8 | Tris(isopropenyloxy)phenylsilan | 411-340-8 | 52301-18-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H400 H410 | |||
014-022-00-3 | Reaktionsprodukt von (2-Hydroxy-4-(3-propenoxy)benzophenon und Triethoxysilan) mit (Hydrolyseprodukt von Siliciumdioxid und Methyltrimethoxysilan) | 401-530-9 | - | Flam. Sol. 1 STOT SE 1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H228 H370 ** H332 H312 H302 | GHS02 GHS08 GHS07 Gef. | H228 H370 ** H332 H312 H302 | T | ||
014-023-00-9 | α, ω-Dihydroxypoly(hex-5-en-1-ylmethylsiloxan) | 408-160-7 | 125613-45-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
014-024-00-4 | 1-((3-(3-Chlor-4-fluorphenyl)propyl)dimethylsilanyl)-4-ethoxybenzol | 412-620-2 | 121626-74-2 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
014-025-00-X | 4-[3-(Diethoxymethylsilylpropoxy)-2,2,6,6-tetramethyl]piperidin | 411-400-3 | 102089-33-8 | Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H302 H373 ** H315 H318 H412 | GHS08 GHS05 GHS07 Gef. | H302 H373 ** H315 H318 H412 | |||
014-026-00-5 | Dichlor-(3-(3-chlor-4-fluorphenyl)propyl)methylsilan | 407-180-3 | 770722-36-6 | Skin Corr. 1A | H314 | GHS05 Gef. | H314 | |||
014-027-00-0 | Chlor(3-(3-chlor-4-fluorphenyl)propyl)dimethylsilan | 410-270-5 | 770722-46-8 | Skin Corr. 1A | H314 | GHS05 Gef. | H314 | |||
014-028-00-6 | α-[3-(1-Oxoprop-2-eny)l-1-oxypropyl]dimethoxysilyloxy-ω -[3(1-oxoprop-2-enyl)-1-oxypropyl]dimethoxysilylpoly(dimethylsiloxan) | 415-290-8 | 193159-06-7 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
014-029-00-1 | O, O"-(Ethenylmethylsilylen)di[(4-methylpentan-2-on)oxim] | 421-870-1 | 156145-66-3 | Repr. 2 Acute Tox. 4 * STOT RE 2 * | H361f *** H302 H373 ** | GHS08 GHS07 Achtg. | H361f *** H302 H373 ** | |||
014-030-00-7 | [(Dimethylsilylen)bis((1,2,3,3a,7a-η)-1 H-inden-1-yliden)dimethyl]hafnium | 422-060-0 | 137390-08-0 | Acute Tox. 2 * | H300 | GHS06 Gef. | H300 | |||
014-031-00-2 | Bis(1-methylethyl)-dimethoxysilan | 421-540-7 | 18230-61-0 | Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H226 H315 H317 H412 | GHS02 GHS07 Achtg. | H226 H315 H317 H412 | |||
014-032-00-8 | Dicyclopentyldimethoxysilan | 404-370-8 | 126990-35-0 | Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H400 H410 | GHS05 GHS09 Gef. | H315 H318 H410 | |||
014-033-00-3 | 2-Methyl-3-(trimethoxysilyl)propyl-2-propenoat, Hydrolyseprodukt mit Siliciumdioxid | 419-030-4 | 125804-20-8 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H336 | GHS02 GHS07 Gef. | H225 H319 H336 | |||
014-034-00-9 | 3-Hexylheptamethyltrisiloxan | 428-700-5 | 1873-90-1 | Acute Tox. 4 * Aquatic Chronic 4 | H332 H413 | GHS07 Achtg. | H332 H413 | |||
014-035-00-4 | 2-(3,4-Epoxycyclohexyl)ethyltriethoxysilan | 425-050-4 | 10217-34-2 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
014-036-00-X | (4-Ethoxyphenyl)(3-(4-fluor-3-phenoxyphenyl)propyl)dimethylsilan | 405-020-7 | 105024-66-6 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360F*** H400 H410 | GHS08 GHS09 Gef. | H360F*** H410 | M=1000 | ||
014-037-00-5 | 2-Butanon- O, O",O""-(phenylsilylidin)trioxim | 433-360-6 | 34036-80-1 | STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 | H373** H317 H412 | GHS08 GHS07 Achtg. | H373** H317 H412 | |||
014-038-00-0 | S-(3-(Triethoxysilyl)propyl)octanthioat | 436-690-9 | 220727-26-4 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
014-039-00-6 | (2,3-Dimethylbut-2-yl)-trimethoxysilan | 439-360-2 | 142877-45-0 | Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H315 H318 H412 | GHS05 Gef. | H315 H318 H412 | |||
014-041-00-7 | N, N-Bis(trimethylsilyl)aminopropylmethyldiethoxysilan | 445-890-5 | 201290-01-9 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
014-042-00-2 | Reaktionsmasse aus O, O", O"", O-Silantetrayl-tetrakis(4-methyl-2-pentanonoxim) (3 Stereoisomere) | 423-010-0 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
014-043-00-8 | Reaktionsprodukt von amorphem Siliciumdioxid (50-85 %), Butyl-(1-methylpropyl)magnesium (3-15 %), Tetraethylorthosilicat (5-15 %) und Titantetrachlorid (5-20 %) | 432-200-2 | - | STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H335 H315 H318 H412 | GHS05 GHS07 Gef. | H335 H315 H318 H412 | |||
014-044-00-3 | 3-[(4"-Acetoxy-3"-methoxyphenyl)-propyl]-trimethoxysilan | 433-050-0 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
014-045-00-9 | Magnesium-Natrium-Fluorid-Silicat | 442-650-1 | - | STOT RE 2 * | H373** | GHS08 Achtg. | H373** | |||
014-046-00-4 | E-Glas-Mikrofasern in repräsentativer Zusammensetzung; [ungerichtete Calcium-Aluminium-Silicat-Fasern mit folgender repräsentativer Zusammensetzung (Angabe in % Massenanteil): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Verfahren: Herstellung typischerweise im Düsenblasverfahren oder im Schleuderverfahren. (Weitere Einzelelemente können in geringen Mengen vorhanden sein. Die Verfahrensliste schließt Innovationen nicht aus).] | - | - | Carc. 1B | H350i | GHS08 Gef. | H350i | A | ||
014-047-00-X | Glas-Mikrofasern in repräsentativer Zusammensetzung; [ungerichtete Calcium-Aluminium-Silicat-Fasern mit folgender Zusammensetzung (Angabe in % Massenanteil): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Verfahren: Herstellung typischerweise im Düsenblasverfahren oder im Schleuderverfahren. (Weitere Einzelelemente können in geringen Mengen vorhanden sein. Die Verfahrensliste schließt Innovationen nicht aus).] | - | - | Carc. 2 | H351 (Einatmen) | GHS08 Achtg. | H351 (Einatmen) | A | ||
014-048-00-5 | Siliciumcarbidfasern (mit Durchmesser < 3μm, Länge > 5μm und Seitenverhältnis ≥ 3:1) | 206-991-8 | 409-21-2 308076-74-6 | Carc. 1B | H350i | GHS08 Dgr | H350i | |||
014-049-00-0 | Trimethoxyvinylsilan; Trimethoxy(vinyl)silan | 220-449-8 | 2768-02-7 | Skin Sens. 1B | H317 | GHS07 Wng | H317 | |||
014-050-00-6 | Tris(2-methoxyethoxy)vinylsilan; 6-(2-Methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecan | 213-934-0 | 1067-53-4 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
014-052-00-7 | Silanamin, 1,1,1-Trimethyl- N-(trimethylsilyl)-, Hydrolyseprodukte mit Siliciumdioxid; pyrogenes, synthetisch amorphes, oberflächenbehandeltes Siliciumdioxid in Nanoform | 272-697-1 | 68909-20-6 | STOT RE 2 | H373 (Lunge) (Einatmen) | GHS08 Wng | H373 (Lunge) (Einatmen) | EUH066) | ||
015-001-00-1 | Weißer Phosphor; Tetraphosphor | 231-768-7 | 12185-10-3 | Pyr. Sol. 1 Acute Tox. 2 * Acute Tox. 2 * Skin Corr. 1A Aquatic Acute 1 | H250 H330 H300 H314 H400 | GHS02 GHS06 GHS05 GHS09 Gef. | H250 H330 H300 H314 H400 | |||
015-002-00-7 | Roter Phosphor | 231-768-7 | 7723-14-0 | Flam. Sol. 1 Aquatic Chronic 3 | H228 H412 | GHS02 Gef. | H228 H412 | |||
015-003-00-2 | Calciumphosphid; Tricalciumdiphosphid | 215-142-0 | 1305-99-3 | Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Eye Dam. 1 Aquatic Acute 1 | H260 H300 H311 H330 H318 H400 | GHS02 GHS06 GHS05 GHS09 Gef. | H260 H300 H311 H330 H318 H400 | EUH029 EUH032 | M = 100 | |
015-004-00-8 | Aluminiumphosphid | 244-088-0 | 20859-73-8 | Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Aquatic Acute 1 | H260 H300 H311 H330 H400 | GHS02 GHS06 GHS09 Gef. | H260 H300 H311 H330 H400 | EUH029 EUH032 | M = 100 | |
015-005-00-3 | Magnesiumphosphid; Trimagnesiumdiphosphid | 235-023-7 | 12057-74-8 | Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Aquatic Acute 1 | H260 H300 H311 H330 H400 | GHS02 GHS06 GHS09 Gef. | H260 H300 H311 H330 H400 | EUH029 EUH032 | M = 100 | |
015-006-00-9 | Trizinkdiphosphid; Zinkphosphid | 215-244-5 | 1314-84-7 | Water-react. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H260 H300 H400 H410 | GHS02 GHS06 GHS09 Gef. | H260 H300 H410 | EUH029 EUH032 | M=100 | T |
015-007-00-4 | Phosphortrichlorid | 231-749-3 | 7719-12-2 | Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Skin Corr. 1A | H330 H300 H373 ** H314 | GHS06 GHS08 GHS05 Gef. | H330 H300 H373 ** H314 | EUH014 EUH029 | ||
015-008-00-X | Phosphorpentachlorid | 233-060-3 | 10026-13-8 | Acute Tox. 2 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B | H330 H302 H373 ** H314 | GHS06 GHS08 GHS05 Gef. | H330 H302 H373 ** H314 | EUH014 EUH029 | ||
015-009-00-5 | Phosphoryltrichlorid; Phosphoroxidchlorid; Phosphorylchlorid | 233-046-7 | 10025-87-3 | Acute Tox. 2 * STOT RE 1 Acute Tox. 4 * Skin Corr. 1A | H330 H372 ** H302 H314 | GHS06 GHS08 GHS05 Gef. | H330 H372 ** H302 H314 | EUH014 EUH029 | ||
015-010-00-0 | Phosphorpentoxid | 215-236-1 | 1314-56-3 | Skin Corr. 1A | H314 | GHS05 Gef. | H314 | |||
015-011-00-6 | Phosphorsäure ...%, ortho-Phosphorsäure ...% | 231-633-2 | 7664-38-2 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % | B | |
015-012-00-1 | Tetraphosphortrisulfid; Phosphorsesquisulfid | 215-245-0 | 1314-85-8 | Flam. Sol. 2 Water-react. 1 Acute Tox. 4 * Aquatic Acute 1 | H228 H260 H302 H400 | GHS02 GHS07 GHS09 Gef. | H228 H260 H302 H400 | T | ||
015-013-00-7 | Triethylphosphat | 201-114-5 | 78-40-0 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
015-014-00-2 | Tributylphosphat | 204-800-2 | 126-73-8 | Carc. 2 Acute Tox. 4 * Skin Irrit. 2 | H351 H302 H315 | GHS08 GHS07 Achtg. | H351 H302 H315 | |||
015-015-00-8 | Trikresylphosphat (o- o- o-, o- o- m-, o- o- p-, o- m- m-, o- m- p-, o- p- p-); Tritolylphosphat (o- o- o-, o- o- m-, o- o- p-, o- m- m-, o- m- p-, o- p- p-) | 201-103-5 | 78-30-8 | STOT SE 1 Aquatic Chronic 2 | H370 ** H411 | GHS08 GHS09 Gef. | H370 ** H411 | STOT SE 1; H370: C ≥ 1 % STOT SE 2; H371: 0,2 % ≤ C < 1 % | C | |
015-016-00-3 | Trikresylphosphat (m- m- m-, m- m- p-, m- p- p-, p- p- p-); Tritolylphosphat (m- m- m-, m- m- p-, m- p- p-, p- p- p-) | 201-105-6 | 78-32-0 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H312 H302 H411 | GHS07 GHS09 Achtg. | H312 H302 H411 | * | C | |
015-019-00-X | Dichlorvos (ISO); 2,2-Dichlorvinyldimethylphosphat; Phosphorsäure-2,2-dichlorvinyl-dimethylester | 200-547-7 | 62-73-7 | Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 | H330 H311 H301 H317 H400 | GHS06 GHS09 Gef. | H330 H311 H301 H317 H400 | M=1000 | ||
015-020-00-5 | Mevinphos (ISO); 2-Methoxycarbonyl-1-methylvinyldimethylphosphat | 232-095-1 | 7786-34-7 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | M = 10000 | ||
015-021-00-0 | Trichlorfon (ISO); Dimethyl-2,2,2-trichlor-1-hydroxyethylphosphonat | 200-149-3 | 52-68-6 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H400 H410 | M = 1000 | ||
015-022-00-6 | Phosphamidon (ISO); 2-Chlor-2-diethylcarbamoyl-1-methylvinyldimethylphosphat | 236-116-5 | 13171-21-6 | Muta. 2 Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H341 H300 H311 H400 H410 | GHS06 GHS08 GHS09 Gef. | H341 H300 H311 H410 | |||
015-023-00-1 | Pyrazoxon; Diethyl- 3-methylpyrazol-5-ylphosphat | - | 108-34-9 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * | H330 H310 H300 | GHS06 Gef. | H330 H310 H300 | |||
015-024-00-7 | Triamiphos (ISO); 5-Amino-3-phenyl-1,2,4-triazol-1-yl- N, N,N",N"-tetramethylphosphonsäurediamid | - | 1031-47-6 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
015-025-00-2 | TEPP (ISO); Tetraethylpyrophosphat | 203-495-3 | 107-49-3 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 | H310 H300 H400 | GHS06 GHS09 Gef. | H310 H300 H400 | |||
015-026-00-8 | Schradan (ISO); Octamethylpyrophosphoramid | 205-801-0 | 152-16-9 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
015-027-00-3 | Sulfotep (ISO); O, O,O, O-Tetraethyldithiopyrophosphat | 222-995-2 | 3689-24-5 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | M = 1000 | ||
015-028-00-9 | Demeton- O (ISO); O, O-diethyl- O-2-(ethylthio)ethyl) phosphorothioat | 206-053-8 | 298-03-3 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 | H310 H300 H400 | GHS06 GHS09 Gef. | H310 H300 H400 | |||
015-029-00-4 | Demeton- S (ISO); O, O-Diethyl- S-(2-ethylthioethyl) phosphorothioat | 204-801-8 | 126-75-0 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
015-030-00-X | Demeton- O-methyl (ISO); O-2-Ethylthioethyl- O, O-dimethyl phosphorothioat | 212-758-1 | 867-27-6 | Acute Tox. 3 * | H301 | GHS06 Gef. | H301 | |||
015-031-00-5 | Demeton- S-methyl (ISO); S-2-Ethylthioethyldimethyl phosphorothioat | 213-052-6 | 919-86-8 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H311 H301 H411 | GHS06 GHS09 Gef. | H311 H301 H411 | |||
015-032-00-0 | Prothoat (ISO); O, O-Diethylisopropylcarbamoylmethyl phosphorodithioat | 218-893-2 | 2275-18-5 | Acute Tox. 1 Acute Tox. 2 * Aquatic Chronic 3 | H310 H300 H412 | GHS06 Gef. | H310 H300 H412 | |||
015-033-00-6 | Phorat (ISO); O, O-Diethylethylthiomethyl phosphorodithioat | 206-052-2 | 298-02-2 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | M = 1000 | ||
015-034-00-1 | Parathion (ISO); O, O-Diethyl- O-4-nitrophenylphosphorothioat | 200-271-7 | 56-38-2 | Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H311 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H300 H311 H372 ** H410 | M = 100 | ||
015-035-00-7 | Parathion-methyl (ISO); O, O-Dimethyl- O-(4-nitrophenyl) phosphorothioat | 206-050-1 | 298-00-0 | Flam. Liq. 3 Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H226 H330 H300 H311 H373 ** H400 H410 | GHS02 GHS06 GHS08 GHS09 Gef. | H226 H330 H300 H311 H373 ** H410 | M = 100 | ||
015-036-00-2 | O-Ethyl- O-4-nitrophenylphenylthiophosphonat; EPN | 218-276-8 | 2104-64-5 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | |||
015-037-00-8 | Phenkapton (ISO); S-(2,5-Dichlorphenylthiomethyl)- O, O-diethyldithiophosphat | 218-892-7 | 2275-14-1 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | |||
015-038-00-3 | Coumaphos (ISO); O-3-Chlor-4-methylcumarin-7-yl- O, O-diethylphosphorothioat | 200-285-3 | 56-72-4 | Acute Tox. 2 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H312 H400 H410 | GHS06 GHS09 Gef. | H300 H312 H410 | |||
015-039-00-9 | Azinphos-methyl (ISO); O, O-Dimethyl-4-oxobenzotriazin-3-ylmethylphosphorodithioat | 201-676-1 | 86-50-0 | Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H311 H317 H400 H410 | GHS06 GHS09 Gef. | H330 H300 H311 H317 H410 | |||
015-040-00-4 | Diazinon (ISO); O, O-Diethyl- O-2-isopropyl-6-methylpyrimidin-4-ylphosphorothioat | 206-373-8 | 333-41-5 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H400 H410 | |||
015-041-00-X | Malathion (ISO); 1,2-Bis(ethoxycarbonyl)-ethyl- O, O-dimethylphosphorodithioat; [Gehalt an Isomalathiongehalt ≤ 0,03 %] | 204-497-7 | 121-75-5 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | M=1000 | ||
015-042-00-5 | Chlorthion; O-(3-Chlor-4-nitrophenyl)- O, O- dimethylphosphorothioat | 207-902-5 | 500-28-7 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | M = 100 | ||
015-043-00-0 | Phosnichlor (ISO); O-(4-Chlor-3-nitrophenyl)- O, O- dimethylphosphorothioat | - | 5826-76-6 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H332 H312 H302 | GHS07 Achtg. | H332 H312 H302 | |||
015-044-00-6 | Carbophenothion (ISO); 4-Chlorphenylthiomethyl- O, O-diethylphosphorodithioat | 212-324-1 | 786-19-6 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H410 | |||
015-045-00-1 | Mecarbam (ISO); N-Ethoxycarbonyl- N-methylcarbamoylmethyl- O, O-diethylphosphorodithioat | 219-993-9 | 2595-54-2 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H400 H410 | |||
015-046-00-7 | Oxydemeton-methyl; S-2-(Ethylsulfinyl)-ethyl- O, O-dimethylphosphorothioat | 206-110-7 | 301-12-2 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 | H311 H301 H400 | GHS06 GHS09 Gef. | H311 H301 H400 | |||
015-047-00-2 | Ethion (ISO); O, O,O",O"-Tetraethyl- S, S"-methylendi(phosphorodithioat); Diethion | 209-242-3 | 563-12-2 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H312 H400 H410 | GHS06 GHS09 Gef. | H301 H312 H410 | M = 10000 | ||
015-048-00-8 | Fenthion (ISO); O, O-Dimethyl- O-(4-methylthion- m-tolyl)- phosphorothioat | 200-231-9 | 55-38-9 | Muta. 2 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H341 H331 H312 H302 H372** H400 H410 | GHS06 GHS08 GHS09 Gef. | H341 H331 H312 H302 H372** H410 | M=100 | ||
015-049-00-3 | Endothion (ISO); S-5-methoxy-4-oxopyran-2-ylmethyldimethylphosphorothioat | 220-472-3 | 2778-04-3 | Acute Tox. 3 * Acute Tox. 3 * | H311 H301 | GHS06 Gef. | H311 H301 | |||
015-050-00-9 | Thiometon (ISO); S-2-Ethylthioethyl- O, O-dimethylphosphorodithioat | 211-362-6 | 640-15-3 | Acute Tox. 3 * Acute Tox. 4 * | H301 H312 | GHS06 Gef. | H301 H312 | |||
015-051-00-4 | Dimethoat (ISO); O, O-Dimethylmethylcarbamoylmethylphosphorodithioat | 200-480-3 | 60-51-5 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
015-052-00-X | Fenchlorphos (ISO); O, O-Dimethyl- O-2,4,5-trichlorphenylphosphorothioat | 206-082-6 | 299-84-3 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
015-053-00-5 | Menazon (ISO); S-[(4,6-Diamino-1,3,5-triazin-2- yl)-methyl]- O, O-dimethylphosphorodithioat | 201-123-4 | 78-57-9 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
015-054-00-0 | Fenitrothion (ISO); O, O-Dimethyl- O-4-nitro- m-tolylphosphorothioat | 204-524-2 | 122-14-5 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
015-055-00-6 | Naled (ISO); 1,2-Dibrom-2,2-dichlorethyldimethylphosphat | 206-098-3 | 300-76-5 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 | H312 H302 H319 H315 H400 | GHS07 GHS09 Achtg. | H312 H302 H319 H315 H400 | M = 1000 | ||
015-056-00-1 | Azinphos-ethyl (ISO); O, O-Diethyl-4-oxobenzotriazin-3-ylmethylphosphorodithioat | 220-147-6 | 2642-71-9 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H311 H400 H410 | GHS06 GHS09 Gef. | H300 H311 H410 | M=100 | ||
015-057-00-7 | Formothion (ISO); N-Formyl- N-methylcarbamoylmethyl- O, O-dimethylphosphorodithioat | 219-818-6 | 2540-82-1 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
015-058-00-2 | Morphothion (ISO); O, O-Dimethyl- S-(morpholinocarbonyl)methylphosphorodithioat | 205-628-0 | 144-41-2 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | |||
015-059-00-8 | Vamidothion (ISO); O, O-Dimethyl- S-5-( N-methyl-2-methyl-3-thiavaleramid)- phosphorothioat | 218-894-8 | 2275-23-2 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 | H301 H312 H400 | GHS06 GHS09 Gef. | H301 H312 H400 | |||
015-060-00-3 | Disulfoton (ISO); O, O-Diethyl-2-ethylthioethylphosphorodithioat | 206-054-3 | 298-04-4 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | |||
015-061-00-9 | Dimefox (ISO); Tetramethylphosphordiamidsäurefluorid | 204-076-8 | 115-26-4 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
015-062-00-4 | Mipafox (ISO); N, N"-Diisopropyldiamidophosphorsäurefluorid | 206-742-3 | 371-86-8 | STOT SE 1 | H370 ** | GHS08 Gef. | H370 ** | |||
015-063-00-X | Dioxathion (ISO); 1,4-Dioxan-2,3-diyl- O, O, O", O"-tetraethyldi(phosphorodithioat) | 201-107-7 | 78-34-2 | Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H311 H400 H410 | GHS06 GHS09 Gef. | H330 H300 H311 H410 | M = 1000 | ||
015-064-00-5 | Bromophos-ethyl (ISO); O-4-Brom-2,5-dichlorphenyl- O, O-diethylphosphorothioat | 225-399-0 | 4824-78-6 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H312 H400 H410 | GHS06 GHS09 Gef. | H301 H312 H410 | |||
015-065-00-0 | S-[2-(Ethylsulfinyl)-ethyl]- O, O-dimethylphosphorodithioat | - | 2703-37-9 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Chronic 2 | H330 H310 H300 H411 | GHS06 GHS09 Gef. | H330 H310 H300 H411 | |||
015-066-00-6 | Omethoat (ISO); O, O-Dimethyl- S-methylcarbamoylmethylphosphorothioat | 214-197-8 | 1113-02-6 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 | H301 H312 H400 | GHS06 GHS09 Gef. | H301 H312 H400 | |||
015-067-00-1 | Phosalon (ISO); S-6-Chlor-2-oxobenzoxazolin-3-ylmethyl)- O, O-diethylphosphordithioat; O, O-Diethyl-S-(6-chlor-2-oxo-benz(b)1,3- oxazolin-3-yl)-methyldithiophosphatdiethylphosphorodithioat | 218-996-2 | 2310-17-0 | Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H332 H312 H317 H400 H410 | GHS06 GHS09 Gef. | H301 H332 H312 H317 H410 | M=1000 | ||
015-068-00-7 | Dichlofenthion (ISO); O-2,4-Dichlorphenyl- O, O-diethylphosphorothioat | 202-564-5 | 97-17-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H400 H410 | |||
015-069-00-2 | Methidathion (ISO); 2,3-Dihydro-5-methoxy-2-oxo-1,3,4-thiadiazol-3-ylmethyl- O, O-dimethylphosphorodithioat | 213-449-4 | 950-37-8 | Acute Tox. 2 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H312 H400 H410 | GHS06 GHS09 Gef. | H300 H312 H410 | |||
015-070-00-8 | Cyanthoat (ISO); S-( N-(1-Cyan-1-methylethyl)carbamoylmethyl)- O, O-diethylphosphorothioat | 223-099-4 | 3734-95-0 | Acute Tox. 2 * Acute Tox. 3 * | H300 H311 | GHS06 Gef. | H300 H311 | |||
015-071-00-3 | Chlorfenvinphos (ISO); 2-Chlor-1-(2,4-dichlorphenyl)vinyldiethylphosphat | 207-432-0 | 470-90-6 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H311 H400 H410 | GHS06 GHS09 Gef. | H300 H311 H410 | |||
015-072-00-9 | Monocrotophos (ISO); Dimethyl-1-methyl-2-(methylcarbamoyl)vinylphosphat | 230-042-7 | 6923-22-4 | Muta. 2 Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H341 H330 H300 H311 H400 H410 | GHS06 GHS08 GHS09 Gef. | H341 H330 H300 H311 H410 | |||
015-073-00-4 | Dicrotophos (ISO); (Z)-2-Dimethylcarbamoyl-1-methylvinyldimethylphosphat | 205-494-3 | 141-66-2 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H311 H400 H410 | GHS06 GHS09 Gef. | H300 H311 H410 | |||
015-074-00-X | Crufomat (ISO); 4- tert-Butyl-2-chlorphenylmethylmethylphosphoramidat | 206-083-1 | 299-86-5 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
015-075-00-5 | S-2-(Isopropylsulfinyl)ethyl]- O, O-dimethylphosphorothioat | - | 2635-50-9 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | |||
015-076-00-0 | Potasan; O, O-Diethyl- O-(4-methylcumarin-7-yl)- phosphorothioat | - | 299-45-6 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H300 H410 | M = 1000 | ||
015-077-00-6 | (2,2-Dichlorvinyl)-2-ethylsulfinyl)ethyl-methylphosphat | - | 7076-53-1 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | |||
015-078-00-1 | Demeton- S-methylsulfon (ISO); S-2-Ethylsulfonylethyl- O, O-dimethylphosphorothioat | 241-109-5 | 17040-19-6 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Chronic 2 | H301 H312 H411 | GHS06 GHS09 Gef. | H301 H312 H411 | |||
015-079-00-7 | Acephat (ISO); O, S-Dimethyl-acetylphosphoramidothioat | 250-241-2 | 30560-19-1 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
015-080-00-2 | Amidithion (ISO); 2-Methoxyethylcarbamoylmethyl- O, O-dimethylphosphorodithioat | - | 919-76-6 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
015-081-00-8 | O, O,O",O"-Tetrapropyldithiopyrophosphat | 221-817-0 | 3244-90-4 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
015-082-00-3 | Azothoat (ISO); O-4-(4-Chlorphenylazo)phenyl- O, O-dimethylphosphorothioat | 227-419-3 | 5834-96-8 | Acute Tox. 4 * Acute Tox. 4 * | H332 H302 | GHS07 Achtg. | H332 H302 | |||
015-083-00-9 | Bensulid (ISO); O, O-Diisopropyl- S-2-phenylsulfonylaminoethylphosphorodithioat | 212-010-4 | 741-58-2 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
015-084-00-4 | Chlorpyrifos (ISO); O, O-Diethyl- O-3,5,6-Trichlor-2- pyridylphosphorothioat | 220-864-4 | 2921-88-2 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H400 H410 | M = 10000 | ||
015-085-00-X | Chlorphoniumchlorid (ISO); Tributyl-(2,4-dichlorbenzyl)phosphoniumchlorid | 204-105-4 | 115-78-6 | Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 | H301 H312 H319 H315 | GHS06 Gef. | H301 H312 H319 H315 | |||
015-086-00-5 | Coumithoat (ISO); O, O-Diethyl- O-7,8,9,10-tetrahydro-6-oxo-benzo(c)chromen-3-ylphosphorothioat | - | 572-48-5 | Acute Tox. 3 * | H301 | GHS06 Gef. | H301 | |||
015-087-00-0 | Cyanophos (ISO); O-4-Cyanphenyl- O, O-dimethylphosphorothioat | 220-130-3 | 2636-26-2 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
015-088-00-6 | Dialifos (ISO); S-[2-Chlor-1-phthalimidoethyl]- O, O-diethylphosphorodithioat | 233-689-3 | 10311-84-9 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H311 H400 H410 | GHS06 GHS09 Gef. | H300 H311 H400 H410 | |||
015-089-00-1 | Ethoat-methyl (ISO); Ethylcarbamoylmethyl- O, O-dimethylphosphorodithioat | 204-121-1 | 116-01-8 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
015-090-00-7 | Fensulfothion (ISO); O, O-Diethyl- O-4-methylsulfinylphenylphosphorothioat | 204-114-3 | 115-90-2 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | |||
015-091-00-2 | Fonofos (ISO); O-Ethyl -S-phenylethyl- phosphonodithioat | 213-408-0 | 944-22-9 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | |||
015-092-00-8 | Phosacetim (ISO); O, O-Bis(4-chlorphenyl)- N-acetimidoylphosphoramidothioat | 223-874-7 | 4104-14-7 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | |||
015-093-00-3 | Leptophos (ISO); O-4-Brom-2,5-dichlorphenyl- O-methylphenylphosphorothioat | 244-472-8 | 21609-90-5 | Acute Tox. 3 * STOT SE 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H370 ** H312 H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H370 ** H312 H410 | |||
015-094-00-9 | Mephosfolan (ISO); Diethyl-4-methyl-1,3-dithiolan-2-ylidenphosphoramidat | 213-447-3 | 950-10-7 | Acute Tox. 1 Acute Tox. 2 * Aquatic Chronic 2 | H310 H300 H411 | GHS06 GHS09 Gef. | H310 H300 H411 | |||
015-095-00-4 | Methamidophos (ISO); O, S-Dimethylphosphoramidothioat | 233-606-0 | 10265-92-6 | Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 | H330 H300 H311 H400 | GHS06 GHS09 Gef. | H330 H300 H311 H400 | |||
015-096-00-X | Oxydisulfoton (ISO); O, O-Diethyl- S-2-ethylsulfinylethylphosphorodithioat | 219-679-1 | 2497-07-6 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H311 H400 H410 | GHS06 GHS09 Gef. | H300 H311 H410 | M = 10 | ||
015-097-00-5 | Phenthoat (ISO); Ethyl-2-(dimethoxyphosphinothioylthio)-2-phenylacetat | 219-997-0 | 2597-03-7 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | M = 100 | ||
015-098-00-0 | Trichloronat (ISO); O-Ethyl- O-2,4,5-trichlorphenylethylphosphonothioat | 206-326-1 | 327-98-0 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H311 H400 H410 | GHS06 GHS09 Gef. | H300 H311 H410 | |||
015-099-00-6 | Pirimiphos-ethyl (ISO); O, O-Diethyl- O-2-diethylamino-6-methylpyrimidin-4-ylphosphorothioat | 245-704-0 | 23505-41-1 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H312 H400 H410 | GHS06 GHS09 Gef. | H301 H312 H410 | |||
015-100-00-X | Phoxim (ISO); α-(Diethoxyphosphinothioylimino)phenylacetonitril | 238-887-3 | 14816-18-3 | Repr. 2 Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f*** H302 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361f*** H302 H317 H410 | M=1000 | ||
015-101-00-5 | Phosmet (ISO); S-[(1,3-Dioxo-1,3-dihydro-2 H-isoindol-2-yl)methyl] O,O-Dimethyldithiophosphat; O,O-Dimethyl-S-phthalimidomethyldithiophosphat | 211-987-4 | 732-11-6 | Repr. 2 Acute Tox. 4 Acute Tox. 3 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f H332 H301 H370 (Nervensystem) H400 H410 | GHS08 GHS06 GHS09 Dgr | H361f H332 H301 H370 (Nervensystem) H410 | M = 100 M = 100 | ) | |
015-102-00-0 | Tris(2-chlorethyl)phosphat | 204-118-5 | 115-96-8 | Carc. 2 Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 | H351 H360F*** H302 H411 | GHS08 GHS07 GHS09 Gef. | H351 H360F*** H302 H411 | |||
015-103-00-6 | Phosphortribromid | 232-178-2 | 7789-60-8 | Skin Corr. 1B STOT SE 3 | H314 H335 | GHS05 GHS07 Gef. | H314 H335 | EUH014 | ||
015-104-00-1 | Diphosphorpentasulfid; Phosphorpentasulfid | 215-242-4 | 1314-80-3 | Flam. Sol. 1 Water-react. 1 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 | H228 H260 H332 H302 H400 | GHS02 GHS07 GHS09 Gef. | H228 H260 H332 H302 H400 | EUH029 | T | |
015-105-00-7 | Triphenylphosphit | 202-908-4 | 101-02-0 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H315 H410 | Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % | ||
015-106-00-2 | Hexamethylphosphorsäuretriamid; Hexamethylphosphoramid | 211-653-8 | 680-31-9 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | Carc. 1B; H350: C ≥ 0,01 % | ||
015-107-00-8 | Ethoprophos (ISO); Ethyl- S, S-dipropylphosphorodithioat | 236-152-1 | 13194-48-4 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H301 H317 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H301 H317 H410 | |||
015-108-00-3 | Bromophos (ISO); O-4-Brom-2,5-dichlorphenyl- O, O-dimethylphosphorothioat | 218-277-3 | 2104-96-3 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M = 100 | ||
015-109-00-9 | Crotoxyphos (ISO); 1-Phenylethyl-3-(dimethoxyphosphinyloxy)isocrotonat | 231-720-5 | 7700-17-6 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H410 | M = 10 | ||
015-110-00-4 | Cyanofenphos (ISO); O-4-Cyanophenyl- O-ethylphenylphosphonothioat | - | 13067-93-1 | Acute Tox. 3 * STOT SE 1 Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 2 | H301 H370 ** H312 H319 H411 | GHS06 GHS08 GHS09 Gef. | H301 H370 ** H312 H319 H411 | |||
015-111-00-X | Phosfolan (ISO); Diethyl-1,3-dithiolan-2-ylidenphosphoramidat | 213-423-2 | 947-02-4 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
015-112-00-5 | Thionazin (ISO); O, O-Diethyl- O-pyrazin-2-ylphosphorothioat | 206-049-6 | 297-97-2 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
015-113-00-0 | Tolclofos-methyl (ISO); O-(2,6-Dichlor- p-tolyl) O, O-dimethylthiophosphat | 260-515-3 | 57018-04-9 | Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 1 M = 1 | ||
015-114-00-6 | Chlormephos (ISO); S-Chlormethyl- O, O-diethylphosphorodithioat | 246-538-1 | 24934-91-6 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | M = 10 | ||
015-115-00-1 | Chlorthiophos (ISO); [Reaktionsmasse aus Isomeren, in der O-2,5-Dichlorphenyl-4-methylthiophenyl- O, O-diethylphosphorothioat überwiegt] | 244-663-6 | 21923-23-9 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H311 H400 H410 | GHS06 GHS09 Gef. | H300 H311 H410 | M = 1000 | ||
015-116-00-7 | Demephion- O (ISO); O, O-Dimethyl- O-2-methylthioethylphosphorothioat | 211-666-9 | 682-80-4 | Acute Tox. 2 * Acute Tox. 3 * | H300 H311 | GHS06 Gef. | H300 H311 | |||
015-117-00-2 | Demephion- S (ISO); O, O-Dimethyl- S-2-methylthioethylphosphorothioat | 219-971-9 | 2587-90-8 | Acute Tox. 2 * Acute Tox. 3 * | H300 H311 | GHS06 Gef. | H300 H311 | |||
015-118-00-8 | Demeton | - | 8065-48-3 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 | H310 H300 H400 | GHS06 GHS09 Gef. | H310 H300 H400 | |||
015-119-00-3 | Dimethyl-4-(methylthio)-phenylphosphat | - | 3254-63-5 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
015-120-00-9 | Ditalimfos (ISO); O, O-Diethylphthalimidophosphonothioat | 225-875-8 | 5131-24-8 | Skin Irrit. 2 Skin Sens. 1 | H315 H317 | GHS07 Achtg. | H315 H317 | |||
015-121-00-4 | Edifenphos (ISO); O-Ethyl- S, S-diphenylphosphorodithioat | 241-178-1 | 17109-49-8 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H312 H317 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H312 H317 H410 | |||
015-122-00-X | Etrimfos (ISO); O-6-Ethoxy-2-ethylpyrimidin-4- yl- O, O-dimethylphosphorothioat | 253-855-9 | 38260-54-7 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M = 10 | ||
015-123-00-5 | Fenamiphos (ISO); Ethyl-4-methylthio- m-tolylisopropylphosphoramidat | 244-848-1 | 22224-92-6 | Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H300 H310 H330 H319 H400 H410 | GHS06 GHS09 Gef. | H300 H310 H330 H319 H410 | M = 100 M = 100 | ||
015-124-00-0 | Fosthietan (ISO); Diethyl-1,3-dithietan-2-ylidenphosphoramidat | 244-437-7 | 21548-32-3 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
015-125-00-6 | Glyphosin (ISO); N, N-Bis(phosphonomethyl)-glycin | 219-468-4 | 2439-99-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
015-126-00-1 | Heptenophos (ISO); 7-Chlorbicyclo(3.2.0)-hepta-2,6-dien-6-yldimethylphosphat | 245-737-0 | 23560-59-0 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H410 | M = 100 | ||
015-127-00-7 | Iprobenfos (ISO); S-Benzyldiisopropylphosphorothioat | 247-449-0 | 26087-47-8 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
015-128-00-2 | IPSP; S-Ethylsulfinylmethyl- O, O-diisopropylphosphorodithioat | - | 5827-05-4 | Acute Tox. 1 Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H301 H400 H410 | GHS06 GHS09 Gef. | H310 H301 H410 | M = 100 | ||
015-129-00-8 | Isofenphos (ISO); O-Ethyl-O-2-isopropoxycarbonylphenyl- N-isopropylphosphoramidothioat | 246-814-1 | 25311-71-1 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H410 | M = 100 | ||
015-130-00-3 | Isothioat (ISO); S-2-Isopropylthioethyl- O, O-dimethylphosphorodithioat | - | 36614-38-7 | Acute Tox. 3 * Acute Tox. 3 * | H311 H301 | GHS06 Gef. | H311 H301 | |||
015-131-00-9 | Isoxathion (ISO); O, O-Diethyl- O-5-phenylisoxazol-3-ylphosphorothioat | 242-624-8 | 18854-01-8 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H410 | |||
015-132-00-4 | S-(Chlorphenylthiomethyl)-O, O-dimethylphosphorodithioat; Methylcarbophenothion | - | 953-17-3 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H410 | M = 1000 | ||
015-133-00-X | Piperophos (ISO); S-2-Methylpiperidincarbonylmethyl- O, O-dipropyldphosphorodithioat | - | 24151-93-7 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M = 10 | ||
015-134-00-5 | Pirimiphos-methyl (ISO); O-[2-(Diethylamino)-6-methylpyrimidin-4-yl] O, O-dimethyl phosphorthioat | 249-528-5 | 29232-93-7 | Acute Tox. 4 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H372 (Nervensystem) H400 H410 | GHS07 GHS08 GHS09 Dgr | H302 H372 (Nervensystem) H410 | oral:
ATE = 1414 mg/kg KG M = 1000 M = 1000 | ||
015-135-00-0 | Profenofos (ISO); O-(4-Brom-2-chlorphenyl)- O-ethyl- S-propylphosphorothioat | 255-255-2 | 41198-08-7 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | M = 1000 | ||
015-136-00-6 | Propetamphos (ISO); Isopropyl-3-[[(ethylamino)methoxyphosphinothioyl]oxy]crotonat; Isopropyl-3-[[(ethylamino)methoxyphosphinothioyl]oxy]crotonat; | 250-517-2 | 31218-83-4 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H410 | M = 100 | ||
015-137-00-1 | Pyrazophos (ISO); O, O-Diethyl- O-(6-ethoxycarbonyl-5-methylpyrazolo[2,3-a]-pyrimidin-2-yl)thiophosphat; phosphorothioat O, O-Diethyl-O-(6-ethoxycarbonyl-5- methylpyrazolo[2,3-a]pyrimidin-2- yl)thiophosphat | 236-656-1 | 13457-18-6 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H302 H410 | |||
015-138-00-7 | Quinalphos (ISO); O, O-Diethyl- O-chinoxalin-2-ylphosphorothioat | 237-031-6 | 13593-03-8 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H312 H400 H410 | GHS06 GHS09 Gef. | H301 H312 H410 | M = 1000 | ||
015-139-00-2 | Terbufos (ISO); S-tert-Butylthiomethyl- O, O-diethylphosphorodithioat | 235-963-8 | 13071-79-9 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | M = 1000 | ||
015-140-00-8 | Triazophos (ISO); O, O-Diethyl- O-(1-phenyl-1 H-1,2,4-triazol-3-yl)phosphorothioat | 245-986-5 | 24017-47-8 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H312 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H312 H410 | M=100 | ||
015-141-00-3 | Ethylendiammonium- O, O-bis(octyl)phosphorodithioat, Isomerengemisch | 400-520-1 | - | Skin Corr. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H314 H302 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H302 H410 | |||
015-142-00-9 | Butyl(dialkyloxy(dibutoxyphosphoryloxy))titan(trialkyloxy)titanphosphat | 401-100-0 | - | Flam. Liq. 2 Eye Irrit. 2 Aquatic Chronic 2 | H225 H319 H411 | GHS02 GHS07 GHS09 Gef. | H225 H319 H411 | T | ||
015-143-00-4 | Reaktionsmasse aus 2-Chlorethylchlorpropyl-2-chlorethylphosphonat, Reaktionsmasse aus Isomeren und 2-Chlorethylchlorpropyl-2-chlorpropylphosphonat, Reaktionsmasse aus Isomeren | 401-740-0 | - | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
015-144-00-X | Reaktionsmasse aus Pentylmethylphosphinat und 2-Methylbutylmethylphosphinat | 402-090-0 | 87025-52-3 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
015-145-00-5 | Reaktionsmasse aus Kupfer(I)- O, O-diisopropylphosphorodithioat und Kupfer(I)- O-isopropyl- O-(4-methylpent-2-yl) phosphorodithioat und Kupfer(I)- O, O-bis(4-methylpent-2-yl)phosphorodithioat | 401-520-4 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
015-146-00-0 | S-(Tricyclo(5.2.1.02,6)deca-3-en- 8(oder 9)-yl- O-(isopropyl oder isobutyl oder 2-ethylhexyl)- O-(isopropyl oder isobutyl oder 2-ethylhexyl)phosphorodithioat | 401-850-9 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
015-147-00-6 | Reaktionsmasse aus C12-14- tert-Alkylammoniumdiphenylphosphorothioat und Dinonylsulfid (oder -disulfid) | 400-930-0 | - | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H315 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H411 | |||
015-148-00-1 | 2-(Diphosphonomethyl)bernsteinsäure | 403-070-4 | 51395-42-7 | Skin Corr. 1B Skin Sens. 1 | H314 H317 | GHS05 GHS07 Gef. | H314 H317 | |||
015-149-00-7 | Reaktionsmasse aus Hexyldioctylphosphinoxid; Dihexyloctylphosphinoxid; Trioctylphosphinoxid | 403-470-9 | - | Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Gef. | H314 H410 | |||
015-150-00-2 | (2-(1,3-Dioxolan-2-yl)ethyl)triphenylphosphoniumbromid | 404-940-6 | 86608-70-0 | Acute Tox. 4 * Eye Dam. 1 STOT RE 2 * Aquatic Chronic 3 | H302 H318 H373 ** H412 | GHS08 GHS05 GHS07 Gef. | H302 H318 H373 ** H412 | |||
015-151-00-8 | Tris(isopropyl/ tert-butylphenyl) phosphat | 405-010-2 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
015-152-00-3 | Dioxabenzofos (ISO); 2-Methoxy-4 H-1,3,2-benzodioxaphosphorin-2-sulfid | 223-292-3 | 3811-49-2 | Acute Tox. 3 * Acute Tox. 3 * STOT SE 1 Aquatic Chronic 2 | H311 H301 H370 ** H411 | GHS06 GHS08 GHS09 Gef. | H311 H301 H370 ** H411 | |||
015-153-00-9 | Isazofos (ISO); O-(5-Chlor-1-isopropyl-1,2,4-triazol-3-yl)- O, O-diethylphosphorothioat | 255-863-8 | 42509-80-8 | Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H311 H301 H373 ** H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H311 H301 H373 ** H317 H410 | |||
015-154-00-4 | Ethephon; 2-Chlorethylphosphonsäure | 240-718-3 | 16672-87-0 | Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 Skin Corr. 1C Aquatic Chronic 2 | H311 H332 H302 H314 H411 | GHS06 GHS05 GHS09 Gef. | H311 H332 H302 H314 H411 | EUH071 | ||
015-155-00-X | Glufosinat-Ammonium (ISO); Ammonium-2-amino-4-(hydroxymethylphosphinyl)butyrat | 278-636-5 | 77182-82-2 | Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * | H360Fd H332 H312 H302 H373** | GHS08 GHS07 Gef. | H360Fd H332 H312 H302 H373** | |||
015-156-00-5 | Methyl-3-[(dimethoxyphosphinothioyl)oxy]methacrylate [1]; Methacrifos (ISO); Methyl-( E)-3-[(dimethoxyphosphinothioyl)oxy]methacrylat [2] | 250-366-9 [1]- [2] | 30864-28-9 [1] 62610-77-9 [2] | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
015-157-00-0 | Phosphonsäure [1]; Phosphorige Säure [2] | 237-066-7 [1] 233-663-1 [2] | 13598-36-2 [1] 10294-56-1 [2] | Acute Tox. 4 * Skin Corr. 1A | H302 H314 | GHS05 GHS07 Gef. | H302 H314 | |||
015-158-00-6 | (η-Cyclopentadienyl)(η-cumenyl)eisen(1+)hexafluorphosphat(1-) | 402-340-9 | 32760-80-8 | Aquatic Chronic 3 | H412 | - | H412 | |||
015-159-00-1 | Hydroxyphosphonessigsäure | 405-710-8 | 23783-26-8 | Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 | H302 H373 ** H314 H317 | GHS08 GHS05 GHS07 Gef. | H302 H373 ** H314 H317 | |||
015-160-00-7 | Vanadylpyrophosphat | 406-260-5 | 58834-75-6 | Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H319 H317 H412 | GHS07 Achtg. | H319 H317 H412 | |||
015-161-00-2 | Divanadylpyrophosphat | 407-130-0 | 65232-89-5 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | |||
015-162-00-8 | Vanadium(IV)oxidhydrogenphosphat-Hemihydrat, lithium-, zink-, molybdän-, eisen- und chlordotiert | 407-350-7 | - | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 | H332 H373 ** H318 H411 | GHS08 GHS05 GHS07 GHS09 Gef. | H332 H373 ** H318 H411 | |||
015-163-00-3 | Bis(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentylphosphinoxid | 412-010-6 | 145052-34-2 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
015-164-00-9 | Calcium- P, P"-(1-hydroxyethylen)-bis(hydrogenphosphonat)-dihydrat | 400-480-5 | 36669-85-9 | Aquatic Chronic 3 | H412 | - | H412 | |||
015-165-00-4 | Reaktionsmasse aus Thiobis(4,1-phenylen)- S, S,S",S"-tetraphenyldisulfoniumbishexafluorphosphat und Diphenyl(4-phenylthiophenyl)sulfoniumhexafluorphosphat | 404-986-7 | - | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
015-166-00-X | 3,9-Bis(2,6-di- tert-butyl-4-methylphenoxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecan | 410-290-4 | 80693-00-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
015-167-00-5 | 3-(Hydroxyphenylphosphinyl)propansäure | 411-200-6 | 14657-64-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
015-168-00-0 | Fosthiazate (ISO); (RS)- S-sec-Butyl- O-ethyl-2-oxo- 1,3-thiazolidin-3-ylphosphonothioat | - | 98886-44-3 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H312 H317 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H312 H317 H410 | EUH070 | ||
015-169-00-6 | Tributyltetradecylphosphoniumtetrafluorborat | 413-520-1 | - | Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H314 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H302 H373 ** H314 H317 H410 | |||
015-170-00-1 | Reaktionsmasse aus Di-(1-octyl- N, N,N-trimethylammonium)octylphosphat; 1-Octyl- N, N,N-trimethylammoniumdioctylphosphat und 1-Octyl- N, N,N-trimethylammoniumoctylphosphat | 407-490-9 | - | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | |||
015-171-00-7 | O, O,O-Tris(2(oder 4)-C9-10-isoalkylphenyl) phosphorothioat | 406-940-1 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
015-172-00-2 | Reaktionsmasse aus Bis(isotridecylammonium)mono(di-(4-methylpent-2-yloxy)thiophosphorothionylisopropyl)phosphat und Isotridecylammoniumbis(di-(4-methylpent-2-yloxy)thiophosphorothionylisopropyl)phosphat | 406-240-6 | - | Flam. Liq. 3 Skin Corr. 1B Aquatic Chronic 2 | H226 H314 H411 | GHS02 GHS05 GHS09 Gef. | H226 H314 H411 | |||
015-173-00-8 | Methyl[2-(1,1-dimethylethyl)-6- methoxypyrimidin-4-yl]ethylphosphonothioat | 414-080-3 | 117291-73-3 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
015-174-00-3 | 1-Chlor- N, N-diethyl-1,1-diphenyl-1-(phenylmethyl)phosphoramin | 411-370-1 | 82857-68-9 | Acute Tox. 3 * Eye Dam. 1 Aquatic Chronic 2 | H301 H318 H411 | GHS06 GHS05 GHS09 Gef. | H301 H318 H411 | |||
015-175-00-9 | tert-Butyl-(triphenylphosphoranyliden)acetat | 412-880-7 | 35000-38-5 | Acute Tox. 3 * STOT RE 2 * Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H301 H373 ** H319 H317 H411 | GHS06 GHS08 GHS09 Gef. | H301 H373 ** H319 H317 H411 | |||
015-176-00-4 | 1,3-Bis-(di- ortho-methoxyphenylphosphino)propan; P, P,P",P"-Tetrakis-(o-methoxyphenyl)- propan-1,3-diphosphin | 413-430-2 | 116163-96-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
015-177-00-X | ((4-Phenylbutyl)hydroxyphosphoryl)essigsäure | 412-170-7 | 83623-61-4 | STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H373 ** H318 H317 | GHS08 GHS05 Gef. | H373 ** H318 H317 | |||
015-178-00-5 | (R)-α-Phenylethylammonium-(-)-(1 R,2 S)-(1,2-epoxypropyl)phosphonatmonohydrat | 418-570-8 | 25383-07-7 | Repr. 2 Aquatic Chronic 2 | H361f *** H411 | GHS08 GHS09 Achtg. | H361f *** H411 | |||
015-179-00-0 | UVCB-Kondensationsprodukt aus Tetrakis(hydroxymethyl)phosphoniumchlorid mit Harnstoff und destilliertem hydriertem C16-18-Talgalkylamin | 422-720-8 | 166242-53-1 | Carc. 2 Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H373 ** H314 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H351 H302 H373 ** H314 H317 H410 | |||
015-180-00-6 | [R-(R*,S*)]-[[2-Methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphinyl]essigsäure, (-)-Cinchonidin (1:1)-Salz | 415-820-8 | 137590-32-0 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
015-181-00-1 | Phosphin | 232-260-8 | 7803-51-2 | Flam. Gas 1 Press. Gas Acute Tox. 1 Skin Corr. 1B Aquatic Acute 1 | H220 H330 H314 H400 | GHS02 GHS04 GHS06 GHS05 GHS09 Dgr | H220 H330 H314 H400 | Einatmen: ATE = 10 ppmV (Gase) | U | |
015-182-00-7 | Tetrapropan-2-yl (dichlormethandiyl)bisphosphonat | 430-630-5 | 10596-22-2 | Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 | H302 H319 H317 | GHS07 Achtg. | H302 H319 H317 | |||
015-183-00-2 | (1-Hydroxydodecyliden)diphosphonsäure | 425-230-2 | 16610-63-2 | Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Gef. | H314 H410 | |||
015-184-00-8 | Salze von Glyphosat, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | A | ||
015-186-00-9 | Chlorpyrifos-methyl (ISO); O, O-Dimethyl- O-3,5,6-trichlor- 2-pyridylphosphorothioat | 227-011-5 | 5598-13-0 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | M = 10000 | ||
015-187-00-4 | Reaktionsmasse aus Tetranatrium-(((2-hydroxyethyl)-imino)bis(methylen))bisphosphonat, N-oxid; Trinatrium-((tetrahydro-2-hydroxy-4 H-1,4,2-oxazaphosphorin-4-yl)methyl)-phosphonate, N-Oxid, P-Oxid | 417-540-1 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
015-189-00-5 | Phenylbis(2,4,6-trimethylbenzoyl)phosphinoxid | 423-340-5 | 162881-26-7 | Skin Sens. 1A Aquatic Chronic 4 | H317 H413 | GHS07 Wng | H317 H413 | |||
015-190-00-0 | Bis(2,4-dicumylphenyl)neopentyldiphosphit; 3,9-Bis[2,4-bis(1-methyl-1-phenylethyl)-phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecan | 421-920-2 | 154862-43-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
015-191-00-6 | Dodecyldiphenylphosphat | 431-760-5 | 27460-02-2 | Skin Irrit. 2 Aquatic Chronic 3 | H315 H412 | GHS07 Achtg. | H315 H412 | |||
| - gestrichen - | |||||||||
015-193-00-7 | Triphenyl(phenylmethyl)phosphonium-1,1,2,2,3,3,4,4,4-nonafluor- N-methyl-1-butansulfonamid (1:1) | 442-960-7 | 332350-93-3 | Acute Tox. 3 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H318 H400 H410 | GHS05 GHS06 GHS09 Gef. | H301 H318 H410 | |||
015-194-00-2 | Tetrabutylphosphoniumnonafluorbutan-1-sulfonat | 444-440-5 | 220689-12-3 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
015-195-00-8 | Reaktionsmasse aus Kalium- o-toluolphosphonat, Kalium- m-toluolphosphonat und Kalium- p-toluolphosphonat | 433-860-4 | - | Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H319 H317 H412 | GHS07 Achtg. | H319 H317 H412 | |||
015-196-00-3 | Reaktionsmasse aus Dimethyl-(2-(hydroxymethylcarbamoyl)ethyl)phosphonat, Diethyl(2-(hydroxymethylcarbamoyl)ethyl)phosphonat und Methylethyl(2-(hydroxymethyl-carbamoyl)ethyl)phosphonat | 435-960-3 | - | Carc. 1B Muta. 1B Skin Sens. 1 | H350 H340 H317 | GHS08 GHS07 Gef. | H350 H340 H317 | |||
015-197-00-9 | Bis(2,4,4-trimethylpentyl)dithiophosphonsäure | 420-160-9 | 107667-02-7 | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 | H226 H331 H302 H314 H411 | GHS02 GHS06 GHS05 GHS09 Gef. | H226 H331 H302 H314 H411 | |||
015-198-00-4 | (4-Phenylbutyl)phosphinsäure | 420-450-5 | 86552-32-1 | Carc. 2 Eye Dam. 1 | H351 H318 | GHS05 GHS08 Gef. | H351 H318 | |||
015-199-00-X | Tris[2-chlor-1-chlormethyl)-ethyl]phosphat | 237-159-2 | 13674-87-8 | Carc. 2 | H351 | GSH08 Achtg. | H351 | |||
015-200-00-3 | Indiumphosphid | 244-959-5 | 22398-80-7 | Carc. 1B Repr. 2 STOT RE 1 | H350 H361f H372 (Lunge) | GHS08 Gef. | H350 H361f H372 (Lunge) | STOT RE 1; H372: C ≥0,1 % Carc 1B; H350: C ≥0,01 % STOT RE 2; H373: 0,01 % ≤ C < 0,1 % | ||
015-201-00-9 | Trixylylphosphat | 246-677-8 | 25155-23-1 | Repr. 1B | H360F | GHS08 Gef. | H360F | |||
015-202-00-4 | Tris(nonylphenyl)phosphit | 247-759-6 | 26523-78-4 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
015-203-00-X | Diphenyl(2,4,6-trimethylbenzoyl)phosphinoxid | 278-355-8 | 75980-60-8 | Repr. 2 | H361f (verursacht Hodenatrophie) | GHS08 Achtg. | H361f (verursacht Hodenatrophie) | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
015-203-00-X | Diphenyl(2,4,6-trimethylbenzoyl)phosphinoxid | 278-355-8 | 75980-60-8 | Repr. 1B Skin Sens. 1B | H360Fd H317 | GHS08 GHS07 Dgr | H360Fd H317 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
015-204-00-5 | Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluor-2-(4-hydroxyphenyl)propan-2-yl]phenolat | 479-100-5 | 577705-90-9 | Repr. 1B | H360F | GHS08 Dgr | H360F | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
015-205-00-0 | Benzyltriphenylphosphonium, Salz mit 4,4"-[2,2,2-Trifluor-1-(trifluormethyl)ethyliden]bis[phenol] (1:1) | 278-305-5 | 75768-65-9 | Repr. 1B | H360F | GHS08 Dgr | H360F | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
015-206-00-6 | Reaktionsmasse aus 4,4"-[2,2,2-Trifluor-1-(trifluormethyl)ethyliden]diphenol und Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluor-2-(4-hydroxyphenyl)propan-2-yl]phenolat (1:1) | - | - | Repr. 1B | H360F | GHS08 Dgr | H360F" | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
015-207-00-1 | Reaktionsmasse aus 4,4"-[2,2,2-Trifluor-1-(trifluormethyl)ethyliden]diphenol und Benzyltriphenylphosphonium, Salz mit 4"4"-[2,2,2-Trifluor-1-(trifluormethyl)ethyliden]diphenol (1:1) | - | - | Repr. 1B | H360F | GHS08 Dgr | H360F | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
015-208-00-7 | Dimethylpropylphosphonat | 242-555-3 | 18755-43-6 | Muta. 1B Repr. 1B | H340 H360Df | GHS08 Dgr | H340 H360Df | ) | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
016-001-00-4 | Schwefelwasserstoff | 231-977-3 | 7783-06-4 | Flam. Gas 1 Press. Gas Acute Tox. 2 * Aquatic Acute 1 | H220 H330 H400 | GHS02 GHS04 GHS06 GHS09 Gef. | H220 H330 H400 | U) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
016-001-00-4 | Schwefelwasserstoff | 231-977-3 | 7783-06-4 | Flam. Gas 1A Press. Gas Acute Tox. 2 Aquatic Acute 1 | H220 H330 H400 | GHS02 GHS06 GHS09 Dgr | H220 H330 H400 | Inhalation: ATE = 440 ppmV (Gase) |
U) | |
016-002-00-X | Bariumsulfid | 244-214-4 | 21109-95-5 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 | H332 H302 H400 | GHS07 GHS09 Achtg. | H332 H302 H400 | EUH031 | ||
016-003-00-5 | Bariumpolysulfide | 256-814-3 | 50864-67-0 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 | H319 H335 H315 H400 | GHS07 GHS09 Achtg. | H319 H335 H315 H400 | EUH031 | ||
016-004-00-0 | Calciumsulfid | 243-873-5 | 20548-54-3 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 | H319 H335 H315 H400 | GHS07 GHS09 Achtg. | H319 H335 H315 H400 | EUH031 | ||
016-005-00-6 | Calciumpolysulfide | 215-709-2 | 1344-81-6 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 | H319 H335 H315 H400 | GHS07 GHS09 Achtg. | H319 H335 H315 H400 | EUH031 | ||
016-006-00-1 | Dikaliumsulfid; Kaliumsulfid | 215-197-0 | 1312-73-8 | Skin Corr. 1B Aquatic Acute 1 | H314 H400 | GHS05 GHS09 Gef. | H314 H400 | EUH031 | ||
016-007-00-7 | Kaliumpolysulfide | 253-390-1 | 37199-66-9 | Skin Corr. 1B Aquatic Acute 1 | H314 H400 | GHS05 GHS09 Gef. | H314 H400 | EUH031 | ||
016-008-00-2 | Ammoniumpolysulfide | 232-989-1 | 9080-17-5 | Skin Corr. 1B Aquatic Acute 1 | H314 H400 | GHS05 GHS09 Gef. | H314 H400 | EUH031 | EUH031: C ≥ 1 % | |
016-009-00-8 | Dinatriumsulfid; Natriumsulfid | 215-211-5 | 1313-82-2 | Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 | H311 H302 H314 H400 | GHS06 GHS05 GHS09 Gef. | H311 H302 H314 H400 | |||
016-010-00-3 | Natriumpolysulfide; | 215-686-9 | 1344-08-7 | Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 | H301 H314 H400 | GHS06 GHS05 GHS09 Gef. | H301 H314 H400 | EUH031 | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
016-011-00-9 | Schwefeldioxid | 231-195-2 | 7446-09-5 | Press.
Gas Acute Tox. 3 * Skin Corr. 1B | H331 H314 | GHS04 GHS06 GHS05 Gef. | H331 H314 | * | U5) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
016-011-00-9 | Schwefeldioxid | 231-195-2 | 7446-09-5 | Press.
Gas Acute Tox. 3 STOT SE 1 Skin. Corr. 1B | H331 H370 (Atmungsorgane) (Inhalation) H314 | GHS04 GHS06 GHS08 GHS05 Dgr | H331 H370 (Atmungsorgane) (Inhalation) H314 | Inhalation: ATE = 1.000 ppmV (Gase) |
U, 5) | |
016-012-00-4 | Dischwefeldichlorid; Schwefelmonochlorid | 233-036-2 | 10025-67-9 | Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 | H301 H332 H314 H400 | GHS06 GHS05 GHS09 Gef. | H301 H332 H314 H400 | EUH014 EUH029 | STOT SE 3; H335: C ≥ 1 % | |
016-013-00-X | Schwefeldichlorid | 234-129-0 | 10545-99-0 | Skin Corr. 1B STOT SE 3 Aquatic Acute 1 | H314 H335 H400 | GHS05 GHS07 GHS09 Gef. | H314 H335 H400 | EUH014 | STOT SE 3; H335: C ≥ 5 % | |
016-014-00-5 | Schwefeltetrachlorid | - | 13451-08-6 | Skin Corr. 1B Aquatic Acute 1 | H314 H400 | GHS05 GHS09 Gef. | H314 H400 | EUH014 | STOT SE 3; H335: C ≥ 5 % | |
016-015-00-0 | Thionyldichlorid; Thionylchlorid | 231-748-8 | 7719-09-7 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H332 H302 H314 | GHS05 GHS07 Gef. | H332 H302 H314 | EUH014 EUH029 | STOT SE 3; H335: C ≥ 1 % | |
016-016-00-6 | Sulfurylchlorid | 232-245-6 | 7791-25-5 | Skin Corr. 1B STOT SE 3 | H314 H335 | GHS05 GHS07 Gef. | H314 H335 | EUH014 | ||
016-017-00-1 | Chlorschwefelsäure; Chlorsulfonsäure | 232-234-6 | 7790-94-5 | Skin Corr. 1A STOT SE 3 | H314 H335 | GHS05 GHS07 Gef. | H314 H335 | EUH014 | ||
016-018-00-7 | Fluorsulfonsäure | 232-149-4 | 7789-21-1 | Acute Tox. 4 * Skin Corr. 1A | H332 H314 | GHS05 GHS07 Gef. | H332 H314 | |||
016-019-00-2 | Oleum ... % SO3 | - | - | Skin Corr. 1A STOT SE 3 | H314 H335 | GHS05 GHS07 Gef. | H314 H335 | EUH014 | B | |
016-020-00-8 | Schwefelsäure ... % | 231-639-5 | 7664-93-9 | Skin Corr. 1A | H314 | GHS05 Gef. | H314 | Skin Corr. 1A; H314: C ≥ 15 % Skin Irrit. 2; H315: 5 % ≤ C < 15 % Eye Irrit. 2; H319: 5 % ≤ C < 15 % | B | |
016-021-00-3 | Methanthiol; Methylmercaptan | 200-822-1 | 74-93-1 | Flam. Gas. 1 Press. Gas Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H220 H331 H400 H410 | GHS02 GHS04 GHS06 GHS09 Gef. | H220 H331 H410 | U | ||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
016-022-00-9 | Ethanethiol; Ethylmercaptan | 200-837-3 | 75-08-1 | Flam. Liq. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H225 H332 H400 H410 | GHS02 GHS07 GHS09 Gef. | H225 H332 H410 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
016-022-00-9 | Ethanethiol; Ethylmercaptan | 200-837-3 | 75-08-1 | Flam. Liq. 1 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H224 H331 H302 H400 H410 | GHS02 GHS06 GHS09 Dgr | H224 H331 H302 H410 | Einatmung:
ATE = 7,1 mg/L (Dämpfe) Oral: ATE = 680 mg/kg KG | ) | |
016-023-00-4 | Dimethylsulfat | 201-058-1 | 77-78-1 | Carc. 1B Muta. 2 Acute Tox. 2 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 | H350 H341 H330 H301 H314 H317 | GHS06 GHS08 GHS05 Gef. | H350 H341 H330 H301 H314 H317 | Carc. 1B; H350: C ≥ 0,01 % Muta. 2 H341: C ≥ 0,01 % STOT SE 3; H335: C ≥ 5 % | ||
016-024-00-X | Dimexano (ISO); Bis(methoxythiocarbonyl)disulfide; O, O-Dimethyldithiobis(thioformiat) | 215-993-8 | 1468-37-7 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
016-025-00-5 | Disul (ISO); 2-(2,4-Dichlorphenoxy)ethylhydrogensulfat; 2,4-DES | 205-259-5 | 149-26-8 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 | H302 H315 H318 | GHS05 GHS07 Gef. | H302 H315 H318 | |||
016-026-00-0 | Sulfamidsäure; Sulfaminsäure; AmidosulfonsäureSulfamsäure | 226-218-8 | 5329-14-6 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3 | H319 H315 H412 | GHS07 Achtg. | H319 H315 H412 | |||
016-027-00-6 | Diethylsulfat | 200-589-6 | 64-67-5 | Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H350 H340 H332 H312 H302 H314 | GHS05 GHS08 GHS07 Gef. | H350 H340 H332 H312 H302 H314 | |||
016-028-00-1 | Natriumdithionit; Natriumhydrosulfit | 231-890-0 | 7775-14-6 | Self-heat. 1 Acute Tox. 4 * | H251 H302 | GHS02 GHS07 Gef. | H251 H302 | EUH031 | ||
016-029-00-7 | p-Toluolsulfonsäure (mit mehr als 5 % H2SO4) | - | - | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % | ||
016-030-00-2 | p-Toluolsulfonsäure (mit höchstens 5 % H2SO4) | 203-180-0 | 104-15-4 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | STOT SE 3; H335: C ≥ 20 % | ||
016-031-00-8 | Tetrahydrothiophen-1,1-dioxid; Sulfolan | 204-783-1 | 126-33-0 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
016-032-00-3 | 1,3-Propansulton; 1,2-Oxathiolan-2,2-dioxid | 214-317-9 | 1120-71-4 | Carc. 1B Acute Tox. 4 * Acute Tox. 4 * | H350 H312 H302 | GHS08 GHS07 Gef. | H350 H312 H302 | Carc. 1B; H350: C ≥ 0,01 % | ||
016-033-00-9 | Dimethylsulfamoylchlorid | 236-412-4 | 13360-57-1 | Carc. 1B Acute Tox. 2 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H350 H330 H312 H302 H314 | GHS06 GHS05 GHS08 Gef. | H350 H330 H312 H302 H314 | |||
016-034-00-4 | Tetranatrium-3,3"-(piperazin-1,4-diylbis((6-chlor-1,3,5-triazin-2,4-diyl)imino(2-acetamido)-4,1-phenylenazo))bis(naphthalin-1,5-disulfonat) | 400-010-9 | 81898-60-4 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
016-035-00-X | Pentanatrium-5-anilino-3-(4-(4-(6-chlor-4-(3-sulfonatoanilino)-1,3,5-triazin-2-ylamino)-2,5-dimethylphenylazo)-2,5-disulfonatophenylazo)-4-hydroxynaphthalin-2,7-disulfonat | 400-120-7 | - | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
016-036-00-5 | Tetranatrium-5-(4,6-dichlor-5-cyanpyrimidin-2-ylamino)-4-hydroxy-2,3-azodinaphthalin-1,2,5,7-disulfonat | 400-130-1 | - | Resp. Sens. 1 Aquatic Chronic 2 | H334 H411 | GHS08 GHS09 Gef. | H334 H411 | |||
016-037-00-0 | Dinatrium-1-amino-4-(4-benzolsulfonamido-3-sulfonatoanilino)anthrachinon-2- sulfonat | 400-350-8 | 85153-93-1 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
016-038-00-6 | Dinatrium-6-((4-chlor-6-( N-methyl)-2-toluidino)-1,3,5-triazin-2-ylamino)-1-hydroxy-2- (4-methoxy-2-sulfonatophenylazo)naphthalin-3-sulfonat | 400-380-1 | 86393-35-3 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
016-039-00-1 | Tetranatrium-2-(6-chlor-4-(4-(2,5-dimethyl-4-(2,5-disulfonatophenylazo)phenylazo)-3-ureidoanilino)-1,3,5-triazin-2-ylamino)-benzol-1,4-disulfonat | 400-430-2 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
016-040-00-7 | Reaktionsmasse aus Dinatrium-6-(2,4-dihydroxyphenylazo)-3-(4-(4-(2,4-dihydroxyphenylazo)anilino)-3-sulfonatophenylazo)-4-hydroxynaphthalin-2-sulfonat und Dinatrium-6-(2,4-diaminophenylazo)-3-(4-(4-(2,4-diaminophenylazo)anilino)-3-sulfonatophenylazo)-4-hydroxynaphthalin-2-sulfonat und Trinatrium-6-(2,4-dihydroxyphenylazo)-3-(4-(4-(7-(2,4-dihydroxyphenylazo)-1-hydroxy-3-sulfonato-2-naphthylazo)anilino)-3-sulfonatophenylazo)-4-hydroxynaphthalin-2-sulfonat | 400-570-4 | - | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
016-041-00-2 | Calcium-2,5-dichlor-4-(4-((5-chlor-4-methyl-2-sulfonatophenyl)azo)-5-hydroxy-3-methylpyrazol-1-yl)benzolsulfonat | 400-710-4 | - | Acute Tox. 4 * | H332 | GHS07 Achtg. | H332 | |||
016-042-00-8 | Tetranatrium-5-benzamido-3-(5- (4-fluor-6-(1-sulfonato-2-naphthylamino)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-4-hydroxynaphthalin-2,7-disulfonat | 400-790-0 | 85665-97-0 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | |||
016-043-00-3 | Dilithium-6-acetamido-4-hydroxy-3-(4-((2-sulfonatooxy)-ethylsulfonyl)phenylazo)-naphthalin-2-sulfonat | 401-010-1 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
016-044-00-9 | Dinatrium- S, S-hexan-1,6-diyldi(thiosulfat)dihydrat | 401-320-7 | - | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
016-045-00-4 | Lithiumnatriumhydrogen-4-amino-6-(5-(5-chlor-2,6-difluorpyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo)naphthalin-2,7-disulfonat | 401-560-2 | 108624-00-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
016-046-00-X | Natriumhydrogensulfat | 231-665-7 | 7681-38-1 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
016-047-00-5 | Hexanatrium-7-(4-(4-(4-(2,5-disulfonatoanilino)-6-fluor-1,3,5-triazin-2-ylamino)-2-methylphenylazo)-7-sulfonatonaphthylazo)naphthalin-1,3,5-trisulfonat | 401-650-1 | 85665-96-9 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
016-048-00-0 | Natrium-3,5-dichlor-2-(5-cyan-2,6-bis(3-hydroxypropylamino)-4-methylpyridin-3-ylazo)benzolsulfonat | 401-870-8 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
016-049-00-6 | Calciumoctadecylxylolsulfonat | 402-040-8 | - | Skin Corr. 1B Aquatic Chronic 2 | H314 H411 | GHS05 GHS09 Gef. | H314 H411 | |||
016-050-00-1 | Kaliumnatrium-5-(4-chlor-6-( N-(4-(4-chlor-6-(5-hydroxy-2,7-disulfonato-6-(2-sulfonatophenylazo)-4-naphthylamino)-1,3,5-triazin-2-ylamino)phenyl- N-methyl)-amino)-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(2-sulfonatophenylazo)-naphthalin-2,7-disulfonat | 402-150-6 | - | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
016-051-00-7 | Trinatrium-7-(4-(6-fluor-4-(2-(2-vinylsulfonylethoxy)-ethylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)-naphthalin-1,3,6-trisulfonat | 402-170-5 | 106359-91-5 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
016-052-00-2 | Benzyltributylammonium-4-hydroxynaphthalin-1-sulfonat | 402-240-5 | 102561-46-6 | Acute Tox. 4 * Aquatic Chronic 2 | H332 H411 | GHS07 GHS09 Achtg. | H332 H411 | |||
016-053-00-8 | (C16- oder C18- n-Alkyl)(C16- oder C18- n-Alkyl)ammonium-2-((C16- oder C18- n-Alkyl)(C16- oder C18- n-Alkyl)carbamoyl)benzolsulfonat | 402-460-1 | - | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 | H315 H317 H413 | GHS07 Achtg. | H315 H317 H413 | |||
016-054-00-3 | Natrium-4-(2,4,4-trimethylpentylcarbonyloxy)benzolsulfonat | 400-030-8 | - | Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Sens. 1 | H331 H372 ** H302 H319 H335 H317 | GHS06 GHS08 Gef. | H331 H372 ** H302 H319 H335 H317 | |||
016-055-00-9 | Tetranatrium-4-amino-3,6-bis(5-(6-chlor-4-(2-hydroxyethylamino)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxynaphthalin-2,7-sulfonat (mit > 35 %Natriumchlorid und Natriumacetat) | 400-510-7 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
016-056-00-4 | Kaliumhydrogensulfat | 231-594-1 | 7646-93-7 | Skin Corr. 1B STOT SE 3 | H314 H335 | GHS05 GHS07 Gef. | H314 H335 | |||
016-057-00-X | Styrol-4-sulfonylchlorid | 404-770-2 | 2633-67-2 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H315 H318 H317 | GHS05 GHS07 Gef. | H315 H318 H317 | |||
016-058-00-5 | Thionylchlorid, Reaktionsprodukte mit 1,3,4-Thiadiazol-2,5-dithiol, tert-Nonanthiol und C12-14- tert-Alkylamin | 404-820-3 | - | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H315 H317 H412 | GHS07 Achtg. | H315 H317 H412 | |||
016-059-00-0 | N, N,N",N"-Tetramethyldithiobis(ethylen)diamindihydrochlorid | 405-300-9 | 17339-60-5 | Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H317 H410 | |||
016-060-00-6 | Diammoniumperoxodisulfat; Ammoniumpersulfat | 231-786-5 | 7727-54-0 | Ox. Sol. 3 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 | H272 H302 H319 H335 H315 H334 H317 | GHS03 GHS08 GHS07 Gef. | H272 H302 H319 H335 H315 H334 H317 | |||
016-061-00-1 | Dikaliumperoxodisulfat; Kaliumpersulfat | 231-781-8 | 7727-21-1 | Ox. Sol. 3 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 | H272 H302 H319 H335 H315 H334 H317 | GHS03 GHS08 GHS07 Gef. | H272 H302 H319 H335 H315 H334 H317 | |||
016-062-00-7 | Bensultap (ISO); 1,3-Bis(phenylsulfonylthio)-2-( N, N-dimethylamino)propan | - | 17606-31-4 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
016-063-00-2 | Dinatriumdisulfit; Natriummetabisulfit | 231-673-0 | 7681-57-4 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | EUH031 | ||
016-064-00-8 | Natriumhydrogensulfit . . . %; Natriumdisulfit . . . %; Natriumbisulfit ... % Natriumbisulfit . . . % | 231-548-0 | 7631-90-5 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | EUH031 | B | |
016-065-00-3 | Natrium-1-amino-4-[2-methyl-5-(4-methylphenylsulfonylamino)phenylamino]anthrachinon-2-sulfonat | 400-100-8 | 84057-97-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
016-066-00-9 | Tetranatrium[5-((4-amino-6-chlor-1,3,5-triazin-2-yl)amino)-2-((2-hydroxy-3,5-disulfonatophenylazo)-2-sulfonatobenzylidenhydrazino)benzoat]kupfer(II) | 404-070-7 | 116912-62-0 | Aquatic Chronic 3 | H412 | - | H412 | |||
016-067-00-4 | (4-Methylphenyl)mesitylensulfonat | 407-530-5 | 67811-06-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
016-068-00-X | Natrium-3,5-bis(tetradecyloxycarbonyl)benzolsulfinat | 407-720-8 | 155160-86-4 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
016-069-00-5 | 3,5-Bis(tetradecyloxycarbonyl)benzolsulfinsäure | 407-990-7 | 141915-64-2 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
016-070-00-0 | 4-Benzyloxy-4"-(2,3-epoxy-2-methylprop-1-yloxy)diphenylsulfon | 408-220-2 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
016-071-00-6 | Trinatrium-3-amino-6,13-dichlor-10-((3-((4-chlor-6-(2-sulfophenylamino)-1,3,5-triazin- 2-yl)amino)propyl)amino)-4,11-triphenoxydioxazindisulfonat | 410-130-3 | 136248-03-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
016-072-00-1 | 3-Amino-4-hydroxy- N-(2-methoxyethyl)-benzolsulfonamid | 411-520-6 | 112195-27-4 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
016-073-00-7 | Tetrakis(phenylmethyl)thioperoxydi(carbothioamid) | 404-310-0 | 10591-85-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
016-074-00-2 | 6-Fluor-2-methyl-3-(4-methylthiobenzyl)inden | 405-410-7 | - | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H315 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H411 | |||
016-075-00-8 | 2,2"-Diallyl-4,4"-sulfonyldiphenol | 411-570-9 | 41481-66-7 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
016-076-00-3 | 2,3-Bis((2-mercaptoethyl)thio)-1-propanthiol | 411-290-7 | 131538-00-6 | Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H410 | |||
016-077-00-9 | 2-Chlor- p-toluolsulfochlorid; 2-Chlor-p-toluolsulfochlorid | 412-890-1 | 42413-03-6 | Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 | H314 H317 H412 | GHS05 GHS07 Gef. | H314 H317 H412 | |||
016-078-00-4 | 4-Methyl- N, N-bis(2-(((4-methyl phenyl)sulfonyl)amino)ethyl)benzolsulfonamid | 413-300-5 | 56187-04-3 | Aquatic Chronic 4 | H413 | - | ||||
016-079-00-X | N, N-Bis(2-( p-toluolsulfonyloxy)ethyl)- p-toluolsulfonamid | 412-920-3 | 16695-22-0 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
016-080-00-5 | Natrium-2-anilino-5-(2-nitro-4-( N-phenylsulfamoyl))anilinobenzolsulfonat | 412-320-1 | 31361-99-6 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
016-081-00-0 | Hexahydrocyclopenta[ c]pyrrol-1-(1 H)-ammonium- N-ethoxycarbonyl- N-( p-tolylsulfonyl)azanid | 418-350-1 | - | Muta. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H341 H302 H319 H317 H411 | GHS08 GHS07 GHS09 Achtg. | H341 H302 H319 H317 H411 | |||
016-082-00-6 | Ethoxysulfuron (ISO); 1-(4,6-Dimethoxypyrimidin-2-yl)-3-(2-ethoxyphenoxysulfonyl)harnstoff | - | 126801-58-9 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
016-083-00-1 | Acibenzolar- S-methyl; Benzo[1,2,3]thiadiazol-7-thiocarbonsäure- S-methylester | 420-050-0 | 135158-54-2 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H319 H335 H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H319 H335 H315 H317 H410 | |||
016-084-00-7 | Prosulfuron (ISO); 1-(4-Methoxy-6-methyl-1,3,5-triazin-2-yl)-3-[2-(3,3,3-trifluorpropyl)phenylsulfonyl]harnstoff | - | 94125-34-5 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M=100 | ||
016-085-00-2 | Flazasulfuron (ISO); 1-(4,6-Dimethoxypyrimidin-2-yl)-3-(3-trifluormethyl-2-pyridylsulfonyl)harnstoff | - | 104040-78-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
016-086-00-8 | Tetranatrium-10-amino-6,13-dichlor-3-(3-(4-(2,5-disulfonatoanilino)-6-fluor-1,3,5-triazin-2-ylamino)prop-3-ylamino)-5,12-dioxa-7,14-diazapentacen-4,11-disulfonat | 402-590-9 | 109125-56-6 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
016-087-00-3 | Reaktionsmasse aus Thiobis(4,1- phenylen)- S, S,S",S"-tetraphenyldisulfoniumbishexafluorphosphat, Diphenyl(4-phenylthiophenyl)sulfoniumhexafluorphosphat und Propylencarbonat | 403-490-8 | 104558-95-4 | Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H319 H317 H400 H410 | GHS07 GHS09 Achtg. | H319 H317 H410 | |||
016-088-00-9 | 4-(Bis(4-(diethylamino)phenyl)methyl)benzol-1,2-dimethansulfonsäure | 407-280-7 | 71297-11-5 | Aquatic Chronic 3 | H412 | - | H412 | |||
016-089-00-4 | Reaktionsmasse aus Estern von 5,5",6,6",7,7"-Hexahydroxy-3,3,3",3"-tetramethyl-1,1"-spirobiindan und 2-Diazo-1,2-dihydro-1-oxo-5-sulfonaphthalin | 413-840-1 | - | Self-react.
C **** Aquatic Chronic 4 | H242 H413 | GHS02 Gef. | H242 H413 | |||
016-090-00-X | 4-Methyl- N-(methylsulfonyl)benzolsulfonamid | 415-040-8 | 14653-91-9 | Acute Tox. 4 * STOT SE 3 Eye Dam. 1 | H302 H335 H318 | GHS05 GHS07 Gef. | H302 H335 H318 | |||
016-091-00-5 | C12-14- tert-Alkylammonium-1-amino-9,10-dihydro-9,10-dioxo-4-(2,4,6-trimethylanilino)-anthracen-2-sulfonat | 414-110-5 | - | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
016-092-00-0 | Reaktionsmasse aus 4,7-Bis(mercaptomethyl)-3,6,9-trithia-1,11-undecandithiol, 4,8-Bis(mercaptomethyl)-3,6,9-trithia-1,11-undecandithiol und 5,7-Bis(mercaptomethyl)-3,6,9-trithia-1,11-undecandithiol | 427-050-1 | - | Repr. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f H315 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361f H315 H317 H410 | |||
016-093-00-6 | Reaktionsmasse aus 4-(7-Hydroxy-2,4,4-trimethyl-2-chromanyl)resorcinol-4-yl-tris(6-diazo-5,6-dihydro-5-oxonaphthalin-1-sulfonat) und 4-(7-Hydroxy-2,4,4-trimethyl-2-chromanyl)resorcinolbis(6-diazo-5,6-dihydro-5-oxonaphthalin-1-sulfonat) (2:1) | 414-770-4 | 140698-96-0 | Self-react.
C **** Carc. 2 | H242 H351 | GHS02 GHS08 Gef. | H242 H351 | |||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
016-094-00-1 | Schwefel | 231-722-6 | 7704-34-9 | Skin Irrit. 2 | H315 | GHS07 Achtg. | H315 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
016-094-00-1 | Schwefel | 231-722-6 | 7704-34-9 | Skin Irrit. 2 | H315 | GHS07 Wng | H315 | ) | ||
016-095-00-7 | Reaktionsmasse aus dem Reaktionsprodukt von 4,4"-Methylenbis[2-(4-hydroxybenzyl)-3,6-dimethylphenol] und 6-Diazo-5,6-dihydro-5-oxo-naphthalinsulfonat (1:2) und dem Reaktionsprodukt von 4,4"-Methylenbis[2-(4-hydroxybenzyl)-3,6-dimethylphenol] und 6-Diazo-5,6-dihydro-5-oxonaphthalinsulfonat (1:3) | 417-980-4 | - | Self-react. C **** Carc. 2 | H242 H351 | GHS02 GHS08 Gef. | H242 H351 | |||
016-096-00-2 | Thifensulfuron-methyl (ISO); Methyl-3-(4-methoxy-6-methyl-1,3,5-triazin- 2-ylcarbamoylsulfamoyl)thiophen-2-carboxylat | - | 79277-27-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 100 M = 100 | ||
016-097-00-8 | 1-Amino-2-methyl-2-propanthiolhydrochlorid | 434-480-1 | 32047-53-3 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 | H302 H314 H317 H412 | GHS05 GHS07 Gef. | H302 H314 H317 H412 | |||
016-098-00-3 | Dimethyldisulfid | 210-871-0 | 624-92-0 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H225 H331 H301 H336 H370 (obere Atemwege, Einatmen) H319 H317 H400 H410 | GHS02 GHS06 GHS08 GHS09 Dgr | H225 H331 H301 H336 H370 (obere Atemwege, Einatmen) H319 H317 H410 | Einatmen:
ATE = 5 mg/L (Dämpfe) oral:
ATE = 190 mg/kg KG M = 1 M = 10 | ||
017-001-00-7 | Chlor | 231-959-5 | 7782-50-5 | Ox. Gas 1 Press. Gas Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 | H270 H331 H319 H335 H315 H400 | GHS03 GHS04 GHS06 GHS09 Gef. | H270 H331 H319 H335 H315 H400 | M = 100 | U | |
017-002-00-2 | Hydrogenchlorid; Chlorwasserstoff | 231-595-7 | 7647-01-0 | Press.
Gas Acute Tox. 3 * Skin Corr. 1A | H331 H314 | GHS04 GHS06 GHS05 Gef. | H331 H314 | U5 | ||
017-002-01-X | Salzsäure ... %; Chlorwasserstoffsäure ...% | 231-595-7 | - | Skin Corr. 1B STOT SE 3 | H314 H335 | GHS05 GHS07 Gef. | H314 H335 | Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % EyeIrrit. 2; H319: 10 % ≤ C < 25 % STOT SE 3; H335: C ≥ 10 % | B | |
017-003-00-8 | Bariumchlorat | 236-760-7 | 13477-00-4 | Ox. Sol. 1 Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H271 H332 H302 H411 | GHS03 GHS07 GHS09 Gef. | H271 H332 H302 H411 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
017-004-00-3 | Kaliumchlorat | 223-289-7 | 3811-04-9 | Ox. Sol. 1 Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H271 H332 H302 H411 | GHS03 GHS07 GHS09 Gef. | H271 H332 H302 H411 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
017-004-00-3 | Kaliumchlorat | 223-289-7 | 3811-04-9 | Ox. Sol. 1 Acute Tox. 3 | H271 H301 | GHS03 GHS06 Dgr | H271 H301 | Oral: ATE = 100 mg/kg KG | ) | |
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
017-005-00-9 | Natriumchlorat | 231-887-4 | 7775-09-9 | Ox. Sol. 1 Acute Tox. 4 * Aquatic Chronic 2 | H271 H302 H411 | GHS03 GHS07 GHS09 Gef. | H271 H302 H411 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
017-005-00-9 | Natriumchlorat | 231-887-4 | 7775-09-9 | Ox. Sol. 1 Acute Tox. 3 | H271 H301 | GHS03 GHS06 Dgr | H271 H301 | Oral: ATE = 100 mg/kg KG | ) | |
017-006-00-4 | Perchlorsäure ... % | 231-512-4 | 7601-90-3 | Ox. Liq. 1 Skin Corr. 1A | H271 H314 | GHS03 GHS05 Gef. | H271 H314 | Skin Corr. 1A; H314: C ≥ 50 % Skin Corr. 1B; H314: 10 % ≤ C < 50 % Skin Irrit. 2; H315: 1 % ≤ C < 10 % Eye Irrit. 2; H319: 1 % ≤ C < 10 % Ox. Liq. 1; H271: C > 50 %: Ox. Liq. 2; H272: C ≤ 50 %: | B | |
017-007-00-X | Bariumperchlorat | 236-710-4 | 13465-95-7 | Ox. Sol. 1 Acute Tox. 4 * Acute Tox. 4 * | H271 H332 H302 | GHS03 GHS07 Gef. | H271 H332 H302 | |||
017-008-00-5 | Kaliumperchlorat | 231-912-9 | 7778-74-7 | Ox. Sol. 1 Acute Tox. 4 * | H271 H302 | GHS03 GHS07 Gef. | H271 H302 | |||
017-009-00-0 | Ammoniumperchlorat | 232-235-1 | 7790-98-9 | Expl. 1.1 Ox. Sol. 1 | H201 H271 | GHS01 Gef. | H201 H271 | T | ||
017-010-00-6 | Natriumperchlorat | 231-511-9 | 7601-89-0 | Ox. Sol. 1 Acute Tox. 4 * | H271 H302 | GHS03 GHS07 Gef. | H271 H302 | |||
017-011-00-1 | Natriumhypochloritlösung ... % Cl aktiv | 231-668-3 | 7681-52-9 | Skin Corr. 1B Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H318 H400 H410 | GHS05 GHS09 Dgr | H314 H410 | EUH031 | M = 10 M = 1 EUH031: C ≥ 5 % | B |
017-012-00-7 | Calciumhypochlorit | 231-908-7 | 7778-54-3 | Ox. Sol. 2 Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 | H272 H302 H314 H400 | GHS03 GHS05 GHS07 GHS09 Gef. | H272 H302 H314 H400 | EUH031 | Skin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 1 % ≤ C < 5 % Eye Dam.1; H318: 3 % ≤ C < 5 % Eye Irrit. 2; H319: 0,5 % ≤ C < 3 % M = 10 | T |
017-013-00-2 | Calciumchlorid | 233-140-8 | 10043-52-4 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
017-014-00-8 | Ammoniumchlorid | 235-186-4 | 12125-02-9 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
017-015-00-3 | (2-(Aminomethyl)phenyl)-acetylchloridhydrochlorid | 417-410-4 | 61807-67-8 | Acute Tox. 4 * Skin Corr. 1A Skin Sens. 1 | H302 H314 H317 | GHS05 GHS07 Gef. | H302 H314 H317 | |||
017-016-00-9 | Methyltriphenylphosphoniumchlorid | 418-400-2 | 1031-15-8 | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H312 H302 H315 H318 H411 | GHS05 GHS07 GHS09 Gef. | H312 H302 H315 H318 H411 | |||
017-017-00-4 | (Z)-13-Docosenyl- N, N-bis(2-hydroxyethyl)- N-methylammoniumchlorid | 426-210-6 | 120086-58-0 | Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Gef. | H314 H410 | |||
017-018-00-X | N, N,N-Trimethyl-2,3-bis(stearoyloxy)propylammoniumchlorid | 405-660-7 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
017-019-00-5 | (R)-1,2,3,4-Tetrahydro-6,7-dimethoxy-1-veratrylisochinolinhydrochlorid | 415-110-8 | 54417-53-7 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
017-020-00-0 | Ethylpropoxyaluminiumchlorid | 421-790-7 | 13014-29-4 | Water-react. 1 Skin Corr. 1A | H260 H314 | GHS02 GHS05 Gef. | H260 H314 | EUH014 | ||
017-021-00-6 | Behenamidopropyldimethyl(dihydroxypropyl)ammoniumchlorid | 423-420-1 | 136920-10-0 | Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H318 H317 H410 | |||
017-023-00-7 | [Phosphinyldyntris(oxy)]tris[3-aminopropyl-2-hydroxy- N, N-dimethyl- N-(C6-18)-alkyl]-trichloride | 425-520-9 | 197179-61-6 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
017-026-00-3 | Chlordioxid | 233-162-8 | 10049-04-4 | Press.
Gas Ox. Gas 1 Acute Tox. 2 * Skin Corr. 1B Aquatic Acute 1 | H270 H330 H314 H400 | GHS04 GHS03 GHS06 GHS05 GHS09 Gef. | H270 H330 H314 H400 | M = 10 | 5 | |
017-026-01-0 | Chlordioxid ... % | 233-162-8 | 10049-04-4 | Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 | H301 H314 H400 | GHS06 GHS05 GHS09 Gef. | H301 H314 H400 | Skin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 1 % ≤ C < 5 % Eye Dam.1; H318: 3 % ≤ C < 5 % Eye Irrit. 2; H319: 0,3 % ≤ C < 3 % STOT SE 3; H335: C ≥ 3 % M = 10 | B | |
019-001-00-2 | Kalium | 231-119-8 | 7440-09-7 | Water-react. 1 Skin Corr. 1B | H260 H314 | GHS02 GHS05 Gef. | H260 H314 | EUH014 | ||
019-002-00-8 | Kaliumhydroxid; Ätzkali; Kalilauge | 215-181-3 | 1310-58-3 | Acute Tox. 4 * Skin Corr. 1A | H302 H314 | GHS05 GHS07 Gef. | H302 H314 | Skin Corr. 1A; H314: C ≥ 5 % Skin Corr. 1B; H314: 2 % ≤ C < 5 % Skin Irrit. 2; H315: 0,5 % ≤ C < 2 % Eye Irrit. 2; H319: 0,5 % ≤ C < 2 % | ||
019-003-00-3 | Kalium-(E,E)-hexa-2,4-dienoat | 246-376-1 | 24634-61-5 | Eye Irrit. 2 | H319 | GSH07 Achtg. | H319 | |||
020-001-00-X | Calcium | 231-179-5 | 7440-70-2 | Water-react. 2 | H261 | GHS02 Gef. | H261 | |||
020-002-00-5 | Calciumcyanid | 209-740-0 | 592-01-8 | Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H400 H410 | GHS06 GHS09 Gef. | H300 H410 | EUH032 | ||
020-003-00-0 | Reaktionsmasse aus Dicalcium-(bis(2-hydroxy-5-tetra-propenylphenylmethyl)-methylamin)dihydroxid, Tricalcium(tris(2-hydroxy-5-tetrapropenylphenylmethyl)-methylamin)trihydroxid und Poly[calcium((2-hydroxy-5-tetrapropenylphenylmethyl)methylamin)hydroxid] | 420-470-4 | - | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | |||
022-001-00-5 | Titantetrachlorid; Titan(IV)-chlorid | 231-441-9 | 7550-45-0 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | EUH014 | ||
022-002-00-0 | Titan(4+)oxalat | 403-260-7 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
022-003-00-6 | Bis(cyclopentadienid-bis(2,6-difluor-3-[1 H-pyrrol-1-yl]phenyl)titan(IV); Bis (η5-cyclopentadienyl)-bis(2,6-difluor- 3-[pyrrol-1-yl]-phenyl)titan) | 412-000-1 | 125051-32-3 | Flam. Sol. 1 Repr. 2 STOT RE 2 * Aquatic Chronic 2 | H228 H361f *** H373 ** H411 | GHS02 GHS08 GHS09 Gef. | H228 H361f *** H373 ** H411 | T | ||
022-004-00-1 | Kaliumtitanoxid (K2Ti6O13) | 432-240-0 | 12056-51-8 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
022-005-00-7 | [ N-(1,1-Dimethylethyl)-1,1-dimethyl-1-[(1,2,3,4,5-η)-2,3,4,5-tetramethyl-2,4-cyclopentadien-1-yl]silanaminato(2-)-κN][(1,2,3,4-η)-1,3-pentadien]-titan | 419-840-8 | 169104-71-6 | Flam. Sol. 1**** Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 4 | H228 H314 H317 H413 | GHS02 GHS05 GHS07 Gef. | H228 H314 H317 H413 | |||
022-006-00-2 | Titandioxid; [in Pulverform mit mindestens 1 % Partikel mit aerodynamischem Durchmesser ≤ 10 µm] | 236-675-5 | 13463-67-7 | Carc. 2 | H351 (Einatmen) | GHS08 Wng | H351 (Einatmen) | V, W, 10 | ||
023-001-00-8 | Divanadiumpentaoxid; Vanadiumpentoxid | 215-239-8 | 1314-62-1 | Muta. 2 Carc. 1B Repr. 2 Lact. Acute Tox. 3 Acute Tox. 2 STOT SE 3 STOT RE 1 Aquatic Chronic 2 | H341 H350 H361fd H362 H301 H330 H335 H372 (Atemwege, Einatmen) H411 | GHS06 GHS08 GHS09 Dgr | H341 H350 H361fd H362 H301 H330 H335 H372 (Atemwege, Einatmen) H411 | Einatmung: ATE = 0,05 mg/L (Stäube oder Nebel) Oral: ATE = 220 mg/kg KG | ||
024-001-00-0 | Chrom(VI)trioxid; Chromsäureanhydrid | 215-607-8 | 1333-82-0 | Ox. Sol. 1 Carc. 1A Muta. 1B Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H271 H350 H340 H361f *** H330 H311 H301 H372 ** H314 H334 H317 H400 H410 | GHS03 GHS06 GHS08 GHS05 GHS09 Gef. | H271 H350 H340 H361f *** H330 H311 H301 H372 ** H314 H334 H317 H410 | STOT SE 3; H335: C ≥ 1 % | ||
024-002-00-6 | Kaliumdichromat | 231-906-6 | 7778-50-9 | Ox. Sol. 2 Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H272 H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H400 H410 | GHS03 GHS06 GHS08 GHS05 GHS09 Gef. | H272 H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H410 | STOT SE 3; H335: C ≥ 5 % | 3 | |
024-003-00-1 | Ammoniumdichromat | 232-143-1 | 7789-09-5 | Ox. Sol. 2 **** Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H272 H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H400 H410 | GHS03 GHS06 GHS08 GHS05 GHS09 Gef. | H272 H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H410 | STOT SE 3; H335: C ≥ 5 % Resp. Sens.; H334: C ≥0,2 % Skin Sens.; H317:C ≥0,2 % | G3 | |
024-004-00-7 | Natriumdichromat | 234-190-3 | 10588-01-9 | Ox. Sol. 2 Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 1 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H272 H350 H340 H360FD H330 H301 H312 H372** H314 H334 H317 H400 H410 | GHS03 GHS06 GHS05 GHS08 GHS09 Gef. | H272 H350 H340 H360FD H330 H301 H312 H372** H314 H334 H317 H410 | Resp. Sens. 1; H334: C ≥ 0,2 % Skin Sens. 1; H317:C ≥0,2 % STOT SE 3; H335: C ≥ 5 % | 3 | |
024-005-00-2 | Chromyldichlorid; Chromoxychlorid; Chromdioxiddichlorid | 239-056-8 | 14977-61-8 | Ox. Liq. 1 Carc. 1B Muta. 1B Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H271 H350i H340 H314 H317 H400 H410 | GHS03 GHS08 GHS05 GHS07 GHS09 Gef. | H271 H350i H340 H314 H317 H410 | Skin Corr. 1A; H314: C ≥ 10 % Skin Corr. 1B; H314: 5 % ≤ C < 10 % Skin Irrit. 2; H315: 0,5 % ≤ C < 5 % Eye Irrit. 2; H319: 0,5 % ≤ C < 5 % STOT SE 3; H335: 0,5 % ≤ C < 5 % Skin Sens. 1; H317: C ≥ 0,5 % | T3 | |
024-006-00-8 | Kaliumchromat | 232-140-5 | 7789-00-6 | Carc. 1B Muta. 1B Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H340 H319 H335 H315 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H340 H319 H335 H315 H317 H410 | Skin Sens. 1; H317:C ≥ 0,5 % | 3 | |
024-007-00-3 | Zinkchromate, einschließlich Zinkkaliumchromat | - | - | Carc. 1A Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H317 H410 | A | ||
024-008-00-9 | Calciumchromat | 237-366-8 | 13765-19-0 | Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H410 | |||
024-009-00-4 | Strontiumchromat | 232-142-6 | 7789-06-2 | Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H400 H410 | |||
024-010-00-X | Dichromtris(chromat); Chrom(III)chromat; chromsaures Chromoxid; Chrom(III)-Salz der Chrom(VI)-Säure chromic chromate | 246-356-2 | 24613-89-6 | Ox. Sol. 1 Carc. 1B Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H271 H350 H314 H317 H400 H410 | GHS03 GHS08 GHS05 GHS07 GHS09 Gef. | H271 H350 H314 H317 H410 | T | ||
024-011-00-5 | Ammoniumbis(1-(3,5-dinitro-2-oxidophenylazo)-3-( N-phenylcarbamoyl)-2-naphtholato)chromat(1-) | 400-110-2 | 109125-51-1 | Self-react.
C **** Aquatic Acute 1 Aquatic Chronic 1 | H242 H400 H410 | GHS02 GHS09 Gef. | H242 H410 | |||
024-012-00-0 | Trinatriumbis(7-acetamido-2-(4- nitro-2-oxidophenylazo)-3-sulfonato-1-naphtholato)-chromat(1-) | 400-810-8 | - | Muta. 2 | H341 | GHS08 Achtg. | H341 | |||
024-013-00-6 | Trinatrium(6-anilino-2-(5-nitro-2-oxidophenylazo)-3-sulfonato-1-naphtholato)(4-sulfonato-1,1"-azodi-2,2"naphtholato)chromat(1-) | 402-500-8 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
024-014-00-1 | Trinatriumbis(2-(5-chlor-4-nitro-2-oxidophenylazo)-5-sulfonato-1-naphtholato)chromat(1-) | 402-870-0 | 93952-24-0 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
024-015-00-7 | Dinatrium(3-methyl-4-(5-nitro-2-oxidophenylazo)-1-phenylpyrazololato)(1-(3-nitro-2-oxido-5-sulfonatophenylazo)-2-naphtholato)chromat(1-) | 404-930-1 | - | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H332 H318 H411 | GHS05 GHS07 GHS09 Gef. | H332 H318 H411 | |||
024-016-00-2 | Tetradecylammoniumbis(1-(5-chlor-2-oxidophenylazo)-2-naphtholato)chromat(1-) | 405-110-6 | 88377-66-6 | STOT RE 2 * Aquatic Chronic 4 | H373 ** H413 | GHS08 Achtg. | H373 ** H413 | |||
024-017-00-8 | Chrom(VI)-Verbindungen, ausgenommen Bariumchromat, und soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Carc. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H317 H410 | A | ||
024-018-00-3 | Natriumchromat | 231-889-5 | 7775-11-3 | Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H410 | Resp. Sens.; H334: C ≥ 0,2 % Skin Sens.; H317:C ≥ 0,2 % | 3 | |
024-019-00-9 | Hauptbestandteil:
Acetoessigsäureanilid/3-Amino-1-hydroxybenzol (ATAN-MAP): Trinatrium{6-[(2 oder 3 oder 4)-amino-(4 oder 5 oder 6)-hydroxyphenylazo]-5"-(phenylsulfamoyl)-3-sulfonatonaphthalin-2-azobenzol-1,2"-diolato}-{6""-[1-(phenylcarbamoyl)ethylazo]-5"-(phenylsulfamoyl)-3-sulfonatonaphthalin-2""-azobenzol-1"",2-diolato}chromat(III); Nebenprodukt 1: Acetoessigsäureanilid/Acetoessigsäureanilid (ATAN-ATAN): Trinatriumbis{6-[1-(phenylcarbamoyl)ethylazo]-5-(phenylsulfonyl)-3""-sulfonatonaphthalin-2-azobenzol-1,2"-diolato}chromat(III); Nebenprodukt 2: 3-Amino-1-hydroxybenzol/3-Amino-1-hydroxybenzol (MAP-MAP): Trinatriumbis{6-[(2 oder 3 oder 4)-amino-(4 oder 5 oder 6)-hydroxyphenylazo]-5"-(phenylsulfamoyl)-3-sulfonatonaphthalin-2-azobenzol-1,2"-diolato}chromat(III) | 419-230-1 | - | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
024-020-00-4 | Trinatriumbis[(3"-nitro-5"-sulfonato(6-amino-2-[4-(2-hydroxy-1-naphthylazonaphtylazo)phenylsulfonylamino]pyrimidin-5-azo)benzol-2",4-diolato)]-chromat(III) | 418-220-4 | - | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
024-021-00-X | Kaliumtetranatriumbis[( N, N"- n)-1"-(phenylcarbamoyl)-3,5-disulfonatobenzolazo-1"-prop-1"-en-2,2"-diolato]chromat(III) | 425-830-4 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
025-001-00-3 | Mangandioxid; Braunstein | 215-202-6 | 1313-13-9 | Acute Tox. 4 * Acute Tox. 4 * | H332 H302 | GHS07 Achtg. | H332 H302 | |||
025-002-00-9 | Kaliumpermanganat | 231-760-3 | 7722-64-7 | Ox. Sol. 2 Repr. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H272 H361d H302 H400 H410 | GHS03 GHS08 GHS07 GHS09 Dgr | H272 H361d H302 H410 | |||
025-003-00-4 | Mangansulfat | 232-089-9 | 7785-87-7 | STOT RE 2 * Aquatic Chronic 2 | H373 ** H411 | GHS08 GHS09 Achtg. | H373 ** H411 | |||
025-004-00-X | Bis( N, N",N""-trimethyl-1,4,7-triazacyclononan)-trioxodimangan(IV)-di(hexafluorphosphat)-Monohydrat | 411-760-1 | 116633-53-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
025-005-00-5 | Reaktionsmasse aus Trinatrium[29 H,31 H-phthalocyanin- C, C,C-trisulfonato(6-)- N29, N30, N31, N32]manganat(3-), Tetranatrium[29 H,31 H-phthalocyanin- C, C,C, C-tetrasulfonato(6-)- N29, N30, N31, N32]manganat(3-) und Pentanatrium[29 H,31 H-phthalocyanin- C, C,C, C,C-pentasulfonato(6-)- N29, N30, N31, N32]manganat(3-) | 417-660-4 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
026-001-00-6 | (η-Cumen)-(η-cyclopentadienyl)eisen(II)-hexafluorantimonat | 407-840-0 | 100011-37-8 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
026-002-00-1 | (η-Cumen)-(η-cyclopentadienyl)eisen(II)-trifluormethansulfonat | 407-880-9 | 117549-13-0 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
026-003-00-7 | Eisen(II)-sulfat | 231-753-5 | 7720-78-7 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 | H302 H319 H315 | GHS07 Achtg. | H302 H319 H315 | |||
026-003-01-4 | Eisen(II)-sulfat (1:1), Heptahydrat; Schwefelsäure, Eisen(II)-salz (1:1), Heptahydrat; Eisensulfatheptahydrat | 231-753-5 | 7782-63-0 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 | H302 H319 H315 | GHS07 Achtg. | H302 H319 H315 | Skin Irrit.2; H315: C ≥ 25 % | ||
026-004-00-2 | Kaliumferrit | 430-010-4 | 12160-44-0 | Skin Corr. 1B Skin Sens. 1 | H314 H317 | GHS05 GHS07 Gef. | H314 H317 | |||
027-001-00-9 | Cobalt | 231-158-0 | 7440-48-4 | Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 4 | H350 H341 H360F H334 H317 H413 | GHS08 Dgr | H350 H341 H360F H334 H317 H413 | |||
027-002-00-4 | Cobaltoxid | 215-154-6 | 1307-96-6 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | M=10 | ||
027-003-00-X | Cobaltsulfid | 215-273-3 | 1317-42-6 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | M=10 | ||
027-004-00-5 | Cobaltdichlorid | 231-589-4 | 7646-79-9 | Carc. 1B Muta. 2 Repr. 1B Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360F*** H302 H334 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H341 H360F*** H302 H334 H317 H410 | Carc. 1B; H350i: C ≥ 0,01 % M=10 | 1 | |
027-005-00-0 | Cobaltsulfat | 233-334-2 | 10124-43-3 | Carc. 1B Muta. 2 Repr. 1B Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360F*** H302 H334 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H341 H360F*** H302 H334 H317 H410 | Carc. 1B; H350i: C ≥ 0,01 % M=10 | 1 | |
027-006-00-6 | Cobaltdi(acetat) | 200-755-8 | 71-48-7 | Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360F*** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360F*** H334 H317 H410 | Carc. 1B; H350i: C ≥ 0,01 % M = 10 | 1 | |
027-007-00-1 | Zinkhexacyanocobaltat(III), tertiärer Butylalkohol/Polypropylenglycol-Komplex | 425-240-7 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
027-008-00-7 | Cobalt(III)-bis( N-phenyl-4-(5-ethylsulfonyl-2-hydroxyphenylazo)-3-hydroxynaphthylamid)-Komplex, hydriert (n H2O, 2<n<3) | 427-390-9 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
027-009-00-2 | Cobaltdinitrat | 233-402-1 | 10141-05-6 | Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360F*** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360F*** H334 H317 H410 | Carc. 1B; H350i: C ≥ 0,01 % M = 10 | 1 | |
027-010-00-8 | Cobaltcarbonat | 208-169-4 | 513-79-1 | Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360F*** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360F*** H334 H317 H410 | Carc. 1B; H350i: C ≥ 0,01 % M=10 | 1 | |
028-001-00-1 | Tetracarbonylnickel; Nickeltetracarbonyl | 236-669-2 | 13463-39-3 | Flam. Liq. 2 Carc. 2 Repr. 1B Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H225 H351 H360D *** H330 H400 H410 | GHS02 GHS06 GHS08 GHS09 Gef. | H225 H351 H360D *** H330 H410 | |||
028-002-00-7 | Nickel | 231-111-4 | 7440-02-0 | Carc. 2 STOT RE 1 Skin Sens. 1 | H351 H372** H317 | GHS08 GHS07 Gef. | H351 H372** H317 | S7 | ||
028-002-01-4 | Nickelpulver [Partikeldurchmesser < 1 mm] | 231-111-4 | 7440-02-0 | Carc. 2 STOT RE 1 Skin Sens. 1 Aquatic Chronic 3 | H351 H372** H317 H412 | GHS08 GHS07 Gef. | H351 H372** H317 H412 | |||
028-003-00-2 | Nickelmonoxid; Nickel(II)-oxid [1]; Nickeloxid [2]; Bunsenit [3] | 215-215-7 [1] 234-323-5 [2] - [3] | 1313-99-1 [1] 11099-02-8 [2] 34492-97-2 [3] | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Chronic 4 | H350i H372** H317 H413 | GHS08 GHS07 Gef. | H350i H372** H317 H413 | |||
028-004-00-8 | Nickeldioxid; Nickel(IV)-oxid | 234-823-3 | 12035-36-8 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Chronic 4 | H350i H372** H317 H413 | GHS08 GHS07 Gef. | H350i H372** H317 H413 | |||
028-005-00-3 | Dinickeltrioxid; Nickel(III)-oxid | 215-217-8 | 1314-06-3 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Chronic 4 | H350i H372** H317 H413 | GHS08 GHS07 Gef. | H350i H372** H317 H413 | |||
028-006-00-9 | Nickel(II)-sulfid [1];] Nickelsulfid [2];] Millerit [3] | 240-841-2 [1] 234-349-7 [2] - [3] | 16812-54-7 [1] 11113-75-0 [2] 1314-04-1 [3] | Carc. 1A Muta. 2 STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H341 H372** H317 H410 | |||
028-007-00-4 | Trinickeldisulfid; Nickelsubsulfid; [1] Heazlewoodit [2] | 234-829-6 [1] - [2] | 12035-72-2 [1] 12035-71-1 [2] | Carc. 1A Muta. 2 Acute Tox. 3 STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H331 H372** H317 H400 H410 | GHS08 GHS06 GHS09 Dgr | H350i H341 H331 H372** H317 H410 | Einatmen: ATE = 0,92 mg/L (Stäube oder Nebel) | ||
028-008-00-X | Nickeldihydroxid; Nickel(II)-hydroxid [1]; Nickelhydroxid [2] | 235-008-5 [1] 234-348-1 [2] | 12054-48-7 [1] 11113-74-9 [2] | Carc. 1A Repr. 1B Muta. 2 STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H360D*** H341 H372** H332 H302 H315 H334 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H360D*** H341 H372** H332 H302 H315 H334 H317 H410 | |||
028-009-00-5 | Nickelsulfat; Nickel(II)-sulfat | 232-104-9 | 7786-81-4 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Irrit. 2; H315: C ≥ 20 % Skin Sens. 1; H317: C ≥ 0,01 % M = 1 | ||
028-010-00-0 | Nickelcarbonat; Basisches Nickelcarbonat; Carbonsäure, Nickel(2+)-Salz [1]; Carbonsäure, Nickelsalz [2];] [μ-[Carbonato(2-)- O: O"]]-dihydroxytrinickel [3]; [Carbonato(2-)]-tetrahydroxytrinickel [4] | 222-068-2 [1] 240-408-8 [2] 265-748-4 [3] 235-715-9 [4] | 3333-67-3 [1] 16337-84-1 [2] 65405-96-1 [3] 12607-70-4 [4] | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H410 | |||
028-011-00-6 | Nickeldichlorid; Nickelchlorid | 231-743-0 | 7718-54-9 | Carc. 1A Muta. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H331 H301 H372** H315 H334 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H350i H341 H360D*** H331 H301 H372** 315 H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % < C < 1 % Skin Irrit. 2; H315: C ≥ 20 % Skin Sens. 1; H317: C ≥ 0,01 % M = 1 | ||
028-012-00-1 | Nickeldinitrat [1]; Salpetersäure, Nickelsalz [2] | 236-068-5 [1] 238-076-4 [2] | 13138-45-9 [1] 14216-75-2 [2] | Ox. Sol. 2 Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H272 H350i H341 H360D*** H372** H332 H302 H315 H318 H334 H317 H400 H410 | GHS03 GHS05 GHS08 GHS07 GHS09 Gef. | H272 H350i H341 H360D*** H372** H332 H302 H315 H318 H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % < C < 1 % Skin Irrit. 2; H315: C ≥ 20 % Skin Sens. 1; H317 C ≥0,01 % M = 1 | ||
028-013-00-7 | Nickelmatte | 273-749-6 | 69012-50-6 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-014-00-2 | Schleime und Schlämme, elektrolytische Kupferraffination, entkupfert, Nickelsulfat | 295-859-3 | 92129-57-2 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < % Skin Sens. 1; H317:C ≥ 0,01 % M=1 | ||
028-015-00-8 | Schleime und Schlämme, elektroyltische Kupferraffination, entkupfert | 305-433-1 | 94551-87-8 | Carc. 1A Muta. 2 Repr. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | |||
028-016-00-3 | Nickeldiperchlorat; Perchlorsäure, Nickel(II)-Salz | 237-124-1 | 13637-71-3 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H314 H334 H317 H400 H410 | GHS05 GHS08 GHS09 Gef. | H350i H341 H360D*** H372** 14 H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 | ||
028-017-00-9 | Nickeldikaliumbis(sulfat) [1]; Diammoniumnickelbis(sulfat) [2] | 237-563-9 [1] 239-793-2 [2] | 13842-46-1 [1] 15699-18-0 [2] | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H332 H302 H334 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H341 H360D*** H372** 332 H302 H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥ 0,01 % M=1 | ||
028-018-00-4 | Nickel-bis(sulfamidat); Nickelsulfamat | 237-396-1 | 13770-89-3 | Carc. 1A Muta. 2 Repr. 1B Acute Tox. 4 STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H302 H372** H334 H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H350i H341 H360D*** H302 H372** H334 H317 H410 | Oral: ATE = 853 mg/kg KG (Anhydrat) Oral: ATE = 1098 mg/kg KG (Tetrahydrat) STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M = 1 | ||
028-019-00-X | Nickelbis(tetrafluorborat) | 238-753-4 | 14708-14-6 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥0,01 % M=1 | ||
028-021-00-0 | Nickeldiformiat [1]; Ameisensäure, Nickelsalz [2]; Ameisensäure, Kupfer-Nickelsalz [3] | 222-101-0 [1] 239-946-6 [2] 268-755-0 [3] | 3349-06-2 [1] 15843-02-4 [2] 68134-59-8 [3] | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥0,01 % M=1 | ||
028-022-00-6 | Nickeldi(acetat) [1]; Nickelacetat [2] | 206-761-7 [1] 239-086-1 [2] | 373-02-4 [1] 14998-37-9 [2] | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H332 H302 H334 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H341 H360D*** H372** H332 H302 H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥ 0,01 % M = 1 | ||
028-024-00-7 | Nickeldibenzoat | 209-046-8 | 553-71-9 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥ 0,01 % M=1 | ||
028-025-00-2 | Nickelbis(4-cyclohexylbutyrat) | 223-463-2 | 3906-55-6 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥0,01 % M=1 | ||
028-026-00-8 | Nickel(II)-stearat; Nickel(II)-octadecanoat | 218-744-1 | 2223-95-2 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 % Skin Sens. 1; H317:C;≥0,01 % M=1 | ||
028-027-00-3 | Nickeldilactat | - | 16039-61-5 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372:C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 | ||
028-028-00-9 | Nickel(II)-octanoat | 225-656-7 | 4995-91-9 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H314 H334 H317 H400 H410 | GHS05 GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H314 H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 | ||
028-029-00-4 | Nickeldifluorid [1]; Nickeldibromid [2]; Nickeldiiodid [3]; Nickelkaliumfluorid [4] | 233-071-3 [1] 236-665-0 [2] 236-666-6 [3] - [4] | 10028-18-9 [1] 13462-88-9 [2] 13462-90-3 [3] 11132-10-8 [4] | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥0,01 % M=1 | ||
028-030-00-X | Nickelhexafluorsilicat | 247-430-7 | 26043-11-8 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** 334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥ 0,01 % M=1 | ||
028-031-00-5 | Nickelselenat | 239-125-2 | 15060-62-5 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥0,01 % M=1 | ||
028-032-00-0 | Nickelhydrogenphosphat [1]; Nickelbis(dihydrogenphosphat) [2];] Trinickelbis(orthophosphat) [3];] Dinickeldiphosphat [4]; Nickelbis(phosphinat) [5];] Nickel phosphinat [6];] Phosphorsäure, Calciumnickelsalz [7]; Diphosphorsäure, Nickel(II)- Salz [8] | 238-278-2 [1] 242-522-3 [2] 233-844-5 [3] 238-426-6 [4] 238-511-8 [5] 252-840-4 [6] - [7] - [8] | 14332-34-4 [1] 18718-11-1 [2] 10381-36-9 [3] 14448-18-1 [4] 14507-36-9 [5] 36026-88-7 [6] 17169-61-8 [7] 19372-20-4 [8] | Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H372** H334 H317 H410 | |||
028-033-00-6 | Diammoniumnickelhexacyanoferrat | - | 74195-78-1 | Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H372** H334 H317 H410 | |||
028-034-00-1 | Nickeldicyanid | 209-160-8 | 557-19-7 | Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H372** H334 H317 H410 | EUH032 | ||
028-035-00-7 | Nickelchromat | 238-766-5 | 14721-18-7 | Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H372** H334 H317 H410 | |||
028-036-00-2 | Nickel(II)-silicat [1]; Dinickelorthosilicat [2]; Nickelsilicat (3:4) [3]; Kieselsäure, Nickelsalz [4]; Trihydrogenhydroxybis[orthosilicato(4-)]trinickelat(3-) [5] | 244-578-4 [1] 237-411-1 [2] 250-788-7 [3] 253-461-7 [4] 235-688-3 [5] | 21784-78-1 [1] 13775-54-7 [2] 31748-25-1 [3] 37321-15-6 [4] 12519-85-6 [5] | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-037-00-8 | Dinickelhexacyanoferrat | 238-946-3 | 14874-78-3 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-038-00-3 | Trinickelbis(arsenat); Nickel(II)-arsenat | 236-771-7 | 13477-70-8 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H372** H317 H410 | |||
028-039-00-9 | Nickeloxalat [1]; Oxalsäure, Nickelsalz [2] | 208-933-7 [1] 243-867-2 [2] | 547-67-1 [1] 20543-06-0 [2] | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-040-00-4 | Nickeltellurid | 235-260-6 | 12142-88-0 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-041-00-X | Trinickeltetrasulfid | - | 12137-12-1 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-042-00-5 | Trinickelbis(arsenit) | - | 74646-29-0 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-043-00-0 | Cobalt-Nickel-Gray-Periklas; C.I. Pigment Black 25; C.I. 77332 [1]; Cobaltnickeldioxid [2]; Cobaltnickeloxid [3] | 269-051-6 [1] 261-346-8 [2] - [3] | 68186-89-0 [1] 58591-45-0 [2] 12737-30-3 [3] | Carc. 1A STOT RE 1 Skin Sens. 1 | H350i H372** H317 | GHS08 GHS07 Gef. | H350i H372** H317 | |||
028-044-00-6 | Nickelzinntrioxid; Nickelstannat | 234-824-9 | 12035-38-0 | Carc. 1A STOT RE 1 Skin Sens. 1 | H350i H372** H317 | GHS08 GHS07 Gef. | H350i H372** H317 | |||
028-045-00-1 | Nickeltriurandecaoxid | 239-876-6 | 15780-33-3 | Carc. 1A STOT RE 1 Skin Sens. 1 | H350i H372** H317 | GHS08 GHS07 Gef. | H350i H372** H317 | |||
028-046-00-7 | Nickeldithiocyanat | 237-205-1 | 13689-92-4 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | EUH032 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥0,01 % M=1 | |
028-047-00-2 | Nickeldichromat | 239-646-5 | 15586-38-6 | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372:C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥0,01 % M=1 | ||
028-048-00-8 | Nickel(II)-Selenit | 233-263-7 | 10101-96-9 | Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H372** H334 H317 H410 | |||
028-049-00-3 | Nickelselenid | 215-216-2 | 1314-05-2 | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-050-00-9 | Kieselsäure, Bleinickelsalz | - | 68130-19-8 | Carc. 1A Repr. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H360Df H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H360Df H372** H317 H410 | |||
028-051-00-4 | Nickeldiarsenid [1]; Nickelarsenid [2] | 235-103-1 [1] 248-169-1 [2] | 12068-61-0 [1] 27016-75-7 [2] | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-052-00-X | Nickel-Barium-Titan-Primel-Priderit; C.I. Pigment Yellow 157; C.I. 77900 | 271-853-6 | 68610-24-2 | Carc. 1A STOT RE 1 Skin Sens. 1 | H350i H372** H317 | GHS08 GHS07 Gef. | H350i H372** H317 | |||
028-053-00-5 | Nickeldichlorat [1]; Nickeldibromat [2]; Ethylhydrogensulfat, Nickel(II)-Salz [3] | 267-897-0 [1] 238-596-1 [2] 275-897-7 [3] | 67952-43-6 [1] 14550-87-9 [2] 71720-48-4 [3] | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < % Skin Sens. 1; H317:C≥0,01 %1 M=1 | ||
028-054-00-0 | Nickel(II)-trifluoracetat [1]; Nickel(II)-propionat [2]; Nickelbis(benzolsulfonat) [3]; Nickel(II)-hydrogencitrat[4]; Zitronensäure, Ammoniumnickelsalz [5]; Zitronensäure, Nickelsalz [6]; Nickelbis(2-ethylhexanoat) [7]; 2-Ethylhexansäure, Nickelsalz [8]; Dimethylhexansäure, Nickelsalz [9]; Nickel(II)-isooctanoat [10]; Nickelisooctanoat [11]; Nickelbis(isononanoat) [12]; Nickel(II)-neononanoat [13]; Nickel(II)-isodecanoat [14]: Nickel(II)-neodecanoat [15]; Neodecansäure, Nickelsalz [16]; Nickel(II)-neoundecanoat [17]; Bis(D-gluconato- O1, O2)nickel [18]; Nickel-3,5-bis( tert-butyl)-4- hydroxybenzoat (1:2) [19]; Nickel(II)-palmitat [20]; (2-Ethylhexanoato- O)(isononanoato- O)-nickel [21]; (Isononanoato- O)(isooctanoato- O)-nickel [22]; (Isooctanoato- O)(neodecanoato- O)-nickel [23]; (2-Ethylhexanoato- O)(isodecanoato- O)-nickel [24]; (2-Ethylhexanoato- O)(neodecanoato- O)-nickel [25];] (Isodecanoato- O)(isooctanoato- O)-nickel [26]; (Isodecanoato- O)(isononanoato- O)-nickel [27]; (Isononanoato- O)(neodecanoato- O)-nickel [28]; Fettsäuren, C6-19-verzweigt, Nickelsalze [29]; Fettsäuren, C8-18- und C18-ungesättigt, Nickelsalze [30]; 2,7-Naphthalindisulfonsäure, Nickel(II)-salz [31] | 240-235-8 [1] 222-102-6 [2] 254-642-3 [3] 242-533-3 [4] 242-161-1 [5] 245-119-0 [6] 224-699-9 [7] 231-480-1 [8] 301-323-2 [9] 249-555-2 [10] 248-585-3 [11] 284-349-6 [12] 300-094-6 [13] 287-468-1 [14] 287-469-7 [15] 257-447-1 [16] 300-093-0 [17] 276-205-6 [18] 258-051-1 [19] 237-138-8 [20] 287-470-2 [21] 287-471-8 [22] 284-347-5 [23] 284-351-7 [24] 285-698-7 [25] 285-909-2 [26] 284-348-0 [27] 287-592-6 [28] 294-302-1 [29] 283-972-0 [30] - [31] | 16083-14-0 [1] 3349-08-4 [2] 39819-65-3 [3] 18721-51-2 [4] 18283-82-4 [5] 22605-92-1 [6] 4454-16-4 [7] 7580-31-6 [8] 93983-68-7 [9] 29317-63-3 [10] 27637-46-3 [11] 84852-37-9 [12] 93920-10-6 [13] 85508-43-6 [14] 85508-44-7 [15] 51818-56-5 [16] 93920-09-3 [17] 71957-07-8 [18] 52625-25-9 [19] 13654-40-5 [20] 85508-45-8 [21] 85508-46-9 [22] 84852-35-7 [23] 84852-39-1 [24] 85135-77-9 [25] 85166-19-4 [26] 84852-36-8 [27] 85551-28-6 [28] 91697-41-5 [29] 84776-45-4 [30] 72319-19-8 [31] | Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H341 H360D*** H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H341 H360D*** H372** H334 H317 H410 | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 | ||
028-055-00-6 | Nickel(II)-sulfit [1]; Nickeltellurtrioxid [2]; Nickeltellurtetraoxid [3];Molybdännickelhydroxidoxidphosphat [4] | 231-827-7 [1] 239-967-0 [2] 239-974-9 [3] 268-585-7 [4] | 7757-95-1 [1] 15851-52-2 [2] 15852-21-8 [3] 68130-36-9 [4] | Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H334 H317 H400 H410 | GHS08 GHS09 Gef. | H350i H372** H334 H317 H410 | |||
028-056-00-1 | Nickelborid (NiB) [1]; Dinickelborid [2]; Trinickelborid [3]; Nickelborid [4]; Dinickelsilicid [5]; Nickeldisilicid [6]; Dinickelphosphid [7]; Nickelborphosphid [8] | 234-493-0 [1] 234-494-6 [2] 234-495-1 [3] 235-723-2 [4] 235-033-1 [5] 235-379-3 [6] 234-828-0 [7] - [8] | 12007-00-0 [1] 12007-01-1 [2] 12007-02-2 [3] 12619-90-8 [4] 12059-14-2 [5] 12201-89-7 [6] 12035-64-2 [7] 65229-23-4 [8] | Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H372** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350i H372** H317 H410 | |||
028-057-00-7 | Dialuminiumnickeltetraoxid [1]; Nickeltitantrioxid [2]; Nickeltitanoxid [3]; Nickeldivanadiumhexaoxid [4]; Cobaltdimolybdännickeloctaoxid [5]: Nickelzirconiumtrioxid [6]; Molybdännickeltetraoxid [7]; Nickelwolframtetraoxid [8];Olivin, Nickelgrün [9]; Lithiumnickeldioxid [10]; Molybdännickeloxid [11] | 234-454-8 [1] 234-825-4 [2] 235-752-0 [3] 257-970-5 [4] 268-169-5 [5] 274-755-1 [6] 238-034-5 [7] 238-032-4 [8] 271-112-7 [9] - [10] - [11] | 12004-35-2 [1] 12035-39-1 [2] 12653-76-8 [3] 52502-12-2 [4] 68016-03-5 [5] 70692-93-2 [6] 14177-55-0 [7] 14177-51-6 [8] 68515-84-4 [9] 12031-65-1 [10] 12673-58-4 [11] | Carc. 1A STOT RE 1 Skin Sens. 1 | H350i H372** H317 | GHS08 GHS07 Gef. | H350i H372** H317 | |||
028-058-00-2 | Cobaltlithiumnickeloxid | 442-750-5 | - | Carc. 1A Acute Tox. 2 * STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350i H330 H372** H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H350i H330 H372** H317 H410 | |||
029-001-00-4 | Kupferchlorid; Kupfer(I)-chlorid; | 231-842-9 | 7758-89-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H400 H410 | |||
029-002-00-X | Dikupferoxid; Kupfer(I)-oxid | 215-270-7 | 1317-39-1 | Acute Tox. 4 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H318 H400 H410 | GHS07 GHS05 GHS09 Dgr | H332 H302 H318 H410 | Einatmen:
ATE = 3,34 mg/L (Stäube oder Nebel) oral: ATE = 500 mg/kg KG M = 100 M = 10 | ||
029-003-00-5 | Naphthensäuren, Kupfersalze; Kupfernaphthenat | 215-657-0 | 1338-02-9 | Flam. Liq. 3 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H226 H302 H400 H410 | GHS02 GHS07 GHS09 Achtg. | H226 H302 H410 | |||
029-004-00-0 | Kupfersulfat; Kupfer(II)-sulfat | 231-847-6 | 7758-98-7 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H315 H410 | |||
029-005-00-6 | (Tris(chlormethyl)-phthalocyaninato)-kupfer(II), Reaktionsprodukte mit N-Methylpiperazin und Methoxyessigsäure | 401-260-1 | - | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
029-006-00-1 | Tris(octadec-9-enylammonium)-(trisulfonatophthalocyaninato)-kupfer(II) | 403-210-4 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
029-007-00-7 | (Trinatrium-(2-((3-(6-(2-chlor-5- sulfonato)anilino)-4-(3-carboxypyridinio)-1,3,5-triazin-2-ylamino)-2-oxido-5-sulfonatophenylazo)phenylmethylazo)-4-sulfonatobenzoato)kupfer(3-))-hydroxid | 404-670-9 | 89797-01-3 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | G | ||
029-008-00-2 | Kupfer(II)-methansulfonat | 405-400-2 | 54253-62-2 | Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H318 H410 | |||
029-009-00-8 | Phthalocyanin- N-[3-(diethylamino)propyl]-sulfonamid-Kupferkomplex | 413-650-9 | 93971-95-0 | Aquatic Chronic 3 | H412 | - | H412 | |||
029-010-00-3 | Reaktionsmasse aus Verbindungen von (Dodecakis( p-tolylthio)phthalocyaninato)kupfer(II) bis (Hexadecakis( p-tolylthio)phthalocyaninato)kupfer(II) | 407-700-9 | 101408-30-4 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
029-011-00-9 | Natrium-[29 H,31 H-phthalocyaninato-(2-)- N29, N30, N31, N32]-((3-( N-methyl- N-(2-hydroxyethyl)amino)propyl)amino)-sulfonylsulfonato-Kupferkomplex | 412-730-0 | 150522-10-4 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
029-012-00-4 | Natrium-(( N-(3-trimethylammoniopropyl)-sulfamoyl)methylsulfonatophthalocyaninato)kupfer(II) | 407-340-2 | 124719-24-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
029-013-00-X | Trinatrium-(2-(α -(3-(4-chlor-6-(2-(2-(vinylsulfonyl)ethoxy)ethylamino)-1,3,5-triazin-2-ylamino)-2-oxido-5-sulfonatophenylazo)benzylidenhydrazino)-4-sulfonatobenzoato)kupfer(II) | 407-580-8 | 130201-51-3 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
029-014-00-5 | Reaktionsmasse aus 2,2"-[[ cis-1,2-Cyclohexandiyl-bis(nitrilomethyliden)]bis[phenolat]](2-) N, N",O, O"-Kupferkomplex und 2,2"-[[ trans-1,2-Cyclohexandiyl-bis(nitrilomethylidin)]bis[phenolat]](2-) N, N",O, O"-Kupferkomplex | 419-610-7 | 171866-24-3 | STOT RE 2 * Aquatic Chronic 2 | H373** H411 | GHS08 GHS09 Achtg. | H373** H411 | |||
029-015-00-0 | Kupferthiocyanat | 214-183-1 | 1111-67-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | EUH032 | M = 10 M = 10 | |
029-016-00-6 | Kupfer(II)-oxid | 215-269-1 | 1317-38-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 100 M = 10 | ||
029-017-00-1 | Dikupferchloridtrihydroxid | 215-572-9 | 1332-65-6 | Acute Tox. 4 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H332 H301 H400 H410 | GHS06 GHS09 Dgr | H332 H301 H410 | Einatmen:
ATE = 2,83 mg/L (Stäube oder Nebel) oral: ATE = 299 mg/kg KG M = 10 M = 10 | ||
029-018-00-7 | Tetrakupferhexahydroxidsulfat; [1] Tetrakupferhexahydroxidsulfathydrat [2] | 215-582-3 [1] 215-582-3 [2] | 1333-22-8 [1] 12527-76-3 [2] | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | oral:
ATE = 500 mg/kg KG M = 10 M = 10 | ||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
029-019-01-X | Kupferflocken (mit einem Überzug aus aliphatischer Säure) | - | - | Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H331 H302 H319 H400 H410 | GHS06 GHS09 Dgr | H331 H302 H319 H410 | Einatmen:
ATE = 0,733 mg/L (Stäube oder Nebel) oral: ATE = 500 mg/kg KG M = 10 M = 10 | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
029-019-01-X | Kupferflocken (mit einem Überzug aus aliphatischer Säure) | Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H331 H302 H319 H400 H410 | GHS06 GHS09 Dgr | H331 H302 H319 H410 | Einatmung:
ATE = 0,733 mg/L (Stäube oder Nebel) Oral: ATE = 500 mg/kg KG M = 10 M = 1 | ) | |||
029-020-00-8 | Kupfer(II)-carbonat - Kupfer(II)-hydroxid (1:1) | 235-113-6 | 12069-69-1 | Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H319 H400 H410 | GHS07 GHS09 Wng | H332 H302 H319 H410 | Einatmen:
ATE = 1,2 mg/L (Stäube oder Nebel) oral: ATE = 500 mg/kg KG M = 10 M = 10 | ||
029-021-00-3 | Kupferdihydroxid; Kupfer(II)-hydroxid | 243-815-9 | 20427-59-2 | Acute Tox. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H318 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H302 H318 H410 | Einatmen:
ATE = 0,47 mg/L (Stäube oder Nebel) oral: ATE = 500 mg/kg KG M = 10 M = 10 | ||
029-022-00-9 | Bordeauxbrühe; Reaktionsprodukte von Kupfersulfat mit Calciumdihydroxid | - | 8011-63-0 | Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H332 H318 H400 H410 | GHS07 GHS05 GHS09 Dgr | H332 H318 H410 | Einatmen:
ATE = 1,97 mg/L (Stäube oder Nebel) M = 10 M = 1 | ||
029-023-00-4 | Kupfersulfat-Pentahydrat | 231-847-6 | 7758-99-8 | Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H318 H400 H410 | GHS07 GHS05 GHS09 Dgr | H302 H318 H410 | oral:
ATE = 481 mg/kg KG M = 10 M = 1 | ||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
029-024-00-X | Kupfer, granuliert [Partikellänge: von 0,9 mm bis 6,0 mm; Partikelbreite: von 0,494 mm bis 0,949 mm] | 231-159-6 | 7440-50-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
029-026-00-0 | Kupfer; [spezifische Oberfläche > 0,67 mm2/mg] | 231-159-6 | 7440-50-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 10 M = 1 | ) | |
029-025-00-5 | Bis( N-hydroxy- N-nitrosocyclohexylaminato-O,O")kupfer; Bis( N-cyclohexyl-diazenium-dioxy)-kupfer; [Cu-HDO] | 239-703-4 | 312600-89-8 15627-09-5 | Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H228 H302 H373 (Leber) H318 H400 H410 | GHS02 GHS07 GHS08 GHS05 GHS09 Dgr | H228 H302 H373 (Leber) H318 H410 | oral:
ATE = 360 mg/kg KG M = 1 M = 1 | ||
030-001-00-1 | Zinkpulver - Zinkstaub (pyrophor) | 231-175-3 | 7440-66-6 | Water-react. 1 Pyr. Sol. 1 Aquatic Acute 1 Aquatic Chronic 1 | H260 H250 H400 H410 | GHS02 GHS09 Gef. | H260 H250 H410 | T | ||
030-001-01-9 | Zinkpulver - Zinkstaub (stabilisiert) | 231-175-3 | 7440-66-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
030-003-00-2 | Zinkchlorid; Zink(II)-chlorid | 231-592-0 | 7646-85-7 | Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H314 H410 | STOT SE 3; H335: C ≥ 5 % | ||
030-004-00-8 | Dimethylzink [1]; Diethylzink [2] | 208-884-1 [1] 209-161-3 [2] | 544-97-8 [1] 557-20-0 [2] | Pyr. Liq. 1 Water-react. 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H250 H260 H314 H400 H410 | GHS02 GHS05 GHS09 Gef. | H250 H260 H314 H410 | EUH014 | ||
030-005-00-3 | Diamindiisocyanatozink | 401-610-3 | - | Acute Tox. 4 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 | H302 H318 H334 H317 H400 | GHS05 GHS08 GHS07 GHS09 Gef. | H302 H318 H334 H317 H400 | |||
030-006-00-9 | Zinksulfat (wasserhaltig) (Mono-, Hexa- und Heptahydrat) [1]; Zinksulfat (wasserfrei) [2] | 231-793-3 [1] 231-793-3 [2] | 7446-19-7 [1] 7733-02-0 [2] | Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H318 H410 | |||
030-007-00-4 | Bis(3,5-Di- tert-butylsalicylato- O1, O2)-zink | 403-360-0 | 42405-40-3 | Flam. Sol. 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H228 H302 H400 H410 | GHS02 GHS07 GHS09 Gef. | H228 H302 H410 | T | ||
030-008-00-X | Hydroxo(2-(benzolsulfonamido)-benzoato)-zink(II) | 403-750-0 | 113036-91-2 | Acute Tox. 4 * Aquatic Chronic 2 | H332 H411 | GHS07 GHS09 Achtg. | H332 H411 | |||
030-009-00-5 | Zink-bis(4-( n-octyloxycarbonylamino)salicylat), Dihydrat | 417-130-2 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
030-010-00-0 | 2-Dodec-1-enylbutandisäure, 4-Methylester, Zinksalz | 430-740-3 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
030-011-00-6 | Trizinkbis(orthophosphat) | 231-944-3 | 7779-90-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
030-012-00-1 | Aluminium-Magnesium-Zink-Carbonathydroxid | 423-570-6 | 169314-88-9 | Aquatic Chronic 4 | H413 | H413 | ||||
030-013-00-7 | Zinkoxid | 215-222-5 | 1314-13-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
030-015-00-8 | Tetrazink(2+)bis(hexacyanocobalt(3+))-diacetat | 440-060-9 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
031-001-00-4 | Galliumarsenid | 215-114-8 | 1303-00-0 | Repr. 1B Carc. 1B STOT RE 1 | H360F H350 H372 (Atmungssystem und hämatopoetisches System) | GHS08 Gef. | H360F H350 H372 (Atmungssystem und hämatopoetisches System) | |||
033-001-00-X | Arsen | 231-148-6 | 7440-38-2 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H410 | |||
033-002-00-5 | Arsenverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H410 | * | A1 | |
033-003-00-0 | Diarsentrioxid; Arsentrioxid | 215-481-4 | 1327-53-3 | Carc. 1A Acute Tox. 2 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H300 H314 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H350 H300 H314 H410 | |||
033-004-00-6 | Diarsenpentaoxid; Arsenpentaoxid | 215-116-9 | 1303-28-2 | Carc. 1A Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H331 H301 H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H331 H301 H410 | |||
033-005-00-1 | Arsensäure und ihre Salze, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Carc. 1A Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H331 H301 H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H331 H301 H410 | A | ||
033-006-00-7 | Arsin | 232-066-3 | 7784-42-1 | Flam. Gas 1 Press. Gas Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H220 H330 H373 ** H400 H410 | GHS02 GHS04 GHS06 GHS08 GHS09 Gef. | H220 H330 H373 ** H410 | U | ||
033-007-00-2 | tert-Butylarsin | 423-320-6 | 4262-43-5 | Pyr. Liq. 1 Acute Tox. 2 * | H250 H330 | GHS02 GHS06 Gef. | H250 H330 | |||
034-001-00-2 | Selen | 231-957-4 | 7782-49-2 | Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 4 | H331 H301 H373 ** H413 | GHS06 GHS08 Gef. | H331 H301 H373 ** H413 | |||
34-002-00-8 | Selenverbindingen, ausgenommen Cadmiumsulfoselenid und soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H373** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H301 H373** H410 | A | ||
034-003-00-3 | Natriumselenit | 233-267-9 | 10102-18-8 | Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Chronic 2 | H300 H331 H317 H411 | GHS06 GHS09 Gef. | H300 H331 H317 H411 | EUH031 | ||
035-001-00-5 | Brom | 231-778-1 | 7726-95-6 | Acute Tox. 2 * Skin Corr. 1A Aquatic Acute 1 | H330 H314 H400 | GHS06 GHS05 GHS09 Gef. | H330 H314 H400 | |||
035-002-00-0 | Hydrogenbromid | 233-113-0 | 10035-10-6 | Press. Gas Skin Corr. 1A STOT SE 3 | H314 H335 | GHS04 GHS05 GHS07 Gef. | H314 H335 | U | ||
035-002-01-8 | Bromwasserstoffsäure ... % | - | - | Skin Corr. 1B STOT SE 3 | H314 H335 | GHS05 GHS07 Gef. | H314 H335 | Skin Corr. 1B; H314: C ≥ 40 % Skin Irrit. 2; H315: 10 % ≤ C < 40 % Eye Irrit. 2; H319: 10 % ≤ C < 40 % STOT SE 3; H335: C ≥ 10 % | B | |
035-003-00-6 | Kaliumbromat | 231-829-8 | 7758-01-2 | Ox. Sol. 1 Carc. 1B Acute Tox. 3 * | H271 H350 H301 | GHS03 GHS06 GHS08 Gef. | H271 H350 H301 | |||
035-004-00-1 | 2-Hydroxyethylammoniumperbromid | 407-440-6 | - | Ox. Sol. 2 **** Acute Tox. 4 * Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 | H272 H302 H314 H317 H400 | GHS03 GHS05 GHS07 GHS09 Gef. | H272 H302 H314 H317 H400 | |||
035-005-00-7 | Ammoniumbromid | 235-183-8 | 12124-97-9 | Repr. 1B Lact. STOT SE 3 STOT RE 1 Eye Irrit. 2 | H360FD H362 H336 H372 (Nervensystem) H319 | GHS08 GHS07 Dgr | H360FD H362 H336 H372 (Nervensystem) H319 | |||
040-001-00-3 | Zirconiumpulver (pyrophor) | 231-176-9 | 7440-67-7 | Water-react. 1 Pyr. Sol. 1 | H260 H250 | GHS02 Gef. | H260 H250 | T | ||
040-002-00-9 | Zirconiumpulver, trocken (nicht pyrophor) | - | - | Self-heat. 1 | H251 | GHS02 Gef. | H251 | T | ||
040-003-00-4 | Reaktionsprodukt von 3,5-Di- tert-butylsalicylsäure und Zirconiumoxychlorid, dehydriert, basisches Zr: DTBS= 1,0: 1,0 bis 1,0: 1,5 | 430-610-6 | 226996-19-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
042-001-00-9 | Molybdäntrioxid | 215-204-7 | 1313-27-5 | Carc. 2 Eye Irrit. 2 STOT SE 3 | H351 H319 H335 | GHS08 GHS07 Achtg. | H351 H319 H335 | |||
042-002-00-4 | Tetrakis(dimethylditetradecylammonium)hexa-μ-oxotetra-μ3-oxodi-μ 5-oxotetradecaoxooctamolybdat(4-) | 404-760-8 | 117342-25-3 | Acute Tox. 3 * Eye Dam. 1 | H331 H318 | GHS06 GHS05 Gef. | H331 H318 | |||
042-003-00-X | Tetrakis(trimethylhexadecylammonium)hexa-μ-oxotetra-μ3-oxodi-μ5-oxotetradecaoxooctamolybdat(4-) | 404-860-1 | 116810-46-9 | Flam. Sol. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H228 H318 H400 H410 | GHS02 GHS05 GHS09 Gef. | H228 H318 H410 | T | ||
042-004-00-5 | Reaktionsprodukt von Ammoniummolybdat und C12-C24-diethoxyliertem Alkylamin (1:5 bis 1:3) | 412-780-3 | - | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H315 H317 H411 | GHS07 GHS09 Achtg. | H315 H317 H411 | |||
042-005-00-0 | Reaktionsmasse aus Mono- und Diglycerolen aus Canolaöl; Canolaölsäureamid aus verzweigtem 1,3-Propandiamin, N-[3-(tridecyloxy)propyl]; N, N-Diorganodithiocarbamat-Molybdänkomplex | 434-240-6 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
046-001-00-X | Tetraamminpalladium(II)-hydrogencarbonat | 425-270-0 | 134620-00-1 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H318 H317 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H302 H373** H318 H317 H410 | |||
047-001-00-2 | Silbernitrat | 231-853-9 | 7761-88-8 | Ox. Sol. 2 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H272 H314 H400 H410 | GHS03 GHS05 GHS09 Gef. | H272 H314 H410 | |||
047-002-00-8 | Polyphosphorsäure, Kupfer- Natrium-, Magnesium-, Calcium-, Silber- und Zinksalz | 416-850-4 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
047-003-00-3 | Silber-Zink-Zeolith (Zeolith, Linde Typ A, Oberfläche mit Silber- und Zinkionen modifiziert) [Dieser Eintrag betrifft Zeolith vom Typ LTA (Linde Typ A), dessen Oberfläche mit Silber- und Zinkionen mit einem Gehalt von Ag+ 0,5 %-6 %, Zn2 + 5 %-16 % und möglicherweise Phospor, NH4+, Mg2+ und/oder Ca2+ jeweils < 3 % modifiziert wurde.] | - | 130328-20-0 | Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d H315 H318 H400 H410 | GHS08 GHS05 GHS09 Gef. | H361d H315 H318 H410 | M = 100 M = 100 | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
047-004-00-9 | Silbermasse: [Partikeldurchmesser ≥ 1 mm] | 231-131-3 | 7440-22-4 | Repr. 2 STOT RE 2 | H361f H373 (Nervensystem) | GHS08 Wng | H361f H373 (Nervensystem) | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
047-005-00-4 | Silberpulver: [Partikeldurchmesser > 100 nm < 1 mm] | 231-131-3 | 7440-22-4 | Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H361f H373 (Nervensystem) H400 H410 | GHS08 GHS09 Wng | H361f H373 (Nervensystem) H410 | M = 10 M = 10 | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
047-006-00-X | Silbernanopartikel: [Partikeldurchmesser > 1 nm ≤ 100 nm] | 231-131-3 | 7440-22-4 | Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H361f H373 (Nervensystem) H400 H410 | GHS08 GHS09 Wng | H361f H373 (Nervensystem) H410 | M = 1.000 M = 1.000 | ) | |
048-001-00-5 | Cadmiumverbindungen, ausgenommen Cadmiumsulfoselenid (xCdS.yCdSe), Reaktionsmasse aus Cadmiumsulfid und Zinksulfid (xCdS.yZnS), Reaktionsmasse aus Cadmiumsulfid mit Quecksilbersulfid (xCdS.yHgS), und soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | * | A1 | |
048-002-00-0 | Cadmium (nicht-pyrophor) [1];] Cadmiumoxid (nicht-pyrophor) [2] | 231-152-8 [1] 215-146-2 [2] | 7440-43-9 [1] 1306-19-0 [2] | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 2 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H341 H361fd H330 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H341 H361fd H330 H372 ** H410 | |||
048-003-00-6 | Cadmiumdiformiat; Cadmiumformiat | 224-729-0 | 4464-23-7 | Acute Tox. 3 * Acute Tox. 3 * Carc. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H351 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H301 H351 H373 ** H410 | * STOT RE 2; H373: C ≥0,25 % | ||
048-004-00-1 | Cadmiumcyanid | 208-829-1 | 542-83-6 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Carc. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H351 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H351 H373 ** H410 | EUH032 | STOT RE 2; H373: C ≥0,1 % EUH032:C≥1 % | |
048-005-00-7 | Cadmiumhexafluorsilicat(2-); Cadmiumfluorsilicat | 241-084-0 | 17010-21-8 | Acute Tox. 3 * Acute Tox. 3 * Carc. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H351 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H301 H351 H373 ** H410 | * STOT RE 2; H373: C ≥0,1 % | ||
048-006-00-2 | Cadmiumfluorid | 232-222-0 | 7790-79-6 | Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H340 H360FD H330 H301 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H340 H360FD H330 H301 H372 ** H410 | Carc. 1B; H350: C ≥ 0,01 % * oral STOT RE 1; H372: C ≥ 7 % STOT RE 2: 0,1 % ≤ C <7 % | ||
048-007-00-8 | Cadmiumiodid | 232-223-6 | 7790-80-9 | Acute Tox. 3 * Acute Tox. 3 * Carc. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H351 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H301 H351 H373 ** H410 | * STOT RE 2; H373: C ≥ 0,1 % | ||
048-008-00-3 | Cadmiumchlorid | 233-296-7 | 10108-64-2 | Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H340 H360FD H330 H301 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H340 H360FD H330 H301 H372 ** H410 | Carc. 1B; H350: C ≥ 0,01 % * oral STOT RE 1; H372: C ≥ 7 % STOT RE 2; H373: 0,1 % ≤ C < 7 % | ||
048-009-00-9 | Cadmiumsulfat | 233-331-6 | 10124-36-4 | Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H340 H360FD H330 H301 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H340 H360FD H330 H301 H372 ** H410 | Carc. 1B; H350: C ≥ 0,01 % * oral STOT RE 1; H372: C ≥ 7 % STOT RE 2; H373 0,1 % ≤ C < 7 % | ||
048-010-00-4 | Cadmiumsulfid | 215-147-8 | 1306-23-6 | Carc. 1B Muta. 2 Repr. 2 STOT RE 1 Acute Tox. 4 * Aquatic Chronic 4 | H350 H341 H361fd H372 ** H302 H413 | GHS08 GHS07 Gef. | H350 H341 H361fd H372 ** H302 H413 | * STOT RE 1; H372: C ≥ 10 % STOT RE 2; H373: 0,1 % ≤ C < 10 % | 1 | |
048-011-00-X | Cadmium (pyrophor) | 231-152-8 | 7440-43-9 | Pyr. Sol. 1 Carc. 1B Muta. 2 Repr. 2 Acute Tox. 2 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H250 H350 H341 H361fd H330 H372 ** H400 H410 | GHS02 GHS06 GHS08 GHS09 Gef. | H250 H350 H341 H361fd H330 H372 ** H410 | |||
048-012-00-5 | Cadmiumcarbonat | 208-168-9 | 513-78-0 | Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H340 H332 H312 H302 H372 (Nieren, Knochen) H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H340 H332 H312 H302 H372 (Nieren, Knochen) H410 | A1 | ||
048-013-00-0 | Cadmiumhydroxid; Cadmiumdihydroxid | 244-168-5 | 21041-95-2 | Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H340 H332 H312 H302 H372 (Nieren, Knochen) H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H340 H332 H312 H302 H372 (Nieren, Knochen) H410 | A1 | ||
048-014-00-6 | Cadmiumnitrat; Cadmiumdinitrat | 233-710-6 | 10325-94-7 | Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H340 H332 H312 H302 H372 (Nieren, Knochen) H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H340 H332 H312 H302 H372 (Nieren, Knochen) H410 | Carc. 1B; H350: C ≥ 0,01 % | A1 | |
050-001-00-5 | Zinntetrachlorid; Stannichlorid; Zinn(IV)-chlorid | 231-588-9 | 7646-78-8 | Skin Corr. 1B Aquatic Chronic 3 | H314 H412 | GHS05 Gef. | H314 H412 | STOT SE 3; H335:C≥5 % | ||
050-002-00-0 | Cyhexatin (ISO); Hydroxytricyclohexylstannan; Tricyclohexylzinnhydroxid | 236-049-1 | 13121-70-5 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | M=1000 | ||
050-003-00-6 | Fentinacetat (ISO); Triphenylzinnacetat | 212-984-0 | 900-95-8 | Carc. 2 Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d*** H330 H311 H301 H372** H335 H315 H318 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H351 H361d*** H330 H311 H301 H372** H335 H315 H318 H410 | M=10 | ||
050-004-00-1 | Fentinhydroxid (ISO); Triphenylzinnhydroxid | 200-990-6 | 76-87-9 | Carc. 2 Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d*** H330 H311 H301 H372** H335 H315 H318 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H351 H361d*** H330 H311 H301 H372** H335 H315 H318 H410 | M=10 | ||
050-005-00-7 | Trimethylzinnverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H300 H410 | * | A1 | |
050-006-00-2 | Triethylzinnverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H300 H410 | * | A1 | |
050-007-00-8 | Tripropylzinnverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | * | A1 | |
050-008-00-3 | Tributyl-Zinnverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Repr. 1B Acute Tox. 3 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H360FD H301 H312 H372** H315 H319 H400 H410 | GHS08 GHS06 GHS09 Gef. | H360FD H301 H312 H372** H315 H319 H410 | * STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,25 % ≤ C < 1 % Skin Irrit. 2; H315:C ≥ 1 % Eye Irrit. 2; H319:C ≥ 1 % M = 10 | A 1 | |
050-009-00-9 | Fluortripentylstannan [1]; Hexapentyldistannoxan [2] | 243-546-7 [1] 247-143-7 [2] | 20153-49-5 [1] 25637-27-8 [2] | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | * | 1 | |
050-010-00-4 | Fluortrihexylstannan | 243-547-2 | 20153-50-8 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | * | 1 | |
050-011-00-X | Triphenylzinnverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | * M=100 | A1 | |
050-012-00-5 | Tetracyclohexylstannan [1]; Chlortricyclohexylstannan [2];Butyltricyclohexylstannan [3] | 215-910-5 [1] 221-437-5 [2] 230-358-5 [3] | 1449-55-4 [1] 3091-32-5 [2] 7067-44-9 [3] | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | * | A1 | |
050-013-00-0 | Trioctylzinnverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 4 | H319 H335 H315 H413 | GHS07 Achtg. | H319 H335 H315 H413 | Skin Irrit. 2; H315: C ≥ 1 % Eye Irrit.2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % | A1 | |
050-017-00-2 | Fenbutatinoxid (ISO); Bis(tris(2-methyl-2-phenylpropyl)tin)oxid | 236-407-7 | 13356-08-6 | Acute Tox. 2 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H330 H319 H315 H400 H410 | GHS06 GHS09 Gef. | H330 H319 H315 H410 | |||
050-018-00-8 | Zinn(II)-methansulfonat | 401-640-7 | 53408-94-9 | Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H314 H302 H317 H411 | GHS05 GHS07 GHS09 Gef. | H314 H302 H317 H411 | |||
050-019-00-3 | Azocyclotin (ISO); 1-(Tricyclohexylstannyl)-1 H-1,2,4-triazol | 255-209-1 | 41083-11-8 | Acute Tox. 2 * Acute Tox. 3 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H301 H335 H315 H318 H400 H410 | GHS06 GHS05 GHS09 Gef. | H330 H301 H335 H315 H318 H410 | |||
050-020-00-9 | Trioctylstannan | 413-320-4 | 869-59-0 | STOT RE 1 Skin Irrit. 2 Aquatic Chronic 4 | H372 ** H315 H413 | GHS08 GHS07 Gef. | H372 ** H315 H413 | |||
050-021-00-4 | Dichlordioctylstannan | 222-583-2 | 3542-36-7 | Repr. 1B Acute Tox. 2 STOT RE 1 Aquatic Chronic 3 | H360D H330 H372 ** H412 | GHS08 GHS06 Dgr | H360D H330 H372 ** H412 | Repr. 1B; H360 D: C ≥ 0,03 % Einatmen: ATE = 0,098 mg/L (Stäube oder Nebel) | ||
050-022-00-X | Dibutylzinndichlorid; (DBTC) | 211-670-0 | 683-18-1 | Muta. 2 Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H341 H360FD H330 H301 H312 H372** H314 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H341 H360FD H330 H301 H312 H372** H314 H410 | Skin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 0,01 % ≤ C < 5 % Eye Dam.1; H318: 3 % ≤ C < 5 % Eye Irrit. 2; H319: 0,01 % ≤ C < 3 % M=10 | ||
050-023-00-5 | Reaktionsmasse aus Bis[(2-ethyl-1-oxohexyl)-oxy]-dioctylstannan; Bis[((2-ethyl-1-oxohexyl)-oxy)-dioctylstannyl]-oxid; Bis(1-phenyl-1,3-decandionyl)-dioctylstannan und ((2-Ethyl-1-oxohexyl)-oxy)-(1-phenyl-1,3-decandionyl)-dioctylstannan | 422-920-5 | - | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373** H400 H410 | GHS08 GHS09 Achtg. | H373** H410 | M=10 | ||
050-024-00-0 | Reaktionsmasse aus Tri- p-tolylzinnhydroxid; Hexa- p-tolyldistannoxan | 432-230-6 | - | STOT RE 1 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H372** H302 H315 H318 H317 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H372** H302 H315 H318 H317 H410 | |||
050-025-00-6 | Trichlormethylstannan | 213-608-8 | 993-16-8 | Repr. 2 | H361d | GHS08 Achtg. | H361d | |||
050-026-00-1 | 2-Ethylhexyl-10-ethyl-4-[[2-[(2- ethylhexyl)oxy]-2-oxoethyl]-thio]-4-methyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoat | 260-828-5 | 57583-34-3 | Repr. 2 | H361d | GHS08 Achtg. | H361d | |||
050-027-00-7 | 2-Ethylhexyl-10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4 -stannatetradecanoat; [DOTE] | 239-622-4 | 15571-58-1 | Repr. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H372 (Immunsystem) H400 H410 | GHS08 GHS09 Dgr | H360D H372 (Immunsystem) H410 | |||
050-028-00-2 | 2-Ethylhexyl-10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoat | 260-829-0 | 57583-35-4 | Repr. 2 Acute Tox. 4 STOT RE 1 Skin Sens. 1A | H361d H302 H372 (Nervensystem, Immunsystem) H317 | GHS08 GHS07 Gef. | H361d H302 H372 (Nervensystem, Immunsystem) H317 | |||
050-029-00-8 | Dimethylzinndichlorid | 212-039-2 | 753-73-1 | Repr. 2 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 STOT RE 1 Skin Corr. 1B | H361d H330 H301 H311 H372 (Nervensystem, Immunsystem) H314 | GHS08 GHS06 GHS05 Gef. | H361d H330 H301 H311 H372 (Nervensystem, Immunsystem) H314 | EUH071 | ||
050-030-00-3 | Dibutylzinndilaurat; Dibutyl[bis(dodecanoyloxy)]-stannan | 201-039-8 | 77-58-7 | Muta. 2 Repr. 1B STOT RE 1 | H341 H360FD H372 (Immunsystem) | GHS08 Gef. | H341 H360FD H372 (Immunsystem) | |||
050-031-00-9 | Dioctylzinndilaurat [1]; Dioctyl-, Bis(coco-acyloxy)-stannanderivate [2] | 222-883-3 [1] 293-901-5 [2] | 3648-18-8 [1] 91648-39-4 [2] | Repr. 1B STOT RE 1 | H360D H372 (Immunsystem) | GHS08 Dgr | H360D H372 (Immunsystem) | |||
050-032-00-4 | Dibutylzinnbis(2-ethylhexanoat) | 220-481-2 | 2781-10-4 | Muta. 2 Repr. 1B STOT RE 1 | H341 H360FD H372 (Immunsystem) | GHS08 Dgr | H341 H360FD H372 (Immunsystem) | |||
050-033-00-X | Dibutylzinndi(acetat) | 213-928-8 | 1067-33-0 | Muta 2 Repr. 1B STOT RE 1 | H341 H360FD H372 (Immunsystem) | GHS08 Dgr | H341 H360FD H372 (Immunsystem) | |||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
050-034-00-5 | Dibutylzinnmaleat | 201-077-5 | 78-04-6 | Muta. 2 Repr. 1B Acute Tox. 2 Acute Tox. 4 STOT RE 1 Skin Corr. 1 Eye Dam. 1 | H341 H360FD H330 H302 H372 (Immunsystem) H314 H318 | GHS08 GHS06 GHS05 Dgr | H341 H360FD H330 H302 H372 (Immunsystem) H314 | Inhalation: ATE = 0,317 mg/L (Stäube oder Nebel) Oral: ATE = 510 mg/kg KG | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
050-035-00-0 | Dibutylzinnoxid | 212-449-1 | 818-08-6 | Muta. 2 Repr. 1B Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 | H341 H360FD H301 H372 (Immunsystem) H315 H318 | GHS08 GHS06 GHS05 Dgr | H341 H360FD H301 H372 (Immunsystem) H315 H318 | Oral: ATE = 170 mg/kg KG | ) | |
051-001-00-8 | Antimontrichlorid | 233-047-2 | 10025-91-9 | Skin Corr. 1B Aquatic Chronic 2 | H314 H411 | GHS05 GHS09 Gef. | H314 H411 | STOT SE3; H335: C ≥ 5 % | ||
051-002-00-3 | Antimonpentachlorid | 231-601-8 | 7647-18-9 | Skin Corr. 1B Aquatic Chronic 2 | H314 H411 | GHS05 GHS09 Gef. | H314 H411 | STOT SE 3; H335: C ≥ 5 % | ||
051-003-00-9 | Antimonverbindungen, ausgenommen Diantimontetroxid (Sb2O4), Antimonpentaoxid (Sb2O5), Diantimontrisulfid (Sb2S3), Diantimonpentasulfid (Sb2S5), und soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H332 H302 H411 | GHS07 GHS09 Achtg. | H332 H302 H411 | * | A1 | |
051-004-00-4 | Antimontrifluorid | 232-009-2 | 7783-56-4 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H331 H311 H301 H411 | GHS06 GHS09 Gef. | H331 H311 H301 H411 | |||
051-005-00-X | Diantimontrioxid; Antimontrioxid | 215-175-0 | 1309-64-4 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
051-006-00-5 | Diphenyl(4-phenylthiophenyl)-sulfoniumhexafluorantimonat | 403-500-0 | - | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
051-007-00-0 | Bis(4-dodecylphenyl)-iodonium hexafluorantimonat | 404-420-9 | 71786-70-4 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
052-001-00-0 | Tellur | 236-813-4 | 13494-80-9 | Repr. 1B Lact. | H360Df H362 | GHS08 Dgr | H360Df H362 | |||
"052-002-00-6 | Tellurdioxid | 231-193-1 | 7446-07-3 | Repr. 1B Lact. | H360Df H362 | GHS08 Dgr | H360Df H362" | |||
053-001-00-3 | Iod | 231-442-4 | 7553-56-2 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 | H332 H312 H400 | GHS07 GHS09 Achtg. | H332 H312 H400 | |||
053-002-00-9 | Hydrogeniodid; Iodwasserstoff | 233-109-9 | 10034-85-2 | Press.
Gas Skin Corr. 1A | H314 | GHS04 GHS05 Gef. | H314 | Skin Corr. 1A; H314: C ≥ 10 % Skin Corr. 1B; H314: 0,2 % ≤ C < 10 % Skin Irrit. 2; H315: 0,02 % ≤ C < 0,2 % Eye Irrit. 2; H319: 0,02 % ≤ C < 0,2 % STOT SE 3; H335: C ≥0,02 % | U5 | |
053-002-01-6 | Iodwasserstoffsäure ... % | - | - | Skin Corr. 1B | H314 | GHS05 Gef. | Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % | B | ||
053-003-00-4 | Iodylbenzol | - | 696-33-3 | Expl. **** | **** | **** | **** | |||
053-004-00-X | Calciumiodoxybenzoat | - | - | Expl. **** | **** | **** | **** | C | ||
053-005-00-5 | (4-(1-Methylethyl)phenyl)-(4-methylphenyl)iodoniumtetrakis(pentafluorphenyl)borat(1-) | 422-960-3 | 178233-72-2 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H373 ** H400 H410 | GHS08 GHS07 GHS09 Achtg. | H312 H302 H373 ** H410 | |||
056-001-00-1 | Bariumperoxid | 215-128-4 | 1304-29-6 | Ox. Sol. 2 Acute Tox. 4 * Acute Tox. 4 * | H272 H332 H302 | GHS03 GHS07 Gef. | H272 H332 H302 | |||
056-002-00-7 | Bariumsalze, ausgenommen Bariumsulfat, Salze der 1-Azo-2-hydroxynaphthalenylarylsulfonsäure und die in diesem Anhang gesondert aufgeführten Salze | - | - | Acute Tox. 4 * Acute Tox. 4 * | H332 H302 | GHS07 Achtg. | H332 H302 | * | A1 | |
056-003-00-2 | Bariumcarbonat | 208-167-3 | 513-77-9 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
056-004-00-8 | Bariumchlorid; Bariumdichlorid | 233-788-1 | 10361-37-2 | Acute Tox. 3 * Acute Tox. 4 * | H301 H332 | GHS06 Gef. | H301 H332 | |||
056-005-00-3 | Bariumdibortetraoxid | 237-222-4 | 13701-59-2 | Repr. 1B Acute Tox. 4 Acute Tox. 3 | H360FD H332 H301 | GHS08 GHS06 Dgr | H360FD H332 H301 | Einatmung: ATE = 1,5 mg/L (Stäube oder Nebel) Oral: ATE = 100 mg/kg KG | ||
064-001-00-8 | Gadolinium(III)-sulfit-Trihydrat | 456-900-2 | 51285-81-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
072-001-00-4 | Hafniumtetra- n-butoxid | 411-740-2 | 22411-22-9 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
Hexanatriumwolframathydrat | 412-770-9 | 12141-67-2 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | ||||
074-002-00-5 | Reaktionsprodukte von Wolframhexachlorid und 2-Methylpropan-2-ol, Nonylphenol und Pentan-2,4-dion | 408-250-6 | - | Flam. Liq. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H225 H332 H314 H317 H400 H410 | GHS02 GHS05 GHS07 GHS09 Gef. | H225 H332 H314 H317 H410 | |||
076-001-00-5 | Osmiumtetroxid; Osmiumsäure | 244-058-7 | 20816-12-0 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Corr. 1B | H330 H310 H300 H314 | GHS06 GHS05 Gef. | H330 H310 H300 H314 | |||
078-001-00-0 | Tetrachlorplatinate, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H301 H318 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H318 H334 H317 | A | ||
078-002-00-6 | Diammoniumtetrachlorplatinat | 237-499-1 | 13820-41-2 | Acute Tox. 3 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H301 H315 H318 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H315 H318 H334 H317 | |||
078-003-00-1 | Dinatriumtetrachlorplatinat | 233-051-4 | 10026-00-3 | Acute Tox. 3 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H301 H315 H318 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H315 H318 H334 H317 | |||
078-004-00-7 | Dikaliumtetrachlorplatinat | 233-050-9 | 10025-99-7 | Acute Tox. 3 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H301 H315 H318 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H315 H318 H334 H317 | |||
078-005-00-2 | Hexachlorplatinate, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H301 H318 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H318 H334 H317 | A | ||
078-006-00-8 | Dinatriumhexachlorplatinat | 240-983-5 | 16923-58-3 | Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H301 H318 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H318 H334 H317 | |||
078-007-00-3 | Dikaliumhexachlorplatinat | 240-979-3 | 16921-30-5 | Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H301 H318 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H318 H334 H317 | |||
078-008-00-9 | Diammoniumhexachlorplatinat | 240-973-0 | 16919-58-7 | Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H301 H318 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H318 H334 H317 | |||
078-009-00-4 | Hexachlorplatinsäure | 241-010-7 | 16941-12-1 | Acute Tox. 3 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 | H301 H314 H334 H317 | GHS06 GHS05 GHS08 Gef. | H301 H314 H334 H317 | |||
078-010-00-X | Tetraamminplatin(II)-hydrogencarbonat | 426-730-3 | 123439-82-7 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
078-011-00-5 | Hydroxydisulfitplatin(II)-säure | 423-310-1 | 61420-92-6 | Acute Tox. 4 * STOT RE 2 * Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 | H302 H373 H314 H334 H317 H412 | GHS05 GHS08 GHS07 Gef. | H302 H373 H314 H334 H317 H412 | |||
078-012-00-0 | Platin(IV)-nitrat-/salpetersäurelösung | 432-400-1 | - | Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Gef. | H314 H410 | |||
080-001-00-0 | Quecksilber | 231-106-7 | 7439-97-6 | Repr. 1B Acute Tox. 2 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D*** H330 H372** H400 H410 | GHS06 GHS08 GHS09 Gef. | H360D*** H330 H372** H410 | |||
080-002-00-6 | Anorganische Quecksilberverbindungen, ausgenommen Quecksilber(II)-sulfid (Zinnober), und soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H373 ** H410 | * STOT RE 2; H373: C ≥ 0,1 % | A1 | |
080-003-00-1 | Diquecksilberdichlorid, Quecksilberchlorid; Kalomel; Quecksilber(I)-chlorid | 233-307-5 | 10112-91-1 | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H335 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H335 H315 H410 | |||
080-004-00-7 | Organische Quecksilberverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H373 ** H410 | * STOT RE 2; H373: C ≥0,1 % | A1 | |
080-005-00-2 | Quecksilberdifulminat; Quecksilberfulminat; Knallquecksilber | 211-057-8 | 628-86-4 | Unst. Expl. Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H200 H331 H311 H301 H373 ** H400 H410 | GHS01 GHS06 GHS08 GHS09 Gef. | H200 H331 H311 H301 H373 ** H400 H410 | |||
080-005-01-X | Quecksilberdifulminat; Quecksilberfulminat; Knallquecksilber [≥ 20 % Phlegmatisierungsmittel] | 211-057-8 | 628-86-4 | Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H201 H331 H311 H301 H373 ** H400 H410 | GHS01 GHS06 GHS08 GHS09 Gef. | H201 H331 H311 H301 H373 ** H400 H410 | |||
080-006-00-8 | Diquecksilberdicyanidoxid; Quecksilberoxycyanid | 215-629-8 | 1335-31-5 | Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H201 H331 H311 H301 H373** H400 H410 | GHS01 GHS06 GHS08 GHS09 Gef. | H201 H331 H311 H301 H373** H410 | |||
080-007-00-3 | Dimethylquecksilber [1]; Diethylquecksilber [2] | 209-805-3 [1] 211-000-7 [2] | 593-74-8 [1] 627-44-1 [2] | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H373 ** H410 | * STOT RE 2; H373: C ≥0,05 % | 1 | |
080-008-00-9 | Phenylquecksilbernitrat [1];Phenylquecksilberhydroxid [2]; basisches Phenylquecksilbernitrat [3] | 200-242-9 [1] 202-866-7 [2] -[3] | 55-68-5 [1] 100-57-2 [2] 8003-05-2 [3] | Acute Tox. 3 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H301 H372 ** H314 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H301 H372 ** H314 H410 | |||
080-009-00-4 | 2-Methoxyethylquecksilberchlorid | 204-659-7 | 123-88-6 | Acute Tox. 3 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H301 H372 ** H314 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H301 H372 ** H314 H410 | |||
080-010-00-X | Quecksilberdichlorid; Quecksilberchlorid; Quecksilber(II)-chlorid Sublimat | 231-299-8 | 7487-94-7 | Muta. 2 Repr. 2 Acute Tox. 2 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H341 H361f*** H300 H372** H314 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H341 H361f*** H300 H372** H314 H410 | |||
080-011-00-5 | Phenylquecksilberacetat | 200-532-5 | 62-38-4 | Acute Tox. 3 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H301 H372 ** H314 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H301 H372 ** H314 H410 | |||
080-012-00-0 | Methylquecksilberchlorid | 204-064-2 | 115-09-3 | Carc. 2 Repr. 1A Lact. Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H360Df H362 H330 H310 H300 H372 (Nervensystem, Nieren) H400 H410 | GHS08 GHS06 GHS09 Dgr | H351 H360Df H362 H330 H310 H300 H372 (Nervensystem, Nieren) H410 | Einatmen:
ATE = 0,05 mg/L (Stäube oder Nebel) Dermal: ATE = 50 mg/kg KG Oral: ATE = 5 mg/kg KG | 1 | |
081-001-00-3 | Thallium | 231-138-1 | 7440-28-0 | Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 4 | H330 H300 H373 ** H413 | GHS06 GHS08 Gef. | H330 H300 H373 ** H413 | |||
081-002-00-9 | Thalliumverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 | H330 H300 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H330 H300 H373 ** H411 | A | ||
081-003-00-4 | Dithalliumsulfat; Thallium(I)-sulfat | 231-201-3 | 7446-18-6 | Acute Tox. 2 * STOT RE 1 Skin Irrit. 2 Aquatic Chronic 2 | H300 H372 ** H315 H411 | GHS06 GHS08 GHS09 Gef. | H300 H372 ** H315 H411 | |||
082-001-00-6 | Bleiverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H360Df H332 H302 H373 ** H400 H410 | GHS08 GHS07 GHS09 Gef. | H360Df H332 H302 H373 ** H410 | Repr.2 H361f: C ≥ 2,5 % * STOT RE 2; H373: C ≥0,5 % | A1 | |
082-002-00-1 | Bleialkyle | - | - | Repr. 1A Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H360Df H330 H310 H300 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H360Df H330 H310 H300 H373 ** H410 | Repr.1A; H360D: C≥ 0,1 % * STOT RE 2; H373: C ≥0,05 % | A1 | |
082-003-00-7 | Bleidiazid; Bleiazid | 236-542-1 | 13424-46-9 | Unst. Expl. Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H200 H360Df H332 H302 H373 ** H400 H410 | GHS01 GHS08 GHS07 GHS09 Gef. | H200 H360Df H332 H302 H373 ** H410 | 1 | ||
082-003-01-4 | Bleidiazid; Bleiazid [≥ 20 % Phlegmatisierungsmittel] | 236-542-1 | 13424-46-9 | Expl. 1.1 Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H201 H360Df H332 H302 H373 ** H400 H410 | GHS01 GHS08 GHS07 GHS09 Gef. | H201 H360Df H332 H302 H373 ** H410 | 1 | ||
082-004-00-2 | Bleichromat | 231-846-0 | 7758-97-6 | Carc. 1B Repr. 1A STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H350 H360Df H373** H400 H410 | GHS08 GHS09 Gef. | H350 H360Df H373** H410 | 1 | ||
082-005-00-8 | Blei(II)-acetat | 206-104-4 | 301-04-2 | Repr. 1A STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H360Df H373 ** H400 H410 | GHS08 GHS09 Gef. | H360Df H373 ** H410 | 1 | ||
082-006-00-3 | Triblei-bis(orthophosphat) | 231-205-5 | 7446-27-7 | Repr. 1A STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H360Df H373 ** H400 H410 | GHS08 GHS09 Gef. | H360Df H373 ** H410 | 1 | ||
082-007-00-9 | Bleiacetat, basisch | 215-630-3 | 1335-32-6 | Carc. 2 Repr. 1A STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H360Df H373 ** H400 H410 | GHS08 GHS09 Gef. | H351 H360Df H373 ** H410 | 1 | ||
082-008-00-4 | Blei(II)bis(methansulfonat) | 401-750-5 | 17570-76-2 | Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 | H360Df H332 H302 H373 ** H315 H318 | GHS08 GHS05 GHS07 Gef. | H360Df H332 H302 H373 ** H315 H318 | 1 | ||
082-009-00-X | Bleisulfochromatgelb; C.I. Pigment Gelb34; [Dieser Stoff ist im Colour Index unter der Constitution Number C.I. 77603 verzeichnet.] | 215-693-7 | 1344-37-2 | Carc. 1B Repr. 1A STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H350 H360Df H373** H400 H410 | GHS08 GHS09 Gef. | H350 H360Df H373** H410 | 1 | ||
082-010-00-5 | Bleichromatmolybdatsulfaterot; C.I. Pigment Rot 104; [Dieser Stoff ist im Colour Index unter der Constitution Number C.I. 77605 verzeichnet.] | 235-759-9 | 12656-85-8 | Carc. 1B Repr. 1A STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H350 H360Df H373** H400 H410 | GHS08 GHS09 Gef. | H350 H360Df H373** H410 | 1 | ||
082-011-00-0 | Bleihydrogenarsenat | 232-064-2 | 7784-40-9 | Carc. 1A Repr. 1A Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H360Df H331 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H360Df H331 H301 H373 ** H410 | 1 | ||
082-012-00-6 | Barium-Calcium-Caesium-Blei-Samarium-Strontium-Bromid-Chlorid-Fluorid-Iodid, europiumdotiert | 431-780-4 | 199876-46-5 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 | H302 H373** H411 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H411 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
082-013-00-1 | Bleipulver; [Partikeldurchmesser < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 | H360FD H362 H400 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
082-013-00-1 | Bleipulver; [Partikeldurchmesser < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 | H360FD H362 H400 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | Repr. 1A; H360D: C ≥ 0,03 % M = 10 M = 100 | ) | |
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
082-014-00-7 | Blei, massiv: [Partikeldurchmesser ≥ 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1 A Lakt. | H360FD H362 | GHS08 Gef. | H360FD H362 | |||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
082-014-00-7 | Blei, massiv: [Partikeldurchmesser ≥ 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Chronic 1 | H360FD H362 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | M = 10 | ) | |
092-001-00-8 | Uran | 231-170-6 | 7440-61-1 | Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 4 | H330 H300 H373 ** H413 | GHS06 GHS08 Gef. | H330 H300 H373 ** H413 | |||
092-002-00-3 | Uranverbindungen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 Aquatic Chronic 2 | H330 H300 H373** H411 | GHS06 GHS08 GHS09 Gef. | H330 H300 H373** H411 | A | ||
601-001-00-4 | Methan | 200-812-7 | 74-82-8 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
601-002-00-X | Ethan | 200-814-8 | 74-84-0 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
601-003-00-5 | Propan | 200-827-9 | 74-98-6 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
601-004-00-0 | Butan [1]; und Isobutan 2-Methylpropan [2] | 203-448-7 [1] 200-857-2 [2] | 106-97-8 [1] 75-28-5 [2] | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | C U | ||
601-004-01-8 | Butan (mit ≥ 0,1 % Butadien (203-450-8)) [1]; Isobutan (mit ≥ 0,1 % Butadien (203-450-8)) [2] | 203-448-7 [1] 200-857-2 [2] | 106-97-8 [1] 75-28-5 [2] | Flam. Gas 1 Press. Gas Carc. 1A Muta. 1B | H220 H350 H340 | GHS02 GHS04 GHS08 Gef. | H220 H350 H340 | C S U | ||
601-005-00-6 | 2,2-Dimethylpropan; Neopentan | 207-343-7 | 463-82-1 | Flam. Gas 1 Press. Gas Aquatic Chronic 2 | H220 H411 | GHS02 GHS04 GHS09 Gef. | H220 H411 | U | ||
601-006-00-1 | Pentan | 203-692-4 | 109-66-0 | Flam. Liq. 2 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 | H225 H304 H336 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H304 H336 H411 | EUH066 | C | |
601-007-00-7 | Hexan (mit < 5 % n-Hexan (203-777-6)); 2-Methylpentan [1]; 3-Methylpentan [2]; 2,2-Dimethylbutan [3]; 2,3-Dimethylbutan [4] | 203-523-4 [1] 202-481-4 [2] 200-906-8 [3] 201-193-6 [4] | 107-83-5 [1] 96-14-0 [2] 75-83-2 [3] 79-29-8 [4] | Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 | H225 H304 H315 H336 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H304 H315 H336 H411 | C | ||
601-008-00-2 | Heptan; n-Heptan [1]; 2,4-Dimethylpentan [2]; 2,2,3-Trimethylbutan [3]; 3,3-Dimethylpentan [4]; 2,3-Dimethylpentan [5]; 3-Methylhexan [6]; 2,2-Dimethylpentan [7]; 2-Methylhexan [8]; 3-Ethylpentan [9]; Isoheptan [10] | 205-563-8 [1] 203-548-0 [2] 207-346-3 [3] 209-230-8 [4] 209-280-0 [5] 209-643-3 [6] 209-680-5 [7] 209-730-6 [8] 210-529-0 [9] 250-610-8 [10] | 142-82-5 [1] 108-08-7 [2] 464-06-2 [3] 562-49-2 [4] 565-59-3 [5] 589-34-4 [6] 590-35-2 [7] 591-76-4 [8] 617-78-7 [9] 31394-54-4 [10] | Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H225 H304 H315 H336 H400 H410 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H304 H315 H336 H410 | C | ||
601-009-00-8 | Octan; n-Octan [1]; 2,2,4-Trimethylpentan [2]; 2,3,3-Trimethylpentan [3]; 3,3-Dimethylhexan [4]; 2,2,3-Trimethylpentan [5]; 2,3,4-Trimethylpentan [6]; 3,4-Dimethylhexan [7]; 2,3-Dimethylhexan [8]; 2,4-Dimethylhexan [9]; 4-Methylheptan [10]; 3-Methylheptan [11]; 2,2-Dimethylhexan [12]; 2,5-Dimethylhexan [13]; 2-Methylheptan [14]; 2,2,3,3-Tetramethylbutan [15]; 3-Ethyl-2-methylpentan [16]; 3-Ethylhexan [17]; 3-Ethyl-3-methylpentan [18]; Isooctan [19] | 203-892-1 [1] 208-759-1 [2] 209-207-2 [3] 209-243-9 [4] 209-266-4 [5] 209-292-6 [6] 209-504-7 [7] 209-547-1 [8] 209-649-6 [9] 209-650-1 [10] 209-660-6 [11] 209-689-4 [12] 209-745-8 [13] 209-747-9 [14] 209-855-6 [15] 210-187-2 [16] 210-621-0 [17] 213-923-0 [18] 247-861-0 [19] | 111-65-9 [1] 540-84-1 [2] 560-21-4 [3] 563-16-6 [4] 564-02-3 [5] 565-75-3 [6] 583-48-2 [7] 584-94-1 [8] 589-43-5 [9] 589-53-7 [10] 589-81-1 [11] 590-73-8 [12] 592-13-2 [13] 592-27-8 [14] 594-82-1 [15] 609-26-7 [16] 619-99-8 [17] 1067-08-9 [18] 26635-64-3 [19] | Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H225 H304 H315 H336 H400 H410 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H304 H315 H336 H410 | C | ||
601-010-00-3 | Ethen; Ethylen | 00-815-3 | 74-85-1 | lam. Gas 1 Press. Gas STOT SE 3 | 220 H336 | HS02 GHS04 GHS07 Gef. | H220 H336 | U | ||
601-011-00-9 | Propen; Propylen | 204-062-1 | 115-07-1 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
601-012-00-4 | But-1-en [1]; Buten, Gemisch von 1- und 2-Isomeren [2]; 2-Methylpropen; Isobuten [3] (Z)-But-2-en [4]; (E)-But-2-en [5] | 203-449-2 [1] 203-452-9 [2] 204-066-3 [3] 209-673-7 [4] 210-855-3 [5] | 106-98-9 [1] 107-01-7 [2] 115-11-7 [3] 590-18-1 [4] 624-64-6 [5] | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | C U | ||
601-013-00-X | 1,3-Butadien; Buta-1,3-dien | 203-450-8 | 106-99-0 | Flam. Gas 1 Press. Gas Carc. 1A Muta. 1B | H220 H350 H340 | GHS02 GHS04 GHS08 Gef. | H220 H350 H340 | D U | ||
601-014-00-5 | Isopren (stabilisiert) 2-Methyl-1,3-butadien | 201-143-3 | 78-79-5 | Flam. Liq. 1 Carc. 1B Muta. 2 Aquatic Chronic 3 | H224 H350 H341 H412 | GHS02 GHS08 Gef. | H224 H350 H341 H412 | D | ||
601-015-00-0 | acetylene; ethyne | 200-816-9 | 74-86-2 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
601-016-00-6 | Cyclopropan | 200-847-8 | 75-19-4 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
601-017-00-1 | Cyclohexan | 203-806-2 | 110-82-7 | Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H225 H304 H315 H336 H400 H410 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H304 H315 H336 H410 | |||
601-018-00-7 | Methylcyclohexan | 203-624-3 | 108-87-2 | Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 | H225 H304 H315 H336 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H304 H315 H336 H411 | |||
601-019-00-2 | 1,4-Dimethylcyclohexan | 209-663-2 | 589-90-2 | Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 | H225 H304 H315 H336 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H304 H315 H336 H411 | |||
601-020-00-8 | Benzol | 200-753-7 | 71-43-2 | Flam. Liq. 2 Carc. 1A Muta. 1B STOT RE 1 Asp. Tox. 1 Eye Irrit. 2 Skin Irrit. 2 | H225 H350 H340 H372 ** H304 H319 H315 | GHS02 GHS08 GHS07 Gef. | H225 H350 H340 H372 ** H304 H319 H315 | E | ||
601-021-00-3 | Toluol | 203-625-9 | 108-88-3 | Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT RE 2 * Skin Irrit. 2 STOT SE 3 | H225 H361d *** H304 H373 ** H315 H336 | GHS02 GHS08 GHS07 Gef. | H225 H361d *** H304 H373 ** H315 H336 | |||
601-022-00-9 | o-Xylol [1]; p-Xylol[2]; m-Xylol [3]; Xylol [4] | 202-422-2 [1] 203-396-5 [2] 203-576-3 [3] 215-535-7 [4] | 95-47-6 [1] 106-42-3 [2] 108-38-3 [3] 1330-20-7 [4] | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 | H226 H332 H312 H315 | GHS02 GHS07 Achtg. | H226 H332 H312 H315 | * | C | |
601-023-00-4 | Ethylbenzol | 202-849-4 | 100-41-4 | Flam. Liq. 2 Acute Tox. 4* STOT RE 2 Asp. Tox. 1 | H225 H332 H373 (Hörorgane) H304 | GHS02 GHS07 GHS08 Gef. | H225 H332 H373 (Hörorgane) H304 | |||
601-024-00-X | Cumol Isopropylbenzol | 202-704-5 | 98-82-8 | Flam. Liq. 3 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 | H226 H304 H335 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H226 H304 H335 H411 | C | ||
601-024-00-X | Cumol | 202-704-5 | 98-82-8 | Flam. Liq. 3 Carc. 1B Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 | H226 H350 H304 H335 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H226 H350 H304 H335 H411 | |||
601-025-00-5 | Mesitylen; 1,3,5-Trimethylbenzol | 203-604-4 | 108-67-8 | Flam. Liq. 3 STOT SE 3 Aquatic Chronic 2 | H226 H335 H411 | GHS02 GHS07 GHS09 Achtg. | H226 H335 H411 | STOT SE 3; H335: C ≥ 25 % | ||
601-026-00-0 | Styrol | 202-851-5 | 100-42-5 | Flam. Liq. 3 Repr. 2 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 | H226 H361d H332 H372 (Hörorgane) H315 H319 | GHS02 GHS08 GHS07 Gef. | H226 H361d H332 H372 (Hörorgane) H315 H319 | * | D | |
601-027-00-6 | 2-Phenylpropen; α-Methylstyrol; Isopropenylbenzol | 202-705-0 | 98-83-9 | Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Aquatic Chronic 2 | H226 H319 H335 H411 | GHS02 GHS07 GHS09 Achtg. | H226 H319 H335 H411 | STOT SE 3; H335: C ≥ 25 % | ||
601-028-00-1 | 2-Methylstyrol; 2-Vinyltoluol | 210-256-7 | 611-15-4 | Acute Tox. 4 * Aquatic Chronic 2 | H332 H411 | GHS07 GHS09 Achtg. | H332 H411 | |||
601-029-00-7 | Dipenten; Limonen [1] (S)- p-Mentha-1,8-dien; l-Limonen [2] trans-1-Methyl-4-(1-methylvinyl)cyclohexen; [3] (±)-1-Methyl-4-(1-methylvinyl)-cyclohexen [4] | 205-341-0 [1] 227-815-6 [2] 229-977-3 [3] 231-732-0 [4] | 138-86-3 [1] 5989-54-8 [2] 6876-12-6 [3] 7705-14-8 [4] | Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H226 H315 H317 H400 H410 | GHS02 GHS07 GHS09 Wng | H226 H315 H317 H410 | C | ||
601-030-00-2 | Cyclopentan | 206-016-6 | 287-92-3 | Flam. Liq. 2 Aquatic Chronic 3 | H225 H412 | GHS02 Gef. | H225 H412 | |||
601-031-00-8 | 2,4,4-Trimethylpent-1-en | 203-486-4 | 107-39-1 | Flam. Liq. 2 Aquatic Chronic 2 | H225 H411 | GHS02 GHS09 Gef. | H225 H411 | |||
601-032-00-3 | Benzo[ a]pyren; Benzo[ def]chrysen | 200-028-5 | 50-32-8 | Carc. 1B Muta. 1B Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H340 H360FD H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H340 H360FD H317 H410 | Carc. 1B; H350: C ≥ 0,01 % | ||
601-033-00-9 | Benzo[ a]anthracen | 200-280-6 | 56-55-3 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | M=100 | ||
601-034-00-4 | Benzo[ e]acephenanthrylen; Benzo[b]fluoranthen | 205-911-9 | 205-99-2 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | |||
601-035-00-X | Benzo[ j]fluoranthen | 205-910-3 | 205-82-3 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | |||
601-036-00-5 | Benzo[ k]fluoranthen | 205-916-6 | 207-08-9 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | |||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
601-037-00-0 | n-Hexan | 203-777-6 | 110-54-3 | Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT RE 2 * Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 | H225 H361f *** H304 H373 ** H315 H336 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H361f *** H304 H373 ** H315 H336 H411 | STOT RE 2; H373: C ≥ 5 % | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
601-037-00-0 | n-Hexan | 203-777-6 | 110-54-3 | Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT SE 3 STOT RE 1 Skin Irrit. 2 Aquatic Chronic 2 | H225 H361f*** H304 H336 H372 (Nervensystem) H315 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H225 H361f*** H304 H336 H372 (Nervensystem) H315 H411 | ) | ||
601-041-00-2 | Dibenzo[ a, h]anthracen | 200-181-8 | 53-70-3 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | Carc. 1B; H350: C ≥ 0,01 % M=100 | ||
601-042-00-8 | Biphenyl; Diphenyl | 202-163-5 | 92-52-4 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H335 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H335 H315 H410 | |||
601-043-00-3 | 1,2,4-Trimethylbenzol | 202-436-9 | 95-63-6 | Flam. Liq. 3 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 | H226 H332 H319 H335 H315 H411 | GHS02 GHS07 GHS09 Achtg. | H226 H332 H319 H335 H315 H411 | |||
601-044-00-9 | 3a,4,7,7a-Tetrahydro-4,7-methanoinden; Dicyclopentadien | 201-052-9 | 77-73-6 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 | H225 H332 H302 H319 H335 H315 H411 | GHS02 GHS07 GHS09 Gef. | H225 H332 H302 H319 H335 H315 H411 | |||
601-045-00-4 | 1,2,3,4-Tetrahydronaphthalin; Tetralin | 204-340-2 | 119-64-2 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H319 H315 H411 | GHS07 GHS09 Achtg. | H319 H315 H411 | EUH019 | ||
601-046-00-X | 7-Methylocta-1,6-dien | 404-210-7 | 42152-47-6 | Flam. Liq. 3 Aquatic Acute 1 Aquatic Chronic 1 | H226 H400 H410 | GHS02 GHS09 Achtg. | H226 H410 | |||
601-047-00-5 | m-Mentha-1,3(8)-dien | 404-150-1 | 17092-80-7 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
601-048-00-0 | Chrysen | 205-923-4 | 218-01-9 | Carc. 1B Muta. 2 Aquatic Acute 1 Aquatic Chronic 1 | H350 H341 H400 H410 | GHS08 GHS09 Gef. | H350 H341 H410 | |||
601-049-00-6 | Benzo[ e]pyren | 205-892-7 | 192-97-2 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | |||
601-051-00-7 | 4-Phenylbut-1-en | 405-980-7 | 768-56-9 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
601-052-00-2 | Naphthalin | 202-049-5 | 91-20-3 | Carc. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H400 H410 | GHS07 GHS08 GHS09 Achtg. | H351 H302 H410 | |||
601-053-00-8 | Nonylphenol [1]; 4-Nonylphenol, verzweigt [2] | 246-672-0 [1] 284-325-5 [2] | 25154-52-3 [1] 84852-15-3 [2] | Repr. 2 Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H361fd H302 H314 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H361fd H302 H314 H410 | |||
601-054-00-3 | Reaktionsmasse aus Isomeren von Dibenzylbenzol; Dibenzyl(methyl)-benzol; Dibenzyl(dimethyl)-benzol; Dibenzyl(trimethyl)-benzol | 405-570-8 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
601-055-00-9 | Reaktionsmasse aus Isomeren von Mono-(2-tetradecyl)-naphthalinen, Di-(2-tetradecyl)-naphthalinen und Tri-(2-tetradecyl)-naphthalinen | 410-190-0 | 132983-41-6 | Eye Irrit. 2 Aquatic Chronic 4 | H319 H413 | GHS07 Achtg. | H319 H413 | |||
601-056-00-4 | Reaktionsmasse aus Isomeren von Methyldiphenylmethan und Dimethyldiphenylmethan | 405-470-4 | 73807-39-3 | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
601-057-00-X | N-Dodecyl-[3-(4-(dimethylamino)-benzamido)-propyl]-dimethylammoniumtosylat | 421-130-8 | 156679-41-3 | Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H318 H317 H410 | |||
601-058-00-5 | Di-L- p-menthen Pinolen | 417-870-6 | 83648-84-4 | Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H315 H317 H410 | |||
601-059-00-0 | Methyl-2-benzyliden-3-oxobutyrat | 420-940-9 | 15768-07-7 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H319 H315 H411 | GHS07 GHS09 Achtg. | H319 H315 H411 | |||
601-060-00-6 | 1,2-Bis[4-fluor-6-{4-sulfo-5-(2-(4-sulfonaphthalin-3-ylazo)-1-hydroxy-3,6-disulfo-8-aminonaphthalin-7-ylazo)phenylamino}-1,3,5-triazin-2ylamino]-ethane; x-Natrium-, y-Kaliumsalz x = 7,755 y = 0,245 | 417-610-1 | 155522-09-1 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
601-061-00-1 | (Ethyl-1,2-ethandiyl)[-2-[[[(2-hydroxyethyl)-methylamino]-acetyl]-propyl]ω -(nonylphenoxy)-poly]-oxy-(methyl-1,2-ethandiyl) | 418-960-8 | - | Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H314 H317 H411 | GHS05 GHS07 GHS09 Gef. | H314 H317 H411 | |||
601-062-00-7 | Reaktionsmasse aus verzweigtem Triacontan, verzweigtem Dotriacontan, verzweigtem Tetratriacontan und verzweigtem Hexatriacontan | 417-030-9 | 151006-59-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
601-063-00-2 | Reaktionsmasse aus Isomeren von verzweigtem Tetracosan | 417-060-2 | 151006-61-0 | Acute Tox. 4 * Aquatic Chronic 4 | H332 H413 | GHS07 Achtg. | H332 H413 | |||
| - gestrichen - | |||||||||
601-065-00-3 | Reaktionsmasse aus (1"α,3"α,6"α)-2,2,3",7",7"-Pentamethylspiro(1,3-dioxan-5,2"-norcaran) und (1"α,3"β, 6"α)-2,2,3",7",7"-Penta methylspiro(1,3-dioxan-5,2"-norcaran) | 416-930-9 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
601-066-00-9 | 1-(4-( trans-4-Heptylcyclohexyl)-phenyl)-ethanon | 426-820-2 | 78531-60-9 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
601-067-00-4 | Triethylarsenat | 427-700-2 | 15606-95-8 | Carc. 1A Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H331 H301 H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H331 H301 H410 | |||
601-068-00-X | 1,2-Diacetoxybut-3-en | 421-720-5 | 18085-02-4 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
601-069-00-5 | 2-Ethyl-1-(2-(1,3-dioxanyl)-ethyl)-pyridinium bromid | 422-680-1 | 287933-44-2 | Aquatic Chronic 3 | H412 | - | H412 | |||
601-070-00-0 | Reaktionsmasse aus verzweigtem Icosan, verzweigtem Docosan und verzweigtem Tetracosan | 417-050-8 | 151006-58-5 | Acute Tox. 4 * Aquatic Chronic 4 | H332 H413 | GHS07 Achtg. | H332 H413 | |||
601-071-00-6 | 1-Dimethoxymethyl-2-nitrobenzol | 423-830-9 | 20627-73-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
601-072-00-1 | Reaktionsmasse aus 1-(4-isopropylphenyl)-1-phenylethan, 1-(3-Isopropylphenyl)-1-phenylethan und 1-(2-Isopropylphenyl)-1-phenylethan | 430-690-2 | 52783-21-8 | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
601-073-00-7 | 1-Brom-3,5-difluorbenzol | 416-710-2 | 461-96-1 | Flam. Liq. 3 Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H226 H302 H373 ** H315 H317 H400 H410 | GHS02 GHS08 GHS07 GHS09 Achtg. | H226 H302 H373 ** H315 H317 H410 | |||
601-074-00-2 | Reaktionsmasse aus 4-(2,2,3-Trimethylcyclopent-3-en-1-yl)-1-methyl-2-oxabicyclo[2.2.2]-octan, 1-(2,2,3-Trimethylcyclopent-3-en-1-yl)-5-methyl-6-oxabicyclo[3.2.1]octan, Spiro[cyclohex-3-en-1-yl-[(4,5,6,6a-tetrahydro-3,6",6",6"a-tetramethyl)-1,3"(3"aH)-[2H]-cyclopenta[b]-furan] und Spiro[cyclohex-3-en-1-yl-[4,5,6,6a-tetrahydro-4,6",6",6"a-tetramethyl)-1,3"(3"aH)-[2H]-cyclopenta[b]]-furan] | 422-040-1 | - | Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H319 H315 H411 | GHS07 GHS09 Achtg. | H319 H315 H411 | |||
601-075-00-8 | 4,4"-Bis( N-carbamoyl-4-methylbenzolsulfonamid)-diphenylmethan | 418-770-5 | 151882-81-4 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
601-076-00-3 | Ethinylcyclopropan | 425-430-1 | 6746-94-7 | Flam. Liq. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H225 H315 H318 H412 | GHS02 GHS05 Gef. | H225 H315 H318 H412 | |||
601-077-00-9 | Reaktionsmasse aus 1-Heptyl-4- ethyl-2,6,7-trioxabicyclo[2.2.2]-octan und 1-Nonyl-4-ethyl-2,6,7-trioxabicyclo[2.2.2]-octan | 426-510-7 | 196965-91-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
601-078-00-4 | Reaktionsmasse aus 1,7-dimethyl-2-[(3-methylbicyclo[2.2.1]-hept-2-yl)methyl]-bicyclo[2.2.1]-heptan und 2,3-Dimethyl-2-[(3-methylbicyclo[2.2.1]-hept-2-yl)-methyl]-bicyclo[2.2.1]-heptan | 427-040-5 | - | Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Gef. | H314 H410 | |||
601-079-00-X | Reaktionsmasse aus trans-trans- Cyclohexadeca-1,9-dien und cis-trans-Cyclohexadeca-1,9-dien | 429-620-3 | - | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 | H315 H317 H413 | GHS07 Achtg. | H315 H317 H413 | |||
601-080-00-5 | Reaktionsmasse aus sec-Butylphenyl(phenyl)-methan, Isomerengemisch, 1-(sec-Butylphenyl(phenyl)-2-phenylethan, Isomerengemisch und 1-(sec-Butylphenyl)-1-phenylethan, Isomerengemisch | 431-100-6 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
601-081-00-0 | Cyclohexadeca-1,9-dien | 431-730-1 | 4277-06-9 | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 | H315 H317 H413 | GHS07 Achtg. | H315 H317 H413 | |||
601-082-00-6 | Reaktionsmasse aus endo-2-Methyl- exo-3-methyl- exo-2-[( exo-3-methylbicyclo[2.2.1]-hept- exo-2-yl)-methyl]-bicyclo[2.2.1]heptan und exo-2-Methyl- exo-3-methyl- endo-2-[( endo-3-methylbicyclo[2.2.1]-hept-e xo-2-yl)-methyl]-bicyclo[2.2.1]-heptan | 434-420-4 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H400 H410 | GHS05 GHS09 Gef. | H315 H318 H410 | |||
601-083-00-1 | 5- endo-Hexylbicyclo[2.2.1]-hept-2-en | 435-000-3 | 22094-83-3 | Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 4 | H304 H315 H413 | GHS08 GHS07 Gef. | H304 H315 H413 | |||
601-084-00-7 | Reaktionsmasse aus5- endo-Butylbicyclo[2.2.1]-hept-2-en und 5- exo-Butylbicyclo[2.2.1]-hept-2-en (80:20) | 435-180-3 | - | Asp. Tox. 1 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H304 H315 H400 H410 | GHS08 GHS07 GHS09 Gef. | H304 H315 H410 | |||
601-085-00-2 | Isopentan; 2-Methylbutan | 201-142-8 | 78-78-4 | Flam. Liq. 1 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 | H224 H304 H336 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H224 H304 H336 H411 | EUH066 | ||
601-087-00-3 | 2,4,4-Trimethylpenten | 246-690-9 | 25167-70-8 | Flam. Liq. 2 Asp. Tox. 1 STOT SE 3 | H225 H304 H336 | GHS02 GHS07 GHS08 Gef. | H225 H304 H336 | D | ||
601-088-00-9 | 4-Vinylcyclohexen | 202-848-9 | 100-40-3 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
601-089-00-4 | Muscalur; cis-9-Tricosen | 248-505-7 | 27519-02-4 | Skin Sens. 1B | H317 | GHS07 Achtg. | H317 | |||
601-090-00-X | Benzo[ rst]pentaphen | 205-877-5 | 189-55-9 | Carc. 1B Muta. 2 | H350 H341 | GHS08 Dgr | H350 H341 | 601-091-00-5 | Dibenzo[ b,def]chrysen; Dibenzo[ a,h]pyren | 205-878-0 | 189-64-0 | Carc. 1B Muta. 2 | H350 H341 | GHS08 Dgr | H350 H341 |
601-092-00-0 | Dibenzo[ def,p]chrysen; Dibenzo[ a,l]pyren | 205-886-4 | 191-30-0 | Carc. 1B Muta. 2 | H350 H341 | GHS08 Dgr | H350 H341 | Carc. 1B; H350: C ≥ 0,001 % | ||
601-093-00-6 | 1,4-Dimethylnaphthalin | 209-335-9 | 571-58-4 | Acute Tox. 4 Asp. Tox. 1 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 3 | H302 H304 H319 H400 H412 | GHS07 GHS08 GHS09 Dgr | H302 H304 H319 H410 | oral:
ATE = 1 300 mg/kg KG M = 1 | ||
601-094-00-1 | 1-Isopropyl-4-methylbenzol; p-Cymol | 202-796-7 | 99-87-6 | Flam. Liq. 3 Acute Tox. 3 Asp. Tox. 1 Aquatic Chronic 2 | H226 H331 H304 H411 | GHS02 GHS06 GHS08 GHS09 Dgr | H226 H331 H304 H411 | Einatmen: ATE = 3 mg/L (Dämpfe) | ||
601-095-00-7 | p-Mentha-1,3-dien; 1-Isopropyl-4-methyl-1,3-cyclohexadien; α-Terpinen | 202-795-1 | 99-86-5 | Flam. Liq. 3 Acute Tox. 4 Skin Sens. 1 Asp. Tox. 1 Aquatic Chronic 2 | H226 H302 H317 H304 H411 | GHS02 GHS07 GHS08 GHS09 Dgr | H226 H302 H317 H304 H411 | oral: ATE = 1 680 mg/kg KG | ||
601-096-00-2 | ( R)- p-Mentha-1,8-dien; d-Limonen | 227-813-5 | 5989-27-5 | Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1B Asp. Tox. 1 Aquatic Acute 1 Aquatic Chronic 3 | H226 H315 H317 H304 H400 H412 | GHS02 GHS07 GHS08 GHS09 Dgr | H226 H315 H317 H304 H410 | M = 1 | ||
601-097-00-8 | Propylbenzol | 203-132-9 | 103-65-1 | Flam. Liq. 3 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 | H226 H304 H335 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H226 H304 H335 H411 | |||
602-001-00-7 | Chlormethan; Methylchlorid | 200-817-4 | 74-87-3 | Flam. Gas 1 Press. Gas Carc. 2 STOT RE 2 * | H220 H351 H373 ** | GHS02 GHS04 GHS08 Gef. | H220 H351 H373 ** | U | ||
602-002-00-2 | Brommethan; Methylbromid | 200-813-2 | 74-83-9 | Press.
Gas Muta. 2 Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Ozone 1 | H341 H331 H301 H373** H319 H335 H315 H400 H420 | GHS04 GHS06 GHS08 GHS09 Gef. | H341 H331 H301 H373 ** H319 H335 H315 H400 H420 | U | ||
602-003-00-8 | Dibrommethan; Methylenbromid | 200-824-2 | 74-95-3 | Acute Tox. 4 * Aquatic Chronic 3 | H332 H412 | GHS07 Achtg. | H332 H412 | * | ||
602-004-00-3 | Dichlormethan; Methylenchlorid | 200-838-9 | 75-09-2 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
602-005-00-9 | Methyliodid; Iodmethan | 200-819-5 | 74-88-4 | Carc. 2 Acute Tox. 4 * Acute Tox. 3 * Acute Tox. 3 * STOT SE 3 Skin Irrit. 2 | H351 H312 H331 H301 H335 H315 | GHS06 GHS08 Gef. | H351 H312 H331 H301 H335 H315 | |||
602-006-00-4 | Chloroform; Trichlormethan | 200-663-8 | 67-66-3 | Carc. 2 Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Eye Irrit. 2 Skin Irrit. 2 | H351 H361d H331 H302 H372 H319 H315 | GHS06 GHS08 Gef. | H351 H361d H331 H302 H372 H319 H315 | |||
602-007-00-X | Bromoform; Tribrommethan | 200-854-6 | 75-25-2 | Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H331 H302 H319 H315 H411 | GHS06 GHS09 Gef. | H331 H302 H319 H315 H411 | |||
602-008-00-5 | Kohlenstofftetrachlorid; Tetrachlormethan; Tetrachlorkohlenstoff | 200-262-8 | 56-23-5 | Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Aquatic Chronic 3 Ozone 1 | H351 H331 H311 H301 H372** H412 H420 | GHS06 GHS08 Gef. | H351 H331 H311 H301 H372 ** H412 H420 | * STOT RE 1; H372:C≥1 % STOT RE 2; H373:0,2 % ≤C < 1 % | ||
602-009-00-0 | Chlorethan; Ethylchlorid | 200-830-5 | 75-00-3 | Flam. Gas 1 Press. Gas Carc. 2 Aquatic Chronic 3 | H220 H351 H412 | GHS02 GHS04 GHS08 Gef. | H220 H351 H412 | U | ||
602-010-00-6 | 1,2-Dibromethan; Ethylendibromid | 203-444-5 | 106-93-4 | Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 | H350 H331 H311 H301 H319 H335 H315 H411 | GHS06 GHS08 GHS09 Gef. | H350 H331 H311 H301 H319 H335 H315 H411 | * | ||
602-011-00-1 | 1,1-Dichlorethan; Ethylidendichlorid | 200-863-5 | 75-34-3 | Flam. Liq. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Aquatic Chronic 3 | H225 H302 H319 H335 H412 | GHS02 GHS07 Gef. | H225 H302 H319 H335 H412 | * | ||
602-012-00-7 | 1,2-Dichlorethan; Ethylendichlorid | 203-458-1 | 107-06-2 | Flam. Liq. 2 Carc. 1B Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H225 H350 H302 H319 H335 H315 | GHS02 GHS08 GHS07 Gef. | H225 H350 H302 H319 H335 H315 | |||
602-013-00-2 | 1,1,1-Trichlorethan; Methylchloroform | 200-756-3 | 71-55-6 | Acute Tox. 4 * Ozone 1 | H332 H420 | GHS07 Achtg. | H332 H420 | F | ||
602-014-00-8 | 1,1,2-Trichlorethan | 201-166-9 | 79-00-5 | Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H351 H332 H312 H302 | GHS08 GHS07 Achtg. | H351 H332 H312 H302 | EUH066 | * | |
602-015-00-3 | 1,1,2,2-Tetrachlorethan; Acetylentetrachlorid | 201-197-8 | 79-34-5 | Acute Tox. 2 * Acute Tox. 1 Aquatic Chronic 2 | H330 H310 H411 | GHS06 GHS09 Gef. | H330 H310 H411 | |||
602-016-00-9 | 1,1,2,2-Tetrabromethan; Acetylentetrabromid | 201-191-5 | 79-27-6 | Acute Tox. 2 * Eye Irrit. 2 Aquatic Chronic 3 | H330 H319 H412 | GHS06 Gef. | H330 H319 H412 | |||
602-017-00-4 | Pentachlorethan | 200-925-1 | 76-01-7 | Carc. 2 STOT RE 1 Aquatic Chronic 2 | H351 H372 ** H411 | GHS08 GHS09 Gef. | H351 H372 ** H411 | STOT RE 1; H372: C≥ 1 % STOT RE 2; H373: 0,2 % ≤ C < 1 % | ||
602-018-00-X | 1-Chlorpropan [1]; 2-Chlorpropan [2] | 208-749-7 [1] 200-858-8 [2] | 540-54-5 [1] 75-29-6 [2] | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H225 H332 H312 H302 | GHS02 GHS07 Gef. | H225 H332 H312 H302 | C | ||
602-019-00-5 | 1-Brompropan; n-Propylbromid | 203-445-0 | 106-94-5 | Flam. Liq. 2 Repr. 1B STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 STOT SE 3 | H225 H360FD H373 ** H319 H335 H315 H336 | GHS02 GHS08 GHS07 Gef. | H225 H360FD H373 ** H319 H335 H315 H336 | |||
602-020-00-0 | 1,2-Dichlorpropan; Propylendichlorid | 201-152-2 | 78-87-5 | Flam. Liq. 2 Carc. 1B Acute Tox. 4* Acute Tox. 4* | H225 H350 H332 H302 | GHS02 GHS08 GHS07 Gef. | H225 H350 H332 H302 | |||
602-021-00-6 | 1,2-Dibrom-3-chlorpropan | 202-479-3 | 96-12-8 | Carc. 1B Muta. 1B Repr. 1A Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H350 H340 H360F *** H301 H373 ** H412 | GHS06 GHS08 Gef. | H350 H340 H360F *** H301 H373 ** H412 | |||
602-022-00-1 | 1-Chlorpentan; Amylchlorid-1 [1]; 2-Chlorpentan; Amylchlorid-2 [2]; 3-Chlorpentan; Amylchlorid-3 [3] | 208-846-4 [1] 210-885-7 [2] 210-467-4 [3] | 543-59-9 [1] 625-29-6 [2] 616-20-6 [3] | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H225 H332 H312 H302 | GHS02 GHS07 Gef. | H225 H332 H312 H302 | C | ||
602-023-00-7 | Vinylchlorid; Chlorethen | 200-831-0 | 75-01-4 | Press.
Gas Flam. Gas 1 Carc. 1A | H220 H350 | GHS02 GHS08 Gef. | H220 H350 | D U | ||
602-024-00-2 | Bromethen; Vinylbromid | 209-800-6 | 593-60-2 | Press.
Gas Flam. Gas 1 Carc. 1B | H220 H350 | GHS02 GHS08 Gef. | H220 H350 | U | ||
602-025-00-8 | 1,1-Dichlorethen; Vinylidenchlorid | 200-864-0 | 75-35-4 | Flam. Liq. 1 Carc. 2 Acute Tox. 4 * | H224 H351 H332 | GHS02 GHS08 GHS07 Gef. | H224 H351 H332 | * | D | |
602-026-00-3 | 1,2-Dichlorethen [1]; cis-Dichlorethen [2]; trans-Dichlorethen [3] | 208-750-2 [1] 205-859-7 [2] 205-860-2 [3] | 540-59-0 [1] 156-59-2 [2] 156-60-5 [3] | Flam. Liq. 2 Acute Tox. 4 * Aquatic Chronic 3 | H225 H332 H412 | GHS02 GHS07 Gef. | H225 H332 H412 | * | C | |
602-027-00-9 | Trichlorethylen; Trichlorethen | 201-167-4 | 79-01-6 | Carc. 1B Muta. 2 Eye Irrit. 2 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 3 | H350 H341 H319 H315 H336 H412 | GHS08 GHS07 Gef. | H350 H341 H319 H315 H336 H412 | |||
602-028-00-4 | Tetrachlorethen; Perchlorethylen | 204-825-9 | 127-18-4 | Carc. 2 Aquatic Chronic 2 | H351 H411 | GHS08 GHS09 Achtg. | H351 H411 | |||
602-029-00-X | 3-Chlorpropen; Allylchlorid | 203-457-6 | 107-05-1 | Flam. Liq. 2 Carc. 2 Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 | H225 H351 H341 H332 H312 H302 H373 ** H319 H335 H315 H400 | GHS02 GHS08 GHS07 GHS09 Gef. | H225 H351 H341 H332 H312 H302 H373 ** H319 H335 H315 H400 | D | ||
602-030-00-5 | 1,3-Dichlorpropen [1]; (Z)-1,3-Dichlorpropen [2] | 208-826-5 [1] 233-195-8 [2] | 542-75-6 [1] 10061-01-5 [2] | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Asp. Tox. 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H226 H311 H301 H332 H304 H319 H335 H315 H317 H400 H410 | GHS02 GHS06 GHS08 GHS09 Gef. | H226 H311 H301 H332 H304 H319 H335 H315 H317 H410 | C D | ||
602-031-00-0 | 1,1-Dichlorpropen | 209-253-3 | 563-58-6 | Flam. Liq. 2 Acute Tox. 3 * Aquatic Chronic 3 | H225 H301 H412 | GHS02 GHS06 Gef. | H225 H301 H412 | |||
602-032-00-6 | 3-Chlor-2-methylpropen; Methallylchlorid; 2-Methylallylchlorid | 209-251-2 | 563-47-3 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H225 H332 H302 H314 H317 H411 | GHS02 GHS05 GHS07 GHS09 Gef. | H225 H332 H302 H314 H317 H411 | |||
602-033-00-1 | Chlorbenzol | 203-628-5 | 108-90-7 | Flam. Liq. 3 Acute Tox. 4 Skin Irrit. 2 Aquatic Chronic 2 | H226 H332 H315 H411 | GHS02 GHS07 GHS09 Achtg. | H226 H332 H315 H411 | |||
602-034-00-7 | 1,2-Dichlorbenzol; o-Dichlorbenzol | 202-425-9 | 95-50-1 | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H335 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H335 H315 H410 | * | ||
602-035-00-2 | 1,4-Dichlorbenzol; p-Dichlorbenzol | 203-400-5 | 106-46-7 | Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H319 H400 H410 | GHS08 GHS09 Achtg. | H351 H319 H410 | |||
602-036-00-8 | Chloropren (stabilisiert); 2-Chlorbuta-1,3-dien (stabilisiert) | 204-818-0 | 126-99-8 | Flam. Liq. 2 Carc. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H225 H350 H332 H302 H373 ** H319 H335 H315 | GHS02 GHS08 GHS07 Gef. | H225 H350 H332 H302 H373 ** H319 H335 H315 | D | ||
602-037-00-3 | α-Chlortoluol; Benzylchlorid | 202-853-6 | 100-44-7 | Carc. 1B Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 | H350 H331 H302 H373 ** H335 H315 H318 | GHS06 GHS08 GHS05 Gef. | H350 H331 H302 H373 ** H335 H315 H318 | |||
602-038-00-9 | α, α,α-Trichlortoluol; Benzotrichlorid; Trichlormethylbenzol | 202-634-5 | 98-07-7 | Carc. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 | H350 H331 H302 H335 H315 H318 | GHS06 GHS08 GHS05 Gef. | H350 H331 H302 H335 H315 H318 | |||
602-039-00-4 | Polychlorierte Biphenyle; PCB | 215-648-1 | 1336-36-3 | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H400 H410 | GHS08 GHS09 Achtg. | H373 ** H410 | STOT RE 2; H373: C ≥ 0,005 % | C | |
602-040-00-X | 2-Chlortoluol; o-Chlortoluol [1]; 3-Chlortoluol; m-Chlortoluol [2]; 4-Chlortoluol; p-Chlortoluol [3]; Chlortoluol [4] | 202-424-3 [1] 203-580-5 [2] 203-397-0 [3] 246-698-2 [4] | 95-49-8 [1] 108-41-8 [2] 106-43-4 [3] 25168-05-2 [4] | Acute Tox. 4 * Aquatic Chronic 2 | H332 H411 | GHS07 GHS09 Achtg. | H332 H411 | C | ||
602-041-00-5 | Penthachlornaphthalin | 215-320-8 | 1321-64-8 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H319 H315 H410 | C | ||
602-042-00-0 | 1,2,3,4,5,6-Hexachlorcyclo-hexane, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Carc. 2 Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H301 H312 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H301 H312 H410 | A C | ||
602-043-00-6 | Lindan (ISO); γ-HCH oder γ-BHC; γ-1,2,3,4,5,6-Hexachlorcyclohexan | 200-401-2 | 58-89-9 | Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Lact. Aquatic Acute 1 Aquatic Chronic 1 | H301 H332 H312 H373 ** H362 H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H332 H312 H373 ** H362 H410 | M=10 | ||
602-044-00-1 | Camphechlor (ISO); Toxaphen; Chloriertes Camphen | 232-283-3 | 8001-35-2 | Carc. 2 Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H301 H312 H335 H315 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H301 H312 H335 H315 H410 | |||
602-045-00-7 | DDT (ISO); Clofenotan (INN); Dicophan; 1,1,1-Trichlor-2,2-bis(4-chlorphenyl)-ethan; Dichlorodiphenyltrichlorethan | 200-024-3 | 50-29-3 | Carc. 2 Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H301 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H301 H372 ** H410 | |||
602-046-00-2 | Heptachlor (ISO); 1,4,5,6,7,8,8-Heptachlor-3a,4,7,7a-tetrahydro-4,7-methanoinden | 200-962-3 | 76-44-8 | Carc. 2 Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H311 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H311 H301 H373 ** H410 | |||
602-047-00-8 | Chlordan (ISO); 1,2,4,5,6,7,8,8-Octachlor-3a,4,7,7a-tetrahydro-4,7-methanoindan | 200-349-0 | 57-74-9 | Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H312 H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H312 H302 H410 | |||
602-048-00-3 | Aldrin (ISO) | 206-215-8 | 309-00-2 | Carc. 2 Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H311 H301 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H311 H301 H372 ** H410 | |||
602-049-00-9 | Dieldrin (ISO) | 200-484-5 | 60-57-1 | Carc. 2 Acute Tox. 1 Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H310 H301 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H310 H301 H372 ** H410 | |||
602-050-00-4 | Isodrin; (1α,4α,4aβ,5β,8β,8aβ)-1,2,3,4,10,10-Hexachlor-1,4,4a,5,8,8a-hexahydro-1,4:5,8- dimethannaphthalin | 207-366-2 | 465-73-6 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H300 H410 | M=100 | ||
602-051-00-X | Endrin (ISO); 1,2,3,4,10,10-Hexachlor-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-1,4:5,8-dimethanonaphthalin | 200-775-7 | 72-20-8 | Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H300 H311 H400 H410 | GHS06 GHS09 Gef. | H300 H311 H410 | |||
602-052-00-5 | Endosulfan (ISO); 1,2,3,4,7,7-Hexachlor-8,9,10-trinorborn-2-en-5,6-ylendimethylensulfit; 1,4,5,6,7,7-Hexachlor-8,9,10-trinorborn-5-en-2,3-ylendimethylensulfit | 204-079-4 | 115-29-7 | Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H312 H400 H410 | GHS06 GHS09 Gef. | H330 H300 H312 H410 | |||
602-053-00-0 | Isobenzan (ISO); 1,3,4,5,6,7,8,8-Octachlor-1,3,3a,4,7,7a-hexahydro-4,7-methanoisobenzofuran | 206-045-4 | 297-78-9 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 | H310 H300 H400 | GHS06 GHS09 Gef. | H310 H300 H400 | |||
602-054-00-6 | 3-Iodpropen; Allyliodid | 209-130-4 | 556-56-9 | Flam. Liq. 2 Skin Corr. 1B | H225 H314 | GHS02 GHS05 Gef. | H225 H314 | |||
602-055-00-1 | Bromethan; Ethylbromid | 200-825-8 | 74-96-4 | Flam. Liq. 2 Carc. 2 Acute Tox. 4 * Acute Tox. 4 * | H225 H351 H332 H302 | GHS02 GHS08 GHS07 Gef. | H225 H351 H332 H302 | |||
602-056-00-7 | α, α,α-Trifluortoluol; Benzotrifluorid; Trifluormethanbenzol | 202-635-0 | 98-08-8 | Flam. Liq. 2 Aquatic Chronic 2 | H225 H411 | GHS02 GHS09 Gef. | H225 H411 | |||
602-057-00-2 | α-Bromtoluol; Benzylbromid | 202-847-3 | 100-39-0 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | |||
602-058-00-8 | α, α-Dichlortoluol; Benzylidenchlorid; Benzalchlorid | 202-709-2 | 98-87-3 | Carc. 2 Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 | H351 H331 H302 H335 H315 H318 | GHS06 GHS08 GHS05 Gef. | H351 H331 H302 H335 H315 H318 | |||
602-059-00-3 | 1-Chlorbutan; Butylchlorid | 203-696-6 | 109-69-3 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
602-060-00-9 | Brombenzol | 203-623-8 | 108-86-1 | Flam. Liq. 3 Skin Irrit. 2 Aquatic Chronic 2 | H226 H315 H411 | GHS02 GHS07 GHS09 Achtg. | H226 H315 H411 | |||
602-061-00-4 | Hexafluorpropen; Hexafluorpropylen | 204-127-4 | 116-15-4 | Press.
Gas Acute Tox. 4 * STOT SE 3 | H332 H335 | GHS07 Achtg. | H332 H335 | U | ||
602-062-00-X | 1,2,3-Trichlorpropan | 202-486-1 | 96-18-4 | Carc. 1B Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H350 H360F *** H332 H312 H302 | GHS08 GHS07 Gef. | H350 H360F *** H332 H312 H302 | D | ||
602-063-00-5 | Heptachlorepoxid; 2,3-Epoxy-1,4,5,6,7,8,8-heptachlor-3a,4,7,7a-tetrahydro-4,7-methanoindan | 213-831-0 | 1024-57-3 | Carc. 2 Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H301 H373 ** H410 | |||
602-064-00-0 | 1,3-Dichlor-2-propanol | 202-491-9 | 96-23-1 | Carc. 1B Acute Tox. 3 * Acute Tox. 4 * | H350 H301 H312 | GHS06 GHS08 Gef. | H350 H301 H312 | |||
602-065-00-6 | Hexachlorbenzol | 204-273-9 | 118-74-1 | Carc. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H372 ** H400 H410 | GHS08 GHS09 Gef. | H350 H372 ** H410 | |||
602-066-00-1 | Tetrachlor- p-benzochinon Chloranil | 204-274-4 | 118-75-2 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H315 H410 | |||
602-067-00-7 | 1,3-Dichlorbenzol; m-Dichlorbenzol | 208-792-1 | 541-73-1 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
602-068-00-2 | Ethylenbis(trichloracetat) | 219-732-9 | 2514-53-6 | Skin Irrit. 2 | H315 | GHS07 Achtg. | H315 | |||
602-069-00-8 | Dichloracetylen | - | 7572-29-4 | Unst. Expl. Carc. 2 STOT RE 2 * | H200 H351 H373 ** | GHS01 GHS08 Achtg. | H200 H351 H373 ** | |||
602-070-00-3 | 3-Chlor-4,5,α, α,α-pentafluortoluol | 401-930-3 | 77227-99-7 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 | H226 H332 H302 H400 | GHS02 GHS07 GHS09 Achtg. | H226 H332 H302 H400 | |||
602-071-00-9 | Brombenzylbromtoluol, Reaktionsmasse aus Isomeren | 402-210-1 | 99688-47-8 | STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H373 ** H317 H410 | |||
602-072-00-4 | Dichlor[(dichlorphenyl)-methyl]-methylbenzol, Reaktionsmasse aus Isomeren; (Dichlorphenyl)(dichlortolyl)-methan, Reaktionsmasse aus Isomeren (IUPAC) | 278-404-3 | 76253-60-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
602-073-00-X | 1,4-Dichlorbut-2-en; 1,4-Dichlorbuten-2 | 212-121-8 | 764-41-0 | Carc. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H330 H311 H301 H314 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H350 H330 H311 H301 H314 H410 | Carc. 1B; H350: C ≥ 0,01 % STOT SE 3; H335:C≥5 % | ||
602-074-00-5 | Pentachlorbenzol | 210-172-0 | 608-93-5 | Flam. Sol. 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H228 H302 H400 H410 | GHS02 GHS07 GHS09 Gef. | H228 H302 H410 | T | ||
602-075-00-0 | 4,4,5,5-Tetrachlor-1,3-dioxolan-2-on | 404-060-2 | 22432-68-4 | Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B | H330 H302 H314 | GHS06 GHS05 Gef. | H330 H302 H314 | |||
602-076-00-6 | 2,3,4-Trichlorbut-1-en; 2,3,4-Trichlor-1-buten | 219-397-9 | 2431-50-7 | Carc. 2 Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H331 H302 H319 H335 H315 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H331 H302 H319 H335 H315 H410 | Carc. 2; H351: C ≥ 0,1 % | ||
602-077-00-1 | Dodecachlorpentacyclo [5.2.1.02,6.03,9.05,8] decan; Mirex | 219-196-6 | 2385-85-5 | Carc. 2 Repr. 2 Lact. Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H361fd H362 H312 H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H361fd H362 H312 H302 H410 | |||
602-078-00-7 | Hexachlorcyclopentadien | 201-029-3 | 77-47-4 | Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H330 H311 H302 H314 H400 H410 | GHS06 GHS05 GHS09 Gef. | H330 H311 H302 H314 H410 | |||
602-079-00-2 | 2,3-Dichlorpropen; 2,3-Dichlorpropylen | 201-153-8 | 78-88-6 | Flam. Liq. 2 Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H225 H341 H332 H312 H302 H335 H315 H318 H412 | GHS02 GHS08 GHS05 GHS07 Gef. | H225 H341 H332 H312 H302 H335 H315 H318 H412 | |||
602-080-00-8 | Chloralkane, C10-13; Chlorierte Paraffine, C10-13 | 287-476-5 | 85535-84-8 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | EUH066 | ||
602-081-00-3 | 2-Chlor-4,5-difluorbenzoesäure | 405-380-5 | - | Acute Tox. 4 * Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 | H312 H302 H318 H317 | GHS05 GHS07 Gef. | H312 H302 H318 H317 | |||
602-082-00-9 | 2,2,6,6-Tetrakis(brommethyl)-4- oxaheptan-1,7-diol | 408-020-5 | 109678-33-3 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
602-083-00-4 | Diphenylether, Pentabromderivat; Pentabromdiphenylether | 251-084-2 | 32534-81-9 | STOT RE 2 * Lact. Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H362 H400 H410 | GHS08 GHS09 Achtg. | H373 ** H362 H410 | |||
602-084-00-X | 1,1-Dichlor-1-fluorethan | 404-080-1 | 1717-00-6 | Aquatic Chronic 3 Ozone 1 | H412 H420 | GHS07 Achtg. | H412 H420 | |||
602-085-00-5 | 2-Brompropan | 200-855-1 | 75-26-3 | Flam. Liq. 2 Repr. 1A STOT RE 2 * | H225 H360F *** H373 ** | GHS02 GHS08 Gef. | H225 H360F *** H373 ** | EUH066 | ||
602-086-00-0 | Trifluoriodmethan; Trifluormethyliodid | 219-014-5 | 2314-97-8 | Muta. 2 | H341 | GHS08 Achtg. | H341 | |||
602-087-00-6 | 1,2,4-Trichlorbenzol | 204-428-0 | 120-82-1 | Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H315 H410 | |||
602-088-00-1 | 2,3-Dibrompropan-1-ol; 2,3-Dibrom-1-propanol | 202-480-9 | 96-13-9 | Carc. 1B Repr. 2 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H350 H361f *** H311 H332 H302 H412 | GHS08 GHS07 Gef. | H350 H361f *** H311 H332 H302 H412 | |||
602-089-00-7 | 4-Brom-2-chlorfluorbenzol | 405-580-2 | 60811-21-4 | Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H315 H410 | |||
602-090-00-2 | 1-Allyl-3-chlor-4-fluorbenzol | 406-630-6 | 121626-73-1 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
602-091-00-8 | 1,3-Dichlor-4-fluorbenzol | 406-160-1 | 1435-48-9 | Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 | H302 H373 ** H315 H411 | GHS08 GHS07 Achtg. | H302 H373 ** H315 H411 | |||
602-092-00-3 | 1-Brom-3,4,5-trifluorbenzol | 418-480-9 | 138526-69-9 | Flam. Liq. 3 Carc. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H226 H351 H315 H318 H411 | GHS02 GHS08 GHS05 GHS09 Gef. | H226 H351 H315 H318 H411 | |||
602-093-00-9 | α, α,α,4-Tetrachlortoluol; p-Chlorbenzotrichlorid | 226-009-1 | 5216-25-1 | Carc. 1B Repr. 2 STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 | H350 H361f *** H372 ** H312 H302 H335 H315 | GHS08 GHS07 Gef. | H350 H361f *** H372 ** H312 H302 H335 H315 | |||
602-094-00-4 | Diphenylether; Octabrom-Derivat | 251-087-9 | 32536-52-0 | Repr. 1B | H360Df | GHS08 Gef. | H360Df | |||
602-095-00-X | Chloralkane, C14-17, chlorierte Paraffine, C14-17 | 287-477-0 | 85535-85-9 | Lact. Aquatic Acute 1 Aquatic Chronic 1 | H362 H400 H410 | GHS09 Achtg. | H362 H410 | EUH066 | ||
602-096-00-5 | Malachitgrün Hydrochlorid; C.I. Basic Green 4 [1]; Malachitgrünoxalat [2] | 209-322-8 [1] 219-441-7 [2] | 569-64-2 [1] 2437-29-8 [2] | Repr. 2 Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H302 H318 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H361d *** H302 H318 H410 | |||
602-097-00-0 | 1-Bromo-9-(4,4,5,5,5-pentafluorpentylthio)-nonan | 422-850-5 | 148757-89-5 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
602-098-00-6 | 2-(3-Bromphenoxy)tetrahydro-2 H-pyran | 429-030-6 | 57999-49-2 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
602-099-00-1 | 3-(4-Fluorphenyl)-2-methylpropionylchlorid | 426-370-7 | - | Skin Corr. 1A Acute Tox. 4 * Aquatic Chronic 3 | H314 H302 H412 | GHS05 GHS07 Gef. | H314 H302 H412 | EUH014 EUH029 | ||
602-100-00-5 | Reaktionsmasse aus (R, R)-1,1,1,2,2,3,4,5,5,5-Decafluorpentan und (S, S)-1,1,1,2,2,3,4,5,5,5-decafluorpentan | 420-640-8 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
602-101-00-0 | 2-Chlor-4-fluor-5-nitrophenyl(isobutyl)-carbonat | 427-020-6 | 141772-37-4 | STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H373** H317 H410 | |||
602-102-00-6 | 1,1,1,3,3-Pentafluorbutan | 430-250-1 | 406-58-6 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
602-103-00-1 | 1-(Chlorphenylmethyl)-2-methylbenzol | 431-450-1 | 41870-52-4 | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
602-104-00-7 | 1,1,2,2,3,3,4-Heptafluorcyclopentan | 430-710-1 | 15290-77-4 | Aquatic Chronic 3 | H412 | - | H412 | |||
602-105-00-2 | Natrium-1,1,2,2,3,3,4,4,4-nonafluor-1-butansulfinat | 422-100-7 | 102061-82-5 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
602-106-00-8 | 2-Brom-4,6-difluoranilin | 429-430-0 | 444-14-4 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
602-107-00-3 | 3,3,4,4-Tetrafluor-4-iod-1-buten | 439-500-2 | 33831-83-3 | Acute Tox. 4 * Skin Irrit. 2 Aquatic Chronic 2 | H302 H315 H411 | GHS07 GHS09 Achtg. | H302 H315 H411 | |||
602-108-00-9 | (2,3,5,6-Tetrafluorphenyl)-methanol | 443-840-7 | 4084-38-2 | Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 | H302 H319 H317 | GHS07 Achtg. | H302 H319 H317 | |||
602-109-00-4 | Hexabromcyclododecan [1]; 1,2,5,6,9,10-Hexabromcyclododecan [2] | 247-148-4 [1] 221-695-9[2] | 25637-99-4[1] 3194-55-6[2] | Repr. 2 Lact. | H361 H362 | GHS08 Achtg. | H361 H362 | |||
602-110-00-X | Tetrafluorethylen | 204-126-9 | 116-14-3 | Carc. 1B | H350 | GHS08 Dgr | H350 | |||
603-001-00-X | Methanol; Methylalkohol | 200-659-6 | 67-56-1 | Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT SE 1 | H225 H331 H311 H301 H370 ** | GHS02 GHS06 GHS08 Gef. | H225 H331 H311 H301 H370 ** | * STOT SE 1; H370: C≥10 % STOT SE 2; H371: 3 % ≤ C<10 % | ||
603-002-00-5 | Ethanol; Ethylalkohol | 200-578-6 | 64-17-5 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
603-003-00-0 | Propan-1-ol; n-Propanol; n-Propylalkohol | 200-746-9 | 71-23-8 | Flam. Liq. 2 Eye Dam. 1 STOT SE 3 | H225 H318 H336 | GHS02 GHS05 GHS07 Gef. | H225 H318 H336 | |||
603-004-00-6 | Butan-1-ol; n-Butanol; n-Butylalkohol | 200-751-6 | 71-36-3 | Flam. Liq. 3 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 STOT SE 3 | H226 H302 H335 H315 H318 H336 | GHS02 GHS05 GHS07 Gef. | H226 H302 H335 H315 H318 H336 | |||
603-005-00-1 | 2-Methylpropan-2-ol; tert-Butylalkohol; tert-Butanol | 200-889-7 | 75-65-0 | Flam. Liq. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 | H225 H332 H319 H335 | GHS02 GHS07 Gef. | H225 H332 H319 H335 | |||
603-006-00-7 | Pentanolisomere, soweit in diesem Anhang nicht gesondert aufgeführt | 250-378-8 | Flam. Liq. 3 Acute Tox. 4 * STOT SE 3 | H226 H332 H335 | GHS02 GHS07 Achtg. | H226 H332 H335 | EUH066 | C | ||
603-007-00-2 | 2-Methylbutan-2-ol; tert-Pentanol; tert-Pentylalkohol | 200-908-9 | 75-85-4 | Flam. Liq. 2 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 | H225 H332 H335 H315 | GHS02 GHS07 Gef. | H225 H332 H335 H315 | |||
603-008-00-8 | 4-Methylpentan-2-ol; Methylisobutylcarbinol; Methylamylalkohol | 203-551-7 | 108-11-2 | Flam. Liq. 3 STOT SE 3 | H226 H335 | GHS02 GHS07 Achtg. | H226 H335 | STOT SE 3; H335: C ≥ 25 % | ||
603-009-00-3 | Cyclohexanol | 203-630-6 | 108-93-0 | Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 | H332 H302 H335 H315 | GHS07 Achtg. | H332 H302 H335 H315 | |||
603-010-00-9 | 2-Methylcyclohexanol, Isomerengemisch [1]; cis-2-Methylcyclohexanol [2]; trans-2-Methylcyclohexanol [3]; | 209-512-0 [1] 231-187-9 [2] 231-186-3 [3] | 583-59-5 [1] 7443-70-1 [2] 7443-52-9 [3] | Acute Tox. 4 * | H332 | GHS07 Achtg. | H332 | C | ||
603-011-00-4 | 2-Methoxyethanol; Methylglycol; Ethylenglykol-monomethylether | 203-713-7 | 109-86-4 | Flam. Liq. 3 Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H226 H360FD H332 H312 H302 | GHS02 GHS08 GHS07 Gef. | H226 H360FD H332 H312 H302 | |||
603-012-00-X | 2-Ethoxyethanol; Ethylglycol; Ethylenglykol-monoethylether | 203-804-1 | 110-80-5 | Flam. Liq. 3 Repr. 1B Acute Tox. 3 Acute Tox. 4 | H226 H360FD H331 H302 | GHS02 GHS08 GHS06 Gef. | H26 H360FD H331 H302 | |||
603-013-00-5 | 2-Isopropoxyethanol; Isopropylglycol; Ethylenglykol-monoisopropylether | 203-685-6 | 109-59-1 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 | H332 H312 H319 | GHS07 Achtg. | H332 H312 H319 | |||
603-014-00-0 | 2-Butoxyethanol; Ethylenglycolmonobutylether | 203-905-0 | 111-76-2 | Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 | H331 H302 H315 H319 | GHS06 Dgr | H331 H302 H315 H319 | Einatmung: ATE = 3 mg/L (Dämpfe) Oral: ATE = 1.200 mg/kg KG | ||
603-015-00-6 | Allylalkohol; Prop-2-en-1-ol | 203-470-7 | 107-18-6 | Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 | H225 H331 H311 H301 H319 H335 H315 H400 | GHS02 GHS06 GHS09 Gef. | H225 H331 H311 H301 H319 H335 H315 H400 | |||
603-016-00-1 | 4-Hydroxy-4-methylpentan-2-on; Diacetonalkohol | 204-626-7 | 123-42-2 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | Eye Irrit. 2; H319: C≥ 10 % | ||
603-018-00-2 | Furfurylalkohol | 202-626-1 | 98-00-0 | Carc. 2 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 | H351 H331 H312 H302 H373** H319 H335 | GHS06 GHS08 Gef. | H351 H331 H312 H302 H373** H319 H335 | |||
603-019-00-8 | Dimethylether | 204-065-8 | 115-10-6 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
603-020-00-3 | Ethylmethylether | - | 540-67-0 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | U | ||
603-021-00-9 | Methylvinylether | 203-475-4 | 107-25-5 | Flam. Gas 1 Press. Gas | H220 | GHS02 GHS04 Gef. | H220 | D U | ||
603-022-00-4 | Diethylether; Ether | 200-467-2 | 60-29-7 | Flam. Liq. 1 Acute Tox. 4 * STOT SE 3 | H224 H302 H336 | GHS02 GHS07 Gef. | H224 H302 H336 | EUH019 EUH066 | ||
603-023-00-X | Ethylenoxid; Oxiran | 200-849-9 | 75-21-8 | Flam. Gas 1 Press. Gas Carc. 1B Muta. 1B Repr. 1B Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 3 STOT RE 1 Skin Corr. 1 Eye Dam. 1 | H220 H350 H340 H360Fd H331 H301 H335 H336 H372 (Nervensystem) H314 H318 | GHS02 GHS08 GHS06 GHS05 Dgr | H220 H350 H340 H360Fd H331 H301 H335 H336 H372 (Nervensystem) H314 | Einatmen:
ATE = 700 ppm (Gase) Oral: ATE = 100 mg/kg KG | U | |
603-024-00-5 | 1,4-Dioxan | 204-661-8 | 123-91-1 | Flam. Liq. 2 Carc. 1B STOT SE 3 Eye Irrit. 2 | H225 H350 H335 H319 | GHS02 GHS08 GHS07 Dgr | H225 H350 H335 H319 | EUH019 EUH066 | D | |
603-025-00-0 | Tetrahydrofuran | 203-726-8 | 109-99-9 | Flam. Liq. 2 Carc. 2 Eye Irrit. 2 STOT SE 3 | H225 H351 H319 H335 | GHS02 GHS07 GHS08 Gef. | H225 H351 H319 H335 | EUH019 | STOT SE 3; H335: C≥25 % Eye Irrit.2; H319: C ≥ 25 % | |
603-026-00-6 | 1-Chlor-2,3-epoxypropan; Epichlorhydrin | 203-439-8 | 106-89-8 | Flam. Liq. 3 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 | H226 H350 H331 H311 H301 H314 H317 | GHS02 GHS06 GHS08 GHS05 Gef. | H226 H350 H331 H311 H301 H314 H317 | * | ||
603-027-00-1 | Ethandiol; 1,2-Ethandiol; Ethylenglycol | 203-473-3 | 107-21-1 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
603-028-00-7 | 2-Chlorethanol; Ethylenchlorhydrin | 203-459-7 | 107-07-3 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * | H330 H310 H300 | GHS06 Gef. | H330 H310 H300 | |||
603-029-00-2 | Bis(2-chlorethyl)ether; 2,2"-Dichlor-diethylether | 203-870-1 | 111-44-4 | Carc. 2 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * | H351 H330 H310 H300 | GHS06 GHS08 Gef. | H351 H330 H310 H300 | |||
603-030-00-8 | 2-Aminoethanol; Ethanolamin | 205-483-3 | 141-43-5 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H332 H312 H302 H314 | GHS05 GHS07 Gef. | H332 H312 H302 H314 | STOT SE 3; H335: C ≥ 5 % | ||
603-031-00-3 | 1,2-Dimethoxyethan; Ethylenglycoldimethylether; EGDME | 203-794-9 | 110-71-4 | Flam. Liq. 2 Repr. 1B Acute Tox. 4 * | H225 H360FD H332 | GHS02 GHS08 GHS07 Gef. | H225 H360FD H332 | EUH019 | ||
603-032-00-9 | Ethylendinitrat; Ethylenglycoldinitrat; Glykoldinitrat; Nitroglykol | 211-063-0 | 628-96-6 | Unst. Expl. Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 | H200 H330 H310 H300 H373** | GHS01 GHS06 GHS08 Gef. | H200 H330 H310 H300 H373** | |||
603-033-00-4 | Oxydiethylendinitrat; Diethylenglycoldinitrat | 211-745-8 | 693-21-0 | Unst. Expl Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 3 | H200 H330 H310 H300 H373 ** H412 | GHS01 GHS06 GHS08 Gef. | H200 H330 H310 H300 H373 ** H412 | |||
603-033-01-1 | Oxydiethylendinitrat; Diethylenglycoldinitrat; [>25 % Phlegmatisierungsmittel] | 211-745-8 | 693-21-0 | Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 3 | H201 H330 H310 H300 H373 ** H412 | GHS01 GHS06 GHS08 Gef. | H201 H330 H310 H300 H373 ** H412 | |||
603-034-00-X | Glycerintrinitrat; Nitroglycerin | 200-240-8 | 55-63-0 | Unst. Expl. Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 | H200 H330 H310 H300 H373 ** H411 | GHS01 GHS06 GHS08 GHS09 Gef. | H200 H330 H310 H300 H373 ** H411 | |||
603-034-01-7 | Glycerintrinitrat; Nitroglycerin; [> 40 % Phlegmatisierungsmittel] | 200-240-8 | 55-63-0 | Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 | H201 H330 H310 H300 H373 ** H411 | GHS01 GHS06 GHS08 GHS09 Gef. | H201 H330 H310 H300 H373 ** H411 | |||
603-035-00-5 | Pentaerythritoltetranitrat; Pentaerythrittetranitrat; P.E.T.N. | 201-084-3 | 78-11-5 | Unst. Expl. | H200 | GHS01 Gef. | H200 | |||
603-035-01-2 | Pentaerythritoltetranitrat; Pentaerythrittetranitrat; P.E.T.N.;[> 20 % Phlegamatisierungsmittel] | 201-084-3 | 78-11-5 | Expl. 1.1 | H201 | GHS01 Gef. | H201 | T | ||
603-036-00-0 | Mannithexanitrat; Nitromannit | 239-924-6 | 15825-70-4 | Unst. Expl. | H200 | GHS01 Gef. | H200 | |||
603-036-01-8 | Mannithexanitrat; Nitromannit; [> 40 % Phlegmatisierungsmittel] | 239-924-6 | 15825-70-4 | Expl. 1.1 | H201 | GHS01 Gef. | H201 | |||
603-037-00-6 | Cellulosenitrat; Nitrocellulose | - | - | Expl. 1.1 | H201 | GHS01 Gef. | H201 | T | ||
603-038-00-1 | Allylglycidylether; Allyl-2,3-epoxypropylether; Prop-2-en-1-yl-2,3-epoxypropylether | 203-442-4 | 106-92-3 | Flam. Liq. 3 Carc. 2 Muta. 2 Repr. 2 Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H226 H351 H341 H361f *** H332 H302 H335 H315 H318 H317 H412 | GHS02 GHS08 GHS05 GHS07 Gef. | H226 H351 H341 H361f *** H332 H302 H335 H315 H318 H317 H412 | |||
603-039-00-7 | n-Butylglycidylether; Butylglycidylether; Butyl-2,3-epoxypropylether; 1-Butoxy-2,3-epoxypropan | 219-376-4 | 2426-08-6 | Flam. Liq. 3 Carc. 2 Muta. 2 Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Sens. 1 Aquatic Chronic 3 | H226 H351 H341 H332 H302 H335 H317 H412 | GHS02 GHS08 GHS07 Achtg. | H226 H351 H341 H332 H302 H335 H317 H412 | |||
603-040-00-2 | Natriummethanolat; Natriummethylat; Natriummethoxid [1]; Kaliummethanolat; Kaliummethylat; Kaliummethoxid [2]; Lithiummethanolat; Lithiummethylat; Lithiummethoxid [3] | 204-699-5 [1] 212-736-1 [2] 212-737-7 [3] | 124-41-4 [1] 865-33-8 [2] 865-34-9 [3] | Self-heat 1 Skin Corr. 1B | H251 H314 | GHS02 GHS05 Gef. | H251 H314 | EUH014 | T | |
603-041-00-8 | Kaliumethanolat; Kaliumethylat; Kaliumethoxid [1]; Natriumethanolat; Natriumethylat; Natriumethoxid [2] | 213-029-0 [1] 205-487-5 [2] | 917-58-8 [1] 141-52-6 [2] | Self-heat 1 Skin Corr. 1B | H251 H314 | GHS02 GHS05 Gef. | H251 H314 | EUH014 | T | |
603-042-00-3 | Aluminiumtriisopropoxid | 209-090-8 | 555-31-7 | Flam. Sol. 1 | H228 | GHS02 Gef. | H228 | T | ||
603-043-00-9 | Triarimol (ISO); 2,4-Dichlor-α-(pyrimidin-5-yl)benzhydrylalkohol | - | 26766-27-8 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
603-044-00-4 | Dicofol (ISO); 2,2,2-Trichlor-1,1-bis(4-chlorphenyl)ethanol | 204-082-0 | 115-32-2 | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H315 H317 H410 | |||
603-045-00-X | Diisopropylether [1]; Dipropylether; Di-n-propylether [2] | 203-560-6 [1] 203-869-6 [2] | 108-20-3 [1] 111-43-3 [2] | Flam. Liq. 2 STOT SE 3 | H225 H336 | GHS02 GHS07 Gef. | H225 H336 | EUH019 EUH066 | C | |
603-046-00-5 | Bis(chlormethyl)ether; Oxybis(chlormethan); Dichlordimethylether, symmetrisch | 208-832-8 | 542-88-1 | Flam. Liq. 2 Carc. 1A Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * | H225 H350 H330 H311 H302 | GHS02 GHS06 GHS08 Gef. | H225 H350 H330 H311 H302 | Carc. 1A; H350: C ≥ 0,001 % | ||
603-047-00-0 | 2-Dimethylaminoethanol; N, N-Dimethylethanolamin | 203-542-8 | 108-01-0 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H226 H332 H312 H302 H314 | GHS02 GHS05 GHS07 Gef. | H226 H332 H312 H302 H314 | STOT SE 3; H335: C≥5 % | ||
603-048-00-6 | 2-Diethylaminoethanol; N, N-diethylethanolamin | 202-845-2 | 100-37-8 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H226 H332 H312 H302 H314 | GHS02 GHS05 GHS07 GHS09 Gef. | H226 H332 H312 H302 H314 | STOT SE 3; H335: C≥5 % | ||
603-049-00-1 | Chlorfenethol (ISO); 1,1-Bis(4-chlorphenyl)ethanol | 201-246-3 | 80-06-8 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
603-050-00-7 | 1-(2-Butoxypropoxy)-2-propanol | 246-011-6 | 24083-03-2 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
603-051-00-2 | 2-Ethylbutanol | 202-621-4 | 97-95-0 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
603-052-00-8 | 3-Butoxypropan-2-ol; Propylenglycolmonobutylether | 225-878-4 | 5131-66-8 | Eye Irrit. 2 Skin Irrit. 2 | H319 H315 | GHS07 Achtg. | H319 H315 | |||
603-053-00-3 | 2-Methyl-2,4-pentandiol | 203-489-0 | 107-41-5 | Eye Irrit. 2 Skin Irrit. 2 | H319 H315 | GHS07 Achtg. | H319 H315 | |||
603-054-00-9 | Di- n-butylether; Dibutylether | 205-575-3 | 142-96-1 | Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 3 | H226 H319 H335 H315 H412 | GHS02 GHS07 Achtg. | H226 H319 H335 H315 H412 | STOT SE 3; H335: C≥10 % | ||
603-055-00-4 | Propylenoxid; 1,2-Epoxypropan; Methyloxiran | 200-879-2 | 75-56-9 | Flam. Liq. 1 Carc. 1B Muta. 1B Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Irrit. 2 | H224 H350 H340 H331 H311 H302 H335 H319 | GHS02 GHS08 GHS06 Gef. | H224 H350 H340 H331 H311 H302 H335 H319 | |||
603-056-00-X | [(p-Tolyloxy)methyl]oxiran; [2,3-Epoxypropyl-p-tolylether] [1]; [( m-Tolyloxy)methyl]oxiran [2]; 2,3-Epoxypropyl- o-tolylether [3]; [(Tolyloxy)methyl]oxiran; Kresylglycidylether [4] | 218-574-8 [1] 218-575-3 [2] 218-645-3 [3] 247-711-4 [4] | 2186-24-5 [1] 2186-25-6 [2] 2210-79-9 [3] 26447-14-3 [4] | Muta. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H341 H315 H317 H411 | GHS08 GHS07 GHS09 Achtg. | H341 H315 H317 H411 | C | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
603-057-00-5 | Benzylalkohol | 202-859-9 | 100-51-6 | Acute Tox. 4 * Acute Tox. 4 * | H332 H302 | GHS07 Achtg. | H332 H302 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
603-057-00-5 | Benzylalkohol | 202-859-9 | 100-51-6 | Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1B | H302 H319 H317 | GHS07 Wng | H302 H319 H317 | Oral: ATE = 1.200 mg/kg KG | ) | |
603-058-00-0 | 1,3-Propylenoxid; Oxetan; 1,3-Epoxypropan | 207-964-3 | 503-30-0 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H225 H332 H312 H302 | GHS02 GHS07 Gef. | H225 H332 H312 H302 | |||
603-059-00-6 | 1-Hexanol | 203-852-3 | 111-27-3 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
603-060-00-1 | 2,2"-Bioxiran; 1,2:3,4-Diepoxybutan | 215-979-1 | 1464-53-5 | Carc. 1B Muta. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B | H350 H340 H330 H311 H301 H314 | GHS06 GHS08 GHS05 Gef. | H350 H340 H330 H311 H301 H314 | |||
603-061-00-7 | Tetrahydro-2-furyl-methanol; Tetrahydrofurfurylalkohol | 202-625-6 | 97-99-4 | Repr. 1B Eye Irrit. 2 | H360Df H319 | GHS08 GHS07 Gef. | H360Df H319 | |||
603-062-00-2 | Tetrahydrofuran-2,5-diyldimethanol | 203-239-0 | 104-80-3 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | STOT SE 3; H335: C ≥10 % | ||
603-063-00-8 | 2,3-Epoxypropan-1-ol; Glycidol; Oxiranmethanol | 209-128-3 | 556-52-5 | Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H350 H341 H360F *** H331 H312 H302 H319 H335 H315 | GHS06 GHS08 Gef. | H350 H341 H360F *** H331 H312 H302 H319 H335 H315 | |||
603-064-00-3 | 1-Methoxy-2-propanol; Monopropylenglycolmethylether | 203-539-1 | 107-98-2 | Flam. Liq. 3 STOT SE 3 | H226 H336 | GHS02 GHS07 Achtg. | H226 H336 | |||
603-065-00-9 | m-Bis(2,3-epoxypropoxy)benzol; Resorcinoldiglycidylether | 202-987-5 | 101-90-6 | Carc. 1B Muta. 2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H350 H341 H311 H302 H315 H319 H317 H412 | GHS08 GHS06 Dgr | H350 H341 H311 H302 H315 H319 H317 H412 | dermal: ATE = 300 mg/kg KG oral: ATE = 500 mg/kg KG | ||
603-066-00-4 | 7-Oxa-3-oxiranylbicyclo[4.1.0]heptan; 1,2-Epoxy-4-epoxyethylcyclohexan; 4-Vinylcyclohexendiepoxid | 203-437-7 | 106-87-6 | Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 | H350 H341 H360F H331 H302 | GHS08 GHS06 Dgr | H350 H341 H360F H331 H302 | Einatmen:
ATE = 0,5 mg/L (Stäube oder Nebel) oral: ATE = 1 847 mg/kg KG | ||
603-067-00-X | Phenylglycidylether; 2,3-Epoxypropylphenylether;1,2-Epoxy-3-phenoxypropan | 204-557-2 | 122-60-1 | Carc. 1B Muta. 2 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H350 H341 H332 H335 H315 H317 H412 | GHS08 GHS07 Gef. | H350 H341 H332 H335 H315 H317 H412 | |||
603-068-00-5 | 2,3-Epoxypropyl-2-ethylcyclohexylether; Ethylcyclohexylglycidylether; 1-(2-Ethylcyclohexanoxy)-2,3-epoxypropan | - | 130014-35-6 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | |||
603-069-00-0 | 2,4,6-Tris(dimethylaminomethyl)phenol | 202-013-9 | 90-72-2 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 | H302 H319 H315 | GHS07 Achtg. | H302 H319 H315 | |||
603-070-00-6 | 2-Amino-2-methylpropanol | 204-709-8 | 124-68-5 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3 | H319 H315 H412 | GHS07 Achtg. | H319 H315 H412 | |||
603-071-00-1 | 2,2"-Iminodiethanol; Diethanolamin | 203-868-0 | 111-42-2 | Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 | H302 H373 ** H315 H318 | GHS08 GHS05 GHS07 Gef. | H302 H373 ** H315 H318 | |||
603-072-00-7 | 1,4-Bis(2,3-epoxypropoxy)butan; 1,4-Butandioldiglycidylether | 219-371-7 | 2425-79-8 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H332 H312 H319 H315 H317 | GHS07 Achtg. | H332 H312 H319 H315 H317 | |||
603-073-00-2 | Bis-[4-(2,3-epoxipropoxi)phenyl]propan; 4,4"-Methylen-diphenyldiglycidylether; Bisphenol-A-diglycidylether | 216-823-5 | 1675-54-3 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | Eye Irrit. 2; H319: C≥ 5 % Skin Irrit. 2; H315: C≥5 % | ||
603-074-00-8 | Reaktionsprodukt: Bisphenol-A-Epichlorhydrin; Epoxyharz (durchschnittliches Zahlenmittel des Molekulargewichts ≤ 700) | 500-033-5 | 25068-38-6 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H319 H315 H317 H411 | GHS07 GHS09 Achtg. | H319 H315 H317 H411 | Eye Irrit. 2; H319: C ≥ 5 % Skin Irrit 2; H315: C≥ 5 % | ||
603-075-00-3 | Chlormethylmethylether; Chlordimethylether; Monochlordimethylether | 203-480-1 | 107-30-2 | Flam. Liq. 2 Carc. 1A Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H225 H350 H332 H312 H302 | GHS02 GHS08 GHS07 Gef. | H225 H350 H332 H312 H302 | |||
603-076-00-9 | But-2-in-1,4-diol; 2-Butin-1,4-diol | 203-788-6 | 110-65-6 | Skin Corr. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 | H314 H331 H301 H312 H373 ** H317 | GHS06 GHS05 GHS08 Gef. | H314 H331 H301 H312 H373 ** H317 | Skin Corr. 1B; H314: C≥50 % Skin Irrit. 2; H315: 25 %≤ C < 50 % Eye Irrit. 2; H319: 25 %≤ C<50 % | D | |
603-077-00-4 | 1-Dimethylaminopropan-2-ol; Dimepranol (INN) | 203-556-4 | 108-16-7 | Flam. Liq. 3 Acute Tox. 4 * Skin Corr. 1B | H226 H302 H314 | GHS02 GHS05 GHS07 Gef. | H226 H302 H314 | |||
603-078-00-X | Prop-2-in-1-ol; Propargylalkohol | 203-471-2 | 107-19-7 | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Chronic 2 | H226 H331 H311 H301 H314 H411 | GHS02 GHS06 GHS05 GHS09 Gef. | H226 H331 H311 H301 H314 H411 | |||
603-079-00-5 | 2,2"-(Methylimino)diethanol; N-Methyldiethanolamin | 203-312-7 | 105-59-9 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
603-080-00-0 | 2-Methylaminoethanol; N-Methylethanolamin; N-Methyl-2-ethanolamin; N-Methyl-2-aminoethanol; 2-(Methylamino)ethanol | 203-710-0 | 109-83-1 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | STOT SE 3; H335: C≥5 % | ||
603-081-00-6 | 2,2"-Thiodiethanol; Thiodiglykol | 203-874-3 | 111-48-8 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
603-082-00-1 | 1-Aminopropan-2-ol; Isopropanolamin | 201-162-7 | 78-96-6 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
603-083-00-7 | 1,1"-Iminodipropan-2-ol; Diisopropanolamin | 203-820-9 | 110-97-4 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
603-084-00-2 | Styroloxid; (Epoxyethyl)benzol; Phenyloxiran | 202-476-7 | 96-09-3 | Carc. 1B Acute Tox. 4 * Eye Irrit. 2 | H350 H312 H319 | GHS08 GHS07 Gef. | H350 H312 H319 | |||
603-085-00-8 | Bronopol (INN); 2-Brom-2-nitropropan-1,3-diol | 200-143-0 | 52-51-7 | Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 | H312 H302 H335 H315 H318 H400 | GHS05 GHS07 GHS09 Gef. | H312 H302 H335 H315 H318 H400 | M=10 | ||
603-086-00-3 | Ethirimol (ISO); 5-Butyl-2-ethylamino-6-methylpyrimidin-4-ol | 245-949-3 | 23947-60-6 | Acute Tox. 4 * | H312 | GHS07 Achtg. | H312 | |||
603-087-00-9 | 2-Ethylhexan-1,3-diol; Octylenglycol; Ethoexadiol | 202-377-9 | 94-96-2 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
603-088-00-4 | 2-(Octylthio)ethanol; 2-Hydroxyethyloctylsulfid | 222-598-4 | 3547-33-9 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
603-089-00-X | 7,7-Dimethyl-3-oxa-6-azaoctan-1-ol | 400-390-6 | - | Skin Corr. 1A Acute Tox. 4 * | H314 H302 | GHS05 GHS07 Gef. | H314 H302 | |||
603-090-00-5 | 2-(2-Bromethoxy)anisol; 2-(2-Bromethoxy)-1-methoxybenzol | 402-010-4 | 4463-59-6 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
603-091-00-0 | exo-1-Methyl-4-(1-methylethyl)-7-oxabicyclo[2.2.1]heptan-2-ol; exo-4-Isopropyl-1-methyl- 1,4-epoxycyclohexan-2-ol | 402-470-6 | 87172-89-2 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
603-092-00-6 | 2-Methyl-4-phenylpentanol | 402-770-7 | 92585-24-5 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
603-093-00-1 | Cinmethylin (ISO); exo-(±)-1-Methyl-2-(2-methylbenzyloxy)-4-isopropyl-7-oxabicyclo(2.2.1)heptan | 402-410-9 | 87818-31-3 | Acute Tox. 4 * Aquatic Chronic 2 | H332 H411 | GHS07 GHS09 Gef. | H332 H411 | |||
603-094-00-7 | 1,3-Bis(2,3-epoxypropoxy)-2,2- dimethylpropan | 241-536-7 | 17557-23-2 | Skin Irrit. 2 Skin Sens. 1 | H315 H317 | GHS07 Achtg. | H315 H317 | |||
603-095-00-2 | 2-(Propyloxy)ethanol; EGPE; n-Propylglykol [Ethylenglykol-monopropylether] | 220-548-6 | 2807-30-9 | Acute Tox. 4 * Eye Irrit. 2 | H312 H319 | GHS07 Achtg. | H312 H319 | |||
603-096-00-8 | 2-(2-Butoxyethoxy)ethanol; Diethylenglykolmonobutylether; Butyldiglykol | 203-961-6 | 112-34-5 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
603-097-00-3 | 1,1",1"-Nitrilotripropan-2-ol; Triisopropanolamin | 204-528-4 | 122-20-3 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
603-098-00-9 | 2-Phenoxyethanol | 204-589-7 | 122-99-6 | Acute Tox. 4 STOT SE 3 Eye Dam. 1 | H302 H335 H318 | GHS05 GHS07 Dgr | H302 H335 H318 | oral: ATE = 1 394 mg/kg KG | ||
603-099-00-4 | 3-( N-Methyl- N-(4-methylamino-3-nitrophenyl)amino)propan-1,2-diol-hydrochlorid | 403-440-5 | 93633-79-5 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
603-100-00-8 | 1,2-Dimethoxypropan | 404-630-0 | 7778-85-0 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | EUH019 | ||
603-101-00-3 | Tetrahydro-2-isobutyl-4-methylpyran-4-ol, Isomerengemisch (cis und trans) | 405-040-6 | - | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
603-102-00-9 | 1,2-Epoxybutan | 203-438-2 | 106-88-7 | Flam. Liq. 2 Carc. 2 Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 | H225 H351 H302 H312 H332 H335 H315 H319 | GHS02 GHS08 GHS07 Gef. | H225 H351 H302 H312 H332 H335 H315 H319 | |||
603-103-00-4 | Oxiran, Mono[(C12-14-alkyloxy)methyl]-Derivate; C12-14-Alkylglycidylether | 271-846-8 | 68609-97-2 | Skin Irrit. 2 Skin Sens. 1 | H315 H317 | GHS07 Achtg. | H315 H317 | |||
603-104-00-X | Fenarimol (ISO); 2,4"-Dichlor-α-(pyrimidin-5-yl)benzhydrylalkohol | 262-095-7 | 60168-88-9 | Repr. 2 Lact. Aquatic Chronic 2 | H361fd H362 H411 | GHS08 GHS09 Achtg. | H361fd H362 H411 | |||
603-105-00-5 | Furan | 203-727-3 | 110-00-9 | Flam. Liq. 1 Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Aquatic Chronic 3 | H224 H350 H341 H332 H302 H373 ** H315 H412 | GHS02 GHS08 GHS07 Gef. | H224 H350 H341 H332 H302 H373 ** H315 H412 | EUH019 | ||
603-106-00-0 | 2-Methoxypropanol | 216-455-5 | 1589-47-5 | Flam. Liq. 3 Repr. 1B STOT SE 3 Skin Irrit. 2 Eye Dam. 1 | H226 H360D *** H335 H315 H318 | GHS02 GHS08 GHS05 GHS07 Gef. | H226 H360D *** H335 H315 H318 | |||
603-107-00-6 | 2-(2-Methoxyethoxy)ethanol; Diethylenglykolmonomethylether | 203-906-6 | 111-77-3 | Repr. 1B | H360D | GHS08 Dgr | H360D | Repr. 1B; H360D: C ≥ 3 % | ||
603-108-00-1 | 2-Methyl-1-propanol; Isobutanol; Isobutylalkohol; 2-Methylpropanol-1 | 201-148-0 | 78-83-1 | Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Eye Dam. 1 STOT SE 3 | H226 H335 H315 H318 H336 | GHS02 GHS05 GHS07 Gef. | H226 H335 H315 H318 H336 | |||
603-109-00-7 | Reaktionsmasse aus 1-Ethoxy-1,1,2,3,3,3-hexafluor-2-(trifluormethyl)propan und 1-Ethoxy-1,1,2,2,3,3,4,4,4- nonafluorbutan | 425-340-0 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
603-110-00-2 | Reaktionsmasse aus cis-2-Isobutyl-5-methyl-1,3-dioxan und trans-2-Isobutyl-5-methyl-1,3-dioxan | 426-130-1 | 166301-21-9 | Skin Irrit. 2 Aquatic Chronic 3 | H315 H412 | GHS07 Achtg. | H315 H412 | |||
603-111-00-8 | Reaktionsmasse aus 1-(1,1- Dimethylpropyl)-4-ethoxy- cis- cyclohexan und 1-(1,1-Dimethylpropyl)-4-ethoxy- trans-cyclohexan | 426-530-6 | - | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
603-112-00-3 | Cyclopentyl-2-phenylethylether | 428-340-9 | - | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
603-113-00-9 | 6-Glycidyloxynapht-1-yl-oxymethyloxiran | 429-960-2 | 27610-48-6 | Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H341 H312 H315 H317 H412 | GHS08 GHS07 Achtg. | H341 H312 H315 H317 H412 | |||
603-114-00-4 | 9-(2-Propenyloxy)tri-cyclo[5.2.1.0(2,6)]dec-3(oder-4-)-en | 430-830-2 | 26912-64-1 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
603-115-00-X | Reaktionsmasse aus O, O",O""-(Methylsilantriyl)tris(4-methyl-2-pentanonoxim) (3 Stereoisomere) | 423-580-0 | - | STOT RE 2 * Aquatic Chronic 4 | H373** H413 | GHS08 Achtg. | H373** H413 | |||
603-116-00-5 | (Z)-(2,4-Difluorphenyl)piperidin-4-ylmethanonoximmonohydrochlorid | 424-740-2 | 138271-16-6 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
603-117-00-0 | 2-Propanol; Isopropylalkohol; Isopropanol | 200-661-7 | 67-63-0 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H336 | GHS02 GHS07 Gef. | H225 H319 H336 | |||
603-118-00-6 | 6-Dimethylaminohexan-1-ol | 404-680-3 | 1862-07-3 | Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 3 | H302 H314 H412 | GHS05 GHS07 Gef. | H302 H314 H412 | |||
603-119-00-1 | 1,1"-(1,3-Phenylendioxy)bis(3-(2-(prop-2-enyl)phenoxy)propan-2-ol) | 405-840-5 | - | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
603-120-00-7 | 2-Methyl-5-phenylpentanol | 405-890-8 | 25634-93-9 | Eye Irrit. 2 Skin Irrit. 2 | H319 H315 | GHS07 Achtg. | H319 H315 | |||
603-121-00-2 | 4-[4-(1,3-Dihydroxyprop-2-yl)phenylamino]-1,8-dihydroxy-5-nitroanthrachinon | 406-057-1 | 114565-66-1 | Carc. 2 Skin Sens. 1 Aquatic Chronic 4 | H351 H317 H413 | GHS08 GHS07 Achtg. | H351 H317 H413 | |||
603-122-00-8 | Natrium-2-ethylhexanolat | 406-150-7 | 38411-13-1 | Flam. Sol. 1 Skin Corr. 1B Aquatic Chronic 3 | H228 H314 H412 | GHS02 GHS05 Gef. | H228 H314 H412 | T | ||
603-123-00-3 | 4-Methyl-8-methylen-tricyclo[3.3.1.1 3,7]decan-2-ol | 406-330-5 | 122760-84-3 | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H315 H317 H411 | GHS07 GHS09 Achtg. | H315 H317 H411 | |||
603-124-00-9 | 1,4-Bis[2-(vinyloxy)ethoxy]benzol | 406-900-3 | 84563-49-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
603-125-00-4 | 2-(2,4-Dichlorphenyl)-1-(1 H-1,2,4-triazol-1-yl)pent-4-en-2-ol | 407-850-5 | 89544-40-1 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
603-126-00-X | 2-((4-Methyl-2-nitrophenyl)amino)ethanol | 408-090-7 | 100418-33-5 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H302 H317 H412 | GHS07 Achtg. | H302 H317 H412 | |||
603-127-00-5 | 2-Butanol [1]; (S)-Butan-2-ol [2]: (R)-Butan-2-ol [3]; (±)-Butan-2-ol [4]; | 201-158-5 [1] 224-168-1 [2] 238-967-8 [3] 240-029-8 [4] | 78-92-2 [1] 4221-99-2 [2] 14898-79-4 [3] 15892-23-6 [4] | Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 STOT SE 3 | H226 H319 H335 H336 | GHS02 GHS07 Achtg. | H226 H319 H335 H336 | C | ||
603-128-00-0 | 2-(Phenylmethoxy)naphthalin | 405-490-3 | 613-62-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
603-129-00-6 | 1- tert-Butoxypropan-2-ol | 406-180-0 | 57018-52-7 | Flam. Liq. 3 Eye Dam. 1 | H226 H318 | GHS02 GHS05 Gef. | H226 H318 | |||
603-130-00-1 | Reaktionsmasse aus Isomeren von α-((Dimethyl)biphenyl)-ω-hydroxy-poly(oxyethylen) | 406-325-8 | - | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
603-131-00-7 | Reaktionsmasse aus 1-Deoxy-1-[methyl-(1-oxododecyl)amino]-D-glucitol und 1-Deoxy-1-[methyl-(1-oxotetradecyl)amino]-D-glucitol (3:1) | 407-290-1 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
603-132-00-2 | 2-Hydroxymethyl-9-methyl-6-(1-methylethyl)-1,4-dioxaspiro[4.5]decan | 408-200-3 | 63187-91-7 | Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H315 H318 H412 | GHS05 Gef. | H315 H318 H412 | |||
603-133-00-8 | Reaktionsmasse aus 3-[(4-Amino-2-chlor-5-nitrophenyl)amino]-propan-1,2-diol und 3,3"-(2-Chlor-5-nitro-1,4-phenylendiimino)bis(propan-1,2-diol) | 408-240-1 | - | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
603-134-00-3 | Reaktionsmasse aus substituierten Dodecyl- und/oder Tetradecyldiphenylethern. Der Stoff wird mit der Friedel-Crafts-Reaktion hergestellt. Der Katalysator wird vom Reaktionsprodukt entfernt. Der Diphenylether ist durch C1-C10-Alkylgruppen substituiert. Die Alkylgruppen sind zufällig zwischen C1 und C6 gebunden. Lineare C12 und C14 werden im Verhältnis 50:50 verwendet. | 410-450-3 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
603-135-00-9 | Bis[[2,2",2""-nitrilotris-[ethanolato]]-1- N, O]-bis[2-(2-methoxyethoxy)ethoxy]titan | 410-500-4 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
603-136-00-4 | 3-((4-(Bis(2-hydroxyethyl)amino)-2-nitrophenyl)amino)-1-propanol | 410-910-3 | 104226-19-9 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
603-137-00-X | Reaktionsmasse aus 1-Deoxy-1-[methyl-(1-oxohexadecyl)amino]-D-glucitol und 1-Deoxy-1-[methyl-(1-oxooctadecyl)amino]-D-glucitol | 411-130-6 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
603-138-00-5 | 3-(2,2-Dimethyl-3-hydroxypropyl)toluol; (alt.): 2,2-Dimethyl-3-(3-methylphenyl)propanol | 403-140-4 | 103694-68-4 | Aquatic Chronic 3 | H412 | - | H412 | |||
603-139-00-0 | Bis(2-methoxyethyl)ether | 203-924-4 | 111-96-6 | Flam. Liq. 3 Repr. 1B | H226 H360FD | GHS02 GHS08 Gef. | H226 H360FD | EUH019 | ||
603-140-00-6 | 2,2"-Oxydiethanol; Diethylenglykol | 203-872-2 | 111-46-6 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
603-141-00-1 | Reaktionsmasse aus Dodecyloxy-1-methyl-1-[oxy-poly-(2-hydroxymethylethanoxy)]pentadecan und Dodecyloxy-1-methyl-1-[oxy-poly-(2-hydroxymethylethanoxy)]heptadecan | 413-780-6 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
603-142-00-7 | 2-(2-(2-Hydroxyethoxy)ethyl)-2-aza-bicyclo[2.2.1]heptan | 407-360-1 | 116230-20-7 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 | H312 H302 H373 ** H315 H318 | GHS06 GHS08 GHS05 Gef. | H312 H302 H373 ** H315 H318 | |||
603-143-00-2 | R-2,3-Epoxy-1-propanol | 404-660-4 | 57044-25-4 | Self-react.
C **** Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H242 H350 H341 H360F *** H331 H312 H302 H314 | GHS02 GHS06 GHS08 GHS05 Gef. | H242 H350 H341 H360F *** H331 H312 H302 H314 | |||
603-144-00-8 | Reaktionsmasse aus 2,6,9-Trimethyl-2,5,9-cyclododecatrien-1-ol und 6,9-Dimethyl-2-methylen-5,9-cyclododecadien-1-ol | 413-530-6 | 111850-00-1 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
603-145-00-3 | 2-Isopropyl-2-(1-methylbutyl)-1,3-dimethoxypropan | 406-970-5 | 129228-11-1 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
603-146-00-9 | 2-[(2-[2-(Dimethylamino)ethoxy]ethyl)methylamino]ethanol | 406-080-7 | 83016-70-0 | Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 3 | H302 H314 H412 | GHS05 GHS07 Gef. | H302 H314 H412 | |||
603-147-00-4 | (-)- trans-4-(4"-Fluorphenyl)-3-hydroxymethyl- N-methylpiperidin | 406-030-4 | 105812-81-5 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
603-148-00-X | 1,4-Bis[(vinyloxy)methyl]cyclohexan | 413-370-7 | 17351-75-6 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
603-149-00-5 | Reaktionsmasse aus Diastereomeren von 1-(1-Hydroxyethyl)-4-(1-methylethyl)cyclohe xan | 407-640-3 | 63767-86-2 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H319 H315 H411 | GHS07 GHS09 Achtg. | H319 H315 H411 | |||
603-150-00-0 | (±)- trans-3,3-Dimethyl-5-(2,2,3-trimethylcyclopent-3-en-1-yl)-pent-4-en-2-ol | 411-580-3 | 107898-54-4 | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
603-151-00-6 | (±)-2-(2,4-Dichlorphenyl)-3-(1 H-1,2,4-triazol-1-yl)propan-1-ol | 413-570-4 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
603-152-00-1 | 2-(4- tert-Butylphenyl)ethanol | 410-020-5 | 5406-86-0 | Repr. 2 STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 | H361f *** H373 ** H318 H411 | GHS08 GHS05 GHS09 Gef. | H361f *** H373 ** H318 H411 | |||
603-153-00-7 | 3-((2-Nitro-4-(trifluormethyl)phenyl)amino)propan-1,2-diol | 410-010-0 | 104333-00-8 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
603-154-00-2 | 1-[(2- tert-Butyl)cyclohexyloxy]-2-butanol | 412-300-2 | 139504-68-0 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
603-156-00-3 | 2-(2,4-Dichlorphenyl)-2-(2-propenyl)oxiran | 411-210-0 | 89544-48-9 | Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H315 H317 H410 | |||
603-157-00-9 | 6,9-Bis(hexadecyloxymethyl)-4,7-dioxanonan-1,2,9-triol | 411-450-6 | 143747-72-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
603-158-00-4 | Reaktionsmasse aus 4 Diastereomeren von 2,7-Dimethyl-10-(1-methylethyl)-1-oxaspiro[4.5]deca-3,6-dien | 412-460-3 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
603-159-00-X | 2-Cyclododecylpropan-1-ol | 411-410-8 | 118562-73-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
603-160-00-5 | 1,2-Diethoxypropan | 412-180-1 | 10221-57-5 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | EUH019 | ||
603-161-00-0 | 1,3-Diethoxypropan | 413-140-6 | 3459-83-4 | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | |||
603-162-00-6 | α[2-[[[(2-Hydroxyethyl)methylamino]acetyl]amino]propyl]-ω-nonylphenoxy)-poly-[oxo(methyl-1,2-ethandiyl)] | 413-420-8 | 144736-29-8 | Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H314 H317 H411 | GHS05 GHS07 GHS09 Gef. | H314 H317 H411 | |||
603-163-00-1 | 2-Phenyl-1,3-propandiol | 411-810-2 | 1570-95-2 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
603-164-00-7 | 2-Butyl-4-chlor-4,5-dihydro-5hydroxymethyl-1-[2"-(2-triphenylmethyl-1,2,3,4-2 H-tetrazol-5-yl)-1,1"-biphenyl-4-methyl]-1 H-imidazol | 412-420-5 | 133909-99-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
603-165-00-2 | Reaktionsmasse aus 4-Allyl-2,6bis(2,3-epoxypropyl)phenol, 4-Allyl-6-[3-[6-[3-[6-[3-(4-allyl-2,6-bis(2,3-epoxypropyl)phenoxy)-2-hydroxypropyl]-4-allyl-2-(2,3-epoxypropyl)phenoxy]-2-hydroxypropyl]-4-allyl-2-(2,3-epoxypropyl)phenoxy]-2-hydroxypropyl]-2-(2,3-epoxypropyl)phenol, 4-Allyl-6-[3-(4-allyl-2,6-bis(2,3-epoxypropyl)phenoxy)-2-hydroxypropyl]-2-(2,3-epoxypropyl)phenol und 4-Allyl-6-[3-[6-[3-(4-allyl-2,6-bis(2,3-epoxypropyl)phenoxy)-2-hydroxypropyl]-4-allyl-2-(2,3-epoxypropyl)phenoxy]-2-hydroxypropyl]-2-(2,3-epoxypropyl)phenol | 417-470-1 | - | Muta. 2 Skin Sens. 1 | H341 H317 | GHS08 GHS07 Achtg. | H341 H317 | |||
603-166-00-8 | R-1-Chlor-2,3-epoxypropan | 424-280-2 | 51594-55-9 | Flam. Liq. 3 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 | H226 H350 H331 H311 H301 H314 H317 | GHS02 GHS06 GHS08 GHS05 Gef. | H226 H350 H331 H311 H301 H314 H317 | |||
603-167-00-3 | 3,3",5,5"-Tetra- tert-butylbiphenyl-2,2"-diol | 407-920-5 | 6390-69-8 | Aquatic Chronic 4 | H413 | GHS05 Gef. | H413 | |||
603-168-00-9 | 3-(2-Ethylhexyloxy)propan-1,2-diol | 408-080-2 | 70445-33-9 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
603-169-00-4 | (±)- trans-4-(4-Fluorphenyl)-3-hydroxymethyl- N-methylpiperidin | 415-550-0 | 109887-53-8 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
603-170-00-X | Reaktionsmasse aus 2-Methyl-1-(6-methylbicyclo[2.2.1]hept-5-en-2-yl)pent-1-en-3-ol, 2-Methyl-1-(1-methylbicyclo[2.2.1]hept-5-en-2-yl)-pent-1-en-3-ol und 2-Methyl-1-(5-methylbicyclo[2.2.1]hept-5-en-2-yl)pent-1-en-3-ol | 415-990-3 | 67739-11-1 | Eye Irrit. 2 Aquatic Chronic 2 | H319 H411 | GHS07 GHS09 Achtg. | H319 H411 | |||
603-171-00-5 | 5-Thiazolylmethanol | 414-780-9 | 38585-74-9 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
603-172-00-0 | Mono-2-[2-(4-dibenzo[ b, f][1,4]thiazepin-11-yl)piperazinium-1-yl]ethoxy)ethanol- trans-butendioat | 415-180-1 | 773058-82-5 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
603-173-00-6 | 4,4-Dimethyl-3,5,8-trioxabicyclo[5.1.0]octan | 421-750-9 | 57280-22-5 | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
603-174-00-1 | 4-Cyclohexyl-2-methyl-2-butanol | 420-630-3 | 83926-73-2 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
603-175-00-7 | 2-(2-Hexyloxyethoxy)ethanol; DEGHE; Diethylenglycolmonohexylether; 3,6-Dioxa-1-dodecanol; Hexylcarbitol; 3,6-Dioxadodecan-1-ol | 203-988-3 | 112-59-4 | Acute Tox. 4 * Eye Dam. 1 | H312 H318 | GHS05 GHS07 Gef. | H312 H318 | |||
603-176-00-2 | 1,2-Bis(2-methoxyethoxy)ethan; TEGDME; Triethylenglycoldimethylether; Triglyme | 203-977-3 | 112-49-2 | Repr. 1B | H360Df | GHS08 Gef. | H360Df | EUH019 | ||
603-177-00-8 | 1-Ethoxypropan-2-ol; 2PG1EE; 1-Ethoxy-2-propanol; Propylenglycol-monoethylether; [1]2-Ethoxy-1-methylethylacetat; 2PG1EEA [2] | 216-374-5 [1] 259-370-9 [2] | 1569-02-4 [1] 54839-24-6 [2] | Flam. Liq. 3 STOT SE 3 | H226 H336 | GHS02 GHS07 Achtg. | H226 H336 | |||
603-178-00-3 | 2-Hexyloxyethanol; Ethylenglycolmonohexylether; n-Hexylglycol | 203-951-1 | 112-25-4 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | |||
603-179-00-9 | Ergocalciferol (ISO); Vitamin D2 | 200-014-9 | 50-14-6 | Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 | H330 H311 H301 H372 ** | GHS06 GHS08 Gef. | H330 H311 H301 H372 ** | |||
603-180-00-4 | Colecalciferol; Cholecalciferol; Vitamin D3 | 200-673-2 | 67-97-0 | Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 STOT RE 1 | H330 H310 H300 H372 | GHS06 GHS08 Dgr | H330 H310 H300 H372 | Einatmung: ATE = 0,05 mg/L (Stäube oder Nebel) Dermal: ATE = 50 mg/kg KG Oral: ATE = 35 mg/kg KG STOT RE 1; H372: C ≥ 3 % STOT RE 2; H373: 0,3 % ≤ C < 3 % | ||
603-181-00-X | tert-Butylmethylether; MTBE; 2-Methoxy-2-methylpropan | 216-653-1 | 1634-04-4 | Flam. Liq. 2 Skin Irrit. 2 | H225 H315 | GHS02 GHS07 Gef. | H225 H315 | |||
603-182-00-5 | Reaktionsprodukt von gesättigten sowie einfach und mehrfach ungesättigten, langkettigen, teilweise veresterten Alkoholen pflanzlichen Ursprungs (Brassica napus L., Brassica rapa L., Helianthus annuus L., Glycine hispida, Gossypium hirsutum L., Cocos nucifera L., Elaeis guineensis) mit O, O-Diisobutyldithiophosphat und 2-Ethylhexylamin und Wasserstoffperoxid | 428-630-5 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
603-183-00-0 | 2-[2-(2-Butoxyethoxy)ethoxy]ethanol; TEGBE; Triethylenglycolmonobutylether; Butoxytriethylenglycol | 205-592-6 | 143-22-6 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | Eye Dam.1; H318: C≥30 % Eye Irrit. 2; H319: 20 % ≤C< 30 % | ||
603-184-00-6 | 2-(Hydroxymethyl)-2-[[2-hydroxy-3-(isooctadecyloxy)propoxy]methyl]-1,3-propanediol | 416-380-1 | 146925-83-9 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
603-185-00-1 | 2,4-Dichlor-3-ethyl-6-nitrophenol | 420-740-1 | 99817-36-4 | Acute Tox. 3 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Gef. | H301 H318 H317 H410 | |||
603-186-00-7 | trans-(5 RS,6 SR)-6-Amino-2,2-dimethyl-1,3-dioxepan-5-ol | 419-050-3 | 79944-37-9 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
603-187-00-2 | 2-((4,6-Bis(4-(2-(1-methylpyridinium-4-yl)vinyl)phenylamino)-1,3,5-triazin-2-yl)(2-hydroxyethyl)amino)ethanoldichlorid | 419-360-9 | 163661-77-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
603-188-00-8 | Reaktionsmasse aus 6,7-Epoxy-1,2,3,4,5,6,7,8-octahydro-1,1,2,4,4,7-hexamethylnaphthalin und 7,8-Epoxy-1,2,3,4,6,7,8,8a-octahydro-1,1,2,4,4,7-hexamethylnaphthalin | 426-970-9 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
603-189-00-3 | Reaktionsmasse aus Komplexen vonTitan, 2,2"-Oxydiethanol, Ammoniumlactat, Nitrilotris(2-propanol) und Ethylenglycol | 405-250-8 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
603-190-00-9 | 8,8-Dimethyl-7-isopropyl-6,10-dioxaspiro[4.5]decan | 424-030-2 | 62406-73-9 | Skin Irrit. 2 Aquatic Chronic 3 | H315 H412 | GHS07 Achtg. | H315 H412 | |||
603-191-00-4 | 2-(4,6-Bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl)-5-(3-((2-ethylhexyl)oxy)-2-hydroxypropoxy)phenol | 419-740-4 | 137658-79-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
603-192-00-X | (E, E)-3,7,11-Trimethyldodeca-1,4,6,10-tetraen-3-ol | 423-240-1 | 125474-34-2 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H410 | |||
603-193-00-5 | Dinatrium-9,10-anthracendioxid | 426-030-8 | 46492-07-3 | Skin Corr. 1A | H314 | GHS05 Gef. | H314 | |||
603-194-00-0 | 2-(2-Aminoethylamino)ethanol; (AEEA) | 203-867-5 | 111-41-1 | Repr. 1B Skin Corr. 1B Skin Sens. 1 | H360Df H314 H317 | GHS05 GHS08 GHS07 Gef. | H360Df H314 H317 | STOT SE 3; H335: C≥5 % | ||
603-195-00-6 | 2-[4-(4-Methoxyphenyl)-6-phenyl-1,3,5-triazin-2-yl]-phenol | 430-810-3 | 154825-62-4 | Aquatic Chronic 3 | H412 | - | H412 | |||
603-196-00-1 | 2-(7-Ethyl-1 H-indol-3-yl)ethanol | 431-020-1 | 41340-36-7 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 | H302 H373 ** H411 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H411 | |||
603-197-00-7 | Tebuconazol (ISO); 1-(4-Chlorphenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H361d*** H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361d*** H302 H410 | M = 1 M = 10 | ||
603-199-00-8 | Etoxazol (ISO); (RS)-5- tert-Butyl-2-[2-(2,6-difluorphenyl)-4,5-dihydro-1,3-oxazol-4-yl]phenetol | - | 153233-91-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 100 | ||
603-200-00-1 | 1-Pentanol [1]; 3-Pentanol [2] | 200-752-1 [1] 209-526-7 [2] | 71-41-0 [1] 584-02-1 [2] | Flam. Liq. 3 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 | H226 H332 H335 H315 | GHS02 GHS07 Achtg. | H226 H332 H335 H315 | |||
603-201-00-7 | (E)-(7 R,11 R)-3,7,11,15-Tetramethylhexadec-2-en-1-ol | 416-120-5 | - | Skin Irrit. 2 Aquatic Chronic 4 | H315 H413 | GHS07 Achtg. | H315 H413 | |||
603-202-00-2 | 4,4,5,5,5-Pentafluorpentan-1-ol | 421-360-9 | 148043-73-6 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
603-203-00-8 | (1 R,3 S,7 R,8 R,10 R,13 R)-5,5,7,9,9,13-Hexamethyl-4,6-dioxatetracyclo[6.5.1.01,10.03,7]tetradecan | 427-580-1 | - | Skin Irrit. 2 | H315 | GHS07 Achtg. | H315 | |||
603-204-00-3 | Reaktionsmasse aus 2,2"-(Heptan-1,7-diyl)bis-1,3-dioxolan und 2,2"-(Heptan-1,6-diyl)bis-1,3-dioxolan | 428-110-8 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
603-205-00-9 | (1 S- cis)-4-(2-Amino-6-chlor-9 H-purin-9-yl)-2-cyclopenten-1-methanolhydrochlorid | 426-200-1 | 172015-79-1 | STOT RE 1 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H372** H302 H318 H317 H412 | GHS05 GHS08 GHS07 Gef. | H372** H302 H318 H317 H412 | |||
603-206-00-4 | 2,2-Dichlor-1,3-benzodioxol | 426-850-6 | 2032-75-9 | Flam. Liq. 3 Skin Corr. 1A Acute Tox. 4 * Skin Sens. 1 | H226 H314 H302 H317 | GHS02 GHS05 GHS07 Gef. | H226 H314 H302 H317 | EUH014 | ||
603-207-00-X | 2-Isobutyl-2-isopropyl-1,3-dimethoxypropan | 430-800-9 | 129228-21-3 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
603-208-00-5 | 1,2-Diethoxyethan | 211-076-1 | 629-14-1 | Flam. Liq. 2 Repr. 1A Eye Irrit. 2 | H225 H360Df H319 | GHS02 GHS08 GHS07 Gef. | H225 H360Df H319 | EUH019 | ||
603-209-00-0 | Spinosad (ISO) (Reaktionsmasse aus Spinosyn A und Spinosyn D im Verhältnis von 95:5 bis 50:50); Reaktionsmasse aus 50-95 % (2 R,3a S,5a R,5b S,9 S,13 S,14 R,16a S,16b R)-2-(6-Deoxy-2,3,4-tri- O-methyl-α-l-mannopyranosyloxy)-13-(4-dimethyl amino-2,3,4,6-tetradeoxy-β-d-erythropyranosyloxy)-9-ethyl-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-14-methyl-1H-8-oxacyclododeca[ b]as-indacen-7,15-dion und 50-5 % (2 S,3a R,5a S,5b S,9 S,13 S,14 R,16a S,16b S)-2-(6-Deoxy-2,3,4-tri- O-methyl-α-l-mannopyranosyloxy)-13-(4-dimethylamino-2,3,4,6-tetradeoxy-β-d-erythropyranosyloxy)-9-ethyl-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-4,14-dimethyl-1 H-8-oxacyclododeca[ b]as-indacen-7,15- dion [1]; Spinosyn A [2]; Spinosyn D [3] | - [1] - [2] - [3] | - [1] 131929-60-7 [2] 131929-63-0 [3] | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M=10 | ||
603-210-00-6 | 2,4-Diethyl-1,5-pentandiol | 429-310-8 | 57987-55-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
603-211-00-1 | 2,3-Epoxypropyltrimethylammoniumchlorid ... %; Glycidyltrimethylammoniumchlorid ... % | 221-221-0 | 3033-77-0 | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H350 H341 H361f*** H312 H302 H373** H318 H317 H412 | GHS05 GHS08 GHS07 Gef. | H350 H341 H361f*** H312 H302 H373** H318 H317 H412 | B | ||
603-212-00-7 | 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6- c]pyran; Galaxolid; (HHCB) | 214-946-9 | 1222-05-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
603-213-00-2 | 2-Methoxy-2-methylbutan; tert-Amylmethylether | 213-611-4 | 994-05-8 | Flam. Liq. 2 Acute Tox. 4 * STOT SE 3 | H225 H302 H336 | GHS02 GHS07 Gef. | H225 H302 H336 | |||
603-214-00-8 | 1,1-Diisopropoxycyclohexan | 413-740-8 | 1132-95-2 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
603-215-00-3 | 1-Hydroxy-4-fluor-1,4-diazoniabicyclo[2.2.2]octanbis(tetrafluorborat) | 418-330-2 | 162241-33-0 | Expl. 1.1**** Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H201 H302 H373** H318 H317 H400 H410 | GHS01 GHS05 GHS08 GHS07 GHS09 Gef. | H201 H302 H373** H318 H317 H410 | |||
603-216-00-9 | cis-1-Amino-2,3-dihydro-1 H-inden-2-ol | 422-660-2 | 7480-35-5 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
603-217-00-4 | 2,4,6-Tri- tert-butylphenyl-2-butyl-2-ethyl-1,3-propandiolphosphit | 423-560-1 | 161717-32-4 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
603-220-00-0 | 1-{Benzyl[2-(2-methoxyphenoxy)ethyl]amino}-3-(9 H-carbazol-4-yloxy)propan-2-ol | 432-890-5 | 72955-94-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
603-221-00-6 | 1-(2-Amino-5-chlorphenyl)-2,2,2-trifluor-1,1-ethandiol, Hydrochlorid; [Gehalt an 4-Chloranilin (EG-Nr. 203-401-0) < 0,1 %] | 433-580-2 | 214353-17-0 | Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 | H302 H314 H411 | GHS05 GHS07 GHS09 Gef. | H302 H314 H411 | |||
603-221-01-3 | 1-(2-Amino-5-chlorphenyl)-2,2,2-trifluor-1,1-ethandiol, Hydrochlorid; [Gehalt an 4-Chloranilin (EG-Nr. 203-401-0) ≥ 0,1 %] | 433-580-2 | 214353-17-0 | Carc. 1B Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 | H350 H302 H314 H411 | GHS05 GHS08 GHS07 GHS09 Gef. | H350 H302 H314 H411 | |||
603-222-00-1 | (2 R,3 S,4 R,5 R,7 R,9 R,10 R,11 S,12 S,13 R)-10-[(4-Dimethylamino-3-hydroxy-6-methyltetrahydropyran-2-yl)oxy]-2-ethyl-3,4,12-trihydroxy-9-methoxy-3,5,7,9,11,13-hexamethyl-6,14-dioxo-1-oxacyclotetradecan | 433-820-6 | 118058-74-5 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
603-223-00-7 | 2-Cyclopentyliden-cyclopentanol; 1,1"-Bi(cyclopentyliden)-2-ol | 434-270-1 | 6261-30-9 | Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H315 H318 H412 | GHS05 Gef. | H315 H318 H412 | |||
603-224-00-2 | 3-Ethoxy-1,1,1,2,3,4,4,5,5,6,6,6- dodecafluor-2-(trifluormethyl)-hexan | 435-790-1 | 297730-93-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
603-225-00-8 | Erythromycin A9-oxim (E); (3 R,4 S,5 S,6 R,7 R,9 R,11 R,12 R,13 S,14 R)-4-((2,6-didesoxy-3-C-methyl-3- O-methyl-α-L-ribo-hexopiranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-tridesoxy-3-dimethylamino-β-d-xylohexapiranosyl)oxy)oxacyclotetradecan-2-ona-10-oxim (E) | 437-070-0 | 13127-18-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
603-226-00-3 | 4,4"(4-(4-Methoxyphenyl)-1,3,5-triazin-2,4-diyl)bisbenzol-1,3-diol | 444-500-0 | 1440-00-2 | Aquatic Chronic 3 | H412 | - | H412 | |||
603-227-00-9 | α-Hydro-ω-[[[(1,1-dimethylethyl)dioxy]carbonyl]oxy]-poly[oxy(methyl-1,2-ethandiyl)]ether mit 2,2-Bis(hydroxymethyl)-1,3-propandiol (4:1); Reaktionsprodukt von: α-Hydro-ω-((chlorcarbonyl)oxy)-poly(oxy(methyl-1,2-ethandiyl))ether mit 2,2-Bis(hydroxymethyl)-1,3-propa ndiol mit Kalium-1,1-dimethylethylperoxalat | 445-060-2 | 203574-04-3 | **** Aquatic Acute 1 Aquatic Chronic 1 | **** H400 H410 | **** GHS09 Achtg. | **** H410 | |||
603-228-00-4 | (+/-)-( R*,R*)-6-Fluor-3,4-dihydro-2-oxiranyl-2 H-1-benzopyran; 6-Fluor-2-(2-oxiranyl)chroman | 419-620-1 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
603-229-00-X | Natrium-( Z)-3-chlor-3-(4-chlorphenyl)-1-hydroxy-2-propen-1-sulfonat | 420-800-7 | - | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H410 | |||
603-230-00-5 | 2,6,6,7,8,8-Hexamethyldecahydro-2 H-indeno[4,5-b]furan | 440-030-5 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 4 | H315 H318 H413 | GHS05 Gef. | H315 H318 H413 | |||
603-231-00-0 | (S)-1,1-Diphenyl-1,2-propandiol | 443-220-6 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
603-232-00-6 | 3,3,8,8,10,10-Hexamethyl-9-[1-(4-oxiranylmethoxyphenyl)ethoxy]-1,5-dioxa-9-azaspiro[5.5]undecan | 444-420-6 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
603-233-00-1 | Reaktionsmasse aus 4-(1,3a,4,6,7,7a-Hexahydro-4,7-methanoinden-5-yliden)-3-methylbutan-2-ol, 4-(3,3a,4,6,7,7a-Hexahydro-4,7-methanoinden-5-yliden)-3-methylbutan-2-ol; 1-(1,3a,4,6,7,7a-Hexahydro-4,7-methanoinden-5-yliden)pentan-3-ol; 1-(3,3a,4,6,7,7a-Hexahydro-4,7-methanoinden-5-yliden)pentan-3-ol; (E)-4-(3a,4,5,6,7,7a-Hexahydro-1 H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol; (E)-4-(3a,4,5,6,7,7a-Hexahydro-3 H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol | 444-430-0 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
603-234-00-7 | (1 R,4 R)-4-Methoxy-2,2,7,7-tetramethyltricyclo(6.2.1.0(1,6))undec-5-en | 444-480-3 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
603-235-00-2 | Linalool: 3,7-Dimethyl-1,6-octadien-3-ol; DL-Linalool; [1] Coriandrol; (S)-3,7-Dimethyl-1,6-octadien-3-ol; D- Linalool; [2] Licareol; (R)-3,7-Dimethyl-1,6-octadien-3-ol; L- Linalool [3] | 201-134-4 [1] 204-810-7 [2] 204-811-2 [3] | 78-70-6 [1] 126-90-9 [2] 126-91-0 [3] | Skin Sens. 1B | H317 | GHS07 Achtg. | H317 | |||
603-236-00-8 | Ethanol, 2,2"-Iminobis-, N-(verzweigte und lineare C13-15-Akyl)-Derivate | 308-208-6 | 97925-95-6 | Repr. 1B | H360D | GHS08 Dgr | H360D | |||
603-237-00-3 | Ipconazol (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1- (1 H-1,2,4-triazol-1-ylmethyl)cyclopentanol | - | 125225-28-7 115850-69-6 115937-89-8 | Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1 | H360D H302 H373 (Augen, Haut, Leber) H410 | GHS08 GHS07 GHS09 Dgr | H360D H302 H373 (Augen, Haut, Leber) H410 | oral:
ATE = 500 mg/kg KG M = 100 | ||
603-238-00-9 | Bis(2-(2-methoxyethoxy)ethyl)ether; Tetraethylenglycoldimethylether | 205-594-7 | 143-24-8 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
603-239-00-4 | Paclobutrazol (ISO); (2 RS,3 RS)-1-(4-Chlorphenyl)-4,4-dimethyl-2-(1 H-1,2,4-triazol-1-yl)pentan-3-ol | - | 76738-62-0 | Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H332 H302 H319 H400 H410 | GHS08 GHS07 GHS09 Wng | H361d H332 H302 H319 H410 | Einatmen:
ATE = 3,13 mg/L (Stäube oder Nebel) oral:
ATE = 490 mg/kg KG M = 10 M = 10 | ||
603-240-00-X | 2,2-Bis(brommethyl)propan-1,3-diol | 221-967-7 | 3296-90-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Dgr | H350 H340 | |||
603-241-00-5 | Geraniol; (2 E)-3,7-Dimethylocta-2,6-dien-1-ol | 203-377-1 | 106-24-1 | Skin Sens. 1 | H317 | GHS07 Wng | H317 | |||
603-243-00-6 | 2,2-Dimethylpropan-1-ol, Tribromderivat; 3-Brom-2,2-bis(brommethyl)propan-1-ol; | 253-057-0 - | 36483-57-5; 1522-92-5 | Carc. 1B Muta. 2 | H350 H341 | GHS08 Dgr | H350 H341 | |||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
603-244-00-1 | Reaktionsmasse aus 1-(2,3-Epoxypropoxy)-2,2-bis ((2,3-Epoxypropoxy)methyl)butan und 1-(2,3-Epoxypropoxy)-2-((2,3-Epoxypropoxy)methyl)-2-hydroxymethylbutan | - | - | Muta. 2 Repr. 1B | H341 H360F | GHS08 Dgr | H341 H360F | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
603-245-00-7 | 2,2"-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol | 221-665-5 | 3179-89-3 | Skin Sens. 1 | H317 | GHS07 Wng | H317 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
603-246-00-2 | 3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluoroctan-1-ol | 211-477-1 | 647-42-7 | STOT RE 2 Aquatic Chronic 1 | H373 (Zähne, Knochen) H410 | GHS08 GHS09 Wng | H373 (Zähne, Knochen) H410 | M = 1 | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
603-247-00-8 | Reaktionsmasse aus 1,3-Dioxan-5-ol und 1,3-Dioxolan-4-ylmethanol | - | - | Repr. 1B | H360Df | GHS08 Dgr | H360Df | ) | ||
604-001-00-2 | Phenol; Carbolsäure; Monohydroxybenzol; Phenylalcohol | 203-632-7 | 108-95-2 | Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Corr. 1B | H341 H331 H311 H301 H373 ** H314 | GHS06 GHS08 GHS05 Gef. | H341 H331 H311 H301 H373 ** H314 | * Skin Corr. 1B; H314: C ≥ 3 % Skin Irrit. 2; H315 1 % ≤ C<3 % Eye Irrit. 2; H319:1 % ≤C<3 % | ||
604-002-00-8 | Pentachlorphenol; PCP | 201-778-6 | 87-86-5 | Carc. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H330 H311 H301 H319 H335 H315 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H330 H311 H301 H319 H335 H315 H410 | |||
604-003-00-3 | Natriumpentachlorphenolat [1]; Kaliumpentachlorphenolat [2] | 205-025-2 [1] 231-911-3 [2] | 131-52-2 [1] 7778-73-6 [2] | Carc. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H330 H311 H301 H319 H335 H315 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H330 H311 H301 H319 H335 H315 H410 | |||
604-004-00-9 | m-Kresol [1]; o-Kresol [2]; p-Kresol [3]; gemischtes Kresol Methylphenol [4] | 203-577-9 [1] 202-423-8 [2] 203-398-6 [3] 215-293-2 [4] | 108-39-4 [1] 95-48-7 [2] 106-44-5 [3] 1319-77-3 [4] | Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B | H311 H301 H314 | GHS06 GHS05 Gef. | H311 H301 H314 | * | C | |
604-005-00-4 | 1,4-Dihydroxybenzol; Hydrochinon; Chinol | 204-617-8 | 123-31-9 | Carc. 2 Muta. 2 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 | H351 H341 H302 H318 H317 H400 | GHS05 GHS08 GHS07 GHS09 Gef. | H351 H341 H302 H318 H317 H400 | M=10 | ||
604-006-00-X | 3,4-Xylenol; 2,3-Dimethylphenol [1]; 2,5-Xylenol; 2,5-Dimethylphenol [2]; 2,4-Xylenol; 2,4-Dimethylphenol [3]; 2,3-Xylenol [4]; 2,6-Xylenol; 2,6-Dimethylphenol [5]; Xylenol [6]; 2,4-(oder 2,5)-Xylenol [7] | 202-439-5 [1] 202-461-5 [2] 203-321-6 [3] 208-395-3 [4] 209-400-1 [5] 215-089-3 [6] 276-245-4 [7] | 95-65-8 [1] 95-87-4 [2] 105-67-9 [3] 526-75-0 [4] 576-26-1 [5] 1300-71-6 [6] 71975-58-1 [7] | Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Chronic 2 | H311 H301 H314 H411 | GHS06 GHS05 GHS09 Gef. | H311 H301 H314 H411 | C | ||
604-007-00-5 | 2-Naphthol; β-Naphthol | 205-182-7 | 135-19-3 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 | H332 H302 H400 | GHS07 GHS09 Achtg. | H332 H302 H400 | |||
604-008-00-0 | 2-Chlorphenol; o-Chlorophenol [1]; 4-Chlorphenol; p-Chlorophenol [2]; 3-Chlorphenol; m-Chlorophenol [3]; Chlorphenol [4] | 202-433-2 [1] 203-402-6 [2] 203-582-6 [3] 246-691-4 [4] | 95-57-8 [1] 106-48-9 [2] 108-43-0 [3] 25167-80-0 [4] | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H332 H312 H302 H411 | GHS07 GHS09 Achtg. | H332 H312 H302 H411 | C | ||
604-009-00-6 | Pyrogallol; 1,2,3-Trihydroxybenzol | 201-762-9 | 87-66-1 | Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H341 H332 H312 H302 H412 | GHS08 GHS07 Achtg. | H341 H332 H312 H302 H412 | * | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
604-010-00-1 | Resorcin; 1,3-Dihydroxybenzol | 203-585-2 | 108-46-3 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 | H302 H319 H315 H400 | GHS07 GHS09 Achtg. | H302 H319 H315 H400 | * | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
604-010-00-1 | Resorcin; 1,3-Dihydroxybenzol | 203-585-2 | 108-46-3 | Acute Tox. 4 STOT SE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1B Aquatic Acute 1 | H302 H370 (Nervensystem) H315 H319 H317 H400 | GHS07 GHS08 GHS09 Dgr | H302 H370 (Nervensystem) H315 H319 H317 H400 | Oral: ATE = 500 mg/kg KG M = 1 | ) | |
604-011-00-7 | 2,4-Dichlorphenol | 204-429-6 | 120-83-2 | Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 | H311 H302 H314 H411 | GHS06 GHS05 GHS09 Gef. | H311 H302 H314 H411 | |||
604-012-00-2 | 4-Chlor- o-kresol; 4-Chlor-2-methylphenol | 216-381-3 | 1570-64-5 | Acute Tox. 3 * Skin Corr. 1A Aquatic Acute 1 | H331 H314 H400 | GHS06 GHS05 GHS09 Gef. | H331 H314 H400 | STOT SE 3; H335: C≥1 % | ||
604-013-00-8 | 2,3,4,6-Tetrachlorphenol | 200-402-8 | 58-90-2 | Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H301 H319 H315 H400 H410 | GHS06 GHS09 Gef. | H301 H319 H315 H410 | * Eye Irrit. 2; H319:C≥5 % Skin Irrit. 2; H315: C≥5 % | ||
604-014-00-3 | Chlorkresol; 4-Chlor-m-kresol; 4-Chlor-3-methylphenol | 200-431-6 | 59-50-7 | Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 STOT SE 3 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 3 | H302 H314 H318 H335 H317 H400 H412 | GHS07 GHS05 GHS09 Dgr | H302 H314 H335 H317 H410 | M = 1 | ||
604-015-00-9 | 2,2"-Methylenbis(3,4,6-trichlorphenol); Hexachlorophen | 200-733-8 | 70-30-4 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H301 H400 H410 | GHS06 GHS09 Gef. | H311 H301 H410 | * | ||
604-016-00-4 | 1,2-Dihydroxybenzol; Brenzcatechin | 204-427-5 | 120-80-9 | Carc. 1" Muta. 2 Acute Tox. 3 Acute Tox. 3 Skin Irrit. 2 Eye Irrit. 2 | H350 H341 H311 H301 H315 H319 | GHS08 GHS06 Dgr | H350 H341 H311 H301 H315 H319 | Oral: ATE = 300 mg/kg KG Dermal: ATE = 600 mg/kg KG | ||
604-017-00-X | 2,4,5-Trichlorphenol | 202-467-8 | 95-95-4 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H315 H410 | * Eye Irrit. 2; H319: C≥5 % Skin Irrit.2; H315: C ≥5 % | ||
604-018-00-5 | 2,4,6-Trichlorphenol | 201-795-9 | 88-06-2 | Carc. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H319 H315 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H319 H315 H410 | |||
604-019-00-0 | Dichlorophen (ISO); 2,2"-Methylenbis(4-chlorphenol) | 202-567-1 | 97-23-4 | Acute Tox. 4 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H410 | |||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
604-020-00-6 | 2-Phenylphenol (ISO); Biphenyl-2-ol; 2-Hydroxybiphenyl | 201-993-5 | 90-43-7 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 | H319 H335 H315 H400 | GHS07 GHS09 Achtg. | H319 H335 H315 H400 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
604-020-00-6 | Biphenyl-2-ol; 2-Phenylphenol; 2-Hydroxybiphenyl | 201-993-5 | 90-43-7 | Carc. 2 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H351 H314 H318 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Dgr | H351 H314 H317 H410 | M = 1 M = 1 | ) | |
604-021-00-1 | Natrium-2-biphenylat; 2-Phenylphenol, Natriumsalz | 205-055-6 | 132-27-4 | Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 | H302 H335 H315 H318 H400 | GHS05 GHS07 GHS09 Achtg. | H302 H335 H315 H318 H400 | |||
604-022-00-7 | 2,2-Dimethyl-1,3-benzodioxol-4-ol | 400-900-7 | 22961-82-6 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
604-023-00-2 | 2,4-Dichlor-3-ethylphenol | 401-060-4 | - | Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Gef. | H314 H410 | |||
604-024-00-8 | 4,4-Isobutylethylidendiphenol | 401-720-1 | 6807-17-6 | Repr. 1B Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H360F *** H319 H400 H410 | GHS08 GHS09 Gef. | H360F *** H319 H410 | |||
604-025-00-3 | 2,5-Bis(1,1-dimethylbutyl)hydrochinon | 400-220-0 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
604-026-00-9 | 2,2-Spirobi(6-hydroxy-4,4,7-trimethylchroman) | 400-270-3 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
604-027-00-4 | 2-Methyl-5-(1,1,3,3-tetramethylbutyl)hydrochinon | 400-530-6 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
604-028-00-X | 4-Amino-3-fluorphenol | 402-230-0 | 399-95-1 | Carc. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H350 H302 H317 H411 | GHS08 GHS07 GHS09 Gef. | H350 H302 H317 H411 | |||
604-029-00-5 | 1-Naphtol | 201-969-4 | 90-15-3 | Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 | H312 H302 H335 H315 H318 | GHS05 GHS07 Gef. | H312 H302 H335 H315 H318 | |||
604-030-00-0 | 4,4"-Isopropylidendiphenol; Bisphenol A | 201-245-8 | 80-05-7 | Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360F H335 H318 H317 H400 H410 | GHS08 GHS07 GHS05 GHS09 Dgr | H360F H335 H318 H317 H410 | M = 1 M = 10 | ||
604-031-00-6 | Guajakol; 2-Methoxyphenol | 201-964-7 | 90-05-1 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 | H302 H319 H315 | GHS07 Achtg. | H302 H319 H315 | |||
604-032-00-1 | Thymol | 201-944-8 | 89-83-8 | Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 | H302 H314 H411 | GHS05 GHS07 GHS09 Gef. | H302 H314 H411 | |||
604-033-00-7 | Isobutylbut-3-enoat; Butensäureisobutylester | 401-170-2 | 24342-03-8 | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | |||
604-034-00-2 | 4,4"-Thiodi- o-kresol | 403-330-7 | 24197-34-0 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
604-035-00-8 | 4-Nonylphenol, Reaktionsprodukte mit Formaldehyd und Dodecan-1-thiol | 404-160-6 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
604-036-00-3 | 4,4"-Oxybis(ethylenthio)diphenol | 404-590-4 | 90884-29-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
604-037-00-9 | 3,5-Xylenol; 3,5-Dimethylphenol | 203-606-5 | 108-68-9 | Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B | H311 H301 H314 | GHS06 GHS05 Gef. | H311 H301 H314 | |||
604-038-00-4 | 4-Chlor-3,5-dimethylphenol; 4-Chlor-3,5-dimethylphenol [1]; Chlorxylenol [2] | 201-793-8 [1] 215-316-6 [2] | 88-04-0 [1] 1321-23-9 [2] | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H302 H319 H315 H317 | GHS07 Achtg. | H302 H319 H315 H317 | |||
604-039-00-X | Ethyl-2-[4-[(6-chlorbenzoxazol-2-yl)oxy]phenoxy]propionat; Fenoxaprop-ethyl | 266-362-9 | 66441-23-4 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
604-040-00-5 | Fomesafen (ISO); 5-[2-Chlor-4-(trifluormethyl)phenoxy]-N-(methylsulfonyl)-2-nitrobenzamid | 276-439-9 | 72178-02-0 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
604-041-00-0 | Acifluorfen (ISO); 5-[2-Chlor-4-(trifluormethyl)phenoxy]-2-nitrobenzoesäure [1]; Natrium-5-[2-chlor-4-(trifluormethyl) phenoxy]-2-nitrobenzoat; Acifluorfen-Natrium [2] | 256-634-5 [1] 263-560-7 [2] | 50594-66-6 [1] 62476-59-9 [2] | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H315 H318 H410 | |||
604-042-00-6 | 4-Nitrosophenol | 203-251-6 | 104-91-6 | Muta. 2 Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H341 H302 H318 H411 | GHS08 GHS05 GHS07 GHS09 Gef. | H341 H302 H318 H411 | |||
604-043-00-1 | Monobenzon; 4-Hydroxyphenylbenzylether; Hydrochinonmonobenzylether | 203-083-3 | 103-16-2 | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
604-044-00-7 | Mequinol; 4-Methoxyphenol; Hydrochinonmonomethylether | 205-769-8 | 150-76-5 | Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 | H302 H319 H317 | GHS07 Achtg. | H302 H319 H317 | |||
604-045-00-2 | 2,3,5-Trimethylhydrochinon | 211-838-3 | 700-13-0 | Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H332 H335 H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H332 H335 H315 H318 H317 H410 | |||
604-046-00-8 | 4-(4-Isopropoxyphenylsulfonyl)phenol | 405-520-5 | 95235-30-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
604-047-00-3 | 4-(4-Tolyloxy)biphenyl | 405-730-7 | 51601-57-1 | STOT RE 2 * Aquatic Chronic 4 | H373 ** H413 | GHS08 Achtg. | H373 ** H413 | |||
604-048-00-9 | 4,4",4""-(Ethan-1,1,1-triyl)triphenol | 405-800-7 | 27955-94-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
604-049-00-4 | 4-4"-Methylenbis(oxyethylenthio)diphenol | 407-480-4 | 93589-69-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
604-051-00-5 | 3,5-Bis((3,5-di- tert-butyl-4-hydroxy)benzyl)-2,4,6-trimethylphenol | 401-110-5 | 87113-78-8 | Aquatic Chronic 3 | H412 | - | H412 | |||
604-052-00-0 | 2,2"-Methylenbis(6-(2 H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol) | 403-800-1 | 103597-45-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
604-053-00-6 | 2-Methyl-4-(1,1-dimethylethyl)-6-(1-methylpentadecyl)phenol | 410-760-9 | 157661-93-3 | Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H315 H317 H410 | |||
604-054-00-1 | Reaktionsmasse aus 2-Methoxy-4-(tetrahydro-4-methylen-2 H-pyran-2-yl)-phenol; 4-(3,6-Dihydro-4-methyl-2 H-pyran-2-yl)-2-methoxyphenol | 412-020-0 | - | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
604-055-00-7 | 2,2"-((3,3",5,5"-Tetramethyl-(1,1"-biphenyl)-4,4"-diyl)-bis(oxymethylen))bisoxiran | 413-900-7 | 85954-11-6 | Carc. 2 Skin Sens. 1 | H351 H317 | GHS08 GHS07 Achtg. | H351 H317 | |||
604-056-00-2 | 2-(2-Hydroxy-3,5-dinitroanilin)ethanol | 412-520-9 | 99610-72-7 | Flam. Sol. 2 Repr. 2 Acute Tox. 4 * | H228 H361f *** H302 | GHS02 GHS07 GHS08 Gef. | H228 H361f *** H302 | |||
604-057-00-8 | Reaktionsmasse aus Isomeren von -(2H-Benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; Isomeren von 2-(2H-Benzotriazol- 2-yl)-4-methyl-(n)-tetracosylphenol; Isomeren von -(2H-Benzotriazol-2-yl)- 4-methyl-5,6-didodecylphenol; n = 5 oder 6 | 401-680-5 | - | Aquatic Chronic 4 | H413 | H413" | ||||
604-058-00-3 | 1,2-Bis(3-methylphenoxy)ethan | 402-730-9 | 54914-85-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
604-059-00-9 | 2- n-Hexadecylhydrochinon | 406-400-5 | - | STOT RE 2 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 | H373 ** H315 H317 H413 | GHS08 GHS07 Achtg. | H373 ** H315 H317 H413 | |||
604-060-00-4 | 9,9-Bis(4-hydroxyphenyl)fluoren | 406-950-6 | 3236-71-3 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H315 H410 | |||
604-061-00-X | Reaktionsmasse aus 2-Chlor-5- sec-tetradecylhydrochinonen mit sec-Tetradecyl= 1-Methyltridecyl; 1-Ethyldodecyl; 1-Propylundecyl; 1-Butyldecyl; 1-Pentylnonyl; 1-Hexyloctyl | 407-740-7 | - | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H315 H317 H412 | GHS07 Achtg. | H315 H317 H412 | |||
604-062-00-5 | 2,4-Dimethyl-6-(1-methylpentadecyl)phenol | 411-220-5 | - | Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H315 H317 H410 | |||
604-063-00-0 | 5,6-Dihydroxyindol | 412-130-9 | 3131-52-0 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
604-064-00-6 | 2-(4,6-Diphenyl-1,3,5-triazin-2-yl)-5-((hexyl)oxy)phenol | 411-380-6 | 147315-50-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
604-065-00-1 | 4,4",4""-(1-Methylpropan-1-yl-3-yliden)tris(2-cyclohexyl-5-methylphenol) | 407-460-5 | 111850-25-0 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
604-066-00-7 | Reaktionsmasse aus Phenol, 6-(1,1-Dimethylethyl)-4-tetrapropyl-2-[(2-hydroxy-5-tetra-propylphenyl)methyl (C41-Verbindung) und Methan, 2,2"-Bis[6-(1,1-dimethylethyl)-1-hydroxy-4-tetrapropylphenyl)] (C45-Verbindung); 2,6-Bis(1,1-dimethylethyl)-4-tetra-propylphenol und 2-(1,1-Dimethylethyl)-4-tetrapropylphenol; 2,6-Bis[(6-(1,1-dimethylethyl)-1-hydroxy-4-tetrapropylphenyl)methyl]-4-(tetrapropyl)phenol und 2-[(6-(1,1-Dimethylethyl)-1-hydroxy-4-tetrapropylphenylmethyl]-6-[1-hydroxy-4-tetrapropylphenyl)methyl]-4-(tetrapropyl)phenol | 414-550-8 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
604-067-00-2 | Reaktionsmasse aus 2,2"-[[(2-Hydroxyethyl)imino]bis(methylen)bis[4-dodecylphenol]; Formaldehyd, Oligomer mit 4-Dodecylphenol und 2-Aminoethanol (n = 2); Formaldehyd, Oligomer mit 4-Dodecylphenol und 2-Aminoethanol (n = 3, 4 und höher) | 414-520-4 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H400 H410 | GHS05 GHS09 Gef. | H315 H318 H410 | |||
604-068-00-8 | (±)-4-[2-[[3-(4-Hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenolhydrochlorid | 415-170-5 | 90274-24-1 | Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 | H332 H302 H317 | GHS07 Achtg. | H332 H302 H317 | |||
604-069-00-3 | 2-(1-Methylpropyl)-4- tert-butylphenol | 421-740-4 | 51390-14-8 | Skin Corr. 1B Aquatic Chronic 2 | H314 H411 | GHS05 GHS09 Gef. | H314 H411 | |||
604-070-00-9 | Triclosan; 2,4,4"-Trichlor-2"-hydroxydiphenylether; 5-Chlor-2-(2,4-dichlorphenoxy)phenol | 222-182-2 | 3380-34-5 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H315 H410 | M = 100 | ||
604-071-00-4 | 4,4"-(1-{4-[1-(4-Hydroxyphenyl)-1-methylethyl]phenyl}ethyliden)diphenol | 425-600-3 | 110726-28-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
604-072-00-X | 1,2-Bis(phenoxymethyl)benzol | 428-620-0 | 10403-74-4 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
604-073-00-5 | (E)-3-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol | 428-010-4 | 82413-20-5 | Carc. 2 Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H360F*** H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H351 H360F*** H317 H410 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
604-074-00-0 | Tetrabrombisphenol-A; 2,2",6,6"-Tetrabrom-4,4"-isopropylidendiphenol | 201-236-9 | 79-94-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
604-074-00-0 | 2,2",6,6"-Tetrabrom-4,4"-isopropylidenediphenol; Tetrabrombisphenol-A | 201-236-9 | 79-94-7 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Dgr | H350 H410 | ) | ||
604-075-00-6 | 4-(1,1,3,3-Tetramethylbutyl)phenol; 4- tert-Octylphenol | 205-426-2 | 140-66-9 | Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H400 H410 | GHS05 GHS09 Gef. | H315 H318 H410 | M=10 | ||
604-076-00-1 | Phenolphthalein | 201-004-7 | 77-09-8 | Carc. 1B Muta. 2 Repr. 2 | H350 H341 H361f*** | GHS08 Gef. | H350 H341 H361f*** | Carc. 1B; H350: C ≥1 % | ||
604-077-00-7 | 2-Benzotriazol-2-yl-4-methyl-6-(2-methylallyl)phenol | 419-750-9 | 98809-58-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
604-079-00-8 | 4,4"-(1,3-Phenylen-bis(1-methylethyliden))bisphenol | 428-970-4 | 13595-25-0 | Repr. 2 Skin Sens. 1 Aquatic Chronic 2 | H361f*** H317 H411 | GHS08 GHS07 GHS09 Achtg. | H361f*** H317 H411 | |||
604-080-00-3 | 4-Fluor-3-trifluormethylphenol | 432-560-0 | 61721-07-1 | Acute Tox. 4 * Skin Corr. 1A Skin Sens. 1 Aquatic Chronic 2 | H332 H314 H317 H411 | GHS05 GHS07 GHS09 Gef. | H332 H314 H317 H411 | |||
604-081-00-9 | 1,1-Bis(4-hydroxyphenyl)-1-phenylethan | 433-130-5 | 1571-75-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
604-082-00-4 | 2-Chlor-6-fluorphenol | 433-890-8 | 2040-90-6 | Muta. 1B Repr. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H340 H361f*** H302 H314 H317 H411 | GHS05 GHS08 GHS07 GHS09 Gef. | H340 H361f*** H302 H314 H317 H411 | |||
- gestrichen - | ||||||||||
604-084-00-5 | 1-Ethoxy-2,3-difluorbenzol | 441-000-4 | 121219-07-6 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
604-087-00-1 | Reaktionsmasse aus 1,2-Naphthochinondiazid-5-sulfonylchlorid (oder Sulfonsäure)monoester mit 4,4"-(1-(4-(1-(4-Hydroxyphenyl)-1-methylethyl)phenyl)ethyliden)bisphenol; 1,2-Naphthochinondiazid-5-sulfonylchlorid (oder Sulfonylsäure)diester mit 4,4"-(1-(4-(1-(4-Hydroxyphenyl)-1-methylethyl)phenyl)ethyliden)bisphenol; 1,2-Naphthochinondiazid-5-sulfonylchlorid (oder Sulfonsäure)triester with 4,4"-(1-(4-(1-(4-Hydroxyphenyl)-1-methylethyl)phenyl)ethyliden)bisphenol | 433-640-8 | - | Pyr. Sol. 1 Aquatic Chronic 4 | H250 H413 | GHS02 Gef. | H250 H413 | EUH044 | ||
604-089-00-2 | 2-Methyl-5- tert-butylthiophenol | 444-970-7 | - | Flam. Liq. 3 Repr. 2 STOT RE 2 * Asp. Tox. 1 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H226 H361d*** H373** H304 H319 H315 H317 H336 H400 H410 | GHS02 GHS08 GHS07 GHS09 Gef. | H226 H361d*** H373** H304 H319 H315 H317 H336 H410 | |||
604-090-00-8 | 4- tert-Butylphenol | 202-679-0 | 98-54-4 | Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 1 | H361f H315 H318 H410 | GHS08 GHS05 GHS09 Dgr | H361f H315 H318 H410 | M = 1 | ||
604-091-00-3 | Etofenprox (ISO); 2-(4-Ethoxyphenyl)-2-methylpropyl-3-phenoxybenzylether | 407-980-2 | 80844-07-1 | Lact. Aquatic Acute 1 Aquatic Chronic 1 | H362 H400 H410 | GHS09 Achtg. | H362 H410 | M = 100 M = 1 000 | ||
604-092-00-9 | Phenol, dodecyl-, verzweigt; [1] Phenol, 2-dodecyl-, verzweigt; [2] Phenol, 3-dodecyl-, verzweigt; [3] Phenol, 4-dodecyl-, verzweigt; [4] Phenol, (tetrapropenyl) Derivate [5] | 310-154-3 [1] [2] [3] [4] [5] | 121158-58-5 [1] [2] [3] 210555-94-5 [4] 74499-35-7 [5] | Repr. 1B Skin Corr. 1C Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360F H314 H318 H400 H410 | GHS08 GHS05 GHS09 Gef. | H360F H314 H410 | M = 10 M = 10 | ||
604-093-00-4 | Clorofen; Chlorophen; 2-Benzyl-4-chlorphenol | 204-385-8 | 120-32-1 | Carc. 2 Repr. 2 Acute Tox. 4 Skin Irrit. 2 Skin Sens. 1 Eye Dam. 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361f H332 H315 H317 H318 H373 (Nieren) H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H351 H361f H332 H315 H317 H318 H373 (Nieren) H410 | M = 1 M = 100 | ||
604-094-00-X | Isoeugenol; [1] (E)-2-Methoxy-4-(prop-1-enyl)phenol; [2] (Z)-2-Methoxy-4-(prop-1-enyl)phenol [3] | 202-590-7 [1] 227-678-2 [2] 227-633-7 [3] | 97-54-1 [1] 5932-68-3 [2] 5912-86-7 [3] | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1A; H317: C ≥ 0,01 % | ||
604-095-00-5 | 6,6"-Di- tert-butyl-2,2"-methylendi- p-kresol; [DBMK] | 204-327-1 | 119-47-1 | Repr. 1B | H360F | GHS08 Dgr | H360F | |||
604-096-00-0 | Piperonylbutoxid (ISO); 2-(2-Butoxyethoxy)ethyl-6-propylpiperonylether | 200-076-7 | 51-03-6 | STOT SE 3 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H335 H319 H400 H410 | GHS07 GHS09 Wng | H335 H319 H410 | EUH066 | M = 1 M = 1 | |
604-097-00-6 | 2,4,6-Tri- tert-butylphenol | 211-989-5 | 732-26-3 | Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1B | H360D H302 H373 (Leber) H317 | GHS08 GHS07 Dgr | H360D H302 H373 (Leber) H317 | Oral: ATE = 500 mg/kg KG | ||
604-098-00-1 | 4,4"-Sulfonyldiphenol; Bisphenol S | 201-250-5 | 80-09-1 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
604-099-00-7 | 4,4"-[2,2,2-Trifluor-1-(trifluormethyl)ethyliden]diphenol; Bisphenol AF | 216-036-7 | 1478-61-1 | Repr. 1B | H360F | GHS08 Dgr | H360F | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
604-100-00-0 | Nonylphenol, verzweigt und linear, ethoxyliert (mit durchschnittlicher Molmasse ≤ 1.540 g/mol) [einschließlich Ortho-, Meta-, Para-Isomeren oder einer beliebigen Kombination daraus] | 500-315-8 500-024-6 500-045-0 500-209-1 248-762-5 243-816-4 248-291-5 - 230-770-5 248-743-1 247-555-7 248-293-6 - und andere | 127087-87-0 9016-45-9 26027-38-3 68412-54-4 27986-36-3 20427-84-3 27176-93-8 1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 und andere | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 10 | ) | |
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
605-001-00-5 | Formaldehyd ...% | 200-001-8 | 50-00-0 | Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* Skin Corr. 1B Skin Sens. 1 | H350 H341 H301 H311 H331 H314 H317 | GHS08 GHS06 GHS05 Gef. | H350 H341 H301 H311 H331 H314 H317 | * Skin Corr. 1B; H314: C ≥25 % Skin Irrit. 2; H315: 5 % ≤C < 25 % Eye Irrit. 2; H319: 5 % ≤ C <25 % STOT SE 3; H335: C ≥ 5 % SkinSens.; H317: C ≥ 0,2 % | B, D ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
605-001-00-5 | Formaldehyd ... % | 200-001-8 | 50-00-0 | Carc. 1B Muta. 2 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1B Skin Sens. 1A | H350 H341 H330 H302 H314 H317 | GHS08 GHS06 GHS05 Dgr | H350 H341 H330 H302 H314 H317 | EUH071 | Einatmung:
ATE = 100 ppmV (Gase) Oral: ATE = 500 mg/kg KG STOT SE 3; H335: C ≥ 5 % Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % | B, D, F ) |
605-002-00-0 | 1,3,5-Trioxan; Trioxymethylen | 203-812-5 | 110-88-3 | Flam. Sol. 1 Repr. 2 STOT SE 3 | H228 H361d *** H335 | GHS02 GHS08 GHS07 Gef. | H228 H361d *** H335 | T | ||
605-003-00-6 | Acetaldehyd; Ethanal | 200-836-8 | 75-07-0 | Flam. Liq. 1 Carc. 1B Muta. 2 STOT SE 3 Eye Irrit. 2 | H224 H350 H341 H335 H319 | GHS02 GHS08 GHS07 Dgr | H224 H350 H341 H335 H319 | |||
605-004-00-1 | 2,4,6-Trimethyl-1,3,5-trioxan; Paraldehyd | 204-639-8 | 123-63-7 | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | |||
605-005-00-7 | Metaldehyd (ISO); 2,4,6,8-Tetramethyl-1,3,5,7-tetraoxacyclooctan | 203-600-2 | 108-62-3 | Flam. Sol. 2 Repr. 2 Acute Tox. 3 Aquatic Chronic 3 | H228 H361f H301 H412 | GHS02 GHS08 GHS06 Dgr | H228 H361f H301 H412 | Oral: ATE = 283 mg/kg KG | ||
605-006-00-2 | Butyraldehyd; Butanal | 204-646-6 | 123-72-8 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
605-007-00-8 | 1,1-Dimethoxyethan; Dimethylacetal | 208-589-8 | 534-15-6 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
605-008-00-3 | Acrolein; Prop-2-enal; Acrylaldehyd; Propenal | 203-453-4 | 107-02-8 | Flam. Liq. 2 Acute Tox. 1 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H225 H330 H300 H311 H314 H400 H410 | GHS02 GHS06 GHS05 GHS09 Gef. | H225 H330 H300 H311 H314 H410 | EUH071 | Skin Corr. 1B; H314:C≥ 0,1 % M = 100 M = 1 | D |
605-009-00-9 | Crotonaldehyd; 2-Butenal [1]; (E)-2-Butenal; (E)-Crotonaldehyd [2] | 224-030-0 [1] 204-647-1 [2] | 4170-30-3 [1] 123-73-9 [2] | Flam. Liq. 2 Muta. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 | H225 H341 H330 H311 H301 H373 ** H335 H315 H318 H400 | GHS02 GHS06 GHS08 GHS05 GHS09 Gef. | H225 H341 H330 H311 H301 H373 ** H335 H315 H318 H400 | |||
605-010-00-4 | 2-Furaldehyd; Furfural; 2-Furylmethanal | 202-627-7 | 98-01-1 | Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H351 H331 H301 H312 H319 H335 H315 | GHS06 GHS08 Gef. | H351 H331 H301 H312 H319 H335 H315 | |||
605-011-00-X | 2-Chlorbenzaldehyd; o-Chlorbenzaldehyd | 201-956-3 | 89-98-5 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
605-012-00-5 | Benzaldehyd | 202-860-4 | 100-52-7 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
605-013-00-0 | Chloralose (INN); (R)-1,2-O-(2,2,2-Trichlorethyliden)-α-D-glucofuranose; Glucochloralose; Anhydroglucochloral | 240-016-7 | 15879-93-3 | Acute Tox. 4* Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H332 H301 H336 H400 H410 | GHS06 GHS09 Gef. | H332 H301 H336 H410 | M = 10 M = 10 | C | |
605-014-00-6 | Chloralhydrat; 2,2,2-Trichlorethan-1,1-diol | 206-117-5 | 302-17-0 | Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 | H301 H319 H315 | GHS06 Gef. | H301 H319 H315 | |||
605-015-00-1 | 1,1-Diethoxyethan; Acetal | 203-310-6 | 105-57-7 | Flam. Liq. 2 Eye Irrit. 2 Skin Irrit. 2 | H225 H319 H315 | GHS02 GHS07 Gef. | H225 H319 H315 | |||
605-016-00-7 | Glyoxal ...%; Ethandial ...% | 203-474-9 | 107-22-2 | Muta. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H341 H332 H319 H315 H317 | GHS07 GHS08 Achtg. | H341 H332 H319 H315 H317 | * | B | |
605-017-00-2 | 1,3-Dioxolan | 211-463-5 | 646-06-0 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
605-018-00-8 | Propanal; Propionaldehyd | 204-623-0 | 123-38-6 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H225 H319 H335 H315 | GHS02 GHS07 Gef. | H225 H319 H335 H315 | |||
605-019-00-3 | Citral; 3,7-Dimethyl-2,6-octadienal | 226-394-6 | 5392-40-5 | Skin Irrit. 2 Skin Sens. 1 | H315 H317 | GHS07 Achtg. | H315 H317 | |||
605-020-00-9 | Safrol; 5-Allyl-1,3-benzodioxol; 5-(2-Propenyl)-1,3-benzodioxol | 202-345-4 | 94-59-7 | Carc. 1B Muta. 2 Acute Tox. 4 * | H350 H341 H302 | GHS08 GHS07 Gef. | H350 H341 H302 | |||
605-021-00-4 | Formaldehyd, Reaktionsprodukte mit Butylphenol | 294-145-9 | 91673-30-2 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
605-022-00-X | Glutaral; Glutaraldehyd; 1,5-Pentandial | 203-856-5 | 111-30-8 | Acute Tox. 2 Acute Tox. 3 STOT SE 3 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 A Aquatic Acute 1 Aquatic Chronic 2 | H330 H301 H335 H314 H334 H317 H400 H411 | GHS06 GHS05 GHS08 GHS09 Gef. | H330 H301 H335 H314 H334 H317 H410 | EUH071 | STOT SE 3; H335: 0,5 % ≤ C < 5 % M = 1 | |
605-023-00-5 | 5-Chlor-2-(4-chlorphenoxy)phenol; [DCPP] | 429-290-0 | 3380-30-1 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | M = 10 M = 10" | ||
605-024-00-0 | 2-Brom-5-hydroxy-4-methoxybenzaldehyd | 426-540-0 | 2973-59-3 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
605-025-00-6 | Chloracetaldehyd | 203-472-8 | 107-20-0 | Carc. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 | H351 H330 H311 H301 H314 H400 | GHS06 GHS08 GHS05 GHS09 Gef. | H351 H330 H311 H301 H314 H400 | STOT SE 3; H335: C≥ 5 % | ||
605-026-00-1 | 2,5,7,7-Tetramethyloctanal | 405-690-0 | 114119-97-0 | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H315 H317 H411 | GHS07 GHS09 Achtg. | H315 H317 H411 | |||
605-027-00-7 | Reaktionsmasse aus 3a,4,5,6,7,7a-Hexahydro-4,7-methano-1 H- inden-6-carboxaldehyd; 3a,4,5,6,7,7a-Hexahydro-4,7-methano-1 H-inden-5-carboxaldehyd | 410-480-7 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
605-028-00-2 | β-Methyl-3-(1-methylethyl)-benzolpropanal | 412-050-4 | 125109-85-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
605-029-00-8 | 2-Cyclohexylpropanal | 412-270-0 | 2109-22-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
605-030-00-3 | 1-( p-Methoxyphenyl)acetaldehydoxim | 411-510-1 | 3353-51-3 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
605-031-00-9 | Reaktionsmasse aus 2,2-Dimethoxyethanal [diese Komponente gilt in Bezug auf Identität, Struktur und Zusammensetzung als wasserfrei. 2,2-Dimethoxyethanal existiert jedoch in wasserhaltiger Form. 60 % wasserfrei entspricht 70,4 % wasserhaltig; Wasser (einschließlich freiem Wasser und Wasser in hydriertem 2,2-Dimethoxyethanal)] | 421-890-0 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
605-032-00-4 | 3-[3-(4-Fluorphenyl)-1-(1-methylethyl)-1 H-indol-2-yl]-(E)-2-propenal | 425-370-4 | 93957-50-7 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
605-033-00-X | Reaktionsmasse aus 3,7,11-Trimethyl- cis-6,10-dodecadienal und 3,7,11-Trimethyl- trans-6,10-dodecadienal | 425-910-9 | 32480-08-3 | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
605-034-00-5 | Reaktionsmasse aus (1 RS,2 RS,3 SR,6 RS,9 SR)-9-Methoxytricyclo[5.2.1.0(2,6)]decan-3-carbaldehyd; (1 RS,2 RS,3 RS,6 RS,8 SR)-8-Methoxytricyclo[5.2.1.0(2,6)]decan-3-carbaldehyd und (1 RS,2 RS,4 SR,6 RS,8 SR)-8-Methoxytricyclo[5.2.1.0(2,6)]decan-4-carbaldehyd | 429-860-9 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
605-035-00-0 | (E)-3-(4-(4-Fluorphenyl)-5-methoxymethyl-2,6-bis(1-methoxymethyl)pyridin-3-yl)prop-2-enal | 426-330-9 | 177964-68-0 | Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 | H319 H317 H413 | GHS07 Achtg. | H319 H317 H413 | |||
605-036-00-6 | 2-Brommalonaldehyd | 430-470-6 | 2065-75-0 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
605-037-00-1 | trans-3-[2-(7-Chlor-2-chinolinyl)vinyl]benzaldehyd; 3-[( E)-2-(7-Chlor-2-chinolinyl)vinyl]benzaldehyd | 421-800-1 | 120578-03-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
605-038-00-7 | 3-Methyl-5-phenylpentan-1-al | 433-900-0 | 55066-49-4 | Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H302 H315 H317 H411 | GHS07 GHS09 Achtg. | H302 H315 H317 H411 | |||
605-039-00-2 | 3,4-Dihydroxy-5-nitrobenzaldehyd | 441-810-8 | 116313-85-0 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 | H302 H318 H317 | GHS05 GHS07 Gef. | H302 H318 H317 | |||
605-040-00-8 | Hydroxyisohexyl-3-cyclohexencarboxaldehyd (INCI); Reaktionsmasse von 4-(4-Hydroxy-4-methylpentyl)cyclohex-3-en-1-carbaldehyd und 3-(4-Hydroxy-4-methylpentyl)cyclohex-3-en-1-carbaldehyd; [1] 4-(4-Hydroxy-4-methylpentyl)cyclohex-3-en-1-carbaldehyd; [2] 3-(4-Hydroxy-4-methylpentyl)cyclohex-3-en-1-carbaldehyd; [3] | - [1] 250-863-4 [2] 257-187-9 [3] | 130066-44-3 [1] 31906-04-4 [2] 51414-25-6 [3] | Skin Sens. 1 A | H317 | GHS07 Achtg. | H317 | |||
605-041-00-3 | 2-(4- tert-Butylbenzyl)propionaldehyd | 201-289-8 | 80-54-6 | Repr. 1B | H360Fd | GHS08 Dgr | H360Fd | |||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
605-042-00-9 | α-Methyl-1,3 -benzodioxol-5-propionaldehyd [1] ( S)-α-Methyl-1,3-benzodioxol-5-propionaldehyd; (2 S)-3-(1,3-Benzodioxol-5-yl)-2-methylpropanal [2] ( R)-α-Methyl-1,3-benzodioxol-5-propionaldehyd; (2 R)-3-(1,3-Benzodioxol-5-yl)-2-methylpropanal [3] | 214-881-6 [1] - [2] - [3] | 1205-17-0 [1] 737776-68-0 [2] 737776-59-9 [3] | Skin Sens. 1B | H317 | GHS07 Wng | H317 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
605-043-00-4 | 2,4-Dimethylcyclohex-3-en-1-carbaldehyd [1] (1α,2α,5α)-2,5 -Dimethylcyclohex-3-en-1-carbaldehyd [2] 2,6-Dimethylcyclohex-3-en-1-carbaldehyd [3] 3,5-Dimethylcyclohex-3-en-1-carbaldehyd [4] 3,6-Dimethylcyclohex-3-en-1-carbaldehyd [5] 4,6-Dimethylcyclohex-3-en-1-carbaldehyd [6] Reaktionsmasse aus 3,5-Dimethylcyclohex-3-en-1-carbaldehyd und 2,4-Dimethylcyclohex-3-en-1-carbaldehyd [7] Dimethylcyclohex-3-en-1-carbaldehyd [8] Dimethylcyclohex-3-en-1-carbaldehyd [9] 1,2,4(oder 1,3,5)-Trimethylcyclohex-3-en-1-carbaldehyd [10] 1,3,4-Trimethylcyclohex-3-en-1-carbaldehyd [11] 2,2,4-Trimethylcyclohex-3-en-1-carbaldehyd [12] 2,4,6-Trimethylcyclohex-3-en-1-carbaldehyd [13] Isocyclocitral [14] 3,5,6-Trimethylcyclohex-3-en-1-carbaldehyd [15] 4,6,6-Trimethylcyclohex-3-en-1-carbaldehyd [16] | 268-264-1 [1] 252-395-6 [2] - [3] 268-263-6 [4] 267-186-5 [5] 253-139-6 [6] - [7] 248-742-6 [8] 272-113-5 [9] 276-055-1 [10] - [11] - [12] 215-833-7 [13] 215-638-7 [14] 266-810-3 [15] - [16] | 68039-49-6 [1] 35145-02-9 [2] 6975-94-6 [3] 68039-48-5 [4] 67801-65-4 [5] 36635-35-5 [6] - [7] 27939-60-2 [8] 68737-61-1 [9] 71832-78-5 [10] 40702-26-9 [11] 1726-47-2 [12] 1423-46-7 [13] 1335-66-6 [14] 67634-07-5 [15] 6754-27-4 [16] | Skin Sens. 1 | H317 | GHS07 Wng | H317 | ) | ||
606-001-00-8 | Aceton; Propan-2-on; Propanon | 200-662-2 | 67-64-1 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H336 | GHS02 GHS07 Gef. | H225 H319 H336 | EUH066 | ||
606-002-00-3 | Butanon; Ethylmethylketon | 201-159-0 | 78-93-3 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H336 | GHS02 GHS07 Gef. | H225 H319 H336 | EUH066 | ||
606-003-00-9 | Heptan-3-on; Butylethylketon | 203-388-1 | 106-35-4 | Flam. Liq. 3 Acute Tox. 4 * Eye Irrit. 2 | H226 H332 H319 | GHS02 GHS07 Achtg. | H226 H332 H319 | |||
606-004-00-4 | 4-Methylpentan-2-on; Isobutylmethylketon | 203-550-1 | 108-10-1 | Flam. Liq. 2 Carc. 2 Acute Tox. 4 STOT SE 3 Eye Irrit. 2 | H225 H351 H332 H336 H319 | GHS02 GHS07 GHS08 Dgr | H225 H351 H332 H336 H319 | EUH066 | Einatmen: ATE = 11 mg/L (Dämpfe) | |
606-005-00-X | 2,6-Dimethylheptan-4-on; Diisobutylketon | 203-620-1 | 108-83-8 | Flam. Liq. 3 STOT SE 3 | H226 H335 | GHS02 GHS07 Achtg. | H226 H335 | STOT SE 3; H335: C ≥ 10 % | ||
606-006-00-5 | 3-Pentanon; Diethylketon | 202-490-3 | 96-22-0 | Flam. Liq. 2 STOT SE 3 STOT SE 3 | H225 H335 H336 | GHS02 GHS07 Gef. | H225 H335 H336 | EUH066 | ||
606-007-00-0 | 3-Methylbutan-2-on; Methylisopropylketon | 209-264-3 | 563-80-4 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
606-009-00-1 | 4-Methylpent-3-en-2-on; Mesityloxid | 205-502-5 | 141-79-7 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H226 H332 H312 H302 | GHS02 GHS07 Achtg. | H226 H332 H312 H302 | * | ||
606-010-00-7 | Cyclohexanon | 203-631-1 | 108-94-1 | Flam. Liq. 3 Acute Tox. 4 * | H226 H332 | GHS02 GHS07 Achtg. | H226 H332 | |||
606-011-00-2 | 2-Methylcyclohexanon | 209-513-6 | 583-60-8 | Flam. Liq. 3 Acute Tox. 4 * | H226 H332 | GHS02 GHS07 Achtg. | H226 H332 | |||
606-012-00-8 | 3,5,5-Trimethylcyclohex-2-enon; Isophoron; 3,5,5-Trimethylcyclohex-2-en-1-on | 201-126-0 | 78-59-1 | Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 | H351 H312 H302 H319 H335 | GHS08 GHS07 Achtg. | H351 H312 H302 H319 H335 | STOT SE 3; H335: C ≥10 % | ||
606-013-00-3 | p-Benzochinon; Chinon | 203-405-2 | 106-51-4 | Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 | H331 H301 H319 H335 H315 H400 | GHS06 GHS09 Gef. | H331 H301 H319 H335 H315 H400 | M=10 | ||
606-014-00-9 | Chlorphacinon (ISO); 2-[(4-Chlorphenyl)(phenyl)acetyl]-1H-inden-1,3(2H)-dion | 223-003-0 | 3691-35-8 | Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H310 H300 H372 (Blut) H400 H410 | GHS08 GHS06 GHS09 Gef. | H360D H330 H310 H300 H372 (Blut) H410 | Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 0,1 % STOT RE 2; H373 (Blut): 0,01 % ≤ C < 0,1 % M = 1 M = 1 | ||
606-016-00-X | Pindon (ISO); 2-Pivaloylindan-1,3-dion | 201-462-8 | 83-26-1 | Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H372 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H372 ** H410 | |||
606-017-00-5 | Diketen; 4-Methylen-2-oxetanon | 211-617-1 | 674-82-8 | Flam. Liq. 3 Acute Tox. 4 * | H226 H332 | GHS02 GHS07 Achtg. | H226 H332 | D | ||
606-018-00-0 | Dichlon (ISO); 2,3-Dichlor-1,4-naphthochinon | 204-210-5 | 117-80-6 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H315 H410 | |||
606-019-00-6 | Chlordecon (ISO); Decachlorpentacyclo(5,2,1,02,6,03,9,05,8)decan-4-on | 205-601-3 | 143-50-0 | Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H311 H301 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H311 H301 H410 | |||
606-020-00-1 | 5-Methyl-3-heptanon | 208-793-7 | 541-85-5 | Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 | H226 H319 H335 | GHS02 GHS07 Achtg. | H226 H319 H335 | STOT SE 3; H335: C≥10 % | ||
606-014-00-9 | Chlorphacinon (ISO); 2-[(4-Chlorphenyl)(phenyl)acetyl]-1H-inden-1,3(2H)-dion | 223-003-0 | 3691-35-8 | Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H310 H300 H372 (Blut) H400 H410 | GHS08 GHS06 GHS09 Gef. | H360D H330 H310 H300 H372 (Blut) H410 | Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 0,1 % STOT RE 2; H373 (Blut): 0,01 % ≤ C < 0,1 % M = 1 M = 1 | ||
606-022-00-2 | 1-Phenyl-3-pyrazolidon | 202-155-1 | 92-43-3 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
606-023-00-8 | 4-Methoxy-4-methylpentan-2-on; Diacetonalkoholmethylether | 203-512-4 | 107-70-0 | Flam. Liq. 3 Acute Tox. 4 * | H226 H332 | GHS02 GHS07 Achtg. | H226 H332 | |||
606-024-00-3 | 2-Heptanon; Methylpentylketon; Methylamylketon | 203-767-1 | 110-43-0 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * | H226 H332 H302 | GHS02 GHS07 Achtg. | H226 H332 H302 | |||
606-025-00-9 | Cyclopentanon | 204-435-9 | 120-92-3 | Flam. Liq. 3 Eye Irrit. 2 Skin Irrit. 2 | H226 H319 H315 | GHS02 GHS07 Achtg. | H226 H319 H315 | |||
606-026-00-4 | 5-Methylhexan-2-on; Isoamylmethylketon | 203-737-8 | 110-12-3 | Flam. Liq. 3 Acute Tox. 4 * | H226 H332 | GHS02 GHS07 Achtg. | H226 H332 | |||
606-027-00-X | 4-Heptanon; Di- n-propylketon | 204-608-9 | 123-19-3 | Flam. Liq. 3 Acute Tox. 4 * | H226 H332 | GHS02 GHS07 Achtg. | H226 H332 | |||
606-028-00-5 | 2,4-Dimethylpentan-3-on; Diisopropylketon | 209-294-7 | 565-80-0 | Flam. Liq. 2 Acute Tox. 4 * | H225 H332 | GHS02 GHS07 Gef. | H225 H332 | |||
606-029-00-0 | 2,4-Pentandion; Acetylaceton | 204-634-0 | 123-54-6 | Flam. Liq. 3 Acute Tox. 4 * | H226 H302 | GHS02 GHS07 Achtg. | H226 H302 | |||
606-030-00-6 | 2-Hexanon; Methylbutylketon; Butylmethylketon; Methyl- n-butylketon | 209-731-1 | 591-78-6 | Flam. Liq. 3 Repr. 2 STOT RE 1 STOT SE 3 | H226 H361f *** H372 ** H336 | GHS02 GHS08 GHS07 Gef. | H226 H361f *** H372 ** H336 | |||
606-031-00-1 | 3-Propanolid; 1,3-Propiolacton | 200-340-1 | 57-57-8 | Carc. 1B Acute Tox. 2 * Eye Irrit. 2 Skin Irrit. 2 | H350 H330 H319 H315 | GHS06 GHS08 Gef. | H350 H330 H319 H315 | |||
606-032-00-7 | Hexachloraceton | 204-129-5 | 116-16-5 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
606-033-00-2 | 2-(3,4-Dichlorphenyl)-4-methyl-1,2,4-oxadiazolidindion; Methazol | 243-761-6 | 20354-26-1 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H312 H302 H319 H315 H411 | GHS07 GHS09 Achtg. | H312 H302 H319 H315 H411 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
606-034-00-8 | Metribuzin (ISO); 4-Amino-6- tert-butyl-3-methylthio-1,2,4-triazin-5(4 H)-on; 4-Amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-on | 244-209-7 | 21087-64-9 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M=10 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
606-034-00-8 | Metribuzin (ISO); 4-Amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4 H)-on; 4-Amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-on | 244-209-7 | 21087-64-9 | Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (Blutkreislauf) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (Blutkreislauf) H410 | Oral: ATE = 320 mg/kg KG M = 10 M = 10 | ) | |
606-035-00-3 | Chloridazon (ISO); 5-Amino-4-chlor-2-phenylpyridazin-3-(2 H)-on; Pyrazon | 216-920-2 | 1698-60-8 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
606-036-00-9 | Chinomethionat (ISO); 6-Methyl-1,3-dithiolo(4,5- b)chinoxalin-2-on | 219-455-3 | 2439-01-2 | Repr. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f *** H332 H312 H302 H373 ** H319 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361f *** H332 H312 H302 H373 ** H319 H317 H410 | |||
606-037-00-4 | Triadimefon (ISO); 1-(4-Chlorphenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butanon | 256-103-8 | 43121-43-3 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
606-038-00-X | Diphacinon (ISO); 2-Diphenylacetylindan-1,3-dion | 201-434-5 | 82-66-6 | Acute Tox. 2 * STOT RE 1 | H300 H372 ** | GHS06 GHS08 Gef. | H300 H372 ** | |||
606-039-00-5 | 5(oder 6)- tert-Butyl-2"-chlor-6"-ethylamino-3",7"-dimethylspiro(isobenzofuran-1(1 H),9"-xanthen)-3-on | 400-680-2 | - | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H400 H410 | GHS07 GHS09 Achtg. | H332 H410 | |||
606-040-00-0 | (N-Benzyl- N-ethyl)amino-3-hydroxyacetophenonhydrochlorid | 401-840-4 | 55845-90-4 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
606-041-00-6 | 2-Methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-on | 400-600-6 | 71868-10-5 | Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 | H360FD H302 H411 | GHS08 GHS07 GHS09 Gef. | H360FD H302 H411" | |||
606-042-00-1 | Acetophenon; Methyl-phenylketon | 202-708-7 | 98-86-2 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
606-043-00-7 | 2,4-Di- tert-butylcyclohexanon | 405-340-7 | 13019-04-0 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
606-044-00-2 | 2,4,6-Trimethylbenzophenon | 403-150-9 | 954-16-5 | Acute Tox. 4 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H410 | |||
606-045-00-8 | Oxadiazon (ISO); 3-[2,4-Dichlor-5-(1-methylethoxy)phenyl]-5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2(3 H)-on | 243-215-7 | 19666-30-9 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-046-00-3 | Reaktionsmasse aus cis- und trans-Cyclohexadec-8-en-1-on | 401-700-2 | 3100-36-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-047-00-9 | 2-Benzyl-2-dimethylamino-4"-morpholinobutyrophenon | 404-360-3 | 119313-12-1 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360D H400 H410 | GHS08 GHS09 Dgr | H360D H410 | |||
606-048-00-4 | 2"-Anilino-3"-methyl-6"-dipentylaminospiro(isobenzofuran-1(1 H),9"-xanthen)-3-on | 406-480-1 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
606-049-00-X | 4-( trans-4-Propylcyclohexyl)acetophenon | 406-700-6 | 78531-61-0 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
606-050-00-5 | 6-Anilino-1-benzoyl-4-(4- tert-pentylphenoxy)naphto[1,2,3-de]chinolin-2,7-(3 H)-dion | 412-480-2 | 72453-58-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-051-00-0 | 4-Pentylcyclohexanon | 406-670-4 | 61203-83-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-052-00-6 | 4-( N, N-Dibutylamino)-2-hydroxy-2"-carboxybenzophenon | 410-410-5 | 54574-82-2 | Aquatic Chronic 3 | H412 | - | H412 | |||
606-053-00-1 | Flurtamon (ISO); (RS)-5-Methylamino-2-phenyl-4-(α, α,α-trifluor- m-tolyl)furan-3(2 H)-on | - | 96525-23-4 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-054-00-7 | Isoxaflutol (ISO); 5-Cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluor-2-mesyl-p-tolyl keton | - | 141112-29-0 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d*** H400 H410 | GHS08 GHS09 Achtg. | H361d*** H410 | M = 10 M = 100 | ||
606-055-00-2 | 1-(2,3-Dihydro-1,3,3,6-tetramethyl-1-(1-methylethyl)-1 H-inden-5-yl)ethanon | 411-180-9 | 92836-10-7 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 | H302 H373 ** H411 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H411 | |||
606-056-00-8 | 4-Chlor-3",4"-dimethoxybenzophenon | 404-610-1 | 116412-83-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-057-00-3 | 4-Propylcyclohexanon | 406-810-4 | 40649-36-3 | Skin Irrit. 2 Aquatic Chronic 3 | H315 H412 | GHS07 Achtg. | H315 H412 | |||
606-058-00-9 | 4"-Fluor-2,2-dimethoxyacetophenon | 407-500-1 | 21983-80-2 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
606-059-00-4 | 2,4-Difluor-α-(1 H-1,2,4-triazol-1-yl)acetophenonhydrochlorid | 412-390-3 | 86386-75-6 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 | H302 H318 H317 | GHS05 GHS07 Gef. | H302 H318 H317 | |||
606-060-00-X | Reaktionsmasse aus trans-2,4-Dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalin-2-yl)-1,3-dioxolan; cis-2,4-Dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalin-2-yl)-1,3-dioxolan | 412-950-7 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-061-00-5 | (3-Chlorphenyl)-(4-methoxy-3-nitrophenyl)methanon | 423-290-4 | 66938-41-8 | Muta. 2 Aquatic Acute 1 Aquatic Chronic 1 | H341 H400 H410 | GHS08 GHS09 Achtg. | H341 H410 | |||
606-062-00-0 | Tetrahydrothiopyran-3-carboxaldehyd | 407-330-8 | 61571-06-0 | Repr. 1B Eye Dam. 1 Aquatic Chronic 3 | H360D *** H318 H412 | GHS08 GHS05 Gef. | H360D *** H318 H412 | |||
606-063-00-6 | (E)-3-(2-Chlorphenyl)-2-(4-fluorphenyl)propenal | 410-980-5 | 112704-51-5 | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
606-064-00-1 | Pregn-5-en-3,20-dionbis(ethylenketal) | 407-450-0 | 7093-55-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-065-00-7 | 1-(4-Morpholinophenyl)butan-1-on | 413-790-0 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-066-00-2 | (E)-5[(4-Chlorphenyl)methylen]-2,2-dimethylcyclopentanon | 410-440-9 | 164058-20-2 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-067-00-8 | Reaktionsmasse aus 1-(2,3,6,7,8,9-Hexahydro-1,1-dimethyl-1 H-benz(g)inden-4-yl)ethanon; 1-(2,3,5,6,7,8-Hexahydro-1,1-dimethyl-1 H-benz(f)inden-4-yl)ethanon; 1-(2,3,6,7,8,9-Hexahydro-1,1-dimethyl-1 H-benz(g)inden-5-yl)ethanon; 1-(2,3,6,7,8,9-Hexahydro-3,3-dimethyl-1 H-benz(g)inden-5-yl)ethanon | 414-870-8 | 96792-67-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-068-00-3 | 2,7,11-Trimethyl-13-(2,6,6-trimethylcyclohex-1-en-1-yl)tridecahexaen-2,4,6,8,10,12-al | 415-770-7 | 1638-05-7 | STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 | H373 ** H317 H412 | GHS08 GHS07 Achtg. | H373 ** H317 H412 | |||
606-069-00-9 | Spiro[1,3-dioxolan-2,5"-(4",4",8",8"-Tetramethylhexahydro-3",9"-methannaphthalin)] | 415-460-1 | 154171-76-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-070-00-4 | Butroxydim (ISO); 5-(3-Butyryl-2,4,6-trimethylphenyl)-2-[1-(ethoxyimino)propyl]-3-hydroxycyclohex-2-en-1-on | 414-790-3 | 138164-12-2 | Repr. 2 Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361fd H302 H315 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361fd H302 H315 H410 | |||
606-071-00-X | 17-Spiro(5,5-dimethyl-1,3-dioxan-2-yl)androsta-1,4-dien-3-on | 421-050-3 | 13258-43-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-072-00-5 | 3-Acetyl-1-phenylpyrrolidin-2,4-dion | 421-600-2 | 719-86-8 | STOT RE 2 * Aquatic Chronic 2 | H373 ** H411 | GHS08 GHS09 Achtg. | H373 ** H411 | |||
606-073-00-0 | 4,4"-Bis(dimethylamino)benzophenon; Michlers Keton | 202-027-5 | 90-94-8 | Carc. 1B Muta. 2 Eye Dam. 1 | H350 H341 H318 | GHS08 GHS05 Gef. | H350 H341 H318 | |||
606-074-00-6 | Reaktionsmasse aus (1 R*,2 S*)-2-Acetyl-1,2,3,4,5,6,7,8-octahydro-1,2,8,8-tetramethylnaphthalin und (2 R*,3 S*)-2-Acetyl-1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethylnaphthalin | 425-570-1 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-075-00-1 | 1-Benzyl-5-ethoxyimidazolidin-2,4-dion | 417-340-4 | 65855-02-9 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
606-076-00-7 | 1-((2-Chinolinylcarbonyl)oxy)-2,5-pyrrolidindion | 418-630-3 | 136465-99-1 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
606-077-00-2 | (3 S,4 S)-3-Hexyl-4-[( R)-2-hydroxytridecyl]-2-oxetanon | 418-650-2 | 104872-06-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-078-00-8 | 1-Octylazepin-2-on | 420-040-6 | 59227-88-2 | Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H314 H317 H411 | GHS05 GHS07 GHS09 Gef. | H314 H317 H411 | |||
606-079-00-3 | 2- n-Butylbenzo[ d]isothiazol-3-on | 420-590-7 | 4299-07-4 | Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H317 H410 | |||
606-081-00-4 | (3β,5α,6β)-3-(Acetyloxy)-5-brom-6-hydroxyandrostan-17-on | 419-790-7 | 4229-69-0 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
606-082-00-X | Reaktionsmasse aus Butan-2-on-oxim und syn- O, O"-Di(butan-2-on-oxim)diethoxysilan | 406-930-7 | STOT RE 1 Skin Sens. 1 Aquatic Chronic 3 | H372 ** H317 H412 | GHS08 GHS07 Gef. | H372 ** H317 H412 | ||||
606-083-00-5 | 2-Chlor-5- sec-hexadecylhydrochinon | 407-750-1 | 137193-60-3 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H319 H315 H317 H412 | GHS07 Achtg. | H319 H315 H317 H412 | |||
606-084-00-0 | 1-(4-Methoxy-5-benzofuranyl)-3-phenyl-1,3-propandion | 414-540-3 | 484-33-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-085-00-6 | (1 R,4 S)-2-Azabicyclo[2.2.1]hept-5-en-3-on | 418-530-1 | 79200-56-9 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 | H302 H318 H317 | GHS05 GHS07 Gef. | H302 H318 H317 | |||
606-086-00-1 | 1-(3,3-Dimethylcyclohexyl)pent-4-en-1-on | 422-330-8 | 56973-87-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-087-00-7 | 6-Ethyl-5-fluor-4(3 H)-pyrimidon | 422-460-5 | 137234-87-8 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
606-088-00-2 | 2,4,4,7-Tetramethyl-6-octen-3-on | 422-520-0 | 74338-72-0 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
606-089-00-8 | Reaktionsmasse aus 1,4-Diamino-2-chlor-3-phenoxyanthrachinon und 1,4-Diamino-2,3-bis-phenoxyanthrachinon | 423-220-2 | 12223-77-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-090-00-3 | 1-[3-[(Dimethylamino)methyl]-4-hydroxyphenyl]ethanon | 430-920-1 | 73096-98-7 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
606-091-00-9 | 6-Chlor-5-(2-chlorethyl)-1,3-dihydroindol-2-on | 421-320-0 | 118289-55-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-092-00-4 | Reaktionsmasse aus (E)-Oxacyclohexadec-12-en-2-on; (E)-Oxacyclohexadec-13-en-2-on; a) (Z)-Oxacyclohexadec-(12)-en-2-on und b) (Z)-Oxacyclohexadec-(13)-en-2-on | 422-320-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | ||||
606-093-00-X | 5-Ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3 H-1,2,4-triazol-3-on | 414-470-3 | 95885-13-5 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
606-094-00-5 | N-[Ethyl(3-methylbutyl)amino]-3-methyl-1-phenylspiro[[1]benzo-pyrano[2,3-c]pyrazol-4(1 H),1"(3" H)-isobenzofuran]-3"-on | 417-460-7 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
606-095-00-0 | (R, S)-2-Azabicyclo[2.2.1]hept-5-en-3-on | 421-830-3 | 49805-30-3 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
606-096-00-6 | 3-(6- O-(6-Desoxy-α-l-mannopyranosyl- O-(α-D-glucopyranosyl)-(β-D-glucopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4 H-1-benzopyran-4-on | 424-170-4 | 130603-71-3 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
606-097-00-1 | 2,2""-Dihydroxy-4,4""-(2-hydroxy-propan-1,3-diyldioxy)dibenzophenon | 424-210-0 | 23911-85-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-098-00-7 | 1-Benzyl-5-(hexadecyloxy)-2,4-imidazolidindion | 431-220-9 | 158574-65-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-099-00-2 | 5-Methoxy-4"-(trifluormethyl)valerophenon | 425-000-1 | 61718-80-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-100-00-6 | 2-Butyryl-3-hydroxy-5-thiocyclohexan-3-yl-cyclohex-2-en-1-on | 425-150-8 | 94723-86-1 | Repr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H360F*** H302 H317 H412 | GHS08 GHS07 Gef. | H360F*** H302 H317 H412 | |||
606-101-00-1 | Reaktionsmasse aus 1,5-Bis[(2-ethylhexyl)amino]-9,10-anthracendion; 1-[(2-Ethylhexyl)amino]-5-[3-[(2-ethylhexyl)oxy]propyl]amino-9,10-anthracendion; 1,5-Bis[3-[(2-ethylhexyl)oxy]propyl]amino-9,10-anthracendion; 1-[(2-Ethylhexyl)amino]-5-[(3-methoxypropyl)amino]-9,10-anthracendion; 1-[3-[(2-Ethylhexyl)oxy]propyl]amino-5-[(3-methoxypropyl)amino]-9,10-anthracendion und 1,5-Bis[(3-methyloxypropyl)amino]-9,10-anthracendion | 426-050-7 | 165038-51-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
606-102-00-7 | 4-(3-Triethoxysilylpropoxy)-2-hydroxybenzophenon | 431-490-8 | 79876-59-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-103-00-2 | 1-(4-( trans-4-Ethylcyclohexyl)phenyl)ethanon | 426-460-6 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
606-104-00-8 | 1-(4-( trans-4-Pentylcyclohexyl)phenyl)ethanon | 426-830-7 | 78531-59-6 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
606-105-00-3 | 3,4,3",4"-Tetraphenyl-1,1"-ethandiylbispyrol-2,5-dion | 431-500-0 | 226065-73-2 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
606-106-00-9 | 1-(4-( trans-4-Butylcyclohexyl)phenyl)ethanon | 427-320-7 | 83626-30-6 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
606-107-00-4 | 8-Azaspiro[4.5]decan-7,9-dion | 427-770-4 | 1075-89-4 | Acute Tox. 3 * Aquatic Chronic 2 | H301 H411 | GHS06 GHS09 Gef. | H301 H411 | |||
606-108-00-X | 1,1,1,2,2,4,5,5,5-Nonafluor-4-(trifluormethyl)-3-pentanon | 436-710-6 | 756-13-8 | Aquatic Chronic 3 | H412 | - | H412 | |||
606-109-00-5 | 2-(4-Methyl-3-pentenyl)anthrachinon | 428-320-1 | 71308-16-2 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 4 | H302 H317 H413 | GHS07 Achtg. | H302 H317 H413 | |||
606-110-00-0 | 5-Ethoxy-5 H-furan-2-on | 428-330-4 | 2833-30-9 | Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 | H314 H312 H302 H373** H317 | GHS05 GHS08 GHS07 Gef. | H314 H312 H302 H373** H317 | |||
606-111-00-6 | 5-Amino-6-methyl-1,3-dihydrobenzoimidazol-2-on | 428-410-9 | 67014-36-2 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
606-112-00-1 | (4a R*,8a R*)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-on | 428-690-2 | 1668-86-6 | Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 3 | H302 H319 H412 | GHS07 Achtg. | H302 H319 H412 | |||
606-113-00-7 | 1-[4-(4-Benzoylphenylsulfanyl)phenyl]-2-methyl-2-(4-methylphenylsulfonyl)propan-1-on | 429-040-0 | 272460-97-6 | Eye Dam. 1 Aquatic Chronic 4 | H318 H413 | GHS05 Gef. | H318 H413 | |||
606-114-00-2 | 4,4",5,5",6,6",7,7"-Octachlor-(2,2")biisoindolyl-1,1",3,3"-tetraon | 429-150-9 | 67887-47-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-115-00-8 | Profoxydim (ISO); 2-{( EZ)-1-[(2 RS)-2-(4-Chlorphenoxy)propoxyimino]butyl}-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-on | - | 139001-49-3 | Carc. 2 Repr. 2 Skin Sens. 1 | H351 H361d H317 | GHS08 GHS07 Achtg. | H351 H361d H317 | |||
606-116-00-3 | Tepraloxydim (ISO); (RS)-( EZ)-2-{1-[(2 E)-3-Chlorallyloxyimino]propyl}-3-hydroxy-5-perhydropyran-4-ylcyclohex-2-en-1-on | - | 149979-41-9 | Carc. 2 Repr. 2 | H351 H361fd | GHS08 Achtg. | H351 H361fd | |||
606-117-00-9 | 2,6-Bis(1,1-dimethylethyl)-4-(phenylenmethylen)cyclohexa-2,5-dien-1-on | 429-460-4 | 7078-98-0 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
606-118-00-4 | N-(1,3-Dimethylbutyl)- N"-(phenyl)-1,4-benzochinondiimin | 429-640-2 | 52870-46-9 | Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H400 H410 | GHS07 GHS09 Achtg. | H319 H410 | |||
606-119-00-X | (E)-3-Methyl-5-cyclopentadecen-1-on | 429-900-5 | - | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
606-120-00-5 | 2,5-Dihydroxy-5-methyl-3-(morpholin-4-yl)-2-cyclopenten-1-on | 430-170-5 | 114625-74-0 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
606-121-00-0 | (+)-(1 S,2 S,3 S,5 R)-2,6,6-Trimethylbicyclo[3.1.1]heptan-3-spiro-1"-(cyclohex-2"-en-4"-on) | 430-460-1 | 133636-82-5 | Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H317 H410 | |||
606-122-00-6 | 3-(2-Brompropionoyl)-4,4-dimethyl-1,3-oxazolan-2-on | 430-820-8 | 114341-88-7 | Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H315 H318 H317 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H302 H373** H315 H318 H317 H410 | |||
606-123-00-1 | 4-Hexadecyl-1-phenylpyrazolidin-3-on | 430-840-7 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
606-124-00-7 | 1-Cyclopropyl-3-(2-methylthio-4-trifluormethylphenyl)-1,3-propandion | 421-080-7 | 161462-35-7 | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373** H400 H410 | GHS08 GHS09 Achtg. | H373** H410 | |||
606-125-00-2 | 1-Benzylimidazolidin-2,4-dion | 421-340-1 | 6777-05-5 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
606-126-00-8 | 1,4-Bis(2,3-dihydroxypropylamino)anthrachinon | 421-470-7 | 99788-75-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
606-128-00-9 | 2,2"-(1,3-Phenylen)bis[5-chlor-1 H-isoindol]-1,3(2 H)-dion | 422-650-8 | 148935-94-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-129-00-4 | 5-Amino-[2 S-di(methylphenyl)amino]-1,6-diphenyl-4 Z-hexen-3-on; (2 S,4 Z)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-on | 423-090-7 | 156732-13-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-130-00-X | 4-(1,4-Dioxa-spiro[4.5]dec-8-yl)-cyclohexanon | 423-860-2 | 56309-94-5 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
606-131-00-5 | 3-(1,2-Ethandiylacetal)-estra-5(10),9(11)-dien-3,17-dion, zyklisch | 427-230-8 | 5571-36-8 | Repr. 1B STOT RE 2 * Aquatic Chronic 2 | H360F*** H373** H411 | GHS08 GHS09 Gef. | H360F*** H373** H411 | |||
606-132-00-0 | (6β)-6,19-Epoxyandrost-4-en-3,17-dion | 433-490-3 | 6563-83-3 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
606-134-00-1 | Androsta-1,4,9(11)-trien-3,17-dion | 433-560-3 | 15375-21-0 | Repr. 2 | H361f*** | GHS08 Achtg. | H361f*** | |||
606-135-00-7 | Cyclohexadecanon | 438-930-8 | 2550-52-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-136-00-2 | (3 S,6 R,9 S,12 R,15 S,18 R,21 S,24 R)-6,18-Dibenzyl-3,9,15,21-tetraisobutyl-4,10,12,16,22,24-hexamethyl-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclotetracosan-2,5,8,11,14,17,20,23-octaon | 444-350-6 | 133413-70-4 | Eye Irrit. 2 Aquatic Chronic 4 | H319 H413 | GHS07 Achtg. | H319 H413 | |||
606-137-00-8 | trans-7,7"-Dimethyl-(4 H,4 H")-(2,2")bi[benzo[1,4]thiazinyliden]-3,3"-dion | 444-750-0 | 211387-26-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-138-00-3 | (2-Butyl-5-nitrobenzofuran-3-yl)[4-(3-dibutylaminopropoxy)phenyl]methanon | 444-800-1 | 141645-23-0 | Flam. Liq. 3 Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H226 H302 H373** H315 H318 H317 H400 H410 | GHS02 GHS05 GHS08 GHS07 GHS09 Gef. | H226 H302 H373** H315 H318 H317 H410 | M=10 | ||
606-139-00-9 | (S)-4-(3,4-Dichlorphenyl)-3,4-dihydro-2 H-naphthalen-1-on | 444-830-5 | 124379-29-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
606-140-00-4 | 2-Hydroxy-1-(4-(4-(2-hydroxy-2-methylpropionyl)benzyl)phenyl)-2-methylpropan-1-on | 444-860-9 | 474510-57-1 | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373** H400 H410 | GHS08 GHS09 Wn | H373** H410 | |||
606-141-00-X | Natrium-3-(methoxycarbonyl)-4-oxo-3,4,5,6-tetrahydro-2-pyridinolat | 418-410-7 | - | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
606-142-00-5 | Reaktionsmasse aus (1 RS,2 SR,7 SR,8 SR, E)-9 und 10-Ethyliden-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-on; (1 RS,2 SR,7 SR,8 SR, Z)-10-Ethyliden-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-on; (1 RS,2 SR,7 SR,8 SR, Z)-9-Ethyliden-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-on | 434-290-9 | - | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
606-143-00-0 | Abamectin (Kombination von Avermectin B1a und Avermectin B1b) (ISO) [1]; Avermectin B1a (Reinheit ≥ 80 %); [2] | _ [1] 265-610-3 [2] | 71751-41-2 [1] 65195-55-3 [2] | Repr. 2 Acute Tox. 2 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d H300 H330 H372 (Nerven-system) H400 H410 | GHS06 GHS08 GHS09 Gef. | H361d H300 H330 H372 (Nerven-system) H410 | STOT RE 1; H372: C ≥ 5 % STOT RE 2; H373: 0,5 % ≤C< 5 % M = 10 000 | ||
606-144-00-6 | Acequinocyl (ISO); 3-Dodecyl-1,4-dioxo-1,4-dihydronaphthalin-2-ylacetat | - | 57960-19-7 | Skin Sens. 1 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H317 H370 (Lunge) (Einatmen) H373 (Blutkreislauf) H400 H410 | GHS07 GHS08 GHS09 Gef. | H317 H370 (Lunge) (Einatmen) H373 (Blutkreislauf) H410 | M = 1 000 | ||
606-145-00-1 | Sulcotrion (ISO); 2-[2-Chlor-4-(methylsulfonyl)benzoyl]cyclohexan-1,3-dion | 99105-77-8 | Repr. 2 STOT RE 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (Nieren) H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361d H373 (Nieren) H317 H410 | M = 1 M = 10 | |||
606-146-00-7 | Tralkoxydim (ISO); 2-( N-Ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-on | - | 87820-88-0 | Carc. 2 Acute Tox. 4 Aquatic Chronic 2 | H351 H302 H411 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H411 | |||
606-147-00-2 | Cycloxydim (ISO); 2-( N-Ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2 H-thiopyran-3-yl)cyclohex-2-en-1-on | 405-230-9 | 101205-02-1 | Repr. 2 | H361d | GHS08 Achtg. | H361d | |||
606-148-00-8 | Carvon (ISO); 2-Methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on; [1] d-Carvon; (5S)-2-Methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on; [2] l-Carvon; (5R)-2-Methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-on [3] | 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] | 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
606-149-00-3 | Tembotrion (ISO); 2-{2-Chlor-4-(methylsulfonyl)-3-[(2,2,2-trifluorethoxy)methyl]benzoyl}cyclohexan-1,3-dion | - | 335104-84-2 | Repr. 2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (Augen, Nieren, Leber) H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361d H373 (Augen, Nieren, Leber) H317 H410 | M = 100 M = 10 | ||
606-150-00-9 | Clethodim (ISO); (5RS)-2-{(1EZ)-1-[(2E)-3-Chlorallyloxyimino]propyl}-5-[(2RS)- 2-(ethylthio)propyl]-3-hydroxycyclohex-2-en-1-on | - | 99129-21-2 | Acute Tox. 4 Skin Sens. 1 Aquatic Chronic 3 | H302 H317 H412 | GHS07 Achtg. | H302 H317 H412 | EUH066 | ||
606-151-00-4 | Anthrachinon | 201-549-0 | 84-65-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
606-152-00-X | (5-Chlor-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanon; Pyriofenon | - | 688046-61-9 | Carc. 2 Aquatic Chronic 1 | H351 H410 | GHS08 GHS09 Wng | H351 H410 | M = 1 | ||
606-153-00-5 | Benzophenon | 204-337-6 | 119-61-9 | Carc. 1B | H350 | GHS08 Dgr | H350 | |||
606-154-00-0 | Quinoclamin (ISO); 2-Amino-3-chlor-1,4-naphthochinon | 220-529-2 | 2797-51-5 | Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d H302 H373 (Blutkreislauf, Nieren) H319 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361d H302 H373 (Blutkreislauf, Nieren) H319 H317 H410 | Oral: ATE = 500 mg/kg KG M = 10 M = 10 | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
606-155-00-6 | Zimtaldehyd; 3-Phenylprop-2-enal; Zimtaldehyd; Cinnamal; [1] (2 E)-3-phenylprop-2-enal [2] | 203-213-9 [1] - [2] | 104-55-2 [1] 14371-10-9 [2] | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1; H317: C ≥ 0,01 % | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
606-156-00-1 | Acetonoxim | 204-820-1 | 127-06-0 | Carc. 1B Acute Tox. 4 STOT SE 3 STOT RE 2 Eye Dam. 1 Skin Sens. 1 | H350 H312 H336 H373 (Blutkreislauf) H318 H317 | GHS08 GHS07 GHS05 Dgr | H350 H312 H336 H373 (Blutkreislauf) H318 H317 | Dermal: ATE = 1.100 mg/kg KG | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
606-157-00-7 | (3 E)-3-Decen-2-on | - | 18402-84-1 | Acute Tox. 4 Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 2 | H332 H304 H315 H411 | GHS07 GHS08 GHS09 Dgr | H332 H304 H315 H411 | EUH071 | Einatmung: ATE = 1,5 mg/L (Stäube oder Nebel) | ) |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
606-158-00-2 | 2-(Dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-on | 438-340-0 | 119344-86-4 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360Df H400 H410 | GHS08 GHS09 Dgr | H360Df H410 | M = 1 M = 1 | ) | |
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-001-00-0 | Ameisensäure ... % | 200-579-1 | 64-18-6 | Skin Corr. 1A | H314 | GHS05 Gef. | H314 | Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤C < 10 % Eye Irrit. 2; H319: 2 %≤ <10 % | B ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-001-00-0 | Ameisensäure % | 200-579-1 | 64-18-6 | Flam. Liq. 3 Met. Corr. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 | H226 H290 H331 H302 H314 H318 | GHS02 GHS05 GHS06 Dgr | H226 H290 H331 H302 H314 | EUH071 | Einatmung:
ATE = 7,4 mg/L (Dämpfe) Oral: ATE = 500 mg/kg KG Flam. Liq. 3; H226: C > 85 % Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; 314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤ C < 10 % Eye Dam. 1; H318: C ≥ 10 % Eye Irrit. 2; H319: 2 % ≤ C < 10 % | B ) |
607-002-00-6 | Essigsäure ... % | 200-580-7 | 64-19-7 | Flam. Liq. 3 Skin Corr. 1A | H226 H314 | GHS02 GHS05 Gef. | H226 H314 | Skin Corr. 1A; H314: C ≥90 % Skin Corr. 1B; H314: 25 %≤ C <90 % Skin Irrit. 2; H315: 10 % ≤C <25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % | B | |
607-003-00-1 | Chloressigsäure | 201-178-4 | 79-11-8 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 | H331 H311 H301 H314 H400 | GHS06 GHS05 GHS09 Gef. | H331 H311 H301 H314 H400 | STOT SE 3; H335: C≥ 5 % | ||
607-004-00-7 | TCA (ISO); Trichloressigsäure | 200-927-2 | 76-03-9 | Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Gef. | H314 H410 | STOT SE 3; H335: C ≥ 1 % | ||
607-005-00-2 | TCA-Natrium (ISO); Natriumtrichloracetat; Trichloressigsäure, Natriumsalz | 211-479-2 | 650-51-1 | STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H335 H400 H410 | GHS07 GHS09 Achtg. | H335 H410 | |||
607-006-00-8 | Oxalsäure | 205-634-3 | 144-62-7 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | * | ||
607-007-00-3 | Salze der Oxalsäure, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | * | A | |
607-008-00-9 | Essigsäureanhydrid | 203-564-8 | 108-24-7 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H226 H332 H302 H314 | GHS02 GHS05 GHS07 Gef. | H226 H332 H302 H314 | Skin Corr. 1B; H314: C ≥ 2 % Skin Irrit. 2; H315: 5 % ≤C < 25 % Eye Dam. 1; H318: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 1 % ≤C < 5 % STOT SE 3; H335: C ≥ 5 % | ||
607-009-00-4 | Phthalsäureanhydrid | 201-607-5 | 85-44-9 | Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H302 H335 H315 H318 H334 H317 | GHS08 GHS05 GHS07 Gef. | H302 H335 H315 H318 H334 H317 | |||
607-010-00-X | Propionsäureanhydrid | 204-638-2 | 123-62-6 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % | ||
607-011-00-5 | Acetylchlorid; Essigsäurechlorid | 200-865-6 | 75-36-5 | Flam. Liq. 2 Skin Corr. 1B | H225 H314 | GHS02 GHS05 Gef. | H225 H314 | EUH014 | ||
607-012-00-0 | Benzoylchlorid | 202-710-8 | 98-88-4 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H332 H312 H302 H314 H317 | GHS05 GHS07 Gef. | H332 H312 H302 H314 H317 | |||
607-013-00-6 | Dimethylcarbonat | 210-478-4 | 616-38-6 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
607-014-00-1 | Methylformiat; Ameisensäuremethylester | 203-481-7 | 107-31-3 | Flam. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 | H224 H332 H302 H319 H335 | GHS02 GHS07 Gef. | H224 H332 H302 H319 H335 | |||
607-015-00-7 | Ethylformiat; Ameisensäureethylester | 203-721-0 | 109-94-4 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 | H225 H332 H302 H319 H335 | GHS02 GHS07 Gef. | H225 H332 H302 H319 H335 | |||
607-016-00-2 | Propylformiat; Ameisensäure-n-propylester [1]; Isopropylformiat Ameisensäureisopropylester [2] | 203-798-0 [1] 210-901-2 [2] | 110-74-7 [1] 625-55-8 [2] | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 STOT SE 3 | H225 H319 H335 H336 | GHS02 GHS07 Gef. | H225 H319 H335 H336 | C | ||
607-017-00-8 | Butylformiat [1]; tert-Butylformiat [2]; Isobutylformiat [3] | 209-772-5 [1] 212-105-0 [2] 208-818-1 [3] | 592-84-7 [1] 762-75-4 [2] 542-55-2 [3] | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H335 | GHS02 GHS07 Gef. | H225 H319 H335 | C | ||
607-018-00-3 | Isopentylformiat; 3-Methylbutylformiat [1]; 2-Methylbutylformiat [2] | 203-769-2 [1] 252-343-2 [2] | 110-45-2 [1] 35073-27-9 [2] | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H335 | GHS02 GHS07 Gef. | H225 H319 H335 | C | ||
607-019-00-9 | Methylchlorformiat; Chlorameisensäuremethylester | 201-187-3 | 79-22-1 | Flam. Liq. 2 Acute Tox. 2 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H225 H330 H312 H302 H314 | GHS02 GHS06 GHS05 Gef. | H225 H330 H312 H302 H314 | |||
607-020-00-4 | Ethylchlorformiat; Chlorameisensäureethylester | 208-778-5 | 541-41-3 | Flam. Liq. 2 Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B | H225 H330 H302 H314 | GHS02 GHS06 GHS05 Gef. | H225 H330 H302 H314 | |||
607-021-00-X | Methylacetat; Essigsäuremethylester | 201-185-2 | 79-20-9 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H336 | GHS02 GHS07 Gef. | H225 H319 H336 | EUH066 | ||
607-022-00-5 | Ethylacetat; Essigsäureethylester | 205-500-4 | 141-78-6 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H336 | GHS02 GHS07 Gef. | H225 H319 H336 | EUH066 | ||
607-023-00-0 | Vinylacetat | 203-545-4 | 108-05-4 | Flam. Liq. 2 Carc. 2 Acute Tox. 4 STOT SE 3 | H225 H351 H332 H335 | GHS02 GHS08 GHS07 Gef. | H225 H351 H332 H335 | D | ||
607-024-00-6 | Propylacetat [1]; Isopropylacetat [2] | 203-686-1 [1] 203-561-1 [2] | 109-60-4 [1] 108-21-4 [2] | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 | H225 H319 H336 | GHS02 GHS07 Gef. | H225 H319 H336 | EUH066 | C | |
607-025-00-1 | n-Butylacetat | 204-658-1 | 123-86-4 | Flam. Liq. 3 STOT SE 3 | H226 H336 | GHS02 GHS07 Achtg. | H226 H336 | EUH066 | ||
607-026-00-7 | sec-Butylacetat; 1-Methylpropylacetat [1]; Isobutylacetat; 2-Methylpropylacetat [2]; tert-Butylacetat 1,1-Dimethylethylacetat [3] | 203-300-1 [1] 203-745-1 [2] 208-760-7 [3] | 105-46-4 [1] 110-19-0 [2] 540-88-5 [3] | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | EUH066 | C | |
607-027-00-2 | Methylpropionat; Propionsäuremethylester | 209-060-4 | 554-12-1 | Flam. Liq. 2 Acute Tox. 4 * | H225 H332 | GHS02 GHS07 Gef. | H225 H332 | |||
607-028-00-8 | Ethylpropionat; Propionsäureethylester | 203-291-4 | 105-37-3 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
607-029-00-3 | n-Butylpropionat [1]; sec-Butylpropionat; Propionsäure-(1-methylpropyl)ester [2]; Isobutylpropionat [3] | 209-669-5 [1] - [2] 208-746-0 [3] | 590-01-2 [1] 591-34-4 [2] 540-42-1 [3] | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | C | ||
607-030-00-9 | Propylpropionat | 203-389-7 | 106-36-5 | Flam. Liq. 3 Acute Tox. 4 * | H226 H332 | GHS02 GHS07 Achtg. | H226 H332 | |||
607-031-00-4 | Butylbutyrat | 203-656-8 | 109-21-7 | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | C | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
607-032-00-X | Ethylacrylat | 205-438-8 | 140-88-5 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H225 H332 H312 H302 H319 H335 H315 H317 | GHS02 GHS07 Gef. | H225 H332 H312 H302 H319 H335 H315 H317 | Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % STOT SE 3; H335: C ≥ 5 % | D) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
607-032-00-X | Ethylacrylat | 205-438-8 | 140-88-5 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H225 H331 H312 H302 H335 H315 H319 H317 | GHS02 GHS06 Dgr | H225 H331 H312 H302 H335 H315 H319 H317 | Inhalation:
ATE = 9 mg/L (Dämpfe) dermal: ATE = 1.800 mg/kg KG Oral: ATE = 1.120 mg/kg KG STOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % |
D) | |
607-033-00-5 | n-Butylmethacrylat | 202-615-1 | 97-88-1 | Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H226 H319 H335 H315 H317 | GHS02 GHS07 Achtg. | H226 H319 H335 H315 H317 | D | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
607-034-00-0 | Methylacrylat; Methylpropenoat | 202-500-6 | 96-33-3 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H225 H332 H312 H302 H319 H335 H315 H317 | GHS02 GHS07 Gef. | H225 H332 H312 H302 H319 H335 H315 H317 | D) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
607-034-00-0 | Methylacrylat; Methlproenoat | 202-500-6 | 96-33-3 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H225 H331 H312 H302 H335 H315 H319 H317 | GHS02 GHS06 Dgr | H225 H331 H312 H302 H335 H315 H319 H317 | Inhalation:
ATE = 3 mg/L (Dämpfe) dermal: ATE = 1.100 mg/kg KG Oral: ATE = 500 mg/kg KG |
D) | |
607-035-00-6 | Methylmethacrylat; Methyl-2-methylprop-2-enoat; Methyl-2-methylpropenoat | 201-297-1 | 80-62-6 | Flam. Liq. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H225 H335 H315 H317 | GHS02 GHS07 Gef. | H225 H335 H315 H317 | D | ||
607-036-00-1 | 2-Methoxyethylacetat; Methylglycolacetat | 203-772-9 | 110-49-6 | Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H360FD H332 H312 H302 | GHS08 GHS07 Gef. | H360FD H332 H312 H302 | |||
607-037-00-7 | 2-Ethoxyethylacetat; Ethylglycolacetat | 203-839-2 | 111-15-9 | Flam. Liq. 3 Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H226 H360FD H332 H312 H302 | GHS02 GHS08 GHS07 Gef. | H226 H360FD H332 H312 H302 | |||
607-038-00-2 | 2-Butoxyethylacetat; Butylglycolacetat | 203-933-3 | 112-07-2 | Acute Tox. 4 * Acute Tox. 4 * | H332 H312 | GHS07 Achtg. | H332 H312 | |||
607-039-00-8 | 2,4-D (ISO); 2,4-Dichlorphenoxyessigsäure | 202-361-1 | 94-75-7 | Acute Tox. 4 * STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H302 H335 H318 H317 H412 | GHS05 GHS07 Gef. | H302 H335 H318 H317 H412 | |||
607-040-00-3 | Salze der 2,4-D | - | - | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | A | ||
607-041-00-9 | 2,4,5-T (ISO); 2,4,5-Trichlorphenoxyessigsäure | 202-273-3 | 93-76-5 | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H335 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H335 H315 H410 | |||
607-042-00-4 | Salze und Ester der 2,4,5-T; Salze und Ester der 2,4,5-Trichlorphenoxyessigsäure | - | - | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H335 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H335 H315 H410 | A | ||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-043-00-X | Dicamba (ISO); 2,5-Dichlor-6-methoxybenzoesäure; 3,6-Dichlor-2-methoxybenzoesäure | 217-635-6 | 1918-00-9 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-043-00-X | Dicamba (ISO); 2,5-Dichlor-6-methoxybenzoesäure; 3,6-Dichlor-2-methoxybenzoesäure | 217-635-6 | 1918-00-9 | Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 2 | H332 H302 H335 H336 H318 H400 H411 | GHS07 GHS05 GHS09 Dgr | H332 H302 H335 H336 H318 H410 | Einatmung:
ATE = 4,0 mg/L (Stäube oder Nebel) Oral: ATE = 1.500 mg/kg KG M = 1 | ) | |
607-044-00-5 | 3,6-Dichlor- o-anissäure, Verbindung mit Dimethylamin (1:1) [1]; Kalium-3,6-dichlor- o-anisat [2] | 218-951-7 [1] 233-002-7 [2] | 2300-66-5 [1] 10007-85-9 [2] | Eye Irrit. 2 Aquatic Chronic 3 | H319 H412 | GHS07 Achtg. | H319 H412 | |||
607-045-00-0 | Dichlorprop (ISO); 2-(2,4-Dichlorphenoxy)propionsäure | 204-390-5 | 120-36-5 | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 | H312 H302 H315 H318 | GHS05 GHS07 Gef. | H312 H302 H315 H318 | |||
607-046-00-6 | Salze von Dichlorprop | - | - | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H332 H312 H302 | GHS07 Achtg. | H332 H312 H302 | A | ||
607-047-00-1 | Fenoprop (ISO); 2-(2,4,5-Trichlorphenoxy)propionsäure | 202-271-2 | 93-72-1 | Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H315 H410 | |||
607-048-00-7 | Salze von Fenoprop; Salze der 2-(2,4,5-Trichlorphenoxy)propionsäure | - | - | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | A | ||
607-049-00-2 | Mecoprop (ISO); 2-(4-Chlor- o-tolyloxy)propionsäure; (RS)-2-(4-chlor- o-tolyloxy)propionsäure [1]; 2-(4-Chlor-2-methylphenoxy)propionsäure [2] | 230-386-8 [1] 202-264-4 [2] | 7085-19-0 [1] 708519-0 [2] | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H315 H318 H410 | M=100 | ||
607-050-00-8 | Salze von Mecoprop | - | - | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H315 H318 H410 | A | ||
607-051-00-3 | MCPA (ISO); 4-Chlor- o-tolyloxyessigsäure | 202-360-6 | 94-74-6 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H315 H318 H410 | |||
607-052-00-9 | Salze und Ester von MCPA | - | - | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | A | ||
607-053-00-4 | MCPB (ISO); 4-(4-Chlor- o-tolyloxy)buttersäure | 202-365-3 | 94-81-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-054-00-X | Salze und Ester von MCPB | - | - | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | A | ||
607-055-00-5 | Endothal-Natrium (ISO); Dinatrium-7-oxabicyclo(2,2,1)heptan-2,3-dicarboxylat | 204-959-8 | 129-67-9 | Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H301 H312 H319 H335 H315 | GHS06 Gef. | H301 H312 H319 H335 H315 | |||
607-056-00-0 | Warfarin (ISO); 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-on; [1] (S)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyron; [2] (R)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyron; [3] | 201-377-6 [1] 226-907-3 [2] 226-908-9 [3] | 81-81-2 [1] 5543-57-7 [2] 5543-58-8 [3] | Repr. 1 A Acute Tox. 1 Acute Tox. 1 Acute Tox. 2 STOT RE 1 Aquatic Chronic 2 | H360D H330 H310 H300 H372 (Blut) H411 | GHS08 GHS06 GHS09 Gef. | H360D H330 H310 H300 H372 (Blut) H411 | Repr. 1 A; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 0,5 % STOT RE 2; H373 (Blut): 0,05 % ≤ C < 0,5 % | ||
607-057-00-6 | Coumachlor (ISO); 3-[1-(4-Chlorphenyl)-3-oxobutyl]-4-hydroxycoumarin | 201-378-1 | 81-82-3 | STOT RE 2 * Aquatic Chronic 3 | H373 ** H412 | GHS08 Achtg. | H373 ** H412 | |||
607-058-00-1 | Coumafuryl (ISO); Fumarin; (RS)-3-(1-(2-Furyl)-3-oxobutyl)4-hydroxycumarin; 4-Hydroxy-3-[3-oxo-1-(2-furyl)butyl]cumarin | 204-195-5 | 117-52-2 | Acute Tox. 3 * STOT RE 1 Aquatic Chronic 3 | H301 H372 ** H412 | GHS06 GHS08 Gef. | H301 H372 ** H412 | |||
607-059-00-7 | Coumatetralyl (ISO); 4-Hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)cumarin | 227-424-0 | 5836-29-3 | Repr. 1B Acute Tox. 2 Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Chronic 1 | H360D H330 H311 H300 H372 (Blut) H410 | GHS08 GHS06 GHS09 Gef. | H360D H330 H311 H300 H372 (Blut) H410 | Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 1,0 % STOT RE 2; H373 (Blut) 0,1 % ≤ C < 1,0 % M = 10 | ||
607-060-00-2 | Dicoumarol; 4,4"-Dihydroxy-3,3"-methylenbis(2 H-chromen-2-on) | 200-632-9 | 66-76-2 | STOT RE 1 Acute Tox. 4 * Aquatic Chronic 2 | H372 ** H302 H411 | GHS08 GHS07 GHS09 Gef. | H372 ** H302 H411 | |||
607-061-00-8 | Acrylsäure; Prop-2-ensäure | 201-177-9 | 79-10-7 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 | H226 H332 H312 H302 H314 H400 | GHS02 GHS05 GHS07 GHS09 Gef. | H226 H332 H312 H302 H314 H400 | STOT SE 3; H335: C ≥ 1 % | D | |
607-062-00-3 | n-Butylacrylat | 205-480-7 | 141-32-2 | Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H226 H319 H335 H315 H317 | GHS02 GHS07 Achtg. | H226 H319 H335 H315 H317 | D | ||
607-063-00-9 | Isobuttersäure; Methylpropansäure | 201-195-7 | 79-31-2 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
607-064-00-4 | Benzylchlorformiat; Chlorameisensäurebenzylester | 207-925-0 | 501-53-1 | Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Gef. | H314 H410 | STOT SE 3; H335: C ≥ 5 % | ||
607-065-00-X | Bromessigsäure | 201-175-8 | 79-08-3 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 | H331 H311 H301 H314 H317 H400 | GHS06 GHS05 GHS09 Gef. | H331 H311 H301 H314 H317 H400 | |||
607-066-00-5 | Dichloressigsäure | 201-207-0 | 79-43-6 | Skin Corr. 1A Aquatic Acute 1 | H314 H400 | GHS05 GHS09 Gef. | H314 H400 | |||
607-067-00-0 | Dichloracetylchlorid; α, α-Dichloressigsδ urechlorid | 201-199-9 | 79-36-7 | Skin Corr. 1A Aquatic Acute 1 | H314 H400 | GHS05 GHS09 Gef. | H314 H400 | |||
607-068-00-6 | Iodessigsäure | 200-590-1 | 64-69-7 | Acute Tox. 3 * Skin Corr. 1A | H301 H314 | GHS06 GHS05 Gef. | H301 H314 | |||
607-069-00-1 | Bromessigsäureethylester; Bromessigsäureethylester; Ethylbromoacetat | 203-290-9 | 105-36-2 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * | H330 H310 H300 | GHS06 Gef. | H330 H310 H300 | |||
607-070-00-7 | Chloressigsäureethylester; Chloressigsäureethylester; Ethylchloracetat | 203-294-0 | 105-39-5 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 | H331 H311 H301 H400 | GHS06 GHS09 Gef. | H331 H311 H301 H400 | |||
607-071-00-2 | Methacrylsäureethylester | 202-597-5 | 97-63-2 | Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H225 H319 H335 H315 H317 | GHS02 GHS07 Gef. | H225 H319 H335 H315 H317 | D | ||
607-072-00-8 | 2-Hydroxyethylacrylat | 212-454-9 | 818-61-1 | Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 | H311 H314 H317 H400 | GHS06 GHS05 GHS09 Gef. | H311 H314 H317 H400 | * Skin Sens. 1; H317: C ≥ 0,2 % | D | |
607-073-00-3 | 4-CPA (ISO); 4-Chlorphenoxyessigsäure | 204-581-3 | 122-88-3 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-074-00-9 | Chlorfenac (ISO); 2,3,6-Trichlorphenylessigsäure | 201-599-3 | 85-34-7 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-075-00-4 | Chlorfenprop-methyl (ISO); Methyl-2-chlor-3-(4-chlorphenyl)propionat | 238-413-5 | 14437-17-3 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
607-076-00-X | Dodine (ISO); Dodecylguanidiniumacetat | 219-459-5 | 2439-10-3 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H315 H410 | |||
607-077-00-5 | Erbon (ISO); 2-(2,4,5-Trichlorphenoxy)ethyl-2,2-dichlorpropionat | - | 136-25-4 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-078-00-0 | Fluenetil (ISO); 2-Fluorethylbiphenyl-4-ylacetat | - | 4301-50-2 | Acute Tox. 1 Acute Tox. 2 * | H310 H300 | GHS06 Gef. | H310 H300 | |||
607-079-00-6 | Kelevan (ISO); Ethyl-5-(perchlor-5-hydroxypentacyclo[5,3,0,02,6,03,9,04,8]decan-5-yl)-4-oxopentanoat; Ethyl-5-(1,2,3,5,6,7,8,9,10,10-decachlor-4-hydroxypentacyclo(5,2,1,02,6,03,9,05,8)dec-4-yl)-4-oxovalerat | - | 4234-79-1 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Chronic 2 | H311 H302 H411 | GHS06 GHS09 Gef. | H311 H302 H411 | |||
607-080-00-1 | Chloracetylchlorid; α-Chloressigsδ urechlorid | 201-171-6 | 79-04-9 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Corr. 1A Aquatic Acute 1 | H331 H311 H301 H372 ** H314 H400 | GHS06 GHS08 GHS05 GHS09 Gef. | H331 H311 H301 H372 ** H314 H400 | EUH014 EUH029 | ||
607-081-00-7 | Fluoressigsäure; Monofluoressigsäure | 205-631-7 | 144-49-0 | Acute Tox. 2 * Aquatic Acute 1 | H300 H400 | GHS06 GHS09 Gef. | H300 H400 | |||
607-082-00-2 | Monofluoracetate, lösliche | - | - | Acute Tox. 2 * Aquatic Acute 1 | H300 H400 | GHS06 GHS09 Gef. | H300 H400 | A | ||
607-083-00-8 | 2,4-DB (ISO); 4-(2,4-Dichlorphenoxy)buttersäure | 202-366-9 | 94-82-6 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-084-00-3 | Salze von 2,4-DB | - | - | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | A | ||
607-085-00-9 | Benzylbenzoat; Benzoesäurebenzylester | 204-402-9 | 120-51-4 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-086-00-4 | Diallylphthalat | 205-016-3 | 131-17-9 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
607-088-00-5 | Methacrylsäure; 2-Methylpropensäure | 201-204-4 | 79-41-4 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | STOT SE 3; H335: C ≥ 1 % | D | |
607-089-00-0 | Propionsäure ... % | 201-176-3 | 79-09-4 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H319 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % STOT SE 3; H335: C ≥ 10 % | B | |
607-090-00-6 | Thioglycolsäure; Mercaptoessigsäure; Thiolessigsäure | 200-677-4 | 68-11-1 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B | H331 H311 H301 H314 | GHS06 GHS05 Gef. | H331 H311 H301 H314 | * | ||
607-091-00-1 | Trifluoressigsäure ... % | 200-929-3 | 76-05-1 | Acute Tox. 4 * Skin Corr. 1A Aquatic Chronic 3 | H332 H314 H412 | GHS05 GHS07 Gef. | H332 H314 H412 | * | B | |
607-092-00-7 | Methyllactat [1]; Methyl-(±)-lactat [2]; Methyl-( R)-lactat [3]; Methyl-( S)-(-)-lactat [4] | 208-930-0 [1] 218-449-8 [2] 241-420-6 [3] 248-704-9 [4] | 547-64-8 [1] 2155-30-8 [2] 17392-83-5 [3] 27871-49-4 [4] | Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 | H226 H319 H335 | GHS02 GHS07 Achtg. | H226 H319 H335 | C | ||
607-093-00-2 | Propionylchlorid; Propionsäurechlorid | 201-170-0 | 79-03-8 | Flam. Liq. 2 Skin Corr. 1B | H225 H314 | GHS02 GHS05 Gef. | H225 H314 | EUH014 | B D | |
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-094-00-8 | Peressigsäure ... % | 201-186-8 | 79-21-0 | Flam. Liq. 3 Org. Perox. D **** Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 | H226 H242 H332 H312 H302 H314 H400 | GHS02 GHS05 GHS07 GHS09 Gef. | H226 H242 H332 H312 H302 H314 H400 | * STOT SE 3; H335: C ≥ 1 % | B D ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-094-00-8 | Peressigsäure... % | 201-186-8 | 79-21-0 | Org. Perox.
D Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 | H242 H330 H310 H301 H314 H400 H410 | GHS02 GHS06 GHS05 GHS09 Dgr | H242 H330 H310 H301 H314 H410 | EUH071 | Einatmung:
ATE = 0,2 mg/L (Stäube oder Nebel) Dermal: ATE = 60 mg/kg KG Oral: ATE = 80 mg/kg KG STOT SE 3; H335: C ≥ 1 % M = 10 M = 100 | B, D, T ) |
607-095-00-3 | Maleinsäure | 203-742-5 | 110-16-7 | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H302 H319 H335 H315 H317 | GHS07 Achtg. | H302 H319 H335 H315 H317 | Skin Sens. 1; H317: C ≥0,1 % | ||
607-096-00-9 | Maleinsäureanhydrid | 203-571-6 | 108-31-6 | Acute Tox. 4 STOT RE 1 Skin Corr. 1B Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A | H302 H372 (Atmungsorgane) (Einatmung) H314 H318 H334 H317 | GHS07 GHS08 GHS05 Dgr | H302 H372 (Atmungsorgane) (Einatmung) H314 H334 H317 | EUH071 | Skin Sens. 1A; H317: C ≥ 0,001 % | |
607-097-00-4 | 1,2,4-Benzoltricarbonsäure-1,2-anhydrid; Trimellitsäureanhydrid | 209-008-0 | 552-30-7 | STOT SE 3 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H335 H318 H334 H317 | GHS08 GHS05 GHS07 Gef. | H335 H318 H334 H317 | |||
607-098-00-X | 1,2,4,5-Benzoltetracarbonsäuredianhydrid; Pyromellitsäuredianhydrid | 201-898-9 | 89-32-7 | Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H318 H334 H317 | GHS08 GHS05 Gef. | H318 H334 H317 | |||
607-099-00-5 | 1,2,3,6-Tetrahydrophthaleinsäureanhydrid [1]; cis-1,2,3,6-Tetrahydrophthaleinsäureanhydrid [2]; 3,4,5,6-Tetrahydrophthalein-säureanhydrid [3]; Tetrahydrophthaleinsäureanhydrid [4] | 201-605-4 [1] 213-308-7 [2] 219-374-3 [3] 247-570-9 [4] | 85-43-8 [1] 935-79-5 [2] 2426-02-0 [3] 26266-63-7 [4] | Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H334 H317 H412 | GHS08 GHS05 Gef. | H318 H334 H317 H412 | C | ||
607-100-00-9 | 3,3",4,4"-Benzophenontetracarbonsäuredianhydrid; 4,4"-Carbonyldiphthaleinsäureanhydrid | 219-348-1 | 2421-28-5 | Eye Irrit. 2 STOT SE 3 | H319 H335 | GHS07 Achtg. | H319 H335 | Eye Irrit 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % | ||
607-101-00-4 | 1,4,5,6,7,7-Hexachlorbicyclo-[2,2,1]hept-5-en-2,3-dicarbonsäureanhydrid; Chlorendicanhydrid | 204-077-3 | 115-27-5 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | Skin Irrit.2; H315: C ≥ 1 % Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % | ||
607-102-00-X | Cyclohexan-1,2-dicarbonsäureanhydrid [1]; cis-Cyclohexan-1,2-dicarbonsäureanhydrid [2]; trans-Cyclohexan-1,2-dicarbonsäureanhydrid [3] | 201-604-9 [1] 236-086-3 [2] 238-009-9 [3] | 85-42-7 [1] 13149-00-3 [2] 14166-21-3 [3] | Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H318 H334 H317 | GHS08 GHS05 Gef. | H318 H334 H317 | C | ||
607-103-00-5 | Bernsteinsäureanhydrid | 203-570-0 | 108-30-5 | Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H302 H314 H318 H334 H317 | GHS07 GHS05 GHS08 Dgr | H302 H314 H334 H317 | EUH071 | ||
607-104-00-0 | 1,2,3,4-Cyclopentantetracarbonsäuredianhydrid | 227-964-7 | 6053-68-5 | Eye Irrit. 2 STOT SE 3 | H319 H335 | GHS07 Achtg. | H319 H335 | Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % | ||
607-105-00-6 | endo-3,6-Methylen-1,2,3,6-tetrahydrophthalsäureanhydrid [1]; 1,2,3,6-tetrahydro-3,6-methanophthalsäureanhydrid [2]; exo-3,6-Methylen-1,2,3,6-tetrahydrophthalsäureanhydrid [3] | 204-957-7 [1] 212-557-9 [2] 220-384-5 [3] | 129-64-6 [1] 826-62-0 [2] 2746-19-2 [3] | Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H318 H334 H317 | GHS08 GHS05 Gef. | H318 H334 H317 | C | ||
607-106-00-1 | 8,9-Dinorborn-5-en-2,3-dicarbonsäureanhydrid | - | 123748-85-6 | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H302 H319 H335 H315 H334 | GHS08 GHS07 Gef. | H302 H319 H335 H315 H334 | STOT SE 3; H335: C ≥ 10 % | C | |
607-107-00-7 | 2-Ethylhexylacrylat; Hexamethylendiacrylat | 203-080-7 | 103-11-7 | STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H335 H315 H317 | GHS07 Achtg. | H335 H315 H317 | D | ||
607-108-00-2 | 2-Hydroxy-1-methylethylacrylat [1]; 2-Hydroxypropylacrylat [2]; Acrylsäure, Monoester mit Propan-1,2-diol [3] | 220-852-9 [1] 213-663-8 [2] 247-118-0 [3] | 2918-23-2 [1] 999-61-1 [2] 25584-83-2 [3] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 | H331 H311 H301 H314 H317 | GHS06 GHS05 Gef. | H331 H311 H301 H314 H317 | * Skin Sens. 1; H317:C ≥0,2 % | C D | |
607-109-00-8 | Hexamethylendiacrylat; Hexan-1,6-dioldiacrylat | 235-921-9 | 13048-33-4 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | D | ||
607-110-00-3 | Pentaerythritoltriacrylat | 222-540-8 | 3524-68-3 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | D | ||
607-111-00-9 | 2-Ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propandiyldiacrylat; 2,2-Bis(acryloyloxymethyl)butylacrylat; Trimethylolpropantriacrylat | 239-701-3 | 15625-89-5 | Carc. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H315 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H315 H319 H317 H410 | M = 1 M = 1 | D | |
607-112-00-4 | 2,2-Dimethylpropandiol-1,3-diacrylat; Neopentylglycoldiacrylat | 218-741-5 | 2223-82-7 | Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H311 H319 H315 H317 | GHS06 Gef. | H311 H319 H315 H317 | * | D | |
607-113-00-X | Isobutylmethacrylat | 202-613-0 | 97-86-9 | Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Skin Sens. 1B | H226 H335 H315 H317 | GHS02 GHS07 Wng | H226 H335 H315 H317 | D | ||
607-114-00-5 | Ethylendimethacrylat; Ethylenglykoldimethacrylat | 202-617-2 | 97-90-5 | STOT SE 3 Skin Sens. 1 | H335 H317 | GHS07 Achtg. | H335 H317 | STOT SE 3; H335: C ≥ 10 % | D | |
607-115-00-0 | Isobutylacrylat; 2-Methylpropylacrylat | 203-417-8 | 106-63-8 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 | H226 H332 H312 H315 H317 | GHS02 GHS07 Achtg. | H226 H332 H312 H315 H317 | D | ||
607-116-00-6 | Cyclohexylacrylat | 221-319-3 | 3066-71-5 | STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 | H335 H315 H411 | GHS07 GHS09 Achtg. | H335 H315 H411 | STOT SE 3; H335: C ≥ 10 % | D | |
607-117-00-1 | 2,3-Epoxypropylacrylat; Glycidylacrylat | 203-440-3 | 106-90-1 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 | H331 H311 H301 H314 H317 | GHS06 GHS05 Gef. | H331 H311 H301 H314 H317 | * Skin Sens. 1; H317:C ≥0,2 % | D | |
607-118-00-7 | Butan-1,3-diyldiacrylat | 243-105-9 | 19485-03-1 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H312 H314 H317 | GHS05 GHS07 Gef. | H312 H314 H317 | D | ||
607-119-00-2 | 1,4-Butandiyldiacrylat | 213-979-6 | 1070-70-8 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H312 H314 H317 | GHS05 GHS07 Gef. | H312 H314 H317 | D | ||
607-120-00-8 | OxydiethylendiacrylatDiethylenglycoldiacrylat; 2,2"-Oxydiethyldiacrylat | 223-791-6 | 4074-88-8 | Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H311 H319 H315 H317 | GHS06 Gef. | H311 H319 H315 H317 | * Skin Sens. 1; H317:C≥0,2 % | D | |
607-121-00-3 | 2-Norbornylacrylat; Bicyclo[2.2.1]-2-ylacrylat | - | 10027-06-2 | Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 | H312 H315 H317 | GHS07 Achtg. | H312 H315 H317 | D | ||
607-122-00-9 | Pentaerythritoltetraacrylat | 225-644-1 | 4986-89-4 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | D | ||
607-123-00-4 | 2,3-Epoxypropylmethacrylat; Glycidylmethacrylat | 203-441-9 | 106-91-2 | Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 1 Eye Dam. 1 Skin Corr. 1C Skin Sens. 1 | H350 H341 H360F H311 H302 H335 H372 (Atemwege) (Einatmung) H318 H314 H317 | GHS08 GHS06 GHS05 Gef. | H350 H341 H360F H311 H302 H335 H372 (Atemwege) (Einatmung) H314 H317 | D | ||
607-124-00-X | 2-Hydroxyethylmethacrylat | 212-782-2 | 868-77-9 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | D | ||
607-125-00-5 | 2-Hydroxypropylmethacrylat [1]; 3-Hydroxypropylmethacrylat [2] | 213-090-3 [1] 220-426-2 [2] | 923-26-2 [1] 2761-09-3 [2] | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | C D | ||
607-126-00-0 | Triethylenglycoldiacrylat | 216-853-9 | 1680-21-3 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | D | ||
607-127-00-6 | 2-Diethylaminoethylmethacrylat | 203-275-7 | 105-16-8 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H332 H319 H315 H317 | GHS07 Achtg. | H332 H319 H315 H317 | D | ||
607-128-00-1 | 2- tert-Butylaminoethylmethacrylat | 223-228-4 | 3775-90-4 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | D | ||
607-129-00-7 | Ethyllactat; Ethyl-DL-lactat [1]; Ethyl-(S)-2-hydroxypropionat; Ethyl-L-lactat; Ethyl-(S)-lactat [2] | 202-598-0 [1] 211-694-1 [2] | 97-64-3 [1] 687-47-8 [2] | Flam. Liq. 3 STOT SE 3 Eye Dam. 1 | H226 H335 H318 | GHS02 GHS05 GHS07 Gef. | H226 H335 H318 | C | ||
607-130-00-2 | Pentylacetat; Amylacetat [1]; Isopentylacetat; 3-Methylbutylacetat [2]; 1-Methylbutylacetat [3]; 2-Methylbutylacetat [4]; 2(oder 3)-Methylbutylacetat [5] | 211-047-3 [1] 204-662-3 [2] 210-946-8 [3] 210-843-8 [4] 282-263-3 [5] | 628-63-7 [1] 123-92-2 [2] 626-38-0 [3] 624-41-9 [4] 84145-37-9 [5] | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | EUH066 | C | |
607-131-00-8 | Isopentylpropionat; Propionsäure-3-methylbutylester [1]; Pentylpropionat; Amylpropionat [2]; 2-Methylbutylpropionat [3] | 203-322-1 [1] 210-852-7 [2] 219-449-0 [3] | 105-68-0 [1] 624-54-4 [2] 2438-20-2 [3] | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | C | ||
607-132-00-3 | 2-Dimethylaminoethylmethacrylat | 220-688-8 | 2867-47-2 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H312 H302 H319 H315 H317 | GHS07 Achtg. | H312 H302 H319 H315 H317 | D | ||
607-133-00-9 | Monoalkyl- oder Monoaryl- oder Monoalkylarylester der Acrylsäure, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 | H319 H335 H315 H411 | GHS07 GHS09 Achtg. | H319 H335 H315 H411 | STOT SE 3; H335: C ≥ 10 % | A | |
607-134-00-4 | Monoalkyl- oder Monoaryl- oder Monoalkyarylester der Methacrylsäure, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | STOTSE 3; H335: C ≥ 10 % | A | |
607-135-00-X | Buttersäure; Butansäure | 203-532-3 | 107-92-6 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
607-136-00-5 | Butyrylchlorid; Buttersäurechlorid | 205-498-5 | 141-75-3 | Flam. Liq. 2 Skin Corr. 1B | H225 H314 | GHS02 GHS05 Gef. | H225 H314 | |||
607-137-00-0 | Methylacetoacetat; Acetessigsäuremethylester | 203-299-8 | 105-45-3 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-138-00-6 | Butylchlorformiat; Chlorameisensäurebutylester | 209-750-5 | 592-34-7 | Flam. Liq. 3 Acute Tox. 3 * Skin Corr. 1B | H226 H331 H314 | GHS02 GHS06 GHS05 Gef. | H226 H331 H314 | |||
607-139-00-1 | 2-Chlorpropionsäure | 209-952-3 | 598-78-7 | Acute Tox. 4 * Skin Corr. 1A | H302 H314 | GHS05 GHS07 Gef. | H302 H314 | |||
607-140-00-7 | Isobutyrylchlorid; Isobuttersäurechlorid | 201-194-1 | 79-30-1 | Flam. Liq. 2 Skin Corr. 1A | H225 H314 | GHS02 GHS05 Gef. | H225 H314 | |||
607-141-00-2 | Oxydiethylenbis(chlorformiat) | 203-430-9 | 106-75-2 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H302 H315 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H315 H318 H411 | |||
607-142-00-8 | Propylchlorformiat; Chlorameisensäurepropylester; n-Propylchlorformiat | 203-687-7 | 109-61-5 | Flam. Liq. 2 Acute Tox. 3 * Skin Corr. 1B | H225 H331 H314 | GHS02 GHS06 GHS05 Gef. | H225 H331 H314 | |||
607-143-00-3 | Valeriansäure; Pentansäure | 203-677-2 | 109-52-4 | Skin Corr. 1B Aquatic Chronic 3 | H314 H412 | GHS05 Gef. | H314 H412 | |||
607-144-00-9 | Adipinsäure | 204-673-3 | 124-04-9 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-145-00-4 | Methansulfonsäure | 200-898-6 | 75-75-2 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
607-146-00-X | Fumarsäure | 203-743-0 | 110-17-8 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-147-00-5 | Oxalsäurediethylester; Diethyloxalat | 202-464-1 | 95-92-1 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
607-148-00-0 | Guanidiniumchlorid; Guanadinhydrochlorid | 200-002-3 | 50-01-1 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 | H302 H319 H315 | GHS07 Achtg. | H302 H319 H315 | |||
607-149-00-6 | Urethan (INN); Ethylcarbamat | 200-123-1 | 51-79-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
607-150-00-1 | Endothal (ISO);7-Oxabicyclo(2,2,1)heptan-2,3-dicarbonsäure | 205-660-5 | 145-73-3 | Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H301 H312 H319 H335 H315 | GHS06 Gef. | H301 H312 H319 H335 H315 | |||
607-151-00-7 | Propargit (ISO); 2-(4- tert-Butylphenoxy)cyclohexylprop-2-ynylsulfit | 219-006-1 | 2312-35-8 | Carc. 2 Acute Tox. 3 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H331 H315 H318 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H351 H331 H315 H318 H410 | M = 10 | ||
607-152-00-2 | 2,3,6-TBA (ISO); 2,3,6-Trichlorbenzoesäure | 200-026-4 | 50-31-7 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-153-00-8 | Benazolin (ISO); 4-Chlor-2-oxobenzothiazolin-3-ylessigsäure | 223-297-0 | 3813-05-6 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3 | H319 H315 H412 | GHS07 Achtg. | H319 H315 H412 | |||
607-154-00-3 | Ethyl- N-benzoyl- N-(3,4-dichlorphenyl)-DL-alaninat; Benzoylprop-ethyl (ISO) | 244-845-5 | 22212-55-1 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
607-155-00-9 | 3-(3-Amino-5-(1-methylguanidino)-1-oxopentylamino-6-(4-amino-2-oxo-2,3-dihydro-pyrimidin-1-yl)-2,3-dihydro-(6 H)-pyran-2-carbonsäure; Blasticidin-s | - | 2079-00-7 | Acute Tox. 2 * | H300 | GHS06 Gef. | H300 | |||
607-156-00-4 | Chlorfenson (ISO); 4-Chlorphenyl-4-chlorbenzolsulfonat | 201-270-4 | 80-33-1 | Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H315 H410 | |||
607-157-00-X | Difenacoum (ISO); 3-(3-Biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycumarin | 259-978-4 | 56073-07-5 | Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H310 H300 H372 (Blut) H400 H410 | GHS08 GHS06 GHS09 Gef. | H360D H330 H310 H300 H372 (Blut) H410 | Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 0,02 % STOT RE 2; H373 (Blut): 0,002 % ≤ C < 0,02 % M = 10 M = 10 | ||
607-158-00-5 | Natriumsalz der Chloressigsäure, Natriumchloracetat | 223-498-3 | 3926-62-3 | Acute Tox. 3 * Skin Irrit. 2 Aquatic Acute 1 | H301 H315 H400 | GHS06 GHS09 Gef. | H301 H315 H400 | |||
607-159-00-0 | Chlorobenzilat (ISO); Ethyl-4,4"-dichlorbenzilat; Ethyl-2,2-di(4-chlorphenyl)-2-hydroxyacetat | 208-110-2 | 510-15-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
607-160-00-6 | Isobutyl-2-(4-(4-chlorphenoxy)phenoxy)propionat; Clofop-isobutyl (ISO) | - | 51337-71-4 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-161-00-1 | Diethanolaminsalz von 4-CPA | - | - | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-162-00-7 | Dalapon; 2,2-Dichlorpropionsäure [1]; Dalaponnatrium; Natrium-2,2-dichlorpropionat[2] | 200-923-0 [1] 204-828-5 [2] | 75-99-0 [1] 127-20-8 [2] | Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H315 H318 H412 | GHS05 Gef. | H315 H318 H412 | |||
607-163-00-2 | 3-Acetyl-6-methyl-2 H-pyran-2,4(3 H)-dion; Dehydracetsäure | 208-293-9 | 520-45-6 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-164-00-8 | Natrium-1-(3,4-dihydro-6-methyl-2,4-dioxo-2 H-pyran-3-yliden)ethonolat; Natriumdehydracetat | 224-580-1 | 4418-26-2 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-165-00-3 | Diclofop-methyl (ISO); Methyl-2-(4-(2,4-dichlorphenoxy)phenoxy)propionat; Methyl-( RS)-2-[4-(2,4-dichlorphenoxy)phenoxy]propionat | 257-141-8 | 51338-27-3 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
607-166-00-9 | Medinoterbacetat (ISO); 6- tert-Butyl-3-methyl-2,4-dinitrophenylacetat | 219-634-6 | 2487-01-6 | Acute Tox. 3 * Acute Tox. 4 * | H301 H312 | GHS06 Gef. | H301 H312 | |||
607-167-00-4 | Natrium-3-chloracrylat | - | 4312-97-4 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
607-168-00-X | Dipropyl-6,7-methylendioxy-1,2,3,4-tetrahydro-3-methylnaphthalin-1,2-dicarboxylat; Propylisom | - | 83-59-0 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H311 H302 H400 H410 | GHS06 GHS09 Gef. | H311 H302 H410 | |||
607-169-00-5 | Natriumfluoracetat | 200-548-2 | 62-74-8 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 | H330 H310 H300 H400 | GHS06 GHS09 Gef. | H330 H310 H300 H400 | |||
607-170-00-0 | Bis(1,2,3-trithiacyclohexyldimethylammonium)oxalat; Thiocyclamoxalat | 250-859-2 | 31895-22-4 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
607-172-00-1 | Brodifacoum (ISO); 4-Hydroxy-3-(3-(4′-brom-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)cumarin | 259-980-5 | 56073-10-0 | Repr. 1 A Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H310 H300 H372 (Blut) H400 H410 | GHS08 GHS06 GHS09 Gef. | H360D H330 H310 H300 H372 (Blut) H410 | Repr. 1 A; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 0,02 % STOT RE 2; H373 (Blut): 0,002 % ≤ C < 0,02 % M = 10 M = 10 | ||
607-173-00-7 | Dimethyl-(3-methyl-4-(5-nitro-3-ethoxycarbonyl-2-thienyl)azo)phenylnitrilodipropionat | 400-460-6 | - | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-174-00-2 | Reaktionsmasse aus Dodecyl-3-(2,2,4,4-tetramethyl-21-oxo-7-oxa-3,20-diazadispiro(5,1,11,2)henicosan-20-yl)propionat und Tetradecyl-3-(2,2,4,4-tetramethyl-21-oxo-7-oxa-3,20-diazadispiro(5,1,11,2)henicosan-20-yl)propionat | 400-580-9 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
607-175-00-8 | Methyl-2-(2-nitrobenzyliden)acetoacetat | 400-650-9 | 39562-27-1 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-176-00-3 | Reaktionsmasse aus α-3-(3-(2 H-Benzotriazol-2-yl)-5- tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylen) und α-3-(3-(2 H-Benzotriazol-2-yl)-5- tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2 H-benzotriazol-2-yl)-5- tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylen) | 400-830-7 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-177-00-9 | Tribenuron-methyl (ISO); Methyl-2-[ N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl) - N-methylcarbamoylsulfamoyl]benzoat | 401-190-1 | 101200-48-0 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H373 H317 H410 | M = 100 M = 100 | ||
607-178-00-4 | Methyl-α-((4,6-dimethoxypyrimidin-2-yl)ureidosulfonyl)- o-toluat | 401-340-6 | 83055-99-6 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-179-00-X | (Benzothiazol-2-ylthio)bernsteinsäure | 401-450-4 | 95154-01-1 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-180-00-5 | Kalium-2-hydroxycarbazol-1-carboxylat | 401-630-2 | 96566-70-0 | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Aquatic Chronic 3 | H302 H319 H335 H412 | GHS07 Achtg. | H302 H319 H335 H412 | |||
607-181-00-0 | 3,5-Dichlor-2,4-difluorbenzoylfluorid | 401-800-6 | 101513-70-6 | Acute Tox. 3 * Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H331 H314 H302 H317 H412 | GHS06 GHS05 Gef. | H331 H314 H302 H317 H412 | EUH029 | ||
607-182-00-6 | Methyl-3-sulfamoyl-2-thenoat | 402-050-2 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-183-00-1 | Zink-2-hydroxy-5-C13-18-alkylbenzoat | 402-280-3 | - | Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H319 H315 H411 | GHS07 GHS09 Achtg. | H319 H315 H411 | |||
607-184-00-7 | S-(3-Trimethoxysilyl)propyl-19-isocyanato-11-(6-isocyanatohexyl)-10,12-dioxo-2,9,11,13-tetraazanonadecanthioat | 402-290-8 | 85702-90-5 | Flam. Liq. 3 Resp. Sens. 1 Skin Sens. 1 | H226 H334 H317 | GHS02 GHS08 Gef. | H226 H334 H317 | |||
607-185-00-2 | Ethyl- trans-3-dimethylaminoacrylat | 402-650-4 | 1117-37-9 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-186-00-8 | Quinclorac (ISO); 3,7-Dichlorchinolin-8-carbonsäure | 402-780-1 | 84087-01-4 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-187-00-3 | Bis(2,2,6,6-tetramethyl-4-piperidyl)succinat | 402-940-0 | 62782-03-0 | Eye Irrit. 2 Aquatic Chronic 3 | H319 H412 | GHS07 Achtg. | H319 H412 | |||
607-188-00-9 | Hydrogennatrium- N-carboxylatoethyl- N-octadec-9-enylmaleamat | 402-970-4 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-189-00-4 | Trimethylendiamintetraessigsäure | 400-400-9 | 1939-36-2 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
607-190-00-X | Methylacrylamidomethoxyacetat (mit ≥ 0,1 % Acrylamid) | 401-890-7 | 77402-03-0 | Carc. 1B Muta. 1B Acute Tox. 4 * Eye Irrit. 2 | H350 H340 H302 H319 | GHS08 GHS07 Gef. | H350 H340 H302 H319 | |||
607-191-00-5 | Isobutyl-3,4-epoxybutyrat | 401-920-9 | 100181-71-3 | Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H315 H317 H410 | |||
607-192-00-0 | Dinatrium- N-carboxymethyl- N-(2-(2-hydroxyethoxy)ethyl)glycinat | 402-360-8 | 92511-22-3 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-194-00-1 | Propylencarbonat | 203-572-1 | 108-32-7 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-195-00-7 | 2-Methoxy-1-methylethylacetat; 1-Methoxypropylacetat-2 | 203-603-9 | 108-65-6 | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | |||
607-196-00-2 | Heptansäure | 203-838-7 | 111-14-8 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
607-197-00-8 | Nonansäure | 203-931-2 | 112-05-0 | Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 | H315 H319 H412 | GHS07 Achtg. | H315 H319 H412 | |||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-198-00-3 | Propyl-3,4,5-trihydroxybenzoat; 3,4,5- Trihydroxybenzoesäurepropylester | 204-498-2 | 121-79-9 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-198-00-3 | Propyl-3,4,5-trihydroxybenzoat | 204-498-2 | 121-79-9 | Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Wng | H302 H317 H410 | Oral: ATE = 1.700 mg/kg KG M = 1 M = 1 | ) | |
607-199-00-9 | Octyl-3,4,5-trihydroxybenzoat; 3,4,5- Trihydroxybenzoesäureoctylester | 213-853-0 | 1034-01-1 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
607-200-00-2 | Dodecyl-3,4,5-trihydroxybenzoat; 3,4,5- Trihydroxybenzoesäuredodecylester | 214-620-6 | 1166-52-5 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-201-00-8 | Thiocarbonylchlorid, Thiophosgen | 207-341-6 | 463-71-8 | Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H331 H302 H319 H335 H315 | GHS06 Gef. | H331 H302 H319 H335 H315 | |||
607-203-00-9 | 2-Ethylhexyl[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]thio]acetat | 279-452-8 | 80387-97-9 | Repr. 1B Skin Sens. 1 Aquatic Chronic 3 | H360D *** H317 H412 | GHS08 GHS07 Gef. | H360D *** H317 H412 | |||
607-204-00-4 | (Chlorphenyl)(chlortolyl)methan, Isomerengemisch | 400-140-6 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-205-00-X | Methylchloracetat, Chloressigsäuremethylester | 202-501-1 | 96-34-4 | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 | H226 H331 H301 H335 H315 H318 | GHS02 GHS06 GHS05 Gef. | H226 H331 H301 H335 H315 H318 | |||
607-206-00-5 | Isopropylchloracetat; Chloressigsäureisopropylester | 203-301-7 | 105-48-6 | Flam. Liq. 3 Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H226 H301 H319 H335 H315 | GHS02 GHS06 Gef. | H226 H301 H319 H335 H315 | |||
607-207-00-0 | Haloxyfop-etotyl (ISO); 2-Ethoxyethyl-2-(4-(3-chlor-5-trifluormethyl-2-pyridyloxy)phenoxy)propionat; Haloxyfop-(2-ethoxyethyl) | 402-560-5 | 87237-48-7 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
607-208-00-6 | 4,8,12-Trimethyltrideca-3,7,11-triensäure, Isomerengemisch | 403-000-2 | 91853-67-7 | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
607-209-00-1 | Reaktionsmasse aus O, O"-Diisopropyl-(pentathio)dithioformiat und O, O"-Diisopropyl-(trithio)dithioformiat und O, O"-Diisopropyl-(tetrathio)dithioformiat | 403-030-6 | - | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
607-210-00-7 | Methylacrylamidoglycolat (mit ≥ 0,1 % Acrylamid) | 403-230-3 | 77402-05-2 | Carc. 1B Muta. 1B Skin Corr. 1B Skin Sens. 1 | H350 H340 H314 H317 | GHS08 GHS05 GHS07 Gef. | H350 H340 H314 H317 | |||
607-211-00-2 | Methyl-3-(3- tert-butyl-4-hydroxy-5-methylphenyl)propionat | 403-270-1 | 6386-39-6 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-212-00-8 | Poly(oxypropylencarbonyl-co-oxy(ethylethylen)carbonyl), mit 27 % Hydroxyvalerat | 403-300-3 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-213-00-3 | Ethyl-3,3-bis( tert-pentylperoxy)butyrat | 403-320-2 | 67567-23-1 | Org. Perox.
D**** Flam. Liq. 3 Aquatic Chronic 2 | H242 H226 H411 | GHS02 GHS09 Gef. | H242 H226 H411 | |||
607-214-00-9 | N, N-Hydrazinodiessigsäure | 403-510-5 | 19247-05-3 | Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 | H301 H373 ** H317 H412 | GHS06 GHS08 Gef. | H301 H373 ** H317 H412 | |||
607-215-00-4 | 3-(3- tert-Butyl-4-hydroxyphenyl)propionsäure | 403-920-4 | 107551-67-7 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
607-216-00-X | Glutaminsäure, Produkte der Reaktion mit N-(C12-14-Alkyl)propylendiamin | 403-950-8 | - | Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 | H330 H302 H314 H400 | GHS06 GHS05 GHS09 Gef. | H330 H302 H314 H400 | |||
607-217-00-5 | 2-Ethoxyethyl-2-(4-(2,6-dihydro-2,6-dioxo-7-phenyl-1,5-dioxaindacen-3-yl)phenoxy)acetat | 403-960-2 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
607-218-00-0 | Dichlorprop-P (ISO); (+)- R-2-(2,4-Dichlorphenoxy)propionsäure | 403-980-1 | 15165-67-0 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H302 H315 H318 H317 | GHS05 GHS07 Gef. | H302 H315 H318 H317 | |||
607-219-00-6 | Bis(2-ethylhexyl)dithiodiacetat | 404-510-8 | 62268-47-7 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
607-221-00-7 | 6-Docosyloxy-1-hydroxy-4-(1-(4-hydroxy-3-methylphenanthren-1-yl)-3-oxo-2-oxaphenalen-1-yl)naphthalin-2-carbonsäure | 404-550-6 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
607-222-00-2 | 6-(2,3-Dimethylmaleimido)hexylmethacrylat | 404-870-6 | 63740-41-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
607-223-00-8 | Transfluthrin (ISO); 2,3,5,6-Tetrafluorbenzyl- trans-2-(2,2-dichlorvinyl)-3,3-dimethylcyclopropancarboxylat | 405-060-5 | 118712-89-3 | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
607-223-00-8 | Transfluthrin (ISO); 2,3,5,6-Tetrafluorbenzyl (1 R,3 S)-3-(2,2-dichlorvinyl)-2,2-dimethylcyclopropancarboxylat | 405-060-5 | 118712-89-3 | Carc. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H370 (Nervensystem) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H370 (Nervensystem) H410 | EUH066 | Oral: ATE = 580 mg/kg KG M = 1.000 M = 1.000 | ) |
607-224-00-3 | Methyl-2-(3-nitrobenzyliden)acetoacetat | 405-270-7 | 39562-17-9 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
607-225-00-9 | 3-Azidosulfonylbenzoesäure | 405-310-3 | 15980-11-7 | Self-React.
C **** STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H241 H373 ** H318 H317 | GHS02 GHS08 GHS05 GHS07 Gef. | H241 H373 ** H318 H317 | |||
607-226-00-4 | Reaktionsmasse aus 2-Acryloyloxyethylhydrogencyclohexan-1,2-dicarboxylat und 2-Methacryloyloxyethylhydrogencyclohexan-1,2-dicarboxylat | 405-360-6 | - | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H315 H318 H317 H412 | GHS05 GHS07 Gef. | H315 H318 H317 H412 | |||
607-227-00-X | Kalium-2-amino-2-methylpropionatoctahydrat | 405-560-3 | 120447-91-8 | Acute Tox. 4 * Skin Corr. 1A | H302 H314 | GHS05 GHS07 Gef. | H302 H314 | |||
607-228-00-5 | Bis(2-methoxyethyl)phthalat | 204-212-6 | 117-82-8 | Repr. 1B | H360Df | GHS08 Gef. | H360Df | |||
607-229-00-0 | Diethylcarbamoylchlorid | 201-798-5 | 88-10-8 | Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H351 H332 H302 H319 H335 H315 | GHS08 GHS07 Achtg. | H351 H332 H302 H319 H335 H315 | |||
(Gültig bis 31.01.2025 gem. VO (EU) 2023/1435 | ||||||||||
607-230-00-6 | 2-Ethylhexansäure und ihre Salze, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Repr. 1B | H360D | GHS08 Dgr | H360D | ) ) | ||
(Gültig ab 01.02.2025 gem. VO (EU) 2023/1435 | ||||||||||
607-230-00-6 | 2-Ethylhexansäure und ihre Salze, soweit in diesem Anhang nicht gesondert aufgeführt |
- |
- | Repr. 1B | H360D | GHS08 Dgr | H360D | A, X, 12 ) | ||
607-231-00-1 | Clopyralid (ISO); 3,6-Dichlorpyridine-2-carbonsäure | 216-935-4 | 1702-17-6 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-232-00-7 | Pyridat (ISO); O-(6-Chlor-3-phenylpyridazin-4-yl)-S-octylthiocarbonat | 259-686-7 | 55512-33-9 | Acute Tox. 4 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H317 H400 H410 | GHS07 GHS09 Wng | H302 H315 H317 H410 | Oral: ATE = 500 mg/kg KG M = 1 M = 10 | ||
607-233-00-2 | Hexylacrylat | 219-698-5 | 2499-95-8 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H319 H335 H315 H317 H411 | GHS07 GHS09 Achtg. | H319 H335 H315 H317 H411 | |||
607-234-00-8 | Flurenol (ISO); 9-Hydroxy-9 H-fluoren-9-carbonsäure | 207-397-1 | 467-69-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-235-00-3 | Mecrilat,; Methyl-2-cyanacrylatcyanoacrylat | 205-275-2 | 137-05-3 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | STOT SE 3; H335: C ≥ 10 % | ||
607-236-00-9 | Ethyl-2-cyanacrylat | 230-391-5 | 7085-85-0 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | STOT SE 3; H335: C ≥ 10 % | ||
607-237-00-4 | Benzyl-2-chlor-4-(trifluormethyl)thiazol-5-carboxylat; Flurazol | 276-942-3 | 72850-64-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-238-00-X | Tau-Fluvalinat (ISO); N-(2-Chlor-4-(trifluormethyl)phenyl)-D-valincyano(3-phenoxyphenyl)methylester | - | 102851-06-9 | Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H315 H400 H410 | GHS07 GHS09 Achtg. | H302 H315 H410 | |||
607-239-00-5 | Fenpropathrin (ISO); α-Cyan-3-phenoxybenzyl-2,2,3,3-tetramethylcyclopropancarboxylat | 254-485-0 | 39515-41-8 | Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H301 H312 H400 H410 | GHS06 GHS09 Gef. | H330 H301 H312 H410 | |||
607-240-00-0 | cis-1,2,3,6-Tetrahydro-4-methylphthalsäureanhydrid [1]; 1,2,3,6-Tetrahydro-4-methylphthalsäureanhydrid [2]; 1,2,3,6-Tetrahydro-3-methylphthalsäureanhydrid [3]; Tetrahydromethylphthalsäureanhydrid [4]; 1,2,3,6-Tetrahydromethylphthalsäureanhydrid [5]; Tetrahydro-4-methylphthalsäureanhydrid [6]; 2,3,5,6-Tetrahydro-2-methylphthalsäureanhydrid [7] | 216-906-6 [1] 222-323-8 [2] 226-247-6 [3] 234-290-7 [4] 247-830-1 [5] 251-823-9 [6] 255-853-3 [7] | 1694-82-2 [1] 3425-89-6 [2] 5333-84-6 [3] 11070-44-3 [4] 26590-20-5 [5] 34090-76-1 [6] 42498-58-8 [7] | Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H318 H334 H317 | GHS08 GHS05 Gef. | H318 H334 H317 | C | ||
607-241-00-6 | Hexahydro-4-methylphthalsäureanhydrid [1]; Hexahydromethylphthalsäureanhydrid [2]; Hexahydro-1-methylphthal-säureanhydrid [3]; Hexahydro-3-methylphthalsäureanhydrid [4] | 243-072-0 [1] 247-094-1 [2] 256-356-4 [3] 260-566-1 [4] | 19438-60-9 [1] 25550-51-0 [2] 48122-14-1 [3] 57110-29-9 [4] | Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H318 H334 H317 | GHS08 GHS05 Gef. | H318 H334 H317 | C | ||
607-242-00-1 | Tetrachlorphthalsäureanhydrid | 204-171-4 | 117-08-8 | Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H334 H317 H400 H410 | GHS08 GHS05 GHS09 Gef. | H318 H334 H317 H410 | |||
607-243-00-7 | Natrium-3,6-dichlor- o-anisat [1]; 3,6-Dichlor- o-anissäure, Verbindung mit 2,2"-Iminodiethanol (1:1) [2]; 3,6-Dichlor- o-anissäure, Verbindung mit 2-Aminoethanol (1:1) [3] | 217-846-3 [1] 246-590-5 [2] 258-527-9 [3] | 1982-69-0 [1] 25059-78-3 [2] 53404-28-7 [3] | Aquatic Chronic 3 | H412 | - | H412 | |||
607-244-00-2 | Isooctylacrylat | 249-707-8 | 29590-42-9 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H335 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H335 H315 H410 | STOT SE 3; H335: C ≥ 10 % | ||
607-245-00-8 | tert-Butylacrylat | 216-768-7 | 1663-39-4 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H225 H332 H312 H302 H335 H315 H317 H411 | GHS02 GHS07 GHS09 Gef. | H225 H332 H312 H302 H335 H315 H317 H411 | D | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
607-246-00-3 | Allylmethacrylat; 2-Methyl-2-propionsäure-2-propenylester | 202-473-0 | 96-05-9 | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 | H226 H331 H312 H302 H400 | GHS02 GHS06 GHS09 Gef. | H226 H331 H312 H302 H400 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
607-246-00-3 | Allylmethacrylat; 2-Methyl-2-propensäure 2-propenylester | 202-473-0 | 96-05-9 | Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 | H226 H330 H311 H302 H400 | GHS02 GHS06 GHS09 Dgr | H226 H330 H311 H302 H400 | Inhalation:
ATE = 1,5 mg/L (Dämpfe) dermal: ATE = 300 mg/kg KG Oral: ATE = 400 mg/kg KG | ) | |
607-247-00-9 | Dodecylmethacrylat | 205-570-6 | 142-90-5 | STOT SE 3 | H335 | GHS07 Wng | H335 | STOT SE 3; H335: C ≥ 10 % | ||
607-248-00-4 | Naptalam-Natrium (ISO); Natrium- N-naphth-1-ylphthalamat | 205-073-4 | 132-67-2 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-249-00-X | (1-Methyl-1,2-ethandiyl)bis[oxy(methyl-2,1-ethandiyl)]diacrylat; Tripropylenglykoldiacrylat | 256-032-2 | 42978-66-5 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H319 H335 H315 H317 H411 | GHS07 GHS09 Achtg. | H319 H335 H315 H317 H411 | STOT SE 3; H335: C ≥ 10 % | ||
607-250-00-5 | 4 H-3,1-Benzoxazin-2,4(1 H)-dion | 204-255-0 | 118-48-9 | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
607-251-00-0 | 2-Methoxypropylacetat | 274-724-2 | 70657-70-4 | Flam. Liq. 3 Repr. 1B STOT SE 3 | H226 H360D *** H335 | GHS02 GHS08 GHS07 Gef. | H226 H360D *** H335 | |||
607-252-00-6 | Lambda-Cyhalothrin (ISO); Reaktionsmasse aus (S)-α -Cyan-3-phenoxybenzyl( Z)-(1 R)- cis-3-(2-chlor-3,3,3-trifluorpropenyl)-2,2-dimethylcyclopropancarboxylat und (R)-α-Cyan-3-phenoxybenzyl( Z)-(1 S)- cis-3-(2-chlor-3,3,3-trifluorpropenyl)-2,2-dimethylcyclopropancarboxylat (1:1) | 415-130-7 | 91465-08-6 | Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H301 H312 H400 H410 | GHS06 GHS09 Gef. | H330 H301 H312 H410 | M=10000 | ||
607-253-00-1 | Cyfluthrin (ISO); a-Cyan-4-fluor-3-phenoxybenzyl-3-(2,2-dichlorvinyl)-2,2-dimethylcyclopropancarboxylat | 269-855-7 | 68359-37-5 | Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H362 H330 H300 H370 (Nervensystem) H400 H410 | GHS06 GHS08 GHS09 Dgr | H362 H330 H300 H370 (Nervensystem) H410 | Einatmung: ATE = 0,14 mg/L (Stäube oder Nebel) Oral: ATE = 14 mg/kg KG M = 1.000 000 M = 1.000 000 | ||
607-254-00-7 | beta-Cyfluthrin (ISO); Reaktionsmasse aus rel-( R)-Cyan(4-fluor-3-phenoxyphenyl)methyl (1 S,3 S)-3-(2,2-dichlorethenyl)-2,2-dimethylcyclopropan-1-carboxylat und rel-( R)-Cyan(4-fluor-3-phenoxyphenyl)methyl (1 S,3 R)-3-(2,2-dichlorethenyl)-2,2-dimethylcyclopropan-1-carboxylat | - | 1820573-27-0 | Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H362 H330 H300 H370 (Nervensystem) H400 H410 | GHS06 GHS08 GHS09 Dgr | H362 H330 H300 H370 (Nervensystem) H410 | Einatmung: ATE = 0,081 mg/L (Stäube oder Nebel) Oral: ATE = 11 mg/kg KG M = 1.000 000 M = 1.000 000 | ||
607-255-00-2 | Fluroxypyr (ISO); 4-Amino-3,5-dichlor-6-fluor-2-pyridyloxyessigsäure | - | 69377-81-7 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-256-00-8 | Azoxystrobin (ISO); Methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylat | - | 131860-33-8 | Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H331 H400 H410 | GHS06 GHS09 Dgr | H331 H410 | Einatmen:
ATE = 0,7 mg/L (Stäube oder Nebel) M = 10 M = 10 | ||
607-257-00-3 | Isopropylpropionat | 211-300-8 | 637-78-5 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | |||
607-258-00-9 | Dodecyl-3-(2-(3-benzyl-4-ethoxy-2,5-dioxoimidazolidin-1-yl)-3-(4-methoxybenzoyl)acetamido)-4-chlorbenzoat | 403-990-6 | 70950-45-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-259-00-4 | Methyl-2 R,3 S-(-)-3-(4-methoxyphenyl)oxirancarboxylat | 404-130-2 | 105560-93-8 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
607-260-00-X | Ethyl-2-(3-nitrobenzyliden)acetoacetat | 404-490-0 | 39562-16-8 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
607-261-00-5 | Iso(C10-C14)alkyl-(3,5-di- tert-butyl-4-hydroxyphenyl)methylthioacetat | 404-800-4 | 118832-72-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-262-00-0 | 7-Chlor-1-cyclopropyl-6-fluor-1,4-dihydro-4-oxochinolin-3-carbonsäure | 405-050-0 | 86393-33-1 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
607-263-00-6 | Kalium/Eisen(III)-1,3-propandiamine- N, N,N",N"-tetraacetathemihydrat | 405-680-6 | - | Self-heat. 2 **** Aquatic Chronic 2 | H252 H411 | GHS02 GHS09 Achtg. | H252 H411 | |||
607-264-00-1 | 2-Chlor-4-(methylsulfonyl)benzoesäure | 406-520-8 | 53250-83-2 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-265-00-7 | Ethyl-2-chlor-2,2-diphenylacetat | 406-580-5 | 52460-86-3 | Skin Irrit. 2 Aquatic Chronic 3 | H315 H412 | GHS07 Achtg. | H315 H412 | |||
607-266-00-2 | Reaktionsmasse aus Hydroxyaluminium-bis[2-hydroxy-3,5-di- tert-butylbenzoat]; 3,5-Di- tert-butylsalicylsäure | 406-890-0 | 130296-87-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
607-267-00-8 | tert-Butyl-(5 S,6 R,7 R)-3-brommethyl-5,8-dioxo-7-(2-(2-phenylacetamido)-5-thia-1-azabicyclo[4.2.0]-oct-2-en-2-carboxylat | 407-620-4 | 33610-13-8 | Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 | H334 H317 H412 | GHS08 Gef. | H334 H317 H412 | |||
607-268-00-3 | 2-Methylpropyl-( R)-2-hydroxypropanoat | 407-770-0 | 61597-96-4 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-269-00-9 | (R)-2-(4-Hydroxyphenoxy)propansäure | 407-960-3 | 94050-90-5 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-270-00-4 | 3,9-Bis(2-(3-(3- tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy-1,1-dimethylethyl)-2,4,8,10-tetraoxaspiro[5.5]undecan | 410-730-5 | 90498-90-1 | Acute Tox. 4 * | H312 | GHS07 Achtg. | H312 | |||
607-271-00-X | 2-Isopropyl-5-methylcyclohexyloxycarbonyloxy-2-hydroxypropan | 417-420-9 | 156324-82-2 | Eye Irrit. 2 Aquatic Chronic 2 | H319 H411 | GHS07 GHS09 Achtg. | H319 H411 | |||
607-272-00-5 | Fluroxypyr-meptyl (ISO); Methylheptyl,- O-(4-amino-3,5-dichlor-6-fluor-2-pyridyloxy)acetat [1]; Fluroxypyr-butometyl (ISO); 2-Butoxy-1-methylethyl- O-(4-amino-3,5-dichlor-6-fluor-2-pyridyloxy)acetat [2] | 279-752-9 [1] - [2] | 81406-37-3 [1] 154486-27-8 [2] | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-273-00-0 | Ammonium-7-(2,6-dimethyl-8-(2,2-dimethylbutyryloxy)-1,2,6,7,8,8a-hexahydro-1-naphthyl)-3,5-dihydroxyheptanoat | 404-520-2 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
607-274-00-6 | 2-( N-Benzyl- N-methylamino)ethyl 3-amino-2-butenoat | 405-350-1 | 54527-73-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-275-00-1 | Natrium-benzoyloxybenzol-4-sulfonat | 405-450-5 | 66531-87-1 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-276-00-7 | Bis[(1-methylimidazol)-(2-ethylhexanoat)], Zinkkomplex | 405-635-0 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H400 H410 | GHS05 GHS09 Gef. | H315 H318 H410 | |||
607-277-00-2 | Reaktionsmasse aus 2-(Hexylthio)ethylaminhydrochlorid; Natriumpropionat | 405-720-2 | - | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | |||
607-278-00-8 | Reaktionsmasse aus Isomeren von Natriumphenethylnaphthalinsulfonat; Natriumnaphthylethylbenzolsulfonat | 405-760-0 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
607-279-00-3 | Reaktionsmasse aus n-Octadecylaminodiethylbis(hydrogen maleat); n-Octadecylaminodiethylhydrogenmaleathydrogenphthalat | 405-960-8 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-280-00-9 | Natrium-4-chlor-1-hydroxybutan-1-sulfonat | 406-190-5 | 54322-20-2 | Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 | H302 H319 H317 | GHS07 Achtg. | H302 H319 H317 | |||
607-281-00-4 | Reaktionsmasse aus verzweigten und linearen C7-C9-Alkyl-3-[3-(2 H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxyphenyl]propionaten | 407-000-3 | 127519-17-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-282-00-X | 2-Acetoxymethyl-4-benzyloxybut-1-ylacetat | 407-140-5 | 131266-10-9 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-283-00-5 | E-Ethyl-4-oxo-4-phenylcrotonat | 408-040-4 | 15121-89-8 | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H312 H302 H315 H318 H317 H410 | |||
607-284-00-0 | Reaktionsmasse aus Natrium-3,3"-(1,4-phenylenbis(carbonylimino-3,1-propandiylimino))bis(10-amino-6,13-dichlor-4,11-triphenodioxazindisulfonat); Lithium-3,3"-(1,4-phenylenbis(carbonylimino-3,1-propandiylimino))bis(10-amino-6,13-dichlor)-4,11-triphenodioxazindisulfonat (9:1) | 410-040-4 | 136213-76-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-285-00-6 | Reaktionsmasse aus 7-(((3-Aminophenyl)sulfonyl)amino)-naphthalin-1,3-disulfonsäure; Natrium-7-(((3-aminophenyl)sulfonyl)amino)-naphthalin-1,3-disulfonat; Kalium-7-(((3-aminophenyl)sulfonyl)amino)-naphthalin-1,3-disulfonat | 410-065-0 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | ||||
607-286-00-1 | Reaktionsmasse aus Natrium/Kalium-7-[[[3-[[4-((2-hydroxynaphthyl)azo)phenyl]azo]phenyl]sulfonyl]amino]-naphthalin-1,3-disulfonat | 410-070-8 | 141880-36-6 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-287-00-7 | O"-Methyl- O-(1-methyl-2-methacryloyloxyethyl)-1,2,3,6-tetrahydrophthalat | 410-140-8 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
607-288-00-2 | Tetranatrium-( c-(3-(1-(3-( e-6-dichlor-5-cyanopyrimidin- f-yl(methyl)amino)propyl)-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo)-4-sulfonatophenylsulfamoyl)phthalocyanin- a, b,d-trisulfonato(6-))nickelat(II) (a: 1, 2, 3 oder 4, b: 8, 9, 10 oder 11, c: 15, 16, 17 oder 18, d: 22, 23, 24 oder 25, e, f zusammen: 2 und 4 bzw. 4 und 2) | 410-160-7 | 148732-74-5 | Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H319 H317 H412 | GHS07 Achtg. | H319 H317 H412 | |||
607-289-00-8 | 3-(3-(4-(2,4-Bis(1,1-dimethylpropyl)phenoxy)butylaminocarbonyl-4-hydroxy-1-naphthalinyl)thio)propansäure | 410-370-9 | 105488-33-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-290-00-3 | Reaktionsmasse aus Ammonium-1-C14-C18-Alkyloxycarbonyl-2-(3-allyloxy-2-hydroxypropoxycarbonyl)ethan-1-sulfonat; Ammonium-2-C14-C18-Alkyloxycarbonyl-1-(3-allyloxy-2-hydroxypropoxycarbonyl)ethan-1-sulfonat (Verhältnis nicht bekannt) | 410-540-2 | - | Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H315 H317 H410 | |||
607-291-00-9 | Dodecyl-ω -(C5/C6-cycloalkyl)alkylcarboxylat | 410-630-1 | 104051-92-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-292-00-4 | Reaktionsmasse aus [1-(Methoxymethyl)-2-(C12-alkoxy)-ethoxy]essigsäure; [1-(Methoxymethyl)-2-(C14-alkoxy)-ethoxy]essigsäure | 410-640-6 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H400 H410 | GHS05 GHS09 Gef. | H315 H318 H410 | |||
607-293-00-X | Reaktionsmasse aus N-Aminoethylpiperazonium-mono-2,4,6-trimethylnonyldiphenyletherdi-sulfonat; N-Aminoethylpiperazonium-di-2,4,6-trimethylnonyldiphenyletherdisulfonat | 410-650-0 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
607-294-00-5 | Natrium-2-benzoyloxy-1-hydroxyethan-sulfonat | 410-680-4 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-295-00-0 | Reaktionsmasse aus Tetranatrium-phosphonethan-1,2-dicarboxylat; Hexanatrium-phosphonbutan-1,2,3,4-tetracarboxylat | 410-800-5 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-296-00-6 | Reaktionsmasse aus Tetraestern von Pentaerythriol mit Heptansäure und 2-Ethylhexansäure | 410-830-9 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-297-00-1 | (E-E)-3,3"-(1,4-Phenylendimethyliden)bis(2-oxobornan-10-sulfonsäure) | 410-960-6 | 92761-26-7 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-298-00-7 | 2-(Trimethylammonium)ethoxycarboxybenzol-4-sulfonat | 411-010-3 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-299-00-2 | Methyl-3-(acetylthio)-2-methylpropanoat | 411-040-7 | 97101-46-7 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
607-300-00-6 | Trinatrium-[2-(5-chlor-2,6-difluorpyrimidin-4-ylamino)-5-( b-sulfamoyl- c, d-sulfonatophthalocyanin- a-yl-K4, N29, N30, N31, N32-sulfonylamino)benzoato(5-)]cuprat(II) (a: 1, 2, 3 oder 4, b: 8, 9, 10 oder 11, c: 15, 16, 17 oder 18, d: 22, 23, 24 oder 25 | 411-430-7 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-301-00-1 | Reaktionsmasse aus Dodecansäure und Poly(1-7)lactatestern der Dodecansäure | 411-860-5 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-302-00-7 | Reaktionsmasse aus Tetradecansäure und Poly(1-7)lactatestern der Tetradecansäure | 411-910-6 | - | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H315 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H411 | |||
607-303-00-2 | 1-Cyclopropyl-6,7-difluor-1,4-dihydro-4-oxochinolin-3-carbonsäure | 413-760-7 | 93107-30-3 | Repr. 2 Aquatic Chronic 3 | H361f ***607-303-00-2 H412 | GHS08 Achtg. | H361f ***607-303-00-2 H412 | |||
607-304-00-8 | Fluazifop-butyl (ISO); Butyl-( RS)-2-(4-[5-(trifluormethyl)-2-pyridyloxy)phenoxy]propionat | 274-125-6 | 69806-50-4 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360D ***607-303-00-2 H400 H410 | GHS08 GHS09 Gef. | H360D ***607-303-00-2 H410 | |||
607-305-00-3 | Fluazifop-P-butyl (ISO); Butyl-( R)-2-[4-(5-trifluormethyl-2-pyridyloxy)phenoxy]propionat | - | 79241-46-6 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H400 H410 | GHS08 GHS09 Achtg. | H361d *** H410 | |||
607-306-00-9 | Chlozolinat (ISO); Ethyl-( RS)-3-(3,5-dichlorphenyl)-5-methyl-2,4-dioxo-oxazolidin-5-carboxylat | 282-714-4 | 84332-86-5 | Carc. 2 Aquatic Chronic 2 | H351 H411 | GHS08 GHS09 Achtg. | H351 H411 | |||
607-307-00-4 | Vinclozolin (ISO); N-3,5-Dichlorphenyl-5-methyl-5-vinyl-1,3-oxazolidin-2,4-dion | 256-599-6 | 50471-44-8 | Carc. 2 Repr. 1B Skin Sens. 1 Aquatic Chronic 2 | H351 H360FD607-303-00-2 H317 H411 | GHS08 GHS07 GHS09 Gef. | H351 H360FD607-303-00-2 H317 H411 | |||
607-308-00-X | Ester von 2,4-D | - | - | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | A | ||
607-309-00-5 | Carfentrazon-ethyl (ISO); Ethyl-( RS)-2-chlor-3-[2-chlor-4-fluor-5-[4-difluormethyl-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl]phenyl]propionat | - | 128639-02-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-310-00-0 | Kresoxim-methyl (ISO); Methyl-( E)-2-methoxyimino-[2-( o-tolyloxymethyl)phenyl]acetat | - | 143390-89-0 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
607-311-00-6 | Benazolin-ethyl; Ethyl-4-chlor-2-oxo-2 H-benzothiazol-3-acetat | 246-591-0 | 25059-80-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-312-00-1 | Methoxyessigsäure; Essigsäure-methylether | 210-894-6 | 625-45-6 | Repr. 1B Acute Tox. 4 * Skin Corr. 1B | H360FD H302 H314 | GHS08 GHS05 GHS07 Gef. | H360FD H302 H314 | STOT SE 3; H335: C ≥ 5 % | ||
607-313-00-7 | Neodecanoylchlorid | 254-875-0 | 40292-82-8 | Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B | H330 H302 H314 | GHS06 GHS06 Gef. | H330 H302 H314 | STOT SE 3; H335: C ≥ 5 % | ||
607-314-00-2 | Ethofumesat (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl-methansulfonat | 247-525-3 | 26225-79-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1 | ||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-315-00-8 | Glyphosat (ISO); N-(Phosphonomethyl)glycin | 213-997-4 | 1071-83-6 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-315-00-8 | Glyphosat (ISO) N-(Phosphonomethyl)glycin | 213-997-4 | 1071-83-6 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Dgr | H318 H411 | ) | ||
607-316-00-3 | Glyphosat-trimesium; Glyphosattrimethylsulfonium | - | 81591-81-3 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-317-00-9 | Bis(2-ethylhexyl)phthalat; Di-(2-ethylhexyl)phthalat; DEHP | 204-211-0 | 117-81-7 | Repr. 1B | H360FD | GHS08 Gef. | H360FD | |||
607-318-00-4 | Dibutylphthalat; DBP | 201-557-4 | 84-74-2 | Repr. 1B Aquatic Acute 1 | H360Df H400 | GHS08 GHS09 Gef. | H360Df H400 | |||
607-319-00-X | Deltamethrin (ISO); (S)-α-Cyan-3-phenoxybenzyl( 1R, 3R)-3-(2,2-dibromvinyl)-2,2-dimethylcyclopropancarboxylat | 258-256-6 | 52918-63-5 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H410 | M=1000000 | ||
607-320-00-5 | Bis[4-(ethenyloxy)butyl]-1,3-benzoldicarboxylat | 413-930-0 | 130066-57-8 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
607-321-00-0 | (S)-Methyl-2-chlorpropionat | 412-470-8 | 73246-45-4 | Flam. Liq. 3 STOT RE 2 * Eye Irrit. 2 | H226 H373 ** H319 | GHS02 GHS08 Achtg. | H226 H373 ** H319 | |||
607-322-00-6 | 4-(4,4-Dimethyl-3-oxo-pyrazolidin-1-yl)-benzoesäure | 413-120-7 | 107144-30-9 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-323-00-1 | 2-(1-(2-Hydroxy-3,5-di- tert-pentyl-phenyl)ethyl)-4,6-di- tert-pentylphenylacrylat | 413-850-6 | 123968-25-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-324-00-7 | Reaktionsmasse aus N, N-di(hydrierter Alkyl C14-C18)phtalamsäure und dihydrierten Alkyl(C14-C18)aminen | 413-800-3 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-325-00-2 | (S)-2-Chlorpropionsäure | 411-150-5 | 29617-66-1 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | |||
607-326-00-8 | Reaktionsmasse aus Isobutylhydrogen-2-(α-2,4,6-trimethylnon-2-enyl)succinat und Isobutylhydrogen-2-(ί -2,4,6-trimetyhylnon-2-enyl)succinat | 410-720-0 | 141847-13-4 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
607-327-00-3 | 2-(2-Iodethyl)prop-1,3-diyl-diacetat | 411-780-0 | 127047-77-2 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-328-00-9 | Methyl-4-brommethyl-3-methoxybenzoat | 410-310-1 | 70264-94-7 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H410 | |||
607-329-00-4 | Reaktionsmasse aus Natrium-2-(C12-18- n-alkyl)amino-1,4-butandioat; Natrium-2-octadecenyl-amino-1,4-butandioat | 411-250-9 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-330-00-X | (S)-2,3-Dihydro-1 H-indol-2-carbonsäure | 410-860-2 | 79815-20-6 | Repr. 2 STOT RE 2 * Skin Sens. 1 | H361f *** H373 ** H317 | GHS08 GHS07 Achtg. | H361f *** H373 ** H317 | |||
- gestrichen - | ||||||||||
607-332-00-0 | Cyclopentylchlorformiat | 411-460-0 | 50715-28-1 | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H226 H331 H302 H373 ** H318 H317 | GHS02 GHS06 GHS08 GHS05 Gef. | H226 H331 H302 H373 ** H318 H317 | |||
607-333-00-6 | Reaktionsmasse aus Dodecyl- N-(2,2,6,6-tetramethylpiperidin-4-yl)-β-alaninat; Tetradecyl- N-(2,2,6,6-tetramethylpiperidin-4-yl)-β-alaninat | 405-670-1 | - | Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H314 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H302 H373 ** H314 H410 | |||
607-334-00-1 | Ethyl-1-ethyl-6,7,8-trifluor-1,4-dihydro-4-oxochinolin-3-carboxylat | 405-880-3 | 100501-62-0 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-335-00-7 | Methyl-( R)-2-(4-(3-chlor-5-trifluormethyl-2-pyridyloxy)phenoxy)propionat | 406-250-0 | 72619-32-0 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
607-336-00-2 | 4-Methyl-8-methylentricyclo[3.3.1.13,7]dec-2-ylacetat | 406-560-6 | 122760-85-4 | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H315 H317 H411 | GHS07 GHS09 Achtg. | H315 H317 H411 | |||
607-337-00-8 | Di- tert-(C12-14)-alkylammonium)-2-(benzothiazolylthio)succinat | 406-052-4 | 125078-60-6 | Flam. Liq. 3 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H226 H302 H315 H318 H411 | GHS02 GHS05 GHS07 GHS09 Gef. | H226 H302 H315 H318 H411 | |||
607-338-00-3 | 2-Methylpropyl-2-hydroxy-2-methylbut-3-enoat | 406-235-9 | 72531-53-4 | Eye Irrit. 2 Skin Irrit. 2 | H319 H315 | GHS07 Achtg. | H319 H315 | |||
607-339-00-9 | 2,3,4,5-Tetrachlorbenzoylchlorid | 406-760-3 | 42221-52-3 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H302 H314 H317 | GHS05 GHS07 Gef. | H302 H314 H317 | |||
607-340-00-4 | 1,3-Bis(4-benzoyl-3-hydroxyphenoxy)prop-2-ylacetat | 406-990-4 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-341-00-X | (9 S)-9-amino-9-deoxyerythromycin | 406-790-7 | 26116-56-3 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
607-342-00-5 | 4-Chlorbutylveratrat | 410-950-1 | 69788-75-6 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-343-00-0 | 4,7-Methanooctahydro-1 H-inden-diyldimethylbis(2-carboxybenzoat) | 407-410-2 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-344-00-6 | Reaktionsmasse aus 3-( N-(3-Dimethylaminopropyl)-(C4-8)perfluoralkylsulfonamido)propionsäure; N-[Dimethyl-3-(C4-8-perfluoralkylsulfonamido)propylammoniumpropionat; 3-( N-(3-dimethylpropylammonium)-(C4-8)perfluoralkylsulfonamido)propionsäurepropionat | 407-810-7 | - | STOT RE 2 * | H373 ** | GHS08 Achtg. | H373 ** | |||
607-345-00-1 | Kalium-2-(2,4-dichlorphenoxy)-( R)-propionat | 413-580-9 | 113963-87-4 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H302 H315 H318 H317 | GHS05 GHS07 Gef. | H302 H315 H318 H317 | |||
607-346-00-7 | 3-Icosyl-4-henicosyliden-oxetan-2-on | 401-210-9 | 83708-14-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-347-00-2 | Natrium-( R)-2-(2,4-Dichlorphenoxy)propionat | 413-340-3 | 119299-10-4 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H302 H315 H318 H317 | GHS05 GHS07 Gef. | H302 H315 H318 H317 | |||
607-348-00-8 | Magnesium-bis(( R)-2-(2,4-dichlorphenoxy)propionat) | 413-360-2 | - | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H302 H315 H318 H317 | GHS05 GHS07 Gef. | H302 H315 H318 H317 | |||
607-349-00-3 | Tetrapropylammonium-2-(2-carboxyphenyldisulfanyl)benzoat | 411-270-8 | - | Aquatic Chronic 3 | H412 | H412 | ||||
607-350-00-9 | Bis(4-(1,2-bis(ethoxycarbonyl)ethylamino)-3-methylcyclohexyl)methan | 412-060-9 | 136210-32-7 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-351-00-4 | Methyl- O-(4-amino-3,5-dichlor-6-fluorpyridin-2-yloxy)acetat | 407-550-4 | 69184-17-4 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-352-00-X | 4,4"-Oxydiphthalsäureanhydrid | 412-830-4 | 1823-59-2 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-353-00-5 | Reaktionsmasse aus Ethyl- exo-tricyclo[5.2.1.02,6]decan- endo-2-carboxylat; Ethyl- endo-tricyclo[5.2.1.02,6]decan- exo-2-carboxylat | 407-520-0 | 80657-64-3 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
607-354-00-0 | Ethyl-2-cyclohexylpropionat | 412-280-5 | 2511-00-4 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-355-00-6 | p-Tolyl-4-chlorbenzoat | 411-530-0 | 15024-10-9 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
607-356-00-1 | Ethyl- trans-2,2,6-trimethylcyclohexancarboxylat | 412-540-8 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
607-357-00-7 | Reaktionsmasse aus trans-4-Acetoxy-4-methyl-2-propyl-tetrahydro-2 H-pyran und cis-4-Acetoxy-4-methyl-2-propyl-tetrahydro-2 H-pyran | 412-450-9 | 131766-73-9 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-358-00-2 | (1 S,3 S,5 R,6 R)-(4-Nitrophenylmethyl)-1-dioxo-6-phenylacetamido-penam-3-carboxylat | 412-670-5 | 54275-93-3 | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | |||
607-359-00-8 | (1 S,4 R,6 R,7 R)-(4-Nitrophenylmethyl)3-methylen-1-oxo-7-phenylacetamido-cepham-4-carboxylat | 412-800-0 | 76109-32-5 | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | |||
607-360-00-3 | Natrium-3-acetoacetylamino-4-methoxytolyl-6-sulfonat | 411-680-7 | 133167-77-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-361-00-9 | Methyl-( R)-2-(4-hydroxyphenoxy)propionat | 411-950-4 | 96562-58-2 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-362-00-4 | Reaktionsmasse aus (3-Methoxy)propylammonium/[Tris-(2-hydroxyethyl)]ammonium-2-(2-(bis(2-hydroxyethyl)amino)ethoxycarbonylmethyl)hexadec-4-enoat; (3-Methoxy)propylammonium/[Tris-(2-hydroxyethyl)]ammonium-2-(2-(bis(2-hydroxyethyl)amino)ethoxycarbonylmethyl)tetradec-4-enoat; (3-Methoxy)propylammonium/[Tris-(2-hydroxyethyl)]ammonium-2-(3-methoxypropylcarbamoylmethyl)hexadec-4-enoat; (3-Methoxy)propylammonium/[Tris-(2-hydroxyethyl)]ammonium-2-(3-methoxypropylcarbamoylmethyl)tetradec-4-enoat | 413-500-2 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H315 H318 H411 | GHS05 GHS09 Gef. | H315 H318 H411 | |||
607-363-00-X | Methyl-3-methoxyacrylat | 412-900-4 | 5788-17-0 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-364-00-5 | 3-Phenyl-7-[4-(tetrahydrofuran-2-yl-metoxy)phenyl]-benzo[1,2- b;4,5- b"]difuran-2,6-dion | 413-330-9 | 134724-55-3 | Aquatic Chronic 4 | H413 | H413 | ||||
607-365-00-0 | 2-(2-Amino-1,3-thiazol-4-yl)-( Z)-2-methoxyiminoacetylchloridhydrochlorid | 410-620-7 | 119154-86-8 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H302 H314 H317 | GHS05 GHS07 Gef. | H302 H314 H317 | |||
607-366-00-6 | 3,5-Dimethylbenzoylchlorid | 413-010-9 | 6613-44-1 | Skin Corr. 1B Skin Sens. 1 | H314 H317 | GHS05 GHS07 Gef. | H314 H317 | |||
607-367-00-1 | Kalium-bis( N-carboxymethyl)- N-methyl-glycinato-(2-) N, O,O, N)-ferrat-(1-)monohydrat | 411-640-9 | 153352-59-1 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-368-00-7 | 1-( N, N-Dimethylcarbamoyl)-3- tert-butyl-5-carbethoxymethylthio-1 H-1,2,4-triazol | 411-650-3 | 110895-43-7 | Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H410 | |||
607-369-00-2 | Reaktionsmasse aus trans-(2 R)-5-Acetoxy-1,3-oxathiolan-2-carbonsäure; cis-(2 R)-5-Acetoxy-1,3-oxathiolan-2-carbonsäure | 411-660-8 | 147027-04-1 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H302 H315 H318 H317 | GHS05 GHS07 Gef. | H302 H315 H318 H317 | |||
607-370-00-8 | 2-[[2-(Acetyloxy)-3-(1,1-dimethyl-ethyl)-5-methylphenyl]methyl]-6-(1,1-dimethylethyl)-4-methylphenol | 412-210-3 | 41620-33-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-371-00-3 | 3-Ethyl-5-methyl-4-(2-chlorphenyl)-1,4-dihydro-2-[2-(1,3-dihydro-1,3-dioxo-(2 H)isoindol-2-yl)-ethoxymethyl]-6-methyl-3,5-pyridindicarboxylat | 413-410-3 | 88150-62-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-372-00-9 | Ethoxyliertes Bisphenol-A-di-(norbornencarboxylat) | 412-410-0 | 32492-61-8 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-373-00-4 | Quizalofop-P-tefuryl (ISO); (+/-)-Tetrahydrofurfuryl-(R)-2-[4-(6-chlorchinoxalin-2-yloxy)phenyloxy]propionat | 414-200-4 | 200509-41-7 | Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361fd H302 H373 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361fd H302 H373 H410 | M = 1 M = 1 | ||
607-374-00-X | 5-Amino-2,4,6-triiod-1,3-benzoldicarbonyldichlorid | 417-220-1 | 37441-29-5 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-375-00-5 | Flocoumafen (ISO); Reaktionsmasse aus: cis-4-Hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluormethylbenzyloxy)phenyl)-1-naphthyl)cumarin und trans-4-Hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluormethylbenzyloxy)phenyl)-1-naphthyl)cumarin | 421-960-0 | 90035-08-8 | Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H310 H300 H372 (Blut) H400 H410 | GHS08 GHS06 GHS09 Gef. | H360D H330 H310 H300 H372 (Blut) H410 | Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 0,05 % STOT RE 2; H373 (Blut): 0,005 % ≤ C < 0,05 % M = 10 M = 10 | ||
607-376-00-0 | Benzyl-2,4-dibrombutanoat | 420-710-8 | 23085-60-1 | Repr. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f *** H315 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361f *** H315 H317 H410 | |||
607-377-00-6 | trans-4-Cyclohexyl- L-prolinmonohydrochlorid | 419-160-1 | 90657-55-9 | Repr. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H361f *** H302 H315 H318 H317 | GHS08 GHS05 GHS07 Gef. | H361f *** H302 H315 H318 H317 | |||
607-378-00-1 | Ammonium-( Z)-α-methoxyimino-2-furylacetat | 405-990-1 | 97148-39-5 | Flam. Sol. 2 | H228 | GHS02 Gef. | H228 | T | ||
607-379-00-7 | Reaktionsmasse aus 2-[ N-(2-Hydroxyethyl)stearamido]ethyl-stearat; Natrium-[bis[2-(stearoyloxy)ethyl]amino]methylsulfonat; Natrium-[bis(2-hydroxyethyl)amino]methylsulfonat; N, N-Bis(2-Hydroxyethyl)stearamid | 401-230-8 | Aquatic Chronic 3 | H412 | - | H412 | ||||
607-380-00-2 | Reaktionsmasse aus Ammonium-1,2-bis(hexyloxycarbonyl)ethansulfonat; Ammonium-1-hexyloxycarbonyl-2-octyloxycarbonylethansulfonat; Ammonium-2-hexyloxycarbonyl-1-octyloxycarbonylethansulfonat | 407-320-3 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H315 H318 H412 | GHS05 Gef. | H315 H318 H412 | |||
607-381-00-8 | Reaktionsmasse aus Triestern von 2,2-Bis(hydroxymethyl)butanol mit C7-Alkansäuren und 2-Ethylhexansäure | 413-710-4 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-382-00-3 | 2-((4-Amino-2-nitrophenyl)amino)benzoesäure | 411-260-3 | 117907-43-4 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
607-383-00-9 | Reaktionsmasse aus 2,2,6,6-Tetramethylpiperidin-4-yl-hexadecanoat und 2,2,6,6-Tetramethylpiperidin-4-yl-octadecanoat | 415-430-8 | 86403-32-9 | Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H318 H317 H410 | |||
607-384-00-4 | Reaktionsmasse aus Estern von verzweigten C14-C15-Alkoholen mit 3,5-Di- tert-butyl-4-hydroxyphenylpropionsäure; verzweigtem und linearem C15-Alkyl-3,5-bis(1,1-dimethylethyl)-4-hydroxybenzolpropionat; verzweigtem und linearem C13-Alkyl-3,5-bis(1,1-dimethylethyl)-4-hydroxybenzolpropionat | 413-750-2 | 171090-93-0 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-385-00-X | Copolymer von Vinylalkohol und Vinylacetat, teilweise acetyliert mit 4-(2-(4-Formylphenyl)ethenyl)-1-methylpyridiniummethylsulfat | 414-590-6 | 125229-74-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-386-00-5 | Reaktionsmasse aus Tetradecansäure (42,5 - 47,5 %) und Poly(1-7)lactatestern der Tetradecansäure (52,5 - 57,5 %) | 412-580-6 | 174591-51-6 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H410 | |||
607-387-00-0 | Reaktionsmasse aus Dodecansäure (35 - 40 %) und Poly(1-7)lactatestern der Dodecansäure (60 - 65 %) | 412-590-0 | 58856-63-6 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H410 | |||
607-388-00-6 | 4-Ethylamino-3-nitrobenzoesäure | 412-090-2 | 2788-74-1 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H302 H317 H412 | GHS07 Achtg. | H302 H317 H412 | |||
607-389-00-1 | Trinatrium- N, N-bis(carboxymethyl)-3-amino-2-hydroxypropionat | 414-130-4 | 119710-96-2 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-390-00-7 | 1,2,3,4-Tetrahydro-6-nitrochinoxalin | 414-270-6 | 41959-35-7 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-391-00-2 | Dimethylcyclopropan-1,1-dicarboxylat | 414-240-2 | 6914-71-2 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-392-00-8 | 2-Phenoxyethyl-4-((5-cyano-1,6-dihydro-2-hydroxy-1,4-dimethyl-6-oxo-3-pyridinyl)azo)benzoat | 414-260-1 | 88938-37-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-393-00-3 | 3-( cis-1-Propenyl)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carbonsäure | 415-750-8 | 106447-44-3 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-394-00-9 | 5-Methylpyrazin-2-carbonsäure | 413-260-9 | 5521-55-1 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-395-00-4 | Reaktionsmasse aus Natrium-1-tridecyl-4-allyl-(2 oder 3)-sulfobutandioat und Natrium-1-dodecyl-4-allyl-(2 oder 3)-sulfobutandioat | 410-230-7 | - | Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H314 H317 H411 | GHS05 GHS07 GHS09 Gef. | H314 H317 H411 | |||
607-396-00-X | Bis(1,2,2,6,6-pentamethyl-4-piperidinyl)-2-(4-methoxybenzyliden)malonat | 414-840-4 | 147783-69-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-397-00-5 | Reaktionsmasse aus Calciumsalicylaten (verzweigt C10-14 und C18-30 alkyliert); Calciumphenolaten (verzweigt C10-14 und C18-30 alkyliert); geschwefelten Calciumphenolaten (verzweigt C10-14 und C18-30 alkyliert | 415-930-6 | - | Repr. 2 Skin Sens. 1 | H361f*** H317 | GHS08 GHS07 Achtg. | H361f*** H317 | |||
607-398-00-0 | Ethyl- N-(5-chlor-3-(4-(diethylamino)-2-methylphenylimino)-4-methyl-6-oxo-1,4-cyclohexadienyl)carbamat | 414-820-5 | 125630-94-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-399-00-6 | 2,2-Dimethyl-3-methyl-3-butenylpropanoat | 415-610-6 | 104468-21-5 | Skin Irrit. 2 Aquatic Chronic 3 | H315 H412 | GHS07 Achtg. | H315 H412 | |||
607-400-00-X | Methyl-3-[[(dibutylamino)thioxomethyl]thio]propanoat | 414-400-1 | 32750-89-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-401-00-5 | Ethyl-3-hydroxy-5-oxo-3-cyclohexen-1-carboxylat | 414-450-4 | 88805-65-6 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H315 H318 H317 | GHS05 GHS07 Gef. | H315 H318 H317 | |||
607-402-00-0 | Methyl- N-(phenoxycarbonyl)- L -valinat | 414-500-5 | 153441-77-1 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-403-00-6 | Reaktionsmasse aus Bis(1 S,2 S,4 S)-(1-benzyl-4- tert-butoxycarboxamido-2-hydroxy-5-phenyl)pentylammoniumsuccinat und Isopropylalkohol | 414-810-0 | - | STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H318 H400 H410 | GHS08 GHS05 GHS09 Gef. | H373 ** H318 H410 | |||
607-404-00-1 | Reaktionsmasse aus (( Z)-3,7-Dimethyl-2,6-octadienyl)oxycarbonylpropansäure; Di-(( E)-3,7-dimethyl-2,6-octadienyl)butandioat; Di-(( Z)-3,7-dimethyl-2,6-octadienyl)butandioat; (Z)-3,7-Dimethyl-2,6-octadienylbutandioat und (( E)-3,7-Dimethyl-2,6-octadienyl)oxycarbonylpropansäure | 415-190-4 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-405-00-7 | 2-Hexyldecyl- p-hydroxybenzoat | 415-380-7 | 148348-12-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-406-00-2 | Kalium-2,5-dichlorbenzoat | 415-700-5 | 184637-62-5 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
607-407-00-8 | Ethyl-2-carboxy-3-(2-thienyl)propionat | 415-680-8 | 143468-96-6 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H315 H318 H317 | GHS05 GHS07 Gef. | H315 H318 H317 | |||
607-408-00-3 | Kalium- N-(4-fluorphenyl)glycinat | 415-710-1 | 184637-63-6 | STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H373 ** H318 H317 H412 | GHS08 GHS05 GHS07 Gef. | H373 ** H318 H317 H412 | |||
607-409-00-9 | Reaktionsmasse aus (3 R)-[1 S-(1α,2α,6β-((2 S)-2-Methyl-1-oxo-butoxy)-8aγ)hexahydro-2,6-dimethyl-1-naphthalin]-3,5-dihydroxyheptansδ ure und inerter Biomasse von Aspergillus terreus | 415-840-7 | - | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-410-00-4 | Mono[2-(dimethylamino)ethyl]monohydrogen-2-(hexadec-2-enyl)butandioat und/oder Mono[2-(dimethylamino)ethyl]monohydrogen-3-(hexadec-2-enyl)butandioat | 415-880-5 | 779343-34-9 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H410 | |||
607-411-00-X | Oxiranmethanol, 4-Methylbenzolsulfonat, (S)- Toluolsulfonsäureglycidylester | 417-210-7 | 70987-78-9 | Carc. 1B Muta. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H350 H341 H318 H317 H411 | GHS08 GHS05 GHS07 GHS09 Gef. | H350 H341 H318 H317 H411 | |||
607-412-00-5 | Ethyl-2-(1-cyanocyclohexyl)acetat | 415-970-4 | 133481-10-4 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 | H302 H373 ** H412 | GHS08 GHS07 Achtg. | H302 H373 ** H412 | |||
607-413-00-0 | trans-4-Phenyl- L-prolin | 416-020-1 | 96314-26-0 | Repr. 2 Skin Sens. 1 | H361f *** H317 | GHS08 GHS07 Achtg. | H361f *** H317 | |||
- gestrichen - | ||||||||||
607-415-00-1 | Poly-(methylmethacrylat)-co-(butylmethacrylat)-co-(4-acryloxybutyl-isopropenyl-α, α-dimethylbenzylcarbamate)-co-(maleinsδ ureanhydrid) | 419-590-1 | - | Flam. Sol. 1 Skin Sens. 1 | H228 H317 | GHS02 GHS07 Gef. | H228 H317 | T | ||
607-416-00-7 | 4-(2-Carboxymethylthio)ethoxy-1-hydroxy-5-isobutyloxycarbonylamino- N-(3-dodecyloxypropyl)-2-naphthamid | 420-730-7 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-417-00-2 | 3-Chlorpropylchlorformiat | 425-770-9 | 628-11-5 | Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H331 H302 H373** H315 H318 H317 | GHS06 GHS05 GHS08 Gef. | H331 H302 H373** H315 H318 H317 | |||
607-418-00-8 | 2-Ethylhexyl-4-aminobenzoat | 420-170-3 | 26218-04-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-419-00-3 | (3"-Carboxymethyl-5-(2-(3-ethyl-3 H-benzothiazol-2-yliden)-1-methyl-ethyliden)-4,4"-dioxo-2"-thioxo-(2,5")bithiazolidinyliden-3-yl)-essigsäure | 422-240-9 | 166596-68-5 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-420-00-9 | 2,2-Bis(hydroxymethyl)butansäure | 424-090-1 | 10097-02-6 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-421-00-4 | Cypermethrin (ISO); α-Cyan-3-phenoxybenzyl 3-(2,2-dichlorvinyl)-2,2-dimethylcyclopropancarboxylat; Cypermethrin cis/trans +/-40/60 | 257-842-9 | 52315-07-8 | Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H335 H373 (Nervensystem) H400 H410 | GHS07 GHS08 GHS09 Wng | H332 H302 H335 H373 (Nervensystem) H410 | oral:
ATE = 500 mg/kg KG Einatmen: ATE = 3,3 mg/L (Stäube oder Nebel) M = 100000 M = 100000 | ||
607-422-00-X | α -Cypermethrin (ISO); Racemat mit (R)-α-Cyano-3-phenoxybenzyl-(1 S,3 S)-3-(2,2-dichlorvinyl)-2,2-dimethylcyclopropancarboxylat; (S)-α-Cyano-3-phenoxybenzyl(1 R,3 R)-3-(2,2-dichlorvinyl)-2,2-dimethylcyclopropancarboxylat | 257-842-9 | 67375-30-8 | Acute Tox. 3 * STOT RE 2 * STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H301 H373** H335 H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H373** H335 H410 | M=1000 | ||
607-423-00-5 | Ester von Mecoprop und Mecoprop-P (ISO) | - | - | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | A | ||
607-424-00-0 | Trifloxystrobin (ISO); Methyl( E)-methoxyimino-{( E)-α-[1-(α,α,α-trifluor- m-tolyl)ethylidenaminooxy]- o-tolyl}acetat | - | 141517-21-7 | Lact. Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H362 H317 H400 H410 | GHS07 GHS09 Wng | H362 H317 H410 | M = 100 M = 10 | ||
607-425-00-6 | Metalaxyl (ISO); Methyl- N-(2,6-dimethylphenyl)- N-(methoxyacetyl)- DL -alaninat | 260-979-7 | 57837-19-1 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H302 H317 H412 | GHS07 Achtg. | H302 H317 H412 | |||
607-426-00-1 | 1,2-Benzoldicarbonsäure, Dipentylester, verzweigt und linear [1]; n-Pentyl-isopentylphthalat [2]; Di- n-pentylphthalat [3]; Diisopentylphthalat [4] | 284-032-2 [1] - [2] 205-017-9 [3] 210-088-4 [4] | 84777-06-0 [1] - [2] 131-18-0 [3] 605-50-5 [4] | Repr. 1B Aquatic Acute 1 | H360FD H400 | GHS08 GHS09 Gef. | H360FD H400 | |||
607-427-00-7 | Bromoxynil-Heptanoat (ISO); 2,6-Dibrom-4-cyanphenylheptanoat | 260-300-4 | 56634-95-8 | Repr. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H332 H302 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361d *** H332 H302 H317 H410 | |||
607-428-00-2 | Tetranatriumethylendiamintetraacetat | 200-573-9 | 64-02-8 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
607-429-00-8 | Edetinsäure; (EDTA); Ethylendiamintetraessigsäure | 200-449-4 | 60-00-4 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-430-00-3 | BBP; Benzylbutylphthalat | 201-622-7 | 85-68-7 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360Df H400 H410 | GHS08 GHS09 Gef. | H360Df H410 | |||
607-431-00-9 | Prallethrin (ISO); ETOC; 2-Methyl-4-oxo-3-(prop-2-ynyl)cyclopent-2-en-1-yl-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropancarboxylat | 245-387-9 | 23031-36-9 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H302 H400 H410 | GHS06 GHS09 Gef. | H331 H302 H410 | |||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-432-00-4 | S-Metolachlor; Reaktionsmasse aus (S)-2-Chlor- N-(2-ethyl-6-methylphenyl)- N-(2-methoxy-1-methyl-ethyl)-acetamid (80-100 %) [1]; (R)-2-Chlor- N-(2-ethyl-6-methylphenyl)- N-(2-methoxy-1-methylethyl)-acetamid (0-20 %) [2] | - [1] - [2] | 87392-12-9 [1] 178961-20-1 [2] | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-432-00-4 | S-Metolachlor (ISO); 2-Chlor- N-(2-ethyl-6-methylphenyl)- N-[(2 S)-1-methoxypropan-2-yl]acetamid; ( Ra Sa)-2-Chlor- N-(6-ethyl-o-tolyl)- N-[(1 S)-2-methoxy-1-methylethyl]acetamid [enthält 80-100 % 2-Chlor- N-(2-ethyl-6-methylphenyl)- N-[(2 S)-1-methoxypropan-2-yl]acetamid und 0-20 % 2-Chlor- N-(2-ethyl-6-methylphenyl)- N-[(2 R)-1-methoxypropan-2-yl]acetamid] | - | 87392-12-9 | Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H317 H410 | EUH066 | M = 10 M = 10 | ) |
607-433-00-X | Cypermethrin cis/trans +/-80/20; (RS)-α-Cyan-3-phenoxybenzyl(1 RS,3 RS,1 RS,3 SR)-3-(2,2-dichlorvinyl)-2,2-dimethylcyclopropancarboxylat | 257-842-9 | 52315-07-8 | Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H335 H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H335 H315 H317 H410 | |||
607-434-00-5 | Mecoprop- P (ISO) [1] und seine Salze; (R)-2-(4-Chlor-2-methylphenoxy)propionsäure [1] und ihre Salze | 240-539-0 [1] | 16484-77-8 [1] | Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H318 H400 H410 | GHS07 GHS05 GHS09 Dgr | H302 H318 H410 | oral:
ATE = 431 mg/kg KG M = 10 M = 10 | ||
607-435-00-0 | 2 S-Isopropyl-5 R-methyl-1 R-cyclohexyl-2,2-dihydroxyacetat | 416-810-6 | 111969-64-3 | STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 | H373 ** H318 H411 | GHS08 GHS05 GHS09 Gef. | H373 ** H318 H411 | |||
607-436-00-6 | 2-Hydroxy-3-(2-ethyl-4-methylimidazoyl)propylneodecanoat | 417-350-9 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H400 H410 | GHS05 GHS09 Gef. | H315 H318 H410 | |||
607-437-00-1 | 3-(4-Aminophenyl)-2-cyano-2-propensäure | 417-480-6 | 252977-62-1 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-438-00-7 | Methyl-2-[(aminosulfonyl)methyl]benzoat | 419-010-5 | 112941-26-1 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
607-439-00-2 | Methyltetrahydro-2-furancarboxylat | 420-670-1 | 37443-42-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-440-00-8 | Methyl-2-aminosulfonyl-6-(trifluormethyl)pyridin-3-carboxylat | 421-220-7 | 144740-59-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-441-00-3 | 3-[3-(2-Dodecyloxy-5-methylphenylcarbamoyl)-4-hydroxy-1-naphthylthio]propionsäure | 421-490-6 | 167684-63-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-442-00-9 | Benzyl-[hydroxy-(4-phenylbutyl)phosphinyl]acetat | 416-050-5 | 87460-09-1 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-444-00-X | Reaktionsmasse aus cis-1,4-Dimethylcyclohexyldibenzoat; trans-1,4-Dimethylcyclohexyldibenzoat | 416-230-3 | 35541-81-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-445-00-5 | Eisen(III)-tris(4-methylbenzolsulfonat) | 420-960-8 | 77214-82-5 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-446-00-0 | Methyl-2-[4-(2-chlor-4-nitrophenylazo)-3-(1-oxopropyl)amino]phenylaminopropionat | 416-240-8 | 155522-12-6 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
607-447-00-6 | Natrium-4-[4-(4-hydroxyphenylazo)phenylamino]-3-nitrobenzolsulfonat | 416-370-5 | 156738-27-1 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-448-00-1 | 2,3,5,6-Tetrafluorbenzoesäure | 416-800-1 | 652-18-6 | Skin Irrit. 2 Eye Dam. 1 | H315 H318 | GHS05 Gef. | H315 H318 | |||
607-449-00-7 | Reaktionsmasse aus 4,4",4""-[(2,4,6-Trioxo-1,3,5(2 H,4 H, 6H)-triazin-1,3,5-triyl)tris[methylen(3,5,5-trimethyl-3,1-cyclohexandiyl)iminocarbonyloxy-2,1-ethandiyl(ethyl)amino]]trisbenzoldiazoniumtri[bis(2-methylpropyl)naphthalinsulfonat]; 4,4",4"",4-[[5,5"-[Carbonylbis[imino(1,5,5-trimethyl-3,1-cyclohexandiyl)methylen]]-2,4,6-trioxo-1,3,5(2 H,4 H,6 H)-triazin-1,1",3,3"-tetrayl]tetrakis[methylen(3,5,5-trimethyl-3,1-cyclohexandiyl)iminocarbonyloxy-2,1-ethandiyl(ethyl)amino]]tetrakisbenzoldiazoniumtetra[bis(2-methylpropyl)naphthalinsulfonat] | 417-080-1 | - | Self-react.
D **** Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H242 H317 H400 H410 | GHS02 GHS07 GHS09 Gef. | H242 H317 H410 | |||
607-450-00-2 | 2-Mercaptobenzothiazolyl-( Z)-(2-aminothiazol-4-yl)-2-( tert-butoxycarbonyl)isopropoxyiminoacetat | 419-040-9 | 89604-92-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-451-00-8 | 4-[4-Amino-5-hydroxy-3-(4-(2-sulfoxyethylsulfonyl)phenylazo)-2,7-disulfonapht-6-ylazo]-6-[3-(4-amino-5-hydroxy-3-(4-(2-sulfoxyethylsulfonyl)phenylazo)-2,7-disulfonapht-6-ylazo]phenylcarbonylamino]benolsulfonsäure, Natriumsalz | 417-640-5 | 161935-19-9 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-453-00-9 | 4-Benzyl-2,6-dihydroxy-4-aza-heptylen-bis(2,2-dimethyloctanoat) | 418-100-1 | 172964-15-7 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
607-454-00-4 | Reaktionsmasse aus trans-2-(1-Methylethyl)-1,3-dioxane-5-carbonsäure und cis-2-(1-Methylethyl)-1,3-dioxan-5-carbonsäure | 418-170-3 | 116193-72-7 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-455-00-X | 1-Amino-4-(3-[4-chlor-6-(2,5-disulfophenylamino)-1,3,5-triazin-2-ylamino]-2,2-dimethylpropylamino)-anthrachinon-2-sulfonsäure, Natrium-/Lithiumsalz | 419-520-8 | 172890-93-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-456-00-5 | 3-Amino-4-chlorbenzoesäurehexadecylester | 419-700-6 | 143269-74-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-457-00-0 | Tetranatriumdihydrogen-1,1"" dihydroxy-8,8""-[ p-phenylbis(imino-{6-[4-(2-aminoethyl)piperazin-1-yl]}-1,3,5-triazin-4,2-diyl-imino)]bis(2,2"-azonaphthalin-1",3,6-trisulfonat) | 420-350-1 | 172277-97-3 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
607-458-00-6 | Reaktionsmasse aus 2-Ethyl-[2,6-dibrom-4-[1-[3,5-dibrom-4-(2-hydroxyethoxy)phenyl]-1-methylethyl]phenoxy]propenoat; 2,2"-Diethyl-[4,4"-bis(2,6-dibromphenoxy)-1-methylethyliden]dipropenoat und 2,2"-[(1-Methylethyliden)bis[[2,6-dibrom-4,1-phenylen)oxy]ethanol]] | 420-850-1 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-459-00-1 | Isopentyl-4-{2-[5-cyan-1,2,3,6-tetrahydro-1-(2-isopropoxyethoxycarbonylmethyl)-4-methyl-2,6-dioxo-3-pyridyliden]hydrazin}benzoat | 418-930-4 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-460-00-7 | 3-Tridecyloxypropylammonium-9-octadecenoat | 418-990-1 | 778577-53-0 | STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H319 H315 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H373 ** H319 H315 H410 | |||
607-461-00-2 | Reaktionsmasse aus Pentanatrium-2-{4-{3-methyl-4-[6-sulfonato-4-(2-sulfonato-phenylazo)-naphthalin-1-ylazo]-phenylamino}-6-[3-(2-sulfato-ethansulfonyl)-phenylamino]-1,3,5-triazin-2-ylamino}-benzol-1,4-disulfonat und Pentanatrium-2-{4-{3-methyl-4-[7-sulfonato-4-(2-sulfonato-phenylazo)-naphthalin-1-ylazo]-phenylamino}-6-[3-(2-sulfato-ethansulfonyl)-phenylamino]-1,3,5-triazin-2-ylamino}-benzol-1,4-disulfonat | 421-160-1 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
607-462-00-8 | Reaktionsmasse aus 1-Hexylacetat; 2-Methyl-1-pentylacetat; 3-Methyl-1-pentylacetat; 4-Methyl-1-pentylacetat; weiteren gemischten linearen und verzweigten C6-Alkylacetaten | 421-230-1 | 88230-35-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-463-00-3 | 3-(Phenothiazin-10-yl)propionsäure | 421-260-5 | 362-03-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-464-00-9 | Reaktionsmasse aus 7-Chlor-1-ethyl-6-fluor-1,4-dihydro-4-oxo-chinolin-3-carbonsäure und 5-Chlor-1-ethyl-6-fluor-1,4-dihydro-4-oxo-chinolin-3-carbonsäure | 421-280-4 | Aquatic Chronic 3 | H412 | - | H412 | ||||
607-465-00-4 | Tris(2-hydroxyethyl)ammonium-7-{4-[4-(2-cyanamino-4-hydroxy-6-oxidopyrimidin-5-ylazo)benzamido]-2-ethoxy-phenylazo}naphthalin-1,3-disulfonat | 421-440-3 | 778583-04-3 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-466-00-X | Reaktionsmasse aus Phenyl-1-(1-[2-chlor-5-(hexadecyloxycarbonyl)phenylcarbamoyl]-3,3-dimethyl-2-oxobutyl)-1 H-2,3,3a,7a-tetrahydrobenzotriazol-5-carboxylat; Phenyl-2-(1-(2-chlor-5-(hexadecyloxycarbonyl)phenylcarbamoyl)-3,3-dimethyl-2-oxobutyl)-1 H-2,3,3a,7a-tetrahydrobenzotriazol-5-carboxylat und Phenyl-3-(1-(2-chlor-5-(hexadecyloxycarbonyl)phenylcarbamoyl)-3,3-dimethyl-2-oxobutyl)-1 H-2,3,3a,7a-tetrahydrobenzotriazol-5-carboxylat | 421-480-1 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-467-00-5 | 1,1,3,3-Tetrabutyl-1,3-ditinoxydicaprylat | 419-430-9 | 56533-00-7 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H373 ** H314 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H312 H302 H373 ** H314 H410 | |||
607-468-00-0 | Reaktionsmasse aus Mononatrium-4-((4-(5-sulfonat-2-methoxyphenylamino)-6-chlor-1,3,5-triazin-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl-1,2-dihydropyridin-3-yl)azo)benzolsulfonat; Dinatrium-4-((4-(5-sulfonat-2-methoxyphenylamino)-6-chlor-1,3,5-triazin-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl-1,2-dihydropyridine-3-yl)azo)benzolsulfonat; Trinatrium-4-((4-(5-sulfonat-2-methoxyphenylamino)-6-chlor-1,3,5-triazin-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl-1,2-dihydropyridin-3-yl)azo)benzolsulfonat und Tetranatrium-4-((4-(5-sulfonat-2-methoxyphenylamino)-6-chlor-1,3,5-triazin-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl-1,2-dihydropyridin-3-yl)azo)benzolsulfonat | 419-450-8 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-469-00-6 | Dinatrium-7-((4,6-bis(3-diethylaminopropylamino)-1,3,5-triazin-2-yl)amino)-4-hydroxy-3-(4-(4-sulfonatophenylazo)phenylazo)-2-naphthalinsulfonat | 419-460-2 | 120029-06-3 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-470-00-1 | Kaliumnatrium-6,13-dichlor-3,10-bis{2-[4-[3-(2-hydroxysulfonyloxyethansulfonyl)phenylamino]-6-(2,5-disulfonatphenylamino)-1,3,5-triazin-2-ylamino]ethylamino}benzo[5,6][1,4]oxazino[2,3-b]phenoxazin-4,11-disulfonat | 414-100-0 | 154336-20-6 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-471-00-7 | 1,6-Bis((dibenzylthiocarbamoyl)disulfanyl)hexan | 429-280-6 | 151900-44-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-473-00-8 | Pentaerythritol, Dipentaerythritol, Fettsäuren, C6-10, Gemische von Estern der Adipinsäure, Heptansäure und Isostearinsäure | 426-590-3 | 187412-41-5 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-474-00-3 | (4-(4-(4-Dimethylaminobenzyliden-1-yl)-3-methyl-5-oxo-2-pyrazolin-1-yl)benzoesäure | 410-430-4 | 117573-89-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-475-00-9 | Reaktionsmasse aus Tetranatrium-7-(4-[4-chlor-6-[methyl-(3-sulfonatophenyl)amino]-1,3,5-triazin-2-ylamino]-2-ureidophenylazo)naphthalin-1,3,6-trisulfonat und Tetranatrium-7-(4-[4-chlor-6-[methyl-(4-sulfonatophenyl)amino]-1,3,5-triazin-2-ylamino]-2-ureidophenylazo)naphthalin-1,3,6-trisulfonat (1:1) | 412-940-2 | 148878-18-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-476-00-4 | Trinatrium- N, N-bis(carboxymethyl)-β-alanin | 414-070-9 | 129050-62-0 | Skin Corr. 1B Aquatic Chronic 3 | H314 H412 | GHS05 Gef. | H314 H412 | |||
607-477-00-X | (1α5α6α)-6-Nitro-3-benzyl-3-azabicyclo[3.1.0]hexanmethansulfonatsalz | 426-740-8 | - | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
607-478-00-5 | Tetramethylammoniumhydrogenphthalat | 416-900-5 | 79723-02-7 | Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 | H301 H373 ** H400 | GHS06 GHS08 GHS09 Gef. | H301 H373 ** H400 | |||
607-479-00-0 | Hexadecyl-4-chlor-3-[2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-4,4-dimethyl-3-oxopentamido]benzoat | 418-550-9 | 168689-49-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-480-00-6 | 1,2-Benzoldicarbonsäure; di-C7-11-verzweigte und lineare Alkylester | 271-084-6 | 68515-42-4 | Repr. 1B | H360Df | GHS08 Gef. | H360Df | |||
607-481-00-1 | Reaktionsmasse aus Trihexylcitrat; Dihexyloctylcitrat; Dioctylhexylcitrat und Dihexyldecylcitrat | 430-290-8 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-482-00-7 | N-[1-( S)-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl- N-carboxyanhydrid | 430-360-8 | 84793-24-8 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-483-00-2 | 1,2-Benzoldicarbonsäure; di-C6-8-verzweigte Alkylester, C7-reich | 276-158-1 | 71888-89-6 | Repr. 1B | H360D*** | GHS08 Gef. | H360D*** | |||
607-484-00-8 | Ethyl-2-{[3-acetylamino-4-(6-brom-2-methyl-1,3-dioxo-2,3-dihydro-1 H-isoindol-5-ylazo)phenyl{]ethylamino[}propionat | 430-480-0 | 221452-67-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-485-00-3 | (3 S-trans)-Phenyl-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorphenyl)-1-piperidincarboxylat | 430-510-2 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-486-00-9 | Kaliumnatrium-5"-(6-chlor-4-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino)-4"-hydroxy-2,3"-azodinaphthalin-1,2",5,7"-disulfonat | 402-110-8 | 110081-40-8 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-487-00-4 | Reaktionsmasse aus Dinatrium-4-(3-ethoxycarbonyl-4-(5-(3-ethoxycarbonyl-5-hydroxy-1-(4-sulfonatophenyl)pyrazol-4-yl)penta-2,4-dienyliden)-4,5-dihydro-5-oxopyrazol-1-yl)benzolsulfonat und Trinatrium-4-(3-ethoxycarbonyl-4-(5-(3-ethoxycarbonyl-5-oxido-1-(4-sulfonatophenyl)pyrazol-4-yl)penta-2,4-dienyliden)-4,5-dihydro-5-oxopyrazol-1-yl)benzolsulfonat | 402-660-9 | - | Repr. 1B Aquatic Chronic 3 | H360D *** H412 | GHS08 Gef. | H360D *** H412 | |||
607-488-00-X | Ethyl-(2-acetylamino-5-fluor-4-isothiocyanatophenoxy)acetat | 414-210-9 | 147379-38-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-489-00-5 | Reaktionsmasse aus 2-Ethylhexyllinolenat, -linolat und -oleat; 2-Ethylhexylepoxyoleat; 2-Ethylhexyldiepoxylinolat; 2-Ethylhexyltriepoxylinolenat | 414-890-7 | 71302-79-9 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-490-00-0 | N-[2-Hydroxy-3-(C12-16-alkyloxy)propyl]- N-methylglycinat | 415-060-7 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-491-00-6 | Reaktionsmasse aus Diestern von 4,4"-Methylenbis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethyl phenol] und 6-Diazo-5,6-dihydro-5-oxonaphthalin-1-sulfonsäure (1:2) und Triestern von 4,4"-Methylenbis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] und 6-Diazo-5,6-dihydro-5-oxonaphthalin-1-sulfonsäure (1:3) | 427-140-9 | - | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
607-492-00-1 | 2-(1-(3",3"-Dimethyl-1"-cyclohexyl)ethoxy)-2-methylpropylpropanoat | 415-490-5 | 141773-73-1 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-493-00-7 | Methyl-(3a R,4 R,7a R)-2-methyl-4-(1 S,2 R,3-triacetoxypropyl)-3a,7a-dihydro-4 H-pyrano[3,4-d]oxazol-6-carboxylat | 415-670-3 | 78850-37-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-494-00-2 | Bis(2-ethylhexyl)octylphosphonat | 417-170-0 | 52894-02-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-495-00-8 | Natrium-4-sulfophenyl-6-((1-oxononyl)amino)hexanoat | 417-550-6 | 168151-92-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-496-00-3 | 2,2"-Methylenbis(4,6-di- tert-butyl-phenyl)-2-ethylhexylphosphit | 418-310-3 | 126050-54-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-497-00-9 | Ceriumoxidisostearat | 419-760-3 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-498-00-4 | (E)-3,7-Dimethyl-2,6-octadienylhexadecanoat | 421-370-3 | 3681-73-0 | Skin Irrit. 2 Aquatic Chronic 4 | H315 H413 | GHS07 Achtg. | H315 H413 | |||
607-499-00-X | Bis(dimethyl-(2-hydroxyethyl)ammonium)-1,2-ethandiyl-bis(2-hexadecenylsuccinat) | 421-660-1 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
607-500-00-3 | Calcium-2,2,bis[(5-tetrapropylen-2-hydroxy)phenyl]ethanoat | 421-670-4 | - | Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H315 H400 H410 | GHS07 GHS09 Achtg. | H315 H410 | |||
607-501-00-9 | Reaktionsmasse aus Triphenylthiophosphat und tert-butylierten Phenylderivaten | 421-820-9 | 192268-65-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-502-00-4 | (N-Benzyl- N, N,N-tributyl)ammonium-4-dodecylbenzolsulfonat | 422-200-0 | 178277-55-9 | Skin Corr. 1B Acute Tox. 4 * Aquatic Chronic 2 | H314 H302 H411 | GHS05 GHS07 GHS09 Gef. | H314 H302 H411 | |||
607-503-00-X | 2,4,6-Tri- n-propyl-2,4,6-trioxo-1,3,5,2,4,6-trioxatriphosphorinan | 422-210-5 | 68957-94-8 | Skin Corr. 1B | H314 | GHS05 Gef. | H314 | |||
607-504-00-5 | Diammonium-1-hydroxy-2-(4-(4-carboxyphenylazo)-2,5-dimethoxyphenylazo)-7-amino-3-naphthalinsulfonat | 422-670-7 | - | Repr. 2 Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H361f H301 H373** H400 H410 | GHS06 GHS08 GHS09 Gef. | H361f H301 H373** H410 | |||
607-505-00-0 | Pentanatrium-7-(4-(4-(5-amino-4-sulfonato-2-(4-((2-(sulfonatoethoxy)sulfonyl)phenylazo)phenylamino)-6-chlor-1,3,5-triazin-2-yl)amino-2-ureidophenylazo)naphtalin-1,3,6-trisulfonat | 422-930-1 | Aquatic Chronic 3 | H412 | - | H412 | ||||
607-506-00-6 | Reaktionsmasse aus Strontium-(4-chlor-2-((4,5-dihydro-3-methyl-5-oxo-1-(3-sulfonatophenyl)-1 H-pyrazol-4-yl)azo)-5-methyl)benzolsulfonat und Dinatrium-(4-chlor-2-((4,5-dihydro-3-methyl-5-oxo-1-(3-sulfonatophenyl)-1 H-pyrazol-4-yl)azo)-5-methyl)benzolsulfonat | 422-970-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | ||||
607-507-00-1 | Kalium, Natrium-2,4-diamino-3-[4-(2-sulfonatoethoxysulfonyl)phenylazo]-5-[4-(2-sulfonatoethoxysulfonyl)-2-sulfonatophenylazo]-benzolsulfonat | 422-980-2 | 187026-95-5 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-508-00-7 | Dinatrium-3,3"-[iminobis[sulfonyl-4,1-phenylen-(5-hydroxy-3-methylpyrazol-1,4-diyl)azo-4,1-phenylensulfonylimino-(4-amino-6-hydroxypyrimidin-2,5-diyl)azo-4,1-phenylensulfonylimino(4-amino-6-hydroxypyrimidin-2,5-diyl)azo]bis(benzolsulfonat)] | 423-110-4 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-509-00-2 | 2-Phenoxyethyl-4-aminobenzoat | 430-880-5 | 88938-23-2 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-510-00-8 | (2 S,5 R)-6,6-Dibrom-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-carbonsäure-4,4-dioxid | 427-200-4 | 76646-91-8 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H302 H315 H318 H317 | GHS05 GHS07 Gef. | H302 H315 H318 H317 | |||
607-511-00-3 | Reaktionsmasse aus 4-[(3-Decyloxypropyl)(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)amino]-4-oxobuttersäure und 4-[(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)(3-octyloxypropyl)amino]-4-oxobutttersäure | 423-750-4 | - | Eye Irrit. 2 Aquatic Chronic 2 | H319 H411 | GHS07 GHS09 Achtg. | H319 H411 | |||
607-512-00-9 | Trinatrium-2,4-diamino-3,5-bis-[4-(2-sulfonatoethoxy)sulfonyl)phenylazo]benzolsulfonat | 423-970-0 | 182926-43-8 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-513-00-4 | Reaktionsmasse aus Trinatrium-4-benzoylamino-6-(6-ethensulfonyl-1-sulfatonaphthalin-2-ylazo)-5-hydroxynaphthalin-2,7-disulfonat; 5-(Benzoylamino)-4-hydroxy-3-((1-sulfo-6-((2-(sulfooxy)ethyl)sulfonyl)-2-naphthyl)azo)naphthalin-2,7-disulfonsäurenatriumsalz und 5-(Benzoylamino)-4-hydroxy-3-((1-sulfo-6-((2-(sulfooxy)ethyl)sulfonyl)-2-naphthyl)azo)naphthalin-2,7-disulfonsäure | 423-200-3 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
607-514-00-X | Kalium- N-(1-methoxy-1-oxobut-2-en-3-yl)valinat | 427-240-2 | 134841-35-3 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-515-00-5 | Gemisch aus Dinatriumhexyldiphenyletherdisulfonat und Dinatriumdihexyldiphenyletherdisulfonat | 429-650-7 | 147732-60-3 | Eye Irrit. 2 Aquatic Chronic 2 | H319 H411 | GHS07 GHS09 Achtg. | H319 H411 | |||
607-516-00-0 | N, N"-Bis(trifluoracetyl)- S, S"-bis- L-homocystein | 429-670-6 | 105996-54-1 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-517-00-6 | (S)-α-(Acetylthio)benzolpropans äure | 430-300-0 | 76932-17-7 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 | H302 H318 H317 | GHS05 GHS07 Gef. | H302 H318 H317 | |||
607-518-00-1 | 3-Oxoandrost-4-en-17-β-carbonsδ ure | 414-990-0 | 302-97-6 | Repr. 2 Aquatic Chronic 4 | H361f H413 | GHS08 Achtg. | H361f H413 | |||
607-519-00-7 | Poly-[((4-((4-ethylethylen)amino)phenyl)-((4-(ethyl-(2-oxyethylen)amino)phenyl)methinyl)cyclohexa-2,5-dienyliden)- N-ethyl- N-(2-hydroxyethyl)ammoniumacetat] | 427-280-0 | 176429-27-9 | STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H335 H315 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H335 H315 H318 H410 | |||
607-520-00-2 | Reaktionsmasse aus Natrium-4,5-dihydro-2-[(propionato)(C6-18)alkyl]-3 H-imidazolium- N-ethylphosphat und Dinatrium-4,5-dihydro-2-[(dipropionato)(C6-18)alkyl]-3 H-imidazolium- N-ethylphosphat | 427-740-0 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-521-00-8 | Tetraethyl- N, N"-(methylendicyclohexan-4,1-diyl)bis-DL-aspartat | 429-270-1 | 136210-30-5 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-522-00-3 | Natriumsalz des Polymers von Natrium-2-methyl-buta-1,3-dien-1-sulfonat mit Acrylsäure und 2-Hydroxyethyl-2-methylacrylat | 429-720-7 | 184246-86-4 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-523-00-9 | Reaktionsmasse aus Mono- bis Tetra(lithium und/oder -natrium)3-amino-10-[4-(4-amino-3-sulfonatanilin)-6-[methyl-(2-sulfonatethyl)amino]-1,3,5-triazin-2-ylamino]-6-13-dichlorbenzo[1,2-B:4,5-B"]di[1,4]benzoxazin-4,11-disulfonat; Mono- bis Tetra(lithium und/oder -natrium)3-amino-10-[4,6-bis(4-amino-3-sulfonatanilin)-1,3,5-triazin-2-ylamino]-6-13-dichlorbenzo[1,2-B:4,5-B"]di[1,4]benzoxazin-4,11-disulfonat; Mono- bis Penta(lithium und/oder -natrium)10,10"-diamino-6,6",13,13"-tetrachlor-3,3"-[6-[methyl-(2-sulfonatethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B"]di[1,4]benzoxazin-4,11-disulfonat; Mono- bis Hepta(lithium und/oder -natrium)10- amino-6,6",13,13"-tetrachlor-10"[4-(4-amino-3-sulfonatanilin)-[6-methyl-(2-sulfonatethyl)amino]-1,3,5-triazin-2,4-diimino]bis[benzo[1,2-B:4,5-B"]di[1,4]benzoxazin-4,11-disulfonat; Mono- bis Hepta(lithium und/oder -natrium)10,10"-diamino-6,6",3,3"[(2-sulfonat)-1,4-phenylendiiminobis[6-methyl-(2-sulfonatethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B"]di[1,4]benzoxazin-4,11-disulfonat | 430-200-7 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-524-00-4 | Tallöl-2-[(tetrahydro-2 H-pyran-2-yl)thio]ethylester | 430-310-5 | - | Aquatic Chronic 4 | H413 | H413 | ||||
607-525-00-X | (Z)-2-Methoxyimino-2-[2-(tritylamino)thiazol-4-yl]essigsäure | 431-520-1 | 64485-90-1 | Flam. Sol. 1**** Carc. 2 Aquatic Chronic 3 | H228 H351 H412 | GHS02 GHS08 Gef. | H228 H351 H412 | |||
607-526-00-5 | Cartap (ISO); 1,3-Di(carbamoylthio)-2-dimethylaminopropan | - | 15263-53-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-527-00-0 | Reaktionsmasse aus 1-(1" H,1" H,2" H,2" H-Tridecafluoroctyl)-12-(1"" H,1"" H,2"" H,2"" H- tridecafluoroctyl)dodecandioat; 1-(1" H,1" H,2" H,2" H-Tridecafluoroctyl)-12-(1"" H,1"" H,2"" H,2"" H-heptdecafluordecyl)dodecandioat; 1-(1" H,1" H,2" H,2" H-Tridecafluoroctyl)-12-(1"" H,1"" H,2"" H,2"" H-heneicosafluordodecyl)dodecandioat; 1-(1" H,1" H,2" H,2" H-Tridecafluoroctyl)-12-(1"" H,1"" H,2"" H,2"" H-pentacosafluortetradecyl)dodecandioat; 1-(1" H,1" H,2" H,2" H-Heptadecafluordecyl)-12-(1"" H,1"" H,2"" H,2"" H-heptadecafluordecyl)dodecandioat; 1-(1" H,1" H,2" H,2" H-Heptadecafluordecyl)-12-(1""H,1""H,2""H,2""H- heneicosafluordodecyl)dodecandioat | 423-180-6 | - | STOT RE 2 * | H373 ** | GHS08 Achtg. | H373 ** | |||
607-528-00-6 | (S)-3-Methyl-2-(2-oxotetrahydropyrimidin-1-yl)buttersäure | 430-900-2 | 192725-50-1 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-529-00-1 | Benzyl- cis-4-ammonium-4"-toluolsulfonato-1-cyclohexancarboxylat | 426-070-6 | 67299-45-0 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-530-00-7 | Reaktionsmasse aus Isomeren von C7-9-Alkyl-3-(3,5-di- tert-butyl-4-hydroxyphenyl)propionat | 406-040-9 | 125643-61-0 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-531-00-2 | Methyl-3-amino-4,6-dibrom-2-methylbenzoat | 425-190-6 | 119916-05-1 | STOT RE 2 * Aquatic Chronic 2 | H373** H411 | GHS08 GHS09 Achtg. | H373** H411 | |||
607-532-00-8 | (S)-1-[2- tert-Butoxycarbonyl-3-(2-methoxyethoxy)propyl]-1-cyclopentancarbonsäure, Cyclohexylaminsalz | 425-510-4 | 167944-94-7 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-533-00-3 | Pentanatriummonohydrogen-6-chlor-3,10-bis[2-[4-chlor-6- (2,4-disulfophenylamino)-1,3,5-triazin-2-yl-amino]ethylamino]-13-ethylbenzo[5.6][1.4]oxazino[2,3-b]phenoxazin-4,11-disulfonat | 414-910-4 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-534-00-9 | Ethyl-2-(3-benzoylphenyl)propanoat | 414-920-9 | 60658-04-0 | Acute Tox. 3 * STOT RE 1 Skin Sens. 1 Aquatic Chronic 2 | H301 H372** H317 H411 | GHS06 GHS08 GHS09 Gef. | H301 H372** H317 H411 | |||
607-535-00-4 | Kalium-4-iod-2-sulfonatobenzoesäure | 426-620-5 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-536-00-X | (2,6-Xylyloxy)essigsäure | 430-910-7 | 13335-71-2 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
607-537-00-5 | Isopropylammonium-2-(3-benzoylphenyl)propionat | 417-970-1 | - | Acute Tox. 3 * Acute Tox. 4 * STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H312 H372** H318 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H301 H312 H372** H318 H410 | |||
607-539-00-6 | Propyl((4-(5-oxo-3-propylisoxazolidin-4-ylidenmethin)phenyl)propoxycarbonylmethylenamino)acetat | 431-000-2 | 198705-81-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-540-00-1 | 1-(Mercaptomethyl)cyclopropylessigsäure | 420-240-3 | 162515-68-6 | Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H314 H312 H302 H317 H411 | GHS05 GHS07 GHS09 Gef. | H314 H312 H302 H317 H411 | |||
607-541-00-7 | [(1-Methyl-1,2-ethandiyl)bis[nitrilobis(methylen)]]tetrakis(phosphonsäure) | 421-940-1 | 28698-31-9 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
607-542-00-2 | Methyl-2-(4-butansulfonamidphenoxy)tetradecanoat | 422-110-1 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-543-00-8 | Poly-[((4-((4-(ethyl-ethylen)amino)phenyl)-(4-(ethyl-(2-oxyethylen)amino)phenyl)methinyl)-3-methylcyclohexa-2,5-dienyliden)- N-ethyl- N-(2-hydroxyethyl)ammoniumacetat] | 427-480-8 | 176429-22-4 | STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H335 H315 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H335 H315 H318 H410 | |||
607-544-00-3 | Ethyl-6,8-difluor-1-(formylmethylamino)-1,4-dihydro-7-(4-methyl)piperazin-1-yl)-4-oxo-chinolin-3-carboxylat | 427-490-2 | 158585-86-5 | Aquatic Chronic 3 | H412 | - | H412 | |||
607-545-00-9 | 1,2-Dimethyl-3-(1-methylethenyl)cyclopentylacetat | 424-070-0 | 94346-09-5 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
607-546-00-4 | Reaktionsmasse aus Methyl-{[5-acetylamino-4-(2-chlor-4-nitrophenylazo)phenyl]methoxycarbonylmethylamino}acetat und Methyl-{[5-acetylamino-4-(2-chlor-4-nitrophenylazo)phenyl]ethoxycarbonylmethylamino}acetat | 424-290-7 | 188070-47-5 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-547-00-X | 18-Methylnonadecyl-2,2-dimethylpropanoat | 424-370-1 | 125496-22-2 | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 | H315 H317 H413 | GHS07 Achtg. | H315 H317 H413 | |||
607-548-00-5 | 1-(2,4-Dichlorphenyl)-2-(1 H-imidazol-1-yl)ethanonmethansulfonat | 431-010-7 | 154486-26-7 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
607-549-00-0 | Methyl-( E)-2((3-(1,3-benzodioxol-5-yl)-2-methyl-1-propenyl)amino)benzoat | 424-430-7 | 125778-19-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-550-00-6 | 2-Amino-4-brom-5-chlorbenzoesäure | 424-700-4 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-551-00-1 | Tetrabutylammonium-2-amino-6-iodpurinat | 424-710-9 | 156126-48-6 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H312 H302 H373** H315 H318 H317 H411 | GHS05 GHS08 GHS07 GHS09 Gef. | H312 H302 H373** H315 H318 H317 H411 | |||
607-552-00-7 | Hexadecyl-3-amino-4-isopropoxybenzoat | 424-830-1 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-553-00-2 | 7-Amino-4-hydroxy-2-naphthalinsulfonsäure, gekoppelt mit 5- (oder 8-)Amino-8 (oder 5)-[[4-[[4-[[4-amino-6(oder 7)-sulfo-1-naphthyl]azo]phenyl]amino]-3-sulfophenyl]azo]-2-naphthalinsulfonsäure und 4-hydroxy-7-(phenylamino)-2-naphthalinsulfonsäure, Natriumsalz | 424-850-0 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-554-00-8 | 2,4-Diamino-5-[4-[(2-sulfoxylethyl)sulfonyl]phenylazo]benzolsulfonsäure | 424-870-1 | 27624-67-5 | Expl. 1.1 Eye Dam. 1 Aquatic Chronic 3 | H201 H318 H412 | GHS01 GHS05 Gef. | H201 H318 H412 | |||
607-555-00-3 | 1,1,3,3-Tetramethylbutylperoxypivalat | 424-980-8 | 22288-41-1 | Flam. Liq. 2 Org. Perox. D Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H225 H242 H315 H317 H411 | GHS02 GHS07 GHS09 Gef. | H225 H242 H315 H317 H411 | |||
607-556-00-9 | 2-Acetoxymethylen-4-acetylphenylacetat | 425-160-2 | 24085-06-1 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H318 H317 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H302 H373** H318 H317 H410 | |||
607-557-00-4 | Salz von (1 S- cis)-1-Amino-2,3-dihydro-1 H-inden-2-ol und [ R-[ R* R*]]-2,3-Dihydroxybernsteinsäure | 425-210-3 | 169939-84-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-558-00-X | 2 S-Isopropyl-5 R-methyl-1 R-cyclohexyl-(2 R,5 S)-5-(4-amino-2-oxo-2 H-pyrimidin-1-yl)-[1.3]-oxathiolan-2-carboxylat | 425-250-1 | 147027-10-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-559-00-5 | Kokosöl, Reaktionsprodukte mit Acylglycerinen der 3,5-Bis(1,1-dimethylethyl)-4-hydroxybenzolpropansäure | 425-400-6 | 179986-09-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-560-00-0 | (R, S)-2-Butyloctandisäure | 431-210-4 | 50905-10-7 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-561-00-6 | Natrium-4-hydroxy-3-( N"-(2-(2-hydroxyethylensulfonyl)ethylen)ureido)-5-nitrobenzolsulfonat | 425-460-3 | - | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-562-00-1 | Reaktionsmasse aus (2 R,3 R)-3-(2-Ethoxyphenoxy)-2-hydroxy-3-phenylpropylammoniummethansulfonat und (2 S,3 S)-3-(2-Ethoxyphenoxy)-2-hydroxy-3-phenylpropylammoniummethansulfonat | 425-530-3 | 98769-75-6 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
607-563-00-7 | 5,7-Dichlor-4-hydroxychinolin-3-carbonsäure | 431-250-2 | 171850-30-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-564-00-2 | 1,6-Hexandiammonium, Natrium-5-sulfato-1,3-benzoldicarboxylat | 425-730-0 | 51178-75-7 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-565-00-8 | 3-Ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat | 425-820-1 | 88150-42-9 | Acute Tox. 3 * STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H373** H318 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H301 H373** H318 H410 | |||
607-566-00-3 | Reaktionsmasse aus Dodecylphenyl-dodecylhydroxybenzolcarboxylat und Bis(dodecylphenyl)dodecyl-hydroxybenzoldicarboxylat | 426-140-6 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-567-00-9 | Kalium-3-iod-6-methylbenzolsulfonat | 426-300-5 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-568-00-4 | Kalium-2-chlor-3-(benzyloxy)propionat | 426-350-8 | 138666-92-9 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H302 H373** H318 H317 | GHS05 GHS08 GHS07 Gef. | H302 H373** H318 H317 | |||
607-569-00-X | Reaktionsmasse aus Natrium-2-amino-4-(2,6-difluorpyrimidin-4-ylamino)benzolsulfonat und Natrium-2-amino-4-(4,6-difluorpyrimidin-4-ylamino)benzolsulfonat | 426-470-0 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-570-00-5 | Natrium-(6 R-trans)-7-amino-8-oxo-3-[[[1-(sulfomethyl)-1 H-tetrazol-5-yl]thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylatmonohydrat | 426-520-1 | 71420-85-4 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-571-00-0 | 2-Cyclopenten-1-essigsäure, 3-Hydroxy-2-pentyl-, methyl-esteracetat | 431-400-7 | 57374-49-9 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-572-00-6 | Diethylthiophosphoryl-( Z)-(2-aminothiazol-4-yl)methoxyiminoacetat | 426-790-0 | 162208-27-7 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H373** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H312 H302 H373** H317 H410 | |||
607-573-00-1 | Reaktionsmasse aus Dinatrium-7-(2,4-difluorpyrimidin-6-ylamino)-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)naphthalin-2-sulfonat und Dinatrium-7-(4,6-difluorpyrimidin-2-ylamino)-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)naphthalin-2-sulfonat | 426-840-1 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-574-00-7 | [1 R-(1-α,2β,5α )]-Mono[5-methyl-2-(1-methylethyl)cyclohexyl]butandioat | 426-890-4 | 77341-67-4 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-575-00-2 | 4-(5-(5-[1-(4-Carboxyphenyl)hexahydro-2,4,6-trioxopyrimidin-5-yliden]penta-1,3-dienyl)-1,2,3,4-tetrahydro-6-hydroxy-2,4-dioxopyrimidin-1-yl)benzoesäure, Triethylaminsalz | 426-900-7 | - | STOT SE 3 Aquatic Chronic 3 | H335 H412 | GHS07 Achtg. | H335 H412 | |||
607-576-00-8 | Verzweigtes Octyl-3-[3,5-di( tert-butyl)-4-hydroxyphenyl]propanoat | 427-030-0 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-577-00-3 | (2 R*,3 S*)-2-(2,4-Difluorphenyl)-3-(5-fluor-4-pyrimidinyl)-1-(1 H-1,2,4-triazol-1-yl)butan-2-ol-(1 R)-10-camphersulfonat | 427-100-0 | - | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H302 H318 H317 H412 | GHS05 GHS07 Gef. | H302 H318 H317 H412 | |||
607-578-00-9 | Ethyl-4-((4-diethylamino-2-methylphenyl)imino)-4,5-dihydro-1-isopropyl-5-oxo-1 H-pyrazol-3-carboxylat | 427-110-5 | - | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 4 | H302 H373** H413 | GHS08 GHS07 Achtg. | H302 H373** H413 | |||
607-579-00-4 | Diethyl[( p-ethoxyanilino)methylen]malonat | 431-430-0 | 103976-28-9 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
607-580-00-X | Ethyl-7-chlor-1-(2,4-difluorphenyl)-6-fluor-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylat | 422-360-1 | 100491-29-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-581-00-5 | Ethyl-2-ethoxy-4-carboxymethylbenzoat | 427-630-2 | 99469-99-5 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-582-00-0 | Reaktionsmasse aus Tetranatrium-7-(4-(4-fluor-6-(4-(2-sulfonatoethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalin-1,3,6-trisulfonat und Tetranatrium-7-(4-(4-hydroxy-6-(4-(2-sulfonatoethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalin-1,3,6-trisulfonat | 427-650-1 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
607-583-00-6 | 4-Amino-3-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]-1-naphthalinsulfonsäure | 427-680-5 | 188907-52-0 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
607-584-00-1 | Trinatrium-3-[2-acetylamino-4-[4-chlor-6-[4-(2-sulfonatoxyethylsulfonyl)phenylamino]-1,3,5-triazin-2-ylamino]phenylazo]naphthalin-1,5-disulfonat | 427-710-7 | 215612-56-9 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
607-585-00-7 | Strontium-2-[(2-hydroxy-6-sulfonato-1-naphthyl)azo]naphthalin-1-sulfonat | 427-930-3 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-586-00-2 | Dodecyl-3-amino-4-chlorbenzoat | 428-020-9 | 6195-20-6 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
607-587-00-8 | Ethyl- cis-4-[4-[[2-(2,4-dichlorphenyl)-2-(1 H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-carboxylat | 428-030-3 | 67914-69-6 | Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H410 | |||
607-588-00-3 | Reaktionsmasse aus 2-Ethylhexyl-2,3,4,5-tetrabrombenzoat und Bis(2-ethylhexyl)-3,4,5,6-tetrabromphthalat | 428-050-2 | - | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
607-589-00-9 | Tetrakis(1,2,2,6,6-pentamethyl-4-piperidyl)-1,2,3,4-butantetracarboxylat | 428-070-1 | 91788-83-9 | STOT RE 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H372** H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H372** H302 H410 | |||
607-590-00-4 | Hexadecyl-3-[2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-4,4-dimethyl-3-oxovaleramido]-4-isopropoxybenzoat | 428-140-1 | 210706-50-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-591-00-X | Reaktionsmasse aus Trinatrium-5-(4-fluor-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(4-(2-sulfooxyethansulfonyl)phenylazo)naphthalin-2,7-disulfonat und Dinatrium-3-(4-ethensulfonylphenylazo)-5-(4-fluor-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxynaphthalin-2,7-disulfonat | 428-400-4 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-592-00-5 | Di(C9-11-alkyl)-cyclohexan-1,4-dicarboxylat | 428-870-0 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-593-00-0 | 4-(2-Methylacryloyloxy)phenyl-4-allyloxybenzoat | 429-000-2 | 159235-16-2 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-594-00-6 | Ethyl-(1 S,5 R,6 S)-5-(1-ethylpropoxy)-7-oxabicyclo[4.1.0]hept-3-en-3-carboxylat | 429-020-1 | 204254-96-6 | STOT RE 2 * Skin Sens. 1 | H373** H317 | GHS08 GHS07 Achtg. | H373** H317 | |||
607-595-00-1 | N-Amidino- N-methylglycin-2-oxopropionat | 429-120-5 | 208535-04-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-596-00-7 | Ethyl-2-(4-phenoxyphenyl)lactat | 429-220-9 | 132584-17-9 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
607-597-00-2 | Tetranatrium-4,4"-bis{4-[4-(2-hydroxyethylamino)-6-(4-sulfonatoanilino)-1,3,5-triazin-2-ylamino]phenylazo}stilben-2,2"-disulfonat | 429-230-3 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-598-00-8 | Trinatrium-3-amino-4-[4-[4-(2-(2-ethenylsulfonylethoxy)ethylamino)-6-fluor-1,3,5-triazin-2-ylamino]-2-sulfophenylazo]-5-hydroxynaphthalin-2,7-disulfonat | 429-240-8 | 212652-59-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-599-00-3 | 1,1-Dimethylpropyl-3,5,5-trimethylperoxyhexanoat | 431-610-9 | 68860-54-8 | Org. Perox.
D Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H242 H317 H400 H410 | GHS02 GHS07 GHS09 Gef. | H242 H317 H410 | |||
607-600-00-7 | (1 S,1" R)-[1-(3",3"-Dimethyl-1"-cyclohexyl)ethoxycarbonyl]methylpropanoat | 431-700-8 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-601-00-2 | 1,4-Dihydroxy-2,2,6,6-tetramethylpiperidinium-2-hydroxy-1,2,3-propantricarboxylat | 429-370-5 | 220410-74-2 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-602-00-8 | Ethyl-(3-cyanomethyl-3,4-dihydro-4-oxophthalazin-1-yl)acetat | 429-680-0 | 122665-86-5 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-603-00-3 | Lithium-natrium-4,4",4""-(nitrilotris(ethan-2,1-diylimino(6-chlor-1,3,5-triazin-4,2-diyl)imino))tris(5-hydroxy-6-(1-sulfonaphthalin-2-ylazo)-2,7-naphthalin)disulfonat | 429-730-1 | 193562-37-7 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-604-00-9 | Guanidiniumbenzoat | 429-820-0 | 26739-54-8 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-605-00-4 | Methyl-4-iod-2-(3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)ureidosulfonyl)benzoat | 429-890-2 | 144550-06-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-606-00-X | (Z)-2-(2- tert-Butoxycarbonylamino-4-thiazolyl)pent-2-ensäure | 430-100-3 | 86978-24-7 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-607-00-5 | Reaktionsmasse aus Calcium-bis(C10-14-verzweigtem Alkylsalicylat); Calcium-bis(C18-30-alkylsalicylat); Calcium-C10-14-verzweigtem Alkylsalicylato-C18-30-alkylsalicylat; Calcium-bis(C10-14-verzweigtem Alkylphenolat); Calcium-bis(C18-30-Alkylphenolat); Calcium-C10-14-verzweigtem Alkylphenolato-C18-30-alkylphenolat; C10-14-verzweigtem Alkylphenol und C18-30-Alkylphenol | 430-180-1 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
607-608-00-0 | Pentakalium-2-(4-{5-[1-(2,5-disulfophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-yliden]-3-(2-pyrrolidinon-1-yl)-1,3-pentadienyl}-3-methylcarbamoyl-5-oxopyrazol-1-yl)benzol-1,4-disulfonat | 430-210-1 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-609-00-6 | Ethyl-(3 R)-4-cyano-3-hydroxybutanoat | 430-220-6 | 141942-85-0 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-610-00-1 | Trinatrium-4-hydroxy-6-(sulfonatomethylamino)-5-(2-(2-sulfatoethylsulfonyl)phenylazo)naphthalin-2-sulfonat | 430-280-3 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-611-00-7 | Methyl-3-amino-2,2,3-trimethylbutyrat | 431-720-7 | 90886-53-6 | Skin Corr. 1B Acute Tox. 4 * Aquatic Chronic 3 | H314 H302 H412 | GHS05 GHS07 Gef. | H314 H302 H412 | |||
607-612-00-2 | Reaktionsmasse aus 3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluor-1-octansulfonsäure und Ammonium-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluor-1-octansulfonat | 432-190-1 | 182176-52-9 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 | H302 H373** H318 | GHS05 GHS08 GHS07 Gef. | H302 H373** H318 | |||
607-613-00-8 | Reaktionsmasse aus Bernsteinsäure, Monoperbernsteinsäure, Diperbernsteinsäure, Monomethylester von Bernsteinsäure, Monomethylester von Perbernsteinsäure, Dimethylsuccinat, Glutarsäure, Monoperglutarsäure, Diperglutarsäure, Monomethylester von Glutarsäure, Monomethylester von Perglutarsäure, Dimethylglutarat, Adipinsäure, Monoperadipinsäure, Diperadipinsäure, Monomethylester von Adipinsäure, Monomethylsäure von Peradipinsäure, Dimethyladipat, Wasserstoffperoxid, Methanol und Wasser | 432-790-1 | Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* Skin Corr. 1B STOT SE 2 | H332 H312 H302 H314 H371 (Augen) | GHS07 GHS05 GHS08 Gef. | H332 H312 H302 H314 H371 (Augen) | ||||
607-614-00-3 | 2-(10-Oxo-10 H-9-oxa-10-phosphaphenanthren-10-ylmethyl)bernsteinsäure | 426-480-5 | 63562-33-4 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
607-615-00-9 | Reaktionsprodukt von Thioglycerin und Mercaptoessigsäure, vorwiegend bestehend aus 3-Mercapto-1,2-bismercaptoacetoxypropan und Oligomeren dieses Stoffs | 431-120-5 | - | Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 | H331 H302 H319 H317 | GHS06 Gef. | H331 H302 H319 H317 | |||
607-616-00-4 | 2,4-Dichlor-5-fluorbenzoylchlorid | 428-390-1 | 86393-34-2 | STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H335 H315 H318 H317 H412 | GHS05 GHS07 Gef. | H335 H315 H318 H317 H412 | |||
607-617-00-X | Bis(2-ethylhexyl)-4,5-epoxycyclohexan-1,2-dicarboxylat | 430-700-5 | 10138-36-0 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-618-00-5 | Menadion-Natriumbisulfit; 2-Naphthalinsulfonsäure-1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-, Natriumsalz | 204-987-0 | 130-37-0 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H315 H410 | |||
607-619-00-0 | Menadion-Nicotinamidbisulfit; 1,2,3,4-Tetrahydro-2-methyl-1,4-dioxonaphthalin-2-sulfonsäure, Verbindung mit Nicotin-3-amid (1:1) | 277-543-7 | 73581-79-0 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H315 H410 | |||
607-620-00-6 | Trinatriumnitriltriacetat | 225-768-6 | 5064-31-3 | Carc. 2 Acute Tox. 4 * Eye Irrit. 2 | H351 H302 H319 | GHS08 GHS07 Achtg. | H351 H302 H319 | Carc. 2; H351: C ≥ 5 % | ||
607-621-00-1 | Milbemectin (ISO); [Reaktionsmasse aus Milbemycin A3 (CAS-Nr. 51596-10-2) und Milbemycin A4 (CAS-Nr. 51596-11-3) (30:70)] | - | - | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H302 H410 | M=100 | ||
607-622-00-7 | 2-Ethylhexyl-2-ethylhexanoat | 231-057-1 | 7425-14-1 | Repr. 2 | H361d*** | GHS08 Achtg. | H361d*** | |||
607-623-00-2 | Diisobutylphthalat | 201-553-2 | 84-69-5 | Repr. 1B | H360Df | GHS08 Gef. | H360Df | |||
607-624-00-8 | Perfluoroctansulfonsäure; Heptadecafluoroctan-1-sulfonsäure [1]; Kaliumperfluoroctansulfonat; Kaliumheptadecafluoroctan-1-sulfonat [2]; Diethanolaminperfluoroctansulfonat; [3]; Ammoniumperfluoroctansulfonat; Ammoniumheptadecafluoroctan-sulfonat [4]; Lithiumperfluoroctansulfonat; Lithiumheptadecafluoroctansulfonat [5] | 217-179-8 [1] 220-527-1 [2] 274-460-8 [3] 249-415-0 [4] 249-644-6 [5] | 1763-23-1 [1] 2795-39-3 [2] 70225-14-8 [3] 29081-56-9 [4] 29457-72-5 [5] | Carc. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Lact. Aquatic Chronic 2 | H351 H360D*** H372** H332 H302 H362 H411 | GHS08 GHS07 GHS09 Gef. | H351 H360D*** H372** H332 H302 H362 H411 | |||
607-625-00-3 | Clodinafop-propargyl (ISO) | - | 105512-06-9 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H317 H410 | Skin Sens. 1; H317: C ≥ 0,001 % M=1 | ||
607-626-00-9 | Ethyl-1-(2,4-dichlorphenyl)-5-(trichlormethyl)-1 H-1,2,4-triazol-3-carboxylat | 401-290-5 | 103112-35-2 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | |||
607-627-00-4 | [(4 S,5 S)-4-Benzyl-2-oxo-5-oxazolidinyl]methyl-4-nitrobenzolsulfonat | 416-360-0 | 162221-28-5 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-628-00-X | 4-Oxo-4-( p-tolyl)buttersäureaddukt mit 4-Ethylmorpholin | 419-240-6 | 171054-89-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-629-00-5 | [[2-Methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]essigsäure | 419-270-1 | 123599-82-6 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-630-00-0 | Acrylsäure, 3-(Trimethoxysilyl)propylester | 419-560-6 | 4369-14-6 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 | H332 H314 H317 H412 | GHS05 GHS07 Gef. | H332 H314 H317 H412 | |||
607-631-00-6 | Reaktionsmasse aus 2-(2-((Oxo(phenyl)acetyl)oxy)ethoxy)ethyloxo(phenyl)acetat und (2-(2-Hydroxyethoxy)ethyl)oxo(phenyl)acetat | 442-300-8 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-632-00-1 | N-[3-(2,4-Di-(1,1-dimethylpropyl)phenoxy)-propyl]-1-hydroxy-5-(2-methylpropyl-oxycarbonylamino)-naphthamid | 420-210-1 | 111244-14-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-633-00-7 | Trinatrium-5-{[4-chlor-6-(1-naphthylamino)-1,3,5-triazin-2-yl]amino}-4-hydroxy-3-[( E)-(4-methoxy-2-sulfonatophenyl)diazenyl]-2,7-naphthalindisulfonat | 440-480-2 | 341026-59-3 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-634-00-2 | (S)-(-)-2-Acetoxypropionylchlorid; (1 S)-2-Chlor-1-methyl-2-oxoethylacetat | 420-610-4 | 36394-75-9 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H302 H314 H317 | GHS05 GHS07 Gef. | H302 H314 H317 | |||
607-635-00-8 | Trinatrium- N-(3-propionato)-l-aspartat | 422-090-4 | 172737-80-3 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-636-00-3 | 1-Brom-2-methylpropylpropionat | 422-900-6 | 158894-67-8 | Flam. Liq. 3 Carc. 2 Skin Corr. 1B Skin Sens. 1 | H226 H351 H314 H317 | GHS02 GHS05 GHS08 GHS07 Gef. | H226 H351 H314 H317 | |||
607-637-00-9 | Dinatrium-8-amino-5-{4-[2-(sulfonatoethoxy)sulfonyl]phenylazo}naphthalin-2-sulfonat | 423-730-5 | 250688-43-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-638-00-4 | 2-Hydroxybenzoesäure-2-butyloctylester | 431-090-3 | 190085-41-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-639-00-X | 2-(2-Oxo-5-(1,1,3,3-tetramethylbutyl)-2,3-dihydro-1-benzofuran-3-yl)-4-(1,1,3,3-tetramethylbutyl)phenylacetat | 431-770-1 | 216698-07-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-641-00-0 | 2-(Formylamino)-3-thiophencarbonsäure; 2-Formamido-3-thiophencarbonsäure | 431-930-9 | 43028-69-9 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
607-642-00-6 | 3,6,9-Trithiaundecamethylen-1,11-dimethacrylat | 432-210-7 | 141631-22-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
607-643-00-1 | Dimethyl-(2 S)-2-hydroxysuccinat | 432-310-0 | 617-55-0 | Flam. Liq. 3 Eye Dam. 1 Skin Sens. 1 | H226 H318 H317 | GHS02 GHS05 GHS07 Gef. | H226 H318 H317 | |||
607-644-00-7 | Methyl-2,2-dimethyl-6-methylencyclohexancarboxylat | 432-350-9 | 81752-87-6 | Skin Irrit. 2 | H315 | GHS07 Achtg. | H315 | |||
607-645-00-2 | Tetranatrium-2-(4-fluor-6-(methyl-(2-(sulfatoethylsulfonyl)ethyl)amino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-methyl-2-sulfonatophenylazo)naphthalin-1,7-disulfonat | 432-550-6 | 243858-01-7 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-646-00-8 | D-Erythro-hexansäure-2,4-dideoxy-3,5- O-(1-methylethyliden)-1,1-dimethylethylester; tert-Butyl-2-[(4 R,6 S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetat | 432-960-5 | 124655-09-0 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-647-00-3 | 5-Acetoxy-2-( R, S)butyryloxymethyl-1,3-oxathiolan | 433-530-1 | 143446-73-5 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 | H302 H317 H400 | GHS07 GHS09 Achtg. | H302 H317 H400 | |||
607-649-00-4 | [3-(Chlorcarbonyl)-2-methylphenyl]acetat | 433-690-0 | 167678-46-8 | Skin Corr. 1A Skin Sens. 1 | H314 H317 | GHS05 GHS07 Gef. | H314 H317 | |||
607-650-00-X | 2-Methyl-1,5-pentandiamin-1,3-benzoldicarboxylat | 433-910-5 | 145153-52-2 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-651-00-5 | Natrium-2-(nonanoyloxy)benzolsulfonat | 434-360-9 | 91125-43-8 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-652-00-0 | Ethyl- N2-dodecanoyl-l-argininhydrochlorid | 434-630-6 | 60372-77-2 | Eye Dam. 1 Aquatic Acute 1 | H318 H400 | GHS05 GHS09 Gef. | H318 H400 | |||
607-653-00-6 | Tetrakis(bis(2-hydroxyethyl)methylammonium)-3-(4-(7-acetylamino-1-hydroxy-3-sulfonatonaphthalin-2-ylazo)-5-methoxy-2-sulfonatophenylazo)-7-(4-amino-3-sulfonatophenylamino)-4-hydroxynaphthalin-2-sulfonat | 434-840-8 | 225786-91-4 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-654-00-1 | (S)-3-Hydroxy-γ-butyrolacton | 434-990-4 | 7331-52-4 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-655-00-7 | Ethyl-6,8-dichloroctanoat | 435-080-1 | 1070-64-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-656-00-2 | Natriumsalz der 4-Amino-3,6-bis[[5-[[4-chlor-6-[(2-methyl-4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-5-hydroxy-2,7-naphthalindisulfonsäure | 435-350-7 | 141250-43-3 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-657-00-8 | Pentanatrium-7-(4-(4-(3-(2-sulfatoethansulfonyl)phenylamino)-6-(4-(2-sulfatoethansulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalin-1,3,6-trisulfonat | 436-920-8 | 172399-10-9 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-658-00-3 | 3,10-Diamino-6,13-dichlor-2-((6-(((4-(1,1-dimethylethyl)phenyl)sulfonyl)amino)-2-naphthalenyl)sulfonyl)-4,11-triphenodioxazindisulfonsäure, Lithium-Kalium-Natriumsalz | 440-770-9 | 371921-63-0 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-659-00-9 | Pentanatrium- N-[5-[[4-[[3-[(aminocarbonyl)amino]-4-[(3,6,8-trisulfonatonaphthalin-2-yl)azo]phenyl]amino]-6-chlor-1,3,5-triazin-2-yl]amino]-2-sulfonato-4-[[4-[[-2-(oxysulfonato)ethyl]sulfonyl]phenyl]azo]phenyl]-3-aminopropansäure | 442-030-0 | 321912-47-4 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-660-00-4 | 2-{4-[4-[4-Fluor-6-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino]phenylazophenylazo}naphthalin-4,6,8-trisulfonat, Trinatriumsalz | 442-230-8 | 321679-52-1 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
607-661-00-X | 1,1-Dimethylethyl-4"-(brommethyl)biphenyl-2-carboxylat | 442-850-9 | 114772-40-6 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
607-662-00-5 | Methyl-2-(acetylamino)-3-chlorpropionat | 442-860-3 | 87333-22-0 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
607-663-00-0 | Bis(2-ethylhexyl)naphthalin-2,6-dicarboxylat | 442-980-6 | 127474-91-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-664-00-6 | Methyl-2-chlorsulfonyl-4-(methansulfonylaminomethyl)benzoat | 443-120-2 | 393509-79-0 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
607-665-00-1 | trans-Methyl-2-ethyl-but-2-enoat | 443-150-6 | 101226-85-1 | Flam. Liq. 3 | H226 | GHS02 Achtg. | H226 | |||
607-666-00-7 | (2 S)-5-(Benzyloxy)-2-(1,3-dioxo-1,3-dihydro-2 H-isoindol-2-yl)-5-oxopentansäure | 443-560-5 | 88784-33-2 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
607-667-00-2 | Chlor-1-ethylcyclohexylcarbonat | 444-950-8 | 99464-83-2 | Muta. 2 Skin Sens. 1 | H341 H317 | GHS08 GHS07 Achtg. | H341 H317 | |||
607-668-00-8 | trans-2-Isopropyl-5-carboxy-1,3-dioxan | 445-770-2 | 42031-28-7 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
607-669-00-3 | Methyl(9-acetoxy-3,8,10-triethyl-7,8,10-trimethyl-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl)octadecanoat | 445-990-9 | 376588-17-9 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
607-670-00-9 | Dibutyl-3-(4-(5-ammonio-2-butyl)benzofuran-3-yl)carbonyl)phenoxy)propylammoniumoxalat; (5-Amino-2-butylbenzofuran-3-yl)-[4-(3-dibutylaminopropoxy)phenyl]methanon, Dioxalat | 448-700-9 | 500791-70-8 | STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373** H318 H317 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H373** H318 H317 H410 | M=10 | ||
607-671-00-4 | Diethyl-1,4-cyclohexandicarboxylat | 417-310-0 | 72903-27-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
607-672-00-X | Reaktionsmasse aus 2-Hydroxy-3-(methacryloyloxy)propyl (2-benzoyl)benzoat; 1-Hydroxymethyl-2-(methacryloyloxy)ethyl-(2-benzoyl)benzoat und x-Hydroxy-y-(methacryloyloxy)propyl(oder -ethyl)-(2-benzoyl)benzoat | 419-000-0 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-673-00-5 | 1-Ethyl-5,6,7,8-tetrahydrochinoliniumtosylat | 419-570-0 | - | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
607-675-00-6 | Reaktionsmasse aus cis-9-Octadecendisäure; cis-9- cis-12-Octadecadiendisäure; Hexadecandisäure und Octadecandisäure | 422-260-8 | - | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
607-676-00-1 | Reaktionsmasse aus 2-Methylnonandisäure; 2,4-Dimethyl-4-methoxycarbonylundecandisäure; 2,4,6-Trimethyl-4,6-dimethoxycarbonyltridecandisäure und 8,9-Dimethyl-8,9-dimethoxycarbonylhexadecandisäure | 423-670-1 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
607-677-00-7 | 2,5-Dioxopyrrolidin-1-yl- N-{[methyl[[2-(1-methylethyl)-4-thiazolyl]methylaminocarbonyl}-L-valinat | 424-660-8 | - | STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H373** H318 H317 | GHS05 GHS08 GHS07 Gef. | H373** H318 H317 | |||
607-678-00-2 | Reaktionsmasse aus Ethyl-(2 R,3 R)-3-isopropylbicyclo[2.2.1]hept-5-en-2-carboxylat und Ethyl-(2 S,3 S)-3-isopropylbicyclo[2.2.1]hept-5-en-2-carboxylat | 427-090-8 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-679-00-8 | Reaktionsmasse aus 3-{5-[3-(4-{1,6-Dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo[}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(methyl)ammoniumdi(acetat); 3-{5-[4-(3-{1,6-Dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo}benzamido]phenylazo-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammonium di(acetate); 3-{5-[3-(4-{1-[3-(Dimethylammonio)propyl]-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammoniumdi(acetat) | 431-440-5 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
607-680-00-3 | tert-Butyl(6-{2-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylvinyl}(4S, 6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetat | 432-810-9 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-681-00-9 | Reaktionsmasse aus 9-Nonyl-10-octyl-19-carbonyloxyhexadecylnonadecansäure; 9-Nonyl-10-octyl-19-carbonyloxyoctadecylnonadecansäure; Dihexadecyl-9-nonyl-10-octylnonadecandioat; 1-Octadecyl-19-hexadecyl-9-nonyl-10-octylnonadecandioat und Dioctadecyl-9-nonyl-10-octylnonadecandioat | 432-910-2 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-682-00-4 | Komplexe Reaktionsmasse aus chinesischem Balsamharz, nachreagiert mit Acrylsäure | 434-230-1 | 144413-22-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
607-683-00-X | Reaktionsmasse aus Methyl-3-((1 E)-2-methylprop-1-enyl)-2,2-dimethylcyclopropancarboxylat und Methyl-3-((1 Z)-2-methylprop-1-enyl)-2,2-dimethylcyclopropancarboxylat (20:80) | 435-450-0 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
607-684-00-5 | Alkene, C12-14, Hydroformylierungsprodukte, Destillationsrückstände, C-(hydrogensulfobutandioate), Dinatriumsalze | 435-660-2 | 243662-67-1 | Skin Irrit. 2 Skin Sens. 1 | H315 H317 | GHS07 Achtg. | H315 H317 | |||
607-685-00-0 | Ammonium-2-cocoyloxyethansulfonat | 441-050-7 | - | Skin Irrit. 2 Eye Dam. 1 | H315 H318 | GHS05 Gef. | H315 H318 | |||
607-686-00-6 | 6,6"-Bis(diazo-5,5",6,6"-tetrahydro-5,5"-dioxo)[methylen-bis(5-(6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonyloxy)-6-methyl-2-phenylen]di(naphthalin-1-sulfonat) | 441-550-5 | - | Self-react. C **** Carc. 2 | H242 H351 | GHS02 GHS08 Gef. | H242 H351 | |||
607-687-00-1 | Reaktionsmasse aus 2-{3,6-Bis-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl[}-benzolsulfonat (2-10 %); 2-{3,6-Bis-[(2,3-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (2-10 %); 2-{3,6-Bis-[(2,4-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (2-10 %); 2-{3,6-Bis-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (2-10 %); 2-{3-[(2,3-Dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (7-20 %); 2-{3-[(2,4-Dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (7-20 %); 2-{3-[(2,5-Dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (7-20 %); 2-{3-[(2,3-Dimethylphenyl)-methylamino]-6-[(2,4-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (7-20 %); 2-{3-[(2,3-Dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (7-20 %); 2-{3-[(2,4-Dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzolsulfonat (7-20 %) | 442-800-6 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
607-688-00-7 | (R)-1-Cyclohexa-1,4-dienyl-1-methoxycarbonylmethylammoniumchlorid | 444-320-2 | - | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
607-689-00-2 | Reaktionsmasse aus Methyl-1,4-dimethylcyclohexancarboxylat ("para-Isomer", einschl. cis- und trans-Isomere); Methyl-1,3-dimethylcyclohexancarboxylat ("meta-Isomer", einschl. cis- und trans-Isomere) | 444-920-4 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
607-690-00-8 | Dimethyl-[2 S,2 S"]-6,6,6"6"-tetramethoxy-2,2"-[ N, N"-bis(trifluoracetyl)- S, S"-bi(L-homocysteinyl)diimino]dihexanoat | 432-860-1 | 255387-46-3 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
607-691-00-3 | Magnesiumsalze, Fettsäuren, C16-18 und C18 ungesättigt, verzweigt und linear | 448-690-6 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
607-692-00-9 | Zinksalze, Fettsäuren, C16-18 und C18 ungesättigt, verzweigt und linear | 446-470-4 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
| - gestrichen - | |||||||||
607-694-00-X | Ethyl-5,5-diphenyl-2-isoxazolin-3-carboxylat | 443-870-0 | 163520-33-0 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
607-696-00-0 | Amylformiat; n-Pentylformiat | 211-340-6 | 638-49-3 | Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 | H226 H319 H335 | GHS02 GHS07 Gef. | H226 H319 H335 | C | ||
607-697-00-6 | tert-Butylpropionat | - | 20487-40-5 | Flam. Liq. 2 | H225 | GHS02 Gef. | H225 | C | ||
607-698-00-1 | 4- tert-Butylbenzoesäure | 202-696-3 | 98-73-7 | Repr. 1B STOT RE 1 Acute Tox. 4 | H360F H372 H302 | GHS07 GHS08 Gef. | H360F H372 H302 | |||
607-699-00-7 | Bifenthrin (ISO); (2-Methylbiphenyl-3-yl)methylrel-(1 R,3 R)-3-[(1 Z)-2-chlor-3,3,3-trifluorprop-1-en-1-yl]-2,2-dimethylcyclopropancarboxylat | 82657-04-3 | Carc. 2 Acute Tox. 3 Acute Tox. 2 STOT RE 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H351 H331 H300 H372 (Nerven-system) H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H331 H300 H372 (Nerven-system) H317 H410 | M = 10 000 M = 100 000 | |||
607-700-00-0 | Indoxacarb (ISO); Methyl-(4a S)-7-chlor-2-{(methoxycarbonyl)[4-(trifluormethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazin-4a(3 H)-carboxylat [1]; Reaktionsmasse aus (S)-Indoxacarb und (R)-Indoxacarb 75:25; Methyl-7-chlor-2-{(methoxycarbonyl)[4-(trifluormethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2- e][1,3,4]oxadiazin-4a(3 H)-carboxylat [2] | 173584-44-6 [1] 144171-61-9 [2] | Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H301 H332 H372 (Blut, Nerven-system, Herz) H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H332 H372 (Blut, Nerven-system, Herz) H317 H410 | M = 1 M = 1 | |||
607-702-00-1 | Dihexylphthalat | 201-559-5 | 84-75-3 | Repr. 1B | H360FD | GHS08 Gef. | H360FD | |||
607-703-00-7 | Ammoniumpentadecafluoroctanoat | 223-320-4 | 3825-26-1 | Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam.1 | H351 H360D H362 H332 H302 H372 (Leber) H318 | GHS08 GHS07 GHS05 Gef. | H351 H360D H362 H332 H302 H372 (Leber) H318 | |||
607-704-00-2 | Perfluoroctansäure | 206-397-9 | 335-67-1 | Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam. 1 | H351 H360D H362 H332 H302 H372 (Leber) H318 | GHS08 GHS07 GHS05 Gef. | H351 H360D H362 H332 H302 H372 (Leber) H318 | |||
607-705-00-8 | Benzoesäure | 200-618-2 | 65-85-0 | STOT RE 1 Skin Irrit. 2 Eye Dam. 1 | H372 (Lunge) (Einatmen) H315 H318 | GHS08 GHS05 Gef. | H372 (Lunge) (Einatmen) H315 H318 | |||
607-706-00-3 | Methyl-2,5-dichlorbenzoat | 220-815-7 | 2905-69-3 | Acute Tox. 4 STOT SE 3 Aquatic Chronic 2 | H302 H336 H411 | GHS07 GHS09 Achtg. | H302 H336 H411 | |||
607-707-00-9 | Fenoxaprop-P-ethyl (ISO); Ethyl (2R)-2-{4-[(6-chlor-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoat | - | 71283-80-2 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 (Nieren) H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H373 (Nieren) H317 H410 | M = 1 M = 1 | ||
607-708-00-4 | Octansäure | 204-677-5 | 124-07-2 | Skin Corr. 1C Aquatic Chronic 3 | H314 H412 | GHS05 Gef. | H314 H412 | |||
607-709-00-X | Decansäure | 206-376-4 | 334-48-5 | Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 | H315 H319 H412 | GHS07 Achtg. | H315 H319 H412 | |||
607-710-00-5 | 1,2-Benzoldicarbonsäure, Dihexylester, verzweigt und linear | 271-093-5 | 68515-50-4 | Repr. 1B | H360FD | GHS08 Gef. | H360FD | |||
607-711-00-0 | Spirotetramat (ISO); (5s,8s)-3-(2,5-Dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-ylethylcarbonat | - | 203313-25-1 | Repr. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H361fd H335 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361fd H335 H319 H317 H410 | M = 1 M = 1 | ||
607-712-00-6 | Dodemorphacetat; 4-Cyclododecyl-2,6-dimethylmorpholin-4-ium acetat | 250-778-2 | 31717-87-0 | Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Chronic 1 | H361d H373 (Leber) H314 H317 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H361d H373 (Leber) H314 H317 H410 | EUH071 | M = 1 | |
607-713-00-1 | Fenpyroximat (ISO); Tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylen]amino}oxy)methyl]benzoat | - | 134098-61-6 | Acute Tox. 3 Acute Tox. 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H301 H330 H317 H400 H410 | GHS06 GHS09 Gef. | H301 H330 H317 H410 | M = 100 M = 1 000 | ||
607-714-00-7 | Triflusulfuron-methyl; Methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluorethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoat | - | 126535-15-7 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | M = 100 M = 10 | ||
607-715-00-2 | Bifenazat (ISO); Isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazincarboxylat | 442-820-5 | 149877-41-8 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H373 H317 H410 | M = 1 M = 1 | ||
607-716-00-8 | Bromadiolon (ISO); 3-[3-(4′-Brombiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2 H-chromen-2-on | 249-205-9 | 28772-56-7 | Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H310 H300 H372 (Blut) H400 H410 | GHS08 GHS06 GHS09 Gef. | H360D H330 H310 H300 H372 (Blut) H410 | Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 0,005 % STOT RE 2; H373 (Blut): 0,0005 % ≤ C < 0,005 % M = 1 M = 1 | ||
607-717-00-3 | Difethialon (ISO); 3-[3-(4′-Brombiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2 H-1-benzothiopyran-2-on | - | 104653-34-1 | Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H310 H300 H372 (Blut) H400 H410 | GHS08 GHS06 GHS09 Gef. | H360D H330 H310 H300 H372 (Blut) H410 | EUH070 | Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (Blut): C ≥ 0,02 % STOT RE 2; H373 (Blut): 0,002 % ≤ C < 0,02 % M = 100 M = 100 | |
607-718-00-9 | Perfluornonan-1-säure [1] und ihre Natrium- [2] und Ammoniumsalze [3] | 206-801-3 [1] [2] [3] | 375-95-1 [1] 21049-39-8 [2] 4149-60-4 [3] | Carc. 2 Repr. 1B Lakt. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam. 1 | H351 H360Df H362 H332 H302 H372 (Leber, Thymus, Milz) H318 | GSH08 GSH07 GHS05 Gef. | H351 H360Df H362 H332 H302 H372 (Leber, Thymus, Milz) H318 | |||
607-719-00-4 | Dicyclohexylphthalat | 201-545-9 | 84-61-7 | Repr. 1B Skin Sens. 1 | H360D H317 | GHS08 GHS07 Gef. | H360D H317 | |||
607-720-00-X | Nonadecafluordecansäure; [1] Ammoniumnonadecafluordecanoat; [2] Natriumnonadecafluordecanoat [3] | 206-400-3 [1] 221-470-5 [2] [3] | 335-76-2 [1] 3108-42-7 [2] 3830-45-3 [3] | Carc. 2 Repr. 1B Lact. | H351 H360Df H362 | GHS08 Gef. | H351 H360Df H362 | |||
607-721-00-5 | N,N"-Methylendimorpholin; N,N"-Methylenbismorpholin; [aus N,N2-Methylenbismorpholin freigesetztes Formaldehyd]; [MBM] | 227-062-3 | 5625-90-1 | Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Corr. 1B Skin Sens. 1 Eye Dam.1 | H350 H341 H332 H312 H302 H373 (Magen-Darm-Trakt, Atemwege) H314 H317 H318 | GHS08 GHS07 GHS05 Gef. | H350 H341 H332 H312 H302 H373 (Magen-Darm-Trakt, Atemwege) H314 H317 | EUH071 | 8 9 | |
607-722-00-0 | 2,3,5,6-Tetrafluor-4-(methoxymethyl)benzyl-(Z)-(1R,3R)-3-(2-cyanoprop- 1-enyl)-2,2-dimethylcyclopropancarboxylat; Epsilon-momfluorothrin | - | 1065124-65-3 | Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H371 (Nervensystem) H400 H410 | GHS07 GHS08 GHS09 Achtg. | H302 H371 (Nervensystem) H410 | M = 100 M = 100 | ||
607-723-00-6 | Tefluthrin (ISO); 2,3,5,6-Tetrafluor-4-methylbenzyl-(1RS,3RS)-3- [(Z)-2-chlor-3,3,3-trifluorprop-1-enyl]-2,2-dimethylcyclopropancarboxylat | - | 79538-32-2 | Acute Tox. 1 Acute Tox. 2 Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H300 H410 | M = 10.000 M = 10.000 | ||
607-724-00-1 | 2,3,5,6-Tetrafluor-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropancarboxylat; Epsilon-metofluthrin | - | 240494-71-7 | Acute Tox. 4 Acute Tox. 3 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H332 H301 H370 (Nervensystem) H373 H400 H410 | GHS06 GHS08 GHS09 Dgr | H332 H301 H370 (Nervensystem) H373 H410 | M = 100 M = 100 | ||
607-725-00-7 | Isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoat; S-Methopren | - | 65733-16-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1 | ||
607-726-00-2 | Pinoxaden (ISO); 8-(2,6-Diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoat | - | 243973-20-8 | Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 STOT SE 3 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 3 | H361d H332 H302 H319 H335 H317 H400 H412 | GHS08 GHS07 GHS09 Wng | H361d H332 H302 H319 H335 H317 H410 | Einatmung: ATE = 4,63 mg/L (Stäube oder Nebel) Oral: ATE = 500 mg/kg KG M = 1 | ||
607-727-00-8 | Tetramethrin (ISO); (1,3-Dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropancarboxylat | 231-711-6 | 7696-12-0 | Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H371 (Nervensystem) (Einatmung) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H371 (Nervensystem) (Einatmung) H410 | M = 100 M = 100 | ||
607-728-00-3 | (1,3,4,5,6,7-Hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropancarboxylat | 214-619-0 | 1166-46-7 | Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H371 (Nervensystem) (Einatmung) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H371 (Nervensystem) (Einatmung) H410 | M = 100 M = 100 | ||
607-729-00-9 | Mesosulfuron-methyl (ISO); Methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methansulfonamido)-p-toluat; | - | 208465-21-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 100 M = 100 | ||
607-730-00-4 | Spirodiclofen (ISO); 3-(2,4-Dichlorphenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrat | - | 148477-71-8 | Carc. 1B Repr. 2 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 | H350 H361f H373 H317 H410 | GHS08 GHS07 GHS09 Dgr | H350 H361f H373 H317 H410 | M = 10 | ||
607-731-00-X | Natriummethyl[(4-aminophenyl)sulfonyl]carbamat: Natriummethyl (EZ)-sulfanilylcarbonimidat; Asulam-Natrium | 218-953-8 | 2302-17-2 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 1 M = 1 | ||
607-732-00-5 | Salicylsäure | 200-712-3 | 69-72-7 | Repr. 2 Acute Tox. 4 Eye Dam. 1 | H361d H302 H318 | GHS08 GHS07 GHS05 Dgr | H361d H302 H318 | |||
607-733-00-0 | Cyflumetofen (ISO); 2-Methoxyethyl-(RS)-2-(4- tert-butylphenyl)-2-cyano-3-oxo-3-(α,α,α-trifluor- o-tolyl)propionat | - | 400882-07-7 | Carc. 2 Skin Sens. 1A | H351 H317 | GHS08 GHS07 Wng | H351 H317 | |||
607-734-00-6 | Pentakalium 2,2",2"",2,2-(ethan-1,2-diylnitrilo)pentaacetat | 404-290-3 | 7216-95-7 | Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2 | H360D H332 H373 (Einatmen) H319 | GHS08 GHS07 Dgr | H360D H332 H373 (Einatmen) H319 | Repr. 1B; H360D: C ≥ 3 % Einatmung: ATE = 1,5 mg/L (Stäube oder Nebel) | ||
607-735-00-1 | N-Carboxymethyliminobis(ethylennitrilo)-tetraessigsäure | 200-652-8 | 67-43-6 | Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2 | H360D H332 H373 (Einatmen) H319 | GHS08 GHS07 Dgr | H360D H332 H373 (Einatmen) H319 | Repr. 1B; H360D: C ≥ 3 % Einatmung: ATE = 1,5 mg/L (Stäube oder Nebel) | ||
607-736-00-7 | Pentanatrium-(carboxylatomethyl)iminobis(ethylennitrilo)tetraacetat | 205-391-3 | 140-01-2 | Repr. 1B Acute Tox. 4 STOT RE 2 | H360D H332 H373 (Einatmen) | GHS08 GHS07 Dgr | H360D H332 H373 (Einatmen) | Repr. 1B; H360D: C ≥ 3 % Einatmung: ATE = 1,5 mg/L (Stäube oder Nebel) | ||
607-737-00-2 | Diisohexylphthalat | 276-090-2 | 71850-09-4 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
607-738-00-8 | MCPA-thioethyl (ISO); S-ethyl (4-chlor-2-methylphenoxy)ethanthioat; S-ethyl 4-chlor- o-tolyloxythioacetat | 246-831-4 | 25319-90-8 | Acute Tox. 4 STOT RE. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (Leber) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (Leber) H410 | oral:
ATE = 450 mg/kg KG M = 10 M = 10 | ||
607-740-00-9 | Diisooctylphthalat | 248-523-5 | 27554-26-3 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
607-741-00-4 | 4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}Furan-2( 5H)-on; Flupyradifuron | - | 951659-40-8 | Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (Muskel) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (Muskel) H410 | oral:
ATE = 500 mg/kg KG M = 10 M = 10 | ||
607-742-00-X | Thiencarbazon-methyl (ISO); Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophen-3-carboxylat | - | 317815-83-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1000 M = 1000 | ||
607-743-00-5 | L-(+)-Milchsäure; (2S)-2-Hydroxypropansäure | 201-196-2 | 79-33-4 | Skin Corr. 1C Eye Dam. 1 | H314 H318 | GHS05 Dgr | H314 | EUH071 | ||
607-744-00-0 | 2-Methoxyethylacrylat | 221-499-3 | 3121-61-7 | Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1 | H226 H341 H360FD H331 H302 H314 H318 H317 | GHS02 GHS05 GHS06 GHS08 Dgr | H226 H341 H360FD H331 H302 H314 H317 | EUH071 | Einatmen: ATE = 2,7 mg/L (Dämpfe) oral: ATE = 404 mg/kg KG | |
607-745-00-6 | Glyoxylsäure ... % | 206-058-5 | 298-12-4 | Eye Dam. 1 Skin Sens. 1B | H318 H317 | GHS05 GHS07 Dgr | H318 H317 | B | ||
607-746-00-1 | Natrium- N-(hydroxymethyl)glycinat; [aus Natrium- N-(hydroxymethyl)glycinat freigesetztes Formaldehyd] | 274-357-8 | 70161-44-3 | Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H350 H341 H332 H302 H335 H315 H319 H317 | GHS08 GHS07 Dgr | H350 H341 H332 H302 H335 H315 H319 H317 | Einatmen: ATE = 3 mg/L (Stäube oder Nebel) oral: ATE = 1100 mg/kg KG | 8 | |
607-747-00-7 | 2,2-Dibrom-2-cyanacetamid [DBNPA] | 233-539-7 | 10222-01-2 | Acute Tox. 2 Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H301 H372 (Atemwege) (Einatmen) H315 H318 H317 H400 H410 | GHS06 GHS08 GHS05 GHS09 Dgr | H330 H301 H372 (Atemwege) (Einatmen) H315 H318 H317 H410 | Einatmen:
ATE = 0,24 mg/L (Stäube oder Nebel) oral: ATE = 118 mg/kg KG M = 1 M = 1 | ||
607-748-00-2 | [ S-( Z, E)]-5-(1-Hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-diensäure; S-Abscisinsäure | 244-319-5 | 21293-29-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1 | ||
607-749-00-8 | Methylsalicylat | 204-317-7 | 119-36-8 | Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Chronic 3 | H361d H302 H317 H412 | GHS07 GHS08 Wng | H361d H302 H317 H412 | oral: ATE = 890 mg/kg KG | ||
607-750-00-3 | Citronensäure | 201-069-1 | 77-92-9 | Eye Irrit. 2 STOT SE 3 | H319 H335 | GHS07 Wng | H319 H335 | |||
607-751-00-9 | Ethametsulfuron-methyl (ISO); Methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoat | - | 97780-06-8 | Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H400 H410 | GHS07 GHS09 Wng | H319 H410 | M = 1 000 M = 100 | ||
607-752-00-4 | Trinexapac-ethyl (ISO); Ethyl-4-[cyclopropyl(hydroxy)methylen]-3,5-dioxocyclohexancarboxylat | - | 95266-40-3 | STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 | H373 (Magen-Darm-Trakt) H317 H410 | GHS08 GHS07 GHS09 Wng | H373 (Magen-Darm-Trakt) H317 H410 | M = 1 | ||
607-753-00-X | (3a S,5 S,6 R,7a R,7b S,9a S,10 R,12a S,12b S)-10-[(2 S,3 R,4 R,5 R)-3,4- Dihydroxy-5,6- dimethylheptan-2-yl]-5,6- dihydroxy-7a,9a- dimethylhexadecahydro-3 H- benzo[c]indeno[5,4-e]oxepin-3-on; 24-Epibrassinolid; | - | 78821-43-9 | Aquatic Chronic 4 | H413 | H413 | ||||
607-754-00-5 | Benzylsalicylat | 204-262-9 | 118-58-1 | Skin Sens. 1B | H317 | GHS07 Wng | H317 | |||
607-755-00-0 | ( RS)-1-{1-Ethyl-4-[4-mesyl-3-(2-methoxyethoxy)- o-toluoyl]pyrazol-5-yloxy}ethylmethylcarbonat; Tolpyralat | - | 1101132-67-5 | Carc. 2 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361fd H373 (Augen) H400 H410 | GHS08 GHS09 Wng | H351 H361fd H373 (Augen) H410 | M = 10 M = 100 | ||
607-756-00-6 | exo-1,7,7-Trimethylbicyclo[2.2.1]hept-2-ylacrylat; Isobornylacrylat | 227-561-6 | 5888-33-5 | Skin Sens. 1A | H317 | GHS07 Wng | H317 | |||
607-757-00-1 | Daminozid (ISO); 4-(2,2-Dimethylhydrazino)-4-oxobutansäure; N-Dimethylaminosuccinamidsäure | 216-485-9 | 1596-84-5 | Carc. 2 | H351 | GHS08 Wng | H351 | |||
607-758-00-7 | 4,4"-Oxydi(benzolsulfonohydrazid) | 201-286-1 | 80-51-3 | Selfreact.
D Aquatic Acute 1 Aquatic Chronic 1 | H242 H400 H410 | GHS02 GHS09 Dgr | H242 H410 | M = 1 M = 1 | ||
607-759-00-2 | Toluol-4-sulfonohydrazid | 216-407-3 | 1576-35-8 | Selfreact. D | H242 | GHS02 Dgr | H242 | |||
607-760-00-8 | 2-[ N-Ethyl-4-[(5-nitrothiazol-2-yl)azo]- m-toluidino]ethylacetat; C.I. Disperse Blue 124 | 239-203-6 | 15141-18-1 | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1A; H317: C ≥ 0,001 % | ||
607-761-00-3 | Perfluorheptansäure; Tridecafluorheptansäure | 206-798-9 | 375-85-9 | Repr. 1B STOT RE 1 | H360D H372 (Leber) | GHS08 Dgr | H360D H372 (Leber) | |||
607-762-00-9 | Methyl- N-(isopropoxycarbonyl)- L-valyl-(3 RS)-3-(4-chlorphenyl)- ß-alaninat; Valifenalat | - | 283159-90-0 | Carc. 2 Aquatic Chronic 2 | H351 H411 | GHS08 GHS09 Wng | H351 H411 | |||
607-763-00-4 | 6-[C12-18-Alkyl-(verzweigt, ungesättigt)-2,5-dioxopyrrolidin-1-yl]hexansäure, Natrium- und Tris(2-hydroxyethyl)ammoniumsalze | - | - | Repr. 1B Eye Irrit. 2 | H360FD H319 | GHS08 GHS07 Dgr | H360FD H319 | |||
607-764-00-X | 6-[(C10-C13)-Alkyl-(verzweigt, ungesättigt)-2,5-dioxopyrrolidin-1-yl]hexansäure | - | 2156592-54-8 | Repr. 1B Eye Irrit. 2 | H360FD H319 | GHS08 GHS07 Dgr | H360FD H319 | |||
607-765-00-5 | 6-[(C12-18)-Alkyl-(verzweigt, ungesättigt)-2,5-dioxopyrrolidin-1-yl]hexansäure | - | - | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
607-766-00-0 | Tetramethylendimethacrylat | 218-218-1 | 2082-81-7 | Skin Sens. 1B | H317 | GHS07 Wng | H317 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
607-767-00-6 | 7,7,9(oder 7,9,9)-Trimethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecan-1,16-diyl bismethacrylat | 276-957-5 | 72869-86-4 | Skin Sens. 1B | H317 | GHS07 Wng | H317 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
607-768-00-1 | 2,2"-Ethylendioxydiethyldimethacrylat | 203-652-6 | 109-16-0 | Skin Sens. 1B | H317 | GHS07 Wng | H317 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
607-769-00-7 | Bifenox (ISO); Methyl-5-(2,4-dichlorphenoxy)-2-nitrobenzoat | 255-894-7 | 42576-02-3 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | Oral: ATE = 1.500 mg/kg KG M = 1.000 M = 1.000 | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-770-00-2 | 2,3-Epoxypropylneodecanoat | 247-979-2 | 26761-45-5 | Muta. 2 Skin Sens. 1A | H341 H317 | GHS08 GHS07 Wng | H341 H317 | Skin Sens. 1A; H317: C ≥ 0,001 % | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-771-00-8 | Benthiavalicarb-Isopropyl (ISO); Isopropyl [( S)-1-{[( R)-1-(6-fluor-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamat | - | 177406-68-7 | Carc. 1B Repr. 2 Skin Sens. 1 Aquatic Chronic 2 | H350 H361fd H317 H411 | GHS08 GHS07 GHS09 Dgr | H350 H361fd H317 H411 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-772-00-3 | Hexylsalicylat | 228-408-6 | 6259-76-3 | Repr. 2 Skin Sens. 1 | H361d H317 | GHS08 GHS07 Wng | H361d H317 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-773-00-9 | 7-Oxabicyclo[4.1.0]hept-3-ylmethyl-7-oxabicyclo[4.1.0]heptan-3-carboxylat | 219-207-4 | 2386-87-0 | Muta. 2 STOT RE 2 Skin Sens. 1 | H341 H373 (Nasenhöhle) H317 | GHS08 GHS07 Wng | H341 H373 (Nasenhöhle) H317 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-774-00-4 | Tetranatrium-4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulfonatooxy)ethyl]sulfonyl] phenyl]azo]naphthalin-2,7-disulfonat [1] Reaktionsprodukte von 4-Amino-5-hydroxynaphthalin-2,7-disulfonsäure, doppelte Kupplungsreaktion mit diazotiertem 2-[(4-Aminophenyl)sulfonyl]ethylhydrogensulfat, Natriumsalze [2] Dinatrium-4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl)phenyl]diazenyl}naphthalen-2,7-disulfonat [3] | 241-164-5 [1] - [2] - [3] | 17095-24-8 [1] - [2] 100556-82-9 [3] | Resp. Sens. 1A Skin Sens. 1 | H334 H317 | GHS08 Dgr | H334 H317 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
607-775-00-X | Natrium-3-(allyloxy)-2-hydroxypropansulphonat | 258-004-5 | 52556-42-0 | Repr. 1B Eye Dam. 1 | H360F H318 | GHS08 GHS05 Dgr | H360F H318 | ) | ||
608-001-00-3 | Acetonitril; Cyanomethan | 200-835-2 | 75-05-8 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 | H225 H332 H312 H302 H319 | GHS02 GHS07 Gef. | H225 H332 H312 H302 H319 | |||
608-002-00-9 | Trichloracetonitril | 208-885-7 | 545-06-2 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H331 H311 H301 H411 | GHS06 GHS09 Gef. | H331 H311 H301 H411 | |||
608-003-00-4 | Acrylnitril | 203-466-5 | 107-13-1 | Flam. Liq. 2 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H225 H350 H331 H311 H301 H335 H315 H318 H317 H411 | GHS02 GHS06 GHS08 GHS05 GHS09 Gef. | H225 H350 H331 H311 H301 H335 H315 H318 H317 H411 | * | D | |
608-004-00-X | 2-Hydroxy-2-methylpropionitril; 2-Cyanopropan-2-ol; Acetoncyanhydrin | 200-909-4 | 75-86-5 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H310 H300 H410 | |||
608-005-00-5 | n-Butyronitril | 203-700-6 | 109-74-0 | Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H225 H331 H311 H301 | GHS02 GHS06 Gef. | H225 H331 H311 H301 | |||
608-006-00-0 | Bromoxynil (ISO); 3,5-Dibrom-4-hydroxybenzonitril | 216-882-7 | 1689-84-5 | Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H330 H301 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H361d *** H330 H301 H317 H410 | M = 10 | ||
608-007-00-6 | Ioxynil (ISO); 4-Hydroxy-3,5-diiodbenzonitril | 216-881-1 | 1689-83-4 | Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H331 H301 H312 H373 ** H319 H400 H410 | GHS06 GHS08 GHS09 Gef. | H361d *** H331 H301 H312 H373 ** H319 H410 | M = 10 | ||
608-008-00-1 | Chloracetonitril | 203-467-0 | 107-14-2 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H331 H311 H301 H411 | GHS06 GHS09 Gef. | H331 H311 H301 H411 | |||
608-009-00-7 | Malonsäuredinitril; Malononitril; Propandinitril | 203-703-2 | 109-77-3 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | |||
608-010-00-2 | Methacrylnitril; 2-Methyl-2-propennitril | 204-817-5 | 126-98-7 | Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 | H225 H331 H311 H301 H317 | GHS02 GHS06 Gef. | H225 H331 H311 H301 H317 | * Skin Sens. 1; H317: C ≥0,2 % | D | |
608-011-00-8 | Dicyan; Oxalyldinitril; Cyanogen | 207-306-5 | 460-19-5 | Press.
Gas Flam. Gas 1 Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H220 H331 H400 H410 | GHS02 GHS04 GHS06 GHS09 Gef. | H220 H331 H410 | U | ||
608-012-00-3 | Benzonitril | 202-855-7 | 100-47-0 | Acute Tox. 4 * Acute Tox. 4 * | H312 H302 | GHS07 Achtg. | H312 H302 | |||
608-013-00-9 | 2-Chlorbenzonitril | 212-836-5 | 873-32-5 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 | H312 H302 H319 | GHS07 Achtg. | H312 H302 H319 | |||
608-014-00-4 | Chlorthalonil (ISO); Tetrachlorisophthalonitril | 217-588-1 | 1897-45-6 | Carc. 2 Acute Tox. 2 * STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H330 H335 H318 H317 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H351 H330 H335 H318 H317 H410 | M=10 | ||
608-015-00-X | Dichlobenil (ISO); 2,6-Dichlorbenzonitril | 214-787-5 | 1194-65-6 | Acute Tox. 4 * Aquatic Chronic 2 | H312 H411 | GHS07 GHS09 Achtg. | H312 H411 | |||
608-016-00-5 | 1,4-Dicyano-2,3,5,6-tetrachlorbenzol; Tetrachlorterephthalonitril | 401-550-8 | 1897-41-2 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
608-017-00-0 | Bromoxyniloctanoat (ISO); 2,6-Dibrom-4-cyanophenyloctanoat | 216-885-3 | 1689-99-2 | Repr. 2 Acute Tox. 3 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H331 H302 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H361d *** H331 H302 H317 H410 | M = 10 | ||
608-018-00-6 | Ioxyniloctanoat (ISO); 4-Cyano-2,6-diiodphenyloctanoat | 223-375-4 | 3861-47-0 | Repr. 2 Acute Tox. 3 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H301 H319 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H361d *** H301 H319 H317 H410 | M = 10 | ||
608-019-00-1 | 2,2"-Dimethyl-2,2"-azodipropiononitril | 201-132-3 | 78-67-1 | Self-react.
C Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H242 H332 H302 H412 | GHS02 GHS07 Gef. | H242 H332 H302 H412 | T | ||
608-020-00-7 | Diphenoxymethylencyanamid | 427-300-8 | 79463-77-7 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
608-021-00-2 | 3-(2-(Diaminomethylenamino)thiazol-4-ylmethylthio)propionitril | 403-710-2 | 76823-93-3 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
608-022-00-8 | 3,7-Dimethyloctannitril | 403-620-3 | 40188-41-8 | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H315 H317 H411 | GHS07 GHS09 Achtg. | H315 H317 H411 | |||
608-023-00-3 | Fenbuconazol (ISO); 4-(4-Chlorphenyl)-2-phenyl-2-[(1 H-1,2,4-triazol-1-yl)methyl]butannitril | 406-140-2 | 114369-43-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
608-024-00-9 | 2-(4-( N-Butyl- N-phenethylamino)phenyl)ethylen-1,1,2-tricarbonitril | 407-650-8 | 97460-76-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
608-025-00-4 | 2-Nitro-4,5-bis(benzyloxy)phenylacetonitril | 410-970-0 | 117568-27-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
608-026-00-X | 3-Cyano-3,5,5-trimethylcyclohexanon | 411-490-4 | 7027-11-4 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 | H302 H373 ** H317 H412 | GHS08 GHS07 Achtg. | H302 H373 ** H317 H412 | |||
608-027-00-5 | Reaktionsmasse aus 3-(4-Ethylphenyl)-2,2-dimethylpropannitril; 3-(2-Ethylphenyl)-2,2-dimethylpropanenitril und 3-(3-Ethylphenyl)-2,2-dimethylpropannitril | 412-660-0 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
608-028-00-0 | 4-(2-Cyano-3-phenylamino)-acryloyloxymethylcyclohexylmethyl-2-cyano-3-phenylamino)acrylat | 413-510-7 | 147374-67-2 | STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H373 ** H317 H411 | GHS08 GHS09 Achtg. | H373 ** H317 H411 | |||
608-029-00-6 | 1,2-Dihydro-6-hydroxy-4-methyl-1-[3-(1-methylethoxy)propyl]-2-oxo-3-pyridincarbonitril | 411-990-2 | 68612-94-2 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
608-030-00-1 | N-Acetyl- N-[5-cyano-3-(2- dibutylamino-4-phenylthiazol-5-yl-methylen)-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyridin-1-yl]benzamid | 412-340-0 | 147741-93-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
608-031-00-7 | 2-Benzyl-2-methyl-3-butennitril | 407-870-4 | 97384-48-0 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
608-032-00-2 | Acetamiprid (ISO); (1 E)- N-[(6-Chlorpyridin-3-yl)methyl]- N"-cyan- N-methylethanimidamid; (E)- N1-[(6-Chlor-3-pyridyl)methyl]- N2-cyano- N1-methylacetamidin | - | 135410-20-7 160430-64-8 | Repr. 2 Acute Tox. 3 Aquatic Chronic 1 Aquatic Acute 1 | H361d H301 H410 H400 | GHS08 GHS06 GHS09 Dgr | H361d H301 H410 | Oral: ATE = 140 mg/kg KG M = 10 M = 10 | ||
608-033-00-8 | N-Butyl-3-(2-chlor-4-nitrophenylhydrazono)-1-cyano-2-methylprop-1-en-1,3-dicarboximid | 407-970-8 | 75511-91-0 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
608-034-00-3 | Chlorfenapyr (ISO); 4-Brom-2-(4-chlorphenyl)-1-ethoxymethyl-5-trifluormethylpyrrol-3-carbonitril | - | 122453-73-0 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H302 H400 H410 | GHS06 GHS09 Gef. | H331 H302 H410 | M=100 | ||
608-035-00-9 | (±)-α -[(2-Acetyl-5-methylphenyl)-amino]-2,6-dichlorbenzol-acetonitril | 419-290-9 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
608-036-00-4 | 3-(2-{4-[2-(4-Cyanophenyl)vinyl]phenyl}vinyl)benzonitril | 419-060-8 | 79026-02-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
608-037-00-X | Reaktionsmasse aus (E)-2,12-Tridecadiennitril, (E)-3,12-Tridecadiennitril und (Z)-3,12-Tridecadiennitril | 422-190-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | ||||
608-038-00-5 | 2,2,4-Trimethyl-4-phenylbutannitril | 422-580-8 | 75490-39-0 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
608-039-00-0 | 2-Phenylhexannitril | 423-460-8 | 3508-98-3 | Acute Tox. 4 Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Wng | H302 H411 | Oral: ATE = 500 mg/kg KG | ||
608-040-00-6 | 4,4"-Dithiobis(5-amino-1-(2,6-dichlor-4-(trifluormethyl)phenyl)-1 H-pyrazol-3-carbonitril) | 423-490-1 | 130755-46-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
608-041-00-1 | 4"-((2-Butyl-4-oxo-1,3-diazaspiro[4,4]non-1-en-3-yl)methyl)(1,1"-biphenyl)-2-carbonitril | 423-500-4 | 138401-24-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
608-042-00-7 | (S)-2,2-Diphenyl-2-(3-pyrrolidinyl)acetonitrilhydrobromid | 421-810-4 | 194602-27-2 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | |||
608-043-00-2 | 3-( cis-3-Hexenyloxy)propannitril | 415-220-6 | 142653-61-0 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H302 H400 H410 | GHS06 GHS09 Gef. | H331 H302 H410 | |||
608-044-00-8 | 2-Cyclohexyliden-2-phenylacetonitril | 423-740-1 | 10461-98-0 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
608-046-00-9 | 5-(4-Chlor-2-nitrophenylazo)-1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxopyridin-3-carbonitril | 425-310-7 | 77889-90-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
608-047-00-4 | 2-Piperidin-1-yl-benzonitril | 427-330-1 | 72752-52-4 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
608-048-00-X | 1-(3-Cyclopentyloxy-4-methoxyphenyl)-4-oxocyclohexancarbonitril | 427-450-4 | 152630-47-2 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H302 H373** H317 H411 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H317 H411 | |||
608-049-00-5 | 2-(4-(4-(Butyl-(1-methylhexyl)amino)phenyl)-3-cyano-5-oxo-1,5-dihydropyrrol-2-yliden)propandinitril | 429-180-2 | 157362-53-3 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
608-050-00-0 | Reaktionsmasse aus 5-(2-Cyano-4- nitrophenylazo)-2-(2-(2-hydroxyethoxy)ethylamino)-4-methyl-6-phenylaminonicotinonitril und 5-(2-Cyano-4-nitrophenylazo)-6-(2-(2-hydroxyethoxy)ethylamino)-4-methyl-2-phenylaminonicotinonitril | 429-760-5 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
608-051-00-6 | (R)-4-(4-Dimethylamino-1-(4- fluorphenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitril | 430-760-2 | 219861-18-4 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
608-052-00-1 | (S)-4-(4-Dimethylamino-1-(4- fluorphenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitril | 430-770-7 | 128173-52-4 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
608-053-00-7 | (R, S)-4-(4-Dimethylamino-1-(4- fluorphenyl)-1-hydroxybutyl)- 3-(hydroxymethyl)benzonitril | 430-780-1 | 103146-25-4 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
608-054-00-2 | (R, S)-4-(4-Dimethylamino-1-(4- fluorphenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrilhemisulfat | 430-790-6 | - | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | |||
608-055-00-8 | Fipronil (ISO); (±)-5-Amino-1-(2,6-dichlor-α,α,α-trifluor- p-tolyl)-4-trifluormethylsulfinylpyrazol-3-carbonitril | 424-610-5 | 120068-37-3 | Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H311 H331 H372* H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H311 H331 H372* H410 | M = 1 000 M = 10 000 | ||
608-056-00-3 | N-Methyl- N-cyanmethylmorpholiniummethylsulfat | 429-340-1 | - | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
608-057-00-9 | 4-(Cyanomethyl)-4-methylmorpholin-4-iumhydrogensulfat | 431-200-1 | 208538-34-5 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 | H302 H318 H317 | GHS05 GHS07 Gef. | H302 H318 H317 | |||
608-058-00-4 | Esfenvalerat (ISO); (S)-α-Cyan-3-phenoxybenzyl-( S)-2-(4-chlorphenyl)-3-methylbutyrat | - | 66230-04-4 | Acute Tox. 3 Acute Tox. 3 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H370 (Nervensystem) H373 H317 H400 H410 | GHS06 GHS08 GHS09 Dgr | H331 H301 H370 (Nervensystem) H373 H317 H410 | oral; ATE = 88,5 mg/kg KG Einatmen: ATE = 0,53 mg/L (Stäube oder Nebel) M = 10 000 M = 10 000 | ||
608-059-00-X | 5-Amino-1-(2,6-dichlor-4-(trifluormethyl)phenyl)-1 H- pyrazol-3-carbonitril | 421-240-6 | 120068-79-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
608-060-00-5 | 5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophencarbonitril | 421-300-1 | 138564-59-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
608-062-00-6 | 2-Fluor-4-hydroxybenzonitril | 422-810-7 | 82380-18-5 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
608-063-00-1 | (S)-α-Hydroxy-3-phenoxy- benzolacetonitril | 441-070-6 | 61826-76-4 | Acute Tox. 3 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Gef. | H301 H318 H317 H410 | |||
608-064-00-7 | Cyanomethyltrimethylammoniummethylsulfat | 433-720-2 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
608-065-00-2 | Salze von Bromoxynil, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H330 H301 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H361d *** H330 H301 H317 H410 | M = 10 | A | |
608-066-00-8 | Salze von Ioxynil, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d *** H331 H301 H312 H373 ** H319 H400 H410 | GHS06 GHS08 GHS09 Gef. | H361d *** H331 H301 H312 H373 ** H319 H410 | M = 10 | A | |
608-067-00-3 | 3,7-Dimethylocta-2,6-diennitril | 225-918-0 | 5146-66-7 | Muta. 1B | H340 | GHS08 Gef. | H340 | |||
608-069-00-4 | Fludioxonil (ISO); 4-(2,2-Difluor-1,3-benzodioxol-4-yl)-1 H-pyrrol-3-carbonitril | - | 131341-86-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 10 | ||
609-001-00-6 | 1-Nitropropan | 203-544-9 | 108-03-2 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H226 H332 H312 H302 | GHS02 GHS07 Achtg. | H226 H332 H312 H302 | * | ||
609-002-00-1 | 2-Nitropropan | 201-209-1 | 79-46-9 | Flam. Liq. 3 Carc. 1B Acute Tox. 4 * Acute Tox. 4 * | H226 H350 H332 H302 | GHS02 GHS08 GHS07 Gef. | H226 H350 H332 H302 | |||
609-003-00-7 | Nitrobenzol | 202-716-0 | 98-95-3 | Carc. 2. Repr. 1B Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 STOT RE 1 Aquatic Chronic 3 | H351 H360F H301 H331 H311 H372 (Blut) H412 | GHS06 GHS08 Gef. | H351 H360F H301 H331 H311 H372 (Blut) H412 | |||
609-004-00-2 | Dinitrobenzol [1]; 1,4-Dinitrobenzol [2]; 1,3-Dinitrobenzol [3]; 1,2-Dinitrobenzol [4] | 246-673-6 [1] 202-833-7 [2] 202-776-8 [3] 208-431-8 [4] | 25154-54-5 [1] 100-25-4 [2] 99-65-0 [3] 528-29-0 [4] | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H373 ** H410 | |||
609-005-00-8 | 1,3,5-Trinitrobenzol | 202-752-7 | 99-35-4 | Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H201 H330 H310 H300 H373** H400 H410 | GHS01 GHS06 GHS08 GHS09 Gef. | H201 H330 H310 H300 H373** H410 | |||
609-006-00-3 | 4-Nitrotoluol | 202-808-0 | 99-99-0 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H411 | |||
609-007-00-9 | 2,4-Dinitrotoluol [1]; Dinitrotoluol [2] | 204-450-0 [1] 246-836-1 [2] | 121-14-2 [1] 25321-14-6 [2] | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H341 H361f*** H331 H311 H301 H373** H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H341 H361f*** H331 H311 H301 H373** H410 | |||
609-008-00-4 | 2,4,6-Trinitrotoluol; TNT | 204-289-6 | 118-96-7 | Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H201 H331 H311 H301 H373 ** H411 | GHS01 GHS06 GHS08 GHS09 Gef. | H201 H331 H311 H301 H373 ** H411 | |||
609-009-00-X | 2,4,6-Trinitrophenol; Pikrinsäure | 201-865-9 | 88-89-1 | Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H201 H331 H311 H301 | GHS01 GHS06 Gef. | H201 H331 H311 H301 | |||
609-010-00-5 | Salze der Pikrinsäure; Pikrate | - | - | Unst. Expl Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H201 H331 H311 H301 | GHS01 GHS06 Gef. | H201 H331 H311 H301 | T | ||
609-011-00-0 | 2,4,6-Trinitroanisol; 2,4,6-Trinitro-1-methoxybenzol | - | 606-35-9 | Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H201 H332 H312 H302 H411 | GHS01 GHS07 GHS09 Achtg. | H201 H332 H312 H302 H411 | |||
609-012-00-6 | 2,4,6- Trinitro-m-kresol; 2,4,6-Trinitro-3-methylphenol | 210-027-1 | 602-99-3 | Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H201 H332 H312 H302 | GHS01 GHS07 Achtg. | H201 H332 H312 H302 | |||
609-013-00-1 | 2,4,6- Trinitro-m-xylol; 2,4,6-Trinitro-1,3-dimethylbenzol | 211-187-5 | 632-92-8 | Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * | H201 H332 H312 H302 H373 ** | GHS01 GHS08 GHS07 Achtg. | H201 H332 H312 H302 H373 ** | |||
609-015-00-2 | 4-Nitrophenol; p-Nitrophenol | 202-811-7 | 100-02-7 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * | H332 H312 H302 H373 ** | GHS08 GHS07 Achtg. | H332 H312 H302 H373 ** | |||
609-016-00-8 | Dinitrophenol (Reaktionsmasse aus Isomeren) [1]; 2,4(oder 2,6)-Dinitrophenol [2] | 247-096-2 [1] 275-732-9 [2] | 25550-58-7 [1] 71629-74-8 [2] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H410 | |||
609-018-00-9 | 2,4,6-Trinitroresorcin; Styphninsäure; 2,4,6-Trinitro-1,3-dihydroxybenzol | 201-436-6 | 82-71-3 | Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H201 H332 H312 H302 | GHS01 GHS07 Gef. | H201 H332 H312 H302 | |||
609-019-00-4 | Blei 2,4,6-trinitro-m-phenylendioxid; Blei 2,4,6-Trinitroresorcinoxid; Bleistyphnat; Trizinat | 239-290-0 | 15245-44-0 | Unst. Expl Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H200 H360Df H332 H302 H373 ** H400 H410 | GHS01 GHS08 GHS07 GHS09 Gef. | H200 H360Df H332 H302 H373 ** H410 | 1 | ||
609-019-01-1 | Blei 2,4,6-trinitro- m-phenylendioxid; Blei 2,4,6-trinitroresorcinoxid; Bleistyphnat (≥ 20 % Phlegmatisierungsmittel) | 239-290-0 | 15245-44-0 | Expl. 1.1 Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H201 H360Df H332 H302 H373 ** H400 H410 | GHS01 GHS08 GHS07 GHS09 Gef. | H201 H360Df H332 H302 H373 ** H410 | 1 | ||
609-020-00-X | DNOC (ISO); 4,6-Dinitro- o-kresol | 208-601-1 | 534-52-1 | Muta. 2 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H341 H330 H310 H300 H315 H318 H317 H400 H410 | GHS06 GHS08 GHS05 GHS07 GHS09 Gef. | H341 H330 H310 H300 H315 H318 H317 H410 | EUH044 | ||
609-021-00-5 | Natriumsalz von DNOC; Natrium 4,6-dinitro- o-kresolat [1]; Kaliumsaz von DNOC; Kalium 4,6-dinitro- o-kresolat [2] | 219-007-7 [1] - [2] | 2312-76-7 [1] 5787-96-2 [2] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H410 | |||
609-022-00-0 | Ammoniumsalz von DNOC; Ammonium 4,6-dinitro- o-tolyloxid | 221-037-0 | 2980-64-5 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H300 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H373 ** H410 | |||
609-023-00-6 | Dinocap (ISO); (RS)-2,6-Dinitro-4-octylphenylcrotonat und (RS)-2,4-Dinitro-6-octylphenylcrotonat, wobei "octyl" eine Reaktionsmasse aus 1-Methylheptyl-, 1-Ethylhexyl- und 1-Propylpentyl-Gruppen ist | 254-408-0 | 39300-45-3 | Repr. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D*** H332 H302 H373** H315 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H360D*** H332 H302 H373** H315 H317 H410 | M=100 | ||
609-024-00-1 | Binapacryl (ISO); 2- sec-Butyl-4,6-dinitrophenyl-3-methylcrotonat | 207-612-9 | 485-31-4 | Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H360D *** H312 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H360D *** H312 H302 H410 | |||
609-025-00-7 | Dinoseb(ISO); 6- sec-Butyl-2,4-dinitrophenol | 201-861-7 | 88-85-7 | Repr. 1B Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H360Df H311 H301 H319 H400 H410 | GHS06 GHS08 GHS09 Gef. | H360Df H311 H301 H319 H410 | EUH044 | ||
609-026-00-2 | Salze und Ester von Dinoseb, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Repr. 1B Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H360Df H311 H301 H319 H400 H410 | GHS06 GHS08 GHS09 Gef. | H360Df H311 H301 H319 H410 | EUH044 | A | |
609-027-00-8 | Dinocton; Reaktionsmasse aus Isomeren: Methyl-(2,6-dinitro-4-octylphenyl)carbonat und Methyl-(2,4-dinitro-6-octylphenyl)carbonat | - | 63919-26-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
609-028-00-3 | Dinex (ISO); 2-Cyclohexyl-4,6-dinitrophenol | 205-042-5 | 131-89-5 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | |||
609-029-00-9 | Salze und Ester von Dinex | - | - | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | A | ||
609-030-00-4 | Dinoterb (ISO); 2- tert-Butyl-4,6-dinitrophenol | 215-813-8 | 1420-07-1 | Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H360D *** H300 H311 H400 H410 | GHS06 GHS08 GHS09 Gef. | H360D *** H300 H311 H410 | EUH044 | ||
609-031-00-X | Salze und Ester von Dinoterb | - | - | Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H360D *** H300 H311 H400 H410 | GHS06 GHS08 GHS09 Gef. | H360D *** H300 H311 H410 | A | ||
609-032-00-5 | Bromfenoxim (ISO); 3,5-Dibrom-4-hydroxybenzaldehyd- O-(2,4-dinitrophenyl)oxim | 236-129-6 | 13181-17-4 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
609-033-00-0 | Dinosam (ISO); 2-(1-Methylbutyl)-4,6-dinitrophenol | - | 4097-36-3 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | |||
609-034-00-6 | Salze und Ester von Dinosam | - | - | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H410 | A | ||
609-035-00-1 | Nitroethan | 201-188-9 | 79-24-3 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * | H226 H332 H302 | GHS02 GHS07 Achtg. | H226 H332 H302 | * | ||
609-036-00-7 | Nitromethan | 200-876-6 | 75-52-5 | Flam. Liq. 3 Acute Tox. 4 * | H226 H302 | GHS02 GHS07 Achtg. | H226 H302 | * | ||
609-037-00-2 | 5-Nitroacenaphthen | 210-025-0 | 602-87-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
609-038-00-8 | 2-Nitronaphthalin | 209-474-5 | 581-89-5 | Carc. 1B Aquatic Chronic 2 | H350 H411 | GHS08 GHS09 Gef. | H350 H411 | |||
609-039-00-3 | 4-Nitrobiphenyl | 202-204-7 | 92-93-3 | Carc. 1B Aquatic Chronic 2 | H350 H411 | GHS08 GHS09 Gef. | H350 H411 | |||
609-040-00-9 | Nitrofen (ISO); 2,4-Dichlorpheny-4-nitrophenylether | 217-406-0 | 1836-75-5 | Carc. 1B Repr. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H360D *** H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H360D *** H302 H410 | |||
609-041-00-4 | 2,4-Dinitrophenol | 200-087-7 | 51-28-5 | Acute Tox. 3 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Acute 1 | H331 H311 H300 H372 H400 | GHS06 GHS08 GHS09 Dgr | H331 H311 H300 H372 H400 | dermal: ATE = 300 mg/kg KG oral: ATE = 30 mg/kg KG | ||
609-042-00-X | Pendimethalin (ISO); N-(1-Ethylpropyl)-2,6-dinitro-3,4-xyliden | 254-938-2 | 40487-42-1 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H400 H410 | GHS08 GSH09 Wng | H361d H410 | M = 100 M = 10 | ||
609-043-00-5 | Quintozen (ISO); Pentachlornitrobenzol | 201-435-0 | 82-68-8 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
609-044-00-0 | Tecnazen (ISO); 1,2,4,5-Tetrachlor-3-nitrobenzol | 204-178-2 | 117-18-0 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
609-045-00-6 | Reaktionsmasse aus 4,6-Dinitro-2-(3-octyl)phenylmethylcarbonat und 4,6-Dinitro-2-(4-octyl)phenylmethylcarbonat; Dinocton-6 | - | 8069-76-9 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
609-046-00-1 | Trifluralin (ISO) (enthält <0,5 ppm NPDA); α, α, α-Trifluor-2,6-dinitro- N, N- dipropyl- p-toluidin (enthält < 0,5 ppm NPDA); 2,6-Dinitro- N, N-dipropyl-4-trifluormethylanilin (enthält < 0,5 ppm NPDA); N, N-Dipropyl-2,6-dinitro-4-trifluormethylanilin (enthält < 0,5 ppm NPDA) | 216-428-8 | 1582-09-8 | Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H317 H410 | M=10 | ||
609-047-00-7 | 2-Nitroanisol; 2-Methoxynitrobenzol | 202-052-1 | 91-23-6 | Carc. 1B Acute Tox. 4 * | H350 H302 | GHS08 GHS07 Gef. | H350 H302 | |||
609-048-00-2 | Natrium 3-nitrobenzolsulfonat | 204-857-3 | 127-68-4 | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
609-049-00-8 | 2,6-Dinitrotoluol | 210-106-0 | 606-20-2 | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H350 H341 H361f *** H331 H311 H301 H373 ** H412 | GHS06 GHS08 Gef. | H350 H341 H361f *** H331 H311 H301 H373 ** H412 | |||
609-050-00-3 | 2,3-Dinitrotoluol | 210-013-5 | 602-01-7 | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H341 H361f *** H331 H311 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H341 H361f *** H331 H311 H301 H373 ** H410 | |||
609-051-00-9 | 3,4-Dinitrotoluol | 210-222-1 | 610-39-9 | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H350 H341 H361f *** H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H350 H341 H361f *** H331 H311 H301 H373 ** H411 | |||
609-052-00-4 | 3,5-Dinitrotoluol | 210-566-2 | 618-85-9 | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H350 H341 H361f *** H331 H311 H301 H373 ** H412 | GHS06 GHS08 Gef. | H350 H341 H361f *** H331 H311 H301 H373 ** H412 | |||
609-053-00-X | Hydrazintrinitromethan | 414-850-9 | - | Expl. 1.1 **** Self-react. A Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 | H201 H240 H350 H331 H301 H317 | GHS01 GHS06 GHS08 Gef. | H201 H240 H350 H331 H301 H317 | |||
609-054-00-5 | 2,3-Dinitrophenol [1]; 2,5-Dinitrophenol [2]; 2,6-Dinitrophenol [3]; 3,4-Dinitrophenol [4]; Salze von Dinitrophenol [5] | 200-628-7 [1] 206-348-1 [2] 209-357-9 [3] 209-415-3 [4] - [5] | 66-56-8 [1] 329-71-5 [2] 573-56-8 [3] 577-71-9 [4] - [5] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H411 | |||
609-055-00-0 | 2,5-Dinitrotoluol | 210-581-4 | 619-15-8 | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H350 H341 H361f *** H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H350 H341 H361f *** H331 H311 H301 H373 ** H411 | |||
609-056-00-6 | 2,2-Dibrom-2-nitroethanol | 412-380-9 | 69094-18-4 | Expl. 1.1 Carc. 2 Acute Tox. 4 * STOT RE 2 * Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H201 H351 H302 H373 ** H314 H317 H400 H410 | GHS01 GHS08 GHS05 GHS07 GHS09 Gef. | H201 H351 H302 H373 ** H314 H317 H410 | * STOT SE 3; H335: C ≥ 1 % | T | |
609-057-00-1 | 3-Chlor-2,4-difluornitrobenzol | 411-980-8 | 3847-58-3 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H314 H317 H410 | |||
609-058-00-7 | 2-Nitro-2-phenyl-1,3-propandiol | 410-360-4 | 5428-02-4 | STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H372 ** H312 H302 H317 H411 | GHS08 GHS07 GHS09 Gef. | H372 ** H312 H302 H317 H411 | EUH070 | ||
609-059-00-2 | 2-Chlor-6-(ethylamino)-4-nitrophenol | 411-440-1 | 131657-78-8 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
609-060-00-8 | 4-[(3-Hydroxypropyl)amino]-3- nitrophenol | 406-305-9 | 92952-81-3 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
609-061-00-3 | (E, Z)-4-Chlorphenyl(cyclopropyl)keton- O-(4-nitrophenylmethyl)oxim | 406-100-4 | 94097-88-8 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
609-062-00-9 | 2-Brom-2-nitropropanol | 407-030-7 | 24403-04-1 | Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H311 H302 H373 ** H314 H317 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H311 H302 H373 ** H314 H317 H410 | |||
609-063-00-4 | 2-[(4-Chlor-2-nitrophenyl)amino]ethanol | 413-280-8 | 59320-13-7 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
609-064-00-X | Mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexandion | - | 104206-82-8 | Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (Augen, Nervensystem) H400 H410 | GHS08 GHS09 Wng | H361d H373 (Augen, Nervensystem) H410 | M = 10 M = 10 | ||
609-065-00-5 | 2-Nitrotoluol | 201-853-3 | 88-72-2 | Carc. 1B Muta. 1B Repr. 2 Acute Tox. 4 * Aquatic Chronic 2 | H350 H340 H361f *** H302 H411 | GHS08 GHS07 GHS09 Gef. | H350 H340 H361f *** H302 H411 | |||
- gestrichen - | ||||||||||
609-067-00-6 | Natrium und Kalium-4-(3- aminopropylamino)-2,6-bis[3- (4-methoxy-2-sulfophenylazo)- 4-hydroxy-2-sulfo-7-naphthylamino]-1,3,5-triazin | 416-280-6 | 156769-97-0 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
609-068-00-1 | Moschusxylol; 5- tert-Butyl-2,4,6-trinitro- m- xylol | 201-329-4 | 81-15-2 | Expl. 1.1 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H201 H351 H400 H410 | GHS01 GHS08 GHS09 Achtg. | H201 H351 H410 | T | ||
609-069-00-7 | Moschus-Keton; 3,5-Dinitro-2,6-dimethyl-4- tert- butylacetophenon; 4"- tert-Butyl-2", 6"-dimethyl-3", 5"-dinitroacetophenon | 201-328-9 | 81-14-1 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
609-070-00-2 | 1,4-Dichlor-2-(1,1,2,3,3,3- hexafluorpropoxy)-5-nitrobenzol | 415-580-4 | 130841-23-5 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
609-071-00-8 | Reaktionsmasse aus 2-Methylsulfanyl-4,6-bis(2-hydroxy-4-methoxyphenyl)-1,3,5-triazin und 2-(4,6-Bis-methylsulfanyl-1,3,5- triazin-2-yl)-5-methoxyphenol | 423-520-3 | 156137-33-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
609-072-00-3 | 4-Mesyl-2-nitrotoluol | 430-550-0 | 1671-49-4 | Repr. 2 Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H361f*** H302 H317 H412 | GHS08 GHS07 Achtg. | H361f*** H302 H317 H412 | |||
609-073-00-9 | Lithium-Kalium-Natrium- N, N""-Bis{6-[7-[4-(4-chlor-1,3,5-triazin-2-yl)amino-4-(2-ureidophenylazo)]naphthalin-1,3,6-trisulfonato}- N"-(2-aminoethyl)piperazin | 427-850-9 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
609-074-00-4 | 1,4-Dichlor-2-nitrobenzol | 201-923-3 | 89-61-2 | Carc. 1B | H350 | GHS08 Dgr | H350 | ) | ||
610-001-00-3 | Trichlornitromethan; Chlorpikrin | 200-930-9 | 76-06-2 | Acute Tox. 2 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H330 H302 H319 H335 H315 | GHS06 Gef. | H330 H302 H319 H335 H315 | |||
610-002-00-9 | 1,1-Dichlor-1-nitroethan | 209-854-0 | 594-72-9 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | |||
610-003-00-4 | Chlordinitrobenzol | - | - | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H410 | C | ||
610-004-00-X | 2-Chlor-1,3,5-trinitrobenzol | 201-864-3 | 88-88-0 | Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H201 H330 H310 H300 H400 H410 | GHS01 GHS06 GHS09 Gef. | H201 H330 H310 H300 H410 | |||
610-005-00-5 | 1-Chlor-4-nitrobenzol; p-Chlornitrobenzol | 202-809-6 | 100-00-5 | Carc. 2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H351 H341 H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H351 H341 H331 H311 H301 H373 ** H411 | |||
610-006-00-0 | Chlornitroaniline, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 | H330 H310 H300 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H373 ** H411 | A C | ||
610-007-00-6 | 1-Chlor-1-nitropropan | 209-990-0 | 600-25-9 | Acute Tox. 4 * Acute Tox. 4 * | H332 H302 | GHS07 Achtg. | H332 H302 | * | ||
610-008-00-1 | 2,6-Dichlor-4-nitroanisol; 3,5-Dichlor-4-methoxy-nitrobenzol | 403-350-6 | 17742-69-7 | Acute Tox. 3 * Aquatic Chronic 2 | H301 H411 | GHS06 GHS09 Gef. | H301 H411 | |||
610-009-00-7 | 2-Chlor-4-nitroanilin | 204-502-2 | 121-87-9 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
610-010-00-2 | 2-Brom-1-(2-furyl)-2-nitroethylen | 406-110-9 | 35950-52-8 | Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H314 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H302 H373 ** H314 H317 H410 | |||
611-001-00-6 | Azobenzol | 203-102-5 | 103-33-3 | Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H341 H332 H302 H373 ** H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H341 H332 H302 H373 ** H410 | |||
611-002-00-1 | Azoxybenzol | 207-802-1 | 495-48-7 | Acute Tox. 4 * Acute Tox. 4 * | H332 H302 | GHS07 Achtg. | H332 H302 | |||
611-003-00-7 | Natrium-4-dimethylaminobenzoldiazosulfonat; Fenaminosulf (ISO) | 205-419-4 | 140-56-7 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Chronic 3 | H301 H312 H412 | GHS06 Gef. | H301 H312 H412 | |||
611-004-00-2 | (Methyl- ONN-azoxy)-methylacetat; Methylazoxymethylacetat | 209-765-7 | 592-62-1 | Carc. 1B Repr. 1B | H350 H360D *** | GHS08 Gef. | H350 H360D *** | |||
611-005-00-8 | Dinatrium-{5-[(4"-((2,6-dihydroxy-3-((2-hydroxy-5-sulfophenyl)azo)phenyl)azo)(1,1"-biphenyl)-4-yl)azo]salicylato(4-)}cuprat(2-); CI Direct Brown 95 | 240-221-1 | 16071-86-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
611-006-00-3 | 4- o-Tolylazo- o-toluidin; 4-Amino-2",3-dimethylazobenzol; Echtgranat-GBC-Base; AAT; o-Aminoazotoluol | 202-591-2 | 97-56-3 | Carc. 1B Skin Sens. 1 | H350 H317 | GHS08 Gef. | H350 H317 | |||
611-007-00-9 | Tricyclazol (ISO); 5-Methyl-1,2,4-triazolo(3,4- b)benzo-1,3-thiazol; | 255-559-5 | 41814-78-2 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
611-008-00-4 | 4-Aminoazobenzol; 4-Phenylazoanilin | 200-453-6 | 60-09-3 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | |||
611-009-00-X | Natrium(1-(5-(4-(4-anilino-3-sulfophenylazo)-2-methyl-5-methylsulfonamidophenylazo)-4-hydroxy-2-oxido-3-(phenylazo)phenylazo)-5-nitro-4-sulfonato-2-naphtholato)eisen(II) | 401-220-3 | - | Acute Tox. 4 * Aquatic Chronic 3 | H332 H412 | GHS07 Achtg. | H332 H412 | |||
611-010-00-5 | 2"-(2-Cyan-4,6-dinitrophenylazo)-5"-( N, N-dipropylamino)propionanilid | 403-010-7 | 106359-94-8 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
611-011-00-0 | N, N,N",N"-Tetramethyl-3,3"- (propylenbis(iminocarbonyl-4,1-phenylenazo(1,6-dihydro-2- hydroxy-4-methyl-6-oxopyridin-3,1-diyl)))di(propylammonium)dilactat | 403-340-1 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Dg | H318 H411 | |||
611-012-00-6 | Reaktionsmasse aus 2,2-Iminodiethanol-6-methyl-2-(4-(2,4,6- triaminopyrimidin-5-ylazo)phenyl)benzothiazol-7-sulfonat, 2-Methylaminoethanol-6-methyl-2-(4-(2,4,6-triaminopyrimidin-5-ylazo)phenyl)benzothiazol-7-sulfonat und N, N- Diethylpropan-1,3-diamin-6-methyl-2-(4-(2,4,6-triaminopyrimidin-5-ylazo)phenyl)benzothiazol-7-sulfonat | 403-410-1 | 114565-65-0 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-013-00-1 | Trilithium-1-hydroxy-7-(3- sulfonatoanilino)-2-(3-methyl-4-(2-methoxy-4-(3-sulfonatophenylazo)phenylazo) phenylazo)naphthalin-3-sulfonat | 403-650-7 | 117409-78-6 | Expl. 1.3 **** Aquatic Chronic 2 | H203 H411 | GHS01 GHS09 Gef. | H203 H411 | |||
611-014-00-7 | (Tetranatrium-1-(4-(3-acetamido- 4-(4"-nitro-2,2"-disulfonatostilben-4-ylazo)anilino)-6-(2,5- disulfonatoanilino)-1,3,5-triazin-2-yl)-3-carboxypyridinium)hydroxid | 404-250-5 | 115099-55-3 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-015-00-2 | Tetranatrium-4-amino-5-hydroxy-6-(4-(2-(2-(sulfonatooxy)ethylsulfonyl)ethylcarbamoyl)phenylazo)-3-(4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo)naphthalin-2,7-disulfonat | 404-320-5 | 116889-78-2 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-016-00-8 | Reaktionsmasse aus 1,1"-((dihydroxyphenylen)bis(azo-3,1-phenylenazo(1-(3-dimethylaminopropyl)-1,2-dihydro-6-hydroxy-4-methyl-2-oxopyridin-5,3- diyl)))dipyridiniumdichlorid, Dihydrochlorid, Isomerengemisch und 1-(1-(3-Dimethylaminopropyl)-5-(3-((4-(1-(3- dimethylaminopropyl)-1,6-dihydro-2-hydroxy-4-methyl-6- oxo-5-pyridinio-3-pyridylazo)phenylazo)-2,4(oder 2,6 oder 3,5)dihydroxyphenylazo)phenylazo)-1,2-dihydro-6- hydroxy-4-methyl-2-oxo-3-pyridyl)pyridiniumdichlorid | 404-540-1 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-017-00-3 | 2-(4-(Diethylaminopropylcarbamoyl) phenylazo)-3-oxo- N-(2,3- dihydro-2-oxobenzimidazol-5-yl)butyramid | 404-910-2 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
611-018-00-9 | Tetraammonium-5-(4-(7-amino- 1-hydroxy-3-sulfonato-2-naphthylazo)-6-sulfonato-1-naphthylazo)isophthalat | 405-130-5 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-019-00-4 | Tetralithium 6-amino-4-hydroxy- 3-(7-sulfonato-4-(4-sulfonatophenylazo)-1-naphthylazo)naphthalin-2,7-disulfonat | 405-150-4 | 106028-58-4 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-020-00-X | Tetrakis(tetramethylammonium)-6-amino-4-hydroxy-3-(7-sulfonato-4-(4-sulfonatophenylazo)-1-naphthylazo)naphthalin-2,7-disulfonat | 405-170-3 | 116340-05-7 | Acute Tox. 3 * Skin Sens. 1 Aquatic Chronic 3 | H301 H317 H412 | GHS06 Gef. | H301 H317 H412 | |||
611-021-00-5 | 2-(4-(4-Cyan-3-methylisothiazol-5-ylazo)- N-ethyl-3-methylanilino)ethylacetat | 405-480-9 | - | Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Aquatic Chronic 4 | H302 H373 ** H315 H413 | GHS08 GHS07 Achtg. | H302 H373 ** H315 H413 | |||
611-022-00-0 | 4-Dimethylaminobenzoldiazonium-3-carboxy-4-hydroxybenzolsulfonat | 404-980-4 | - | Self-react.
C Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H242 H331 H301 H312 H373 ** H318 H317 H400 H410 | GHS02 GHS06 GHS08 GHS05 GHS09 Gef. | H242 H331 H301 H312 H373 ** H318 H317 H410 | T | ||
611-023-00-6 | Dinatrium-7-(4,6-dichlor-1,3,5- triazin-2-ylamino)-4-hydroxy-3-(4-(2-(sulfonatooxy) ethylsulfonyl)phenylazo)naphthalin-2-sulfonat | 404-600-7 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-024-00-1 | Azofarbstoffe auf Benzidinbasis; 4,4"-Diarylazobiphenyl-Farbstoffe, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Carc. 1B | H350 | GHS08 Gef. | H350 | A | ||
611-025-00-7 | Dinatrium 4-amino-3-[[4"-[(2,4- diaminophenyl)azo][1,1"-biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)naphtalin-2,7-disulfphonat; C.I. Direct Black 38 | 217-710-3 | 1937-37-7 | Carc. 1B Repr. 2 | H350 H361d *** | GHS08 Gef. | H350 H361d *** | |||
611-026-00-2 | Tetranatrium 3,3"-[[1,1"- biphenyl]-4,4"- diylbis(azo)]bis[5-amino-4- hydroxynaphthalin-2,7- disulfonat]; C.I. Direct Blue 6 | 220-012-1 | 2602-46-2 | Carc. 1B Repr. 2 | H350 H361d *** | GHS08 Gef. | H350 H361d *** | |||
611-027-00-8 | Dinatrium 3,3"-[[1,1"-biphenyl]- 4,4"-diylbis(azo)]bis(4-aminonaphthalin-1-sulfonat); C.I. Direct Red 28 | 209-358-4 | 573-58-0 | Carc. 1B Repr. 2 | H350 H361d *** | GHS08 Gef. | H350 H361d *** | |||
611-028-00-3 | C, C"-Azodi(formamid); Azodicarbonamid | 204-650-8 | 123-77-3 | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | G | ||
611-029-00-9 | Azofarbstoffe auf o-Dianisidin-Basis; 4,4"-Diarylazo-3,3"-dimethoxybiphenyl-Farbstoffe, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Carc. 1B | H350 | GHS08 Gef. | H350 | A | ||
611-030-00-4 | Farbstoffe auf o-Tolidin-Basis; 4,4"-Diarylazo-3,3"-dimethylbiphenyl-Farbstoffe, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Carc. 1B | H350 | GHS08 Gef. | H350 | A | ||
611-031-00-X | 4,4"-(4-Iminocyclohexa-2,5- dienylidenmethylen)dianilinhydrochlorid; C.I. Basic Red 9 | 209-321-2 | 569-61-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
611-032-00-5 | 1,4,5,8-Tetraaminoanthrachinon; C.I. Disperse Blue 1 | 219-603-7 | 2475-45-8 | Carc. 1B Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H350 H315 H318 H317 | GHS08 GHS05 GHS07 Gef. | H350 H315 H318 H317 | |||
611-033-00-0 | Hexanatrium[4,4""-azoxybis(2,2"-disulfonatostilben-4,4"-diylazo)]bis[5"-sulfonatobenzol-2,2"-diolato- O(2), O(2), N(1)]kupfer (II) | 400-020-3 | 82027-60-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-034-00-6 | N-(5-(Bis(2-methoxyethyl)amino)-2-((5-nitro-2,1- benzisothiazol-3-yl)azo)phenylacetamid | 402-430-8 | 105076-77-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
611-035-00-1 | Tetralithium-6-amino-4-hydroxy-3-[7-sulfonato-4-(5-sulfonato-2-naphthylazo)-1-naphthylazo]naphthalin-2,7-disulfonat | 403-660-1 | 107246-80-0 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-036-00-7 | 2-(4-(5,6(oder 6,7)-Dichlor-1,3-benzothiazol-2-ylazo)- N-methyl- m-toluidino)ethylacetat | 405-440-0 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-037-00-2 | 3(oder 5)-(4-( N-Benzyl- N-ethylamino)-2-ethylphenylazo)-1,4-dimethyl-1,2,4-triazoliummethylsulfat | 406-055-0 | 124584-00-5 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | |||
611-038-00-8 | Trinatrium-1-hydroxynaphthalin-2-azo-4"(5",5""-dimethylbiphenyl)-4""-azo(4""-phenylsulfonyloxybenzol)-2",2"",4-trisulfonat | 406-820-9 | - | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
611-039-00-3 | 7-[((4,6-Dichlor-1,3,5-triazin-2- yl)amino)-4-hydroxy-3-(4-((2- sulfoxy)ethyl)sulfonyl)phenylazo]naphthalin-2-sulfonsäure | 407-050-6 | 117715-57-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-040-00-9 | 3-(5-Acetylamino-4-(4-[4,6- bis(3-diethylaminopropylamino)-1,3,5-triazin-2-ylamino]phenylazo)-2-(2-methoxyethoxy)phenylazo)-6-amino-4-hydroxy-2-naphthalinsulfonsäure | 407-670-7 | 115099-58-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
611-041-00-4 | 2-[[4[[4,6-Bis[[3-(diethylamino)propyl]amino]-1,3,5- triazin-2-yl]amino]phenyl]azo]- N-(2,3-dihydro-2-oxo-1 H-benzimidazol-5-yl)-3-oxobutanamid | 407-680-1 | 98809-11-1 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
611-042-00-X | Trinatrium-5-amino-3-[5-(2- bromacryloylamino)-2-sulfonatophenylazo]-4-hydroxy-6-(4-vinylsulfonylphenylazo)naphthalin-2,7-disulfonat | 411-770-6 | 136213-71-3 | Aquatic Chronic 3 | H412 | - | H412 | |||
611-043-00-5 | Reaktionsmasse aus Trinatrium- N(1")- N(2): N(1)- N(2"")-η-6-[2- amino-4-(oder 6)-hydroxy-(oder 4-amino-2-hydroxy)phenylazo]-6""-(1-carbaniloyl-2-hydroxyprop-1-enylazo)-5",5-disulfamoyl-3,3""-disulfonatobis(naphthalin-2,1"-azobenzol-1,2"-diolato- O(1), O(2"))-chromat, Trinatrium- N(1")-N(2): N(1)- N(2"")-η-6,6""-bis(1-carbaniloyl-2- hydroxyprop-1-enylazo)-5",5'""- disulfamoyl-3,3""-disulfonato bis(naphthalin-2,1"azobenzol- 1,2"-diolato-O(1),O(2"))chromat und Trinatrium N(1")- N(2): N(1)- N(2"")-η -6,6""-bis[2-amino-4-(oder 6)-hydroxy-(oder 4-amino-2- hydroxy)phenylazo]5",5'""- disulfamoyl-3,3""-disulfonato bis(naphthalin-2,1"azobenzol-1,2"-diolato- O(1), O(2"))chromat (2:1:1) | 402-850-1 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-044-00-0 | Reaktionmasse aus tert-Alkyl(C12- C14)ammoniumbis[1-[(2- hydroxy-5-nitrophenyl)azo]-2- naphthalinolato(2-)]-chromat(1-), Tert-Alkyl(C12-C14)ammoniumbis[1-[(2-hydroxy-4-nitrophenyl)azo]-2-naphthalinolato(2-)]chromat(1-), tert-Alkyl(C12-C14)ammoniumbis[1-[[5-(1,1-dimethylpropyl)-2-hydroxy-3-nitrophenyl]azo]-2- naphthalinolato(2-)]]chromat(1-), tert-Alkyl(C12-C14)ammonium [[1-[(2-hydroxy-5-nitrophenyl)azo]-2-naphthalinolato(2-)]-[1-[(2-hydroxy-5-nitrophenyl)azo]-2-naphthalinolato(2-) ]]chromat(1-), Tert-Alkyl(C12-C14)ammonium [[1-[[5-(1,1-dimethylpropyl)-2-hydroxy-3-nitrophenyl]azo]-2-naphthalinolato(2-)]-[1-[(2- hydroxy-5-nitrophenyl)azo]-2- naphthalinolato(2-)]]chromat(1-) und tert-Alkyl(C12-C14)ammonium ((1-(4(oder 5)-nitro-2-oxidophenylazo)-2-naphtholato)(1-(3-nitro-2-oxido-5-pentylphenylazo)-2- naphtholato))chromat(1-) | 403-720-7 | 117527-94-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-045-00-6 | 2-[4-[ N-(4-Acetoxybutyl)- N- ethyl]amino-2-methylphenylazo]-3-acetyl-5-nitrothiophen | 404-830-8 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
611-046-00-1 | 4,4"-Diamino-2-methylazobenzol | 407-590-2 | 43151-99-1 | Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H373 ** H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H373 ** H317 H410 | |||
611-047-00-7 | Reaktionsmasse aus 2-[[4-[ N-Ethyl- N-(2-acetoxyethyl)amino]phenyl]azo]-5,6-dichlorbenzothiazol und 2-[[4-[ N-ethyl- N-(2-acetoxyethyl)amino]phenyl]azo]-6,7-dichlorbenzothiazol (1:1) | 407-890-3 | 111381-11-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
611-048-00-2 | Reaktionsmasse aus 2-[[4-[Bis(2- acetoxyethyl)amino]phenyl]azo]-5,6-dichlorbenzothiazol und 2-[[4-[Bis(2-acetoxyethyl)amino]phenyl]azo]-6,7- dichlorbenzothiazol (1:1) | 407-900-6 | 111381-12-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
611-049-00-8 | Reaktionsmasse aus 7-[4-(3-Diethylaminopropylamino)-6-(3-diethylammoniopropylamino)-1,3,5- triazin-2-ylamino]-4-hydroxy-3-(4-phenylazophenylazo)naphthalin-2-sulfonat, Essigsäure, Milchsäure (2:1:1) | 408-000-6 | 118658-98-3 | STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 | H373 ** H317 H412 | GHS08 Achtg. | H373 ** H317 H412 | |||
611-050-00-3 | Reaktionsmasse aus Pentanatrium-7-amino-3-[[4-[[4-[[4-[[4-[(6-amino-1-hydroxy-3-sulfonato-2-naphthyl)azo]-7-sulfonato-1-naphthyl]azo]phenyl]amino]-3- sulfonatophenyl]azo]-6-sulfonato-1-naphthyl]azo]-4-hydroxynaphthalin-2-sulfonat, Pentanatrium-7-amino-8-[4-[4- [4-[4-(2-amino-5-hydroxy-7-sulfonatonaphthalin-1-ylazo)-7-sulfonatonaphthalin-1-ylazo]- phenylamino]-3-sulfonatophenylazo]-6-sulfonatonaphthalin-1-ylazo]-4-hydroxynaphthalin-2-sulfonat; Pentanatrium-7-amino-8-[4-[4- [4-[4-(6-amino-1-hydroxy-3- sulfonatonaphthalin-1-ylazo)-7-sulfonatonaphthalin-1-ylazo]- phenylamino]-3-sulfonatophenylazo]-6-sulfonatonaphthalin-1-ylazo]-4-hydroxynaphthalin-2-sulfonat, Tetranatrium-7-amino-4-hydroxy-3-[4-[4-[4-(4-hydroxy-7- sulfonatonaphthalin-1-ylazo)-2-sulfonatophenylamino]phenylazo]-6-sulfonatonaphthalin-1- ylazo]naphthalin-2-sulfonat Tetranatrium-7-amino-4-hydroxy-3-[4-[4-[4-(4-amino-7-sulfonatonaphthalin-1-ylazo)-2-sulfonatophenylamino]phenylazo]-6- sulfonatonaphthalin-1- ylazo]naphthalin-2-sulfonat | 415-350-3 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-051-00-9 | 2-(4-( N-Ethyl- N-(2-hydroxy)ethyl)amino-2-methylphenyl)azo-6-methoxy-3- Methylbenzothiazoliumchlorid | 411-110-7 | 136213-74-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
611-052-00-4 | Mononatrium-aqua-[5-[[2,4-dihydroxy-5-[(2-hydroxy-3,5-dinitrophenyl)azo]phenyl]azo]-2-naphthalinsulfonat], Eisenkomplex | 400-720-9 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
611-053-00-X | 2,2"-Azobis[2-methylpropionamidin]dihydrochlorid | 221-070-0 | 2997-92-4 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
611-055-00-0 | C.I. Disperse Yellow 3; N-[4-[(2-Hydroxy-5-methylphenyl)azo]phenyl]acetamid | 220-600-8 | 2832-40-8 | Carc. 2 Skin Sens. 1 | H351 H317 | GHS08 GHS07 Achtg. | H351 H317 | |||
611-056-00-6 | C.I. Solvent Yellow 14; 1-Phenylazo-2-naphthol | 212-668-2 | 842-07-9 | Carc. 2 Muta. 2 Skin Sens. 1 Aquatic Chronic 4 | H351 H341 H317 H413 | GHS08 GHS07 Achtg. | H351 H341 H317 H413 | |||
611-057-00-1 | 6-Hydroxy-1-(3-isopropoxypropyl)-4-methyl-2-oxo-5-[4-(phenylazo)phenylazo]-1,2-dihydro-3-pyridincarbonitril | 400-340-3 | 85136-74-9 | Carc. 1B Aquatic Chronic 4 | H350 H413 | GHS08 Achtg. | H350 H413 | |||
611-058-00-7 | (6-(4-Hydroxy-3-(2-methoxyphenylazo)-2-sulfonato-7-naphthylamino)-1,3,5-triazin-2,4- diyl)bis[(amino-1-methylethyl)ammonium]format | 402-060-7 | 108225-03-2 | Carc. 1B Eye Dam. 1 Aquatic Chronic 2 | H350 H318 H411 | GHS08 GHS05 GHS09 Gef. | H350 H318 H411 | |||
611-059-00-2 | Octanatrium-2-(6-(4-Chlor-6-(3-( N-methyl-N-(4-chlor-6-(3,5- disulfonato-2-naphthylazo)-1- hydroxy-6-naphthylamino)-1,3,5-triazin-2-yl)aminomethyl)phenylamino)-1,3,5-triazin-2-ylamino)-3,5-disulfonato-1-hydroxy-2-naphthylazo)naphthalin-1,5-disulfonat | 412-960-1 | 148878-21-1 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
611-060-00-8 | Reaktionsmasse aus Natrium-5-[8-[4-[4-[4-[7-(3,5-dicarboxylatophenylazo)-8-hydroxy-3,6- disulfonatonaphthalin-1-ylamino]-6-hydroxy-1,3,5-triazin-2-yl]-2,5-dimethylpiperazin-1-yl]-6-hydroxy-1,3,5-triazin-2-ylamino]-1-hydroxy-3,6-disulfonatonaphthalin-2- ylazo]-isophthalat und Ammonium 5-[8-[4-[4-[4-[7-(3,5-dicarboxylatophenylazo)-8-hydroxy-3,6-disulfonatonaphthalin-1-ylamino]-6-hydroxy-1,3,5-triazin-2-yl]-2,5-dimethylpiperazin-1-yl]-6-hydroxy-1,3,5-triazin-2-ylamino]-1-hydroxy- 3,6-disulfonatonaphthalin-2-ylazo]-isophthalat 5-[8-[4-[4-[4-[7-(3,5-dicarboxylatophenylazo)-8-hydroxy-3,6- disulfonatonaphthalin-1-ylamino]-6-hydroxy-1,3,5-triazin-2-yl]-2,5-dimethylpiperazin-1-yl]-6-hydroxy-1,3,5-triazin-2-ylamino]-1-hydroxy-3,6-disulfonaphthalin-2-ylazo]isophthalsäure | 413-180-4 | 187285-15-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-061-00-3 | Dinatrium-5-[5-[4-(5-chlor-2,6-difluoropyrimidin-4-ylamino)benzamido]-2-sulfonatophenylazo]-1-ethyl-6-hydroxy-4-methyl-2-oxo-3-pyridylmethylsulfonat | 412-530-3 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-062-00-9 | Octanatrium-2-(8-(4-chlor-6-(3-((4-chlor-6-(3,6-disulfonato-2-(1,5-disulfonatonaphthalin-2- ylazo)-1-hydroxynaphthalin-8-ylamino)-1,3,5-triazin-2-yl)aminomethyl)phenylamino)-1,3,5- triazin-2-ylamino)-3,6- disulfonat-1-hydroxynaphthalin-2-ylazo)naphthalin-1,5-disulfonat | 413-550-5 | - | Skin Irrit. 2 Eye Dam. 1 | H315 H318 | GHS05 Gef. | H315 H318 | |||
611-063-00-4 | Trinatrium[4"-(8-acetylamino-3,6-disulfonato-2-naphthylazo)-4""-(6-benzoylamino-3-sulfonato-2-naphthylazo)biphenyl-1,3",3"",1-tetraolato- O, O", O"", O]kupfer (II) | 413-590-3 | 164058-22-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
611-064-00-X | 4-(3,4-Dichlorphenylazo)-2,6-di- sec-butylphenol | 410-600-8 | 124719-26-2 | STOT RE 2 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H315 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H373 ** H315 H410 | |||
611-065-00-5 | 4-(4-Nitrophenylazo)-2,6-di- sec- butylphenol | 410-610-2 | 111850-24-9 | STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H319 H315 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H373 ** H319 H315 H317 H410 | |||
611-066-00-0 | Tetranatrium-5-[4-chlor-6-( N-ethylanilino)-1,3,5-triazin-2- ylamino]-4-hydroxy-3-(1,5- disulfonatonaphthalin-2-ylazo)-naphthalin-2,7-disulfonat | 411-540-5 | 130201-57-9 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
611-067-00-6 | Reaktionsmasse aus Bis(tris(2-(2- hydroxy(1-methyl)ethoxy)ethyl)ammonium)-7-anilino-4-hydroxy-3-(2-methoxy-5-methyl-4-(4- sulfonatophenylazo)phenylazo)naphthalin-2-sulfonat und Bis(tris(2-(2-hydroxy(2- methyl)ethoxy)ethyl)ammonium)-7-anilino-4-hydroxy-3- (2-methoxy-5-methyl-4-(4- sulfonatophenylazo)phenylazo)naphthalin-2-sulfonat | 406-910-8 | - | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
611-068-00-1 | Tetranatrium-4-amino-3,6-bis(5- [4-chlor-6-(2-hydroxyethylamino)-1,3,5-triazin-2-ylamino]-2-sulfonatophenylazo)-5-hydroxynaphthalin-2,7-disulfonat | 400-690-7 | 85665-98-1 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-069-00-7 | N, N-Di[poly(oxyethylen)copoly(oxypropylen)]-4-[(3,5-dicyano-4-methyl-2-thienyl)azo)]-3-methylanilin | 413-380-1 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-070-00-2 | Reaktionsmasse aus Dinatrium(6-(4-anisidino)-3-sulfonato-2-(3,5-dinitro-2-oxidophenylazo)-1-naphtholato)(1-(5-chlor-2- oxidophenylazo)-2-naphtholato)chromat(1-) und Trinatrium-bis(5-(4-anisidino)-3-sulfonato-2-(3,5-dinitro-2-oxidophenylazo)-1-naphtholato)chromat(1-) | 405-665-4 | - | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
611-071-00-8 | Tris(tetramethylammonium)-5-hydroxy-1-(4-sulphonatophenyl)-4-(4-sulphonatophenylazo)pyrazol-3-carboxylat | 406-073-9 | 131013-81-5 | Acute Tox. 3 * Aquatic Chronic 3 | H301 H412 | GHS06 Gef. | H301 H412 | |||
611-072-00-3 | 2,4-Bis[2,2"-[2-( N, N-dimethylamino)ethyloxycarbonyl]phenylazo]-1,3-dihydroxybenzol, Dihydrochlorid | 407-010-8 | 118208-02-9 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
611-073-00-9 | Dimethyl- 3,3"-( N-(4-(4-brom-2,6-dicyanophenylazo)-3-hydroxyphenyl)imino)dipropionat | 407-310-9 | 122630-55-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
611-074-00-4 | Reaktionsmasse aus Natrium/Kalium (3-(4-(5-(5-chlor-2,6-difluorpyrimidin-4-ylamino)-2-methoxy-3-sulfonatophenylazo)-2-oxidophenylazo)-2,5,7-trisulfonato-4-naphtholato)kupfer(II) und Natrium/Kalium(3-(4-(5-(5-chlor-4,6-difluorpyrimidin-2-ylamino)-2-methoxy-3-sulfonatophenylazo)-2-oxidophenylazo)-2,5,7-trisulfonato-4-naphtholato)kupfer(II) | 407-100-7 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-075-00-X | Reaktionsmasse aus Tris(3,5,5- trimethylhexylammonium)-4-amino-3-(4-(4-(2-amino-4-hydroxyphenylazo)anilino)-3- sulfonatophenylazo)-5,6-dihydro-5-oxo-6-phenylhydrazononaphthalin-2,7-disulfonat und Tris(3,5,5-trimethylhexylammonium) - 4-amino-3-(4-(4-(4-amino-2-hydroxyphenylazo)anilino)-3-sulfonatophenylazo)-5,6-dihydro-5-oxo-6-phenylhydrazononaphthalin-2,7-disulfonat(2:1) | 406-000-0 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
611-076-00-5 | 3-(2,6-Dichlor-4-nitrophenylazo)-1-methyl-2-phenylindol | 406-280-4 | 117584-16-4 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
611-077-00-0 | Dilithiumdinatrium(5,5"-diamino(μ-4,4"-dihydroxy-1:2-κ-2, O4, O4",-3,3"-[3,3"-dihydroxy-1:2-κ-2- O3, O3"-biphenyl-4,4"-ylenbisazo-1:2-( N3, N4- η: N3", N4"-η )]-dinaphthalin-2,7-disulfonato(8)))dicuprat(2-) | 407-230-4 | 126637-70-5 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
611-078-00-6 | (2,2"-(3,3"-Dioxidobiphenyl-4,4"-diyldiazo)bis(6-(4-(3-(diethylamino)propylamino)-6-(3-(diethylammonio)propylamino)-1,3,5-triazin-2-ylamino)-3-sulfonato-1-naphtholato))dikupfer(II)acetatlactat | 407-240-9 | 159604-94-1 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
611-079-00-1 | Dinatrium-7-[4-chlor-6-( N-ethyl- o-toluidino)-1,3,5-triazin-2-ylamino]-4-hydroxy-3-(4- methoxy-2-sulfonatophenylazo)-2-naphthalinsulfonat | 410-390-8 | 147703-64-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-080-00-7 | Natrium-3-(2-acetamido-4-(4-(2- hydroxybutoxy)phenylazo)phenylazo)benzolsulfonat | 410-150-2 | 147703-65-9 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-081-00-2 | Tetranatrium[7-(2,5-dihydroxy-K O2-7-sulfonato-6-[4-(2,5,6- trichlor-pyrimidin-4- ylamino)phenylazo]-( N1, N7- N)-1-naphthylazo)-8-hydroxy-K O8- naphthalin-1,3,5-trisulfonato(6-)]cuprat(II) | 411-470-5 | 141048-13-7 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
611-082-00-8 | Reaktionsmasse aus Pentanatrium-bis(1-(3(oder 5)-(4-anilino-3-sulfonatophenylazo)-4-hydroxy-2-oxidophenylazo)-6-nitro-4-sulfonato-2-naphtholato)ferrat(1-) und Pentanatrium[(1-(3-(4-anilino-3-sulfonatophenylazo)-4-hydroxy-2-oxidophenylazo)-6-nitro-4-sulfonato-2-naphtholato)-(5-(4-anilino-3-sulfonatophenylazo)-4-hydroxy-2-oxidophenylazo)-6-nitro-4-sulfonato-2-naphtholato]ferrat(1-) | 407-570-3 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-083-00-3 | Reaktionsmasse aus 2-[ N-ethyl-4-[(5,6-dichlorbenzothiazol-2-yl)azo]-m-toludino]ethylacetat und 2-[ N-Ethyl-4-[(6,7-dichlorbenzothiazol-2-yl)azo]- m-toludino]ethylacetat (1:1) | 411-560-4 | - | STOT RE 1 Skin Sens. 1 Aquatic Chronic 2 | H372 ** H317 H411 | GHS08 GHS07 GHS09 Gef. | H372 ** H317 H411 | |||
611-085-00-4 | Reaktionsmasse aus 3-Cyan-5-(2-cyan-4-nitrophenylazo)-2-(2-hydroxyethylamino)-4-methyl-6-[3-(2-phenoxyethoxy)propylamino]pyridin, 3-Cyan-5-(2-cyan-4-nitrophenylazo)-6-(2-hydroxyethylamino)-4-methyl-2-[3-(2-phenoxyethoxy)propylamino]pyridin, 3-Cyan-5-(2-cyan-4-nitrophenylazo)-2-amino-4-methyl-6- [3-(3-hydroxypropoxy)propylamino] pyridin und 3-Cyan-5-(2-cyan-4-nitrophenylazo)-6-amino-4-methyl-2- [3-(3-ethoxypropoxy)propylamino]pyridin | 411-880-4 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
611-086-00-X | Monolithium-5-[[2,4-dihydroxy-5-[(2-hydroxy-3,5-dinitrophenyl)azo]phenyl]azo]-2-naphthalinsulfonat], Eisenkomplex, Monohydrat | 411-360-7 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
611-087-00-5 | Reaktionsmasse aus 3-((5-Cyan-1,6-dihydro-1,4-dimethyl-2- hydroxyl-6-oxo-3-pyridinyl)azo)-benzoyloxy-2-phenoxyethan und 3-((5-Cyan-1,6-dihydro-1,4-dimethyl-2-hydroxy-6-oxo-3- pyridinyl)azo)-benzoyloxy-2-ethyloxy-2-(ethylphenol) | 411-710-9 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
611-088-00-0 | Reaktionsmasse aus Trilithium-4-amino-3-((4-((4-((2-amino-4-hydroxyphenyl)azo)phenyl)amino)-3-sulfophenyl)azo)-5-hydroxy-6-(phenylazo)naphthalin-2,7-disulfonat und Trilithium-4-amino-3-((4-((4-((4- amino-2-hydroxyphenyl)azo)phenyl)amino)-3-sulfophenyl)azo)-5-hydroxy-6-(phenylazo)naphthalin-2,7-disulfonat | 411-890-9 | - | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
611-089-00-6 | 2-((4-(Ethyl-(2-hydroxyehyl)amino)-2-methylphenyl)azo)-6-methoxy-3-methylbenzothiazoliummethylsulfat | 411-100-2 | 136213-73-5 | STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H373 ** H317 H410 | |||
611-090-00-1 | 2,5-Dibutoxy-4-(morpholin-4-yl)benzoldiazonium-4-methylbenzolsulfonat | 413-290-2 | 93672-52-7 | Self-react.
C Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H242 H302 H318 H317 H412 | GHS02 GHS05 GHS07 Gef. | H242 H302 H318 H317 H412 | T | ||
611-091-00-7 | Natrium(1,0-1,95)/Lithium(0,05-1)-5-((5-((5-chlor-6-fluor-pyrimidin-4-yl)amino)-2-sulfonatophenyl)azo)-1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxo-3-pyridinmethylsulfonat | 413-470-0 | 134595-59-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-092-00-2 | tert-(Dodecyl/Tetradecyl)ammonium-bis(3-(4-((5-(1,1-dimethylpropyl)-2-hydroxy-3-nitrophenyl)azo)-3-methyl-5-hydroxy-(1 H)pyrazol-1-yl)benzolsulfonamidat)chromat | 413-210-6 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-093-00-8 | Natrium-2-(4-(4-fluor-6-(2-sulfoethylamino)-[1,3,5]triazin-2-ylamino)-2-ureido-phenylazo)-5-(4-sulfophenylazo)benzol-1-sulfonat | 410-770-3 | 146177-84-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-094-00-3 | Reaktionsmasse aus 2-[2-acetylamino-4-[ N, N-bis[2-ethoxy-carbonyloxy)ethyl]amino]phenylazo]-5,6-dichlor-1,3-benzothiazol und 2-[2-Acetylamino-4-[ N, N-bis[2- ethoxycarbonyloxy)ethyl]amino]phenylazo]-6,7-dichlor-1,3-benzotriazol (1:1) | 411-600-0 | 143145-93-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
611-095-00-9 | Hexanatrium-1,1"-[(1-amino-8- hydroxy-3,6-disulfonat-2,7-naphthalindiyl)bis(azo(4- sulfonat-1,3-phenyl)imino[6-[(4-chlor-3-sulfonatophenyl)amino]-1,3,5-triazin-2,4-diyl]]]bis[3-carboxypyridinium]dihydroxid | 412-240-7 | 89797-03-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-096-00-4 | Methyl- N-[3-acetylamino)-4-(2-cyan-4-nitrophenylazo)phenyl]- N-[(1-methoxy)acetyl]glycinat | 413-040-2 | 149850-30-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-097-00-X | Reaktionsmasse aus Eisenkomplexen aus 1,3-Dihydroxy-4-[(5-phenylaminosulfonyl)-2-hydroxyphenylazo]- n-(5-aminosulfonyl-2-hydroxyphenylazo)benzol und 1,3-Dihydroxy-4-[(5-phenylaminosulfonyl)-2-hydroxyphenylazo]- n-[4-(4-nitro-2-sulfophenylamino)phenylazo]benzol (n=2,5,6) | 414-150-3 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
611-098-00-5 | Tetrakis(tetramethylammonium)-3,3"-(6-(2-hydroxyethylamino)-1,3,5-triazin-2,4-diyl)-bis(imino(2-methyl-4,1-phenylen)azo))bisnaphthalin-1,5-disulfonat | 405-950-3 | 131013-83-7 | Acute Tox. 3 * Aquatic Chronic 3 | H301 H412 | GHS06 Gef. | H301 H412 | |||
611-099-00-0 | (Methylenbis(4,1-phenylenazo(1-(3-(dimethylamino)propyl)-1,2-dihydro-6-hydroxy-4-methyl-2-oxopyridin-5,3-diyl)))-1,1"- dipyridiniumdichloriddihydrochlorid | 401-500-5 | 118658-99-4 | Carc. 1B Aquatic Chronic 2 | H350 H411 | GHS08 GHS09 Gef. | H350 H411 | |||
611-100-00-4 | Kalium-Natrium-3,3"-(3(oder 4)- methyl-1,2-phenylenbis(imino(6-chlor)-1,3,5- triazin-4,2-diylimino(2-acetamido-5-methoxy)-4,1-phenylenazo)dinaphthalin-1,5-disulfonat | 403-810-6 | 140876-13-7 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-101-00-X | 2"-(4-Chlor-3-cyan-5-formyl-2-thienyl)azo-5"-diethylaminoacetanilid | 405-200-5 | 104366-25-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-102-00-5 | Reaktionsprodukt von C.I. Leuco Schwefelschwarz 1 und Reaktionsmasse aus Dinatrium-4-{4-[8-amino-1-hydroxy-7-(4-sulfamoylphenylazo)-3,6-disulfonato-2-naphthylazo]phenylsulfonylamino}benzoldiazoniumchlorid und Dinatrium-4-{4-[2,6-dihydroxy-3-(8-hydroxy-3,6-disulfonato-1-naphthylazo)phenylazo]phenylsulfonylamino}benzoldiazoniumchlorid | 424-500-7 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
611-103-00-0 | Trinatrium(1-(3-carboxylato-2-oxido-5-sulfonatophenylazo)-5-hydroxy-7-sulfonatonaphthalin-2-amido)nickel(II) | 407-110-1 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
611-104-00-6 | Reaktionsmasse aus Trinatrium(2,4(oder 2,6 oder 4,6)bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(oder 4 oder 6)-(3,5-dinitro-2-oxidophenylazo)-5-hydroxy-4(oder 2 oder 6)-(4-(4-nitro-2-sulfonatoanilino)phenylazo)phenolato)ferrat(1-), Trinatriumbis(2,4(oder 2,6 oder 4,6)bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)ferrat(1-), Trinatrium(2,4(oder 2,6 oder 4,6)bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(oder 4 oder 6)-(3,5-dinitro-2-oxidophenylazo)-5-hydroxy-4(or 2 oder 6)-(4-nitro-2-sulfonatophenylazo)phenolato)ferrat(1-), Trinatrium(2,4 (oder 2,6 oder 4,6)bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(oder 4 oder 6)-(3,5-dinitro-2-oxidophenylazo)-5-hydroxy-4(oder 2 oder 6)-(3-sulfonatophenylazo)phenolato)ferrat(1-) und Dinatrium-3,3"-(2,4-dihydroxy-1,3(oder 1,5 oder 3,5)-phenylendiazo)dibenzolsulfonat | 406-870-1 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
611-105-00-1 | Natrium-4-(4-chlor-6-( N-ethylanilino)-1,3,5-triazin-2-ylamino)-2-(1-(2-chlorphenyl)-5-hydroxy-3-methyl-1 H-pyrazol-4- ylazo)benzolsulfonat | 407-800-2 | 136213-75-7 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
611-106-00-7 | Hexanatrium-4,4"-dihydroxy-3,3"-bis[2-sulfonato-4-(4-sulfonatophenylazo)phenylazo]-7,7"[ p- phenylenbis[imino(6-chlor-1,3,5-triazin-4,2-diyl)imino]]dinaphthalin-2-sulfonat | 410-180-6 | 157627-99-1 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-107-00-2 | Kalium-Natrium-4-(4-chlor-6-(3,6-disulfonato-7-(5,8-disulfonatonaphthalin-2-ylazo)-8-hydroxynaphthalin-1-ylamino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-(2-sulfatoethansulfonyl)-phenylazo)naphthalin-1,7-disulfonat | 412-490-7 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-108-00-8 | Dinatrium-5-((4-((4-chlor-3-sulfonatophenyl)azo)-1-naphthyl)azo)-8-(phenylamino)-1-naphthalinsulfonat | 413-600-6 | 6527-62-4 | Aquatic Chronic 3 | H412 | - | H412 | |||
611-109-00-3 | Reaktionprodukte von Kupfer(II)sulfat und Tetranatrium-2,4-bis[6-(2-methoxy-5-sulfonatophenylazo)-5-hydroxy-7-sulfonato-2-naphthylamino]-6-(2-hydroxyethylamino)-1,3,5-triazin (2:1) | 407-710-3 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-110-00-9 | Tetranatrium/-lithium-4,4"-bis(8- amino-3,6-disulfonato-1-naphthol-2-ylazo)-3-methylazobenzol | 408-210-8 | 124605-82-9 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
611-111-00-4 | Dinatrium-2-[[4-(2-chlorethylsulfonyl)phenyl]-[(2- hydroxy-5-sulfo-3-[3-[2-(2-(sulfooxy)ethylsulfonyl)ethylazo]-4-sulfobenzoato(3-)cuprat(1-) | 414-230-8 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-112-00-X | Tetranatrium-4-hydroxy-5-[4-[3-(2-sulfatoethansulfonyl)phenylamino]-6-morpholin-4-yl-1,3,5-triazin-2-ylamino]-3-(1-sulfonatonaphthalin-2-ylazo)naphthalin-2,7-disulfonat | 413-070-6 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-113-00-5 | Lithium-Natrium(2-(((5-((2,5- dichlorphenyl)azo)-2-hydroxyphenyl)methylen)amino)benzoato(2-))(2-((4,5-dihydro-3-methyl-5-oxo-1-phenyl-1 H-pyrazol-4-yl)azo)-5-sulfobenzoato(3-))chromat(2-) | 414-280-0 | 149626-00-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-114-00-0 | Lithium-Natrium-(4-((5-chlor-2- hydroxyphenyl)azo)-2,4-dihydro-5-methyl-3 H-pyrazol-3-onato(2-))(3-((4,5-dihydro-3-methyl-1-(4-methylphenyl)-5-oxo-1 H-pyrazol-4-yl)azo)-4-hydroxy-5-nitrobenzolsulfonato(3-))chromat(2-) | 414-250-7 | 149564-66-9 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
611-115-00-6 | Trilithiumbis(4-((4-(diethylamino)-2-hydroxyphenyl)azo)-3-hydroxy-1-naphthalinsulfonato(3))chromat(3-) | 414-290-5 | 149564-65-8 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
611-116-00-1 | Reaktionsmasse aus Trinatrium-5-{4-chlor-6-[2-(2,6-dichlor-5-cyanopyrimidin-4-ylamino)propylamino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonatonaphthalin-2-ylazo)naphthalin-2,7-disulfonat, Trinatrium-5-{4-chlor-6-[2-(2,6-dichlor-5-cyanopyrimidin-4-ylamino)-1-methyl-ethylamino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonatonaphthalin-2-ylazo)-naphthalin-2,7-disulfonat; Trinatrium-{4-chlor-6-[2-(4,6-dichlor-5-cyanopyrimidin-2-ylamino)propylamino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonatonaphthalin-2-ylazo)naphthalin-2,7-disulfonat und Trinatrium-5-{4-chlor-6-[2-(4,6-dichlor-5-cyanopyrimidin-2-ylamino)-1-methylethylamino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonatonaphthalin-2-ylazo)naphthalin-2,7-disulfonat | 414-620-8 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-117-00-7 | 1,3-Bis{6-fluor-4-[1,5-disulfo-4-(3-aminocarbonyl-1-ethyl-6- hydroxy-4-methylpyrid-2-on-5-ylazo)-phenyl-2-ylamino]-1,3,5-triazin-2-ylamino}propan, Lithium-/Natriumsalz | 415-100-3 | 149850-29-3 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
611-118-00-2 | Natrium-1,2-bis[4-[4-{4-(4- sulfophenylazo)-2-sulfophenylazo}-2-ureidophenylamino]-6-fluor-1,3,5-triazin-2-ylamino]propan, Natriumsalz | 413-990-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | ||||
611-119-00-8 | Tetranatrium-4-[4-chlor-6-(4- methyl-2-sulfophenylamino)-1,3,5-triazin-2-ylamino]-6-(4,5-dimethyl-2-sulfophenylazo)-5-hydroxynaphthalin-2,7- disulfonat | 415-400-4 | 148878-22-2 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-120-00-3 | 5-{4-[5-Amino-2-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4- sulfophenylamino]-6-chlor-1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-sulfonaphthalin-2-ylazo)-naphthalin-2,7-Disulfonsäure, Natriumsalz | 418-340-7 | 157707-94-3 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-121-00-9 | Hauptbestandteil 6 (Isomer): asym. 1:2 Cr(III)-Komplex von A: 3-Hydroxy-4-(2-hydroxynaphthalin-1-ylazo)naphthalin-1-sulfonsäure, Natriumsalz, und B: 1-[2-Hydroxy-5-(4-methoxyphenylazo) phenylazo]naphthalin-2-ol; Hauptbestandteil 8 (Isomer): asym. 1:2 Cr-Komplex von A: 3-Hydroxy-4-(2-hydroxynaphthalin-1-ylazo)-naphthalin-1-sulfonsäure, Natriumsalz, und B: 1-[2-Hydroxy-5-(4-methoxyphenylazo)-phenylazo]-naphthalin-2-ol | 417-280-9 | 30785-74-1 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
611-122-00-4 | Hexanatrium(di[ N-(3-(4-[5-(5-amino-3-methyl-1-phenylpyrazol-4-yl-azo)-2,4-disulfoanilino]-6-chlor-1,3,5-triazin-2-yl-amino)phenyl)sulfamoyl](disulfo)phthalocyaninato)nickel | 417-250-5 | 151436-99-6 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-123-00-X | 3-(2,4-Bis(4-((5-(4,6-bis(2-aminopropylamino)-1,3,5-triazin-2- ylamino)-4-hydroxy-2,7- disulfonaphthalin-3-yl)azo)phenylamino)-1,3,5-triazin-6-ylamino)propyldiethylammoniumlactat | 424-310-4 | 178452-66-9 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-124-00-5 | Reaktionsmasse aus Pentanatrium-5-amino-3-(5-{4-chlor-6-[4-(2-sulfoxyethoxysulfonato)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-6-[5-(2,3-dibrompropionylamino)-2-sulfonatophenylazo]-4-hydroxynaphthalin-2,7-disulfonat, Pentanatrium-5-amino-6-[5-(2- bromacryloylamino)-2-sulfonatophenylazo]-3-(5-{4-chlor-6- [4-(2-sulfoxyethoxysulfonato)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-4-hydroxynaphthalin-2,7-disulfonat und Tetranatrium-5-amino-3-[5-{4- chlor-6-[4-(vinylsulfonyl)phenylamino]-1,3,5-triazin- 2-ylamino}-2-sulfonatophenylazo]-6-[5-(2,3-dibrompropionylamino)-2-sulfonatophenylazo]-4-hydroxynaphthalin-2,7-disulfonat | 424-320-9 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | ||||
611-125-00-0 | Reaktionsmasse aus Dinatrium-6-[3-carboxy-4,5-dihydro-5-oxo-4- sulfonatophenyl)pyrazolin-4-ylazo]-3-[2-oxido-4-(ethensulfonyl)-5-methoxyphenylazo]-4-oxidonaphthalin-2-sulfonat, Kupfer(II)-Komplex, Dinatrium-6-[3-carboxy-4,5-dihydro-5-oxo-4-sulfonatophenyl)pyrazolin-4-ylazo]-3-[2-oxido-4-(2-hydroxyethylsulfonyl)-5-methoxyphenylazo]-4- oxidonaphthalin-2-sulfonat, Kupfer(II)-Komplex | 423-940-7 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
611-126-00-6 | 2,6-Bis(2-(4-(4-amino-phenylamino)phenylazo)-1,3-dimethyl-3 H-imidazolium)-4-dimethylamino-1,3,5-triazin, Dichlorid | 424-120-1 | 174514-06-8 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
611-127-00-1 | Pentanatrium-4-amino-6-(5-(4- (2-ethylphenylamino)-6-(2- sulfatoethansulfonyl)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-sulfatoethansulfonyl)phenylazo) naphthalin-2,7-disulfonat | 423-790-2 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | G | ||
611-128-00-7 | N, N"-Bis{6-chlor-4-[6-(4-vinylsulfonylphenylazo)-2,7-disulfonsäure-5-hydroxynaphth-4-ylamino]-1,3,5-triazin-2-yl}- N-(2-hydroxyethyl)ethan-1,2-diamin, Natriumsalz | 419-500-9 | 171599-85-2 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-129-00-2 | Reaktionsmasse aus 5-[(4-[(7-Amino-1-hydroxy-3-sulfo-2- naphthyl)azo]-2,5-diethoxyphenyl)azo]-2-[(3-phosphonophenyl)azo]benzoesäure und 5-[(4-[(7-Amino-1-hydroxy-3-sulfo-2-naphthyl)azo]-2,5-diethoxyphenyl)azo]-3-[(3-phosphonophenyl)azo]benzoesäure | 418-230-9 | 163879-69-4 | Expl. 1.3 **** Repr. 2 STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H203 H361f *** H373 ** H317 H411 | GHS01 GHS08 GHS07 GHS09 Gef. | H203 H361f *** H373 ** H317 H411 | |||
611-130-00-8 | Tetraammonium-2-[6-[7-(2- carboxylatophenylazo)-8-hydroxy-3,6-disulfonato-1-naphthylamino]-4-hydroxy-1,3,5-triazin-2-ylamino]benzoat | 418-520-5 | 183130-96-3 | Eye Irrit. 2 Aquatic Chronic 3 | H319 H412 | GHS07 Achtg. | H319 H412 | |||
611-131-00-3 | 2-[2-Hydroxy-3-(2-chlorphenyl)carbamoyl-1-naphthylazo]-7-[2-hydroxy-3-(3-methylphenyl)carbamoyl-1-naphthylazo]fluorenon | 420-580-2 | 151798-26-4 | Repr. 1B Aquatic Chronic 4 | H360D *** H413 | GHS08 Gef. | H360D *** H413 | |||
611-132-00-9 | Pentanatriumbis{7-[4-(1-butyl-5-cyano-1,2-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo)phenylsulfonylamino]-5"-nitro-3,3"-disulfonatonaphthalin-2-azobenzol-1,2"-diolato}chromat(III) | 419-210-2 | 178452-71-6 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-133-00-4 | Eisenkomplex von Azofarbstoffen, erhalten durch Kupplung eines Gemisches aus diazotiziertem 2-Amino-1- hydroxybenzol-4-sulfanilid und 2-Amino-1-hydroxybenzol-4-sulfonamid mit Resorcin, wobei das so erhaltene Gemisch anschließend einer zweiten Kupplung mit einem Gemisch aus 3-Aminobenzol-1-sulfonsäure (Metanilsäure) und 4"-Amino-4-nitro-1,1"-diphenylamin-2-sulfonsäure sowie einer Metallisierung mit Eisenchlorid unterzogen wird, Natriumsalz | 419-260-5 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
611-134-00-X | Trinatrium-2-{α[2-hydroxy-3-[4- chlor-6-[4-(2,3-dibrompropionylamino)-2-sulfonatophenylamino]-1,3,5-triazin-2-ylamino]-5-sulfonatophenylazo]- benzylidenhydrazino}-4-sulfonatobenzoat, Kupferkomplex | 423-770-3 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
611-135-00-5 | Reaktionsprodukt von 2-[[4-Amino-2-ureidophenylazo]-5-[(2-sulfooxy)ethyl)sulfonyl]]benzolsulfonsäure mit 2,4,6-Trifluorpyrimidin und Teilhydrolyse mit dem entsprechenden Vinylsulfonylderivat, gemischtes Kalium-/Natriumsalz | 424-250-9 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-136-00-0 | 2-{4-(2-Ammoniopropylamino)-6-[4-hydroxy-3-(5-methyl-2-methoxy-4-sulfamoylphenylazo)-2-sulfonatonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-2-aminopropylformat | 424-260-3 | - | Repr. 2 Eye Dam. 1 Aquatic Chronic 2 | H361f *** H318 H411 | GHS05 GHS08 GHS09 Gef. | H361f *** H318 H411 | |||
611-137-00-6 | 6- tert-Butyl-7-chlor-3-tridecyl-7,7a-dihydro-1 H-pyrazolo[5,1- c]-1,2,4-triazol | 419-870-1 | 159038-16-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
611-138-00-1 | 2-(4-Aminophenyl)-6- tert-butyl-1 H-pyrazolo[1,5- b][1,2,4]triazol | 415-910-7 | 152828-25-6 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
611-139-00-7 | Reaktionprodukt von sulfuriertem 2,4-Dinitrophenol (Leukoderivat) mit (3-Chlor-2-hydroxypropyl)trimethylammoniumchlorid | 424-510-1 | - | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Gef. | H318 H411 | |||
611-140-00-2 | Azafenidin (ISO); 2-(2,4-Dichlor-5-prop-2-ynyloxyphenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3- a]pyridin-3(2 H)-on | - | 68049-83-2 | Repr. 1B STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H360Df H373 ** H400 H410 | GHS08 GHS09 Gef. | H360Df H373 ** H410 | M = 1 000 | ||
611-141-00-8 | 5-(4-[4-[4-(3,5-Dicarboxyphenylazo)phenylamino]-6- morpholin-4-yl-1,3,5-triazin-2- ylamino]phenylazo)isophthalsäure, gemischtes Mononatrium- und Diammoniumsalz | 414-410-6 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-142-00-3 | Polyazofarbstoff, erhalten durch Kupplung von 4-[4-(1-Amino-8-hydroxy-3,6-disulfo-2-naphthylazo)phenylsulfonylamino]benzoldiazonium mit einer Reaktionsmasse aus 4-Carboxybenzoldiazonium und Diphenylamin-3-sulfo-4,4"-bisdiazonium sowie einer weiteren Kupplung der entstandenen Reaktionsprodukte mit einem Gemisch aus Naphth-2-ol- und 3-Aminophenol-Natriumsalzen, Natriumchlorid | 425-740-5 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-143-00-9 | Reaktionsmasse aus Trinatrium-2-(2-[α-(2-carboxylato-κ- O-4- sulfonatophenylazo)benzyliden]hydrazino-κ- N")-6-(2,6- difluorpyrimidin-4-ylamino)-4-sulfonatophenolatocuprat(II) und Trinatrium-2-(2-[α-(2-carboxylato-κ-O-4-sulfonatophenylazo)benzyliden]hydrazino-κ- N")-6-(4,6-difluorpyrimidin-2-ylamino)-4-sulfonatophenolatocuprat(II) | 428-260-4 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-144-00-4 | Reaktionsmasse aus 7-Amino-3,8- bis[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-hydroxynaphthalin-2-sulfonsäure, Natrium-/Kaliumsalz, 7-Amino-3-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-hydroxy-8-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]naphthalin-2-sulfonsäure, Natrium-/Kaliumsalz, 7-Amino-8-[4-(2-sulfoxyethylsulfonyl)-phenylazo]-4-hydroxy-3-[4-(2-sulfoxyethylsulfonyl)-2- sulfophenylazo]naphthalin-2-sulfonsäure, Natrium-/Kaliumsalz, und 7-Amino-3,8-bis[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]-4-hydroxynaphthalin-2-sulfonsäure, Natrium-/Kaliumsalz | 429-070-4 | 214362-06-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-145-00-X | Reaktionsmasse aus Tetranatrium-3-(1,5-disulfonatonaphthalin-2-ylazo)-4-hydroxy-7-{4-chlor-6-[4-(2-sulfoxyethylsulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}naphthalin-2-sulfonat und 3-(2,5-Disulfophenylazo)-4-hydroxy-7-{4-chlor-6-[4-(2-sulfoxyethylsulfonyl)phenylamino{-1,3,5-triazin-2-ylamino}naphthalin-2-sulfonsäure, Natriumsalz | 429-440-5 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-146-00-5 | Reaktionsmasse aus Pentanatrium-3-(4-(4-(7-(2,4-diamino-5-sulfonato-3-(4-sulfonatophenylazo)phenylazo)-1-hydroxy-3-sulfonatonaphthalin-2-ylazo)-2- sulfonatophenylamino)phenylazo)-4-hydroxy-6-(2-oxo-1-phenylcarbamoylpropylazo)naphthalin-2-sulfonat, Pentanatrium-6-((2,4-diamino-5- sulfonatophenyl)azo)-3-((4-((4-((7-((2,4-diamino-5-sulfonatophenyl)azo)-1-hydroxy-3-sulfonatonaphthalin-2-yl)azo)phenyl)amino)-2-sulfonatophenyl)azo)-4-hydroxynaphthalin-2-sulfonat, Pentanatrium-6-((2,4-diamino-5-sulfonato-3-((4-sulfonatophenyl)azo)phenyl)azo)-3-((4-((4-((1,7-dihydroxy-3-sulfonatonaphthalin-2-yl)azo)-2-sulfonatophenyl)amino)phenyl)azo)-4-hydroxynaphthalin-2-sulfonat und Hexanatrium-6-((2,4-diamino-5- sulfonatophenyl)azo)-3-((4-((4- ((7-((2,4-diamino-5-sulfonato-3-((4-sulfonatophenyl)azo)phenyl)azo)-1-hydroxy-3-sulfonatonaphthalin-2-yl)azo)-2- sulfonatophenyl)amino)phenyl)azo)-4-hydroxynaphthalin-2-sulfonat | 430-070-1 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-147-00-0 | Natrium- Kalium-Lithium-5-amino-3,6-bis(5-(4-chlor-6- (methyl-(2-methylaminoacetyl)amino)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)- 4-hydroxynaphthalin-2,7-disulfonat | 430-090-0 | 205764-96-1 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-148-00-6 | Reaktionsmasse aus 2-(3-(2,6-Dichlor-4-nitrophenylazo)carbazol-9-yl)ethanol, 2-(2-(3-(2,6-Dichlor-4-nitrophenylazo)carbazol-9-yl)-ethoxy)ethanol und 3-(2,6-Dichlor-4-nitrophenylazo)carbazol | 429-590-1 | - | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
611-149-00-1 | 2-(2-Chloracetoxy)ethyl-3-((4-(2,5-dichlor-4-fluorsulfonylphenylazo)-3-methylphenyl)ethylamino)propionat | 427-570-7 | 193486-83-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-150-00-7 | Tetralithium 2-[6-[7-[2-(carboxylato)phenylazo]-8-hydroxy-3,6-disulfonato-1-naphthylamino]-4- hydroxy-1,3,5-triazin-2-ylamino]benzoat | 440-460-3 | - | Eye Irrit. 2 Aquatic Chronic 3 | H319 H412 | GHS07 Achtg. | H319 H412 | |||
611-151-00-2 | Chrysoidin; 4-(Phenylazo)benzol-1,3-diamin | 207-803-7 | 495-54-5 | Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H341 H302 H315 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H341 H302 H315 H410 | |||
611-152-00-8 | Chrysoidinmonohydrochlorid; 4-Phenylazophenylen-1,3-C [1]; Chrysoidinemonoacetat; 4-(Phenylazo)benzol-1,3-diaminmonoacetat [2]; Chrysoidinacetat; 4-(Phenylazo)benzol-1,3-diaminacetat [3]; Chrysoidin- p-dodecylbenzolsulfonat; dodecylbenzolsulfonsäure, Verbindung mit 4-(phenylazo)benzol-1,3-diamin (1:1) [4]; Chrysoidindihydrochlorid; 4-(phenylazo)benzol-1,3-diamindihydrochlorid [5]; Chrysoidinsulfat; Bis[4-(phenylazo)benzol-1,3-diamin]sulfat [6] | 208-545-8 [1] 278-290-5 [2] 279-116-0 [3] 264-409-8 [4] 281-549-5 [5] 282-432-1 [6] | 532-82-1 [1] 75660-25-2 [2] 79234-33-6 [3] 63681-54-9 [4] 83968-67-6 [5] 84196-22-5 [6] | Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H341 H302 H315 H318 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H341 H302 H315 H318 H410 | |||
611-153-00-3 | Chrysoidin-C10-14-Alkylderivate; Benzolsulfonsäure, Mono-C10- 14-Alkylderivate, Verbindungen mit 4-(Phenylazo)-1,3-benzoldiamin [1]; Chrysoidin, Verbindung mit Dibutylnaphthalsulfonsäure; Dibutylnaphthalsulfonsäure, Verbindung mit 4-(Phenylazo)benzol-1,3-diamin (1:1) [2] | 286-946-7 [1] 304-236-8 [2] | 85407-90-5 [1] 94247-67-3 [2] | Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 | H341 H302 H315 H318 | GHS05 GHS08 GHS07 Gef. | H341 H302 H315 H318 | |||
611-154-00-9 | Trinatrium-5-benzamido-4-hydroxy-3-(4-methyl-2-sulfonatophenylazo)naphthalin-2,7-disulfonat | 403-670-6 | 92408-46-3 | Aquatic Chronic 3 | H412 | - | H412 | |||
611-155-00-4 | 4,4"-Oxybis(benzolsulfonylazid) | 431-850-4 | 7456-68-0 | Expl. 1.1**** STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H201 H373** H400 H410 | GHS01 GHS08 GHS09 Gef. | H201 H373** H410 | |||
611-156-00-X | Triammonium-4-[4-[7-(4-carboxylatoanilino)-1-hydroxy-3-sulfonato-2-naphthylazo]-2,5- dimethoxyphenylazo]benzoat | 432-270-4 | 221354-37-6 | Repr. 2 STOT RE 2 * Aquatic Chronic 2 | H361f*** H373** H411 | GHS08 GHS09 Achtg. | H361f*** H373** H411 | |||
611-157-00-5 | Benzolsulfonsäure, 3,3"-(Methylenbis((dihydroxyphenylen)azo))bis-, Kaliumnatriumsalz; Kaliumnatrium-3-[( E)-(6{3,4-dihydroxy-2-}( Z)-(3-sulfonatophenyl)diazenyl]benzyl}-2,3-dihydroxyphenyl)diazenyl]benzolsulfonat | 432-590-4 | 243869-48-9 | Eye Irrit. 2 Aquatic Chronic 3 | H319 H412 | GHS07 Achtg. | H319 H412 | |||
611-158-00-0 | Reaktionsprodukt von 2,3,4,2", 3",4"-Hexahydroxy-5,5"-diacethyldiphenylmethan mit 6-Diazo-5,6-dihydro-5-oxo-1-naphthalinsulfonylchlorid und 3-Diazo-3,4-dihydro-6-methoxy-4-oxo-1-naphthalinsulfonylchlorid | 421-520-8 | - | **** Aquatic Chronic 4 | **** H413 | **** | **** H413 | |||
- gestrichen - | ||||||||||
611-160-00-1 | Reaktionsmasse aus 1,1,1-Tris(phenyl-4"-(3""-diazo-3"", 4""-dihydro-4""-oxo-naphthalin-1""-sulfonato)ethan und 1,1,1-Tris(phenyl-4"-(6""-diazo-5"",6""-dihydro-5""-oxo-naphthalin-1""-sulfonato)ethan; Reaktionsprodukt von 1,1,1-Tris( p-hydroxyphenyl)ethan mit 6-Diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchlorid und 3-Diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchlorid (2:1); Reaktionsprodukt von 1,1,1-Tris( p-hydroxyphenyl)ethan mit 6-Diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchlorid und 3-Diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchlorid (1:2) | 422-760-6 | - | **** Aquatic Chronic 4 | **** H413 | **** | **** H413 | |||
611-161-00-7 | Trinatrium[1,2"-(2-(8-amino-3,5-disulfonatonaphthalin)azo)-(4"-nitrobenzol)diolato- O, O,N][( Z)-2,2-((phenylcarbamoylprop-1"-enyl)azo)-5-sulfamoylbenzol)diolato- O, O,N]chromat(III) | 423-100-1 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-162-00-2 | 2,4-Bis(((2-(dimethylammonio)ethyloxy)carbonyl)phen-2-ylazo)benzol-1,3-diolbis(methansulfonat) | 429-600-4 | - | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
611-163-00-8 | 2,4-Bis(((2-(dimethylammonio)ethyloxy)carbonyl)phen-2-ylazo)benzol-1,3-diolsulfat | 429-610-9 | - | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 | H302 H318 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H411 | |||
611-164-00-3 | Reaktionsmasse aus 2,2"-Dimethyl-2,2"-azobutannitril, 2-Methylpentannitril-2-azo-2"-(2"-methylpropannitril), 2,2"-Dimethyl-2,2"-azoheptannitril, 2-Methylheptannitril-2-azo-2"-(2"-methylpropannitril) und 2-Methylheptannitril-2-azo-2"-(2"-methylbutannitril) | 429-710-2 | - | Self-react.
D Acute Tox. 4 * Aquatic Chronic 2 | H242 H302 H411 | GHS02 GHS07 GHS09 Gef. | H242 H302 H411 | |||
611-165-00-9 | Reaktionsmasse aus Tetranatrium-4-amino-6-(5-(2,6-difluorpyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(sulfatoethylsulfonyl)phenylazo)naphthalin-2,7-disulfonat und Tetranatrium-4-amino-6-(5-(4,6-difluorpyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-sulfatoethylsulfonyl)phenylazo)naphthalin-2,7-disulfonat | 431-830-5 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
611-166-00-4 | Reaktionsmasse aus Pentanatrium-4-amino-5-hydroxy-3-{( E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-{( E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}naphthalin-2,7-disulfonat, Tetranatrium-4-amino-5-hydroxy-3-{( E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-[( E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalin-2,7-disulfonat und Tetranatrium-4-amino-5-hydroxy-6-( E)-2-sulfonato-4-}2-(sulfonatooxy)ethylsulfonyl{phenylazo}-3-[( E)-4-(vinylsulfonyl)phenylazo]naphthalin-2,7-disulfonat | 432-100-9 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-167-00-X | Natriumbis[tris(2-hydroxyethyl)ammonium][6-anilino-4"-(4,8-disulfonato-2-naphthylazo)-5"-methyl-3-sulfonatonaphthalin-2-azobenzol-1,2"-diolato]cuprat(II) | 435-240-9 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
611-168-00-5 | Reaktionsmasse aus 3-[[4-Chlor-6- [[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]-5-[[4-chlor-6-[[8-hydroxy-3,6-disulfo-7-[(2- sulfophenyl)azo]-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoesäure und 3,5-Bis[[4-chlor-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8- hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2- yl]amino]benzoesäure | 435-440-6 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-169-00-0 | Natrium-5-(2-carboxyphenylazo)- 6-hydroxynaphthalin-2-sulfonat | 435-800-2 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
611-170-00-6 | Reaktionsmasse aus Trinatrium-2-((1-(2-hydroxy-κ- O-5-(2-sulfonatoethansulfonyl)phenylazo-κ-N 2)-1-phenylmethyl)azo-κ-N 1)4-sulfonatobenzoat-(5-)-κ- O)cuprat(II) und Dinatrium-2-((1-(5-ethensulfonyl-2-hydroxy-κ- O-phenylazo-κ-N 2)-1-phenylmethyl)azo-κ-N 1)-4-sulfonatobenzoat-κ- O-(5))cuprat(II) | 435-880-9 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
611-171-00-1 | Reaktionsmasse aus Trinatrium-3-(5-(2,6-difluorpyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-(4-fluor-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalindisulfonat und Trinatrium-3-(5-(4,6-difluorpyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-(4-fluor-6-morpholin-4-yl-1,3,5-triazin-2- ylamino)-4-hydroxy-2,7-naphthalindisulfonat | 436-890-6 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-172-00-7 | Reaktionsmasse aus Triammonium-6-amino-3-((2,5-diethoxy-4-(3-phosphonophenyl)azo)phenyl)azo-4-hydroxy-2-naphthalinsulfonat und Diammonium-3-((4-((7-amino-1-hydroxy-3-sulfonaphthalin-2-yl)azo)-2,5-diethoxyphenyl)azo)benzoat | 438-310-7 | - | Self-react.
C**** Repr. 2 Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 | H242 H361f*** H302 H373** H412 | GHS02 GHS08 GHS07 Gef. | H242 H361f*** H302 H373** H412 | |||
611-173-00-2 | Reaktionsmasse aus 3-[3-Carbamoyl-5-(5-{4-chlor-6-[4-(2-sulfonatooxyethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propansäure, Trinatriumsalz, und 3-[3-Carbamoyl-5-(5-{4-chlor-6-[4-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-2- sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propansäure, Dinatriumsalz | 440-510-4 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-174-00-8 | Reaktionsmasse aus 3-[5-(4-Ethensulfonylbutyrylamino)-2-sulfophenylazo]-5-4-chlor-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalin-4-ylazo)-3-sulfophenylamino]-1,3,5-triazin-2-ylamino[-4-hydroxynaphthalin-2,7-disulfonsäure, Natriumsalz, und 3-[5-(4-(2-Chlorethansulfonyl)butyrylamino)-2-sulfophenylazo]-5-4-chlor-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalin-4-ylazo)-3-sulfophenylamino]-1,3,5-triazin-2-ylamino}-4-hydroxynaphthalin-2,7-disulfonsäure, Natriumsalz | 442-290-5 | 457624-86-1 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
611-175-00-3 | Reaktionsmasse aus Trinatrium-5-{4-Chlor-6-[ N-ethyl-(3-(2-sulfonatooxy)ethylsulfonyl)anilin]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[4-(vinylsulfonyl)phenylazo{naphthalin-2,7-disulfonat, Trinatrium-5-4-chlor-6-[ N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]naphthalin-2,7-disulfonat, Dinatrium 5-4-chlor-6-[ N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[(4-vinylsulfonyl)phenylazo]naphthalin-2,7-disulfonat, Dinatrium-5-4-chlor-6-[ N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[(4-vinylsulfonyl)phenylazo]naphthalin-2,7-disulfonat und Tetranatrium-5-4-chlor-6-[ N- ethyl-3-(2-(sulfonatooxy)ethylsulfonyl)anilino]- 1,3,5-triazin-2-ylamino}-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]-4-hydroxynaphthalin-2,7-disulfonat | 444-050-5 | - | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
611-176-00-9 | 2,6-Bis(2,3,4-trihydroxybenzyl)- p-cresolester mit 6-diazo-5,6-dihydro-5-oxo-1-naphthalinsulfonat | 444-250-2 | - | Self-react. C**** Aquatic Chronic 2 | H242 H411 | GHS02 GHS09 Gef. | H242 H411 | |||
611-177-00-4 | Reaktionsmasse aus Pentanatriumbis[6-anilino-3,5"-disulfonatonaphthalin-2-azobenzol-1,2"-diolato]cobaltat(III), Tetranatrium [6-anilino-3,5"-disulfonatonaphthalin-2-azobenzol-1,2"-diolato][6-anilino-5"-sulfamoyl-3-sulfonatonaphthalin-2-azobenzol-1,2"-diolato]cobaltat(III) und Trinatrium bis[6-anilino-5"-sulfamoyl-3-sulfonatonaphthalin-2-azobenzol-1,2"- diolato]cobaltat(III) | 444-290-0 | 508202-43-5 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
611-178-00-X | Reaktionsmasse aus Pentanatrium-4-amino-5-hydroxy-3-{( E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-{( E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}naphthalin-2,7-disulfonat, Tetranatrium-4-amino-5-hydroxy-3-{( E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-[( E)-2-sulfonato-4-(vinylsulfonyl)phenylazo] naphthalin-2,7-disulfonat, Tetranatrium-4-amino-5-hydroxy-6-{( E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-3-[(E)-4-(vinylsulfonyl)phenylazo]naphthalin-2,7-disulfonat, Trinatrium-4-amino-5-hydroxy-3-[( E)-4-(vinylsulfonyl)phenylazo]-6-[( E)-2-sulfonato-4(vinylsulfonyl)phenylazo]naphthalin-2,7-disulfonat, Trinatrium-4-amino-5-hydroxy-3- [(2-hydroxyethylsulfonyl)phenylazo]-6-[( E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalin-2,7-disulfonat und Trinatrium-4-amino-5-hydroxy-3-[( E)-4-(vinylsulfonyl)phenylazo]-6-[-2-sulfonato-4-(2-hydroxyethylsulfonyl)phenylazo]naphthalin-2,7-disulfonat | 445-280-9 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
611-179-00-5 | Reaktionsmasse aus Pentanatrium-2-[[8-[[4-chlor-6-[[4-(2-sulfonatethylsulfonyl)]phenyl]amino]-1,3,5-triazin-2-yl]amino-1-hydroxy-3,6- disulfonato-2-naphthalenyl]azo]naphthalin-1,5-Disulfonat und 2-[[8-[[4-Chlor-6-[[4-[[2-ethenyl]sulfonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-1-hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalin-1,5-disulfonat | 450-010-8 | - | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
611-180-00-0 | Eisen, Komplexe mit diazotiertem 4-Aminobenzolsulfonamid, diazotierter 3-Aminobenzolsulfonsäure, diazotiertem 3- Amino-4-hydroxybenzolsulfonamid, diazotiertem 3-Amino-4-hydroxy- N-phenylbenzolsulfonamid, diazotierter 5-Amino-2-(phenylamino)benzolsulfonsäure und Resorcinol, Natriumsalze | 417-850-7 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
611-181-00-6 | Kalium(oxido- NNO-azoxy)cyclohexan; Cyclohexylhydroxydiazen-1-oxid, Kaliumsalz; [K-HDO] | - | 66603-10-9 | Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H228 H301 H373 (Leber) H315 H318 H411 | GHS02 GHS06 GHS08 GHS05 GHS09 Dgr | H228 H301 H373 (Leber) H315 H318 H411 | oral: ATE = 136 mg/kg KG | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
611-182-00-1 | 2-[Ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol | 271-183-4 | 68516-81-4 | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1A; H317: C ≥ 0,001 % | ) | |
612-001-00-9 | Monomethylamin [1]; Dimethylamin [2]; Trimethylamin [3] | 200-820-0 [1] 204-697-4 [2] 200-875-0 [3] | 74-89-5 [1] 124-40-3 [2] 75-50-3 [3] | Flam. Gas 1 Press. Gas Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 | H220 H332 H335 H315 H318 | GHS02 GHS04 GHS05 GHS07 Gef. | H220 H332 H335 H315 H318 | * Skin Irrit. 2; H315: C ≥ 5 % Eye Dam. 1; H318: C ≥ 5 % Eye Irrit. 2; H319: 0,5 % ≤ C < 5 % STOT SE 3; H335: C ≥ 5 % | U5 | |
612-001-01-6 | Monomethylamin ... % [1]; Dimethylamin ... % [2]; Trimethylamin ... % [3] | 200-820-0 [1] 204-697-4 [2] 200-875-0 [3] | 74-89-5 [1] 124-40-3 [2] 75-50-3 [3] | Flam. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H224 H332 H302 H314 | GHS02 GHS05 GHS07 Gef. | H224 H332 H302 H314 | * STOT SE 3; H335: C ≥ 5 % | B | |
612-002-00-4 | Ethylamin | 200-834-7 | 75-04-7 | Flam. Gas 1 Press. Gas Eye Irrit. 2 STOT SE 3 | H220 H319 H335 | GHS02 GHS04 GHS07 Gef. | H220 H319 H335 | U | ||
612-003-00-X | Diethylamin | 203-716-3 | 109-89-7 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H225 H332 H312 H302 H314 | GHS02 GHS05 GHS07 Gef. | H225 H332 H312 H302 H314 | STOT SE 3; H335: C ≥ 1 % | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
612-004-00-5 | Triethylamin | 204-469-4 | 121-44-8 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H225 H332 H312 H302 H314 | GHS02 GHS05 GHS07 Gef. | H225 H332 H312 H302 H314 | STOT SE 3; H335: C ≥ 1 % | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
612-004-00-5 | Triethylamin | 204-469-4 | 121-44-8 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1A Eye Dam. 1 | H225 H331 H311 H301 H314 H318 | GHS02 GHS06 GHS05 Dgr | H225 H331 H311 H301 H314 | Inhalation:
ATE = 7,2 mg/L (Dämpfe) dermal: ATE = 300 mg/kg KG oral: ATE = 100 mg/kg KG STOT SE 3; H335: C ≥ 1 % | ) | |
612-005-00-0 | Butylamin; 1-Aminobutan | 203-699-2 | 109-73-9 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H225 H332 H312 H302 H314 | GHS02 GHS05 GHS07 Gef. | H225 H332 H312 H302 H314 | STOT SE 3; H335: C ≥ 1 % | ||
612-006-00-6 | Ethylendiamin; 1,2-Diaminoethan | 203-468-6 | 107-15-3 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 | H226 H312 H302 H314 H334 H317 | GHS02 GHS08 GHS05 GHS07 Gef. | H226 H312 H302 H314 H334 H317 | |||
612-007-00-1 | 2-Aminopropan; Isopropylamin | 200-860-9 | 75-31-0 | Flam. Liq. 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H224 H319 H335 H315 | GHS02 GHS07 Gef. | H224 H319 H335 H315 | |||
612-008-00-7 | Anilin | 200-539-3 | 62-53-3 | Carc. 2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 | H351 H341 H331 H311 H301 H372 ** H318 H317 H400 | GHS06 GHS08 GHS05 GHS09 Gef. | H351 H341 H331 H311 H301 H372 ** H318 H317 H400 | * STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,2 % ≤ C < 1 % | ||
612-009-00-2 | Salze von Anilin | - | - | Carc. 2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 | H351 H341 H331 H311 H301 H372 ** H318 H317 H400 | GHS06 GHS08 GHS05 GHS09 Gef. | H351 H341 H331 H311 H301 H372 ** H318 H317 H400 | * STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,2 % ≤ C < 1 % | A | |
612-010-00-8 | Chloraniline (soweit in diesem Anhang nicht gesondert aufgeführt) | - | - | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H410 | C | ||
612-011-00-3 | 4-Nitrosoanilin | 211-535-6 | 659-49-4 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H332 H312 H302 | GHS07 Achtg. | H332 H312 H302 | |||
612-012-00-9 | o-Nitroanilin [1]; m-nitroanilin [2]; p-nitroanilin [3] | 201-855-4 [1] 202-729-1 [2] 202-810-1 [3] | 88-74-4 [1] 99-09-2 [2] 100-01-6 [3] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H331 H311 H301 H373 ** H412 | GHS06 GHS08 Gef. | H331 H311 H301 H373 ** H412 | C | ||
612-013-00-4 | 3-Aminobenzolsulfonsäure; Metanilsäure | 204-473-6 | 121-47-1 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H332 H312 H302 | GHS07 Achtg. | H332 H312 H302 | |||
612-014-00-X | Sulfanilsäure; 4-Aminobenzolsulfonsäure | 204-482-5 | 121-57-3 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H319 H315 H317 | GHS07 Achtg. | H319 H315 H317 | |||
612-015-00-5 | N-Methylanilin | 202-870-9 | 100-61-8 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H410 | |||
612-016-00-0 | N, N-Dimethylanilin | 204-493-5 | 121-69-7 | Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H351 H331 H311 H301 H411 | GHS06 GHS08 GHS09 Gef. | H351 H331 H311 H301 H411 | |||
612-017-00-6 | N-Methyl- N-2,4,6-tetranitroanilin; Tetryl | 207-531-9 | 479-45-8 | Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 | H201 H331 H311 H301 H373** | GHS01 GHS06 GHS08 Gef. | H201 H331 H311 H301 H373** | |||
612-018-00-1 | Bis(2,4,6-trinitrophenyl)amin; Hexyl | 205-037-8 | 131-73-7 | Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 Aquatic Chronic 2 | H201 H330 H310 H300 H373** H411 | GHS01 GHS06 GHS08 GHS09 Gef. | H201 H330 H310 H300 H373** H411 | |||
612-019-00-7 | Dipicrylamin, Ammoniumsalz; Ammonium-bis(2,4,6-trinitrophenyl)amin | 220-639-0 | 2844-92-0 | Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 Aquatic Chronic 2 | H201 H330 H310 H300 H373** H411 | GHS01 GHS06 GHS08 GHS09 Gef. | H201 H330 H310 H300 H373** H411 | |||
612-020-00-2 | 1-Naphthylamin; α-Naphthylamin | 205-138-7 | 134-32-7 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
612-022-00-3 | 2-Naphthylamin; β-Naphthylamin | 202-080-4 | 91-59-8 | Carc. 1A Acute Tox. 4 * Aquatic Chronic 2 | H350 H302 H411 | GHS08 GHS07 GHS09 Gef. | H350 H302 H411 | Carc. 1A; H350: C ≥ 0,01 % | ||
612-023-00-9 | Phenylhydrazin [1]; Phenylhydraziniumchlorid [2]; Phenylhydrazinhydrochlorid [3]; Phenylhydraziniumsulfat (2:1) [4] | 202-873-5 [1] 200-444-7 [2] 248-259-0 [3] 257-622-2 [4] | 100-63-0 [1] 59-88-1 [2] 27140-08-5 [3] 52033-74-6 [4] | Carc. 1B Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H350 H341 H331 H311 H301 H372 ** H319 H315 H317 H400 | GHS06 GHS08 GHS09 Gef. | H350 H341 H331 H311 H301 H372 ** H319 H315 H317 H400 | |||
612-024-00-4 | m-Toluidin; 3-Aminotoluol | 203-583-1 | 108-44-1 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 | H331 H311 H301 H373 ** H400 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H400 | |||
612-025-00-X | Nitrotoluidine, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H411 | C | ||
612-026-00-5 | Diphenylamin | 204-539-4 | 122-39-4 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H373 ** H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H410 | |||
612-027-00-0 | Xylidine, soweit in diesem Anhang nicht gesondert aufgeführt; Dimethylaniline, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H411 | C | ||
612-028-00-6 | p-Phenylendiamin; 1,4-Diaminobenzol | 203-404-7 | 106-50-3 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H319 H317 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H319 H317 H410 | |||
612-029-00-1 | Benzol-1,4-diamindihydrochlorid; p-Phenylendiamindihydrochlorid | 210-834-9 | 624-18-0 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H319 H317 H400 H410 | GHS06 GHS09 Gef. | H331 H311 H301 H319 H317 H410 | |||
612-030-00-7 | 2-Methyl- p-phenylendiaminsulfat; 2,5-Diaminotoluol-sulfat; | 210-431-8 228-871-4 | 615-50-9 6369-59-1 | Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H301 H332 H312 H317 H411 | GHS06 GHS09 Gef. | H301 H332 H312 H317 H411 | |||
612-031-00-2 | N, N-Dimethylbenzol-1,3-diamin [1]; 4-Amino- N, N-dimethylanilin; 3-Amino- N, N"-dimethylanilin[2] | 220-623-3 [1] 202-807-5 [2] | 2836-04-6 [1] 99-98-9 [2] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H331 H311 H301 | GHS06 Gef. | H331 H311 H301 | C | ||
612-032-00-8 | N, N,N",N"-Tetramethyl- p-phenylendiamin | 202-831-6 | 100-22-1 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H332 H312 H302 | GHS07 Achtg. | H332 H312 H302 | |||
612-033-00-3 | 2-Aminophenol; o-Aminophenol | 202-431-1 | 95-55-6 | Muta. 2 Acute Tox. 4 * Acute Tox. 4 * | H341 H332 H302 | GHS08 GHS07 Achtg. | H341 H332 H302 | |||
612-034-00-9 | 2-Amino-4,6-dinitrophenol; Pikraminsäure | 202-544-6 | 96-91-3 | Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H201 H332 H312 H302 H412 | GHS01 GHS07 Gef. | H201 H332 H312 H302 H412 | |||
612-034-01-6 | 2-Amino-4,6-dinitrophenol; Pikraminsäure; [≥ 20 % Wasser] | 202-544-6 | 96-91-3 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H332 H312 H302 H412 | GHS07 Achtg. | H332 H312 H302 H412 | G | ||
612-035-00-4 | 2-Methoxyanilin; o-Anisidin | 201-963-1 | 90-04-0 | Carc. 1B Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * | H350 H341 H331 H311 H301 | GHS06 GHS08 Gef. | H350 H341 H331 H311 H301 | |||
612-036-00-X | 3,3"-Dimethoxybenzidin; o-Dianisidin | 204-355-4 | 119-90-4 | Carc. 1B Acute Tox. 4 * | H350 H302 | GHS08 GHS07 Gef. | H350 H302 | |||
612-037-00-5 | Salze von 3,3"-Dimethoxybenzidin; Salze von o-Dianisidin | - | - | Carc. 1B Acute Tox. 4 * | H350 H302 | GHS08 GHS07 Gef. | H350 H302 | A | ||
612-038-00-0 | 2-Nitro- p-anisidin; 4-Methoxy-2-nitroanilin | 202-547-2 | 96-96-8 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 3 | H330 H310 H300 H373 ** H412 | GHS06 GHS08 Gef. | H330 H310 H300 H373 ** H412 | |||
612-039-00-6 | 2-Ethoxyanilin; o-Phenetidin | 202-356-4 | 94-70-2 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * | H331 H311 H301 H373 ** | GHS06 GHS08 Gef. | H331 H311 H301 H373 ** | |||
612-040-00-1 | 2,4-Dinitroanilin | 202-553-5 | 97-02-9 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 | H330 H310 H300 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H373 ** H411 | |||
612-041-00-7 | 4,4"-Bi- o-toluidin; 3,3"-Dimethylbenzidin; o-Tolidin | 204-358-0 | 119-93-7 | Carc. 1B Acute Tox. 4 * Aquatic Chronic 2 | H350 H302 H411 | GHS08 GHS07 GHS09 Gef. | H350 H302 H411 | |||
612-042-00-2 | Benzidin; 1,1"-Biphenyl-4,4"-diamin; 4,4"-Diaminobiphenyl; Biphenyl-4,4"-ylendiamin | 202-199-1 | 92-87-5 | Carc. 1A Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H410 | Carc. 1A; H350: C ≥ 0,01 % | ||
612-043-00-8 | N, N"-Dimethylbenzidin | - | 2810-74-4 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H332 H312 H302 | GHS07 Achtg. | H332 H312 H302 | |||
612-044-00-3 | N, N"-Diacetylbenzidin | 210-338-2 | 613-35-4 | Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H350 H341 H332 H312 H302 | GHS08 GHS07 Gef. | H350 H341 H332 H312 H302 | |||
612-046-00-4 | Allylamin; 2-Propen-1-amin | 203-463-9 | 107-11-9 | Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H225 H331 H311 H301 H411 | GHS02 GHS06 GHS09 Gef. | H225 H331 H311 H301 H411 | |||
612-047-00-X | Benzylamin; α-Aminotoluol | 202-854-1 | 100-46-9 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | |||
612-048-00-5 | Dipropylamin; Di-n-propylamin | 205-565-9 | 142-84-7 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H225 H332 H312 H302 H314 | GHS02 GHS05 GHS07 Gef. | H225 H332 H312 H302 H314 | STOT SE 3; H335: C ≥ 1 % | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
612-049-00-0 | Di-n-butylamin [1]; Di-sec-butylamin Di-(1-methylpropyl)amin [2] | 203-921-8 [1] 210-937-9 [2] | 111-92-2 [1] 626-23-3 [2] | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H226 H332 H312 H302 | GHS02 GHS07 Achtg. | H226 H332 H312 H302 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
612-049-00-0 | Di-n-Butylamin | 203-921-8 | 111-92-2 | Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 | H226 H330 H311 H301 H314 H318 | GHS02 GHS06 GHS05 Dgr | H226 H330 H311 H301 H314 | EUH 071 | Inhalation:
ATE = 1,2 mg/L (Dämpfe) dermal:
ATE = 300 mg/kg KG Oral: ATE = 220 mg/kg KG | ) |
612-050-00-6 | Cyclohexylamin | 203-629-0 | 108-91-8 | Flam. Liq. 3 Repr. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H226 H361f*** H312 H302 H314 | GHS02 GHS05 GHS08 GHS07 Gef. | H226 H361f*** H312 H302 H314 | |||
612-051-00-1 | 4,4"-Diaminodiphenylmethan; 4,4"-Methylendianilin | 202-974-4 | 101-77-9 | Carc. 1B Muta. 2 STOT SE 1 STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H350 H341 H370 ** H373 ** H317 H411 | GHS08 GHS07 GHS09 Gef. | H350 H341 H370 ** H373 ** H317 H411 | |||
612-052-00-7 | (S)- sec-Butylamin; (S)-2-Aminobutan [1]; (R)- sec-Butylamin;( R)-2-Aminobutan [2]; sec-Butylamin; 2-Aminobutan [3] | 208-164-7 [1] 236-232-6 [2] 237-732-7 [3] | 513-49-5 [1] 13250-12-9 [2] 13952-84-6 [3] | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 | H225 H332 H302 H314 H400 | GHS02 GHS05 GHS07 GHS09 Gef. | H225 H332 H302 H314 H400 | C | ||
612-053-00-2 | N-Ethylanilin | 203-135-5 | 103-69-5 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * | H331 H311 H301 H373 ** | GHS06 GHS08 Gef. | H331 H311 H301 H373 ** | |||
612-054-00-8 | N, N-Diethylanilin | 202-088-8 | 91-66-7 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H411 | * | ||
612-055-00-3 | N-Methyl- o-toluidin [1]; N-Methyl- m-toluidin [2]; N-Methyl- p-toluidin [3] | 210-260-9 [1] 211-795-0 [2] 210-769-6 [3] | 611-21-2 [1] 696-44-6 [2] 623-08-5 [3] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H331 H311 H301 H373 ** H412 | GHS06 GHS08 Gef. | H331 H311 H301 H373 ** H412 | C | ||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
612-056-00-9 | N, N-Dimethyl- p-toluidin [1]; N, N-Dimethyl- m-toluidin [2]; N, N-Dimethyl- o-toluidin [3] | 202-805-4 [1] 204-495-6 [2] 210-199-8 [3] | 99-97-8 [1] 121-72-2 [2] 609-72-3 [3] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H331 H311 H301 H373 ** H412 | GHS06 GHS08 Gef. | H331 H311 H301 H373 ** H412 | * | C) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
612-056-00-9 | N, N-Dimethyl-m-toluidin; [1] N, N-Dimethyl-o-toluidin [2] | 204-495-6 [1] 210-199-8 [2] | 121-72-2 [1] 609-72-3 [2] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H331 H311 H301 H373 ** H412 | GHS06 GHS08 Dgr | H331 H311 H301 H373 ** H412 | * |
C) | |
612-057-00-4 | Piperazin; [fest] | 203-808-3 | 110-85-0 | Repr. 2 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 | H361fd H314 H334 H317 | GHS05 GHS08 Gef. | H361fd H314 H334 H317 | |||
612-057-01-1 | Piperazin; [flüssig] | 203-808-3 | 110-85-0 | Repr. 2 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 | H361fd H314 H334 H317 | GHS05 GHS08 Gef. | H361fd H314 H334 H317 | |||
612-058-00-X | 2,2"-Iminodiethylamin; Diethylentriamin | 203-865-4 | 111-40-0 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H312 H302 H314 H317 | GHS05 GHS07 Gef. | H312 H302 H314 H317 | |||
612-059-00-5 | 3,6-Diazaoctanethylendiamin; Triethylentetramin | 203-950-6 | 112-24-3 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 | H312 H314 H317 H412 | GHS05 GHS07 Gef. | H312 H314 H317 H412 | |||
612-060-00-0 | 3,6,9-Triazaundecamethylendiamin; Tetraethylenpentamin | 203-986-2 | 112-57-2 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H312 H302 H314 H317 H411 | GHS05 GHS07 GHS09 Gef. | H312 H302 H314 H317 H411 | |||
612-061-00-6 | 3-Aminopropyldimethylamin; N, N-dimethyl-1,3-diaminopropan | 203-680-9 | 109-55-7 | Flam. Liq. 3 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H226 H302 H314 H317 | GHS02 GHS05 GHS07 Gef. | H226 H302 H314 H317 | |||
612-062-00-1 | 3-Aminopropyldiethylamin; N, N-Diethyl-1,3-diaminopropan | 203-236-4 | 104-78-9 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H226 H312 H302 H314 H317 | GHS02 GHS05 GHS07 Gef. | H226 H312 H302 H314 H317 | |||
612-063-00-7 | 3,3"-Iminodi(propylamin); Dipropylentriamin | 200-261-2 | 56-18-8 | Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1A Skin Sens. 1 | H330 H311 H302 H314 H317 | GHS06 GHS05 Gef. | H330 H311 H302 H314 H317 | |||
612-064-00-2 | 3,6,9,12-Tetraazatetradecamethylendiamin; Pentaethylenhexamin | 223-775-9 | 4067-16-7 | Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H317 H410 | |||
612-065-00-8 | Polyethlyenpolyamine, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H312 H302 H314 H317 H410 | |||
612-066-00-3 | Dicyclohexylamin | 202-980-7 | 101-83-7 | Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H314 H410 | |||
612-067-00-9 | 3-Aminomethyl-3,5,5-trimethylcyclohexylamin | 220-666-8 | 2855-13-2 | Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A | H302 H314 H318 H317 | GHS05 GHS07 Dgr | H302 H314 H317 | oral:
ATE = 1 030 mg/kg KG Skin Sens. 1A; H317: C ≥ 0,001 % | ||
612-068-00-4 | 3,3"-Dichlorbenzidin; 3,3"-Dichlorbiphenyl-4,4"-ylendiamin | 202-109-0 | 91-94-1 | Carc. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H312 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H312 H317 H410 | |||
612-069-00-X | Salze von 3,3"-Dichlorbenzidin; Salze von 3,3"-Dichlorbiphenyl-4,4"-ylendiamin | - | - | Carc. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H312 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H312 H317 H410 | A | ||
612-070-00-5 | Salze von Benzidin | 208-519-6 208-520-1 244-236-4 252-984-8 | 531-85-1 531-86-2 21136-70-9 36341-27-2 | Carc. 1A Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H410 | A | ||
612-071-00-0 | Salze von 2-Naphthylamin | 209-030-0 210-313-6 | 553-00-4 612-52-2 | Carc. 1A Acute Tox. 4 * Aquatic Chronic 2 | H350 H302 H411 | GHS08 GHS07 GHS09 Gef. | H350 H302 H411 | A | ||
612-072-00-6 | Biphenyl-4-ylamin; Xenylamin; 4-Aminobiphenyl | 202-177-1 | 92-67-1 | Carc. 1A Acute Tox. 4 * | H350 H302 | GHS08 GHS07 Gef. | H350 H302 | |||
612-073-00-1 | Salze von Biphenyl-4-ylamin; Salze von Xenylamin; Salze von 4-Aminobiphenyl | - | - | Carc. 1A Acute Tox. 4 * | H350 H302 | GHS08 GHS07 Gef. | H350 H302 | A | ||
612-074-00-7 | Benzyldimethylamin | 203-149-1 | 103-83-3 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 3 | H226 H332 H312 H302 H314 H412 | GHS02 GHS05 GHS07 Gef. | H226 H332 H312 H302 H314 H412 | |||
612-075-00-2 | 2-Aminoethyldimethylamin; 2-Dimethylaminoethylamin | 203-541-2 | 108-00-9 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H225 H312 H302 H314 | GHS02 GHS05 GHS07 Gef. | H225 H312 H302 H314 | |||
612-076-00-8 | Ethyldimethylamin; N, N-Dimethylethylamin | 209-940-8 | 598-56-1 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H225 H332 H302 H314 | GHS02 GHS05 GHS07 Gef. | H225 H332 H302 H314 | |||
612-077-00-3 | Dimethylnitrosamin; N-Nitrosodimethylamin | 200-549-8 | 62-75-9 | Carc. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Chronic 2 | H350 H330 H301 H372 ** H411 | GHS06 GHS08 GHS09 Gef. | H350 H330 H301 H372 ** H411 | Carc. 1B; H350: C ≥ 0,001 % | ||
612-078-00-9 | 2,2"-Dichlor-4,4"-methylendianilin; 4,4"-Methylen-bis(2-chloranilin) MOCA | 202-918-9 | 101-14-4 | Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H410 | |||
612-079-00-4 | Salze von 2,2"-dichlor-4,4"-methylendianilin; Salze von 4,4"-methylenbis(2-chloranilin) | - | - | Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H410 | A | ||
612-080-00-X | 4-Amino- N, N-diethylanilin; N, N-Diethyl- p-phenylendiamin | 202-214-1 | 93-05-0 | Acute Tox. 3 * Skin Corr. 1B | H301 H314 | GHS06 GHS05 Gef. | H301 H314 | |||
612-081-00-5 | Salze von 4,4"-Bi- o-toluidin; Salze von 3,3"-Imethylbenzidin; Salze von o-tolidin | 210-322-5 265-294-7 277-985-0 | 612-82-8 64969-36-4 74753-18-7 | Carc. 1B Acute Tox. 4 * Aquatic Chronic 2 | H350 H302 H411 | GHS08 GHS07 GHS09 Gef. | H350 H302 H411 | A | ||
612-082-00-0 | Thioharnstoff; Thiocarbamid | 200-543-5 | 62-56-6 | Carc. 2 Repr. 2 Acute Tox. 4 * Aquatic Chronic 2 | H351 H361d *** H302 H411 | GHS08 GHS07 GHS09 Achtg. | H351 H361d *** H302 H411 | |||
612-083-00-6 | 1-Methyl-3-nitro-1-nitrosoguanidin | 200-730-1 | 70-25-7 | Carc. 1B Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H350 H332 H319 H315 H411 | GHS08 GHS07 GHS09 Gef. | H350 H332 H319 H315 H411 | Carc. 1B; H350: C ≥ 0,01 % | ||
612-084-00-1 | Dapson; 4,4"-Diaminodiphenylsulfon | 201-248-4 | 80-08-0 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
612-085-00-7 | 4,4"-Methylendi-o-toluidin; 3,3"-Dimethyl-4,4"-diamino-diphenylmethan | 212-658-8 | 838-88-0 | Carc. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H350 H302 H317 H410 | |||
612-086-00-2 | Amitraz (ISO); N, N-Bis(2,4-xylyliminomethyl) methylamin | 251-375-4 | 33089-61-1 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H317 H410 | M = 10 | ||
612-087-00-8 | Guazatin (ISO); 1,1"-Iminobis(octamethylen)diguanidin | 108173-90-6 | Acute Tox. 2 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H312 H302 H335 H315 H318 H400 H410 | GHS06 GHS05 GHS09 Gef. | H330 H312 H302 H335 H315 H318 H410 | ||||
612-088-00-3 | Simazin (ISO); 6-Chlor- N, N"-diethyl-1,3,5-triazin-2,4-diamin | 204-535-2 | 122-34-9 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
612-089-00-9 | 1,5-Naphthylendiamin | 218-817-8 | 2243-62-1 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
612-090-00-4 | 2,2"-(Nitrosoimino)bisethanol; N-Nitrosodiethanolamin | 214-237-4 | 1116-54-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
612-091-00-X | o-Toluidin; 2-Aminotoluol; 2-Methylanilin | 202-429-0 | 95-53-4 | Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Aquatic Acute 1 | H350 H331 H301 H319 H400 | GHS06 GHS08 GHS09 Gef. | H350 H331 H301 H319 H400 | |||
612-092-00-5 | N, N"-(2,2-Dimethylpropyliden)hexamethylendiamin | 401-660-6 | 1000-78-8 | Skin Irrit. 2 Skin Sens. 1 | H315 H317 | GHS07 Achtg. | H315 H317 | |||
612-093-00-0 | 3,5-Dichlor-4-(1,1,2,2-tetrafluorethoxy)anilin | 401-790-3 | 104147-32-2 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
612-094-00-6 | 4-(2-Chlor-4-trifluormethyl)phenoxy-2-fluoranilinhydrochlorid | 402-190-4 | 113674-95-6 | STOT RE 1 Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H372** H302 H373** H318 H317 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H372** H302 H373** H318 H317 H410 | |||
612-095-00-1 | Benzyl-2-hydroxydodecyldimethylammoniumbenzoat | 402-610-6 | 113694-52-3 | Skin Corr. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H314 H302 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H302 H410 | |||
612-096-00-7 | 4,4"-Carbonimidoyl-bis[ N, N-dimethylanilin]; Auramin; C.I. Solvent Yellow 34 | 207-762-5 | 492-80-8 | Carc. 2 Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 2 | H351 H302 H319 H411 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H319 H411 | |||
612-097-00-2 | Salze von 4,4"-Carbonimidoylbis[ N, N-dimethylanilin]; Auraminsalze | - | - | Carc. 2 Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 2 | H351 H302 H319 H411 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H319 H411 | A | ||
612-098-00-8 | Nitrosodipropylamin; N-Nitrosodi-n-propylamin | 210-698-0 | 621-64-7 | Carc. 1B Acute Tox. 4 * Aquatic Chronic 2 | H350 H302 H411 | GHS08 GHS07 GHS09 Gef. | H350 H302 H411 | Carc. 1B; H350: C ≥ 0,001 % | ||
612-099-00-3 | 4-Methyl-m-phenylendiamin; 2,4-Toluylendiamin; 2,4-Diaminotoluol | 202-453-1 | 95-80-7 | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H350 H341 H361f*** H301 H312 H373** H317 H411 | GHS06 GHS08 GHS09 Gef. | H350 H341 H361f*** H301 H312 H373** H317 H411 | |||
612-100-00-7 | Propylendiamin | 201-155-9 | 78-90-0 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A | H226 H312 H302 H314 | GHS02 GHS05 GHS07 Gef. | H226 H312 H302 H314 | |||
612-101-00-2 | Methenamin; Hexamethylentetramin | 202-905-8 | 100-97-0 | Flam. Sol. 2 Skin Sens. 1 | H228 H317 | GHS02 GHS07 Achtg. | H228 H317 | |||
612-102-00-8 | N, N-Bis(3-aminopropyl)methylamin | 203-336-8 | 105-83-9 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B | H331 H311 H302 H314 | GHS06 GHS05 Gef. | H331 H311 H302 H314 | |||
612-103-00-3 | N, N,N",N"-Tetramethylethylendiamin | 203-744-6 | 110-18-9 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H225 H332 H302 H314 | GHS02 GHS05 GHS07 Gef. | H225 H332 H302 H314 | |||
612-104-00-9 | Hexamethylendiamin; 1,6-Diaminohexan | 204-679-6 | 124-09-4 | Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Corr. 1B | H312 H302 H335 H314 | GHS05 GHS07 Gef. | H312 H302 H335 H314 | |||
612-105-00-4 | 2-Piperazin-1-ylethylamin | 205-411-0 | 140-31-8 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 | H312 H302 H314 H317 H412 | GHS05 GHS07 Gef. | H312 H302 H314 H317 H412 | |||
612-106-00-X | 2,6-Diethylanilin | 209-445-7 | 579-66-8 | Acute Tox. 4 * | H302 | - | H302 | |||
612-107-00-5 | 1-Phenylethylamin [1]; DL-α-Methylbenzylamin [2] | 202-706-6 [1] 210-545-8 [2] | 98-84-0 [1] 618-36-0 [2] | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | |||
612-108-00-0 | 3-Aminopropyltriethoxysilan; 3-(Triethoxysilan)-propan-1-amin | 213-048-4 | 919-30-2 | Acute Tox. 4 * Skin Corr. 1B | H302 H314 | GHS05 GHS07 Gef. | H302 H314 | |||
612-109-00-6 | Bis(2-dimethylaminoethyl)(methyl)amin | 221-201-1 | 3030-47-5 | Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B | H311 H302 H314 | GHS06 GHS05 Gef. | H311 H302 H314 | |||
612-110-00-1 | 2,2"-Dimethyl-4,4"-methylenbis(cyclohexylamin) | 229-962-1 | 6864-37-5 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1A Aquatic Chronic 2 | H331 H311 H302 H314 H411 | GHS06 GHS05 GHS09 Gef. | H331 H311 H302 H314 H411 | |||
612-111-00-7 | 2-Methyl-m-phenylendiamin; 2,6-Toluylendiamin; 2,6-Toluoldiamin; 2,6-Diaminotoluol | 212-513-9 | 823-40-5 | Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H341 H312 H302 H317 H411 | GHS08 GHS07 GHS09 Achtg. | H341 H312 H302 H317 H411 | |||
612-112-00-2 | p-Anisidin; 4-Methoxyanilin | 203-254-2 | 104-94-9 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 | H330 H310 H300 H373 ** H400 | GHS06 GHS08 GHS09 Gef. | H330 H310 H300 H373 ** H400 | |||
612-113-00-8 | 6-Methyl-2,4-bis(methylthio)phenylen-1,3-diamin | 403-240-8 | 106264-79-3 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
612-114-00-3 | R, R-2-Hydroxy-5-(1-hydroxy-2-(4-phenylbut-2- ylamino)ethyl)benzamidhydrogen-2,3-bis(benzoyloxy)succinat | 404-390-7 | - | Flam. Sol. 1 Skin Sens. 1 Aquatic Chronic 3 | H228 H317 H412 | GHS02 GHS07 Achtg. | H228 H317 H412 | |||
612-115-00-9 | Dimethyldioctadecylammoniumhydrogensulfat | 404-050-8 | 123312-54-9 | Eye Irrit. 2 Aquatic Chronic 4 | H319 H413 | GHS07 Achtg. | H319 H413 | |||
612-116-00-4 | C8-18-Alkylbis(2-hydroxyethyl)ammoniumbis(2-ethylhexyl)phosphat | 404-690-8 | 68132-19-4 | Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H314 H317 H400 H410 | GHS06 GHS05 GHS09 Gef. | H331 H314 H317 H410 | |||
612-117-00-X | C12-14- tert-Alkylamin, Methylphosphonsäuresalz | 404-750-3 | 119415-07-5 | Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 | H302 H314 H411 | GHS05 GHS07 GHS09 Gef. | H302 H314 H411 | |||
612-118-00-5 | Reaktionsmasse aus (1,3-Dioxo-2 H-benz(de)isochinolin-2-ylpropyl)hexadecyldimethylammonium-4-toluolsulfonat und (1,3-Dioxo-2 H-benz(de)isochinolin-2-ylpropyl)hexadecyldimethylammoniumbromid | 405-080-4 | - | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
612-119-00-0 | Benzyldimethyloctadecylammonium-3-nitrobenzolsulfonat | 405-330-2 | - | Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H400 H410 | GHS05 GHS09 Gef. | H315 H318 H410 | |||
612-120-00-6 | Aclonifen (ISO); 2-Chlor-6-nitro-3-phenoxyanilin | 277-704-1 | 74070-46-5 | Carc. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H351 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H317 H410 | M = 100 M = 10 | ||
612-121-00-1 | Polyethylenpolyamine; HEPA | 268-626-9 | 68131-73-7 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H312 H302 H314 H317 H410 | |||
612-122-00-7 | Hydroxylamin ... % [> 55 % in wässriger Lösung] | 232-259-2 | 7803-49-8 | Unst. Expl. Met. Corr. 1 Carc. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 | H200 H290 H351 H312 H302 H373** H335 H315 H318 H317 H400 | GHS01 GHS05 GHS08 GHS07 GHS09 Gef. | H200 H290 H351 H312 H302 H373** H335 H315 H318 H317 H400 | B | ||
612-122-01-4 | Hydroxylamin ...% [≤ 55 % in wässriger Lösung] | 232-259-2 | 7803-49-8 | Met. Corr. 1 Carc. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 | H290 H351 H312 H302 H373** H335 H315 H318 H317 H400 | GHS05 GHS08 GHS07 GHS09 Gef. | H290 H351 H312 H302 H373** H335 H315 H318 H317 H400 | B | ||
612-123-00-2 | Hydroxylammoniumchlorid; Hydroxylaminhydrochlorid [1]; Bis(hydroxylammonium)sulfat; Hydroxylaminsulfat (2:1) [2] | 226-798-2 [1] 233-118-8 [2] | 5470-11-1 [1] 10039-54-0 [2] | Met. Corr. 1 Carc. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H290 H351 H312 H302 H373** H319 H315 H317 H400 | GHS05 GHS08 GHS07 GHS09 Achtg. | H290 H351 H312 H302 H373** H319 H315 H317 H400 | |||
612-124-00-8 | N, N, N-Trimethylaniliniumchlorid | 205-319-0 | 138-24-9 | Acute Tox. 3 * Acute Tox. 3 * | H311 H301 | GHS06 Gef. | H311 H301 | |||
612-125-00-3 | 2-Methyl-p-phenylendiamin; 2,5-Toluoldiamin; 2,5-Diaminotoluol | 202-442-1 | 95-70-5 | Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H301 H332 H312 H317 H411 | GHS06 GHS09 Gef. | H301 H332 H312 H317 H411 | |||
612-126-00-9 | Toluol-2,4-diammoniumsulfat; 4-Methyl-m-phenylendiaminsulfat; Toluylen-2,4-diaminsulfat | 265-697-8 | 65321-67-7 | Carc. 1B Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H350 H301 H312 H319 H317 H411 | GHS06 GHS08 GHS09 Gef. | H350 H301 H312 H319 H317 H411 | |||
612-127-00-4 | 3-Aminophenol | 209-711-2 | 591-27-5 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H332 H302 H411 | GHS07 GHS09 Achtg. | H332 H302 H411 | |||
612-128-00-X | 4-Aminophenol | 204-616-2 | 123-30-8 | Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H341 H332 H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H341 H332 H302 H410 | |||
612-129-00-5 | Diisopropylamin | 203-558-5 | 108-18-9 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H225 H332 H302 H314 | GHS02 GHS05 GHS07 Gef. | H225 H332 H302 H314 | STOT SE 3; H335: C ≥ 5 % | ||
612-130-00-0 | 2,6-Diamino-3,5-diethyltoluol; 4,6-Diethyl-2-methyl-1,3-benzoldiamin [1]; 2,4-Diamino-3,5-diethyltoluol; 2,4-Diethyl-6-methyl-1,3- benzoldiamin [2]; Diethylmethylbenzoldiamin [3] | 218-255-3 [1] 218-256-9 [2] 270-877-4 [3] | 2095-01-4 [1] 2095-02-5 [2] 68479-98-1 [3] | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H373 ** H319 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H312 H302 H373 ** H319 H410 | C | ||
612-131-00-6 | Didecyldimethylammoniumchlorid | 230-525-2 | 7173-51-5 | Acute Tox. 4 * Skin Corr. 1B | H302 H314 | GHS05 GHS07 Gef. | H302 H314 | |||
612-132-00-1 | N, N"-Diphenyl- p-phenylendiamin; N, N"-Diphenyl-1,4-benzoldiamin | 200-806-4 | 74-31-7 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
612-133-00-7 | (4-Ammonio- m-tolyl)ethyl(2- hydroxyethyl)ammoniumsulfat; 4-( N-Ehyl- N-2-hydroxyethyl)-2- methylphenylendiaminsulfat | 247-162-0 | 25646-77-9 | Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H373 ** H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H373 ** H317 H410 | |||
612-134-00-2 | N-(2-(4-Amino-N-ethyl- m-toluidino)ethyl)methansulfonamidsesquisulfat; 4-( N-ethyl- N-2-methansulfonylaminoethyl)-2-methylphenylendiaminsesquisulfatmonohydrat | 247-161-5 | 25646-71-3 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
612-135-00-8 | N-2-Naphthylanilin; N-Phenyl-2-naphthylamin | 205-223-9 | 135-88-6 | Carc. 2 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H351 H319 H315 H317 H411 | GHS08 GHS07 GHS09 Achtg. | H351 H319 H315 H317 H411 | |||
612-136-00-3 | N-Isopropyl- N"-phenyl -p-phenylendiamin | 202-969-7 | 101-72-4 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | Skin Sens. 1; H317:C ≥0,1 % | ||
612-137-00-9 | 4-Chloranilin | 203-401-0 | 106-47-8 | Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H331 H311 H301 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H331 H311 H301 H317 H410 | |||
612-138-00-4 | Furalaxyl (ISO); Methyl- N-(2,6-dimethylphenyl)- N-(2-furylcarbonyl)-DL-alaninat | 260-875-1 | 57646-30-7 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
612-139-00-X | Mefenacet (ISO); 2-(Benzothiazol-2-yloxy)- N-methyl- N-phenylacetamid | 277-328-8 | 73250-68-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
612-140-00-5 | Quartäre Ammoniumverbindungen, Benzyl-C8-18-alkyldimethyl, Chloride; (C8-18)Alkylbenzyldimetylammoniumchlorid | 264-151-6 | 63449-41-2 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 | H312 H302 H314 H400 | GHS05 GHS07 GHS09 Gef. | H312 H302 H314 H400 | |||
612-141-00-0 | 4,4"-Methylenbis(2-ethylanilin); 4,4"-methylenbis(2-ethylbenzolamin) | 243-420-1 | 19900-65-3 | Carc. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H410 | |||
612-142-00-6 | Biphenyl-2-ylamin; 2-Aminobiphenyl | 201-990-9 | 90-41-5 | Carc. 2 Acute Tox. 4 * Aquatic Chronic 3 | H351 H302 H412 | GHS08 GHS07 Achtg. | H351 H302 H412 | |||
612-143-00-1 | N5,N5-Diethyltoluol-2,5-diaminmonohydrochlorid; 4-Diethylamino-2-methylanilinmonohydrochlorid | 218-130-3 | 2051-79-8 | Acute Tox. 3 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H319 H317 H400 H410 | GHS06 GHS09 Gef. | H301 H319 H317 H410 | |||
612-144-00-7 | Flumetralin (ISO); N-(2-Chlor-6-fluorbenzyl)- N-ethyl-α, α,α-trifluor-2,6-dinitro- p-toluidin | - | 62924-70-3 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H319 H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H319 H315 H317 H410 | |||
612-145-00-2 | o-Phenylendiamin; 1,2-Diaminobenzol | 202-430-6 | 95-54-5 | Carc. 2 Muta. 2 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H341 H301 H332 H312 H319 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H341 H301 H332 H312 H319 H317 H410 | |||
612-146-00-8 | o-Phenylendiamindihydrochlorid | 210-418-7 | 615-28-1 | Carc. 2 Muta. 2 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H341 H301 H332 H312 H319 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H351 H341 H301 H332 H312 H319 H317 H410 | |||
612-147-00-3 | m-Phenylendiamin; 1,3-Diaminobenzol | 203-584-7 | 108-45-2 | Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H341 H331 H311 H301 H319 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H341 H331 H311 H301 H319 H317 H410 | |||
612-148-00-9 | m-Phenylendiamindihydrochlorid | 208-790-0 | 541-69-5 | Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H341 H331 H311 H301 H319 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H341 H331 H311 H301 H319 H317 H410 | |||
612-149-00-4 | 1,3-Diphenylguanidin | 203-002-1 | 102-06-7 | Repr. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 | H361f *** H302 H319 H335 H315 H411 | GHS08 GHS07 GHS09 Achtg. | H361f *** H302 H319 H335 H315 H411 | |||
612-150-00-X | Spiroxamin (ISO); 8- tert-Butyl-1,4-dioxa-spiro[4.5]dec-2-ylmethyl-ethylpropylamin | - | 118134-30-8 | Repr. 2 Acute Tox. 4 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d H332 H312 H302 H373 (Augen) H315 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361d H332 H312 H302 H373 (Augen) H315 H317 H410 | M = 100 M = 100 | ||
612-151-00-5 | Methylphenylendiamin; Diaminotoluol; [technisches Produkt - Reaktionsmasse aus 4-Methyl- m-phenylendiamin (EG-Nr. 202-453-1) und 2-Methyl- m-phenylendiamin (EG-Nr. 212-513-9)] | - | - | Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H350 H341 H361f*** H301 H312 H373** H319 H317 H411 | GHS06 GHS08 GHS09 Gef. | H350 H341 H361f*** H301 H312 H373** H319 H317 H411 | |||
612-152-00-0 | N, N-Diethyl- N",N"-dimethylpropan-1,3-diyldiamin | 406-610-7 | 62478-82-4 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1A Aquatic Chronic 3 | H226 H332 H302 H373 ** H314 H412 | GHS02 GHS08 GHS05 GHS07 Gef. | H226 H332 H302 H373 ** H314 H412 | |||
612-153-00-6 | 4-[ N-Ethyl- N-(2-hydroxyethyl)amino]-1-(2-hydroxyethyl)amino-2-nitrobenzol, Monohydrochlorid | 407-020-2 | 132885-85-9 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H302 H317 H412 | GHS07 Achtg. | H302 H317 H412 | |||
612-154-00-1 | 6"-(Isobutylethylamino)-3"-methyl-2"-phenylaminospiro[isobenzo-2-oxofuran-7,9"-[9 H]-xanthen] | 410-890-6 | 95235-29-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
612-155-00-7 | 2"-Anilino-6"-((3-ethoxypropyl)ethylamino)-3"-methylspiro(isobenzo-3-oxofuran)-1-(1 H)-9"-xanthen | 411-730-8 | 93071-94-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
612-156-00-2 | Reaktionsmasse aus Trihexadecylmethylammoniumchlorid und Dihexadecyldimethylammoniumchlorid | 405-620-9 | - | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
612-157-00-8 | (Z)-1-Benzo[ b]thien-2- ylethanonoximehydrochlorid | 410-780-8 | - | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H373 ** H318 H317 H411 | GHS08 GHS05 GHS07 GHS09 Gef. | H302 H373 ** H318 H317 H411 | |||
612-158-00-3 | Reaktionsmasse aus Bis(5-dodecyl-2-hydroxybenzaldoximat)kupfer(II) [C12-Alkylgruppe ist verzweigt]; 4-Dodecylsalicylaldoxim | 410-820-4 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
612-159-00-9 | Reaktionsprodukte von Trimethylhexamethylendiamin (Mischung aus 2,2,4-Trimethyl-1,6- hexandiamin und 2,4,4-Trimethyl-1,6-hexandiamin, EINECS-gelistet), mit Epoxid-8-(mono[(C10-C16-alkyloxy)methyl]oxiran-Derivaten) und p-Toluolsulfonsäure | 410-880-1 | - | Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H314 H410 | |||
612-160-00-4 | p-Toluidin; 4-Aminotoluol [1]; Toluidiniumchlorid [2]; Toluidinsulfat (1:1) [3] | 203-403-1 [1] 208-740-8 [2] 208-741-3 [3] | 106-49-0 [1] 540-23-8 [2] 540-25-0 [3] | Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H351 H331 H311 H301 H319 H317 H400 | GHS06 GHS08 GHS09 Gef. | H351 H331 H311 H301 H319 H317 H400 | |||
612-161-00-X | 2,6-Xylidin; 2,6-Dimethylanilin | 201-758-7 | 87-62-7 | Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 | H351 H332 H312 H302 H335 H315 H411 | GHS08 GHS07 GHS09 Achtg. | H351 H332 H312 H302 H335 H315 H411 | |||
612-162-00-5 | Dimethyldioctadecylammoniumchlorid; DODMAC | 203-508-2 | 107-64-2 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
612-163-00-0 | Metalaxyl- M (ISO); Mefenoxam; (R)-2-[(2,6-Dimethylphenyl)methoxyacetylamino]propionsäuremethylester | - | 70630-17-0 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
612-164-00-6 | 2-Butyl-2-ethyl-1,5-diaminopentan | 412-700-7 | 137605-95-9 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 | H312 H302 H373 ** H314 H317 H412 | GHS08 GHS05 GHS07 Gef. | H312 H302 H373 ** H314 H317 H412 | |||
612-165-00-1 | N, N"-Diphenyl- N, N"-bis(3- methylphenyl)-(1,1"-diphenyl)-4,4"-diamin | 413-810-8 | 65181-78-4 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
612-166-00-7 | Reaktionsmasse aus cis-(5-Ammonium-1,3,3-trimethyl)- cyclohexanmethylammoniumphosphat (1:1) und trans-(5-Ammonium-1,3,3-trimethyl)-cyclohexanmethylammoniumphosphat (1:1) | 411-830-1 | 114765-88-7 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
612-167-00-2 | 5-Acetyl-3-amino-10,11-dihydro-5 H-dibenz[ b, f]azepinhydrochlorid | 410-490-1 | - | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H373 ** H318 H317 H411 | GHS08 GHS05 GHS07 GHS09 Gef. | H302 H373 ** H318 H317 H411 | |||
612-168-00-8 | 3,5-Dichlor-2,6-difluorpyrdin-4-amin | 220-630-1 | 2840-00-8 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H312 H302 H411 | GHS07 GHS09 Achtg. | H312 H302 H411 | |||
612-169-00-3 | Bis( N-methyl- N-phenylhydrazin)sulfat | 423-170-1 | 618-26-8 | Flam. Liq. 2 STOT RE 1 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H225 H372** H302 H318 H317 H400 H410 | GHS02 GHS05 GHS08 GHS07 GHS09 Gef. | H225 H372** H302 H318 H317 H410 | |||
612-170-00-9 | 4-Chlorphenylcyclopropylketon O-(4-aminobenzyl)oxim | 405-260-2 | - | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
612-171-00-4 | N, N, N", N"-Tetraglycidyl-4,4"-diamino-3,3"-diethyldiphenylmethan | 410-060-3 | 130728-76-6 | Muta. 2 Skin Sens. 1 Aquatic Chronic 2 | H341 H317 H411 | GHS08 GHS09 Achtg. | H341 H317 H411 | |||
612-172-00-X | 4,4"-Methylenbis( N, N"- dimethylcyclohexanamin; Bis(4-dimethylamino-cyclohexyl)methan | 412-840-9 | 13474-64-1 | Acute Tox. 4 * STOT RE 2 * Skin Corr. 1A Aquatic Chronic 3 | H302 H373 ** H314 H412 | GHS08 GHS05 GHS07 Gef. | H302 H373 ** H314 H412 | |||
612-173-00-5 | Lithium-1-amino-4-(4- tert-butylanilino)anthrachinon-2-sulfonat | 411-140-0 | 125328-86-1 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
612-174-00-0 | 4,4-Dimethoxybutylamin | 407-690-6 | 19060-15-2 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 | H302 H314 H317 H412 | GHS05 GHS07 Gef. | H302 H314 H317 H412 | |||
612-175-00-6 | 2-( O-Aminooxy)ethylamindihydrochlorid | 412-310-7 | 37866-45-8 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
612-176-00-1 | Polymer aus1,3-Dibrompropan und N, N-Diethyl- N", N"-dimethyl-1,3-propandiamin | 410-570-6 | 143747-73-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
612-177-00-7 | 2-Naphthylamino-6-sulfomethylamid | 412-120-4 | 104295-55-8 | STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H373 ** H317 H411 | GHS08 GHS09 Achtg. | H373 ** H317 H411 | |||
612-178-00-2 | 1,4,7,10-Tetraazacyclododecandisulfat | 412-080-8 | 112193-77-8 | Acute Tox. 4 * STOT SE 3 Eye Dam. 1 Aquatic Chronic 3 | H302 H335 H318 H412 | GHS05 GHS07 Gef. | H302 H335 H318 H412 | |||
612-179-00-8 | 1-(2-Propenyl)pyridiniumchlorid | 412-740-5 | 25965-81-5 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
612-180-00-3 | 3-Aminobenzylamin | 412-230-2 | 4403-70-7 | Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 | H302 H314 H411 | GHS05 GHS07 GHS09 Gef. | H302 H314 H411 | |||
612-181-00-9 | 2-Phenylthioanilin | 413-030-8 | 1134-94-7 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
612-182-00-4 | 1-Ethyl-1-methylmorpholiniumbromid | 418-210-1 | 65756-41-4 | Muta. 2 | H341 | GHS08 Achtg. | H341 | |||
612-183-00-X | 1-Ethyl-1-methylpyrrolidiniumbromid | 418-200-5 | 69227-51-6 | Muta. 2 | H341 | GHS08 Achtg. | H341 | |||
612-184-00-5 | 6"-(Dibutylamino)-3"-methyl-2"- (phenylamino)spiro[isobenzofuran-1(3 H),9-(9 H)-xanthen]-3-on | 403-830-5 | 89331-94-2 | Aquatic Chronic 3 | H412 | - | H412 | |||
612-185-00-0 | 1-[3-[4-((Heptadecafluoronyl)oxy)-benzamido]propyl]- N, N,N-trimethylammoniumiodid | 407-400-8 | 59493-72-0 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
612-186-00-6 | Bis( N-(7-hydroxy-8-methyl-5-phenylphenazin-3-yliden)dimethylammonium)sulfat | 406-770-8 | 149057-64-7 | STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H318 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H373 ** H318 H317 H410 | |||
612-187-00-1 | 2,3,4-Trifluoranilin | 407-170-9 | 3862-73-5 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H312 H302 H373 ** H315 H318 H411 | GHS08 GHS05 GHS07 GHS09 Gef. | H312 H302 H373 ** H315 H318 H411 | |||
612-188-00-7 | 4,4"-(9 H-Fluoren-9-yliden)bis(2-chloranilin) | 407-560-9 | 107934-68-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
612-189-00-2 | 4-Amino-2-(aminomethyl)phenoldihydrochlorid | 412-510-4 | 135043-64-0 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
612-190-00-8 | 4,4"-Methylenbis(2-isopropyl-6-methylanilin) | 415-150-6 | 16298-38-7 | STOT RE 2 * Aquatic Chronic 2 | H373 ** H411 | GHS08 GHS09 Achtg. | H373 ** H411 | |||
612-191-00-3 | Polymer aus Allylaminhydrochlorid | 415-050-2 | 71550-12-4 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
612-192-00-9 | 2-Isopropyl-4-( N-methyl)aminomethylthiazol | 414-800-6 | 154212-60-9 | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H312 H302 H315 H318 H411 | GHS05 GHS07 GHS09 Gef. | H312 H302 H315 H318 H411 | |||
612-193-00-4 | 3-Methylaminomethylphenylamin | 414-570-7 | 18759-96-1 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H312 H302 H314 H317 H410 | |||
612-194-00-X | 2-Hydroxy-3-[(2-hydroxyethyl)-[2-(1-oxotetradecyl)amino]ethyl]amino]- N, N, N-trimethyl-1-propanammoniumchlorid | 414-670-0 | 141890-30-4 | Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H318 H410 | |||
612-195-00-5 | Bis[tributyl-4-(methylbenzyl)ammonium]-1,5-naphthalindisulfonat | 415-210-1 | 160236-81-7 | Acute Tox. 4 * Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H332 H302 H318 H410 | |||
612-196-00-0 | 4-Chlor- o-toluidin [1]; 4-Chlor- o-toluidinhydrochlorid [2] | 202-441-6 [1] 221-627-8 [2] | 95-69-2 [1] 3165-93-3 [2] | Carc. 1B Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H350 H341 H331 H311 H301 H400 H410 | GHS06 GHS08 GHS09 Gef. | H350 H341 H331 H311 H301 H410 | |||
612-197-00-6 | 2,4,5-Trimethylanilin [1]; 2,4,5-Trimethylanilinhydrochlorid [2] | 205-282-0 [1] - [2] | 137-17-7 [1] 21436-97-5 [2] | Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H350 H331 H311 H301 H411 | GHS06 GHS08 GHS09 Gef. | H350 H331 H311 H301 H411 | |||
612-198-00-1 | 4,4"-Thiodianilin und seine Salze | 205-370-9 | 139-65-1 | Carc. 1B Acute Tox. 4 * Aquatic Chronic 2 | H350 H302 H411 | GHS08 GHS07 GHS09 Gef. | H350 H302 H411 | |||
612-199-00-7 | 4,4"-Oxydianilin und seine Salze; p-Aminophenylether | 202-977-0 | 101-80-4 | Carc. 1B Muta. 1B Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 | H350 H340 H361f *** H331 H311 H301 H411 | GHS06 GHS08 GHS09 Gef. | H350 H340 H361f *** H331 H311 H301 H411 | |||
612-200-00-0 | 2,4-Diaminoanisol; 4-Methoxy- m-phenylendiamin [1]; 2,4-Diaminoanisolsulfat [2] | 210-406-1 [1] 254-323-9 [2] | 615-05-4 [1] 39156-41-7 [2] | Carc. 1B Muta. 2 Acute Tox. 4 * Aquatic Chronic 2 | H350 H341 H302 H411 | GHS08 GHS07 GHS09 Gef. | H350 H341 H302 H411 | |||
612-201-00-6 | N, N, N", N"-Tetramethyl-4,4"-methylendianilin | 202-959-2 | 101-61-1 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Gef. | H350 H410 | |||
612-202-00-1 | 3,4-Dichloranilin | 202-448-4 | 95-76-1 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Gef. | H331 H311 H301 H318 H317 H410 | |||
612-203-00-7 | C8-10-alkyldimethylhydroxyethylammoniumchlorid (Kette < C8: < 3 %, Kette = C8: 15 %-70 %, Kette = C10: 30 % - 85 %, Kette > C10: < 3 %) | 417-360-3 | - | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 | H312 H302 H315 | GHS07 Achtg. | H312 H302 H315 | |||
612-204-00-2 | C.I. Basic Violet 3; 4-[4,4"-Bis(dimethylamino) benzhydryliden]cyclohexa-2,5-dien-1-yliden]dimethylammoniumchlorid; Kristallviolett | 208-953-6 | 548-62-9 | Carc. 2 Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H318 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H351 H302 H318 H410 | |||
612-205-00-8 | C.I. Basic Violet 3 mit ≥ 0,1 % Michlers Keton (EG-Nr. 202-027-5) | 208-953-6 | 548-62-9 | Carc. 1B Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H302 H318 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H350 H302 H318 H410 | |||
612-206-00-3 | Famoxadon (ISO); 3-Anilino-5-methyl-5-(4-phenoxyphenyl)-1,3-oxazolidin-2,4-dion | - | 131807-57-3 | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H400 H410 | GHS08 GHS09 Achtg. | H373 ** H410 | |||
612-207-00-9 | 4-Ethoxyanilin; p-Phenetidin | 205-855-5 | 156-43-4 | Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 | H341 H332 H312 H302 H319 H317 | GHS08 GHS07 Achtg. | H341 H332 H312 H302 H319 H317 | |||
612-208-00-4 | N-Methylbenzol-1,2-diammoniumhydrogenphosphat | 424-460-0 | - | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
612-209-00-X | 6-Methoxy-m-toluidin; p-Cresidin; 2-Methoxy-5-methylanilin | 204-419-1 | 120-71-8 | Carc. 1B Acute Tox. 4 * | H350 H302 | GHS08 GHS07 Gef. | H350 H302 | |||
612-210-00-5 | 5-Nitro- o-toluidin [1]; 5-Nitro- o-toluidinhydrochlorid [2] | 202-765-8 [1] 256-960-8 [2] | 99-55-8 [1] 51085-52-0 [2] | Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 3 | H351 H331 H311 H301 H412 | GHS06 GHS08 Gef. | H351 H331 H311 H301 H412 | |||
612-211-00-0 | N-[(Benzotriazol-1-yl)methyl)]- 4-carboxybenzolsulfonamid | 416-470-9 | 170292-97-4 | Eye Irrit. 2 Aquatic Chronic 2 | H319 H411 | GHS07 GHS09 Achtg. | H319 H411 | |||
612-212-00-6 | 2,6-Dichlor-4-trifluormethylanilin | 416-430-0 | 24279-39-8 | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H332 H302 H315 H317 H410 | |||
612-213-00-1 | Isobutyliden-(2-(2-isopropyl-4,4-dimethyloxazolidin-3-yl)-1,1-dimethylethyl)amin | 419-850-2 | 148348-13-4 | Skin Corr. 1B Aquatic Chronic 3 | H314 H412 | GHS05 Gef. | H314 H412 | |||
612-214-00-7 | 4-(2,2-Diphenylethenyl)- N, N-diphenylbenzenamin | 421-390-2 | 89114-90-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
612-215-00-2 | 3-Chlor-2-(isopropylthio)anilin | 421-700-6 | 179104-32-6 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
612-216-00-8 | 1-Amino-1-cyanamino-2,2-dicyanoethylen, Natriumsalz | 425-870-2 | 19450-38-5 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
612-217-00-3 | 1-Methoxy-2-propylamin | 422-550-4 | 37143-54-7 | Flam. Liq. 2 Skin Corr. 1B Acute Tox. 4 * Aquatic Chronic 3 | H225 H314 H302 H412 | GHS02 GHS05 GHS07 Gef. | H225 H314 H302 H412 | |||
612-219-00-4 | (2-Hydroxy-3-(3,4-dimethyl-9-oxo-10-thiaanthracen-2- yloxy)propyl)trimethylammoniumchlorid | 402-200-7 | - | Aquatic Chronic 3 | H412 | - | H412 | |||
612-220-00-X | N-Nitro- N-(3-methyl-3,6- dihydro-2 H-1,3,5-oxadiazin-4-yl)amin | 431-060-1 | 153719-38-1 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H302 H317 H412 | GHS07 Achtg. | H302 H317 H412 | |||
612-221-00-5 | 2-Amino-4-(trifluormethyl)benzolthiolhydrochlorid | 429-560-8 | 4274-38-8 | Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 | H314 H332 H312 H302 H373** H317 H400 | GHS05 GHS08 GHS07 GHS09 Gef. | H314 H332 H312 H302 H373** H317 H400 | |||
612-222-00-0 | cis-1-(3-(4-Fluorphenoxy)propyl)-3-methoxy-4-piperidinamin | 425-080-8 | 104860-26-6 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H373** H318 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H312 H302 H373** H318 H410 | |||
612-223-00-6 | N-Benzyl- N-ethyl-(4-(5-nitrobenzo[ c]isothiazol-3-ylazo)phenyl)amin | 425-300-2 | 186450-73-7 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
612-224-00-1 | N2, N4, N6-Tris{4-[(1,4-dimethylpentyl)amino]phenyl}-1,3,5-triazin-2,4,6-triamin | 426-150-0 | 121246-28-4 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
612-225-00-7 | 1,4,7,10-Tetraazacyclododecan | 425-450-9 | 294-90-6 | Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H314 H312 H302 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H312 H302 H410 | |||
612-226-00-2 | 3-(2"-Phenoxyethoxy)propylamin | 427-870-8 | 6903-18-0 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H302 H315 H318 H412 | GHS05 GHS07 Gef. | H302 H315 H318 H412 | |||
612-227-00-8 | Benzyl- N-(2-(2-methoxyphenoxy)ethyl)aminhydrochlorid | 428-290-8 | 120606-08-8 | Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H318 H410 | |||
612-228-00-3 | Reaktionsmasse aus N-(3-(Trimethoxysilyl)propyl)ethylendiamin, N-Benzyl-N-(3-(trimethoxysilyl)propyl)ethylendiamin, N-benzyl- N"-[3-(trimethoxysilyl)propyl]ethylendiamin, N, N"-bisbenzyl- N"-[3-(trimethoxysilyl)propyl]ethylendiamin, N, N,N"-trisbenzyl- N"-[3-(trimethoxysilyl)propyl]ethylendiamin und N, N-Bis-benzyl- N"-[3-(trimethoxysilyl)propyl]ethylendiamin | 414-340-6 | - | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H226 H332 H312 H302 H371 H318 H317 H412 | GHS02 GHS05 GHS08 GHS07 Gef. | H226 H332 H312 H302 H371 H318 H317 H412 | |||
612-229-00-9 | Mepanipyrim; 4-Methyl- N-phenyl-6-(1- propynyl)-2-pyrimidinamin | - | 110235-47-7 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
612-230-00-4 | N, N-Bis(cocoyl-2-oxypropyl)- N, N-Dibutylammoniumbromid | 431-530-4 | - | Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H317 H410 | |||
612-231-00-X | 3-((C12-18)-Acylamino)- N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)- N, N-dimethyl-1-propanaminiumchlorid | 427-370-1 | 164288-56-6 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
612-232-00-5 | Reaktionsmasse aus Triisopropanolaminsalzen von 1-Amino-4-(3-propionamidoanilino)anthrachinon-2-sulfonsäure und Triisopropanolaminsalzen von 1-Amino-4-[3,4-dimethyl-5-(2-hydroxyethylaminosulfonyl)anilino]anthrachinon-2-sulfonsäure | 430-410-9 | 186148-38-9 | Aquatic Chronic 3 | H412 | - | H412 | |||
612-237-00-2 | Hydroxylammoniumhydrogensulfat; Hydroxylaminsulfat (1:1) [1]; Hydroxylaminphosphat [2]; Hydroxylamindihydrogenphosphat [3]; Hydroxylamin-4-methylbenzolsulfonat [4] | 233-154-4 [1] 244-077-0 [2] 242-818-2 [3] 258-872-5 [4] | 10046-00-1 [1] 20845-01-6 [2] 19098-16-9 [3] 53933-48-5 [4] | Expl. 1.1 Carc. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H201 H351 H312 H302 H373** H319 H315 H317 H400 | GHS01 GHS08 GHS07 GHS09 Gef. | H201 H351 H312 H302 H373** H319 H315 H317 H400 | T | ||
612-238-00-8 | (3-Chlor-2-hydroxypropyl)trimethylammoniumchlorid ... % | 222-048-3 | 3327-22-8 | Carc. 2 Aquatic Chronic 3 | H351 H412 | GHS08 Achtg. | H351 H412 | B | ||
612-239-00-3 | Biphenyl-3,3", 4,4"-tetrayltetraamin; Diaminobenzidin | 202-110-6 | 91-95-2 | Carc. 1B Muta. 2 | H350 H341 | GHS08 Gef. | H350 H341 | |||
612-240-00-9 | Pyrimethanil (ISO); N-(4,6-Dimethylpyrimidin-2-yl)anilin | - | 53112-28-0 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
612-241-00-4 | Piperazinhydrochlorid [1]; Piperazindihydrochlorid [2]; Piperazinphosphat [3] | 228-042-7 [1] 205-551-2 [2] 217-775-8 [3] | 6094-40-2 [1] 142-64-3 [2] 1951-97-9 [3] | Repr. 2 Eye Irrit. 2 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 | H361fd H319 H315 H334 H317 H412 | GHS08 Gef. | H361fd H319 H315 H334 H317 H412 | |||
612-242-00-X | Cyprodinil (ISO); 4-Cyclopropyl-6-methyl- N- phenylpyrimidin-2-amin | - | 121552-61-2 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | M=10 | ||
612-243-00-5 | (1 S-cis)-4-(3,4-Dichlorphenyl)- 1,2,3,4-tetrahydro- N-methyl-1-naphthalenamin - 2-hydroxy-2-phenylacetat | 420-560-3 | 79617-97-3 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | M=10 | ||
612-244-00-0 | 3-(Piperazin-1-yl)-benzo[d]isothiazolhydrochlorid | 421-310-6 | 87691-88-1 | Repr. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f*** H302 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361f*** H302 H319 H317 H410 | |||
612-245-00-6 | 2-Ethylphenylhydrazinhydrochlorid | 421-460-2 | 19398-06-2 | Carc. 2 STOT RE 1 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H372** H302 H318 H317 H400 H410 | GHS05 GHS08 GHS07 GHS09 Gef. | H351 H372** H302 H318 H317 H410 | M=10 | ||
612-246-00-1 | (2-Chlorethyl)(3-hydroxypropyl)ammoniumchlorid | 429-740-6 | 40722-80-3 | Carc. 1B Muta. 1B STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 | H350 H340 H373** H317 H412 | GHS08 GHS07 Gef. | H350 H340 H373** H317 H412 | |||
612-247-00-7 | N-[3-(1,1-Dimethylethyl)-1 H-pyrazol-5-yl]- N"-hydroxy-4-nitrobenzolcarboximidamid | 423-530-8 | 152828-23-4 | STOT RE 1 Acute Tox. 4 * Aquatic Chronic 3 | H372** H302 H412 | GHS08 GHS07 Gef. | H372** H302 H412 | |||
612-248-00-2 | Reaktionsprodukt von Diphenylamin, Phenothiazin mit Alkenen, verzweigt (C8-10, C9-reich) | 439-540-0 | - | Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 | H315 H317 H413 | GHS07 Achtg. | H315 H317 H413 | |||
612-249-00-8 | 4-[(3-Chlorphenyl)(1 H- imidazol-1-yl)methyl]-1,2-benzoldiamindihydrochlorid | 425-030-5 | 159939-85-2 | Repr. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H361f*** H302 H314 H317 H411 | GHS05 GHS08 GHS07 GHS09 Gef. | H361f*** H302 H314 H317 H411 | |||
612-250-00-3 | Chlor- N, N-dimethylformiminiumchlorid | 425-970-6 | 3724-43-4 | Repr. 1B Acute Tox. 4 * Skin Corr. 1A | H360D*** H302 H314 | GHS05 GHS08 GHS07 Gef. | H360D*** H302 H314 | EUH014 | ||
612-251-00-9 | cis-1-(3-Chlorallyl)-3,5,7-triaza-1-azoniaadamantanchlorid | 426-020-3 | 51229-78-8 | Flam. Sol. 2 Repr. 2 Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H228 H361d*** H302 H315 H317 H411 | GHS02 GHS08 GHS07 GHS09 Achtg. | H228 H361d*** H302 H315 H317 H411 | |||
612-252-00-4 | Imidacloprid (ISO); (E)-1-(6-Chlor-3-pyridylmethyl)- N-nitroimidazolidin-2-ylideneamin; (2 E)-1-[(6-Chlorpyridin-3-yl) methyl]- N-nitroimidazolidin-2-imin | 428-040-8 | 138261-41-3 | Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Dgr | H301 H410 | oral:
ATE = 131 mg/kg KG M = 100 M = 1 000 | ||
612-253-00-X | 7-Methoxy-6-(3-morpholin-4-yl-propoxy)-3 H-chinazolin-4-on; [mit < 0,5 % Formamid (EG-Nr. 200-842-0)] | 429-400-7 | 199327-61-2 | Aquatic Chronic 3 | H412 | - | H412 | |||
612-253-01-7 | 7-Methoxy-6-(3-morpholin-4-yl- propoxy)-3 H-chinazolin-4-on; [mit ≥ 0,5 % Formamid (EG-Nr. 200-842-0)] | 429-400-7 | 199327-61-2 | Repr. 1B Aquatic Chronic 3 | H360D*** H412 | GHS08 Gef. | H360D*** H412 | |||
612-254-00-5 | Reaktionsprodukte von Diisopropanolamin mit Formaldehyd (1:4) | 432-440-8 | 220444-73-5 | Carc. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H351 H302 H314 H317 H411 | GHS05 GHS08 GHS07 GHS09 Gef. | H351 H302 H314 H317 H411 | |||
612-255-00-0 | 1-(3-Methoxypropyl)-4-piperidinamin | 431-950-8 | 179474-79-4 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 3 | H312 H302 H314 H412 | GHS05 GHS07 Gef. | H312 H302 H314 H412 | |||
612-256-00-6 | Benzyl-( S)-2-[(2"-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyrat | 427-470-3 | 137864-22-3 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
612-257-00-1 | Tripropylammoniumdihydrogenphosphat | 433-700-3 | 35687-90-2 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
612-259-00-2 | N-Ethyl-3-trimethoxysilyl-2-methylpropanamin | 437-720-3 | 227085-51-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
612-261-00-3 | 3,5-Dichlor-2-fluor-4-(1,1,2,3,3,3-hexafluorpropoxy)anilin | 441-190-9 | 121451-05-6 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | M=10 | ||
612-265-00-5 | Bis(2-hydroxyethyl)-(2-hydroxypropyl)ammoniumacetat | 444-360-0 | 191617-13-7 | Aquatic Chronic 3 | H412 | - | H412 | |||
612-266-00-0 | 3-Chlor-4-(3-fluorbenzyloxy)anilin | 445-590-4 | 202197-26-0 | Muta. 2 Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H341 H302 H373** H400 H410 | GHS08 GHS07 GHS09 Achtg. | H341 H302 H373** H410 | |||
612-267-00-6 | Bis(hydriertes Talg-C16-C18-Alkyl)hydroxylamin | 418-370-0 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
612-269-00-7 | Reaktionsmasse aus 1-[Di(4-octylphenyl)aminomethyl]-5-methyl-1 H-benzotriazol und 1-[Di(4-octylphenyl)aminomethyl]-4-methyl-1 H-benzotriazol; Reaktionsmasse aus N-[(5-Methyl-1 H-benzotriazol-1-yl)methyl]-4-octyl- N-(4-octylphenyl)anilin und N-[(4-methyl-1 H-benzotriazol-1-yl)methyl]-4-octyl- N-(4-octylphenyl)anilin | 420-720-2 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
612-270-00-2 | (S)-Azetidin-2-carboxylsäure-4-cyanobenzylamidhydrochlorid | 433-010-2 | - | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H302 H317 H412 | GHS07 Achtg. | H302 H317 H412 | |||
612-271-00-8 | Reaktionsmasse aus Ethyl-2-((4- (5,6-dichlorbenzothiazol-2-ylazo)phenyl)ethylamino)benzoat und Ethyl-2-((4-(6,7-dichlorbenzothiazol-2-ylazo)phenyl)ethylamino)benzoat | 434-970-5 | 160987-57-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
612-272-00-3 | Ammonium(η-6-2-(2-(1,2-dicarboxylatoethylamino)ethylamino)butan-1,4-dioato(4-))eisen(3+)monohydrat | 435-210-5 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
612-273-00-9 | Alkyl (Rapsöl), Bis(2-hydroxyethyl)ammoniumfluorid | 435-650-8 | - | Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H314 H410 | |||
612-274-00-4 | (R, S)-1-[2-Amino-1(4-methoxyphenyl)ethyl]cyclohexanolacetat | 445-750-3 | - | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H302 H318 H317 H412 | GHS05 GHS07 Gef. | H302 H318 H317 H412 | |||
612-275-00-X | Fettsäuren, C18-ungesättigt, Dimere, Reaktionsprodukte mit with 1-Piperazinethanamin und Tallöl | 447-880-6 | 206565-89-1 | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H410 | M=10 | ||
612-276-00-5 | 1-Amino-4-[(4-amino-2-sulfofenyl)amino]-9,10-dihydro-9,10- dioxo-2-anthracensulfonsäure, Dinatriumsalz; Reaktionprodukte mit 2-[[3-[(4,6-Dichlor-1,3,5- triazin-2-yl)ethylamino]phenyl]sulfonyl]ethylhydrogensulfat, Natriumsalze | 451-430-4 | 500717-36-2 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
612-277-00-0 | Reaktionsmasse aus 4-Amino-3-(4-ethensulfonyl-2-sulfonatophenylazo)-5-hydroxy-6-(5-{4-chlor-6-[4-(2-sulfonatooxyethansulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)naphthalin-2,7-disulfonat und 4-Amino-5-hydroxy-6-(5-{4-chlor-6-[4-(2-sulfonatooxyethansulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-3-(2-sulfonato-4-(2-sulfonatooxyethansulfonyl)phenylazo)naphthalin-2,7-disulfonat, Kalium/Natrium | 451-440-9 | 586372-44-3 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
612-278-00-6 | Ethidiumbromid; 3,8-Diamino-1-ethyl-6-phenylphenantridiniumbromid | 214-984-6 | 1239-45-8 | Muta. 2 Acute Tox. 2 * Acute Tox. 4 * | H341 H330 H302 | GHS06 GHS08 Gef. | H341 H330 H302 | |||
612-279-00-1 | (R, S)-2-Amino-3,3-dimethylbutanamid | 447-860-7 | 144177-62-8 | Repr. 2 STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H361f*** H373** H319 H315 H317 | GHS08 GHS07 Achtg. | H361f*** H373** H319 H315 H317 | |||
612-280-00-7 | 3-Amino-9-ethylcarbazol; 9-Ethylcarbazol-3-ylamin | 205-057-7 | 132-32-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
612-281-00-2 | Leukomalachitgrün; N, N,N",N"-Tetramethyl-4,4"-benzylidendianilin | 204-961-9 | 129-73-7 | Carc. 2 Muta. 2 | H351 H341 | GHS08 Achtg. | H351 H341 | |||
612-282-00-8 | Octadecylamin | 204-695-3 | 124-30-1 | Asp. Tox. 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H304 H373 (Magen- Darm-Trakt, Leber, Immunsystem) H315 H318 H400 H410 | GHS05 GHS08 GHS09 Gef. | H304 H373 (Magen- Darm-Trakt, Leber, Immunsystem) H315 H318 H410 | M = 10 M = 10 | ||
612-283-00-3 | (Z)-Octadec-9-enylamin | 204-015-5 | 112-90-3 | Acute Tox. 4 Asp Tox. 1 STOT SE 3 STOT RE 2 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H302 H304 H335 H373 (Magen- Darm-Trakt, Leber, Immunsystem) H314 H400 H410 | GHS05 GHS07 GHS08 GHS09 Gef. | H302 H304 H335 H373 (Magen- Darm-Trakt, Leber, Immunsystem) H314 H410 | M = 10 M = 10 | ||
612-284-00-9 | Amine, hydriertes Talgalkyl | 262-976-6 | 61788-45-2 | Asp Tox. 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H304 H373 (Magen- Darm-Trakt, Leber, Immunsystem) H315 H318 H400 H410 | GHS08 GHS05 GHS09 Gef. | H304 H373 (Magen- Darm-Trakt, Leber, Immunsystem) H315 H318 H410 | M = 10 M = 10 | ||
612-285-00-4 | Amine, Kokosalkyl | 262-977-1 | 61788-46-3 | Acute Tox. 4 Asp. Tox. 1 STOT SE 3 STOT RE 2 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H302 H304 H335 H373 (Magen- Darm-Trakt, Leber, Immunsystem) H314 H400 H410 | GHS05 GHS07 GHS08 GHS09 Gef. | H302 H304 H335 H373 Magen- Darm-Trakt, Leber, Immunsystem) H314 H410 | M = 10 M = 10 | ||
612-286-00-X | Amine, Talgalkyl | 263-125-1 | 61790-33-8 | Acute Tox. 4 Asp. Tox. 1 STOT RE 2 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H302 H304 H373 (Magen- Darm-Trakt, Leber, Immunsystem) H314 H400 H410 | GHS05 GHS07 GHS08 GHS09 Gef. | H302 H304 H373 Magen- Darm-Trakt, Leber, Immunsystem) H314 H410 | M = 10 M = 10 | ||
612-287-00-5 | Fluazinam (ISO); 3-Chlor- N-[3-chlor-2,6-dinitro-4-(trifluormethyl)phenyl]-5-(trifluormethyl)pyridin-2-amin | - | 79622-59-6 | Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H361d H332 H318 H317 H400 H410 | GHS08 GHS07 GHS05 GHS09 Gef. | H361d H332 H318 H317 H410 | M = 10 M = 10 | ||
612-288-00-0 | Bupirimat (ISO); 5-Butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulfamat | 255-391-2 | 41483-43-6 | Carc. 2 Skin Sens. 1B Aquatic Chronic 1 | H351 H317 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H317 H410 | M = 1 | ||
612-289-00-6 | Triflumizol (ISO); (1 E)- N-[4-Chlor-2-(trifluormethyl)phenyl]-1-(1 H-imidazol-1-yl)-2-propoxyethanimin | - | 68694-11-1 | Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H302 H373 (Leber) H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H360D H302 H373 (Leber) H317 H410 | M = 1 M = 1 | ||
612-290-00-1 | Reaktionsprodukte von Paraformaldehyd und 2-Hydroxypropylamin (Verhältnis 3:2); [aus 3,3"-Methylenbis[5-methyloxazolidin freigesetztes Formaldehyd] [aus Oxazolidin freigesetztes Formaldehyd]; [MBO] | - | - | Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 3 Acute Tox. 4 STOT RE 2 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2 | H350 H341 H332 H311 H302 H373 (Magen-Darm-Trakt, Atemwege) H314 H318 H317 H411 | GHS08 GHS06 GHS05 GHS09 Gef. | H350 H341 H332 H311 H302 H373 (Magen-Darm-Trakt, Atemwege) H314 H317 H411 | EUH071 | 8 9 | |
612-291-00-7 | Reaktionsprodukte von Paraformaldehyd und 2-Hydroxypropylamin (Verhältnis 1: 1); [aus α,α,α-Trimethyl-1,3,5-triazin-1,3,5 (2H,4H,6H)-triethanol freigesetztes Formaldehyd]; [HPT] | - | - | Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2 | H350 H341 H332 H302 H373 (Magen-Darm-Trakt, Atemwege) H314 H318 H317 H411 | GHS08 GHS07 GHS05 GHS09 Gef. | H350 H341 H332 H302 H373 (Magen-Darm-Trakt, Atemwege) H314 H317 H411 | EUH071 | 8 9 | |
612-292-00-2 | Methylhydrazin | 200-471-4 | 60-34-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
612-293-00-8 | Reaktionsmasse aus 1-[2-(2-Aminobutoxy)ethoxy]but-2-ylamin und 1-({[2-(2-Aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamin | 447-920-2 | - | Repr. 2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 | H361f H302 H314 H318 | GHS08 GHS07 GHS05 Dgr | H361f H302 H314 | EUH071 | ||
612-294-00-3 | Mecetroniumetilsulfat; N-ethyl- N,N-dimethylhexadecan-1-aminiumethylsulfat; Mecetroniumethylsulfat; [MES] | 221-106-5 | 3006-10-8 | Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H318 H400 H410 | GHS05 GHS09 Dgr | H314 H410 | EUH071 | M = 100 M = 1000 | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
612-295-00-9 | Benfluralin (ISO); N-Butyl- N-ethyl-α,α-trifluor-2,6-dinitro-p-toluidin; | 217-465-2 | 1861-40-1 | Carc. 2 Repr. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d H315 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361d H315 H319 H317 H410 | M = 10 M = 10 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
612-296-00-4 | N,N-Dimethyl-p-toluidin | 202-805-4 | 99-97-8 | Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 | H350 H332 H301 H373 (Blutkreislauf, Atemwege) H412 | GHS08 GHS06 Dgr | H350 H332 H301 H373 (Blutkreislauf, Atemwege) H412 | Inhalation: ATE = 1,4 mg/L (Stäube oder Nebel) Oral: ATE = 140 mg/kg KG | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
612-297-00-X | 1-Phenylethan-1-on (1-Phenylethyliden)hydrazon | 211-979-0 | 729-43-1 | Skin Sens. 1 | H317 | GHS07 Wng | H317 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
612-298-00-5 | 1,4-Benzoldiamin, N,N"-gemischte Ph und Tolylderivate | 273-227-8 | 68953-84-4 | Repr. 1B Skin Sens. 1 | H360FD H317 | GHS08 GHS07 Dgr | H360FD H317 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
612-299-00-0 | Fenpropidin (ISO); ( R, S)-1-[3-(4-tert-Butylphenyl)-2-methylpropyl]piperidin | - | 67306-00-7 | Repr. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d H332 H302 H335 H336 H373 (Nervensystem, Augen, Lunge) H315 H318 H317 H400 H410 | GHS08 GHS07 GHS05 GHS09 Dgr | H361d H332 H302 H335 H336 H373 (Nervensystem, Augen, Lunge) H315 H318 H317 H410 | Einatmung:
ATE = 1,2 mg/L (Stäube oder Nebel) Oral: ATE = 1.330 mg/kg KG M = 1.000 M = 10.000 | ) | |
613-001-00-1 | Ethylenimin; Aziridin | 205-793-9 | 151-56-4 | Flam. Liq. 2 Carc. 1B Muta. 1B Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Corr. 1B Aquatic Chronic 2 | H225 H350 H340 H330 H310 H300 H314 H411 | GHS02 GHS06 GHS08 GHS05 GHS09 Gef. | H225 H350 H340 H330 H310 H300 H314 H411 | D | ||
613-002-00-7 | Pyridin | 203-809-9 | 110-86-1 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H225 H332 H312 H302 | GHS02 GHS07 Gef. | H225 H332 H312 H302 | * | ||
613-003-00-2 | 1,2,3,4-Tetranitrocarbazol | - | 6202-15-9 | Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * | H201 H332 H312 H302 | GHS01 GHS07 Gef. | H201 H332 H312 H302 | |||
613-004-00-8 | Crimidin (ISO); 2-Chlor-6-methylpyrimidin-4-yldimethylamin | 208-622-6 | 535-89-7 | Acute Tox. 2 * | H300 | GHS06 Gef. | H300 | |||
613-007-00-4 | Desmetryn (ISO); 6-Isopropylamino-2-methylamino-4-methylthio-1,3,5- triazin | 213-800-1 | 1014-69-3 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
613-008-00-X | Dazomet (ISO); Tetrahydro-3,5-dimethyl-1,3,5- thiadiazin-2-thion | 208-576-7 | 533-74-4 | Acute Tox. 4 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H410 | |||
613-009-00-5 | 2,4,6-Trichlor-1,3,5-triazin; Cyanurchlorid | 203-614-9 | 108-77-0 | Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 | H330 H302 H314 H317 | GHS06 GHS05 Gef. | H330 H302 H314 H317 | EUH014 | STOT SE 3; H335: C ≥ 5 % | |
613-010-00-0 | Ametryn (ISO); N-Ethyl- N"-isopropyl-6-(methylthio)-1,3,5-triazin-2,4-diamin | 212-634-7 | 834-12-8 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M = 100 | ||
613-011-00-6 | Amitrol (ISO); 1,2,4-triazol-3-ylamin | 200-521-5 | 61-82-5 | Repr. 2 STOT RE 2 * Aquatic Chronic 2 | H361d *** H373 ** H411 | GHS08 GHS09 Achtg. | H361d *** H373 ** H411 | |||
613-012-00-1 | Bentazon (ISO); 3-Isopropyl-2,1,3-benzothiadiazin-4-on-2,2-dioxid | 246-585-8 | 25057-89-0 | Repr. 2 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1 | H361d H302 H319 H317 | GHS08 GHS07 Wng | H361d H302 H319 H317 | Oral: ATE = 1.600 mg/kg KG | ||
613-013-00-7 | Cyanazin (ISO); 2-(4-Chlor-6-ethylamino-1,3,5-triazin-2-ylamino)-2-methylpropionitril | 244-544-9 | 21725-46-2 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-014-00-2 | Ethoxyquin (ISO); 6-Ethoxy-1,2-dihydro-2,2,4-trimethylinolin | 202-075-7 | 91-53-2 | Acute Tox. 4* | H302 | GHS07 Achtg. | H302 | |||
613-015-00-8 | Fenazaflor (ISO); Phenyl-5,6-dichlor-2-trifluormethylbenzimidazol-1-carboxylat | 238-134-9 | 14255-88-0 | Acute Tox. 4* Acute Tox. 4* Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
613-016-00-3 | Fuberidazol (ISO); 2-(2-Furyl)-1 H-benzimidazol | 223-404-0 | 3878-19-1 | Carc. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H373 (Herz) H317 H400 H410 | GHS07 GHS08 GHS09 Achtg. | H351 H302 H373 (Herz) H317 H410 | M = 1 | ||
613-017-00-9 | Bis(8-hydroxyquinolinium)sulfat | 205-137-1 | 134-31-6 | Acute Tox. 4* | H302 | GHS07 Achtg. | H302 | |||
613-018-00-4 | Morfamquat (ISO); 1,1"-Bis(3,5-dimethylmorpholinocarbonylmethyl)-4,4"-bipyridiliumion | 7411-47-4 | Acute Tox. 4* Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 3 | H302 H319 H335 H315 H412 | GHS07 Achtg. | H302 H319 H335 H315 H412 | ||||
613-019-00-X | Thioquinox(ISO); 2-Thio-1,3-dithiolo(4,5,b)chinoxalin | 202-272-8 | 93-75-4 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
613-020-00-5 | Tridemorph (ISO); 2,6-Dimethyl-4-tridecylmorpholin | 246-347-3 | 24602-86-6 | Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H360D *** H332 H302 H315 H400 H410 | GHS08 GHS07 GHS09 Gef. | H360D *** H332 H302 H315 H410 | |||
613-021-00-0 | Dithianon (ISO); 5,10-Dihydro-5,10-dioxonaphtho(2,3-b)(1,4)dithiazin-2,3-dicarbonitril | 222-098-6 | 3347-22-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-022-00-6 | Pyrethrine, einschließlich Cinerine, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | A | ||
613-023-00-1 | 2-Methyl-4-oxo-3-(penta-2,4- dienyl)cyclopent-2-enyl[1 R-[1α[ S*( Z)], 3β]]chrysanthemat; Pyrethrin I | 204-455-8 | 121-21-1 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | |||
613-024-00-7 | 2-Methyl-4-oxo-3-(penta-2,4-dienyl)cyclopent-2-enyl[1 R-[1α[ S*( Z)](3β)]]-3-(3-methoxy-2-methyl-3-oxoprop-1-enyl)-2,2-dimethylcyclopropancarboxylat; Pyrethrin II | 204-462-6 | 121-29-9 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | |||
613-025-00-2 | Cinerin I; 3-(But-2-enyl)-2-methyl-4-oxocyclopent-2-enyl-2,2- dimethyl-3-(2-methylprop-1-enyl)cyclopropancarboxylat | 246-948-0 | 25402-06-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-026-00-8 | Cinerin II; 3-(But-2-enyl)-2-methyl-4-oxocyclopent-2-enyl 2,2-dimethyl-3-(3-methoxy-2-methyl-3-oxoprop-1-enyl)cyclopropancarboxylat | 204-454-2 | 121-20-0 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-027-00-3 | Piperidin | 203-813-0 | 110-89-4 | Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B | H225 H331 H311 H314 | GHS02 GHS06 GHS05 Gef. | H225 H331 H311 H314 | * | ||
613-028-00-9 | Morpholin | 203-815-1 | 110-91-8 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H226 H332 H312 H302 H314 | GHS02 GHS05 GHS07 Dg | H226 H332 H312 H302 H314 | |||
613-029-00-4 | Dichlor-1,3,5-triazintrion; Dichlorisocyanursäure; Troclosen | 220-487-5 | 2782-57-2 | Ox. Sol. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H272 H302 H319 H335 H400 H410 | GHS03 GHS07 GHS09 Gef. | H272 H302 H319 H335 H410 | EUH031 | T | |
613-030-00-X | Troclosenkalium [1]; Troclosennatrium [2] | 218-828-8 [1] 220-767-7 [2] | 2244-21-5 [1] 2893-78-9 [2] | Ox. Sol. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H272 H302 H319 H335 H400 H410 | GHS03 GHS07 GHS09 Gef. | H272 H302 H319 H335 H410 | EUH031 | * STOT SE 3; H335: C ≥ 10 % EUH031: C ≥10 % | G |
613-030-01-7 | Troclosennatrium, dihydrat | 220-767-7 | 51580-86-0 | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H335 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H335 H410 | EUH031 | ||
613-031-00-5 | Symclosen; Trichlorisocyanursäure; Trichlor-1,3,5-triazintrion | 201-782-8 | 87-90-1 | Ox. Sol. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H272 H302 H319 H335 H400 H410 | GHS03 GHS07 GHS09 Gef. | H272 H302 H319 H335 H410 | EUH031 | ||
613-032-00-0 | Methyl-2,3,5,6-tetrachlor-4-pyridylsulphon; 2,3,5,6-Tetrachlor-4-(methylsulphonyl)pyridin | 236-035-5 | 13108-52-6 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 | H312 H302 H319 H317 | GHS07 Achtg. | H312 H302 H319 H317 | |||
613-033-00-6 | 2-Methylaziridin; Propylenimin | 200-878-7 | 75-55-8 | Flam. Liq. 2 Carc. 1B Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Eye Dam. 1 Aquatic Chronic 2 | H225 H350 H330 H310 H300 H318 H411 | GHS02 GHS06 GHS08 GHS05 GHS09 Gef. | H225 H350 H330 H310 H300 H318 H411 | Carc. 1B; H350: C ≥ 0,01 % | ||
613-034-00-1 | 1,2-Dimethylimidazol | 217-101-2 | 1739-84-0 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 | H302 H315 H318 | GHS05 GHS07 Gef. | H302 H315 H318 | |||
613-035-00-7 | 1-Methylimidazol | 210-484-7 | 616-47-7 | Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B | H312 H302 H314 | GHS05 GHS07 Gef. | H312 H302 H314 | |||
613-036-00-2 | 2-Methylpyridin; 2-Picolin | 203-643-7 | 109-06-8 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 | H226 H332 H312 H302 H319 H335 | GHS02 GHS07 Achtg. | H226 H332 H312 H302 H319 H335 | |||
613-037-00-8 | 4-Methylpyridin; 4-Picolin | 203-626-4 | 108-89-4 | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H226 H311 H332 H302 H319 H335 H315 | GHS02 GHS06 Gef. | H226 H311 H332 H302 H319 H335 H315 | |||
613-038-00-3 | 6-Phenyl-1,3,5-triazin-2,4-diyldiamin; 6-Phenyl-1,3,5-triazin-2,4-diamin; Benzoguanamin | 202-095-6 | 91-76-9 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
613-039-00-9 | Eethylenthioharnstoff; Imidazolidin-2-thion; 2-Imidazolin-2-thiol | 202-506-9 | 96-45-7 | Repr. 1B Acute Tox. 4 * | H360D *** H302 | GHS08 GHS07 Gef. | H360D *** H302 | |||
613-040-00-4 | Azaconazol (ISO); 1-{[2-(2,4-Dichlorphenyl)-1,3-dioxolan-2-yl]methyl}-1 H-1,2.4-triazol | 262-102-3 | 60207-31-0 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
613-041-00-X | Morpholin-4-carbonylchlorid; N-Chlorformylmorpholin | 239-213-0 | 15159-40-7 | Carc. 2 Eye Irrit. 2 Skin Irrit. 2 | H351 H319 H315 | GHS08 Achtg. | H351 H319 H315 | EUH014 | ||
613-042-00-5 | Imazalil (ISO); 1-[2-(Allyloxy)-2-(2,4-dichlorphenyl)ethyl]-1 H-imidazol | 252-615-0 | 35554-44-0 | Carc. 2 Acute Tox. 3 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 1 | H351 H301 H332 H318 H410 | GHS08 GHS06 GHS05 GHS09 Gef. | H351 H301 H332 H318 H410 | M = 10 | ||
613-043-00-0 | Imazalilsulfat (ISO), Pulver; 1-[2-(Allyloxy)ethyl-2-(2,4-dichlorphenyl)]-1 H-imidazoliumhydrogensulfat [1]; (±)-1-[2-(Allyloxy)ethyl-2-(2,4-dichlorphenyl)]-1 H-imidazoliumhydrogensulfat [2]; | 261-351-5 [1] 281-291-3 [2] | 58594-72-2 [1] 83918-57-4 [2] | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
613-043-01-8 | Imazalilsulfat (ISO), wässrige Lösung; 1-[2-(Allyloxy)ethyl-2-(2,4-dichlorphenyl)]-1 H-imidazoliumhydrogensulfat [1]; (±)-1-[2-(Allyloxy)ethyl-2-(2,4-dichlorphenyl)]-1 H-imidazoliumhydrogensulfat [2]; | 261-351-5 [1] 281-291-3 [2] | 58594-72-2 [1] 83918-57-4 [2] | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H317 H400 H410 | GHS05 GHS07 GHS09 Achtg. | H302 H314 H317 H410 | Skin Corr. 1B; H314: C ≥ 50 % Skin Irrit. 2; H315: 30 % ≤ C < 50 % Eye Dam. 1; H318: 15 % ≤ C < 50 % Eye Irrit. 2; H319: 5 % ≤ C < 15 % | ||
613-044-00-6 | Captan (ISO); 1,2,3,6-Tetrahydro- N-(trichlormethylthio)phthalimid | 205-087-0 | 133-06-2 | Carc. 2 Acute Tox. 3 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 | H351 H331 H318 H317 H400 | GHS06 GHS05 GHS08 GHS09 Gef. | H351 H331 H318 H317 H400 | M=10 | ||
613-045-00-1 | Folpet (ISO); N-(Trichlormethylthio)phthalimid | 205-088-6 | 133-07-3 | Carc. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H351 H332 H319 H317 H400 | GHS08 GHS07 GHS09 Achtg. | H351 H332 H319 H317 H400 | M=10 | ||
613-046-00-7 | Captafol (ISO); 1,2,3,6-Tetrahydro- N-(1,1,2,2-tetrachlorethylthio)phthalimid | 219-363-3 | 2425-06-1 | Carc. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H350 H317 H400 H410 | GHS08 GHS09 Gef. | H350 H317 H410 | |||
613-047-00-2 | 1-Dimethylcarbamoyl-5-methylpyrazol-3-yldimethylcarbamat; Dimetilan (ISO) | 211-420-0 | 644-64-4 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H312 H400 H410 | GHS06 GHS09 Gef. | H301 H312 H410 | |||
613-048-00-8 | Carbendazim (ISO); Methylbenzimidazol-2-ylcarbamat | 234-232-0 | 10605-21-7 | Muta. 1B Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H340 H360FD H317 H400 H410 | GHS07 GHS08 GHS09 Dgr | H340 H360FD H317 H410 | M = 10 M = 10 | ||
613-049-00-3 | Benomyl (ISO); Methyl-1-(butylcarbamoyl)benzimidazol-2-ylcarbamat | 241-775-7 | 17804-35-2 | Muta. 1B Repr. 1B STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H340 H360FD H335 H315 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H340 H360FD H335 H315 H317 H410 | M = 10 | ||
613-050-00-9 | Carbadox (INN); Methyl-3-(chinoxalin-2-ylmethylen)carbazat-1,4-dioxid; 2-(Methoxycarbonylhydrazonomethyl)chinoxalin-1,4-dioxid | 229-879-0 | 6804-07-5 | Flam. Sol. 1 Carc. 1B Acute Tox. 4 * | H228 H350 H302 | GHS02 GHS08 GHS07 Gef. | H228 H350 H302 | T | ||
613-051-00-4 | Molinat (ISO); S-ethyl-1-perhydroazepincarbothioat; S-ethyl-perhydroazepin-1-carbothioat | 218-661-0 | 2212-67-1 | Carc. 2 Repr. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361f *** H332 H302 H373 ** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H361f *** H332 H302 H373 ** H317 H410 | M = 100 | ||
613-052-00-X | Trifenmorph (ISO); 4-Tritylmorpholin | 215-812-2 | 1420-06-0 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-053-00-5 | Anilazin (ISO); 2-Chlor- N-(4,6-dichlor-1,3,5-triazin-2-yl)anilin | 202-910-5 | 101-05-3 | Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H315 H400 H410 | GHS07 GHS09 Achtg. | H319 H315 H410 | |||
613-054-00-0 | Thiabendazol (ISO); 2-(Thiazol-4-yl)benzimidazol | 205-725-8 | 148-79-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1 | ||
613-056-00-1 | 1,2-Dimethyl-3,5-diphenylpyrazoliummethylsulfat; Difenzoquatmethylsulfat; Difenzoquat-methylsulfat (ISO) | 256-152-5 | 43222-48-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS09 Achtg. | H302 H410 | |||
613-057-00-7 | Dodemorph (ISO); 4-Cyclododecyl-2,6-dimethylmorpholin | 216-474-9 | 1593-77-7 | Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (Leber) H314 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H361d H373 (Leber) H314 H317 H410 | EUH071 | M = 1 M = 1 | |
613-058-00-2 | Permethrin (ISO); m-Phenoxybenzyl 3-(2,2-dichlorvinyl)-2,2-dimethylcyclopropancarboxylat | 258-067-9 | 52645-53-1 | Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H332 H302 H317 H410 | M = 1 000 | ||
613-059-00-8 | Profluralin (ISO); N-(Cyclopropylmethyl)-α, α,α-trifluor-2,6-dinitro- N-propyl- p-toluidin | 247-656-6 | 26399-36-0 | Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H400 H410 | GHS07 GHS09 Achtg. | H319 H410 | |||
613-060-00-3 | Resmethrin (ISO); 5-Benzyl-3-furylmethyl (±)- cis-transchrysanthemat | 233-940-7 | 10453-86-8 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M=1000 | ||
613-061-00-9 | 6-(1α,5aβ,8aβ,9-Pentahydroxy-7β-isopropyl-2β,5β,8β-trimethylperhydro-8bα,9-epoxy-5,8-ethanocyclopenta[1,2-b]indenyl)pyrrol-2-carboxylat; Ryania | 239-732-2 | 15662-33-6 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
613-062-00-4 | Sabadilla (ISO); Veratrin | - | 8051-02-3 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H319 H335 H315 | GHS07 Achtg. | H319 H335 H315 | |||
613-063-00-X | Secbumeton (ISO); 2-Secbutylamino-4-ethylamino-6-methoxy-1,3,5-triazin | 247-554-1 | 26259-45-0 | Acute Tox. 4 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H410 | |||
613-064-00-5 | 5-(3,6,9-Trioxa-2-undecyloxy)benzo(d)-1,3-dioxolan; Sesamex | - | 51-14-9 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
613-065-00-0 | Simetryn (ISO); 2,4-Bis(ethylamino)-6-methylthio-1,3,5-triazin | 213-801-7 | 1014-70-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-066-00-6 | Terbumeton (ISO); 2- tert-Butylamino-4-ethylamino-6-methoxy-1,3,5-triazin | 251-637-8 | 33693-04-8 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-067-00-1 | Propazin (ISO); 2-Chlor-4,6-bis(isopropylamino)-1,3,5-triazin | 205-359-9 | 139-40-2 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
613-068-00-7 | Atrazin (ISO); 2-Chlor-4-ethylamin-6-isopropylamin-1,3,5-triazin | 217-617-8 | 1912-24-9 | STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H317 H400 H410 | GHS08 GHS09 Achtg. | H373 ** H317 H410 | |||
613-069-00-2 | ε-Caprolactam | 203-313-2 | 105-60-2 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 | H332 H302 H319 H335 H315 | GHS07 Achtg. | H332 H302 H319 H335 H315 | |||
613-070-00-8 | Propylenthioharnstoff | - | 2122-19-2 | Repr. 2 Acute Tox. 4 * Aquatic Chronic 3 | H361d *** H302 H412 | GHS08 GHS07 Achtg. | H361d *** H302 H412 | |||
613-071-00-3 | 2-Fluor-5-trifluormethylpyridin | 400-290-2 | 69045-82-5 | Flam. Liq. 3 Skin Sens. 1 Aquatic Chronic 3 | H226 H317 H412 | GHS02 GHS07 Achtg. | H226 H317 H412 | |||
613-072-00-9 | N, N-Bis(2-ethylhexyl)-((1,2,4-triazol-1-yl)methyl)amin | 401-280-0 | 91273-04-0 | Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H314 H317 H411 | GHS05 GHS07 GHS09 Gef. | H314 H317 H411 | |||
613-073-00-4 | N, N-Dimethyl-2-(3-(4-chlorphenyl)-4,5-dihydropyrazol-1-ylphenylsulfonyl)ethylamin | 401-410-6 | 10357-99-0 | STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H373 ** H317 H411 | GHS08 GHS09 Achtg. | H373 ** H317 H411 | |||
613-074-00-X | 3-(3-methylpent-3-yl)isoxazol-5-ylamine | 401-460-9 | 82560-06-3 | Acute Tox. 3 * Acute Tox. 3 * Eye Dam. 1 Aquatic Chronic 3 | H331 H301 H318 H412 | GHS06 GHS05 Gef. | H331 H301 H318 H412 | |||
613-075-00-5 | 1,3-Dichlor-5-ethyl-5-methylimidazolidin-2,4-dion | 401-570-7 | 89415-87-2 | Ox. Sol. 1 **** Acute Tox. 3 * Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 | H271 H331 H314 H302 H317 H400 | GHS03 GHS06 GHS05 GHS09 Gef. | H271 H331 H314 H302 H317 H400 | |||
613-076-00-0 | 3-Chlor-5-trifluormethyl-2-pyridylamin | 401-670-0 | 79456-26-1 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
613-077-00-6 | Reaktionsmasse aus 5-Heptyl-1,2,4-triazol-3-ylamin und 5-Nonyl-1,2,4-triazol-3-ylamin | 401-940-8 | - | Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 2 | H302 H319 H411 | GHS07 GHS09 Achtg. | H302 H319 H411 | |||
613-078-00-1 | N, N, N, N-Tetrakis(4,6-bis(butyl-( N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecan-1,10-diamin | 401-990-0 | 106990-43-6 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
613-079-00-7 | 4-(1(oder 4 oder 5 oder 6)-Methyl-8,9,10-trinorborn-5-en-2-yl)pyridin, Reaktionsmasse aus Isomeren | 402-520-7 | - | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H315 H317 H410 | |||
613-080-00-2 | 3-(Bis(2-ethylhexyl)aminomethyl)benzothiazol-2(3 H)-thion | 402-540-6 | 105254-85-1 | Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H317 H410 | |||
613-081-00-8 | 1-Butyl-2-methylpyridiniumbromid | 402-680-8 | 26576-84-1 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
613-082-00-3 | 2-Methyl-1-pentylpyridiniumbromid | 402-690-2 | - | Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H312 H302 H412 | GHS07 Achtg. | H312 H302 H412 | |||
613-083-00-9 | 2-(4-(3-(4Chlorphenyl)-2-pyrazolin-1-yl)phenylsulfonyl)ethyldimethylammoniumformat | 402-120-2 | - | Skin Corr. 1B STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H373 ** H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H314 H373 ** H317 H410 | |||
613-084-00-4 | 2-(4-(3-(4-Chlorphenyl)-4,5-dihydropyrazolyl)phenylsulphonyl)ethyldimethylammomiumhydrogenphosphonat | 402-490-5 | 106359-93-7 | Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H400 H410 | GHS07 GHS09 Achtg. | H319 H410 | |||
613-085-00-X | Reaktionsmass e aus 1,1"-(Methylenbis(4,1-phenylen))dipyrrol-2,5-dion, N-(4-(4-(2,5-Dioxopyrrol-1-)benzyl)phenyl)acetamid und 1-(4-(4-(5-Oxo-2 H-2-furylidinamino)benzyl)phenyl)pyrrol-2,5-dion | 401-970-1 | - | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
613-086-00-5 | Caffein; Coffein | 200-362-1 | 58-08-2 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
613-087-00-0 | Tetrahydrothiophen | 203-728-9 | 110-01-0 | Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3 | H225 H332 H312 H302 H319 H315 H412 | GHS02 GHS07 Gef. | H225 H332 H312 H302 H319 H315 H412 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
613-088-00-6 | 1,2-Benzisothiazol-3(2 H)-on; 1,2-Benzisothiazolin-3-on | 220-120-9 | 2634-33-5 | Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 | H302 H315 H318 H317 H400 | GHS05 GHS07 GHS09 Gef. | H302 H315 H318 H317 H400 | Skin Sens. 1; H317: C≥0,05 % | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
613-088-00-6 | 1,2-Benzisothiazol-3(2H)-on; 1,2-Benzisothiazolin-3-on | 220-120-9 | 2634-33-5 | Acute Tox. 2 Acute Tox. 4 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H315 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H302 H315 H318 H317 H410 | Inhalation: ATE = 0,21 mg/L (Stäube oder Nebel) Oral: ATE = 450 mg/kg KG Skin Sens. 1A; H317: C ≥ 0,036 % M = 1 M = 1 | ) | |
613-089-00-1 | Diquatdibromid [1]; Diquatdichlorid [2]; 6,7-Dihydrodipyrido[1,2-α:2",1"- c]pyrazindiylium dihydroxid [3] | 201-579-4 [1] 223-714-6 [2] 301-467-6 [3] | 85-00-7 [1] 4032-26-2 [2] 94021-76-8 [3] | Acute Tox. 2 * STOT RE 1 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H372 ** H302 H319 H335 H315 H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H372 ** H302 H319 H335 H315 H317 H410 | |||
613-090-00-7 | Paraquatdichlorid; 1,1-Dimethyl-4,4"-bipyridiniumdichlorid [1]; Paraquatdimethylsulfat; 1,1-Dimethyl-4,4"-bipyridiniumdimethylsulfat [2] | 217-615-7 [1] 218-196-3 [2] | 1910-42-5 [1] 2074-50-2 [2] | Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H330 H311 H301 H372 ** H319 H335 H315 H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H311 H301 H372 ** H319 H335 H315 H410 | |||
613-091-00-2 | Morfamquatdichlorid (ISO)[1]; Morfamquatsulfat (ISO)[2] | 225-062-8 [1] [2] | 4636-83-3 [1] 29873-36-7 [2] | Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 3 | H302 H319 H335 H315 H412 | GHS07 Achtg. | H302 H319 H335 H315 H412 | |||
613-092-00-8 | 1,10-Phenanthrolin | 200-629-2 | 66-71-7 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H410 | |||
613-093-00-3 | Hexanatrium-6,13-dichlor-3,10-bis((4-(2,5-disulfonatoanilino)-6-fluor-1,3,5-triazin-2- ylamino)prop-3-ylamino)-5,12-dioxa-7,14-diazapentacen-4,11-disulfonat | 400-050-7 | 85153-92-0 | Resp. Sens. 1 Skin Sens. 1 | H334 H317 | GHS08 Gef. | H334 H317 | |||
613-094-00-9 | 4-Methoxy- N,6-dimethyl-1,3,5-triazin-2-ylamin | 401-360-5 | 5248-39-5 | Acute Tox. 4 * STOT RE 2 * | H302 H373 ** | GHS08 GHS07 Achtg. | H302 H373 ** | |||
613-095-00-4 | Natrium-3-(2 H-benzotriazol-2-yl)-5- sec-butyl-4-hydroxybenzolsulfonat | 403-080-9 | 92484-48-5 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-096-00-X | 2-Amino-6-ethoxy-4-methylamino-1,3,5-triazin | 403-580-7 | 62096-63-3 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
613-097-00-5 | 7-Amino-3-((5-carboxymethyl-4-methyl-1,3-thiazol-2-ylthio)methyl)-8-oxo-5-thia-1-zabicyclo(4,2,0)oct-2-en-2-carboxylsäure | 403-690-5 | 111298-82-9 | Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 | H334 H317 H412 | GHS08 Gef. | H334 H317 H412 | |||
613-098-00-0 | N-( n-Octyl)-2-pyrrolidon | 403-700-8 | 2687-94-7 | Skin Corr. 1B Aquatic Chronic 2 | H314 H411 | GHS05 GHS09 Gef. | H314 H411 | |||
613-099-00-6 | 1-Dodecyl-2-pyrrolidon | 403-730-1 | 2687-96-9 | Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H317 H410 | |||
613-100-00-X | 2,9-Bis(3-(diethylamino)propylsulfamoyl)chino(2,3- b)acridin-7,14-dion | 404-230-6 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
613-101-00-5 | N-tert-Pentyl-2-benzothiazolsulfonamid | 404-380-2 | 110799-28-5 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
613-102-00-0 | Dimethomorph (ISO); (E, Z)-4-(3-(4-Chlorphenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholin | 404-200-2 | 110488-70-5 | Repr. 1B Aquatic Chronic 2 | H360F H411 | GHS08 GHS09 Dgr | H360F H411 | |||
613-103-00-6 | Natrium-5- n-butylbenzotriazol | 404-450-2 | 118685-34-0 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H302 H314 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H314 H317 H411 | |||
613-104-00-1 | 5- tert-Butyl-3-isoxazolylaminhydrochlorid | 404-840-2 | - | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Aquatic Chronic 3 | H302 H373 ** H318 H412 | GHS08 GHS05 GHS07 Gef. | H302 H373 ** H318 H412 | |||
613-105-00-7 | Hexakis(tetramethylammonium)-4,4"-vinylenbis((3-sulfonato-4,1-phenylen)imino(6-morpholino-1,3,5-triazin-4,2-diyl)imino)bis(5-hydroxy-6- phenylazonaphthalin-2,7-disulfonat) | 405-160-9 | 124537-30-0 | Acute Tox. 3 * Skin Sens. 1 Aquatic Chronic 3 | H301 H317 H412 | GHS06 Gef. | H301 H317 H412 | |||
613-106-00-2 | Tetrakalium 2-(4-(5-(1-(2,5-disulfonatophenyl)-3-ethoxycarbonyl-5-hydroxypyrazol-4-yl)penta-2,4-dienyliden)-3-ethoxycarbonyl-5-oxo-2-pyrazolin-1-yl)benzol-1,4-disulfonat | 405-240-3 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
613-107-00-8 | Hexanatrium-2,2"-vinylenbis((3-sulfonato-4,1-phenylen)imino(6-( N-cyanoethyl- N- (2-hydroxypropyl)amino)-1,3,5-triazin-4,2-diyl)imino)dibenzol-1,4-disulfonat | 405-280-1 | 76508-02-6 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
613-108-00-3 | Benzothiazol-2-thiol | 205-736-8 | 149-30-4 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
613-109-00-9 | Bis(piperidinothiocarbonyl)disulfid | 202-328-1 | 94-37-1 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 | H319 H335 H315 H317 | GHS07 Achtg. | H319 H335 H315 H317 | |||
613-110-00-4 | Dimepiperat (ISO); S-(1-Methyl-1-phenylethyl)piperidin-1-carbothioat | 262-784-2 | 61432-55-1 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
613-111-00-X | 1,2,4-Triazol | 206-022-9 | 288-88-0 | Repr. 1B Acute Tox. 4 Eye Irrit. 2 | H360FD H302 H319 | GHS08 GHS07 Dgr | H360FD H302 H319 | oral: ATE = 1 320 mg/kg KG | ||
613-112-00-5 | Octhilinon (ISO); 2-Octyl-2 H-isothiazol-3-on; [OIT] | 247-761-7 | 26530-20-1 | Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H311 H301 H314 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H311 H301 H314 H317 H410 | EUH071 | Einatmen:
ATE = 0,27 mg/L (Stäube oder Nebel) dermal:
ATE = 311 mg/kg KG oral:
ATE = 125 mg/kg KG Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 | |
613-113-00-0 | 2-(morpholinothio)benzothiazole | 203-052-4 | 102-77-2 | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H319 H315 H317 H411 | GHS07 GHS09 Achtg. | H319 H315 H317 H411 | |||
613-114-00-6 | 2,2",2""-(Hexahydro-1,3,5- triazin-1,3,5-triyl)triethanol; 1,3,5-Tris(2-hydroxyethyl)hexahydro-1,3,5-triazin | 225-208-0 | 4719-04-4 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | Skin Sens. 1; H317: C ≥ 0,1 % | ||
613-115-00-1 | Hymexazol (ISO); 3-Hydroxy-5-methylisoxazol | 233-000-6 | 10004-44-1 | Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H361d H302 H318 H317 H411 | GHS08 GHS07 GHS05 GHS09 Dgr | H361d H302 H318 H317 H411 | oral: ATE = 1600 mg/kg KG | ||
613-116-00-7 | Tolylfluanid (ISO); Dichlor- N-[(dimethylamino)sulphonyl]fluor- N-( p-tolyl)methansulfonamid; [mit ≥0,1 % (w/w) Partikeln mit einem aerodynamischen Diameter von weniger als 50 μm] | 211-986-9 | 731-27-1 | Acute Tox. 2 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H330 H372** H319 H335 H315 H317 H400 | GHS06 GHS08 GHS09 Gef. | H330 H372** H319 H335 H315 H317 H400 | M=10 | ||
613-116-01-4 | Tolylfluanid (ISO); Dichlor- N-[(dimethylamino)sulphonyl]fluor- N-( p-tolyl)methansulfonamid; [mit < 0,1 % (w/w) Partikeln mit einem aerodynamischen Diameter von weniger als 50 μm] | 211-986-9 | 731-27-1 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H319 H335 H315 H317 H400 | GHS07 GHS09 Achtg. | H319 H335 H315 H317 H400 | M=10 | ||
613-117-00-2 | Diniconazol (ISO); (E)-β-[(2,4-Dichlorphenyl)methylen]-α-(1,1-dimethylethyl)-1 H-1,2,4-triazol-1-ethanol; (E)-( RS)-1-(2,4-Dichlorphenyl)-4,4-dimethyl-2-(1 H-1,2,4-triazol-1-yl)pent-1-en-3-ol | - | 76714-88-0 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-118-00-8 | Flubenzimin (ISO); N-[3-Phenyl-4,5-bis[(trifluormethyl)imino]thiazolidin-2-yliden]anilin | 253-703-1 | 37893-02-0 | Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H319 H400 H410 | GHS07 GHS09 Achtg. | H319 H410 | |||
613-119-00-3 | (Benzothiazol-2-ylthio)methylthiocyanat; TCMTB | 244-445-0 | 21564-17-0 | Acute Tox. 2 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H319 H315 H317 H400 H410 | GHS06 GHS09 Gef. | H330 H302 H319 H315 H317 H410 | |||
613-120-00-9 | Bioresmethrin (ISO); (5-Benzyl-3-furyl)methyl(1 R)-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropancarboxylat | 249-014-0 | 28434-01-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 1000 | ||
613-121-00-4 | Chlorsulfuron (ISO); 2-Chlor-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzolsulfonamid | 265-268-5 | 64902-72-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 1 000 M = 100 | ||
613-122-00-X | Diclobutrazol (ISO); (R*, R*)-(±)-β-[(2,4-Dichlorphenyl)methyl]-α-(1,1-dimethylethyl)-1 H-1,2,4-triazol-1-ethanol; (2 RS, 3 RS)-1-(2,4-Dichlorphenyl)-4,4-dimethyl-2-(1 H-1,2,4-triazol-1yl)pentan-3-ol | - | 75736-33-3 | Eye Irrit. 2 Aquatic Chronic 2 | H319 H411 | GHS07 GHS09 Achtg. | H319 H411 | |||
613-123-00-5 | 5,6-Dihydro-3 H-imidazo[2,1- c]-1,2,4-dithiazol-3-thion; Etem | 251-684-4 | 33813-20-6 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-124-00-0 | Fenpropimorph (ISO); cis-4-[3-( p- tert-Butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholin | 266-719-9 | 67564-91-4 | Repr. 2 Acute Tox. 4 * Skin Irrit. 2 Aquatic Chronic 2 | H361d *** H302 H315 H411 | GHS08 GHS07 GHS09 Achtg. | H361d *** H302 H315 H411 | |||
613-125-00-6 | Hexythiazox (ISO); Trans-5-(4-chlorphenyl)- N-cyclohexyl-4-methyl-2-oxo-3-thiazolidin-carboxamid | - | 78587-05-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1 | ||
613-126-00-1 | Imazapyr (ISO); 2-[4,5-Dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1 H- imidazol-2-yl]-3-pyridincarboxylat | - | 81334-34-1 | Eye Irrit. 2 Aquatic Chronic 3 | H319 H412 | GHS07 Achtg. | H319 H412 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
613-127-00-7 | 1,1-Dimethylpiperidiniumchlorid; Mepiquatchlorid (ISO) | 246-147-6 | 24307-26-4 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
613-127-00-7 | Mepiquatchlorid (ISO); 1,1-Dimethylpiperidiniumchlorid | 246-147-6 | 24307-26-4 | Acute Tox. 4 Acute Tox. 3 Aquatic Chronic 3 | H332 H301 H412 | GHS06 Dgr | H332 H301 H412 | Inhalation:
ATE = 2,8 mg/L (Stäube oder Nebel) Oral: ATE = 270 mg/kg KG | ) | |
613-128-00-2 | Prochloraz (ISO); N-Propyl- N-[2-(2,4,6-trichlorphenoxy)ethyl]-1 H-imidazol-1-carboxamid | 266-994-5 | 67747-09-5 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-129-00-8 | Metamitron (ISO); 4-Amino-3-methyl-6-phenyl-1,2,4-triazin-5-on | 255-349-3 | 41394-05-2 | Acute Tox. 4 * Aquatic Acute 1 | H302 H400 | GHS07 GHS09 Achtg. | H302 H400 | |||
613-131-00-9 | Pyroquilon (ISO); 1,2,5,6-Tetrahydropyrrolo[3,2,1- ij]chinolin-4-on | - | 57369-32-1 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
613-132-00-4 | Hexazinon (ISO); 3-Cyclohexyl-6-dimethylamino-1-methyl-1,2,3,4-tetrahydro-1,3,5-triazin-2,4-dion | 257-074-4 | 51235-04-2 | Acute Tox. 4 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H410 | |||
613-133-00-X | Etridiazol (ISO); 5-Ethoxy-3-trichlormethyl-1,2,4-thiadiazol | 219-991-8 | 2593-15-9 | Carc. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H317 H410 | M = 1 M = 1 | ||
613-134-00-5 | Myclobutanil (ISO); 2-(4-Chlorphenyl)-2-(1 H-1,2,4- triazol-1-ylmethyl)hexanenitril | - | 88671-89-0 | Repr. 2 Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 2 | H361d *** H302 H319 H411 | GHS08 GHS07 GHS09 Achtg. | H361d *** H302 H319 H411 | |||
613-135-00-0 | Di(benzothiazol-2-yl)disulfide; 2,2"-Dithiobis(benzothiazol) | 204-424-9 | 120-78-5 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | EUH031 | ||
613-136-00-6 | N-Cyclohexylbenzothiazol-2-sulfonamid | 202-411-2 | 95-33-0 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
613-137-00-1 | Methabenzthiazuron (ISO); 1-(1,3-Benzothiazol-2-yl)1,3-dimethylharnstoff | 242-505-0 | 18691-97-9 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
613-138-00-7 | Quinoxyfen (ISO); 5,7-Dichlor-4-(4-fluorphenoxy)chinolin | - | 124495-18-7 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
613-139-00-2 | Metsulfuronmethyl (ISO); Methyl-2-{[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamoyl]sulfamoyl}benzoat | - | 74223-64-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 1000 | ||
613-140-00-8 | Cycloheximid (ISO); 4-{(2 R)-2-[(1 S,3 S,5 S)-3,5-Dimethyl-2-oxocyclohexyl]-2-hydroxyethyl}piperidin-2,6-dion | 200-636-0 | 66-81-9 | Muta. 2 Repr. 1B Acute Tox. 2 * Aquatic Chronic 2 | H341 H360D *** H300 H411 | GHS06 GHS08 GHS09 Gef. | H341 H360D *** H300 H411 | |||
613-141-00-3 | 1,4-Diamino-2-(2-butyltetrazol-5-yl)-3-cyanoanthrachinon | 401-470-3 | 93686-63-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-142-00-9 | trans-N-Methyl-2-styryl-[4"-aminomethin-(1-acetyl-1-(2-methoxyphenyl)acetamido)]pyridiniumacetat | 405-860-4 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
613-143-00-4 | 1-(3-Phenylpropyl)-2-methylpyridiniumbromid | 405-930-4 | 10551-42-5 | Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 3 | H302 H319 H412 | GHS07 Achtg. | H302 H319 H412 | |||
613-144-00-X | Reaktionsprodukte von Poly(vinylacetat), teilweise hydrolysiert, mit (E)-2-(4-Formylstyryl)-3,4-dimethylthiazoliummethylsulfat | 406-460-2 | 125139-08-4 | Aquatic Chronic 3 | H412 | - | H412 | |||
613-145-00-5 | (S)-3-Benzyloxycarbonyl-1,2,3,4-tetrahydroisochinolinium-4-methylbenzolsulfonat | 406-960-0 | 77497-97-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
613-146-00-0 | N-ethyl- N-methylpiperidiniumiodid | 407-780-5 | 4186-71-4 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
613-147-00-6 | 4-[2-(1-Methyl-2-(4-morpholinyl)ethoxy)ethyl]morpholin | 407-940-4 | 111681-72-2 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-148-00-1 | Tetranatrium-1,2-bis(4-fluor-6-[5-(1-amino-2-sulfonatoanthrachinon-4-ylamino)-2,4,6-trimethyl-3-sulfonatophenylamino]-1,3,5-triazin-2-ylamino)ethan | 411-240-4 | 143683-23-2 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
613-149-00-7 | Pyridaben (ISO); 2-tert-Butyl-5-(4-tert-butylbenzylthio)-4-chlorpyridazin-3(2H)-on | 405-700-3 | 96489-71-3 | Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H410 | M = 1 000 M = 1 000 | ||
613-150-00-2 | 2,2"-[3,3"-(Piperazin-1,4-diyl)dipropyl]bis(1 H-benzimidazo[2,1- b]benzo[ l, m,n][3,8]phenanthrolin-1,3,6-trion | 406-295-6 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
613-151-00-8 | 1-(3-Mesyloxy-5-trityloxymethyl-2-D-threofuryl)thymin | 406-360-9 | 104218-44-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-152-00-3 | Phenyl- N-(4,6-dimethoxypyrimidin-2-yl)carbamat | 406-600-2 | 89392-03-0 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
613-153-00-9 | 2,3,5-Trichlorpyridin | 407-270-2 | 16063-70-0 | Aquatic Chronic 3 | H412 | - | H412 | |||
613-154-00-4 | 2-Amino-4-chlor-6-methoxypyrimidin | 410-050-9 | 5734-64-5 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
613-155-00-X | 5-Chlor-2,3-difluorpyridin | 410-090-7 | 89402-43-7 | Flam. Liq. 3 Acute Tox. 4 * Aquatic Chronic 3 | H226 H302 H412 | GHS02 GHS07 Achtg. | H226 H302 H412 | |||
613-156-00-5 | 2-Butyl-4-chlor-5-formylimidazol | 410-260-0 | 83857-96-9 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
613-157-00-0 | 2,4-Diamino-5-methoxymethylpyrimidin | 410-330-0 | 54236-98-5 | Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 | H302 H373 ** H319 | GHS08 GHS07 Achtg. | H302 H373 ** H319 | |||
613-158-00-6 | 2,3-Dichlor-5-trifluormethylpyridin | 410-340-5 | 69045-84-7 | Acute Tox. 4 * Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H332 H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H332 H302 H318 H317 H411 | |||
613-159-00-1 | Fenazaquin (ISO); 4-[2-[4-(1,1-Dimethylethyl)phenyl]ethoxy]chinazolin | 410-580-0 | 120928-09-8 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H332 H400 H410 | GHS06 GHS09 Gef. | H301 H332 H410 | |||
613-160-00-7 | (1 S)-2-Methyl-2,5-diazobicyclo[2,2,1]heptandihydrobromid | 411-000-9 | 125224-62-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
613-161-00-2 | (2,4-Diaminopteridin-6-yl)methanolhydrobromid | 430-620-0 | 76145-91-0 | STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 | H373** H317 H412 | GHS08 GHS07 Achtg. | H373** H317 H412 | |||
613-162-00-8 | (6 R- trans)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4,2,0]oct-2-en-3-yl)methyl)pyridiniumiodid | 423-260-0 | 100988-63-4 | Muta. 2 Skin Sens. 1 Aquatic Chronic 2 | H341 H317 H411 | GHS08 GHS07 GHS09 Achtg. | H341 H317 H411 | |||
613-163-00-3 | Azimsulfuron (ISO); 1-(4,6-Dimethoxypyrimidin-2-yl)-3-[1-methyl-4-(2-methyl-2 H-tetrazol-5-yl)pyrazol-5-ylsulfonyl]harnstoff | - | 120162-55-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M=1000 | ||
613-164-00-9 | Flufenacet (ISO); N-(4-Fluorphenyl)- N-isopropyl-2-(5-trifluormethyl-[1,3,4]thiadiazol-2-yloxy)acetamid | - | 142459-58-3 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H317 H410 | M=100 | ||
613-165-00-4 | Flupyrsulfuronmethylnatrium (ISO); Methyl-2-[[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-6-trifluormethyl]nicotinat, Mononatriumsalz | - | 144740-54-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M=100 | ||
613-166-00-X | Flumioxazin (ISO); N-(7-Fluor-3,4-dihydro-3-oxo-4-prop-2-ynyl-2 H-1,4-benzoxazin-6-yl)cyclohex-1-en-1,2-dicarboximid | - | 103361-09-7 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H400 H410 | GHS08 GHS09 Wng | H361d H410 | M = 1 000 M = 1 000 | ||
613-167-00-5 | Reaktionsmasse aus 5-Chlor-2-methyl-2H-isothiazol-3-on und 2-Methyl-2H-isothiazol-3-on (3:1) | - | 55965-84-9 | Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H301 H314 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H310 H301 H314 H317 H410 | EUH071 | Skin Corr. 1C; H314: C ≥ 0,6 % Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 % Eye Dam. 1; H318: C ≥ 0,6 % Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 | B |
613-168-00-0 | 1-Vinyl-2-pyrrolidon; N-Vinyl-2-pyrrolidon | 201-800-4 | 88-12-0 | Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * STOT SE 3 Eye Dam. 1 | H351 H332 H312 H302 H373 ** H335 H318 | GHS06 GHS05 GHS09 Gef. | H351 H332 H312 H302 H373 ** H335 H318 | D | ||
613-169-00-6 | 9-Vinylcarbazol | 216-055-0 | 1484-13-5 | Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H341 H312 H302 H315 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H341 H312 H302 H315 H317 H410 | M=100 | ||
613-170-00-1 | 2,2-Ethylmethylthiazolidin | 404-500-3 | 694-64-4 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | |||
613-171-00-7 | Hexaconazol (ISO); (RS)-2-(2,4-Dichlorphenyl)-1-(1 H-1,2,4-triazol-1-yl)hexan-2-ol | 413-050-7 | 79983-71-4 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
613-172-00-2 | 5-Chlor-1,3-dihydro-2 H-indol-2-on | 412-200-9 | 17630-75-0 | Repr. 2 Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 | H361f *** H302 H317 H412 | GHS08 GHS07 Achtg. | H361f *** H302 H317 H412 | |||
613-173-00-8 | Fluquinconazol (ISO); 3-(2,4-Dichlorphenyl)-6-fluor-2-(1 H-1,2,4-triazol-1-yl)chinazolin-4-(3 H)-on | 411-960-9 | 136426-54-5 | Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H372 ** H312 H315 H400 H410 | GHS06 GHS08 GHS09 Gef. | H331 H301 H372 ** H312 H315 H410 | |||
613-174-00-3 | Tetraconazol (ISO); (±) 2-(2,4-Dichlorphenyl)-3-(1 H-1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluorethylether | 407-760-6 | 112281-77-3 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 | H332 H302 H411 | GHS07 GHS09 Achtg. | H332 H302 H411 | |||
613-175-00-9 | Epoxiconazol (ISO); (2 RS,3 SR)-3-(2-Chlorphenyl)-2-(4-fluorphenyl)-[(1 H-1,2,4-triazol-1-yl)methyl]oxiran | 406-850-2 | 133855-98-8 | Carc. 2 Repr. 1B Aquatic Chronic 2 | H351 H360Df H411 | GHS08 GHS09 Gef. | H351 H360Df H411 | |||
613-176-00-4 | 2-Methyl-2-azabicyclo[2,2,1]heptan | 404-810-9 | 4524-95-2 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B | H226 H312 H302 H373 ** H314 | GHS02 GHS08 GHS05 GHS07 Gef. | H226 H312 H302 H373 ** H314 | |||
613-177-00-X | 8-Amino-7-methylchinolin | 412-760-4 | 5470-82-6 | Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H312 H302 H317 H411 | GHS07 GHS09 Achtg. | H312 H302 H317 H411 | |||
613-178-00-5 | 4-Ethyl-2-methyl-2-isopentyl-1,3-oxazolidin | 410-470-2 | 137796-06-6 | Skin Corr. 1B Skin Sens. 1 | H314 H317 | GHS05 GHS07 Gef. | H314 H317 | STOT SE 3; H335: C ≥ 5 % | ||
613-179-00-0 | Lithium-3-oxo-1,2(2 H)-benzisothiazol-2-id | 411-690-1 | 111337-53-2 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H302 H314 H317 H411 | GHS05 GHS07 Gef. | H302 H314 H317 H411 | |||
613-180-00-6 | N-(1,1-Dimethylethyl)bis(2- benzothiazolsulfen)amid | 407-430-1 | 3741-80-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
613-181-00-1 | 5,5-Dimethylperhydropyrimidin-2-on-α-(4-trifluormethylstyryl)-α-(4-trifluormethyl)cinnamylidenhydrazon | 405-090-9 | 67485-29-4 | STOT RE 1 Acute Tox. 4 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H372 ** H302 H319 H400 H410 | GHS08 GHS07 GHS09 Gef. | H372 ** H302 H319 H410 | |||
613-182-00-7 | 1-(1-Naphthylmethyl)chinoliniumchlorid | 406-220-7 | 65322-65-8 | Carc. 2 Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H351 H341 H302 H315 H318 H412 | GHS08 GHS05 GHS07 Gef. | H351 H341 H302 H315 H318 H412 | |||
613-183-00-2 | Reaktionsmasse aus 5-( N-Methyl perfluoroctylsulfonamido)methyl-3-octadecyl-1,3-oxazolidin-2-on und 5-( N-Methylperfluorheptylsulfonamido)methyl-3-octadecyl-1,3-oxazolidin-2-on | 413-640-4 | - | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H400 H410 | GHS08 GHS09 Achtg. | H373 ** H410 | |||
613-184-00-8 | Nitrilotriethylenammoniopropan-2-ol-2-ethylhexanat | 413-670-8 | - | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
613-185-00-3 | 2,3,5,6-Tetrahydro-2-methyl-2 H-cyclopenta[ d]-1,2-thiazol-3-on | 407-630-9 | 82633-79-2 | Acute Tox. 3 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Gef. | H301 H318 H317 H410 | |||
613-186-00-9 | (2 R,3 R)-3-(( R)-1-( tert-Butyldimethylsiloxy)ethyl)-4-oxoazetidin-2-yl-acetat | 408-050-9 | 76855-69-1 | Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H319 H317 H411 | GHS07 GHS09 Achtg. | H319 H317 H411 | |||
613-187-00-4 | 5-(2-Amino-5-cyano-6-[2-(2- hydroxyethoxy)ethylamino]-4-methylpyridin-3-ylazo)-3-methyl-2,4-dicarbonitrilethiophen | 410-530-8 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
613-188-00-X | 1-(3-(4-Fluorphenoxy)propyl)-3-methoxy-4-piperidinon | 411-500-7 | 116256-11-2 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | |||
613-189-00-5 | 1,4,7,10-Tetrakis( p-toluolsulfonyl)-1,4,7,10-tetraazacyclododecan | 414-030-0 | 52667-88-6 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
613-190-00-0 | Dinatrium-1-amino-4-(2-(5- chlor-6-fluorpyrimidin-4-ylamino-methyl)-4-methyl-6-sulfophenylamino)-9,10-dioxo-9,10-dihydroanthracen-2-sulfonat | 414-040-5 | 149530-93-8 | Acute Tox. 4 * Skin Sens. 1 | H302 H317 | GHS07 Achtg. | H302 H317 | |||
613-191-00-6 | 3-Ethyl-2-methyl-2-(3-methylbutyl)-1,3-oxazolidin | 421-150-7 | 143860-04-2 | Repr. 1B Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360F *** H314 H400 H410 | GHS08 GHS05 GHS09 Gef. | H360F *** H314 H410 | |||
613-192-00-1 | 3-Benzyl-exo-6-nitro-2,4-dioxo- 3-aza- cis-bicyclo[3,1,0]hexan | 426-750-2 | 151860-15-0 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
613-193-00-7 | Pentakis[3-(dimethylammonio)propylsulfamoyl]-[(6-hydroxy-4,4,8,8-tetramethyl-4,8- diazoniaundecan-1,11-diyldisulfamoyl)di[phthalocyaninkupfer(II)]]heptalactat | 414-930-3 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
613-194-00-2 | 6,13-Dichlor-3,10-bis{2-[4-fluor-6-(2-sulfophenylamino)-1,3,5-triazin-2-ylamino]propylamino}benzo[5,6][1,4]oxazino[2,3-b]phenoxazin-4,11-disulfonsäure, Lithium-/Natriumsalz | 418-000-8 | 163062-28-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-195-00-8 | 2,2-(1,4-Phenylen)bis((4 H-3,1-benzoxazin-4-on) | 418-280-1 | 18600-59-4 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
613-196-00-3 | 5-[[4-Chlor-6-[[2-[[4-fluor-6-[[5-hydroxy-6-[(4-methoxy-2- sulfophenyl)azo]-7-sulfo-2-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]-1-methylethyl]amino]-1,3,5-triazin-2-yl]amino]-3-[[4-(ethenylsulfonyl)phenyl]azo]-4-hydroxynaphtalin-2,7-disulfonsäure, Natriumsalz | 418-380-5 | 168113-78-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-197-00-9 | Reaktionsmasse aus 2,4,6-Tri(butylcarbamoyl)-1,3,5-triazin, 2,4,6-Tri(methylcarbamoyl)-1,3,5-triazin, [(2-Butyl-4,6-dimethyl)tricarbamoyl]-1,3,5-triazin und [(2,4-Dibutyl-6-ethyl)tricarbamoyl]-1,3,5-triazin | 420-390-1 | 187547-46-2 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
613-198-00-4 | 2-Amino-4-dimethylamino-6- trifluorethoxy-1,3,5-triazin | 415-500-8 | 145963-84-4 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 | H302 H373** H412 | GHS08 GHS07 Achtg. | H302 H373** H412 | |||
613-199-00-X | Reaktionsmasse aus 1,3,5-Tris(3-aminomethylphenyl)-1,3,5-(1 H,3 H,5 H)triazin-2,4,6-trion; Reaktionsmasse aus Oligomeren von 3,5-Bis(3-aminomethylphenyl)-1-poly[3,5-bis(3-minomethylphenyl)-2,4,6-trioxo-1,3,5-(1 H,3 H,5 H)triazin-1-yl]-1,3,5- (1 H,3 H,5 H)triazin-2,4,6-trion | 421-550-1 | - | Carc. 1B Repr. 1B Skin Sens. 1 Aquatic Chronic 3 | H350 H360D *** H317 H412 | GHS08 Gef. | H350 H360D *** H317 H412 | |||
613-200-00-3 | Reaktionsprodukt von Kupfer, (29 H, 31 H-Phthalocyaninato (2-)- N29, N30, N31, N32), Chlorschwefelsäure und 3-(2-sulfooxyethylsulfonyl)anilin, Natriumsalze | 420-980-7 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-201-00-9 | (R)-5-Brom-3-(1-methyl-2-pyrrolidinylmethyl)-1 H-indol | 422-390-5 | 143322-57-0 | Repr. 2 STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f *** H372 ** H332 H302 H317 H400 H410 | GHS08 GHS07 GHS09 Gef. | H361f *** H372 ** H332 H302 H317 H410 | EUH070 | ||
613-202-00-4 | Pymetrozin (ISO); (E)-4,5-Dihydro-6-methyl-4-(3-pyridylmethylenamino)-1,2,4-triazin-3(2 H)-on | - | 123312-89-0 | Carc. 2 Repr. 2 Aquatic Chronic 1 | H351 H361fd H410 | GHS08 GHS09 Wng | H351 H361fd H410 | M = 1 | ||
613-203-00-X | Pyraflufenethyl (ISO); 2-Chlor-5-(4-chlor-5-difluormethoxy-1-methylpyrazol-3-yl)-4-fluorphenoxyessigsäureethylester [1]; Pyraflufen (ISO); 2-Chlor-5-(4-chlor-5-difluormethoxy-1-methylpyrazol-3-yl)-4-fluorphenoxyessigsäure [2] | - [1] - [2] | 129630-19-9 [1] 129630-17-7 [2] | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M=1000 | ||
613-204-00-5 | Oxadiargyl (ISO); 3-[2,4-Chlor-5-(2-propynyloxy)phenyl]-5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2(3 H)-on | 254-637-6 | 39807-15-3 | Repr. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H361d*** H373** H400 H410 | GHS08 GHS09 Achtg. | H361d*** H373** H410 | M = 1000 | ||
613-205-00-0 | Propiconazol (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-Dichlorphenyl)- 4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazol | 262-104-4 | 60207-90-1 | Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H302 H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H360D H302 H317 H410 | M = 1 M = 1 | ||
613-206-00-6 | Fenamidon (ISO); (S)-5-Methyl-2-methylthio-5-phenyl-3-phenylamino-3,5-dihydroimidazol-4-on | - | 161326-34-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
613-208-00-7 | Imazamox (ISO); (RS)-2-(4-Isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinsäure | - | 114311-32-9 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H400 H410 | GHS08 GHS09 Wng | H361d H410 | M = 10 M = 10 | ||
613-209-00-2 | cis-1-(3-Chlorpropyl)-2,6- dimethylpiperidinhydrochlorid | 417-430-3 | 63645-17-0 | Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 | H301 H373 ** H317 H411 | GHS06 GHS08 GHS09 Gef. | H301 H373 ** H317 H411 | |||
613-210-00-8 | 2-(3-Chlorpropyl)-2,5,5-trimethyl-1,3-dioxan | 417-650-1 | 88128-57-8 | STOT RE 2 * Aquatic Chronic 3 | H373 ** H412 | GHS08 Achtg. | H373 ** H412 | |||
613-211-00-3 | N-Methyl-4-( p-formylstyryl)pyridiniummethylsulfat | 418-240-3 | 74401-04-0 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
613-212-00-9 | 4-[4-(2-Ethylhexyloxy)phenyl](1,4-thiazinan-1,1-dioxid) | 418-320-8 | 133467-41-1 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
613-213-00-4 | cis-1-Benzoyl-4-[(4-methylsulfonyl)oxy]-L-prolin | 416-040-0 | 120807-02-5 | Aquatic Chronic 3 | H412 | - | H412 | |||
613-214-00-X | N, N-Di- n-butyl-2-(1,2-dihydro-3-hydroxy-6-isopropyl-2-chinolyliden)-1,3-dioxoindan-5-carboxamid | 416-260-7 | 147613-95-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-215-00-5 | 2-Chlormethyl-3,4-dimethoxypyridiniumchlorid | 416-440-5 | 72830-09-2 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H312 H302 H373 ** H315 H318 H317 H411 | GHS08 GHS05 GHS07 GHS09 Gef. | H312 H302 H373 ** H315 H318 H317 H411 | |||
613-216-00-0 | 6- tert-Butyl-7-(6-diethylamino-2-methyl-3-pyridylimino)-3-(3-methylphenyl)pyrazolo[3,2- c][1,2,4]triazol | 416-490-8 | 162208-01-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
613-217-00-6 | 4-[3-(3,5-Di- tert-butyl-4-hydroxyphenyl)propionyloxy]-1-[2-[3-(3,5-di- tert-butyl-4-hydrophenyl)propionyloxy]ethyl]-2,2,6,6-tetramethylpiperidin | 416-770-1 | 73754-27-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-218-00-1 | 6-Hydroxyindol | 417-020-4 | 2380-86-1 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H302 H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H302 H318 H317 H411 | |||
613-219-00-7 | 7 a-Ethyl-3,5-bis(1-methylethyl)-2,3,4,5-tetrahydrooxazolo[3,4- c]-2,3,4,5-tetrahydrooxazol | 417-140-7 | 79185-77-6 | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
613-220-00-2 | trans-(4 S,6 S)-5,6-Dihydro-6-methyl-4 H-thieno[2,3- b]thiopyran-4-ol, 7,7-dioxid | 417-290-3 | 147086-81-5 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
613-221-00-8 | 2-Chlor-5-methylpyridin | 418-050-0 | 18368-64-4 | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Aquatic Chronic 3 | H312 H302 H315 H412 | GHS07 Achtg. | H312 H302 H315 H412 | |||
613-222-00-3 | 4-(1-Oxo-2-propenyl)morpholin | 418-140-1 | 5117-12-4 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H302 H373 ** H318 H317 | GHS08 GHS05 GHS07 Gef. | H302 H373 ** H318 H317 | |||
613-223-00-9 | N-Isopropyl-3-(4-fluorphenyl)-1 H-indol | 418-790-4 | 93957-49-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-224-00-4 | 2,5-Dimercaptomethyl-1,4-dithian | 419-770-8 | 136122-15-1 | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H314 H317 H410 | |||
613-225-00-X | Reaktionsmasse aus [2-(Anthrachinon-1-ylamino)-6-[(5-benzoylamino)-anthrachinon-1-ylamino]-4-phenyl]-1,3,5-triazin und 2,6-Bis[(5-benzoylamino)-anthrachinon-1-ylamino]-4-phenyl-1,3,5-triazin | 421-290-9 | - | STOT RE 2 * Aquatic Chronic 4 | H373 ** H413 | GHS08 Achtg. | H373 ** H413 | |||
613-226-00-5 | 1-(2-(Ethyl-(4-(4-(4-(4-(ethyl(2- pyridinoethyl)amino)-2-methylphenylazo)benzoylamino)phenylazo)-3-methylphenyl)amino)ethyl)pyridiniumdichlorid | 420-950-3 | 163831-67-2 | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
613-227-00-0 | (±)[( R*, R*) und (R*, S*)]-6-Fluor-3,4-dihydro-2-oxiranyl-2 H-1-benzopyran | 419-600-2 | 99199-90-3 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
613-228-00-6 | (±)( R*, S*)-6-Fluor-3,4-dihydro-2-oxiranyl-2 H-1-benzopyran | 419-630-6 | 793669-26-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
613-229-00-1 | 1-Acetyl-4-(3-dodecyl-2,5-dioxo-1-pyrrolidinyl)-2,2,6,6-tetramethylpiperidin | 411-930-5 | 106917-31-1 | Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H315 H317 H410 | |||
613-230-00-7 | Florasulam (ISO); 2",6",8-Trifluor-5-methoxy-5-triazolo[1,5- c]; Pyrimidin-2-sulfonanilid | - | 145701-23-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
613-231-00-2 | 2,6-Diamino-3-((pyridin-3-yl)azo)pyridin | 421-430-9 | 28365-08-4 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 | H302 H373** H411 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H411 | |||
613-232-00-8 | 3-(Benzo[ b]thien-2-yl)-5,6-dihydro-1,4,2-oxathiazin-4-oxid | 431-030-6 | 163269-30-5 | Acute Tox. 3 * STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H373** H318 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H331 H373** H318 H410 | |||
613-233-00-3 | 4,4"-(Oxy-(bismethylen))bis-1,3-dioxolan | 423-230-7 | 56552-15-9 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-234-00-9 | Imidazo[1,2- b]pyridazinhydrochlorid | 431-510-5 | 18087-70-2 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
613-235-00-4 | 2,3-Dihydro-2,2-dimethyl-1 H-perimidin | 424-060-6 | 6364-17-6 | Acute Tox. 4* STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H317 H410 | |||
613-236-00-X | 2-Chlor-3-trifluormethylpyridin | 424-520-6 | 65753-47-1 | Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Corr. 1B Aquatic Chronic 3 | H311 H301 H372** H314 H412 | GHS06 GHS05 GHS08 Gef. | H311 H301 H372** H314 H412 | |||
613-237-00-5 | 6- tert-Butyl-3-(3-dodecylsulfonyl)propyl-7 H-1,2,4-triazolo[3,4 b][1,3,4]thiadiazin | 424-950-4 | 133949-92-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-238-00-0 | Natrium-2-[[4-[(4,6-dichlor-1,3,5-triazin-2-yl)amino]phenyl]sulfonyl]ethylsulfat | 430-890-1 | 81992-66-7 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
613-239-00-6 | 2-[3-(Methylamino)propyl]-1 H-benzimidazol | 425-760-4 | 64137-52-6 | Eye Dam. 1 Aquatic Chronic 3 | H318 H412 | GHS05 Gef. | H318 H412 | |||
613-241-00-7 | 3-(2 H-Tetrazol-5-yl)pyridin | 426-810-8 | 3250-74-6 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-242-00-2 | Reaktionsprodukte von 3,10-Bis((2-aminopropyl)amino)-6,13-dichlor-4,11-triphenodioxazindisulfonsäure mit 2-amino-1,4-benzoldisulfonsäure, 2-((4-aminophenyl)sulfonyl)ethylhydrogensulfat und 2,4,6-trifluor-1,3,5-triazin, Natriumsalze | 426-860-0 | 191877-09-5 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-243-00-8 | 4,4"-(1,6-Hexamethylen-bis(formylimino))bis(2,2,6,6-tetramethyl-1-oxylpiperidin) | 427-350-0 | 182235-14-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
613-244-00-3 | 5,7-Dichlor-4-hydroxychinolin | 427-420-0 | 21873-52-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
613-245-00-9 | 2-Fluor-6-trifluormethylpyridin | 428-100-3 | 94239-04-0 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H226 H332 H302 H412 | GHS02 GHS07 Achtg. | H226 H332 H302 H412 | |||
613-246-00-4 | 2-Hydroxymethyl-3-methyl-4-(2,2,2-trifluorethoxy)pyridin | 428-200-7 | 103577-66-8 | Aquatic Chronic 3 | H412 | - | H412 | |||
613-247-00-X | 3-(2-Methoxy-4-methoxycarboxybenzyl)-5-nitroindol | 428-910-7 | 107786-36-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-248-00-5 | 3,4-Dimethyl-1 H-pyrazol | 429-130-1 | 2820-37-3 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
613-249-00-0 | 1-(2-Hydroxyethyl)-1 H-pyrazol-4,5-diyldiammoniumsulfat | 429-300-3 | 155601-30-2 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
613-250-00-6 | Reaktionsmasse aus Carbonato-bis- N-ethyl-2-isopropyl-1,3-oxazolidin, Methylcarbonato- N-ethyl-2-isopropyl-1,3-oxazolidin und 2-Isopropyl- N-hydroxyethyl-1,3-oxazolidin | 429-990-6 | - | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H318 H317 H412 | GHS05 GHS07 Gef. | H318 H317 H412 | |||
613-251-00-1 | (R)-3-[(1-Methylpyrrolidin-2-yl)methyl]-5-[2-(phenylsulfonyl)ethenyl]-1 H-indol | 430-560-5 | 180637-89-2 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H302 H373** H318 H317 | GHS05 GHS08 GHS07 Gef. | H302 H373** H318 H317 | |||
613-253-00-2 | 2,2-Dialkyl-4-hydroxymethyl-1,3-dioxolan; Reaktionsprodukt mit Ethylenoxid (C1-12-Alkyle mit der Summe C13; durchschnittlicher Ethoxylierungsgrad ist 3,5) | 430-580-4 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | EUH019 | ||
613-254-00-8 | Forchlorfenuron (ISO); 1-(2-Chlor-4-pyridyl)-3-phenylharnstoff | - | 68157-60-8 | Carc. 2 Aquatic Chronic 2 | H351 H411 | GHS08 GHS09 Achtg. | H351 H411 | |||
613-255-00-3 | Reaktionsmasse aus Isomeren von Natrium-[(2-hydroxyethylsulfamoyl){][}2-(2-piperazin-1-lethylamino)ethylsulfamoyl][2-(4-aminoethylpiperazin-1-yl)ethylsulfamoyl{](sulfamoyl)[}(sulfonatophthalocyaninato)]kupfer(II) | 424-270-8 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-256-00-9 | 3"5"-Anhydrothymidin | 425-810-5 | 38313-48-3 | Aquatic Chronic 3 | H412 | - | H412 | |||
613-257-00-4 | 2-Phthalimidoethyl- N-[4-(2-cyano-4-nitrophenylazo)phenyl]- N-methyl-β-alaninat | 426-400-9 | 170222-39-6 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
613-258-00-X | Reaktionsmasse aus 4-Chlor-7- methylbenzotriazol-Natriumsalz, 4-Chlor-5-methylbenzotriazol-Natriumsalz und 5-Chlor-4-methylbenzotriazol-Natriumsalz | 427-730-6 | 202420-04-0 | Skin Corr. 1B Aquatic Chronic 3 | H314 H412 | GHS05 Gef. | H314 H412 | |||
613-259-00-5 | Imiprothrin (ISO); Reaktionsmasse von: [2,4-Dioxo(prop-2-in-1-yl)imidazolidin-3-yl]methyl-(1 R)-cis-chrysanthemat; [2,4-Dioxo(prop-2-in-1-yl)imidazolidin-3-yl]methyl-(1 R)-trans-chrysanthemat; | 428-790-6 | 72963-72-5 | Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H332 H302 H371 (Nervensystem; oral, Einatmen) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H332 H302 H371 (Nervensystem; oral, Einatmen) H410 | Einatmen:
ATE = 1,4 mg/L (Stäube oder Nebel) oral: ATE = 550 mg/kg KG M = 10 M = 10 | ||
613-260-00-0 | (±)-4-(3-Chlorphenyl)-6-[(4-chlorphenyl)hydroxy(1-methyl- 1 H-imidazol-5-yl)methyl]-1-methyl-2(1 H)-chinolin | 430-730-9 | - | Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H400 H410 | GHS05 GHS09 Gef. | H318 H410 | |||
613-261-00-6 | Pyrazol-1-carboxamidinmonohydrochlorid | 429-520-1 | 4023-02-3 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H302 H373** H318 H317 H412 | GHS05 GHS08 GHS07 Gef. | H302 H373** H318 H317 H412 | |||
613-262-00-1 | Dinatrium-( E)-1,2-bis(4-(4-methylamino-6-(4-methylcarbamoylphenylamino)-1,3,5-triazin-2-ylamino)phenyl-2-sulfonato)ethen | 427-310-2 | 180850-95-7 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-263-00-7 | Mononatrium-3-cyano-5-fluor-6-hydroxypyridin-2-olat | 429-570-2 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
613-266-00-3 | 2-Chlor-5-chlormethylthiazol | 429-830-5 | 105827-91-6 | Acute Tox. 3 * Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H311 H314 H302 H317 H411 | GHS06 GHS05 GHS09 Gef. | H311 H314 H302 H317 H411 | |||
613-267-00-9 | Thiamethoxam (ISO); 3-(2-Chlor-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-yliden- N-nitroamin | 428-650-4 | 153719-23-4 | Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H361fd H302 H400 H410 | GHS07 GHS08 GHS09 Wng | H361fd H302 H410 | oral:
ATE = 780 mg/kg KG M = 10 M = 10 | ||
613-268-00-4 | (4a S- cis-)-6-benzyl-octahydropyrrolo[3,4-b]pyridin | 425-930-8 | 151213-39-7 | Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 | H314 H332 H302 H373** H411 | GHS05 GHS08 GHS07 GHS09 Gef. | H314 H332 H302 H373** H411 | |||
613-269-00-X | 2-Thiazolidinylidencyanamid | 427-720-1 | 26364-65-8 | Acute Tox. 4* STOT RE 2 * Aquatic Chronic 3 | H302 H373** H412 | GHS08 GHS07 Achtg. | H302 H373** H412 | |||
613-270-00-5 | 5-Amino- N-(2,6-dichlor-3-methylphenyl)-1 H-1,2,4-triazol-3-sulfonamid | 428-150-6 | 113171-13-4 | Aquatic Chronic 3 | H412 | - | H412 | |||
613-271-00-0 | Tritosulfuron (ISO) (mit ≤ 0,02 % AMTT); 1-[4-Methoxy-6-(trifluormethyl)-1,3,5-triazin-2-yl]-3-[2-(trifluormethyl)benzolsulfonyl]harnstoff (mit ≤ 0,02 % AMTT) | - | 142469-14-5 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | M=10 | ||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
613-272-00-6 | Pyraclostrobin (ISO); Methyl- N-{2-[1-(4-chlorphenyl)-1 H-pyrazol-3-yloxymethyl]phenyl}( N-methoxy)carbamat | - | - | Acute Tox. 3 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H331 H315 H400 H410 | GHS06 GHS09 Gef. | H331 H315 H410 | M=100 | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
613-272-00-6 | Pyraclostrobin (ISO); Methyl- N-(2-{[1-(4-chlorphenyl)-1 H-pyrazol-3-yl]oxymethyl}phenyl)- N-methoxycarbamat; | - | 175013-18-0 | Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H331 H302 H335 H373 (Leber, Magen-Darm-Trakt, Nasenhöhle) H315 H400 H410 | GHS08 GHS06 GHS09 Dgr | H361d H331 H302 H335 H373 (Leber, Magen-Darm-Trakt, Nasenhöhle) H315 H410 | Einatmung:
ATE = 0,58 mg/L (Stäube oder Nebel) Oral: ATE = 450 mg/kg KG M = 100 M = 100 | ) | |
613-273-00-1 | Tetrahydro-3-methyl-5-((2- phenylthio)thiazol-5-ylmethyl)[4 H]-1,3,5-oxadiazinan-4-yliden- N-nitroamin | 427-600-9 | 192439-46-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
613-274-00-7 | 2,6-Dichlor-1-fluorpyridiniumtetrafluorborat | 427-400-1 | 140623-89-8 | Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H302 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H314 H302 H317 H410 | |||
613-275-00-2 | 3-(2-Chlorethyl)-6,7,8,9-tetrahydro-2-methyl-4 H-pyrido[1,2-a]pyrimidin-4-on-monohydrochlorid | 424-530-0 | 93076-03-0 | Acute Tox. 3 * STOT SE 2 STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H301 H371** H373** H318 H317 H411 | GHS06 GHS05 GHS08 GHS09 Gef. | H301 H371** H373** H318 H317 H411 | |||
613-276-00-8 | 1-(2-Chlorphenyl)-1,2-dihydro-5 H-tetrazol-5-on | 426-110-2 | 98377-35-6 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
613-277-00-3 | (4-(6-Diethylamino-2-methylpyridin-3-yl)imino-4,5-dihydro-3-methyl-1-(4-methylphenyl)-1 H-pyrazol-5-on | 427-070-9 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
613-278-00-9 | (3-Aminophenyl)pyridin-3-ylmethanon | 428-230-0 | 79568-06-2 | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373** H400 H410 | GHS08 GHS09 Achtg. | H373** H410 | |||
613-279-00-4 | 2-Ethyl-2,3-dihydro-2-methyl-1 H-perimidin | 424-380-6 | 43057-68-7 | Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H410 | |||
613-280-00-X | Tetrahydro-1,3-dimethyl-1 H-pyrimidin-2-on; Dimethylpropylenharnstoff | 230-625-6 | 7226-23-5 | Repr. 2 Acute Tox. 4 * Eye Dam. 1 | H361f*** H302 H318 | GHS05 GHS08 GHS07 Gef. | H361f*** H302 H318 | |||
613-281-00-5 | Chinolin | 202-051-6 | 91-22-5 | Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H350 H341 H312 H302 H319 H315 H411 | GHS08 GHS07 GHS09 Gef. | H350 H341 H312 H302 H319 H315 H411 | |||
613-282-00-0 | Triticonazol (ISO); (RS)-( E)-5-(4-Chlorbenzylidene)-2,2-dimethyl-1-(1 H-1,2,4-triazol-1-methyl)cyclopentanol | - | 138182-18-0 | Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H361f H373 H400 H410 | GHS08 GHS09 Wng | H361f H373 H410 | M = 1 M = 1 | ||
613-283-00-6 | Ketoconazol; 1-[4-[4-[[(2 SR, 4 RS)-2-(2,4- Dichlorphenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanon | 265-667-4 | 65277-42-1 | Repr. 1B Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H360F*** H301 H373** H400 H410 | GHS06 GHS08 GHS09 Gef. | H360F*** H301 H373** H410 | |||
613-284-00-1 | Metconazol (ISO); (1 RS, 5 RS;1 RS, 5 SR)-5-(4-Chlorbenzyl)-2,2-dimethyl-1-(1 H-1,2,4-triazol-1-ylmethyl)cyclopentanol | - | 125116-23-6 | Repr. 2 Acute Tox. 4 * Aquatic Chronic 2 | H361d*** H302 H411 | GHS08 GHS07 GHS09 Achtg. | H361d*** H302 H411 | |||
613-285-00-7 | 1-Hydroxybenzotriazol, wasserfrei [1]; 1-H2592-95-2-hydroxybenzotriazol, monohydriert [2] | 219-989-7 [1] 219-989-7 [2] | 2592-95-2 [1] 123333-53-9 [2] | Expl. 1.3 | H203 | GHS01 Gef. | H203 | |||
613-286-00-2 | Kalium-1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-yliden)-1-propenyl]pyrazol-5-olat; [mit < 0,5 % N, N- Dimethylformamid (EG-Nr. 200-679-5)] | 418-260-2 | 183196-57-8 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
613-286-01-X | Kalium-1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3- morpholinocarbonyl-5-oxo-2-pyrazolin-4-yliden)-1-propenyl]pyrazol-5-olat; [mit ≥ 0,5 % N, N- Dimethylformamid (EG-Nr. 200-679-5)] | 418-260-2 | 183196-57-8 | Repr. 1B Skin Sens. 1 | H360D*** H317 | GHS08 GHS07 Gef. | H360D*** H317 | |||
613-287-00-8 | 1-(3-Jod-4-aminobenzyl)-1 H-1,2,4-triazol | 419-540-7 | 160194-26-3 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
613-288-00-3 | 1,3-Bis(dimethylcarbamoyl)imidazoliumchlorid | 420-930-4 | 135756-61-5 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
613-289-00-9 | 3-(4-Chlor-2-fluor-5-methylphenyl)-1-methyl-5-(trifluormethyl)-1 H-pyrazol | 432-020-4 | 142623-48-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
613-290-00-4 | 4-Hydroxy-7-(2-aminoethyl)-1,3-benzothiazol-2(3 H)-on-hydrochlorid | 432-470-1 | 189012-93-9 | Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H318 H317 H410 | |||
613-291-00-X | 2,4-Dihydro-4-(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-2-(1-methylpropyl)-3 H-1,2,4-triazol-3-on | 434-820-9 | 106461-41-0 | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373** H400 H410 | GHS08 GHS09 Achtg. | H373** H410 | |||
613-292-00-5 | N, N",N""-Tris(2-methyl-2,3-epoxypropyl)perhydro-2,4,6-oxo-1,3,5-triazin | 435-010-8 | 26157-73-3 | Muta. 2 Aquatic Chronic 3 | H341 H412 | GHS08 Achtg. | H341 H412 | |||
613-293-00-0 | 2-(4- tert-Butylphenyl)-6-cyano-5-[bis(ethoxycarbonylmethyl)carbamoyloxy]-1 H- pyrrolo[1,2- b][1,2,4]triazol-7-carbonsäure 2,6-di- tert-butyl-4-methylcyclohexylester | 448-050-6 | 444065-11-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-294-00-6 | 2-Hexyldecansäure[4-(6- tert-butyl-7-chlor-1 H-pyrazolo[1,5- b][1,2,4]triazol-2-yl)phenylcarbamoyl]methylester | 448-260-8 | 379268-96-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-295-00-1 | 11-Amino-3-chlor-6,11-dihydro-5,5-dioxo-6-methyldibenzo[ c, f][1,2]thiazepinhydrochlorid | 448-720-8 | 363138-44-7 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
613-296-00-7 | Pentakalium-2-(4-(5-[1-(2,5-disulfonatophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-yliden]-3-methyl-1,3-pentadienyl)-3-methylcarbamoyl-5-oxidopyrazol-1-yl)benzol-1,4-disulfonat | 418-270-7 | - | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
613-297-00-2 | 5-(2-Bromphenyl)-2- tert-butyl-2 H-tetrazol | 420-820-6 | - | Flam. Liq. 3 Acute Tox. 4 * Aquatic Chronic 2 | H226 H302 H411 | GHS02 GHS07 GHS09 Achtg. | H226 H302 H411 | |||
613-298-00-8 | Bis(6-hydroxy-4-methyl-5-(3- methylimidazolium-1-yl)-3-(4- phenylazo)-1 H-pyridin-2-on)ethylendilactat | 421-560-6 | - | STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 | H373** H318 H411 | GHS05 GHS08 GHS09 Gef. | H373** H318 H411 | |||
613-299-00-3 | Hauptbestandteil 1 (Isomer 1): 2-{6-Fluor-4-[-3-(2,5-disulfophenylazo)-4-hydroxy-2-sulfonapht-7-ylamino]-1,3,5-triazin-2-ylamino}-3-{6-fluor-4-[-3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}propan, Natriumsalz; Hauptbestandteil 1 (Isomer 2): 2-{6-Fluor-4-[-3-(2,5-disulfophenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-3-{6-fluor-4-[3-(2,5-disulfophenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2- ylamino}propan, Natriumsalz; Hauptbestandteil 2: 2,3-Bis{6-fluor-4-[3-(2,5-disulfophenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}propan, Natriumsalz; Hauptbestandteil 3: 2,3-Bis{6-fluor-4-[3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}propan, Natriumsalz | 422-610-1 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-300-00-7 | 1-Imidazol-1-yl-octadecan-2-ol | 434-120-3 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
613-301-00-2 | Dimethyl-1-{[2-methoxy-5-(2-methylbutoxycarbonyl)phenylcarbamoyl]-[2-octadecyl-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]methyl}imidazol-4,5-dicarboxylat | 443-910-7 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
613-302-00-8 | Dinatrium-2-(5-carbamoyl-1-ethyl-2-hydroxy-4-methyl-6-oxo-1,6-dihydropyridin-3-ylazo)-4-(4-fluor-6-(4-(2-sulfonyloxyethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)benzolsulfonat | 432-980-4 | 243858-60-8 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
613-303-00-3 | 2-(1-Methyl-2-(4-phenoxyphenoxy)ethoxy)pyridin | 429-800-1 | 95737-68-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
613-304-00-9 | 5,6-Dihydroxy-2,3-dihydro-1 H-indoliumromid | 421-170-6 | 138937-28-7 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
613-305-00-4 | 2-(2-Hydroxy-4-octyloxyphenyl)-2 H-benzotriazol | 448-630-9 | 3147-77-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
613-306-00-X | (2,5-Dioxopyrrolidin-1-yl)-9 H-fluoren-9-ylmethylcarbonat | 433-520-5 | 82911-69-1 | Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 | H302 H317 H411 | GHS07 GHS09 Achtg. | H302 H317 H411 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
613-307-00-5 | Clothianidin (ISO); 3-[(2-Chlor-1,3-thiazol-5-yl)methyl]-2-methyl-1-nitroguanidin | - | 210880-92-5 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M=10 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
613-307-00-5 | Clothianidin (ISO); (E)-1-(2-Chlor-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidin | 433-460-1 | 210880-92-5 | Repr. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f H302 H370 (Nervensystem) H400 H410 | GHS08 GHS07 GHS09 Dgr | H361f H302 H370 (Nervensystem) H410 | Oral: ATE = 390 mg/kg KG M = 10 M = 100 | ) | |
613-308-00-0 | 2-Amino-5-methylthiazol | 423-800-5 | 7305-71-7 | Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H373** H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373** H410 | |||
613-309-00-6 | 1-Methyl-3-phenyl-1-piperazin | 431-180-2 | 5271-27-2 | Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 | H312 H302 H315 H318 H412 | GHS05 GHS07 Gef. | H312 H302 H315 H318 H412 | |||
613-310-00-1 | (-)(3 S, 4 R)-4-(4-Fluorphenyl)-3-(3,4-methylendioxyphenoxymethyl)- N-benzylpiperidinhydrochlorid | 432-360-3 | 105813-13-6 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
613-311-00-7 | Methyl-5-nitrophenylguanidin | 435-500-1 | 152460-07-6 | Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H302 H319 H317 H412 | GHS07 Achtg. | H302 H319 H317 H412 | |||
613-312-00-2 | 2-(4-Methyl-2-phenyl-1-piperazinyl)benzolmethanolmonohydrochlorid | 420-200-5 | - | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H302 H318 H317 H412 | GHS05 GHS07 Gef. | H302 H318 H317 H412 | |||
613-313-00-8 | 2-(4-(4-(3-Pyridinyl)-1 H-imidazol-1-yl)butyl)-1 H-isoindol-1,3(2 H)dion | 442-780-9 | 173838-67-0 | Aquatic Chronic 3 | H412 | - | H412 | |||
613-314-00-3 | 4-Decyloxazolidin-2-on; 4-Decyl-1,3-oxazolidin-2-on | 443-770-7 | 7693-82-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
613-315-00-9 | Tetrakalium-4-[5-[3-carboxylato-4,5-dihydro-5-oxo-1-(4-sulfonatophenyl)pyrazol-4-yliden]-3-(piperidinocarbonyl)penta-1,3-dienyliden]-5-hydroxy-1-(4-sulfonatophenyl)pyrazol-3-carboxylat | 430-390-1 | - | Acute Tox. 4 * Aquatic Chronic 3 | H332 H412 | GHS07 Achtg. | H332 H412 | |||
613-316-00-4 | Trimethylopropan-tri(3-aziridinylpropanoat); (TAZ) | 257-765-0 | 52234-82-9 | Muta. 2 Eye Dam. 1 Skin Sens. 1 | H341 H318 H317 | GHS05 GHS08 GHS07 Gef. | H341 H318 H317 | |||
613-317-00-X | Penconazol (ISO); 1-[2-(2,4-Dichlorphenyl)pentyl]-1 H-1,2,4-triazol | 266-275-6 | 66246-88-6 | Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H361d H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361d H302 H410 | M = 1 M = 1 | ||
613-318-00-5 | Fenpyrazamin (ISO); S-Allyl-5-amino-2,3-dihydro-2-isopropyl-3-oxo-4-( o-tolyl)pyrazol-1-carbothioat; S-Allyl-5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydropyrazol-1-carbothioat | - | 473798-59-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 10 M = 1 | ||
613-319-00-0 | Imidazol | 206-019-2 | 288-32-4 | Repr. 1B Acute Tox. 4 Skin Corr. 1C | H360D H302 H314 | GHS08 GHS07 GHS05 Gef. | H360D H302 H314 | |||
613-320-00-6 | Lenacil (ISO); 3-Cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidin-2,4(3H,5H)-dion | 218-499-0 | 2164-08-1 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | M = 10 M = 10 | ||
613-321-00-1 | (RS)-4-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol; Medetomidin | - | 86347-14-0 | Acute Tox. 2 Acute Tox. 2 STOT SE 3 STOT SE 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H336 H370 (Augen) H372 H400 H410 | GHS06 GHS08 GHS09 Gef. | H330 H300 H336 H370 (Augen) H372 H410 | M = 1 M = 100 | ||
613-322-00-7 | Triadimenol (ISO); (1RS,2RS;1RS,2SR)-1-(4-Chlorphenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; α-tert-Butyl-β-(4-chlorphenoxy)-1H-1,2,4-triazol-1-ethanol | 259-537-6 | 55219-65-3 | Repr. 1B Lact. Acute Tox. 4 Aquatic Chronic 2 | H360 H362 H302 H411 | GHS08 GHS07 GHS09 Gef. | H360 H362 H302 H411 | |||
613-323-00-2 | Terbuthylazin (ISO); N-tert-Butyl-6-chlor-N"-ethyl-1,3,5-triazin-2,4-diamin | 227-637-9 | 5915-41-3 | Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 H400 H410 | GHS07 GHS08 GHS09 Achtg. | H302 H373 H410 | M = 10 M = 10 | ||
613-324-00-8 | Chinolin-8-ol 8-Hydroxychinolin | 205-711-1 | 148-24-3 | Repr. 1B Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H301 H318 H317 H400 H410 | GHS08 GHS06 GHS05 GHS09 Gef. | H360D H301 H318 H317 H410 | M = 1 M = 1 | ||
613-325-00-3 | Thiacloprid (ISO); (Z)-3-(6-Chlor-3-pyridyl-methyl)-1,3-thiazolidin-2-ylidencyanamid; {(2Z)-3-[(6-Chlorpyridin-3-yl)methyl]-1,3-thiazolidin-2-yliden}cyanamid | - | 111988-49-9 | Carc. 2 Repr. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 | H351 H360FD H332 H301 H336 H400 H410 | GHS08 GHS06 GHS09 Gef. | H351 H360FD H332 H301 H336 H410 | M = 100 M = 100 | ||
613-326-00-9 | 2-Methyl-2H-isothiazol-3-on | 220-239-6 | 2682-20-4 | Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H311 H301 H314 H318 H317 H400 H410 | GHS05 GHS06 GHS09 Dgr | H330 H311 H301 H314 H317 H410 | EUH071 | Skin Sens. 1A; H317: C ≥ 0,0015 % M = 10 M = 1 | |
613-327-00-4 | Pyroxsulam (ISO); N-(5,7-Dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluormethyl)pyridin-3-sulfonamid | - | 422556-08-9 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 100 M = 100 | ||
613-328-00-X | 1-Vinylimidazol | 214-012-0 | 1072-63-5 | Repr. 1B | H360D | GHS08 Dgr | H360D | Repr. 1B; H360D: C ≥ 0,03 % | ||
613-329-00-5 | Halosulfuron-methyl (ISO); Methyl-3-chlor-5-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-1-methyl-1- H-pyrazol-4-carboxylat | - | 100784-20-1 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360D H400 H410 | GHS08 GHS09 Dgr | H360D H410 | M = 1000 M = 1000 | ||
613-330-00-0 | 2-Methylimidazol | 211-765-7 | 693-98-1 | Repr. 1B | H360Df | GHS08 Dgr | H360Df | |||
613-331-00-6 | (2 RS)-2-[4-(4-chlorphenoxy)-2-(trifluormethyl)phenyl]-1-(1 H-1,2,4-triazol-1-yl)propan-2-ol; Mefentrifluconazol | - | 1417782-03-6 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 1 M = 1 | ||
613-332-00-1 | Oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorphenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl) -2-[5-methyl-3-(trifluormethyl)-1 H-pyrazol-1-yl]ethanon | - | 1003318-67-9 | Aquatic Chronic 1 | H410 | GHS09 Wng | H410 | M = 1 | < | |
613-333-00-7 | Zink-Pyrithion; (T-4)-bis[1-(hydroxy-.kappa. O)pyridin-2(1 H)-thionato-.kappa.S]zink | 236-671-3 | 13463-41-7 | Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H301 H372 H318 H400 H410 | GHS08 GHS06 GHS05 GHS09 Dgr | H360D H330 H301 H372 H318 H410 | Einatmen:
ATE = 0,14 mg/L (Stäube oder Nebel) oral:
ATE = 221 mg/kg KG M = 1000 M = 10 | ||
613-334-00-2 | Flurochloridon (ISO); 3-Chlor-4-(chlormethyl)-1-[3-(trifluormethyl)phenyl]pyrrolidin-2-on | 262-661-3 | 61213-25-0 | Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360FD H302 H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H360FD H302 H317 H410 | oral:
ATE = 500 mg/kg KG M = 100 M = 100 | ||
613-335-00-8 | 4,5-Dichlor-2-octyl-2 H-isothiazol-3-on; [DCOIT] | 264-843-8 | 64359-81-5 | Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H314 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H302 H314 H317 H410 | EUH071 | Einatmen:
ATE = 0,16 mg/L (Stäube oder Nebel) oral:
ATE = 567 mg/kg KG Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 | |
613-336-00-3 | 2-Methyl-1,2-benzothiazol-3(2 H)-on; [MBIT] | - | 2527-66-4 | Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 | H312 H301 H314 H318 H317 H400 H411 | GHS06 GHS05 GHS09 Dgr | H312 H301 H314 H317 H410 | EUH071 | dermal:
ATE = 1100 mg/kg KG oral:
ATE = 175 mg/kg KG Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1 | |
613-337-00-9 | Prothioconazol (ISO); 2-[2-(1-Chlorcyclopropyl)-3-(2-chlorphenyl)-2-hydroxypropyl]-2,4-dihydro-3 H-1,2,4-triazol-3-thion | - | 178928-70-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 10 M = 1 | ||
613-338-00-4 | Azamethiphos (ISO); S-[(6-Chlor-2-oxooxazolo[4,5- b]pyridin-3(2 H)-yl)methyl]- O, O-dimethylthiophosphat | 252-626-0 | 35575-96-3 | Carc. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H331 H302 H370 (Nervensystem) H317 H400 H410 | GHS06 GHS08 GHS09 Dgr | H351 H331 H302 H370 (Nervensystem) H317 H410 | Einatmen:
ATE = 0,5 mg/L (Stäube oder Nebel) oral: ATE = 500 mg/kg KG M = 1 000 M = 1 000 | ||
613-339-00-X | 3-Methylpyrazol | 215-925-7 | 1453-58-3 | Repr. 1B Acute Tox. 4 STOT RE 2 Skin Corr. 1 Eye Dam. 1 | H360D H302 H373 (Lunge) H314 H318 | GHS08 GHS07 GHS05 Dgr | H360D H302 H373 (Lunge) H314 | oral: ATE = 500 mg/kg KG | ||
613-340-00-5 | Clomazon (ISO); 2-(2-Chlorbenzyl)-4,4-dimethyl-1,2-oxazolidin-3-on | - | 81777-89-1 | Acute Tox. 4 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H400 H410 | GHS07 GHS09 Wng | H332 H302 H410 | Einatmen:
ATE = 4,85 mg/L (Stäube oder Nebel) oral: ATE = 768 mg/kg KG M = 1 M = 1 | ||
613-341-00-0 | Clofentezin (ISO); 3,6-Bis(o-chlorphenyl)-1,2,4,5-tetrazin | 277-728-2 | 74115-24-5 | Aquatic Chronic 1 | H410 | GHS09 Wng | H410 | M = 1 | ||
613-342-00-6 | Theophyllin; 1,3-Dimethyl-3,7-dihydro-1 H-purin-2,6-dion | 200-385-7 | 58-55-9 | Repr. 1B | H360D | GHS08 Dgr | H360D | |||
613-343-00-1 | Pyridalyl (ISO); 2,6-Dichlor-4-(3,3-dichlorallyloxy)phenyl 3-[5-(trifluormethyl)-2-pyridyloxy]propylether | - | 179101-81-6 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 1.000 M = 100 | ||
613-344-00-7 | Pyridin-2-thiol-1-oxid, Natriumsalz; Pyrithionnatrium; Natriumpyrithion | 223-296-5; 240-062-8 | 3811-73-2; 15922-78-8 | Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 2 | H331 H311 H302 H372 (Nervensystem) H315 H319 H317 H400 H411 | GHS06 GHS08 GHS09 Dgr | H331 H311 H302 H372 (Nervensystem) H315 H319 H317 H410 | EUH070 | Einatmung: ATE = 0,5 mg/L (Stäube oder Nebel) Dermal: ATE = 790 mg/kg KG Oral: ATE = 500 mg/kg KG M = 100 | |
613-345-00-2 | 2,4,6-Triamino-1,3,5-triazin; Melamin | 203-615-4 | 108-78-1 | Carc. 2 STOT RE 2 | H351 H373 (Harnwege) | GHS08 Wng | H351 H373 (Harnwege) | |||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
613-346-00-8 | 4-Nitrosomorpholin | - | 59-89-2 | Carc. 1B Muta. 2 STOT RE 1 | H350 H341 H372 (Leber) | GHS08 Dgr | H350 H341 H372 (Leber) | Carc. 1B; H350: C ≥ 0,001 % | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
613-347-00-3 | Difenoconazol (ISO); 1-({2-[2-Chlor-4-(4-chlorphenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazol; 3-Chlor-4-[(2 RS,4 RS;2 RS,4 SR)-4-methyl-2-(1 H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenylether | - | 119446-68-3 | Carc. 2 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H319 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H319 H410 | Oral: ATE = 1.450 mg/kg KG M = 10 M = 10 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
613-348-00-9 | 9-[2-(Ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethylxanthyliumchlorid; Basic Red 1 | 213-584-9 | 989-38-8 | Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H301 H318 H317 H410 | Oral: ATE = 280 mg/kg KG M = 10 M = 1 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
613-349-00-4 | 4-Methylimidazol | 212-497-3 | 822-36-6 | Carc. 1B Repr. 1B | H350 H360Fd | GHS08 Dgr | H350 H360Fd | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
613-350-00-X | 1 H-Benzotriazol | 202-394-1 | 95-14-7 | Aquatic Chronic 2 | H411 | GHS09 Wng | H411 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
613-351-00-5 | Methyl-1 H-benzotriazol | 249-596-6 | 29385-43-1 | Aquatic Chronic 2 | H411 | GHS09 Wng | H411 | ) | ||
614-001-00-4 | Nikotin (ISO); 3-[(2S)-1-Methylpyrrolidin-2-yl]pyridin | 200-193-3 | 54-11-5 | Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 | H330 H310 H300 H411 | GHS06 GHS09 Dgr | H330 H310 H300 H411 | Einatmung: ATE = 0,19 mg/L (Stäube oder Nebel) Dermal: ATE = 70 mg/kg KG Oral: ATE = 5 mg/kg KG | ||
614-002-00-X | Nikotinsalze | - | - | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Chronic 2 | H330 H310 H300 H411 | GHS06 GHS09 Gef. | H330 H310 H300 H411 | A | ||
614-003-00-5 | Strychnin | 200-319-7 | 57-24-9 | Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H310 H300 H400 H410 | GHS06 GHS09 Gef. | H310 H300 H410 | |||
614-004-00-0 | Strychninsalze | - | - | Acute Tox. 2 * Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 | H330 H300 H400 H410 | GHS06 GHS09 Gef. | H330 H300 H410 | A | ||
614-005-00-6 | Colchicin; 7-Acetamido-1,2,3,10-tetramethoxy-5,6,7,9-tetrahydrobenzo[a]heptalen-9-on | 200-598-5 | 64-86-8 | Muta. 1B Acute Tox. 2 * | H340 H300 | GHS06 GHS08 Gef. | H340 H300 | |||
614-006-00-1 | Brucin; 2,3-Dimethoxystrychnin | 206-614-7 | 357-57-3 | Acute Tox. 2 * Acute Tox. 2 * Aquatic Chronic 3 | H330 H300 H412 | GHS06 Gef. | H330 H300 H412 | |||
614-007-00-7 | Brucinsulfat [1]; Brucinnitrat [2]; Strychnidin-10-on, 2,3-Dimethoxy-, mono[( R)-1-methylheptyl-1,2-benzoldicarboxylat] [3]; Strychnidin-10-on, 2,3-Dimethoxy im Vergleich zu (S)-Mono(1-methylheptyl)-1,2-benzoldicarboxylat (1:1) [4] | 225-432-9 [1] 227-317-9 [2] 269-439-5 [3] 269-710-8 [4] | 4845-99-2 [1] 5786-97-0 [2] 68239-26-9 [3] 68310-42-9 [4] | Acute Tox. 2 * Acute Tox. 2 * Aquatic Chronic 3 | H330 H300 H412 | GHS06 Gef. | H330 H300 H412 | A | ||
614-008-00-2 | Aconitin | 206-121-7 | 302-27-2 | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | |||
614-009-00-8 | Aconitinsalze | - | - | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | A | ||
614-010-00-3 | Atropin; DL-Tropyl-tropat | 200-104-8 | 51-55-8 | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | |||
614-011-00-9 | Atropinsalze | - | - | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | A | ||
614-012-00-4 | Hyoscyamin; L-Tropyl-tropat | 202-933-0 | 101-31-5 | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | |||
614-013-00-X | Hyoscyaminsalze | - | - | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | A | ||
614-014-00-5 | Hyoscin; Scopolamin L-6,7-Epoxy-tropyl-tropat | 200-090-3 | 51-34-3 | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * | H330 H310 H300 | GHS06 Gef. | H330 H310 H300 | |||
614-015-00-0 | Hyoscinsalze | - | - | Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * | H330 H310 H300 | GHS06 Gef. | H330 H310 H300 | A | ||
614-016-00-6 | Pilocarpin; 3-Ethyl-4-(1-methyl-imidazol-5-yl-methyl)-tetrahydrofuran-2-on | 202-128-4 | 92-13-7 | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | |||
614-017-00-1 | Pilocarpinsalze | - | - | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | A | ||
614-018-00-7 | Papaverin; 1-(3",4"-Dimethoxy-benzyl)-6,7-dimethoxy-isochinolin | 200-397-2 | 58-74-2 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
614-019-00-2 | Papaverinsalze | - | - | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | A | ||
614-020-00-8 | Physostigmin; Eserin; 1,3a,8-Trimethyl-5-methylcarbamoyloxy-1,2,3,3a,8a-hexahydropixiolo[2,3-b]indol | 200-332-8 | 57-47-6 | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | |||
614-021-00-3 | Physostigminsalze | - | - | Acute Tox. 2 * Acute Tox. 2 * | H330 H300 | GHS06 Gef. | H330 H300 | A | ||
614-022-00-9 | Digitoxin; 3β,14β-Dihydroxy-5β-carden-20(22)-olid-3-tridigitoxid | 200-760-5 | 71-63-6 | Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * | H331 H301 H373 ** | GHS06 GHS08 Gef. | H331 H301 H373 ** | |||
614-023-00-4 | Ephedrin; L-erythro-2-Methylamino-1-phenyl- propan-1-ol | 206-080-5 | 299-42-3 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
614-024-00-X | Ephedrinesalze | - | - | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | A | ||
614-025-00-5 | g-Strophanthin; G-Strophantin; 1β,3β,5β,11β,14β,19-Hexahydroxy- [20(22)-cardenolid]-3-L-rhamnosid | 211-139-3 | 630-60-4 | Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * | H331 H301 H373 ** | GHS06 GHS08 Gef. | H331 H301 H373 ** | |||
614-026-00-0 | K-Strophantin; 5β,14β-Dihydroxy-3β-(β-D-glucopyranosido-4β-D-glucopyranosido-β-D-cymaropyranosido)-19-oxo-card-20(22)-enolid | 234-239-9 | 11005-63-3 | Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * | H331 H301 H373 ** | GHS06 GHS08 Gef. | H331 H301 H373 ** | |||
614-027-00-6 | Bufa-4,20,22-trienolid, 6-(acetyloxy)-3-(β-D-glucopyranosyloxy)-8,14-dihydroxy-, (3β, 6β)-; Rote Meerzwiebel; Scillirosid | 208-077-4 | 507-60-8 | Acute Tox. 2 * | H300 | GHS06 Gef. | H300 | |||
614-028-00-1 | Reaktionsmasse aus 2-Ethylhexyl-mono-D-glucopyranosid und 2-Ethylhexyl-di-D-glucopyranosid | 414-420-0 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
614-029-00-7 | Konstitutionsisomere von Penta- O-allyl-β-D-fructofuranosyl-α-D-glucopyranosid; Konstitutionsis omere von Hexa- O-allyl-β-D-fructofuranosyl-α-D-glucopyranosid; Konstitutionsisomere von Hepta- O-allyl-β-D-fructofuransoyl-α-D-glucopyranosid | 419-640-0 | 68784-14-5 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
614-030-00-2 | Emamectinbenzoat (ISO); (4" R)-4-Deoxy-4"-(methylamino)avermectin B1 benzoat | - | 155569-91-8 | Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 STOT SE 1 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H311 H301 H370 (Nervensystem) H372 (Nervensystem) H318 H400 H410 | GHS06 GHS05 GHS08 GHS09 Dgr | H331 H311 H301 H370 (Nervensystem) H372 (Nervensystem) H318 H410 | Einatmen: ATE = 0,663 mg/L (Stäube oder Nebel) dermal: ATE = 300 mg/kg KG oral: ATE = 60 mg/kg KG STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 % M = 10 000 M = 10 000 | ||
615-001-00-7 | Methylisocyanat | 210-866-3 | 624-83-9 | Flam. Liq. 2 Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Resp. Sens. 1 Skin Sens. 1 STOT SE 3 Skin Irrit. 2 Eye Dam. 1 | H225 H361d*** H330 H311 H301 H334 H317 H335 H315 H318 | GHS02 GHS06 GHS05 GHS08 Gef. | H225 H361d*** H330 H311 H301 H334 H317 H335 H315 H318 | |||
615-002-00-2 | Methylisothiocyanat | 209-132-5 | 556-61-6 | Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H314 H317 H400 H410 | GHS06 GHS05 GHS09 Gef. | H331 H301 H314 H317 H410 | |||
615-003-00-8 | Thiocyansäure; Rhodanwasserstoffsäure | 207-337-4 | 463-56-9 | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H332 H312 H302 H412 | GHS07 Achtg. | H332 H312 H302 H412 | EUH032 | ||
615-004-00-3 | Thiocyansäuresalze, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H332 H312 H302 H412 | GHS07 Achtg. | H332 H312 H302 H412 | EUH032 | A | |
615-005-00-9 | 4,4"-Methylendiphenyldiisocyanat; Diphenylmethan-4,4"-diisocyanat [1]; 2,2"-Methylendiphenyldiisocyanat; Diphenylmethan-2,2"-diisocyanat [2]; o-( p-Isocyanatobenzyl)phenylisocyanat; Diphenylmethan-2,4"-diisocyanat [3]; Methylendiphenyldiisocyanat [4] | 202-966-0 [1] 219-799-4 [2] 227-534-9 [3] 247-714-0 [4] | 101-68-8 [1] 2536-05-2 [2] 5873-54-1 [3] 26447-40-5 [4] | Carc. 2 Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 | H351 H332 H373** H319 H335 H315 H334 H317 | GHS08 GHS07 Gef. | H351 H332 H373** H319 H335 H315 H334 H317 | Eye Irrit. 2; H319: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % Resp. Sens. 1; H334: C ≥ 0,1 % STOT SE 3; H335: C ≥ 5 % | C2 | |
615-006-00-4 | 2-Methyl- m-phenylendiisocyanat; Toluol-2,4-diisocyanat [1]; 4-Ethyl- m-phenylendiisocyanat; Toluol-2,6-diisocyanat [2]; m-Tolylidendiisocyanat; Toluoldiisocyanat [3] | 202-039-0 [1] 209-544-5 [2] 247-722-4 [3] | 91-08-7 [1] 584-84-9 [2] 26471-62-5 [3] | Carc. 2 Acute Tox. 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 | H351 H330 H319 H335 H315 H334 H317 H412 | GHS06 GHS08 Gef. | H351 H330 H319 H335 H315 H334 H317 H412 | Resp. Sens. 1; H334: C ≥ 0,1 % | C | |
| - gestrichen - | |||||||||
615-008-00-5 | 3-Isocyanatomethyl-3,5,5- trimethylcyclohexylisocyanat; Isophorondiisocyanat | 223-861-6 | 4098-71-9 | Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 2 | H331 H319 H335 H315 H334 H317 H411 | GHS06 GHS08 GHS09 Gef. | H331 H319 H335 H315 H334 H317 H411 | * Resp. Sens. 1; H334: C ≥0,5 % Skin Sens.1; H317: C ≥0,5 % | 2 | |
615-009-00-0 | 4,4"-Methylendi(cyclohexylisocyanat); Dicyclohexylmethan-4,4"-diisocyanat | 225-863-2 | 5124-30-1 | Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 | H331 H319 H335 H315 H334 H317 | GHS06 GHS08 Gef. | H331 H319 H335 H315 H334 H317 | * Resp. Sens. 1; H334: C ≥0,5 % Skin Sens. 1; H317: C ≥0,5 % | 2 | |
615-010-00-6 | 2,2,4-Trimethylhexamethylen-1,6-diisocyanat [1]; 2,4,4-Trimethylhexamethylen-1,6-diisocyanat [2] | 241-001-8 [1] 239-714-4 [2] | 16938-22-0 [1] 15646-96-5 [2] | Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H331 H319 H335 H315 H334 | GHS06 GHS08 Gef. | H331 H319 H335 H315 H334 | * Resp. Sens. 1; H334: C ≥0,5 % Skin Sens. 1; H317: C ≥0,5 % | C2 | |
615-011-00-1 | Hexamethylendiisocyanat | 212-485-8 | 822-06-0 | Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 | H331 H319 H335 H315 H334 H317 | GHS06 GHS08 Gef. | H331 H319 H335 H315 H334 H317 | * Resp. Sens. 1; H334: C ≥ 0,5 % Skin Sens. 1; H317: C ≥0,5 % | 2 | |
615-012-00-7 | 4-Toluolsulfonylisocyanat; Tosylisocyanat | 223-810-8 | 4083-64-1 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | EUH014 | Eye Irrit.; H319: C ≥ 5 % STOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % | |
615-013-00-2 | Cyanamid; Carbamonitril | 206-992-3 | 420-04-2 | Carc. 2 Repr. 2 Acute Tox. 3 Acute Tox. 3 STOT RE 2 Skin Corr. 1 Skin Sens. 1 Eye Dam. 1 Aquatic Chronic 3 | H351 H361fd H311 H301 H373 (Schilddrüse) H314 H317 H318 H412 | GHS08 GHS06 GHS05 Gef. | H351 H361fd H311 H301 H373 (Schilddrüse) H314 H317 H412 | |||
615-014-00-8 | Tris(1-dodecyl-3-methyl-2- phenylbenzimidazolium)hexacyanoferrat | - | 7276-58-6 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
615-015-00-3 | 1,7,7-Trimethylbicyclo(2,2,1)hept-2-yl- thiocyanatoacetat; Isobornylthiocyanoacetat | 204-081-5 | 115-31-1 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
615-016-00-9 | Kaliumcyanat | 209-676-3 | 590-28-3 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
615-017-00-4 | Calciumcyanamid | 205-861-8 | 156-62-7 | Acute Tox. 4 * STOT SE 3 Eye Dam. 1 | H302 H335 H318 | GHS05 GHS07 Gef. | H302 H335 H318 | |||
615-018-00-X | 2-(2-Butoxyethoxy)ethylthiocyanat | 203-985-7 | 112-56-1 | Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * | H226 H311 H301 | GHS02 GHS06 Gef. | H226 H311 H301 | |||
615-019-00-5 | Dicyclohexylcarbodiimid | 208-704-1 | 538-75-0 | Acute Tox. 3 * Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 | H311 H302 H318 H317 | GHS06 GHS05 Gef. | H311 H302 H318 H317 | |||
615-020-00-0 | Methylendithiocyanat; Diisocyanatomethan | 228-652-3 | 6317-18-6 | Acute Tox. 2 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 | H330 H301 H314 H317 H400 | GHS06 GHS05 GHS09 Gef. | H330 H301 H314 H317 H400 | |||
615-021-00-6 | 1,3,5-Tris(oxiranylmethyl)-1,3,5-triazin-2,4,6(1 H,3 H,5 H)trion; TGIC; Triglycidylisocyanurat | 219-514-3 | 2451-62-9 | Muta. 1B Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H340 H331 H301 H373 ** H318 H317 H412 | GHS06 GHS08 GHS05 Gef. | H340 H331 H301 H373 ** H318 H317 H412 | |||
615-022-00-1 | Methyl-3-sulfonylisocyanat-2-thiophencarboxylat | 410-550-7 | 79277-18-2 | STOT RE 2 * Resp. Sens. 1 Skin Sens. 1 | H373** H334 H317 | GHS08 Gef. | H373** H334 H317 | EUH014 | ||
615-023-00-7 | 2-(Methylsulfonylisocyanat)benzoesäuremethylester; Methyl-2-(Methylsulfonylisocyanat)benzoat | 410-900-9 | 83056-32-0 | Flam. Liq. 3 Muta. 2 Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Resp. Sens. 1 | H226 H341 H332 H373 ** H318 H334 | GHS02 GHS08 GHS05 GHS07 Gef. | H226 H341 H332 H373 ** H318 H334 | EUH014 | ||
615-024-00-2 | 2-Phenylethylisocyanat | 413-080-0 | 1943-82-4 | Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 2 | H331 H302 H314 H334 H317 H411 | GHS06 GHS08 GHS05 GHS09 Gef. | H331 H302 H314 H334 H317 H411 | |||
615-025-00-8 | 4,4"-Ethylidendiphenyldicyanat | 405-740-1 | 47073-92-7 | Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H332 H302 H373 ** H318 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H332 H302 H373 ** H318 H410 | |||
615-026-00-3 | 4,4"-Methylen-bis(2,6-dimethylphenylcyanat) | 405-790-4 | 101657-77-6 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
615-028-00-4 | Ethyl-2-(sulfonylisocyanat)benzoat | 410-220-2 | 77375-79-2 | Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H302 H373** H318 H334 H317 | GHS05 GHS08 GHS07 Gef. | H302 H373** H318 H334 H317 | EUH014 | ||
615-029-00-X | 2,5-Bis(methylisocyanat)bicyclo[2,2,1]heptan | - | Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 | H330 H302 H314 H334 H317 H412 | GHS06 GHS08 GHS05 Gef. | H330 H302 H314 H334 H317 H412 | ||||
615-030-00-5 | Alkalisalze und alkalische Erdsalze von Thiocyansäure, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 | H332 H312 H302 H412 | GHS07 Achtg. | H332 H312 H302 H412 | A | ||
615-031-00-0 | Thalliumthiocyanat | 222-571-7 | 3535-84-0 | Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 4 * STOT RE 2 Aquatic Chronic 2 | H330 H300 H312 H373** H411 | GHS06 GHS08 GHS09 Gef. | H330 H300 H312 H373** H411 | |||
615-032-00-6 | Metallsalze von Thiocyansäure, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H332 H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H332 H312 H302 H410 | A | ||
615-033-00-1 | Reaktionsprodukt von Diphenylmethandiisocyanat, Octylamin, Oleylamin und Cyclohexylamin (1:1,58:0,32:0097) | 430-980-9 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
615-034-00-7 | Reaktionsprodukt von Diphenylmethandiisocyanat, Octylamin, 4-Ethoxyanilin und Ethylendiamin (1:0,37:1,53:0,05) | 430-750-8 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
615-035-00-2 | Reaktionsprodukt von Diphenylmethandiisocyanat, Octylamin und Oleylamin (Stoffmengenverhältnis 1:1,86:0,14) | 430-930-6 | 122886-55-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
615-036-00-8 | Reaktionsprodukt von Diphenylmethandiisocyanat, Toluoldiisocyanat (Reaktionsmasse aus Isomeren: 65 % 2,4- und 35 % 2,6-Diisocyanat), Octylamin, Oleylamin und 4-Ethoxyanilin (Stoffmengenverhältnis 4:1:7:1:2) | 430-940-0 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
615-037-00-3 | Reaktionsprodukt von Diphenylmethandiisocyanat, Toluoldiisocyanat (Reaktionsmasse aus Isomeren: 65 % 2,4- und 35 % 2,6-Diisocyanat), Octylamin und Oleylamin (Stoffmengenverhältnis 4:1:9:1) | 430-950-5 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
615-038-00-9 | Reaktionsprodukt von Toluoldiisocyanat (Reaktionsmasse aus Isomeren: 65 % 2,4- and 35 % 2,6-Diisocyanat) und Anilin (Stoffmengenverhältnis 1:2) | 430-960-1 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
615-039-00-4 | Reaktionsprodukt von Diphenylmethandiisocyanat, Toluoldiisocyanat (Reaktionsmasse aus Isomeren: 65 % 2,4- und 35 % 2,6-Diisocyanat), Octylamin, Oleylamin und 4-Ethoxyanilin (Stoffmengenverhältnis 3,88:1:6,38:0,47:2,91) | 430-970-4 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
615-044-00-1 | 4-Chlorphenylisocyanat | 203-176-9 | 104-12-1 | Acute Tox. 2 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H335 H315 H318 H334 H400 H410 | GHS06 GHS05 GHS08 GHS09 Gef. | H330 H302 H335 H315 H318 H334 H410 | |||
615-045-00-7 | 4,4"-Methylenbis(3-chlor-2,6-diethylphenylisocyanat) | 420-530-1 | - | Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 4 | H334 H317 H413 | GHS08 Gef. | H334 H317 H413 | |||
615-046-00-2 | 1,3-Bis(1-isocyanato-1-methylethyl)benzol; [ m-TMXDI] | 220-474-4 | 2778-42-9 | Resp. Sens. 1 Skin Sens. 1A | H334 H317 | GHS08 Dgr | H334 H317 | |||
615-047-00-8 | 1,3-Bis(isocyanatomethyl)benzol; [ m-XDI] | 222-852-4 | 3634-83-1 | Resp. Sens. 1 Skin Sens. 1A | H334 H317 | GHS08 Dgr | H334 H317 | Skin Sens. 1A; H317: C ≥ 0,001 % | ||
615-048-00-3 | 2,4,6-Triisopropyl- m-phenylendiisocyanat | 218-485-4 | 2162-73-4 | Resp. Sens. 1 Skin Sens. 1 | H334 H317 | GHS08 Dgr | H334 H317 | |||
615-049-00-9 | 1,5-Naphthylendiisocyanat [Gehalt an Partikeln mit einem aerodynamischen Durchmesser unter 50 μm < 0,1 Gewichtsprozent] | 221-641-4 | 3173-72-6 | STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3 | H335 H315 H319 H334 H317 H412 | GHS07 GHS08 Dgr | H335 H315 H319 H334 H317 H412 | |||
615-050-00-4 | 1,5-Naphthylendiisocyanat [Gehalt an Partikeln mit einem aerodynamischen Durchmesser unter 50 μm ≥ 0,1 Gewichtsprozent] | 221-641-4 | 3173-72-6 | Acute Tox. 2 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3 | H330 H335 H315 H319 H334 H317 H412 | GHS06 GHS08 Dgr | H330 H335 H315 H319 H334 H317 H412 | Einatmung: ATE = 0,27 mg/L (Stäube oder Nebel) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
615-051-00-X | 3,3"-Dimethylbiphenyl-4,4"-diyldiisocyanat | 202-112-7 | 91-97-4 | Carc. 2 Resp. Sens. 1 Skin Sens. 1A | H351 H334 H317 | GHS08 Dgr | H351 H334 H317 | Skin Sens. 1A; H317: C ≥ 0,001 % | ) | |
616-001-00-X | N, N-Dimethylformamid; Dimethylformamid | 200-679-5 | 68-12-2 | Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 | H360D *** H332 H312 H319 | GHS08 GHS07 Gef. | H360D *** H332 H312 H319 | |||
616-002-00-5 | 2-Fluoracetamid | 211-363-1 | 640-19-7 | Acute Tox. 2 * Acute Tox. 3 * | H300 H311 | GHS06 Gef. | H300 H311 | |||
616-003-00-0 | Acrylamid; Prop-2-enamid | 201-173-7 | 79-06-1 | Carc. 1B Muta. 1B Repr. 2 Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 | H350 H340 H361f *** H301 H372 ** H332 H312 H319 H315 H317 | GHS06 GHS08 Gef. | H350 H340 H361f *** H301 H372 ** H332 H312 H319 H315 H317 | D | ||
616-004-00-6 | Allidochlor (ISO); N, N-Diallylchloracetamid | 202-270-7 | 93-71-0 | Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 | H312 H302 H319 H315 H411 | GHS07 GHS09 Achtg. | H312 H302 H319 H315 H411 | |||
616-005-00-1 | Chlorthiamid (ISO); 2,6-Dichlor-(thiobenzamid) | 217-637-7 | 1918-13-4 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
616-006-00-7 | Dichlofluanid (ISO); N-[(Dichlorfluormethyl)thio]- N",N"-dimethyl-N-phenylsulfamid | 214-118-7 | 1085-98-9 | Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 | H332 H319 H317 H400 | GHS07 GHS09 Achtg. | H332 H319 H317 H400 | M = 10 | ) | |
616-007-00-2 | Diphenamid (ISO); N, N-Dimethyl-2,2-diphenylacetamid | 213-482-4 | 957-51-7 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
616-008-00-8 | Propachlor (ISO); 2-Chlor- N-isopropylacetanilid; α-Chlor- N-isopropylacetanilid | 217-638-2 | 1918-16-7 | Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H319 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H319 H317 H410 | |||
616-009-00-3 | Propanil (ISO); 3",4"-Dichlorpropionanilid | 211-914-6 | 709-98-8 | Acute Tox. 4 * Aquatic Acute 1 | H302 H400 | GHS07 GHS09 Achtg. | H302 H400 | M=10 | ||
616-010-00-9 | Tosylchloramid-Natrium; Chloramin T (Natriumsalz) | 204-854-7 | 127-65-1 | Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 | H302 H314 H334 | GHS08 GHS05 GHS07 Dg | H302 H314 H334 | EUH031 | ||
616-011-00-4 | N,N-Dimethylacetamid | 204-826-4 | 127-19-5 | Repr. 1B Acute Tox. 4* Acute Tox. 4* | H360D*** H332 H312 | GHS08 GHS07 Gef. | H360D*** H332 H312 | |||
616-012-00-X | N-(Dichlorfluormethylthio)phthalimid; N-(Fluordichlormethylthio)phthalimid | 211-952-3 | 719-96-0 | Skin Irrit. 2 | H315 | GHS07 Achtg. | H315 | |||
616-013-00-5 | Butyraldehydoxim | 203-792-8 | 110-69-0 | Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 | H311 H302 H319 | GHS06 Gef. | H311 H302 H319 | |||
616-014-00-0 | Butanonoxim; Ethylmethylketoxim; Ethylmethylketonoxim | 202-496-6 | 96-29-7 | Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H350 H312 H301 H336 H370 (obere Atemwege) H373 (Blutkreislauf) H315 H318 H317 | GHS08 GHS06 GHS05 Dgr | H350 H312 H301 H336 H370 (obere Atemwege) H373 (Blutkreislauf) H315 H318 H317 | dermal: ATE = 1100 mg/kg KG oral: ATE = 100 mg/kg KG | ||
616-015-00-6 | Alachlor (ISO); 2-Chlor-2",6"-diethyl- N-(methoxymethyl)acetanilid | 240-110-8 | 15972-60-8 | Carc. 2 Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H317 H410 | M=10 | ||
616-016-00-1 | 1-(3,4-Dichlorphenylimino)thiosemicarbazid | - | 5836-73-7 | Acute Tox. 2 * | H300 | GHS06 Gef. | H300 | |||
616-017-00-7 | Cartaphydrochlorid | 239-309-2 | 15263-52-2 | Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H312 H302 H400 H410 | GHS07 GHS09 Achtg. | H312 H302 H410 | |||
616-018-00-2 | Diethyltoluamid (ISO): N, N-Diethyl- m-toluamid [deet] | 205-149-7 | 134-62-3 | Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 | H302 H315 H319 | GHS07 Wng | H302 H315 H319 | Oral: ATE = 1892 mg/kg KG | ||
616-019-00-8 | Perfluidon (ISO); 1,1,1-Trifluor- N-(4-phenylsulfonyl- o-tolyl)methansulfonamid | 253-718-3 | 37924-13-3 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
616-020-00-3 | Tebuthiuron (ISO); 1-(5- tert-Butyl-1,3,4-thiadiazol-2-yl)-1,3-dimethylharnstoff | 251-793-7 | 34014-18-1 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
616-021-00-9 | Thiazafluron (ISO); 1,3-Dimethyl-1-(5-trifluormethyl-1,3,4-thiadiazol-2-yl)harnstoff | 246-901-4 | 25366-23-8 | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
616-022-00-4 | Acetamid; Essigsäureamid | 200-473-5 | 60-35-5 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
616-023-00-X | N-Hexadecyl (oder octadecyl)- N-hexadecyl (oder octadecyl)benzamid | 401-980-6 | - | Skin Irrit. 2 Skin Sens. 1 | H315 H317 | GHS07 Achtg. | H315 H317 | |||
616-024-00-5 | 2-(4,4-Dimethyl-2,5-dioxooxazolidin-1-yl)-2-chlor-5-(2-(2,4-di- tert-pentylphenoxy)butyramido)-4,4-dimethyl-3-oxovaleranilid | 402-260-4 | 54942-74-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-025-00-0 | Valinamid | 402-840-7 | 20108-78-5 | Repr. 2 Eye Irrit. 2 Skin Sens. 1 | H361f *** H319 H317 | GHS08 Achtg. | H361f *** H319 H317 | |||
616-026-00-6 | Thioacetamid | 200-541-4 | 62-55-5 | Carc. 1B Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3 | H350 H302 H319 H315 H412 | GHS08 GHS07 Gef. | H350 H302 H319 H315 H412 | |||
616-027-00-1 | Tris(2-(2-hydroxyethoxy)ethyl)ammonium-3-acetoacetamido-4-methoxybenzolsulfonat | 403-760-5 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
616-028-00-7 | N-(4-(3-(4-cyanophenyl)ureido)-3-hydroxyphenyl)-2-(2,4-di- tert-pentylphenoxy)octanamid | 403-790-9 | 108673-51-4 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-029-00-2 | N, N"-Ethylenbis(vinylsulfonylacetamid) | 404-790-1 | 66710-66-5 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
616-030-00-8 | Ethidimuron (ISO); 1-(5-Ethylsulfonyl-1,3,4-thiadiazol-2-yl)-1,3-dimethylharnstoff | 250-010-6 | 30043-49-3 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
616-031-00-3 | Dimethachlor (ISO); 2-Chlor- N-(2,6-dimethylphenyl)- N-(2-methoxyethyl)acetamid; | 256-625-6 | 50563-36-5 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
616-032-00-9 | Diflufenican (ISO); N-(2,4-Difluorphenyl)-2-[3-(trifluormethyl)phenoxy]-3-pyridincarboxamid; 2",4"-Difluor-2-(α,α,α-trifluor- m-tolyloxy)nicotinanilid | - | 83164-33-4 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 10 000 M = 1 000 | ||
616-033-00-4 | Cyprofuram (ISO); N-(3-Chlorphenyl)- N-(tetrahydro-2-oxo-3-furyl)cyclopropancarboxamid | 274-050-9 | 69581-33-5 | Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H312 H400 H410 | GHS06 GHS09 Gef. | H301 H312 H410 | |||
616-034-00-X | Pyracarbolid; (ISO); 3,4-Dihydro-6-methyl-2 H-pyran-5-carboxanilid | 246-419-4 | 24691-76-7 | Aquatic Chronic 3 | H412 | - | H412 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
616-035-00-5 | Cymoxanil (ISO); 2-Cyano- N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamid | 261-043-0 | 57966-95-7 | Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361fd H302 H373 (Blut, Thymus) H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H361fd H302 H373 (Blut, Thymus) H317 H410 | M = 1 M = 1 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
616-035-00-5 | Cymoxanil (ISO); 2-Cyano- N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamid; [1] (2 E)-2-Cyano- N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamid; [2] | 261-043-0 [1] - [2] | 57966-95-7 [1] 166900-80-7 [2] | Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361fd H302 H373 (Blutkreislauf, Thymusdrüse, Augen) H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361fd H302 H373 (Blutkreislauf, Thymusdrüse, Augen) H317 H410 | Oral: ATE = 360 mg/kg KG M = 1 M = 1 | ) | |
616-036-00-0 | 2-Chloracetamid | 201-174-2 | 79-07-2 | Repr. 2 Acute Tox. 3 * Skin Sens. 1 | H361f *** H301 H317 | GHS06 GHS08 Gef. | H361f *** H301 H317 | Skin Sens. 1; H317: C ≥ 0,1 % | ||
616-037-00-6 | Acetochlor (ISO); 2-Chlor-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamid | 251-899-3 | 34256-82-1 | Carc. 2 Repr. 2 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361f H332 H335 H373 (Nieren) H315 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H361f H332 H335 H373 (Nieren) H315 H317 H410 | M = 1 000 M = 100 | ||
616-038-00-1 | (4-Aminophenyl)- N-methylmethylensulfonamidhydrochlorid | 406-010-5 | 88918-84-7 | Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H318 H317 H411 | GHS05 GHS07 GHS09 Gef. | H318 H317 H411 | |||
616-039-00-7 | 3",5"-Dichlor-4"-ethyl-2"-hydroxypalmitanilid | 406-200-8 | 117827-06-2 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
616-040-00-2 | Kalium- N-(4-toluolsulfonyl)-4-toluolsulfonamid | 406-650-5 | 97888-41-0 | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
616-041-00-8 | 3",5"-Dichlor-2-(2,4-di- tert-pentylphenoxy)-4"-ethyl-2"-hydroxyhexananilid | 406-840-8 | 101664-25-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-042-00-3 | N-(2-(6-Ethyl-7-(4-methylphenoxy)-1 H-pyrazolo[1,5- b][1,2,4]triazol-2-l)propyl)-2-octadecyloxybenzamid | 407-070-5 | 142859-67-4 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-043-00-9 | Isoxaben (ISO); N-[3-(1-Ethyl-1-methylpropyl)-1,2-oxazol-5-yl]-2,6-dimethoxybenzamid | 407-190-8 | 82558-50-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-044-00-4 | N-(3,5-Dichlor-4-ethyl-2-hydroxyphenyl)-2-(3-pentadecylphenoxy)butanamid | 402-510-2 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
616-045-00-X | 2"-(4-Chlor-3-cyano-5-formyl-2- thienylazo)-5"-diethylamino-2-methoxyacetanilid | 405-190-2 | 122371-93-1 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-046-00-5 | N-(2-(6-Chlor-7-methylpyrazolo(1,5- b)-1,2,4-triazol-4-yl)propyl)-2-(2,4-di- tert-pentylphenoxy)octanamid | 406-390-2 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-047-00-0 | Reaktionsmasse aus 2,2",2"",2- (Ethylendinitrilotetrakis- N, N- di(C16)alkylacetamid und 2,2",2"",2-(Ethylendinitrilotetrakis- N, N-di(C18)alkylacetamid | 406-640-0 | - | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
616-048-00-6 | 3"-Trifluormethylisobutyranilid | 406-740-4 | 1939-27-1 | STOT RE 2 * Aquatic Chronic 2 | H373 ** H411 | GHS08 GHS09 Achtg. | H373 ** H411 | |||
616-049-00-1 | 2-(2,4-Bis(1,1-dimethylethyl)phenoxy)- N-(3,5-dichlor-4-ethyl-2-hydroxyphenyl)hexanamid | 408-150-2 | 99141-89-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-050-00-7 | Lufenuron (ISO); N-[2,5-Dichlor-4-(1,1,2,3,3,3-hexafluorpropoxy)phenylaminocarbonyl]-2,6-difluorbenzamid | 410-690-9 | 103055-07-8 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
616-051-00-2 | Reaktionsmasse aus 2,4-Bis( N"-(4-methylphenyl)ureido)toluol und 2,6-Bis( N"-(4-methylphenyl)ureido)toluol | 411-070-0 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
616-052-00-8 | Formamid | 200-842-0 | 75-12-7 | Repr. 1B | H360D *** | GHS08 Gef. | H360D *** | |||
616-053-00-3 | N-Methylacetamid | 201-182-6 | 79-16-3 | Repr. 1B | H360D *** | GHS08 Gef. | H360D *** | |||
616-054-00-9 | Iprodion (ISO); 3-(3,5-Dichlorphenyl)-2,4-dioxo- N-isopropylimidazolidin-1-carboxamid | 253-178-9 | 36734-19-7 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
616-055-00-4 | Propyzamid (ISO); 3,5-Dichlor- N-(1,1-dimethylprop-2-ynyl)benzamid | 245-951-4 | 23950-58-5 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | |||
616-056-00-X | N-Methylformamid | 204-624-6 | 123-39-7 | Repr. 1B Acute Tox. 4 * | H360D *** H312 | GHS08 GHS07 Dg | H360D *** H312 | |||
616-057-00-5 | Reaktionsmasse aus N-[3-hydroxy-2-(2-methylacryloylaminomethoxy)propoxymethyl]-2-methylacrylamid, N-[2,3-Bis(2-methylacryloylaminomethoxy)propoxymethyl]-2-methylacrylamid, Methacrylamid, 2-methyl- N-(2-methylacryloylaminomethoxymethyl)acrylamid und N-(2,3-Dihydroxypropoxymethyl)-2-methylacrylamid | 412-790-8 | - | Carc. 1B Muta. 2 STOT RE 2 * | H350 H341 H373 ** | GHS08 Gef. | H350 H341 H373 ** | |||
616-058-00-0 | 1,3-Bis(3-methyl-2,5-dioxo-1 H-pyrrolinylmethyl)benzol | 412-570-1 | 119462-56-5 | STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H318 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Gef. | H373 ** H318 H317 H410 | |||
616-059-00-6 | 4-((4-(Diethylamino)-2-ethoxyphenyl)imino)-1,4-dihydro-1-oxo- N-propyl-2-naphthalincarboxamid | 412-650-6 | 121487-83-0 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-060-00-1 | Kondensationsprodukt von 3-(7- carboxyhept-1-yl)-6-hexyl-4- cyclohexen-1,2-dicarboxylsäure mit Polyaminen (in erster Linie Aminoethylpiperazin und Triethylentetramin) | 413-770-1 | - | Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H314 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H314 H317 H410 | |||
616-061-00-7 | N, N"-1,6-Hexandiyl-bis( N-(2,2,6,6-tetramethylpiperidin-4-yl)formamid | 413-610-0 | 124172-53-8 | Eye Irrit. 2 Aquatic Chronic 3 | H319 H412 | GHS07 Achtg. | H319 H412 | |||
616-062-00-2 | N-[3-[(2-Acetyloxy)ethyl](phenylmethyl)amino]-4-methoxyphenylacetamid | 411-590-8 | 70693-57-1 | Skin Corr. 1B Aquatic Chronic 3 | H314 H412 | GHS05 Gef. | H314 H412 | |||
616-063-00-8 | 3-Dodecyl-(1-(1,2,2,6,6-pentamethyl-4-piperidin)-yl)-2,5-pyrrolidindion | 411-920-0 | 106917-30-0 | Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 | H331 H302 H373 ** H314 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H331 H302 H373 ** H314 H410 | |||
616-064-00-3 | N-tert-Butyl-3-methylpicolinamid | 406-720-5 | 32998-95-1 | Aquatic Chronic 3 | H412 | - | H412 | |||
616-065-00-9 | 3"-(3-Acetyl-4-hydroxyphenyl)-1,1-diethylharnstoff | 411-970-3 | 79881-89-3 | Acute Tox. 4 * STOT RE 2 * | H302 H373 ** | GHS08 GHS07 Achtg. | H302 H373 ** | |||
616-066-00-4 | 5,6,12,13-Tetrachloroanthra(2,1,9-def:6,5,10- d"e"f")diisochinolin-1,3,8,10(2 H,9 H)tetron | 405-100-1 | 115662-06-1 | Repr. 2 | H361f *** | GHS08 Achtg. | H361f *** | |||
616-067-00-X | Dodecyl-3-(2-(3-benzyl-4-ethoxy-2,5-dioxoimidazolidin-1-yl)-4,4-dimethyl-3-oxovaleramido)-4-chlorbenzoat | 407-300-4 | 92683-20-0 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-068-00-5 | Kalium-4-(11-methacrylamidoundecanamido)benzolsulfonat | 406-500-9 | 174393-75-0 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
616-069-00-0 | 1-Hydroxy-5-(2-methylpropyloxycarbonylamino)- N-(3-dodecyloxypropyl)-2-naphthoamid | 406-210-2 | 110560-22-0 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-070-00-6 | Reaktionsmasse aus 3,3"-Dicyclohexyl-1,1"-methylenbis(4,1-phenylen)diharnstoff, 3-Cyclohexyl-1-(4-(4-(3-octadecylureido)benzyl)phenyl)harnstoff und 3,3"-Dioctadecyl-1,1"-methylenbis(4,1-phenylen)diharnstoff | 406-530-2 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
616-071-00-1 | Reaktionsmasse aus Bis( N-cyclohexyl- N"-phenylenureido)methylen, Bis( N-octadecyl- N"-phenylenureido)methylen und Bis( N-dicyclohexyl- N"-phenylenureido)methylen (1:2:1) | 406-550-1 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-072-00-7 | 1-(2-Deoxy-5- O-trityl-β-D-threopentofuranosyl)thymin | 407-120-6 | 55612-11-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-073-00-2 | 4"-Ethoxy-2-benzimidazoleanilid | 407-600-5 | 120187-29-3 | Muta. 2 Aquatic Chronic 4 | H341 H413 | GHS08 Achtg. | H341 H413 | |||
616-074-00-8 | N-Butyl-2-(4-morpholinylcarbonyl)benzamid | 407-730-2 | 104958-67-0 | Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H319 H317 H412 | GHS07 Achtg. | H319 H317 H412 | |||
616-075-00-3 | D, L-( N, N-diethyl-2-hydroxy-2-phenylacetamid) | 408-120-9 | 65197-96-8 | Acute Tox. 4 * Eye Dam. 1 | H302 H318 | GHS05 GHS07 Gef. | H302 H318 | |||
616-076-00-9 | Tebufenozid (ISO); N- tert-Butyl- N"-(4-ethylbenzoyl)-3,5-dimethylbenzohydrazid | 412-850-3 | 112410-23-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
616-077-00-4 | Reaktionsmasse aus 2-(9-Methyl-1,3,8,10-tetraoxo-2,3,9,10-tetrahydro(1 H,8 H) anthra[2,1,9- Def: 6,5,10- d" e" f"]diisochinolin-2-yl-ethansulfonsäure, Kalium-2-(9-methyl-1,3,8,10-tetraoxo-2,3,9,10-tetrahydro-(1 H,8 H)anthra[2,1,9- Def: 6,5,10- d" e" f"]diisochinolin-2-yl-ethansulfat | 411-310-4 | - | Eye Dam. 1 | H318 | GHS05 Gef. | H318 | |||
616-078-00-X | 2-[2,4-Bis(1,1-dimethylethyl)phenoxy]- N-(2-hydroxy-5-methylhenyl)hexanamid | 411-330-3 | 104541-33-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-079-00-5 | 1,6-Hexanediyl-bis(2-(2-(1-ethylpentyl)-3-oxazolidinyl)ethyl)carbamat | 411-700-4 | 140921-24-0 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
616-080-00-0 | 4-(2-((3-Ethyl-4-methyl-2-oxo-pyrrolin-1-yl)carboxamido)ethyl)benzolsulfonamid) | 411-850-0 | 119018-29-0 | Aquatic Chronic 3 | H412 | - | H412 | |||
616-081-00-6 | 5-Brom-8-naphtholactam | 413-480-5 | 24856-00-6 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | |||
616-082-00-1 | N-(5-Chlor-3-((4-(diethylamino)-2-methylphenyl)imino-4-methyl-6-oxo-1,4-cyclohexadien-1-yl)benzamid | 413-200-1 | 129604-78-0 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
616-083-00-7 | [2-[(4-Nitrophenyl)amino]ethyl]harnstoff | 410-700-1 | 27080-42-8 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
616-084-00-2 | 2,4-Bis[ N"-(4-methylphenyl)ureido]toluol | 411-790-5 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-085-00-8 | 3-(2,4-Dichlorphenyl)-6-fluorchinazolin-2,4(1 H,3 H)dion | 412-190-6 | 168900-02-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-086-00-3 | 2-Acetylamino-6-chlor-4-[(4-diethylamino)2-methylphenylimino]-5-methyl-1-oxo-2,5-cyclohexadien | 412-250-1 | 102387-48-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-087-00-9 | Reaktionmasse aus 7,9,9-trimethyl-3,14-dioxa-4,13-dioxo-5,12-diazahexadecan-1,16-diyl-prop-2-enoat und 7,7,9-Trimethyl-3,14-dioxa-4,13-dioxo-5,12-diazahexadecan-1,16-diyl-prop-2-enoat | 412-260-6 | 52658-19-2 | Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H319 H317 H411 | GHS07 GHS09 Achtg. | H319 H317 H411 | |||
616-088-00-4 | 2-Aminosulfonyl- N, N-dimethylnicotinamid | 413-440-7 | 112006-75-4 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
616-089-00-X | 5-(2,4-Dioxo-1,2,3,4-tetrahydropyrimidin)-3-fluor-2-hydroxymethyltetrahydrofuran | 415-360-8 | 41107-56-6 | Muta. 2 | H341 | GHS08 Achtg. | H341 | |||
616-090-00-5 | 1-(1,4-Benzodioxan-2-ylcarbonyl)piperazinhydrochlorid | 415-660-9 | 70918-74-0 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 | H331 H311 H301 H373 ** H411 | GHS06 GHS08 GHS09 Gef. | H331 H311 H301 H373 ** H411 | |||
616-091-00-0 | 1,3,5-Tris[(2 S und 2 R)-2,3-epoxypropyl]-1,3,5-triazin-2,4,6-(1 H,3 H,5 H)trion | 423-400-0 | 59653-74-6 | Muta. 1B Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 | H340 H331 H302 H373 ** H318 H317 | GHS06 GHS08 GHS05 Gef. | H340 H331 H302 H373 ** H318 H317 | |||
616-092-00-6 | Polymerisches Reaktionsprodukt von Bicyclo[2,2,1]hepta-2,5-dien, ethen, 1,4-hexadien, 1-propen mit N, N-di-2-propenylformamid | 404-035-6 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-093-00-1 | Reaktionsprodukte von Anilin-terephthalaldehyd- o-toluidinkondensat mit Maleinsäureanhydrid | 406-620-1 | 129217-90-9 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
616-094-00-7 | 3,3-Dicyclohexyl-1"1"-methylenbis-(4,1-phenylen)diharnstoff | 406-370-3 | 58890-25-8 | Aquatic Chronic 4 | H413 | H413 | ||||
616-095-00-2 | 3,3"-Dioctadecyl-1,1"-methylenbis(4,1-phenylen)diharnstoff | 406-690-3 | 43136-14-7 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-096-00-8 | N-(3-Hexadecyloxy-2-hydroxyprop-1-yl)- N-(2-hydroxyethyl)palmitamid | 408-110-4 | 110483-07-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-097-00-3 | N, N"-1,4-phenylenbis(2-((2-methoxy-4-nitrophenyl)azo)-3-oxobutanamid | 411-840-6 | 83372-55-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-098-00-9 | 1-[4-Chlor-3-((2,2,3,3,3-pentafluorpropoxy)methyl)phenyl]-5-phenyl-1 H-1,2,4-triazol-3-carboxamid | 411-750-7 | 119126-15-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
616-099-00-4 | 2-[4-[(4-Hydroxyphenyl)sulfonyl]phenoxy]-4,4-dimethyl -N-[5-[(methylsulfonyl)amino]-2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]phenyl]-3- oxopentanamid | 414-170-2 | 135937-20-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-100-00-8 | 1,3-Dimethyl-1,3-bis(trimethylsilyl)harnstoff | 414-180-7 | 10218-17-4 | Acute Tox. 4 * Skin Irrit. 2 | H302 H315 | GHS07 Achtg. | H302 H315 | |||
616-101-00-3 | (S)- N- tert-butyl-1,2,3,4-tetrahydro-3-isochinolincarboxamid | 414-600-9 | 149182-72-9 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
616-102-00-9 | Reaktionsmasse aus α-[3-(3-Mercaptopropanoxycarbonylamino)methylphenylaminocarbonyl]-ω-[3-(3-mercaptopropanoxycarbonylamino)methylphenylaminocarbonyloxy]poly(oxyethylencooxypropylen), 1,2-(oder 1,3-)Bis[α-(3-mercaptopropanoxycarbonylamino)methylphenylaminocarbonyl)-ω-oxypoly(oxyethylencooxypropylen)]-3-(oder 2-)propanol und 1,2,3-Tris[α-(3-Mercaptopropanoxycarbonylamino)methylphenylaminocarbonyl)-ω-oxypoly(ox yethylencooxypropylen)]propan] | 415-870-0 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
616-103-00-4 | (S, S)- trans-4-(Acetylamino)-5,6-dihydro-6-methyl-7,7-dioxo-4 H- thieno[2,3- b]thiopyran-2-sulfonamid | 415-030-3 | 120298-38-6 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | |||
(Gültig bis 31.08.2025 gem. VO (EU) 2024/197 | ||||||||||
616-104-00-X | Benalaxyl (ISO); Methyl- N-(2,6-dimethylphenyl)- N-(phenylacetyl)-DL-alaninat | 275-728-7 | 71626-11-4 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | ) | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
616-104-00-X | Benalaxyl (ISO); Methyl- N-(2,6-dimethylphenyl)- N-(phenylacetyl)-DL-alaninat. | 275-728-7 | 71626-11-4 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | Oral: ATE = 1.000 mg/kg KG M = 1 M = 1" | ) | |
616-105-00-5 | Chlortoluron (ISO); 3-(3-Chlor- p-tolyl)-1,1-dimethylharnstoff | 239-592-2 | 15545-48-9 | Carc. 2 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d *** H400 H410 | GHS08 GHS09 Achtg. | H351 H361d *** H410 | |||
616-106-00-0 | Phenmedipham (ISO); Methyl-3-(3-methylcarbaniloyloxy)carbanilat | 237-199-0 | 13684-63-4 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 10 M = 10 | ||
616-107-00-6 | Cinidonethyl (ISO); Ethyl-( Z)-2-chlor-3-[2-chlor-5-(cyclohex-1-en-1,2-dicarboximido)phenyl]acrylat | - | 142891-20-1 | Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H317 H410 | |||
616-108-00-1 | Iodsulfuron-Methyl-Natrium; Natrium ({[5-iod-2-(methoxycarbonyl)phenyl]sulfonyl}carbamoyl)(4-methoxy-6-methyl-1,3,5-triazin-2-yl)azanid | - | 144550-36-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-109-00-7 | Sulfosulfuron (ISO); 1-(4,6-Dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylharnstoff | - | 141776-32-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-110-00-2 | Cyclanilid (ISO); 1-(2,4-Dichloranilinocarbonyl)cyclopropancarboxylsäure | 419-150-7 | 113136-77-9 | Acute Tox. 4 * Aquatic Chronic 2 | H302 H411 | GHS07 GHS09 Achtg. | H302 H411 | |||
616-111-00-8 | Fenhexamid (ISO); N-(2,3-Dichlor-4-hydroxyphenyl)-1-methylcyclohexancarboxamid | 422-530-5 | 126833-17-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
616-112-00-3 | Oxasulfuron (ISO); Oxetan-3-yl-2-[(4,6-dimethylpyrimidin-2-yl)carbamoylsulfamoyl]benzoat | - | 144651-06-9 | STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 | H373 ** H400 H410 | GHS08 GHS09 Achtg. | H373 ** H410 | |||
616-113-00-9 | Desmedipham (ISO); Ethyl-3-phenylcarbamoyloxyphenylcarbamat | 237-198-5 | 13684-56-5 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H400 H410 | GHS08 GHS09 Wng | H361d H410 | M = 10 M = 10" | ||
616-114-00-4 | Dodecanamid; N, N"-(9,9",10,10"-tetrahydro-9,9",10,10"-tetraoxo(1,1"-bianthracen)-4,4"-diyl)bis | 418-010-2 | 136897-58-0 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-115-00-X | N-(3-Acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamid | 416-150-9 | 136450-06-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-116-00-5 | N-(4-Dimethylaminopyridinium)- 3-methoxy-4-(1-methyl-5-nitroindol-3-ylmethyl)- N-( o-tolylsulfonyl)benzamidat | 416-790-9 | 143052-96-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-117-00-0 | N-[2-(3-Acetyl-5-nitrothiophen-2-ylazo)-5-diethylaminophenyl]acetamid | 416-860-9 | 777891-21-1 | Repr. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f *** H317 H400 H410 | GHS08 GHS09 Achtg. | H361f *** H317 H410 | |||
616-118-00-6 | N-(2",6"-Dmethylphenyl)-2-piperidincarboxamidhydrochlorid | 417-950-0 | 65797-42-4 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
616-119-00-1 | 2-(1-Butyl-3,5-dioxo-2-phenyl- (1,2,4)-triazolidin-4-yl)-4,4-dimethyl-3-oxo- N-(2-methoxy-5-(2-(dodecyl-1-sulfonyl))propionylamino)phenyl)pentanamid | 418-060-5 | 118020-93-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-120-00-7 | Reaktionsmasse aus N-(3-dimethylamino-4-methylphenyl)benzamid, N-(3-dimethylamino-2-methylphenyl)benzamid und N-(3-dimethylamino-3-methylphenyl)benzamid | 420-600-1 | - | STOT RE 2 * Aquatic Chronic 2 | H373 ** H411 | GHS08 GHS09 Achtg. | H373 ** H411 | |||
616-121-00-2 | 2,4-Dihydroxy- N-(2-methoxyphenyl)benzamid | 419-090-1 | 129205-19-2 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
616-122-00-8 | Methylneodecanamid | 414-460-9 | 105726-67-8 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
616-123-00-3 | N-[3-[[4-(Diethylamino)-2-methylphenyl]imino]-6-oxo-1,4-cyclohexadienyl]acetamid | 414-740-0 | 96141-86-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-124-00-9 | Lithiumbis(trifluormethylsulfonyl)imid | 415-300-0 | 90076-65-6 | Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Corr. 1B Aquatic Chronic 3 | H311 H301 H373** H314 H412 | GHS06 GHS05 GHS08 Gef. | H311 H301 H373** H314 H412 | |||
616-125-00-4 | 3-Cyano- N-(1,1-dimethylethyl)androsta-3,5-dien-17-β-carboxamid | 415-730-9 | 151338-11-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | 410 | |||
616-126-00-X | 1-Methyl-4-nitro-3-propyl-1 H-pyrazol-5-carboxamid | 423-960-6 | 139756-01-7 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 | H302 H373** H412 | GHS08 GHS07 Achtg. | H302 H373** H412 | |||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
616-127-00-5 | Reaktionsmasse aus N, N"-Ethan- 1,2-diylbis(decanamid), 12-Hydroxy- N-[2-[1-oxydecyl)amino]ethyl]octadecanamid und N, N"-Ethan-1,2-diylbis(12- hydroxyoctadecanamid) | 430-050-2 | - | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
616-127-00-5 | Reaktionsmasse aus N,N"-Ethan-1,2-diylbis(decanamid) und 12-Hydroxy- N-[2-[(1-oxodecyl)amino]ethyl]octadecanamid und N,N"-Ethan-1,2-diylbis(12-hydroxyoctadecanamid) [1] Reaktionsmasse aus N,N"-Ethan-1,2-diylbis(decanamid) und 12-Hydroxy- N-[2-[(1-oxodecyl)amino]ethyl]octadecanamid [2] | 430-050-2 [1] - [2] | - [1] - [2] | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 100 M = 10 | ) | |
616-128-00-0 | N-(2-(1-Allyl-4,5-dicyanoimidazol-2-ylazo)-5-(dipropylamino)phenyl)acetamid | 417-530-7 | 123590-00-1 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-129-00-6 | N, N"-Bis(2,2,6,6-tetramethyl-4- piperidyl)isophthalamid | 419-710-0 | 42774-15-2 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
616-130-00-1 | N-(3-(2-(4,4-dimethyl-2,5-dioxo-imidazolin-1-yl)-4,4-dimethyl-3-oxopentanoylamino)-4- methoxyphenyl)octadecanamid | 421-780-2 | 150919-56-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-131-00-7 | 1-Aminocyclopentancarboxamid | 422-950-9 | 17193-28-1 | STOT RE 1 Acute Tox. 4 * Eye Dam. 1 | H372** H302 H318 | GHS05 GHS08 GHS07 Gef. | H372** H302 H318 | |||
616-132-00-2 | N-[4-(4-Cyano-2-furfuryliden-2,5-dihydro-5-oxo-3-furyl)phenyl]butan-1-sulfonamid | 423-250-6 | 130016-98-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-133-00-8 | N-cyclohexyl-S, S-dioxobenzo[ b]tiophen-2-carboxamid | 423-990-1 | 149118-66-1 | Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H318 H410 | |||
616-134-00-3 | 3,3"-Bis(dioctyloxyphosphinothioylthio)- N, N"-oxybis(methylen)dipropionamid | 401-820-5 | 793710-14-2 | Aquatic Chronic 3 | H412 | - | H412 | |||
616-135-00-9 | (3 S,4 aS,8 aS)-2-[(2 R,3 S)-3-amino-2-hydroxy-4-phenylbutyl]- N- tert-butyldecahydroisochinolin-3-carboxamid | 430-230-0 | 136522-17-3 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
616-136-00-4 | Reaktionsprodukt von Cocoalkyldiethanolamiden, Cocoalkylmonoglyceriden und Molybdenumtrioxid (1,75-2,2: 0,75-1,0:0,1-1,1) | 430-380-7 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
616-137-00-X | 4-Dichloracetyl-1-oxa-4-azaspiro[4,5]decan | 401-130-4 | 71526-07-3 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
616-138-00-5 | Benzoesäure; N- tert-butyl- N"-(4- chlorbenzoyl)hydrazid | 431-600-4 | 112226-61-6 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
616-139-00-0 | (3 S,4 aS,8 aS)- N-tert-butyldecahydro-3-isochinolincarboxamid | 420-380-5 | 136465-81-1 | Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 | H302 H318 H412 | GHS05 GHS07 Gef. | H302 H318 H412 | |||
616-140-00-6 | N, N'"-(Methylendi-4,1-phenylen)bis[ N"-(4-methylphenyl)harnstoff] | 429-380-1 | 133336-92-2 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-141-00-1 | Zoxamid (ISO); (RS)-3,5-Dichlor- N-(3-chlor-1- ethyl-1-methyl-2-oxopropyl)- p-toluamid | - | 156052-68-5 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Achtg. | H317 H410 | M=10 | ||
616-142-00-7 | 1,3-Bis(vinylsulfonylacetamido)propan | 428-350-3 | 93629-90-4 | Muta. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H341 H318 H317 H412 | GHS08 GHS05 GHS07 Gef. | H341 H318 H317 H412 | |||
616-143-00-2 | N, N"-Dihexadecyl- N, N"-bis(2-hydroxyethyl)propandiamid | 422-560-9 | 149591-38-8 | Repr. 2 Eye Irrit. 2 Aquatic Chronic 4 | H361f *** H319 H413 | GHS08 Achtg. | H361f *** H319 H413 | |||
616-144-00-8 | 3,4-Dichlor- N-[5-chlor-4-[2-[4-dodecyloxyphenylsulfonyl]butyramido]-2-hydroxyphenyl]benzamid | 431-130-1 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
616-145-00-3 | Pethoxamid (ISO); 2-Chlor- N-(2-ethoxyethyl)- N-(2-methyl-1-phenylprop-1-enyl)acetamid | - | 106700-29-2 | Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | M=100 | ||
616-146-00-9 | N-(2-methoxy-5-octadecanoylaminophenyl)-2-(3-benzyl-2,5-dioxoimidazolidin-1-yl)-4,4- dimethyl-3-oxopentansäureamid | 431-330-7 | 142776-95-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-147-00-4 | 1-Methyl-4-(2-methyl-2 H-tetrazol-5-yl)-1 H-pyrazol-5-sulfonamid | 424-160-1 | 139481-22-4 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
616-148-00-X | N-[6,9-Dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6-oxo-1 H-purin-2-yl]acetamid | 424-550-1 | 84245-12-5 | Carc. 1B Muta. 1B Repr. 1B | H350 H340 H360FD | GHS08 Gef. | H350 H340 H360FD | |||
616-150-00-0 | (2 R,3 S)- N-(3-amino-2-hydroxy-4-phenylbutyl)- N-isobutyl-4-nitrobenzolsulfonamidhydrochlorid | 425-260-6 | - | STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H373** H318 H317 H411 | GHS05 GHS08 GHS07 GHS09 Gef. | H373** H318 H317 H411 | |||
616-151-00-6 | N-(2-Amino-4,6-dichlorpyrimidin-5-yl)formamid | 425-650-6 | 171887-03-9 | Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 | H302 H318 H317 H412 | GHS05 GHS07 Gef. | H302 H318 H317 H412 | |||
616-152-00-1 | 4-(4-Fluorphenyl)-2-(2-methyl-1-oxopropyl)-4-oxo-3, N-diphenylbutanamid | 425-850-3 | 125971-96-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-153-00-7 | 4-Methyl-3-oxo- N-phenyl-2-(phenylmethylen)pentanamid | 425-860-8 | 125971-57-5 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
616-154-00-2 | 3,4-Dichlor- N-[5-chlor-4-[2-[4-(hexadecyloxy)phenylsulfonyl]butyramido]-2-hydroxyphenyl]benzamid | 431-110-0 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
616-155-00-8 | N, N, N", N"-Tetracyclohexyl-1,3-benzoldicarboxamid | 431-040-0 | 104560-40-9 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-156-00-3 | 6-(2-Chlor-6-cyano-4-nitrophenylazo)-4-methoxy-3-[ N-(methoxycarbonylmethyl)- N-(1-methoxycarbonylethyl)amino]acetanilid | 430-500-8 | 204277-61-2 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-157-00-9 | 3-Amino-4-hydroxy- N-(3-isopropoxypropyl)benzolsulfonamidhydrochlorid | 427-780-9 | 114565-70-7 | Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H318 H400 H410 | GHS05 GHS07 GHS09 Gef. | H302 H318 H410 | |||
616-158-00-4 | N-[4-Cyano-3-trifluormethylphenyl]methacrylamid | 427-880-2 | 90357-53-2 | STOT RE 2 * Aquatic Chronic 2 | H373** H411 | GHS08 GHS09 Achtg. | H373** H411 | |||
616-160-00-5 | 2,2"-Azobis[ N-(2-hydroxyethyl)-2-methylpropionamid] | 429-090-3 | 61551-69-7 | Skin Sens. 1 Aquatic Chronic 3 | H317 H412 | GHS07 Achtg. | H317 H412 | |||
616-161-00-0 | 2,4-Dichlor-5-hydroxyacetanilid | 429-110-0 | 67669-19-6 | Aquatic Chronic 3 | H412 | - | H412 | |||
616-162-00-6 | Isostearinsäuremonoisopropanolamid | 431-540-9 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
616-163-00-1 | 4,4"-Methylenbis[ N-(4-chlorphenyl)-3-hydroxynaphthalin-2-carboxamid] | 430-350-3 | 192463-88-0 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-164-00-7 | Dimoxystrobin (ISO); (2 E)-2-{2-[(2,5-Dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)- N-methylacetamid; (E)-2-(Methoxyimino)- N-methyl-2-[ a-(2,5-xylyloxy)- o-tolyl]acetamid | 149961-52-4 | Carc. 2 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d H332 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361d H332 H410 | Einatmung: ATE = 1,3 mg/L (Stäube oder Nebel) M = 100 M = 100 | |||
616-165-00-2 | Beflubutamid (ISO); (RS)- N-Benzyl-2-(α, α,α, 4-tetrafluor- m-tolyoxy)butyramid | - | 113614-08-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M=100 | ||
616-166-00-8 | Cyazofamid (ISO); 4-Chlor-2-cyano- N, N-dimethyl-5- p-tolylimidazol-1-sulfonamid | - | 120116-88-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M=10 | ||
616-167-00-3 | N, N-Dibutyl-(2,5-dihydro-5-thioxo-1 H-tetrazol-1-yl)acetamid | 418-290-6 | 168612-06-4 | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
616-168-00-9 | 1-Dimethylcarbamoyl-4-(2-sulfonatoethyl)pyridinium | 418-440-0 | 136997-71-2 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
616-169-00-4 | 4-[4-(2,2-Dimethylpropanamido)]phenylazo-3-(2-chlor-5-(2-(3-pentadecylphenoxy)butylamido)anilino)-1-(2,4,6-trichlorphenyl)-2-pyrazolin-5-on | 420-220-4 | 92771-56-7 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-170-00-X | (2 R)-2-amino-2-phenylacetamid | 420-370-0 | 6485-67-2 | Eye Irrit. 2 Skin Sens. 1 | H319 H317 | GHS07 Achtg. | H319 H317 | |||
616-171-00-5 | 2-(Parachlorphenyl)glycineamid | 420-830-0 | 102333-75-5 | Eye Dam. 1 Skin Sens. 1 | H318 H317 | GHS05 GHS07 Gef. | H318 H317 | |||
616-172-00-0 | N-(2,2,6,6-Tetramethyl-1-oxylpiperidin-4-yl)acetamid; (4-Acetamido-2,2,6,6-tetramethyl-1-piperidinyl)oxidanyl | 423-840-3 | 14691-89-5 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
616-174-00-1 | 2-Butyl-1,3-diazaspiro[4,4]non-1-en-4-on-hydrochlorid | 424-560-4 | 151257-01-1 | Acute Tox. 4 * Eye Irrit. 2 | H302 H319 | GHS07 Achtg. | H302 H319 | |||
616-175-00-7 | 2-(2-Hexyldecyloxy)benzamid | 431-230-3 | 202483-62-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-176-00-2 | 3- N, N-Bis(methoxyethyl)aminoacetanilid | 432-530-7 | 24294-01-7 | Acute Tox. 4 * Aquatic Chronic 3 | H302 H412 | GHS07 Achtg. | H302 H412 | |||
616-177-00-8 | (3-(4-(2-(Butyl-(4-methylphenylsulfonyl)amino)phenylthio)-5-oxo-1-(2,4,6-trichlorphenyl)-4,5-dihydro-1 H-pyrazol-3-ylamino)-4-chlorphenyl)tetradecanamid; N-[3-({4-[(2-{]Butyl[}(4-methylphenyl)sulfonyl{]amino[}phenyl)thio{]-5-oxo-1-(2,4,6-trichlorphenyl)-4,5-dihydro-1 H-pyrazol-3yl[}amino)-4-chlorphenyl]tetradecanamid | 432-970-1 | 217324-98-6 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-178-00-3 | N-(5-(Bis(2-methoxyethyl)amino)-2-((2-cyano-4,6-dinitrophenyl)-azo)phenyl)acetamid | 434-500-9 | 52583-35-4 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-179-00-9 | 2-Chlor- N-(4-methylphenyl)acetamid | 435-170-9 | 16634-82-5 | Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H318 H317 H410 | |||
616-180-00-4 | N, N-(Dimethylamino)thioacetamidhydrochlorid | 435-470-1 | 27366-72-9 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360D*** H400 H410 | GHS08 GHS09 Gef. | H360D*** H410 | |||
616-181-00-X | 4"-Methyldodecan-1-sulfonanilid | 435-490-9 | 17417-32-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-182-00-5 | N"-(1,3-Dimethylbutyliden)-3-hydroxy-2-naphthohydrazid | 435-860-1 | 214417-91-1 | Skin Sens. 1 Aquatic Chronic 2 | H317 H411 | GHS07 GHS09 Achtg. | H317 H411 | |||
616-183-00-0 | N-Dodecyl-4-methoxybenzamid | 442-340-6 | 1854-15-5 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-184-00-6 | 3-Methyl- N-(5,8,13,14- tetrahydro-5,8,14-trioxonaphth[2,3- c]acridin-6-yl)benzamid | 442-560-2 | 105043-55-8 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-186-00-7 | N, N"-(2-Chlor-1,4-phenylen)bis(3-oxobutanamid) | 443-010-4 | 53641-10-4 | Aquatic Chronic 3 | H412 | - | H412 | |||
616-188-00-8 | 2-(5,5-Dimethyl-2,4-dioxooxazolidin-3-yl)-4,4-dimethyl-3-oxo- N-(2-methoxy-5-octadecanoylaminophenyl)pentansäureamid | 443-980-9 | 221215-20-9 | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-189-00-3 | N-[5-(Bis-(2-methoxy-ethyl)-amino]-2-(6-brom-2-methyl-1,3-dioxo-2,3-dihydro-1 H-isoindol-5-ylazo) phenyl]acetamid | 444-780-4 | 452962-97-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-190-00-9 | N-decyl-4-nitrobenzamid | 445-880-0 | 64026-19-3 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-191-00-4 | 2-Ethyl- N-methyl- N-(3-methylphenyl)butanamid | 446-190-2 | 406488-30-0 | Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H302 H319 H315 H317 H411 | GHS07 GHS09 Achtg. | H302 H319 H315 H317 H411 | |||
616-192-00-X | 2-[2-(3-Butoxypropyl)-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]-5"- tert-butyl-2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-2"-[(2-ethylhexyl)thio]acetanilid | 448-060-0 | 727678-39-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-193-00-5 | N-[2-(2-Butyl-4,6-dicyano-1,3- dioxo-2,3-dihydro-1 H-isoindol-5-ylazo)-5-diethylaminophenyl]acetamid | 449-940-7 | 368450-39-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-194-00-0 | 2,2-Diethoxy- N, N-dimethylacetamid | 449-950-1 | 34640-92-1 | Eye Irrit. 2 | H319 | GHS07 Achtg. | H319 | |||
616-196-00-1 | Dinatriumsalz von 1-Hydroxy-4-(β -(4-(1-hydroxy-3,6-disulfo-8-acetylamino-2-naphthylazo)phenoxy)ethoxy)- N-dodecyl-2-naphthamid | 419-990-4 | - | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
616-197-00-7 | Reaktionsmasse aus Kalium- N-[3-(dimethyloxidoamino)propyl]- 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8- heptadecafluoroctansulfonamidat und N-[3-(Dimethyloxidoamino)propyl]- 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8- heptadecafluoroctansulfonamid | 422-500-1 | - | STOT RE 2 * | H373** | GHS08 Achtg. | H373** | |||
616-198-00-2 | 1,3-Bis[12-hydroxyoctadecamid- N-methylen]benzol | 423-300-7 | - | Skin Sens. 1 Aquatic Chronic 4 | H317 H413 | GHS07 Achtg. | H317 H413 | |||
616-200-00-1 | Reaktionsmasse aus N, N"-ethan-1,2-diylbis(hexanamid), 12-Hydroxy- N-[2-[(1-oxyhexyl)amino]ethyl]octadecanamid und N, N"-Ethan-1,2-diylbis(12-hydroxyoctadecanamid) | 432-430-3 | Aquatic Chronic 4 | H413 | H413 | |||||
616-201-00-7 | 12-Hydroxyoctadecansäure, Reaktionsprodukte mit 1,3-Benzoldimethanamin und Hexamethylendiamin | 432-840-2 | 220926-97-6 | Acute Tox. 4 * Aquatic Chronic 4 | H332 H413 | GHS07 Achtg. | H332 H413 | |||
616-202-00-2 | Reaktionsmasse aus 2,2"-[(3,3"- Dichlor[1,1"-biphenyl]-4,4"-diyl)bis(azo)]bis[ N-(2,4-dimethylphenyl)]-3-oxo-butanamid, 2-[[3,3"-Dichlor-4"-[[1[[(2,4- dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1"-biphenyl]-4-yl]azo]- N-(2-methylphenyl)-3-oxo-butanamid und 2-[[3,3"-Dichlor-4"-[[1[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1"-biphenyl]-4-yl]azo]- N-(2-carboxylphenyl)-3-oxo-butanamid | 434-330-5 | - | Carc. 2 Skin Sens. 1 Aquatic Chronic 4 | H351 H317 H413 | GHS08 GHS07 Achtg. | H351 H317 H413 | |||
616-203-00-8 | Reaktionsmasse aus N-[5-[Bis-(2-methoxyethyl)amino]-2-(2- butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl- azo)phenyl]acetamid und N-[2-(2-Butyl-4,6-dicyano-1,3- dioxo-2,3-dihydro-1 H-isoindol- 5-ylazo)5-diethylaminophenyl]acetamid | 442-280-0 | - | Aquatic Chronic 4 | H413 | - | H413 | |||
616-204-00-3 | N, N""-(Methylendi-4,1-phenylen)bis[ N"-octylharnstoff] | 451-060-3 | 122886-55-9 | Aquatic Chronic 4 | H413 | - | H413 | |||
616-205-00-9 | Metazachlor (ISO); 2-Chlor- N-(2,6-dimethylphenyl)- N-(1 H-pyrazol-1-ylmethyl)acetamid | 266-583-0 | 67129-08-2 | Skin Sens. 1B Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H317 H351 H400 H410 | GHS07 GHS08 GHS09 Achtg. | H317 H351 H410 | M = 100 M = 100 | ||
616-206-00-4 | Flufenoxuron (ISO); 1-(4-(2-Chlor-α, α,α-p-trifluortolyloxy)-2-fluorphenyl)-3-(2,6-difluorbenzolyl)harnstoff | 417-680-3 | 101463-69-8 | Lact. Aquatic Acute 1 Aquatic Chronic 1 | H362 H400 H410 | GHS09 Achtg. | H362 H410 | M = 10 000 M = 10 000 | ||
616-207-00-X | Polyhexamethylen-biguanid-hydrochlorid; PHMB | - | 32289-58-0 27083-27-8 | Carc. 2 Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H351 H330 H302 H372 (Atemwege) (Einatmen) H318 H317 H400 H410 | GHS08 GHS06 GHS05 GHS09 Gef. | H351 H330 H302 H372 (Atemwege) (Einatmen) H318 H317 H410 | M = 10 M = 10 | ||
616-208-00-5 | N-Ethyl-2-pyrrolidon; 1-Ethylpyrrolidin-2-on | 220-250-6 | 2687-91-4 | Repr. 1B | H360D | GHS08 Gef. | H360D | |||
616-209-00-0 | Amidosulfuron (ISO); 3-(4,6-Dimethoxypyrimidin-2-yl)-1-(( N-methyl- N-methylsulfonylamino)sulfonyl)harnstoff | 407-380-0 | 120923-37-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 100 M = 100 | ||
616-210-00-6 | Tebufenpyrad (ISO); N-(4-tertbutylbenzyl)-4-chlor-3-ethyl-1-methyl-1 H-pyrazol-5-carboxamid | 119168-77-3 | Acute Tox. 3 Acute Tox. 4 STOT RE 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H301 H332 H373 (Magen- Darm-Trakt) (Oral) H317 H400 H410 | GHS06 GHS08 GHS09 Gef. | H301 H332 H373 (Magen- Darm-Trakt) (Oral) H317 H410 | M = 10 M = 10 | |||
616-211-00-1 | Proquinazid (ISO); 6-Iod-2-propoxy-3-propylchinazolin-4(3 H)-on | 189278-12-4 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Achtg. | H351 H410 | M = 1 M = 10 | |||
616-212-00-7 | 3-Iod-2-propynylbutylcarbamat; 3-Iodprop-2-yn-1-yl-butylcarbamat | 259-627-5 | 55406-53-6 | Acute Tox. 3 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H331 H302 H372 (Kehlkopf) H318 H317 H400 H410 | GHS06 GHS08 GHS05 GHS09 Gef. | H331 H302 H372 (Kehlkopf) H318 H317 H410 | M = 10 M = 1 | ||
616-213-00-2 | Mandipropamid (ISO); 2-(4-Chlorphenyl)- N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1- yloxy)acetamid | - | 374726-62-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 1 M = 1 | ||
616-214-00-8 | Metosulam (ISO); N-(2,6-Dichlor-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2- sulfonamid | - | 139528-85-1 | Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H373 (Augen, Nieren) H400 H410 | GHS08 GHS09 Achtg. | H351 H373 (Augen, Nieren) H410 | M = 1 000 M = 100 | ||
616-215-00-3 | Dimethenamid-P (ISO); 2-Chlor-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamid | - | 163515-14-8 | Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Achtg. | H302 H317 H410 | M = 10 M = 10 | ||
616-216-00-9 | Flonicamid (ISO); N-(Cyanomethyl)-4-(trifluormethyl)pyridin-3-carboxamid | - | 158062-67-0 | Acute Tox. 4 | H302 | GHS07 Achtg. | H302 | |||
616-217-00-4 | Sulfoxaflor (ISO); [Methyl(oxo){1-[6-(trifluormethyl)-3-pyridyl]ethyl}-λ6-sulfanyliden]cyanamid | - | 946578-00-3 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | M = 1 M = 1 | ||
616-218-00-X | Benzovindiflupyr (ISO); N-[9-(Dichlormethylen)-1,2,3,4-tetrahydro-1,4-methanonaphthalin-5-yl]-3-(difluormethyl)-1-methyl-1 H-pyrazol-4-carbonsäureamid | - | 1072957-71-1 | Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H400 H410 | GHS06 GHS09 Gef. | H331 H301 H410 | M = 100 M = 100 | ||
616-219-00-5 | Fluopyram (ISO); N-{2-[3-Chlor-5-(trifluormethyl)pyridin-2-yl]ethyl}-2-(trifluormethyl)benzamid | - | 658066-35-4 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
616-220-00-0 | Pencycuron (ISO); 1-[(4-Chlorphenyl)methyl]-1-cyclopentyl-3-phenylharnstoff | 266-096-3 | 66063-05-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 1 M = 1 | ||
616-221-00-6 | Hexaflumuron (ISO); 1-(3,5-Dichlor-4-(1,1,2,2-tetrafluorethoxy)phenyl)-3-(2,6-difluorbenzoyl) harnstoff | 401-400-1 | 86479-06-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 1 000 M = 10 000 | ||
616-222-00-1 | Penthiopyrad (ISO); (RS)-N-[2-(1,3-Dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluormethyl)pyrazol-4-carboxamid | - | 183675-82-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | M = 1 M = 1 | ||
616-223-00-7 | Carbetamid (ISO); (R)-1-(Ethylcarbamoyl) ethylcarbanilat; (2R)-1-(ethylamino)-1-oxopropan-2-ylphenylcarbamat | 240-286-6 | 16118-49-3 | Carc. 2 Repr. 1B Acute Tox. 4 Aquatic Chronic 2 | H351 H360D H302 H411 | GHS08 GHS07 GHS09 Gef. | H351 H360D H302 H411 | |||
616-224-00-2 | Amisulbrom (ISO); 3-(3-Brom-6-fluor-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazol-1-sulfonamid | - | 348635-87-0 | Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H319 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H319 H410 | M = 10 M = 10 | ||
616-225-00-8 | (RS)-2-Methoxy- N-methyl-2-[α-(2,5-xylyloxy)- o-tolyl]acetamid; Mandestrobin | - | 173662-97-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 10 | ||
616-226-00-3 | Carboxin (ISO); 2-Methyl-N-phenyl-5,6-dihydro-1,4-oxathiin-3-carboxamid; 5,6-Dihydro-2-methyl-1,4-oxathiin-3-carboxanilid | 226-031-1 | 5234-68-4 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 (Nieren) H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H373 (Nieren) H317 H410 | M = 1 M = 1 | ||
616-227-00-9 | Metaflumizon (ISO); (EZ)-2"-[2-(4-Cyanophenyl)-1-(α,α,α-trifluor- m-tolyl)ethyliden][4-(trifluormethoxy)phenyl]carbanilohydrazid [ E-Isomer ≥ 90 %, Z-Isomer ≤ 10 % relativer Anteil]; [1] (E)-2"-[2-(4-Cyanophenyl)-1-(α,α,α-trifluor-m-tolyl)ethyliden][4-(trifluormethoxy)phenyl]carbanilohydrazid [2] | - | 139968-49-3 [1] 852403-68-0 [2] | Repr. 2 Lact. STOT RE 2 | H361fd H362 H373 | GHS08 Wng | H361fd H362 H373 | 616-228-00-4 | 3-(Difluormethyl)-1-methyl- N-(3",4",5"-trifluorbiphenyl-2-yl) pyrazol-4- carboxamid; Fluxapyroxad | - | 907204-31-3 | Lact. Aquatic Acute 1 Aquatic Chronic 1 | H362 H400 H410 | GHS09 Wng | H362 H410 | M = 1 M = 1 |
616-230-00-5 | N-(hydroxymethyl)acrylamid; Methylolacrylamid; [NMA] | 213-103-2 | 924-42-5 | Carc. 1B Muta. 1B STOT RE 1 | H350 H340 H372 (peripheres Nervensystem) | GHS08 Dgr | H350 H340 H372 (peripheres Nervensystem) | |||
616-231-00-0 | 5-Fluor-1,3-dimethyl- N-[2-(4-methylpentan-2-yl)phenyl]-1 H-pyrazol-4-carboxamid; 2"-[( RS)-1,3-dimethylbutyl]-5-fluor-1,3-dimethylpyrazol-4-carboxanilid; Penflufen | - | 494793-67-8 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 1 M = 1 | ||
616-232-00-6 | Iprovalicarb (ISO); Isopropyl [(2 S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamat | - | 140923-17-7 | Carc. 2 | H351 | GHS08 Wng | H351 | |||
616-233-00-1 | Silthiofam (ISO); N-Allyl-4,5-dimethyl-2-(trimethylsilyl)thiophen-3-carboxamid | - | 175217-20-6 | STOT RE 2 Aquatic Chronic 2 | H373 H411 | GHS08 GHS09 Wng | H373 H411 | |||
616-234-00-7 | N-Methoxy- N-[1-methyl-2-(2,4,6-trichlorphenyl)-ethyl]-3-(difluormethyl)-1-methylpyrazol-4-carboxamid; Pydiflumetofen | - | 1228284-64-7 | Carc. 2 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361f H400 H410 | GHS08 GHS09 Wng | H351 H361f H410 | M = 1 M = 1 | ||
616-235-00-2 | N-{2-[[1,1"-Bi(cyclopropyl)]-2-yl]phenyl}-3-(difluormethyl)-1-methyl-1 H-pyrazol-4-carboxamid; Sedaxan | - | 874967-67-6 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 2 | H351 H400 H411 | GHS08 GHS09 Wng | H351 H410 | M = 1" | ||
616-237-00-3 | Fluopicolid (ISO); 2,6-Dichlor- N-[3-chlor-5-(trifluormethyl)-2-pyridylmethyl]benzamid | - | 239110-15-7 | Repr. 2 | H361d | GHS08 Wng | H361d | |||
616-238-00-9 | N-(2-Nitrophenyl)phosphortriamid | 477-690-9 | 874819-71-3 | Repr. 1B STOT RE 2 | H360Fd H373 (Nieren) | GHS08 Dgr | H360Fd H373 (Nieren) | |||
616-239-00-4 | N-(5-Chlor-2-isopropylbenzyl)- N-cyclopropyl-3-(difluormethyl)-5-fluor-1-methyl-1 H-pyrazol-4-carboxamid; Isoflucypram; | - | 1255734-28-1 | Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H361f H332 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361f H332 H317 H410 | Einatmung: ATE = 2,2 mg/L (Stäube oder Nebel) M = 10 M = 1 | ||
616-240-00-X | Reaktionsmasse aus 3-(Difluormethyl)-1-methyl- N-[(1 RS,4 SR,9 RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazol-4-carboxamid und 3-(Difluormethyl)-1-methyl- N-[(1 RS,4 SR,9 SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazol-4-carboxamid [≥ 78 % Z-Isomere, ≤ 15 % E-Isomere relativer Anteil]; Isopyrazam | - | 881685-58-1 | Carc. 2 Repr. 1B Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H351 H360D H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H351 H360D H317 H410 | Repr. 1B; H360D: C ≥ 3 % M = 10 M = 10 | ||
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
616-241-00-5 | Foramsulfuron (ISO); 2-{[(4,6-Dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl-4-formamido- N,N-dimethylbenzamid; 1-(4,6-Dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)harnstoff | - | 173159-57-4 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 1.000 M = 100 | ) | |
(Gültig ab 01.09.2025 gem. VO (EU) 2024/197 | ||||||||||
616-242-00-0 | Picolinafen (ISO); N-(4-Fluorphenyl)-6-[3-(trifluormethyl)phenoxy]-2-pyridincarboxamid; 4"-Fluor-6-[(α,α,α-Trifluor-m-tolyl)oxy]picolinanilid | - | 137641-05-5 | STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H373 (Blutkreislauf, Schilddrüse) H400 H410 | GHS08 GHS09 Wng | H373 (Blutkreislauf, Schilddrüse) H410 | M = 1.000 M = 1.000 | ) | |
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
616-243-00-6 | N,N"-Methylendiacrylamid | 203-750-9 | 110-26-9 | Muta. 1B | H340 | GHS08 Dgr | H340 | ) | ||
617-001-00-2 | Di- tert-butylperoxid | 203-733-6 | 110-05-4 | Org. Perox.
E Flam. Liq. 2 Muta. 2 | H242 H225 H341 | GHS02 GHS08 Gef. | H242 H225 H341 | |||
617-002-00-8 | α, α-Dimethylbenzylhydroperoxid; Cumenhydroperoxid | 201-254-7 | 80-15-9 | Org. Perox.
E Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Aquatic Chronic 2 | H242 H331 H312 H302 H373 ** H314 H411 | GHS02 GHS06 GHS08 GHS05 GHS09 Gef. | H242 H331 H312 H302 H373 ** H314 H411 | Skin Corr. 1B; H314: C ≥ 10 % Skin Irrit. 2; H315: 3 % ≤ C < 10 % Eye Dam. 1; H318: 3 % ≤ C < 10 % Eye Irrit. 2; H319: 1 % ≤ C < 3 % STOT SE 3; H335: C < 10 % | ||
617-003-00-3 | Dilauroylperoxid | 203-326-3 | 105-74-8 | Org. Perox. D | H242 | GHS02 Gef. | H242 | |||
617-004-00-9 | 1,2,3,4-Tetrahydro-1-naphthylhydroperoxid; 1-Tetralinhydroperoxid | 212-230-0 | 771-29-9 | Org. Perox.
D Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H242 H302 H314 H400 H410 | GHS02 GHS05 GHS07 GHS09 Gef. | H242 H302 H314 H410 | STOT SE 3; H335: C ≥ 5 % | ||
617-006-00-X | Bis(α, α-dimethylbenzyl)peroxid | 201-279-3 | 80-43-3 | Org. Perox.
F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 2 | H242 H360D H315 H319 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H242 H360D H315 H319 H411 | |||
617-007-00-5 | tert-Butyl-α, α-dimethylbenzylperoxid | 222-389-8 | 3457-61-2 | Org. Perox. E Skin Irrit. 2 Aquatic Chronic 2 | H242 H315 H411 | GHS02 GHS07 GHS09 Achtg. | H242 H315 H411 | |||
(Gültig bis 30.04.2026 gem. VO (EU) 2024/2564 | ||||||||||
617-008-00-0 | Dibenzoylperoxid; Benzoylperoxid | 202-327-6 | 94-36-0 | Org. Perox.
B Eye Irrit. 2 Skin Sens. 1 | H241 H319 H317 | GHS01 GHS02 GHS07 Gef. | H241 H319 H317 | ) | ||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
617-008-00-0 | Dibenzoylperoxid; Benzoylperoxid | 202-327-6 | 94-36-0 | Org. Perox.
B Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H241 H319 H317 H400 H410 | GHS01 GHS02 GHS07 GHS09 Dgr | H241 H319 H317 H410 | M = 10 M = 10 | ) | |
617-010-00-1 | 1-Hydroperoxycyclohexyl-1-hydroxycyclohexylperoxid [1]; 1,1"-Dioxybiscyclohexan-1-ol [2]; Cyclohexylidenhydroperoxid [3]; Cyclohexanon, Peroxid [4] | 201-091-1 [1] 219-306-2 [2] 220-279-4 [3] 235-527-7 [4] | 78-18-2 [1] 2407-94-5 [2] 2699-11-8 [3] 12262-58-7 [4] | Org. Perox.
A Skin Corr. 1B Acute Tox. 4 * | H240 H314 H302 | GHS01 GHS05 GHS07 Gef. | H240 H314 H302 | STOT SE 3; H335: C ≥ 5 % | C | |
617-010-01-9 | 1-Hydroperoxycyclohexyl-1-hydroxycyclohexylperoxid [1]; 1,1"-Dioxybiscyclohexan-1-ol [2]; Cyclohexylidenhydroperoxid [3]; Cyclohexanon, Peroxid [4] [≤ 91 %-Lösung] | 201-091-1 [1] 219-306-2 [2] 220-279-4 [3] 235-527-7 [4] | 78-18-2 [1] 2407-94-5 [2] 2699-11-8 [3] 12262-58-7 [4] | Org. Perox.
C Acute Tox. 4 * Skin Corr. 1B | H242 H302 H314 | GHS02 GHS05 GHS07 Gef. | H242 H302 H314 | STOT SE 3; H335: C ≥ 5 % | C T | |
617-012-00-2 | 8- p-Menthylhydroperoxid; p-Menthanhydroperoxid | 201-281-4 | 80-47-7 | Org. Perox.
D Skin Corr. 1B Acute Tox. 4 * | H242 H314 H332 | GHS02 GHS05 GHS07 Gef. | H242 H314 H332 | STOT SE 3; H335: C ≥ 5 % | ||
617-013-00-8 | O, O- tert-Butyl- O-docosylmonoperoxyoxalat | 404-300-6 | 116753-76-5 | Org. Perox.
C **** Aquatic Acute 1 Aquatic Chronic 1 | H242 H400 H410 | GHS02 GHS09 Gef. | H242 H410 | |||
617-014-00-3 | 6-(Nonylamino)-6-oxoperoxyhexansäure | 406-680-9 | 104788-63-8 | Org. Perox.
C **** Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 | H242 H318 H317 H400 | GHS02 GHS05 GHS07 GHS09 Gef. | H242 H318 H317 H400 | |||
617-015-00-9 | Bis(4-methylbenzoyl)peroxid | 407-950-9 | 895-85-2 | Org. Perox.
B **** Aquatic Acute 1 Aquatic Chronic 1 | H241 H400 H410 | GHS01 GHS02 GHS09 Gef. | H241 H410 | |||
617-016-00-4 | 3-Hydroxy-1,1-dimethylbutyl-2-ethyl-2-methylheptanperoxoat | 413-910-1 | - | Org. Perox.
C **** Flam. Liq. 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H242 H226 H315 H400 H410 | GHS02 GHS07 GHS09 Gef. | H242 H226 H315 H410 | |||
617-017-00-X | Reaktionsmasse aus 2,2"-Bis( tert- pentylperoxy)- p-diisopropylbenzol und 2,2"-Bis( tert-pentylperoxy)- m- diisopropylbenzol | 412-140-3 | 32144-25-5 | Org. Perox.
D Aquatic Chronic 4 | H242 H413 | GHS02 Gef. | H242 H413 | T | ||
617-018-00-5 | Reaktionsmasse aus 1-Methyl-1-(3-(1-methylethyl)phenyl)ethyl-1-methyl-1-phenylethylperoxid, 63 Gewichts-%, und 1-Methyl-1-(4-(1-methylethyl)phenyl)ethyl-1-methyl-1-phenylethylperoxid, 31 Gewichts-% | 410-840-3 | 71566-50-2 | Org. Perox.
C **** Aquatic Chronic 2 | H242 H411 | GHS02 GHS09 Gef. | H242 H411 | T | ||
617-019-00-0 | 6-(Phthalimido)peroxyhexansäure | 410-850-8 | 128275-31-0 | Org. Perox.
D Eye Dam. 1 Aquatic Acute 1 | H242 H318 H400 | GHS02 GHS05 GHS09 DgGef. | H242 H318 H400 | T | ||
617-020-00-6 | 1,3-Di(prop-2,2-diyl)benzol-bis(neodecanoylperoxid) | 420-060-5 | 117663-11-3 | Flam. Liq. 3 Org. Perox. D **** Aquatic Chronic 2 | H226 H242 H411 | GHS02 GHS09 Gef. | H226 H242 H411 | |||
617-021-00-1 | Methylethylketonperoxid, Trimer | 429-320-2 | - | Org. Perox.
B**** Asp. Tox. 1 Skin Irrit. 2 Skin Sens. 1 | H241 H304 H315 H317 | GHS01 GHS02 GHS08 GHS07 Gef. | H241 H304 H315 H317 | |||
617-022-00-7 | Reaktionsmasse aus 1,2-Dimethylpropylidendihydroperoxid und Dimethyl-1,2-benzoldicarboxylat | 442-480-8 | - | Org. Perox.
C Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 | H242 H302 H314 H317 H411 | GHS02 GHS05 GHS07 GHS09 Gef. | H242 H302 H314 H317 H411 | |||
617-023-00-2 | tert-Butylhydroperoxid | 200-915-7 | 75-91-2 | Muta. 2 | H341 | GHS08 Achtg. | H341 | |||
(Gültig ab 01.05.2026 gem. VO (EU) 2024/2564 | ||||||||||
617-024-00-8 | tert-Butyl-2-ethylperoxyhexanoat | 221-110-7 | 3006-82-4 | Repr. 1B Skin Sens. 1 | H360FD H317 | GHS08 GHS07 Dgr | H360FD H317 | ) | ||
647-001-00-8 | Glucosidase, β- | 232-589-7 | 9001-22-3 | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | |||
647-002-00-3 | Cellulase | 232-734-4 | 9012-54-8 | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | |||
647-003-00-9 | Cellobiohydrolase, exo- | 253-465-9 | 37329-65-0 | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | |||
647-004-00-4 | Cellulasen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | A | ||
647-005-00-X | Bromelain, Saft | 232-572-4 | 9001-00-7 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-006-00-5 | Ficin | 232-599-1 | 9001-33-6 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-007-00-0 | Papain | 232-627-2 | 9001-73-4 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-008-00-6 | Pepsin A | 232-629-3 | 9001-75-6 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-009-00-1 | Rennin | 232-645-0 | 9001-98-3 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-010-00-7 | Trypsin | 232-650-8 | 9002-07-7 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-011-00-2 | Chymotrypsin | 232-671-2 | 9004-07-3 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-012-00-8 | Subtilisin | 232-752-2 | 9014-01-1 | STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 | H335 H315 H318 H334 | GHS08 GHS05 GHS07 Gef. | H335 H315 H318 H334 | |||
647-013-00-3 | Proteinase, mikrobiell neutral | 232-966-6 | 9068-59-1 | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-014-00-9 | Proteasen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 | H319 H335 H315 H334 | GHS08 GHS07 Gef. | H319 H335 H315 H334 | |||
647-015-00-4 |
Amylase, α- | 232-565-6 | 9000-90-2 | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | |||
647-016-00-X | Amylasen, soweit in diesem Anhang nicht gesondert aufgeführt | - | - | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | |||
647-017-00-5 | Laccase | 420-150-4 | 80498-15-3 | Resp. Sens. 1 | H334 | GHS08 Gef. | H334 | |||
648-001-00-0 | Destillate (Kohlenteer), Benzol-Fraktion; Leichtöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Kohlenteer. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C4 bis C10 und destilliert im Bereich von etwa 80 oC bis 160 oC (175 oF bis 320 oF). | 283-482-7 | 84650-02-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
648-002-00-6 | Teeröle, Braunkohle; Leichtöl; [Destillat aus Braunkohlenteer, siedet im Bereich von etwa 80 oC bis 250 oC (176 oF bis 482 oF). Besteht in erster Linie aus aliphatischen und aromatischen Kohlenwasserstoffen und monobasischen Phenolen.] | 302-674-4 | 94114-40-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-003-00-1 | Benzolvorläufe (Kohle); Leichtöl-Redestillat, niedrigsiedend; [Destillat aus Koksofenleichtöl mit einem ungefähren Destillationsbereich von unter 100 oC (212 oF). Besteht in erster Linie aus aliphatischen Kohlenwasserstoffen (C4 bis C6.] | 266-023-5 | 65996-88-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-004-00-7 | Destillate (Kohlenteer), Benzol-Fraktion, BTX-reich; Leichtöl-Redestillat, niedrigsiedend; [Rückstand aus der Destillation von Rohbenzol zur Abtrennung von Benzolvorläufen. Besteht in erster Linie aus Benzol, Toluol und Xylolen mit einem Siedebereich von etwa 75 oC bis 200 oC (167 oF bis 392 oF).] | 309-984-9 | 101896-26-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-005-00-2 | Aromatische Kohlenwasserstoffe, C6-10, C8-reich; Leichtöl-Redestillat, niedrigsiedend | 292-697-5 | 90989-41-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-006-00-8 | Solvent Naphtha (Kohle), leicht; Leichtöl-Redestillat, niedrigsiedend | 287-498-5 | 85536-17-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-007-00-3 | Solvent Naphtha (Kohle), Xylol-Styrolschnitt; Leichtöl-Redestillat, mittelsiedend | 287-502-5 | 85536-20-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-008-00-9 | Solvent Naphtha (Kohle), Cumaron-Styrolhaltig; Leichtöl-Redestillat, mittelsiedend | 287-500-4 | 85536-19-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-009-00-4 | Naphtha (Kohle), Destillationsrückstände; Leichtöl-Redestillat, hochsiedend; [Rückstand, der aus der Destillation von rückgewonnenem Naphtha zurückbleibt. Besteht in erster Linie aus Naphthalin sowie Kondensationsprodukten von Inden und Styrol.] | 292-636-2 | 90641-12-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-010-00-X | Aromatische Kohlenwasserstoffe, C8; Leichtöl-Redestillat, hochsiedend | 292-694-9 | 90989-38-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-012-00-0 | Aromatische Kohlenwasserstoffe, C8-9, Kohlenwasserstoffharz, Polymerisationsnebenprodukt; Leichtöl-Redestillat, hochsiedend; [komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Vakuumverdampfung von Lösungsmittel aus polymerisiertem Kohlenwasserstoffharz. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C8 bis C9 mit einem Siedebereich von etwa 120 oC bis 215 oC (248 oF bis 419 oF).] | 295-281-1 | 91995-20-9 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-013-00-6 | Aromatische Kohlenwasserstoffe, C9-12, Benzoldestillation; Leichtöl-Redestillat, hochsiedend | 295-551-9 | 92062-36-7 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-014-00-1 | Extraktrückstände (Kohle), Benzolfraktion alkalisch, saurer Extrakt; Leichtöl-Extraktrückstände, niedrigsiedend; [Redestillat aus dem von Teersäuren und Teerbasen befreiten Destillat aus Hochtemperaturteer aus bituminöser Kohle, mit einem Siedebereich von etwa 90 oC bis 160 oC (194 oF bis 320 oF). Besteht vorwiegend aus Benzol, Toluol und Xylolen.] | 295-323-9 | 91995-61-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-015-00-7 | Extraktrückstände (Kohlenteer), Benzolfraktion alkalisch, saurer Extrakt; Leichtöl-Extraktrückstände, niedrigsiedend; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Redestillation der Destillate von Hochtemperatur-Kohlenteer (teersäuren- und teerbasenfrei). Besteht vorwiegend aus unsubstituierten und substituierten mononuklearen aromatischen Kohlenwasserstoffen mit einem Siedebereich von etwa 85 oC bis 195 oC (185 oF bis 383 oF).] | 309-868-8 | 101316-63-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-016-00-2 | Extraktrückstände (Kohle), Benzolfraktion sauer; Leichtöl-Extraktrückstände, niedrigsiedend; [saurer Bodensatz, Nebenprodukt der Schwefelsäure-Raffination von roher Hochtemperaturkohle. Besteht in erster Linie aus Schwefelsäure und organischen Verbindungen.] | 298-725-2 | 93821-38-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-017-00-8 | Extraktrückstände (Kohle), Leichtöl alkalisch, Kopfdestillate; Leichtöl-Extraktrückstände, niedrigsiedend; [erste Fraktion aus der Destillation von aromatischen Kohlenwasserstoffen; cumaron-, naphthalin- und indenreiche Sumpfprodukte aus Vorfraktionierung oder gewaschenes Carbolöl mit einem Siedebereich deutlich unter 145 oC (293 oF). Besteht in erster Linie aus aliphatischen und aromatischen Kohlenwasserstoffen (C7 und C8).] | 292-625-2 | 90641-02-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-018-00-3 | Extraktrückstände (Kohle), Leichtöl alkalisch, Säureextrakt, Indenfraktion; Leichtöl-Extraktrückstände, mittelsiedend | 309-867-2 | 101316-62-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-019-00-9 | Extraktrückstände (Kohle), Leichtöl alkalisch, Inden-Naphtha-Fraktion; Leichtöl-Extraktrückstände, hochsiedend; [Destillat aus aromatischen Kohlenwasserstoffen; cumaron-, naphthalin- und indenreiche Sumpfprodukte aus Vorfraktionierung oder gewaschenes Carbolöl mit einem Siedebereich von etwa 155 oC bis 180 oC (311 oF bis 356 oF). Besteht in erster Linie aus Inden, Indan und Trimethylbenzolen.] | 292-626-8 | 90641-03-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-020-00-4 | Solvent Naphtha (Kohle); Leichtöl-Extraktrückstände, hochsiedend; [Destillat aus entweder Hochtemperaturkohlenteer, Koksofenleichtöl oder Rückstand aus alkalischem Extrakt von Kohlenteeröl mit einem ungefähren Destillationsbereich von 130 oC bis 210 oC (266 oF bis 410 oF). Besteht in erster Linie aus Inden und anderen polycyclischen Ringsystemen mit einem einzigen aromatischen Ring. Kann Phenolverbindungen und aromatische Stickstoffbasen enthalten.] | 266-013-0 | 65996-79-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-021-00-X | Destillate (Kohlenteer), Leichtöle, neutrale Fraktion; Leichtöl-Extraktrückstände, hochsiedend; [Destillat aus der fraktionierten Destillation von Hochtemperaturkohlenteer. Besteht in erster Linie aus alkylsubstituierten aromatischen Kohlenwasserstoffen mit einem Ring mit einem Siedebereich von etwa 135 oC bis 210 oC (275 oF bis 410 oF). Kann auch ungesättigte Kohlenwasserstoffe wie Inden und Cumaron enthalten.] | 309-971-8 | 101794-90-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-022-00-5 | Destillate (Kohlenteer), Leichtöle, saure Extrakte; Leichtöl-Extraktrückstände, hochsiedend; [Dieses Öl ist eine komplexe Reaktionsmasse aus aromatischen Kohlenwasserstoffen, in erster Linie Inden, Naphthalin, Cumaron, Phenol und o-, m- und p-Kresol, mit einem Siedebereich von 140 oC bis 215 oC (284 oF bis 419 oF).] | 292-609-5 | 90640-87-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-023-00-0 | Destillate (Kohlenteer), Leichtöle; Carbolöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Kohlenteer. Besteht aus aromatischen und anderen Kohlenwasserstoffen, Phenolverbindungen und aromatischen Stickstoffverbindungen und destilliert im Bereich von etwa 150 oC bis 210 oC (302 oF bis 410 oF).] | 283-483-2 | 84650-03-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-024-00-6 | Teeröle, Kohle; Carbolöl; [Destillat aus Hochtemperaturkohlenteer mit einem Destillationsbereich von etwa 130 oC bis 250 oC (266 oF bis 410 oF). Besteht in erster Linie aus Naphthalin, Alkylnaphthalinen, Phenolverbindungen und aromatischen Stickstoffbasen.] | 266-016-7 | 65996-82-9 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-026-00-7 | Extraktrückstände (Kohle), Leichtöl alkalisch, saurer Extrakt; Carbolöl-Extraktrückstand; [Öl, das bei der Säurewäsche von alkalisch gewaschenem Carbolöl zum Entfernen der geringen Mengen basischer Verbindungen (Teerbasen) anfällt. Besteht in erster Linie aus Inden, Indan und Trimethylbenzolen.] | 292-624-7 | 90641-01-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-027-00-2 | Extraktrückstände (Kohle), Teeröl alkalisch; Carbolöl-Extraktrückstand; [Rückstand aus Kohlenteeröl durch alkalische Wäsche, z.B. mit wässrigem Natriumhydroxid, nach Entfernen von rohen Kohlenteersäuren. Besteht in erster Linie aus Kohlenwasserstoffen und aromatischen Stickstoffbasen.] | 266-021-4 | 65996-87-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-028-00-8 | Extraktöle (Kohle), Leichtöl; saurer Extrakt; [wässriger Extrakt, den man durch Säurewäsche von alkalisch gewaschenem Carbolöl erhält. Besteht in erster Linie aus sauren Salzen verschiedener aromatischer Stickstoffbasen einschließlich Pyridin, Chinolin und ihrer Alkylderivate.] | 292-622-6 | 90640-99-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-029-00-3 | Pyridin, Alkylderivate; Roh-Teerbasen; [komplexe Kombination polyalkylierter Pyridine aus der Kohlenteerdestillation oder als hochsiedende Destillate etwa über 150 oC (302 oF) aus der Reaktion von Ammoniak mit Acetaldehyd, Formaldehyd oder Paraformaldehyd.] | 269-929-9 | 68391-11-7 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-030-00-9 | Teerbasen, Kohle, Pikolin-Fraktion; Destillat-Basen; [Pyridinbasen mit einem Siedebereich von etwa 125 oC bis 160 oC (257 oF bis 320 oF), erhalten durch Destillation von neutralisiertem saurem Extrakt der basenhaltigen Teerfraktion aus der Destillation von Teer aus bituminöser Kohle. Bestehen hauptsächlich aus Lutidinen und Picolinen.] | 295-548-2 | 92062-33-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-031-00-4 | Teerbasen, Kohle, Lutidinfraktion; Destillat-Basen | 293-766-2 | 91082-52-9 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-032-00-X | Extraktöle (Kohle), Teerbase, Kollidinfraktion; Destillat-Basen; [Extrakt, hergestellt durch saure Extraktion von Basen aus aromatischen Ölen von Rohteer, Neutralisation und Destillation der Basen. Besteht in erster Linie aus Kollidinen, Anilin, Toluidinen, Lutidinen und Xylidinen.] | 273-077-3 | 68937-63-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-033-00-5 | Teerbasen, Kohle, Kollidinfraktion; Destillat-Basen; [Destillationsfraktion mit einem Siedebereich von etwa 181 oC bis 186 oC (356 oF bis 367 oF); erhalten durch Destillation von neutralisiertem saurem Extrakt der basenhaltigen Teerfraktionen aus der Destillation von Teer aus bituminöser Kohle. Enthält hauptsächlich Anilin und Kollidine.] | 295-543-5 | 92062-28-7 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-034-00-0 | Teerbasen, Kohle, Anilinfraktion; Destillat-Basen; [Destillationsfraktion, die im Bereich von etwa 180 oC bis 200 oC (356 oF bis 392 oF) siedet und aus den Rohbasen erhalten wird, indem aus dem Öl aus der Destillation von Kohlenteer Phenol und Basen entfernt werden. Enthält hauptsächlich Anilin, Kollidine, Lutidine und Toluidine.] | 295-541-4 | 92062-27-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-035-00-6 | Teerbasen, Kohle, Toluidinfraktion; Destillat-Basen | 293-767-8 | 91082-53-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-036-00-1 | Destillate (Erdöl), Pyrolyseöl aus Alken-/Alkinherstellung, gemischt mit Hochtemperaturkohlenteer, Indenfraktion; Redestillate; [komplexe Kombination von Kohlenwasserstoffen aus der Redestillation der fraktionierten Destillation von Steinkohlen-Hochtemperatur-Teer und Rückstandsölen, die aus der pyrolytischen Herstellung von Alkenen und Alkinen aus Erdölprodukten oder Erdgas stammen. Besteht vorwiegend aus Inden mit einem Siedebereich von etwa 160 oC bis 190 oC (320 oF bis 374 oF).] | 295-292-1 | 91995-31-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-037-00-7 | Destillate (Kohle), Pyrolyseöle aus Kohlenteerrückständen, Naphthalinöle; Redestillate; [Redestillat, erhalten aus fraktionierter Destillation von Steinkohlen-Hochtemperatur-Teer und Pyrolyse-Rückstandsölen; siedet im Bereich von etwa 190 oC bis 270 oC (374 oF bis 518 oF). Besteht in erster Linie aus substituierten dinuklearen Aromaten.] | 295-295-8 | 91995-35-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-038-00-2 | Extraktöle (Kohle), Pyrolyseöle aus Kohlenteerrückständen, Naphthalinöl, Redestillat; Redestillate; [Redestillat aus der nach Phenol- und Basenentzug erfolgten fraktionierten Destillation von Methylnaphthalinöl, erhalten aus Steinkohlen-Hochtemperatur-Teer und Pyrolyse-Rückstandsölen; mit einem Siedebereich von etwa 220 oC bis 230 oC (428 oF bis 446 oF). Besteht vorwiegend aus unsubstituierten und substituierten dinuklearen aromatischen Kohlenwasserstoffen.] | 295-329-1 | 91995-66-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-039-00-8 | Extraktöle (Kohle), Pyrolyseöle aus Kohlenteerrückständen, Naphthalinöle; Redestillate; [neutrales Öl, erhalten durch Basen- und Phenolentzug aus dem Öl aus der Destillation von Hochtemperaturteer und Pyrolyse-Rückstandsölen; mit einem Siedebereich von 225 oC bis 255 oC (437 oF bis 491 oF). Besteht vorwiegend aus substituierten dinuklearen aromatischen Kohlenwasserstoffen.] | 310-170-0 | 122070-79-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-040-00-3 | Extraktöle (Kohle), Pyrolyseöle aus Kohlenteerrückständen, Naphthalinöl, Destillationsrückstände; Redestillate; [Rückstand aus der nach Phenol- und Basenentzug erfolgten Destillation von Methylnaphthalinöl (aus Teer aus bituminöser Kohleteer und Pyrolyse-Rückstandsölen) mit einem Siedebereich von 240 oC bis 260 oC (464 oF bis 500 oF). Besteht vorwiegend aus substituierten dinuklearen aromatischen und heterocyclischen Kohlenwasserstoffen.] | 310-171-6 | 122070-80-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-041-00-9 | Absorptionsöle, bicycloaromatische und heterocyclische Kohlenwasserstoff-Fraktion; Waschöl-Redestillat; [komplexe Kombination von Kohlenwasserstoffen, die man als Redestillat aus der Destillation von Waschöl erhält. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit 2 Ringen und heterocyclischen Kohlenwasserstoffen und siedet im Bereich von etwa 260 oC bis 290 oC (500 oF bis 554 oF).] | 309-851-5 | 101316-45-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-042-00-4 | Destillate (Kohlenteer), obere, fluorenreich; Waschöl-Redestillat; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Kristallisation von Teeröl. Besteht aus aromatischen und polycyclischen Kohlenwasserstoffen, in erster Linie aus Fluoren und einigen Acenaphthenen.] | 284-900-0 | 84989-11-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-043-00-X | Kreosotöl, Acenaphthen-Fraktion, Acenaphthen-frei; Waschöl-Redestillat; [Öl, das nach Entfernen von Acenaphthen aus Acenaphthenöl aus Kohlenteer durch ein Kristallisationsverfahren zurückbleibt. Besteht in erster Linie aus Naphthalin und Alkylnaphthalinen.] | 292-606-9 | 90640-85-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-044-00-5 | Destillate (Kohlenteer), schwere Öle; schweres Anthracenöl (Anthracenöl II); [Destillat aus der fraktionierten Destillation von Kohlenteer aus Steinkohle mit einem Siedebereich von 240 oC bis 400 oC (464 oF bis 752 oF). Besteht in erster Linie aus tri- und polynuklearen Kohlenwasserstoffen und heterocyclischen Verbindungen.] | 292-607-4 | 90640-86-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
648-045-00-0 | Destillate (Kohlenteer), obere; schweres Anthracenöl (Anthracenöl II); [Destillat aus Kohlenteer mit einem Destillationsbereich von etwa 220 oC bis 450 oC (428 oFbis 842 oF). Besteht in erster Linie aus aromatischen Kohlenwasserstoffen mit drei- bis viergliedrigen kondensierten Ringsystemen und anderen Kohlenwasserstoffen.] | 266-026-1 | 65996-91-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-046-00-6 | Anthracenöl, saurer Extrakt; Anthracenölextrakt-Rückstand; [komplexe Kombination von Kohlenwasserstoffen aus der von der basenbefreiten Fraktion, die man aus der Destillation von Kohlenteer erhält. Siedet im Bereich von etwa 325 oC bis 365 oC (617 oF bis 689 oF). Enthält überwiegend Anthracen und Phenanthren und ihre Alkylderivate.] | 295-274-3 | 91995-14-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-047-00-1 | Destillate (Kohlenteer); schweres Anthracenöl (Anthracenöl II); [Destillat aus Kohlenteer mit einem Destillationsbereich von etwa 100 oC bis 450 oC (212 oF bis 842 oF). Besteht in erster Linie aus aromatischen Kohlenwasserstoffen mit zwei- bis viergliedrigen kondensierten Ringsystemen, Penolverbindungen und aromatischen Stickstoffbasen.] | 266-027-7 | 65996-92-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-048-00-7 | Destillate (Kohlenteer), Pech, schwere Öle; schweres Anthracenöl (Anthracenöl II); [Destillat aus der Destillation des Pechs von Hochtemperatur-Steinkohlenteer. Besteht in erster Linie aus tri- und polynuklearen aromatischen Kohlenwasserstoffen und siedet im Bereich von etwa 300 oC bis 470 oC (572 oF bis 878 oF). Das Produkt kann auch Heteroatome enthalten.] | 295-312-9 | 91995-51-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-049-00-2 | Destillate (Kohlenteer), Pech; schweres Anthracenöl (Anthracenöl II); [Öl, das man aus der Kondensation der Dämpfe aus der Wärmebehandlung von Pech erhält. Besteht in erster Linie aus aromatischen Verbindungen mit zwei bis vier Ringen und siedet im Bereich von 200 oC bis höher als 400 oC (392 oF bis höher als 752 oF).] | 309-855-7 | 101316-49-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-050-00-8 | Destillate (Kohlenteer), schwere Öle, Pyren-Fraktion; schweres Anthracenöl-Redestillat; [Redestillat aus fraktionierter Destillation von Pechdestillat. Siedet im Bereich von etwa 350 oC bis 400 oC (662 oF bis 752 oF). Besteht überwiegend aus tri- und polynuklearen aromatischen und heterocyclischen Kohlenwasserstoffen.] | 295-304-5 | 91995-42-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-051-00-3 | Destillate (Kohlenteer), Pech, Pyren-Fraktion; schweres Anthracenöl-Redestillat; [Redestillat aus fraktionierter Destillation von Pechdestillat. Siedet im Bereich von etwa 380 oC bis 410 oC (716 oF bis 770 oF). Besteht in erster Linie aus tri- und polynuklearen Kohlenwasserstoffen und heterocyclischen Verbindungen.] | 295-313-4 | 91995-52-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-052-00-9 | Paraffinwachse (Kohle), Braunkohle Hochtemperatur-Teer, mit Kohlenstoff behandelt; Steinkohlenteer-Extrakt; [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Teer aus der Braunkohlenverkokung mit Aktivkohle erhält, um Spurenbestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 308-296-6 | 97926-76-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-053-00-4 | Paraffinwachse (Kohle), Braunkohle Hochtemperatur-Teer, mit Ton behandelt; Steinkohlenteer-Extrakt; [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Teer aus der Braunkohlenverkokung mit Bentonit erhält, um Spurenbestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 308-297-1 | 97926-77-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-054-00-X | Pech | 263-072-4 | 61789-60-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-055-00-5 | Pech, Kohlenteer, Hochtemperatur; [Rückstand aus der Destillation von Hochtemperatur-Kohlenteer. Schwarzer Feststoff mit einem Erweichungspunkt von etwa 30 °C bis 180 °C (86 °F bis 356 °F). Besteht in erster Linie aus einem komplexen Gemisch von aromatischen Kohlenwasserstoffen mit drei- oder mehrgliedrigen Ringsystemen.] | 266-028-2 | 65996-93-2 | Carc. 1A Muta. 1B Repr. 1B | H350 H340 H360FD | GHS08 Dgr | H350 H340 H360FD | |||
648-056-00-0 | Pech, Kohlenteer, Hochtemperatur, hitzebehandelt; Pech; [hitzebehandelter Rückstand aus der Destillation von Hochtemperatur-Kohlenteer. Schwarzer Feststoff mit einem Erweichungspunkt von etwa 80 oC bis 180 oC (176 oF bis 356 oF). Besteht in erster Linie aus einem komplexen Gemisch von aromatischen Kohlenwasserstoffen mit drei- oder mehrgliedrigen kondensierten Ringsystemen.] | 310-162-7 | 121575-60-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-057-00-6 | Pech, Kohlenteer, Hochtemperatur, sekundär; Pech-Redestillat; [Rückstand, den man während der Destillation von hochsiedenden Fraktionen aus Steinkohlen-Hochtemperatur-Teer und/oder Pechkoksöl erhält, mit einem Erweichungspunkt von 140 oC bis 170 oC (284 oF bis 392 oF) nach DIN 52025. Besteht in erster Linie aus tri- und polynuklearen aromatischen Verbindungen, die auch Heteroatome enthalten können.] | 302-650-3 | 94114-13-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-058-00-1 | Rückstände (Kohlenteer), Pechdestillation; Pech-Redestillat; [Destillat aus der fraktionierten Destillation von Pechdestillat mit einem Siedebereich von etwa 400 oC bis 470 oC (752 oF bis 846 oF). Besteht in erster Linie aus polynuklearen aromatischen Kohlenwasserstoffen und heterocyclischen Verbindungen.] | 295-507-9 | 92061-94-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-059-00-7 | Teer, Kohlen-, Hochtemperatur, Destillations- und Lagerungsrückstände; Steinkohlenteerrückstand, fest; [Koks und Asche enthaltende feste Rückstände, die sich bei der Destillation und der thermischen Behandlung von Steinkohlen-Hochtemperatur-Teer in Destillationsanlagen und Lagerhaltungsgefäßen abtrennen. Bestehen überwiegend aus Kohlenstoff und enthalten eine kleine Menge Heteroverbindungen wie auch Aschekomponenten.] | 295-535-1 | 92062-20-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-060-00-2 | Teer, Kohlen-, Lagerungsrückstände; Steinkohlenteerrückstand, fest; [Niederschlag, der von Aufbewahrungsstätten von rohem Kohlenteer entfernt wird. Besteht in erster Linie aus Kohlenteer und kohlenstoffhaltigen Partikeln.] | 293-764-1 | 91082-50-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-061-00-8 | Teer, Kohlen-, Hochtemperatur, Rückstände; Steinkohlenteerrückstand, fest; [Feststoffe, die während der Verkokung von Steinkohle zur Herstellung von rohem Steinkohlen-Hochtemperatur-Teer gebildet werden. Bestehen in erster Linie aus Koks und Kohleteilchen, hoch aromatisierten Verbindungen und mineralischen Substanzen.] | 309-726-5 | 100684-51-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-062-00-3 | Teer, Kohle-, Hochtemperatur, hohe Feststoffanteile; Steinkohlenteerrückstand, fest; [Kondensat, erhalten durch Kühlen, auf etwa Umgebungstemperatur, des bei der Hochtemperatur-Entgasung (höher als 700 oC (1292 oF) von Kohle sich entwickelnden Gases. Besteht in erster Linie aus einem komplexen Gemisch aromatischer Kohlenwasserstoffe mit kondensierten Ringen mit hohem Bestandteil an festen kohle- und koksähnlichen Stoffen.] | 273-615-7 | 68990-61-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-063-00-9 | Feste Abfallstoffe, Kohlenteer-Pech-Verkokung; Steinkohlenteerrückstand, fest; [Kombination von Abfällen, die durch Verkokung von Steinkohlenteerpech entstehen. Besteht überwiegend aus Kohlenstoff.] | 295-549-8 | 92062-34-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-064-00-4 | Extraktrückstände (Kohle), braun; Steinkohlenteer-Extrakt; [Rückstand aus der Extraktion von getrockneter Braunkohle.] | 294-285-0 | 91697-23-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-065-00-X | Paraffinwachse (Kohle), Braunkohlen-Hochtemperatur-Teer; Steinkohlenteer-Extrakt; [komplexe Kombination von Kohlenwasserstoffen, die man aus Teer aus der Braunkohle-Entgasung durch Lösungsmittelkristallisation (Lösungsmittelentölung), durch Ausschwitzen oder durch ein Adduktionsverfahren erhält. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 295-454-1 | 92045-71-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-066-00-5 | Paraffinwachse (Kohle), Braunkohlen-Hochtemperatur-Teer, mit Wasserstoff behandelt; Steinkohlenteer-Extrakt; [komplexe Kombination von Kohlenwasserstoffen, die man aus Teer aus der Braunkohle-Entgasung durch Lösungsmittelkristallisation (Lösungsmittelentölung), durch Ausschwitzen oder durch ein Adduktionsverfahren mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 295-455-7 | 92045-72-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-067-00-0 | Paraffinwachse (Kohle), Braunkohlen-Hochtemperatur-Teer, mit Kieselsäure behandelt; Steinkohlenteer-Extrakt; [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Teer aus der Braunkohlenverkokung mit Kieselsäure erhält, um Spurenbestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 308-298-7 | 97926-78-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-068-00-6 | Teer, Kohle, Niedrigtemperatur, Destillationsrückstände; Teeröl, mittelsiedend; [Rückstände aus der fraktionierten Destillation von Niedrigtemperatur-Kohlenteer zur Beseitigung von Ölen, die in einem Bereich bis zu ungefähr 300 oC (572 oF) sieden. Besteht in erster Linie aus aromatischen Verbindungen.] | 309-887-1 | 101316-85-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-069-00-1 | Pech, Kohlenteer, Niedrigtemperatur; Pechrückstand; [komplexer schwarzer Feststoff oder Semifeststoff, erhalten aus der Destillation von Niedrigtemperatur-Kohlenteer. Hat einen Erweichungspunkt in einem Bereich von etwa 40 oC bis 180 oC (104 oF bis 356 oF). Besteht in erster Linie aus einem komplexen Gemisch von Kohlenwasserstoffen.] | 292-651-4 | 90669-57-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-070-00-7 | Pech, Kohlenteer, Niedrigtemperatur, oxidiert; Pechrückstand, oxidiert; [Produkt, das man durch Blasen von Luft durch Niedrigtemperatur-Kohlenteerpech bei erhöhter Temperatur erhält. Hat einen Erweichungspunkt in einem Bereich von etwa 70 oC bis 180 oC (158 oF bis 356 oF). Besteht in erster Linie aus einem komplexen Gemisch von Kohlenwasserstoffen.] | 292-654-0 | 90669-59-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-071-00-2 | Pech, Kohlenteer, Niedrigtemperatur, wärmebehandelt; Pechrückstand, oxidiert; Pechrückstand, wärmebehandelt; Komplexer schwarzer Feststoff, erhalten durch Wärmebehandlung von Niedrigtemperatur-Kohlenteer. Hat einen Erweichungspunkt in einem Bereich von etwa 50 oC bis 140 oC (122 oF bis 284 oF). Besteht in erster Linie aus einem komplexen Gemisch von aromatischen Verbindungen.] | 292-653-5 | 90669-58-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-072-00-8 | Destillate (Kohle-Erdöl), kondensierte Ringe aromatisch; Destillate; [Destillat aus einem Gemisch von Kohle, Teer und aromatischen Erdölläufen mit einem Destillationsbereich von etwa 220 oC bis 450 oC (428 oF bis 842 oF). Besteht in erster Linie aus aromatischen Kohlenwasserstoffen mit drei- bis viergliedrigen kondensierten Ringsystemen.] | 269-159-3 | 68188-48-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-073-00-3 | Aromatische Kohlenwasserstoffe, C20-28, polycyclisch, aus der Pyrolyse von gemischtem Kohlenteerpech, Polyethylen und Polypropylen erhalten; Pyrolyseprodukte; [komplexe Kombination von Kohlenwasserstoffen, die man aus der Pyrolyse von gemischtem Kohlenteerpech, Polyethylen und Polypropylen erhält. Besteht in erster Linie aus polycyclischen aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C28und hat einen Erweichungspunkt von 100 oC bis 220 oC (212 oF bis 428 oF) nach DIN 52025.]; | 309-956-6 | 101794-74-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-074-00-9 | Aromatische Kohlenwasserstoffe, C20-28, polycyclisch, aus der Pyrolyse von gemischtem Kohlenteerpech und Polyethylen erhalten; Pyrolyseprodukte; [komplexe Kombination von Kohlenwasserstoffen, die man aus der Pyrolyse von gemischtem Kohlenteerpech und Polyethylen erhält. Besteht in erster Linie aus polycyclischen aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C28 und hat einen Erweichungspunkt von 100 oC bis 220 oC (212 oF bis 428 oF) nach DIN 52025.] | 309-957-1 | 101794-75-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-075-00-4 | Aromatische Kohlenwasserstoffe, C20-28, polycyclisch, aus der Pyrolyse von gemischtem Kohlenteerpech und Polystyrol erhalten; Pyrolyseprodukte; [komplexe Kombination von Kohlenwasserstoffen, die man aus der Pyrolyse von gemischtem Kohlenteerpech und Polystyrol erhält. Besteht in erster Linie aus polycyclischen aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C28 und hat einen Erweichungspunkt von 100 oC bis 220 oC (212 oF bis 428 oF) nach DIN 52025.] | 309-958-7 | 101794-76-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-076-00-X | Pech, Kohlenteer-Erdöl-; Pechrückstände; [Rückstand aus der Destillation eines Gemischs aus Kohlenteer und aromatischen Erdölläufen. Schwarzer Feststoff mit einem Erweichungspunkt von etwa 40 oC bis 180 oC (140 oF bis 356 oF). Besteht in erster Linie aus einer komplexen Kombination von aromatischen Kohlenwasserstoffen mit drei- oder mehrgliedrigen kondensierten Ringsystemen.] | 269-109-0 | 68187-57-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-077-00-5 | Phenanthren, Destillationsrückstände; schweres Anthracenöl-Redestillat; [Rückstand aus der Destillation von Rohphenanthren, mit einem Siedebereich von etwa 340 oC bis 420 oC (644 oF bis 788 oF). Besteht überwiegend aus Phenanthren, Anthracen und Carbazol.] | 310-169-5 | 122070-78-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-078-00-0 | Destillate (Kohlenteer), obere, fluorenfrei; Waschöl-Redestillat; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Kristallisation von Rohöl. Besteht aus aromatischen polycyclischen Kohlenwasserstoffen, in erster Linie Biphenyl, Dibenzofuran und Acenaphthen.] | 284-899-7 | 84989-10-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-079-00-6 | Anthracenöl; Anthracenöl; [komplexe Kombination von polycyclischen aromatischen Kohlenwasserstoffen aus Kohlenteer mit einem Destillationsbereich von etwa 300 oC bis 400 oC (572 oF bis 752 oF). Besteht überwiegend aus Phenanthren, Anthracen und Carbazol.] | 292-602-7 | 90640-80-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-080-00-1 | Rückstände (Kohlenteer), Kreosotöldestillation; Waschöl-Redestillat; [Rückstand aus der fraktionierten Destillation von Waschöl, mit einem Siedebereich von etwa 270 oC bis 330 oC (518 oF bis 626 oF). Besteht vorwiegend aus dinuklearen aromatischen und heterocyclischen Kohlenwasserstoffen.] | 295-506-3 | 92061-93-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-081-00-7 | Teer, Kohlen-; Kohlenteer; [Nebenprodukt bei der Entgasung von Kohle. Fast schwarzer Semifeststoff. Komplexe Kombination von aromatischen Kohlenwasserstoffen, Phenolverbindungen, Stickstoffbasen und Thiophen.] | 232-361-7 | 8007-45-2 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
648-082-00-2 | Teer, Kohlen-, Hochtemperatur-; Kohlenteer; [Kondensat, erhalten durch Kühlen, auf etwa Umgebungstemperatur, des bei der Hochtemperatur-Entgasung (höher als 700 oC (1292 oF) von Kohle sich entwickelnden Gases. Schwarze viskose Flüssigkeit, dichter als Wasser. Besteht in erster Linie aus einer komplexen Mischung von aromatischen Kohlenwasserstoffen mit kondensierten Ringen. Kann geringe Mengen von Phenolverbindungen und aromatischen Stickstoffbasen enthalten.] | 266-024-0 | 65996-89-6 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
648-083-00-8 | Teer, Kohlen-, Niedrigtemperatur-; Kohlenöl; [Kondensat, erhalten durch Kühlen, auf etwa Umgebungstemperatur, des bei der Niedrigtemperatur-Entgasung (weniger als 700 oC (1292 oF) von Kohle sich entwickelnden Gases. Schwarze viskose Flüssigkeit, dichter als Wasser. Besteht in erster Linie aus aromatischen Kohlenwasserstoffen mit kondensierten Ringen, Phenolverbindungen, aromatischen Stickstoffbasen und ihren Alkylderivaten.] | 266-025-6 | 65996-90-9 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
648-084-00-3 | Destillate (Kohle), Koksofenleichtöl, Naphthalin-Schnitt; Naphthalinöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Vorfraktionierung (kontinuierliche Destillation) von Koksofenleichtöl. Besteht vorwiegend aus Naphthalin, Cumaron und Inden und siedet bei über 148 oC (298 oF).] | 285-076-5 | 85029-51-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-085-00-9 | Destillate (Kohlenteer), Naphthalinöle; Naphthalinöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Kohlenteer. [Besteht vorwiegend aus aromatischen und anderen Kohlenwasserstoffen, Phenolverbindungen und aromatischen Stickstoffverbindungen und destilliert im Bereich von etwa 200 oC bis 250 oC (392 oF bis 482 oF).] | 283-484-8 | 84650-04-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-086-00-4 | Destillate (Kohlenteer), Naphthalinöle, naphthalinarm; Naphthalinöl-Redestillat; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Kristallisation von Naphthalinöl. Besteht vorwiegend aus Naphthalin, Alkylnaphthalinen und Phenolverbindungen.] | 284-898-1 | 84989-09-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-087-00-X | Destillate (Kohlenteer), Mutterlauge der Kristallisation von Naphthalinöl; Naphthalinöl-Redestillat; [komplexe Kombination organischer Verbindungen, erhalten als Filtrat aus der Kristallisation der Naphthalinfraktion von Kohlenteer; siedet im Bereich von etwa 200 oC bis 230 oC (392 oF bis 446 oF). Enthält hauptsächlich Naphthalin, Thionaphthen und Alkylnaphthaline.] | 295-310-8 | 91995-49-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-088-00-5 | Extraktrückstände (Kohle), Naphthalinöl, alkalisch; Naphthalinöl-Extraktrückstand; [komplexe Kombination von Kohlenwasserstoffen, erhalten aus alkalischem Waschen von Naphthalinöl zur Entfernung von Phenolverbindungen (Teersäuren). Besteht aus Naphthalin und Alkylnaphthalinen.] | 310-166-9 | 121620-47-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-089-00-0 | Extraktrückstände (Kohle), Naphthalinöl, alkalisch, naphthalinarm; Naphthalinöl-Extraktrückstand; [komplexe Kombination von Kohlenwasserstoffen nach Entfernen von Naphthalin aus alkalisch gewaschenem Naphthalinöl durch ein Kristallisationsverfahren. Besteht in erster Linie aus Naphthalin und Alkylnaphthalinen.] | 310-167-4 | 121620-48-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-090-00-6 | Destillate (Kohlenteer), Naphthalinöle, naphthalinfrei, alkalische Extrakte; Naphthalinöl-Extraktrückstand; [Öl, das nach Entfernen von Phenolverbindungen (Teersäuren) aus abgelassenem Naphthalinöl durch alkalisches Waschen zurückbleibt. Besteht in erster Linie aus Naphthalin und Alkylnaphthalinen.] | 292-612-1 | 90640-90-7 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-091-00-1 | Extraktrückstände (Kohle), Naphthalinöl, alkalisch, Kopfdestillate; Naphthalinöl-Extraktrückstand; [Destillat aus alkalisch gewaschenem Naphthalinöl mit einem Destillationsbereich von etwa 180 oC bis 220 oC (356 oF bis 428 oF). Besteht in erster Linie aus Naphthalin, Alkylbenzolen, Inden und Indan.] | 292-627-3 | 90641-04-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-092-00-7 | Destillate (Kohlenteer), Naphthalinöle, Methylnaphthalin-Fraktion; Methylnaphthalinöl; [Destillat aus der fraktionierten Destillation von Hochtemperatur-Kohlenteer. [Besteht in erster Linie aus substituierten aromatischen Kohlenwasserstoffen mit zwei Ringen sowie aromatischen Stickstoffbasen mit einem Siedebereich von etwa 225 oC bis 255 oC (437 oF bis 491 oF).] | 309-985-4 | 101896-27-9 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-093-00-2 | Destillate (Kohlenteer), Naphthalinöle, Indol-Methylnaphthalin-Fraktion; Methylnaphthalinöl; [Destillat aus der fraktionierten Destillation von Hochtemperatur-Kohlenteer. [Besteht in erster Linie aus Indol und Methylnaphthalin mit einem Siedebereich von etwa 235 oC bis 255 oC (455 oF bis 491 oF).] | 309-972-3 | 101794-91-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-094-00-8 | Destillate (Kohlenteer), Naphthalinöle, saure Extrakte; Methylnaphthalinöl-Extraktrückstand; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Basenentzug aus der Methylnaphthalin-Fraktion aus der Destillation von Kohlenteer; mit einem Siedebereich von etwa 230 oC bis 255 oC (446 oF bis 491 oF). Enthält hauptsächlich 1(2)-Methylnaphthalin, Naphthalin, Dimethylnaphthalin und Biphenyl.] | 295-309-2 | 91995-48-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-095-00-3 | Extraktrückstände (Kohle), Naphthalinöl, alkalisch, Destillationsrückstände; Methylnaphthalinöl-Extraktrückstand; [Rückstand aus der Destillation von alkalisch gewaschenem Naphthalinöl mit einem Destillationsbereich von etwa 220 oC bis 300 oC (428 oF bis 572 oF). Besteht in erster Linie aus Naphthalin, Alkylnaphthalinen und aromatischen Stickstoffbasen.] | 292-628-9 | 90641-05-7 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-096-00-9 | Extraktöle (Kohle), sauer, teerbasenfrei; Methylnaphthalinöl-Extraktrückstand; [Extraktöl, siedet im Bereich von etwa 220 oC bis 265 oC (428 oF bis 509 oF), aus alkalischem Kohlenteer-Extraktrückstand, hergestellt durch saures Waschen z.B. mit wässriger Schwefelsäure nach der Destillation zur Abtrennung der Teerbasen. Besteht in erster Linie aus Alkylnaphthalinen.] | 284-901-6 | 84989-12-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-097-00-4 | Destillate (Kohlenteer), Benzolfraktion, Destillationsrückstände; Waschöl; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Rohbenzol (Hochtemperatur-Kohlenteer). Kann flüssig sein mit einem Destillationsbereich von etwa 150 oC bis 300 oC (302 oF bis 572 oF) oder halbfest oder fest mit einem Schmelzpunkt bis zu 70 oC (158 oF). Besteht in erster Linie aus Naphthalin und Alkylnaphthalinen.] | 310-165-3 | 121620-46-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-098-00-X | Kreosotöl, Acenaphthen-Fraktion; Waschöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Kohlenteer, mit einem Siedebereich von etwa 240 oC bis 280 oC (464 oF bis 536 oF). Besteht in erster Linie aus Acenaphthen, Naphthalin und Alkylnaphthalin.] | 292-605-3 | 90640-84-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-099-00-5 | Kreosotöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Kohlenteer. Besteht in erster Linie aus aromatischen Kohlenwasserstoffen und kann beträchtliche Mengen von Teersäuren und Teerbasen enthalten. Destilliert im Bereich von etwa 200 oC bis 325 oC (392o F bis 617 oF).] | 263-047-8 | 61789-28-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-100-00-9 | Kreosotöl, hochsiedendes Destillat; Waschöl; [hochsiedende Destillationsfraktion, erhalten aus der Hochtemperatur-Verkokung von bitumischer Kohle, die weiter aufbereitet wird, um überschüssige kristalline Salze zu entfernen. Besteht in erster Linie aus Kreosotöl, aus dem einige der normalerweise vorkommenden polynuklearen aromatischen Salze, die Bestandteile von Kohlenteerdestillaten sind, entfernt sind. Ist bei etwa 5 oC (41 oF) kristallfrei.] | 274-565-9 | 70321-79-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-101-00-4 | Kreosot; [Kohlenteerdestillat aus der Hochtemperaturverkokung von bitumischer Kohle. Besteht in erster Linie aus aromatischen Kohlenwasserstoffen, Teersäuren und Teerbasen.] | 232-287-5 | 8001-58-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
648-102-00-X | Extraktrückstände (Kohle), Kreosotölsäure; Waschölextrakt-Rückstand; [komplexe Kombination von Kohlenwasserstoffen aus der von Basen befreiten Fraktion aus der Destillation von Kohlenteer, siedet im Bereich von etwa 250 oC bis 280 oC (482 oF bis 536 oF). Besteht hauptsächlich aus Biphenyl und isomeren Diphenylnaphthalinen.] | 310-189-4 | 122384-77-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-103-00-5 | Anthracenöl, Anthracenpaste; Anthracenölfraktion; [anthracenreicher Feststoff, erhalten durch Kristallisation und Zentrifugieren von Anthracenöl. Besteht in erster Linie aus Anthracen, Carbazol und Phenanthren.] | 292-603-2 | 90640-81-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-104-00-0 | Anthracenöl, anthracenarm; Anthracenölfraktion; [Öl, das nach einem Kristallisationsverfahren zum Entfernen eines anthracenreichen Feststoffes (Anthracenpaste) aus Anthracenöl zurückbleibt. Besteht in erster Linie aus zwei-, drei- und viergliedrigen aromatischen Verbindungen.] | 292-604-8 | 90640-82-7 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-105-00-6 | Rückstände (Kohlenteer), Anthracenöldestillation; Anthracenölfraktion; [Rückstand aus der fraktionierten Destillation von Rohanthracen, mit einem Siedebereich von etwa 340 oC bis 400 oC (644 oF bis 752 oF). Besteht überwiegend aus tri- und polynuklearen aromatischen und heterocyclischen Kohlenwasserstoffen.] | 295-505-8 | 92061-92-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-106-00-1 | Anthracenöl, Anthracenpaste, Anthracenfraktion; Anthracenölfraktion; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Anthracen, erhalten durch Kristallisation des Anthracenöls aus Hochtemperatur-Steinkohlenteer; mit einem Siedebereich von 330 oC bis 350 oC (626 oF bis 662 oF). Enthält hauptsächlich Anthracen, Carbazol und Phenanthren.] | 295-275-9 | 91995-15-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-107-00-7 | Anthracenöl, Anthracenpaste, Carbazolfraktion; Anthracenölfraktion; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Anthracen, erhalten durch Kristallisation des Anthracenöls aus Hochtemperatur-Steinkohlenteer; mit einem Siedebereich von etwa 350 oC bis 360 oC (662 F bis 680 oF). Enthält hauptsächlich Anthracen, Carbazol und Phenanthren.] | 295-276-4 | 91995-16-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-108-00-2 | Anthracenöl, Anthracenpaste, leichte Destillate; Anthracenölfraktion; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Anthracen, erhalten durch Kristallisation des Anthracenöls aus Hochtemperaturteer aus bituminöser Kohle; mit einem Siedebereich von etwa 290 oC bis 340 oC (554 oF bis 644 oF). Enthält hauptsächlich trinukleare Aromaten und ihre Dihydroderivate.] | 295-278-5 | 91995-17-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-109-00-8 | Teeröle, Kohle, Niedertemperatur; Teeröl, hochsiedend; [Destillat aus Niedertemperatur-Kohlenteer. Besteht in erster Linie aus Kohlenwasserstoffen, Phenolverbindungen sowie aromatischen Stickstoffbasen mit einem Siedebereich von etwa 160 oC bis 340 oC (320 oF bis 644 oF).] | 309-889-2 | 101316-87-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-110-00-3 | Extraktrückstände (Kohle), Niedertemperatur-Kohlenteer alkalisch; [Rückstand aus Niedertemperatur-Kohlenteerölen nach alkalischem Waschen, z.B. mit wässrigem Natriumhydroxid, zum Entfernen von rohen Kohlenteersäuren. Besteht in erster Linie aus Kohlenwasserstoffen und aromatischen Stickstoffbasen.] | 310-191-5 | 122384-78-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-111-00-9 | Phenole, Extrakt aus Ammoniaklösung; alkalischer Extrakt; [Kombination von Phenolen, mit Isobutylacetat aus der Ammoniaklösung extrahiert, die aus dem bei der Niedertemperaturpyrolyse (weniger als 700 oC (1292 oF)) von Kohle anfallenden Gas kondensiert. Besteht vorwiegend aus einer Reaktionsmasse aus ein- und zweiwertigen Phenolen.] | 284-881-9 | 84988-93-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-112-00-4 | Destillate (Kohlenteer), leichte Öle, alkalische Extrakte; alkalischer Extrakt; [wässriger Extrakt aus Carbolöl, hergestellt durch alkalisches Waschen z.B. mit wässrigem Natriumhydroxid. Besteht in erster Linie aus den Alkalisalzen verschiedener Phenolverbindungen.] | 292-610-0 | 90640-88-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-113-00-X | Extrakte, Kohlenteeröl alkalisch; alkalischer Extrakt; [Extrakt aus Kohlenteeröl, hergestellt durch alkalisches Waschen, z.B. mit wässrigem Natriumhydroxid. Besteht in erster Linie aus den Alkalisalzen verschiedener Phenolverbindungen.] | 266-017-2 | 65996-83-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-114-00-5 | Destillate (Kohlenteer), Naphthalinöle, alkalische Extrakte; alkalischer Extrakt; [wässriger Extrakt aus Naphthalinöl, hergestellt durch alkalisches Waschen z.B. mit wässrigem Natriumhydroxid. Besteht in erster Linie aus den Alkalisalzen verschiedener Phenolverbindungen.] | 292-611-6 | 90640-89-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-115-00-0 | Extraktrückstände (Kohle), Teeröl alkalisch, mit Kohlendioxid und Calciumoxid behandelt; Rohphenole; [Produkt, erhalten durch Behandlung des alkalischen Extrakts aus Kohlenteer mit CO2und CaO. Besteht in erster Linie aus CaCO3, Ca(OH)2, Na2CO3 und anderen organischen und anorganischen Verunreinigungen.] | 292-629-4 | 90641-06-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-116-00-6 | Teersäuren, Kohle, roh; Rohphenole; [Reaktionsprodukt, erhalten durch Neutralisieren des alkalischen Extrakts von Kohlenteeröl mit einer sauren Lösung, z.B. wässriger Schwefelsäure, oder gasförmigem Kohlendioxid, um die freien Säuren zu erhalten. Besteht in erster Linie aus Teersäuren wie Phenol, Kresolen und Xylenolen.] | 266-019-3 | 65996-85-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-117-00-1 | Teersäuren, Braunkohle, roh; Rohphenole; [angesäuerter alkalischer Extrakt von Braunkohlenteerdestillat. Besteht in erster Linie aus Phenol und Phenolhomologen.] | 309-888-7 | 101316-86-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-118-00-7 | Teersäuren, Braunkohlevergasung; Rohphenole; [komplexe Kombination organischer Verbindungen, erhalten aus der Vergasung von Braunkohle. Besteht in erster Linie aus C6-10-hydroxy-aromatischen Phenolen und ihren Homologen.] | 295-536-7 | 92062-22-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-119-00-2 | Teersäuren, Destillationsrückstände; Destillat-Phenole; [Rückstand aus der Destillation von Rohphenol aus Kohle. Besteht vorwiegend aus Phenolen mit Kohlenstoffzahlen im Bereich von C8 bis C10 und einem Erweichungspunkt von 60 oC bis 80 oC (140 oF bis 176 oF).] | 306-251-5 | 96690-55-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-120-00-8 | Teersäuren, Methylphenol-Fraktion; Destillat-Phenole; [die an 3- und 4-Methylphenol reiche Teersäuren-Fraktion, gewonnen durch Destillation der rohen Teersäuren von Niedertemperatur-Kohlenteer.] | 284-892-9 | 84989-04-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-121-00-3 | Teersäuren, Polyalkylphenol-Fraktion; Destillat-Phenole; [Teersäuren-Fraktion, gewonnen durch Destillation der rohen Teersäuren von Niedertemperatur-Kohlenteer; mit einem Siedebereich von etwa 225 oC bis 320 oC (437 oF bis 608 oF). Besteht in erster Linie aus Polyalkylphenolen.] | 284-893-4 | 84989-05-9 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-122-00-9 | Teersäuren, Xylenolfraktion; Destillat-Phenole; [die an 2,4- und 2,5-Dimethylphenol reiche Teersäuren-Fraktion, gewonnen durch Destillation der rohen Teersäuren von Niedertemperatur-Kohlenteer.] | 284-895-5 | 84989-06-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-123-00-4 | Teersäuren, Ethylphenolfraktion; Destillat-Phenole; [die an 3- und 4-Ethylphenol reiche Teersäuren-Fraktion, gewonnen durch Destillation der rohen Teersäuren von Niedertemperatur-Kohlenteer.] | 284-891-3 | 84989-03-7 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-124-00-X | Teersäuren, 3,5-Xylenol-Fraktion; Destillat-Phenole; [die an 3,5-Dimethylphenol reiche Teersäuren-Fraktion, gewonnen durch Destillation der rohen Teersäuren von Niedertemperatur-Kohlenteer.] | 284-896-0 | 84989-07-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-125-00-5 | Teersäuren, Rückstände, Destillate, erster Schnitt; Destillat-Phenole; [Rückstand aus der Destillation von leichtem Carbolöl im Bereich von 235 oC bis 355 oC (481 oF bis 697 oF).] | 270-713-1 | 68477-23-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-126-00-0 | Teersäuren, Cresylsäure, Rückstände; Destillat-Phenole; [Rückstand aus rohen Kohlenteersäuren nach Entfernen von Phenol, Kresolen, Xylenolen und sämtlichen höhersiedenden Phenolen. Schwarzer Feststoff mit einem Schmelzpunkt von ungefähr 80 oC (176 oF). Besteht in erster Linie aus Polyalkylphenolen, Gummiharzen und anorganischen Salzen.] | 271-418-0 | 68555-24-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-127-00-6 | Phenole, C9-11; Destillat-Phenole | 293-435-2 | 91079-47-9 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-128-00-1 | Teersäuren, Cresylsäure; Destillat-Phenole; [komplexe Kombination organischer Verbindungen, erhalten aus Braunkohle; mit einem Siedebereich von etwa 200 oC bis 230 oC (392 oF bis 446 oF). Enthält hauptsächlich Phenole und Pyridinbasen.] | 295-540-9 | 92062-26-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-129-00-7 | Teersäuren, Braunkohle, C2-Alkylphenol-Fraktion; Destillat-Phenole; [Destillat aus der Ansäuerung von alkalisch gewaschenem Braunkohlenteerdestillat mit einem Siedebereich von etwa 200 oC bis 230 oC (392 oF bis 446 oF). Besteht in erster Linie aus m- und p-Ethylphenol sowie aus Kresolen und Xylenolen.] | 302-662-9 | 94114-29-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-130-00-2 | Extraktöle (Kohle), Naphthalinöle; saurer Extrakt; [wässriger Extrakt, erhalten durch saure Wäsche von alkalisch gewaschenem Naphthalinöl. Besteht in erster Linie aus sauren Salzen verschiedener aromatischer Stickstoffbasen einschließlich Pyridin, Chinolin und ihrer Alkylderivate.] | 292-623-1 | 90641-00-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-131-00-8 | Teerbasen, Chinolinderivate; Destillat-Basen | 271-020-7 | 68513-87-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-132-00-3 | Teerbasen, Kohle, Chinolinderivat-Fraktion; Destillat-Basen | 274-560-1 | 70321-67-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-133-00-9 | Teerbasen, Kohle, Destillationsrückstände; Destillat-Basen; [Destillationsrückstand, erhalten nach der Destillation von neutralisiertem saurem Extrakt der basenhaltigen Teerfraktionen aus der Destillation von Kohlenteer. Enthält hauptsächlich Anilin, Kollidine, Chinolin und Chinolinderivate und Toluidine.] | 295-544-0 | 92062-29-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-134-00-4 | Kohlenwasserstofföle, aromatisch, gemischt mit Polyethylen und Polypropylen, pyrolysiert, Leichtölfraktion; Wärmebehandlungsprodukte; [Öl, erhalten aus der Wärmebehandlung eines Gemischs von Polyethylen/Polypropylen mit Kohlenteerpech oder aromatischen Ölen. Besteht vorwiegend aus Benzol und seinen Homologen mit einem Siedebereich von etwa 70 oC bis 120 oC (158 oF bis 248 oF).] | 309-745-9 | 100801-63-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-135-00-X | Kohlenwasserstofföle, aromatisch, gemischt mit Polyethylen, pyrolysiert, Leichtölfraktion; Wärmebehandlungsprodukte; [Öl, erhalten aus der Wärmebehandlung von Polyethylen gemischt mit Kohlenteerpech oder aromatischen Ölen. Besteht vorwiegend aus Benzol und seinen Homologen mit einem Siedebereich von 70 oC bis 120 oC (158 oF bis 248 oF).] | 309-748-5 | 100801-65-8 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-136-00-5 | Kohlenwasserstofföle, aromatisch, gemischt mit Polystyrol, pyrolysiert, Leichtölfraktion; Wärmebehandlungsprodukte; [Öl, erhalten aus der Wärmebehandlung von Polystyrol gemischt mit Kohlenteerpech oder aromatischen Ölen. Besteht vorwiegend aus Benzol und seinen Homologen mit einem Siedebereich von etwa 70 oC bis 210 oC (158 oF bis 410 oF).] | 309-749-0 | 100801-66-9 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-137-00-0 | Extraktrückstände (Kohle), Teeröl, alkalisch, Naphthalin-Destillationsrückstände; Naphthalinöl-Extraktrückstand; [Rückstand, erhalten aus chemischem Öl, extrahiert nach Entfernen von Naphthalin durch Destillation; besteht in erster Linie aus aromatischen Kohlenwasserstoffen mit zwei- bis viergliedrigen kondensierten Ringsystemen und aromatischen Stickstoffbasen.] | 277-567-8 | 73665-18-6 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-138-00-6 | Kreosotöl, niedrigsiedendes Destillat; Waschöl; [niedrigsiedende Destillationsfraktion, erhalten aus der Hochtemperatur-Verkokung von bitumischer Kohle, die weiter aufbereitet wird, um überschüssige kristalline Salze zu entfernen. Besteht in erster Linie aus Kreosotöl, aus dem einige der normalerweise vorkommenden polynuklearen aromatischen Salze, die Bestandteile von Kohlenteerdestillaten sind, entfernt sind. Ist bei etwa 38 oC (100 oF) kristallfrei.] | 274-566-4 | 70321-80-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-139-00-1 | Teersäuren, Cresylsäure, Natriumsalze, Lösungen kaustischer Alkalien; alkalischer Extrakt | 272-361-4 | 68815-21-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-140-00-7 | Extraktöle (Kohle), Teerbase; saurer Extrakt; [Extrakt aus dem Rückstand vom alkalischen Extrakt aus Kohlenteeröl, hergestellt durch saures Waschen z.B. mit wässriger Schwefelsäure nach der Destillation zum Entfernen von Naphthalin. Besteht in erster Linie aus den sauren Salzen verschiedener aromatischer Stickstoffbasen einschließlich Pyridin, Chinolin und ihren Alkylderivaten.] | 266-020-9 | 65996-86-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-141-00-2 | Teerbasen, Kohle, roh; Roh-Teerbasen; [Reaktionsprodukt, erhalten durch Neutralisieren des Extraktionsöls von Kohlenteerbasen mit einer alkalischen Lösung, z.B. wässrigem Natriumhydroxid, um die freien Basen zu erhalten. Besteht in erster Linie aus organischen Basen wie Acridin, Phenanthridin, Pyridin, Chinolin und ihren Alkylderivaten.] | 266-018-8 | 65996-84-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | JM | ||
648-142-00-8 | Rückstände (Kohle), flüssige Lösungsmittelextraktion; [kohäsives Pulver, das sich aus Kohlenmineralstoff und nicht aufgelöster Kohle nach Extraktion von Kohle durch ein flüssiges Lösungsmittel zusammensetzt.] | 302-681-2 | 94114-46-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-143-00-3 | Kohleflüssigkeiten, flüssige Lösungsmittelextraktion Lösung; [das Produkt, das man durch Filtration von Kohlenmineralstoff und nicht aufgelöster Kohle aus einer Kohlenextraktlösung durch Aufschließen von Kohle in einem flüssigen Lösungsmittel erhält. Die schwarze, viskose, hoch komplexe flüssige Kombination besteht in erster Linie aus aromatischen und teilweise hydrierten aromatischen Kohlenwasserstoffen, aromatischen Stickstoffverbindungen, aromatischen Schwefelverbindungen, phenolhaltigen und anderen aromatischen Sauerstoffverbindungen und ihren Alkylderivaten.] | 302-682-8 | 94114-47-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-144-00-9 | Kohleflüssigkeiten, flüssige Lösungsmittelextraktion; [Das im wesentlichen lösungsmittelfreie Produkt, das man durch Destillation des Lösungsmittels aus abgefilterter Kohlenextraktlösung aus dem Aufschließen von Kohle in einem flüssigen Lösungsmittel erhält. Der schwarze Semifeststoff besteht in erster Linie aus einer komplexen Kombination von aromatischen Kohlenwasserstoffen mit kondensierten Ringen, aromatischen Stickstoffverbindungen, aromatischen Schwefelverbindungen, phenolhaltigen und anderen aromatischen Sauerstoffverbindungen und ihren Alkylderivaten.] | 302-683-3 | 94114-48-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | M | ||
648-145-00-4 | Teer, Braunkohle; [Öl, aus Braunkohlenteer destilliert. Besteht in erster Linie aus aliphatischen, naphthenhaltigen und aromatischen Kohlenwasserstoffen mit einem bis drei Ringen, ihren Alkylderivaten, Heteroaromaten und Phenolen mit einem und zwei Ringen und siedet im Bereich von etwa 150 oC bis 360 oC (302 oF bis 680 oF).] | 309-885-0 | 101316-83-0 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
648-146-00-X | Teer, Braunkohle, Niedrigtemperatur; [Teer, den man aus der Niedrigtemperatur-Verkokung und Niedrigtemperatur-Vergasung von Braunkohle erhält. Besteht in erster Linie aus aliphatischen, naphthenhaltigen und cyclischen aromatischen Kohlenwasserstoffen, heteroaromatischen Kohlenwasserstoffen und cyclischen Phenolen.] | 309-886-6 | 101316-84-1 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
648-147-00-5 | Leichtöl (Kohle), Koksofen; Rohbenzol; [flüchtige organische Flüssigkeit, extrahiert aus dem Gas, das bei der Hochtemperaturpyrolyse (höher als 700 oC (1292 oF)) von Kohle anfällt. Besteht in erster Linie aus Benzol, Toluol und Xylolen. Kann andere kleinere Kohlenwasserstoffbestandteile enthalten.] | 266-012-5 | 65996-78-3 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-148-00-0 | Destillate (Kohle), flüssige Lösungsmittelextraktion, primär; [flüssiges Produkt der Kondensation von Dämpfen, die während der Aufspaltung von Kohle in einem flüssigen Lösungsmittel austreten; mit einem Siedebereich von etwa 30 oC bis 300 oC (86 oF bis 572 oF). Besteht in erster Linie aus teilweise hydrierten aromatischen Kohlenwasserstoffen mit kondensierten Ringen, aromatischen Verbindungen, die Stickstoff, Sauerstoff und Schwefel enthalten, und ihren Alkylderivaten mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C14.] | 302-688-0 | 94114-52-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-149-00-6 | Destillate (Kohle), Lösungsmittelextraktion, hydrogecrackt; [Destillat, erhalten durch Hydrocracken von Kohlenextrakt oder der Lösung, die durch flüssige Lösungsmittelextraktion oder Extraktion mit überkritischen Gasen entsteht, mit einem Siedebereich von etwa 30 oC bis 300 oC (86 oF bis 572 oF). Besteht in erster Linie aus aromatischen, hydrierten aromatischen und naphthenhaltigen Verbindungen, ihren Alkylderivaten und Alkanen mit Kohlenstoffzahlen überwiegend im Bereich von C4 bis C14. Stickstoff, Schwefel und Sauerstoff enthaltende aromatische und hydrierte aromatische Verbindungen sind vorhanden.] | 302-689-6 | 94114-53-1 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-150-00-1 | Naphtha (Kohle), Lösungsmittelextraktion, hydrogecrackt; [Fraktion des Destillats, erhalten durch Hydrocracken von Kohlenextrakt oder der Lösung, die durch flüssige Lösungsmittelextraktion oder Extraktion mit überkritischen Gasen entsteht, mit einem Siedebereich von etwa 30 oC bis 180 oC (86 oF bis 356 oF). Besteht in erster Linie aus aromatischen, hydrierten aromatischen und naphthenhaltigen Verbindungen, ihren Alkylderivaten und Alkanen mit Kohlenstoffzahlen überwiegend im Bereich von C4 bis C9. Stickstoff, Schwefel und Sauerstoff enthaltende aromatische und hydrierte aromatische Verbindungen sind vorhanden.] | 302-690-1 | 94114-54-2 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-151-00-7 | Benzin, Kohle Lösungsmittelextraktion, hydrogecrackt Naphtha; [Motorbrennstoff, der durch Reformieren der aufbereiteten Naphtha-Fraktion der Produkte aus dem Hydrocracken von Kohlenextrakt oder der Lösung entsteht, die durch flüssige Lösungsmittelextraktion oder Extraktion mit überkritischen Gasen entsteht, mit einem Siedebereich von etwa 30 oC bis 180 oC (86 oF bis 356 oF). Besteht in erster Linie aus aromatischen und naphthenhaltigen Kohlenwasserstoffen, ihren Alkylderivaten und Alkylkohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C4 bis C9.] | 302-691-7 | 94114-55-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
648-152-00-2 | Mittlere Destillate (Kohle), Lösungsmittelextraktion, hydrogecrackt; [Destillat, erhalten durch Hydrocracken von Kohlenextrakt oder der Lösung, die durch flüssige Lösungsmittelextraktion oder Extraktion mit überkritischen Gasen entsteht; siedet im Bereich von etwa 180 oC bis 300 oC (356 oF bis 572 o). Besteht in erster Linie aus aromatischen Verbindungen mit zwei Ringen, hydrierten aromatischen und naphthenhaltigen Verbindungen, ihren Alkylderivaten und Alkanen mit Kohlenstoffzahlen vorwiegend im Bereich von C9 bis C14. Stickstoff, Schwefel und Sauerstoff enthaltende Verbindungen sind vorhanden.] | 302-692-2 | 94114-56-4 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-153-00-8 | Mittlere Destillate (Kohle), Lösungsmittelextraktion, hydrogecrackt, hydriert; [Destillat aus der Hydrierung von hydrogecracktem mittlerem Destillat aus Kohlenextrakt oder der Lösung, die durch flüssige Lösungsmittelextraktion oder Extraktion mit überkritischen Gasen entsteht, mit einem Siedebereich von etwa 180 oC bis 280 oC (356 oF bis 536 oF). Besteht in erster Linie aus hydrierten Kohlenwasserstoffen mit zwei Ringen und ihren Alkylderivaten mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C14.] | 302-693-8 | 94114-57-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
648-154-00-3 | Brennstoffe, Düsenflugzeug, Kohle Lösungsmittelextraktion, hydrogecrackte hydrierte; [Düsentriebwerksbrennstoff, hergestellt durch Hydrierung der Mitteldestillat-Fraktion der Hydrocrackprodukte von Kohlenextrakt oder der Lösung, die durch flüssige Lösungsmittelextraktion oder Extraktion mit überkritischen Gasen entsteht und in einem Bereich von etwa 180 oC bis 225 oC (356 oF bis 473 oF) siedet. Besteht in erster Linie aus hydrierten Kohlenwasserstoffen mit zwei Ringen und ihren Alkylderivaten mit Kohlenstoffzahlen überwiegend im Bereich von C10 bis C12.] | 302-694-3 | 94114-58-6 | Carc. 2 | H351 | GHS08 Achtg. | H350 | |||
648-155-00-9 | Brennstoffe, Diesel, Kohle Lösungsmittelextraktion, hydrogecrackte hydrierte; [Dieseltriebwerksbrennstoff, hergestellt durch Hydrierung der Mitteldestillat-Fraktion der Hydrocrackprodukte von Kohlenextrakt oder der Lösung, die durch flüssige Lösungsmittelextraktion oder Extraktion mit überkritischen Gasen entsteht und in einem Bereich von etwa 200o oC bis 280o oC (392 oF bis 536 oF) siedet. Besteht in erster Linie aus hydrierten Kohlenwasserstoffen mit zwei Ringen und ihren Alkylderivaten mit Kohlenstoffzahlen überwiegend im Bereich von C11 bis C14.] | 302-695-9 | 94114-59-7 | Carc. 2 | H351 | GHS08 Achtg. | H350 | |||
648-156-00-4 | Leichtöl (Kohle), Halbverkokungsverfahren; Frischöl; [flüchtige organische Flüssigkeit, die aus dem bei der Niedertemperaturpyrolyse (weniger als 700 oC (1292 oF)) ausströmenden Gas kondensiert. Besteht in erster Linie aus C6-10-Kohlenwasserstoffen.] | 292-635-7 | 90641-11-5 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Gef. | H350 H340 | J | ||
649-001-00-3 | Extrakte (Erdöl), leichtes naphthenhaltiges Destillatlösungsmittel | 265-102-1 | 64742-03-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-002-00-9 | Extrakte (Erdöl), schweres paraffinhaltiges Destillatlösungsmittel | 265-103-7 | 64742-04-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-003-00-4 | Extrakte (Erdöl), leichtes paraffinhaltiges Destillatlösungsmittel | 265-104-2 | 64742-05-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-004-00-X | Extrakte (Erdöl), schweres naphthenhaltiges Destillatlösungsmittel | 265-111-0 | 64742-11-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-005-00-5 | Extrakte (Erdöl), leichtes Vakuum Gasöl Lösungsmittel | 295-341-7 | 91995-78-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-006-00-0 | Kohlenwasserstoffe, C26-55, aromatenreich | 307-753-7 | 97722-04-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-007-00-6 | Fettsäuren, Tallöl, Reaktionsprodukte mit Iminodiethanol und Borsäure | 400-160-5 | - | Skin Irrit. 2 Aquatic Chronic 2 | H315 H411 | GHS07 GHS09 Achtg. | H315 H411 | |||
649-008-00-1 | Rückstände (Erdöl), offener Turm; Schweröl; [komplexer Rückstand aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20 und siedet bei über etwa 350 oC (662 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-045-2 | 64741-45-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-009-00-7 | Gasöle (Erdöl), schwere Vakuum-; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und siedet im Bereich von etwa 350 oC bis 600 oC (662 oF bis 1112 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-058-3 | 64741-57-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-010-00-2 | Destillate (Erdöl), schwere katalytisch gecrackte; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C35 und siedet im Bereich von etwa 260 oC bis 500 oC (500 oF bis 932 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-063-0 | 64741-61-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-011-00-8 | Gereinigte Öle (Erdöl), katalytisch gecrackte; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20 und siedet bei über etwa 350 oC (662 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-064-6 | 64741-62-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-012-00-3 | Rückstände (Erdöl), hydrogecrackt; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion durch Destillation von Produkten aus einem Hydrocrackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20 und siedet bei über etwa 350 oC (662 oF).] | 265-076-1 | 64741-75-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-013-00-9 | Rückstände (Erdöl), thermisch gecrackt; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion durch Destillation des Produkts aus einem thermischen Crackverfahren. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20 und siedet bei über etwa 350 oC (662 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-081-9 | 64741-80-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-014-00-4 | Destillate (Erdöl), schwere thermisch gecrackte; Schweröl; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem thermischen Crackverfahren. Besteht überwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C36 und siedet im Bereich von etwa 260 oC bis 480 oC (500 oF bis 896 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-082-4 | 64741-81-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-015-00-X | Gasöle (Erdöl), mit Wasserstoff behandelte Vakuum-; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion unter Einsatz eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C13 bis C50 und siedet im Bereich von etwa 230 oC bis 600 oC (446 oF bis 1112 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-162-9 | 64742-59-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-016-00-5 | Rückstände (Erdöl), hydrodesulfurierte, offener Turm; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandlung eines Offenen-Turmrückstandes mit Wasserstoff unter Einsatz eines Katalysators unter Bedingungen zum Entfernen organischer Schwefelverbindungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20 und siedet bei über etwa 350 oC (662 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-181-2 | 64742-78-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-017-00-0 | Gasöle (Erdöl), hydrodesulfurierte schwere Vakuum-; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytische Hydrodesulfurierung. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und siedet im Bereich von etwa 350 oC bis 600 oC (662 oF bis 1112 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-189-6 | 64742-86-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-018-00-6 | Rückstände (Erdöl), steamcracked; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten als Rückstandsfraktion aus der Destillation der Produkte eines Steamcrackverfahrens (einschließlich Steamcracken zur Herstellung von Ethylen). Besteht überwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C14 und siedet bei über etwa 260 oC (500 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 265-193-8 | 64742-90-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-019-00-1 | Rückstände (Erdöl), offene; Schweröl; [komplexer Rückstand aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C11 und siedet bei über etwa 200 oC (392 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 269-777-3 | 68333-22-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-020-00-7 | Gereinigte Öle (Erdöl), hydrodesulfurierte katalytisch gecrackte; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von katalytisch gecracktem gereinigtem Öl mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff zu überführen, der entfernt wird. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20 und siedet bei über etwa 350 oC (662 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 269-782-0 | 68333-26-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-021-00-2 | Destillate (Erdöl), hydrodesulfurierte intermediäre katalytisch gecrackte; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von intermediären katalytisch gecrackten Destillaten mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff zu überführen, der entfernt wird. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11 bis C30 und siedet im Bereich von etwa 205 oC bis 450 oC (401 oF bis 842 oF). Enthält eine relativ große Menge tricyclischer aromatischer Kohlenwasserstoffe.] | 269-783-6 | 68333-27-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-022-00-8 | Destillate (Erdöl), hydrodesulfurierte schwere katalytisch gecrackte; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von schweren katalytisch gecrackten Destillaten mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff zu überführen, der entfernt wird. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C35 und siedet im Bereich von etwa 260 oC bis 500 oC (500 oF bis 932 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 269-784-1 | 68333-28-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-023-00-3 | Brennöl, Öle aus Rückständen von straight-run-Benzin, hochschwefelhaltig; Schweröl; | 270-674-0 | 68476-32-4 | Carc. 1B | H350 | HS08 Gef. | H350 | |||
649-024-00-9 | Brennöl, Rückstand; Schweröl; [flüssiges Produkt aus verschiedenen Raffinerieläufen, gewöhnlich Rückstände. Die Zusammensetzung ist komplex und variiert mit der Rohölquelle.] | 270-675-6 | 68476-33-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-025-00-4 | Rückstände (Erdöl), katalytische Reformer Fraktionator Rückstandsdestillation; Schweröl; [komplexer Rückstand aus der Destillation eines katalytischen Reformer Fraktionator Rückstandes. Siedet etwa über 399 oC (750 oF).] | 270-792-2 | 68478-13-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-026-00-X | Rückstände (Erdöl), schweres Kokereigasöl und Vakuumgasöl; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion aus der Destillation von schwerem Kokereigasöl und Vakuumgasöl. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C13 und siedet bei über etwa 230 oC (446 oF).] | 270-796-4 | 68478-17-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-027-00-5 | Rückstände (Erdöl), schwere Kokerei und leichte Vakuum; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion aus der Destillation von schwerem Kokereigasöl und leichtem Vakuumgasöl. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C13 und siedet bei über etwa 230 oC (446 oF).] | 270-983-0 | 68512-61-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-028-00-0 | Rückstände (Erdöl), leichte Vakuum; Schweröl; [komplexer Rückstand aus der Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C13 und siedet bei über etwa 230 oC (446 oF).] | 270-984-6 | 68512-62-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-029-00-6 | Rückstände (Erdöl), steamcracked, leichte; Schweröl; [komplexer Rückstand aus der Destillation von Produkten aus einem Steamcrackverfahren. Besteht überwiegend aus aromatischen und ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen größer als C7 und siedet im Bereich von etwa 101 oC bis 555 oC (214 oF bis 1030 oF).] | 271-013-9 | 68513-69-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-030-00-1 | Brennöl, Nr. 6; Schweröl; [Destillatöl mit einer minimalen Viskosität von 900 SUS bei 37,7 oC (100 oF) und einer maximalen Viskosität von 9000 SUS bei 37,7o C (100 oF).] | 271-384-7 | 68553-00-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-031-00-7 | Rückstände (Erdöl), Topanlage, niedrig-Schwefel; Schweröl; [eine wenig Schwefel enthaltende komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion aus der Topanlagendestillation von Rohöl. Es ist der Rückstand nach dem Entfernen von straight-run Benzinschnitt, Kerosinschnitt und Gasölschnitt.] | 271-763-7 | 68607-30-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-032-00-2 | Gasöle (Erdöl), schwere offene; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C35 und siedet im Bereich von etwa 121 oC bis 510 oC (250 oF bis 950 oF).] | 272-184-2 | 68783-08-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-033-00-8 | Rückstände (Erdöl), Kokswäscher, kondensierte Ring-Aromaten enthaltend; Schweröl; [sehr komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion durch Destillation des Vakuumrückstandes und der Produkte aus einem thermischen Crackverfahren. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20und siedet bei über etwa 350 oC (662 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 272-187-9 | 68783-13-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-034-00-3 | Destillate (Erdöl), Erdölrückstände Vakuum; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. | 273-263-4 | 68955-27-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-035-00-9 | Rückstände (Erdöl), steamcracked, harzartig; Schweröl; [komplexer Rückstand aus der Destillation von steamcracked Erdölrückständen.] | 273-272-3 | 68955-36-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-036-00-4 | Destillate (Erdöl), mittleres Vakuum; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl.] Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C14 bis C42 und siedet im Bereich von etwa 250 oC bis 545 oC (482 oF bis 1013 oF).] Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 274-683-0 | 70592-76-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-037-00-X | Destillate (Erdöl), leichtes Vakuum; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11 bis C35 und siedet im Bereich von etwa 250 oC bis 545 oC (482 oF bis 1013 oF).] | 274-684-6 | 70592-77-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-038-00-5 | Destillate (Erdöl), Vakuum; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C50 und siedet im Bereich von etwa 270 oC bis 600 oC (518 oF bis 1112 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 274-685-1 | 70592-78-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-039-00-0 | Gasöle (Erdöl), hydrodesulfurierte Koker hohes Vakuum-; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Hydrodesulfurierung von schweren Kokereidestillatausgangsstoffen. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C18bis C44 und siedet im Bereich von etwa 304 oC bis 548 oC (579 oF bis 1018 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 285-555-9 | 85117-03-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-040-00-6 | Rückstände (Erdöl), steamcracked, Destillate; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten während der Produktion von aufbereitetem Erdölteer durch Destillation von steamcracked Teer. Besteht überwiegend aus aromatischen und anderen Kohlenwasserstoffen und organischen Schwefelverbindungen.] | 292-657-7 | 90669-75-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-041-00-1 | Rückstände (Erdöl), Vakuum, leicht; Schweröl; [komplexer Rückstand aus der Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C24 und siedet bei über etwa 390 oC (734 oF).] | 292-658-2 | 90669-76-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-042-00-7 | Heizöl, schwer, hochschwefelhaltig; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von rohem Erdöl. Besteht überwiegend aus aliphatischen, aromatischen und cycloaliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend höher als C25 und siedet bei über etwa 400 oC (752 oF).] | 295-396-7 | 92045-14-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-043-00-2 | Rückstände (Erdöl), katalytisches Cracken; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C11 und siedet bei über etwa 200 oC (392 oF).] | 295-511-0 | 92061-97-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-044-00-8 | Destillate (Erdöl), intermediäre katalytisch gecrackte, thermisch abgebaut; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren, das als Wärmetransfer-Flüssigkeit benutzt wurde. Besteht überwiegend aus Kohlenwasserstoffen und siedet im Bereich von etwa 220 oC bis 450 oC (428 oF bis 842 oF). Dieser Lauf enthält wahrscheinlich organische Schwefelverbindungen.] | 295-990-6 | 92201-59-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-045-00-3 | Rückstandsöle (Erdöl); Schweröl; [komplexe Kombination von Kohlenwasserstoffen, Schwefelverbindungen und Metall enthaltenden organischen Verbindungen, die man als Rückstand aus Raffinerie-Fraktionier-Crackverfahren erhält. Ergibt ein Fertigöl mit einer Viskosität größer als 2 cSt bei 100 oC.] | 298-754-0 | 93821-66-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-046-00-9 | Rückstände, steamcracked, thermisch behandelt; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung und Destillation von roher steamcracked Naphtha erhält. Besteht überwiegend aus ungesättigten Kohlenwasserstoffen und siedet im Bereich über etwa 180 oC (356 oF).] | 308-733-0 | 98219-64-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-047-00-4 | Destillate (Erdöl), hydrodesulfurierte gesamte mittlere; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln eines Erdölausgangsstoffes mit Wasserstoff erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C25 und siedet im Bereich von etwa 150 oC bis 400 oC (302 oF bis 752 oF).] | 309-863-0 | 101316-57-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-048-00-X | Rückstände (Erdöl), katalytisch reformierte Fraktionator-; Schweröl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt als Rückstandsfraktion durch Destillation des Produkts aus einem katalytischen Reformingverfahren. Besteht überwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C10 bis C25und siedet im Bereich von etwa 160 oC bis 400 oC (320 oF bis 725 oF). Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- oder 6-gliedrigen kondensierten Ringsystemen.] | 265-069-3 | 64741-67-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-049-00-5 | Erdöl; Rohöl; [komplexe Kombination von Kohlenwasserstoffen. Besteht in erster Linie aus aliphatischen, alicyclischen und aromatischen Kohlenwasserstoffen. Kann auch geringe Mengen Stickstoff, Sauerstoff und Schwefelverbindungen enthalten. Diese Kategorie schließt Leicht-, Mittel- und Schwererdöle ein, auch aus Teersanden extrahierte Öle. Kohlenwasserstoffhaltige Materialien, die zu ihrer Gewinnung oder Konversion zu Erdölraffineriegrundstoffen größere chemische Veränderungen erfordern wie rohe Schieferöle, aufgewertete Schieferöle und flüssige Kohlenbrennstoffe sind in dieser Definition nicht enthalten.] | 232-298-5 | 8002-05-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-050-00-0 | Destillate (Erdöl), leichte paraffinhaltige; nicht oder leicht raffiniertes Basisöl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält einen relativ großen Anteil an gesättigten aliphatischen Kohlenwasserstoffen, die normalerweise in diesem Destillationsbereich von Rohöl vorhanden sind.] | 265-051-5 | 64741-50-0 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-051-00-6 | Destillate (Erdöl), schwere paraffinhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 100 SUS bei 100 oF (19 cSt bei 40 oC) . Enthält eine relativ große Menge gesättigter aliphatischer Kohlenwasserstoffe.] | 265-052-0 | 64741-51-1 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-052-00-1 | Destillate (Erdöl), leichte naphthenhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 100 SUS bei 100 oF (19 cSt bei 40 oC). Enthält relativ wenige normale Paraffine.] | 265-053-6 | 64741-52-2 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-053-00-7 | Destillate (Erdöl), schwere naphthenhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Vakuumdestillation des Rückstands aus der atmosphärischen Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 100 SUS bei 100 oF (19 cSt bei 40 oC). Enthält relativ wenige normale Paraffine.] | 265-054-1 | 64741-53-3 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-054-00-2 | Destillate (Erdöl), säurebehandelte schwere naphthenhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Verfahren durch Einwirkung von Schwefelsäure. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 100 SUS bei 100 oF (19 cSt bei 40 oC) . Enthält relativ wenige normale Paraffine.] | 265-117-3 | 64742-18-3 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-055-00-8 | Destillate (Erdöl), säurebehandelte leichte naphthenhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Verfahren durch Einwirkung von Schwefelsäure. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 100 SUS bei 100 oF (19 cSt bei 40 oC). Enthält relativ wenige normale Paraffine.] | 265-118-9 | 64742-19-4 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-056-00-3 | Destillate (Erdöl), säurebehandelte schwere paraffinhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat durch Schwefelsäurebehandlung. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 100 SUS bei 100 oF (19 cSt bei 40 oC).] | 265-119-4 | 64742-20-7 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-057-00-9 | Destillate (Erdöl), säurebehandelte leichte paraffinhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Verfahren durch Einwirkung von Schwefelsäure. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 100 SUS bei 100 oF (19 cSt bei 40 oC).] | 265-121-5 | 64742-21-8 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-058-00-4 | Destillate (Erdöl), chemisch neutralisierte schwere paraffinhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch ein Behandlungsverfahren zum Entfernen saurer Stoffe. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 100 SUS bei 100 oF (19 cSt bei 40 oC). Enthält eine relativ große Menge aliphatischer Kohlenwasserstoffe.] | 265-127-8 | 64742-27-4 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-059-00-X | Destillate (Erdöl), chemisch neutralisierte leichte paraffinhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch ein Behandlungsverfahren zum Entfernen saurer Stoffe. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 100 SUS bei 100 oF (19 cSt bei 40 oC).] | 265-128-3 | 64742-28-5 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-060-00-5 | Destillate (Erdöl), chemisch neutralisierte schwere naphthenhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch ein Behandlungsverfahren zum Entfernen saurer Stoffe. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 100 SUS bei 100 oF (19 cSt bei 40 oC). Enthält relativ wenige normale Paraffine.] | 265-135-1 | 64742-34-3 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-061-00-0 | Destillate (Erdöl), chemisch neutralisierte leichte naphthenhaltige; Nicht oder leicht raffiniertes Basisöl; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch ein Behandlungsverfahren zum Entfernen saurer Stoffe. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als (100 SUS bei 100 oF (19 cSt bei 40 oC). Enthält relativ wenige normale Paraffine.] | 265-136-7 | 64742-35-4 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
649-062-00-6 | Gase (Erdöl), Kopfprodukte, katalytisch gecrackt, Naphtha, Propanabtrennung, C3-reich, säurefrei; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung katalytisch gecrackter Kohlenwasserstoffe und behandelt, um saure Verunreinigungen zu entfernen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C2 bis C4, überwiegend C3.] | 270-755-0 | 68477-73-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-063-00-1 | Gase (Erdöl), katalytisch gecrackt; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht vorwiegend aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 270-756-6 | 68477-74-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-064-00-7 | Gase (Erdöl), katalytisch gecrackt, C1-5-reich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C6, vorwiegend C1 bis C5.] | 270-757-1 | 68477-75-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-065-00-2 | Gase (Erdöl), Kopfprodukte, katalytisch polymerisiertes Naphtha, Stabilisationskolonne, C2-4-reich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Fraktionierung und Stabilisierung von katalytisch gecracktem Naphtha. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C2 bis C6, vorwiegend C2 bis C4.] | 270-758-7 | 68477-76-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-066-00-8 | Gase (Erdöl), katalytisch reformiert, C1-4-reich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Reforming-Verfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C6, vorwiegend C1 bis C4.] | 270-760-8 | 68477-79-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-067-00-3 | Gase (Erdöl), Alkylierungsbeschickung aus C3-5-Olefinen und -Paraffinen; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Olefinen und Paraffinen mit Kohlenstoffzahlen im Bereich von C3 bis C5, die für die Alkylierungsbeschickung verwendet werden. Umgebungstemperaturen liegen normalerweise über der kritischen Temperatur dieser Kombinationen.] | 270-765-5 | 68477-83-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-068-00-9 | Gase (Erdöl), C4-reich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von Produkten aus einem katalytischen Fraktionierungsverfahren. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C3 bis C5, vorwiegend C4.] | 270-767-6 | 68477-85-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-069-00-4 | Gase (Erdöl), Kopfprodukte, Ethanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation der Gas- und Benzinfraktionen aus dem katalytischen Crackverfahren. Enthält überwiegend Ethan und Ethylen.] | 270-768-1 | 68477-86-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-070-00-X | Gase (Erdöl), Kopfprodukte, Isobutanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch atmosphärische Destillation eines Butan-Butylen-Laufs. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C4.] | 270-769-7 | 68477-87-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-071-00-5 | Gase (Erdöl), Propanabtrennung trocken, propenreich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus den Gas- und Benzinfraktionen aus einem katalytischen Crackverfahren. Besteht vorwiegend aus Propylen sowie etwas Ethan und Propan.] | 270-772-3 | 68477-90-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-072-00-0 | Gase (Erdöl), Kopfprodukte, Propanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus den Gas- und Benzinfraktionen aus einem katalytischen Crackverfahren. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C4.] | 270-773-9 | 68477-91-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-073-00-6 | Gase (Erdöl), Gasrückgewinnungsanlage, Kopfprodukte, Propanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Fraktionierung verschiedener Kohlenwasserstoffläufe. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C4, überwiegend Propan.] | 270-777-0 | 68477-94-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-074-00-1 | Gase (Erdöl), Beschickung der Girbotolanlage; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, verwendet zur Beschickung einer Girbotolanlage zur Entfernung von Schwefelwasserstoff. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C4.] | 270-778-6 | 68477-95-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-075-00-7 | Gase (Erdöl), isomerisiert, Naphthafraktionierung, C4-reich, schwefelwasserstofffrei; Gase aus der Erdölverarbeitung | 270-782-8 | 68477-99-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-076-00-2 | Restgas (Erdöl), Fraktionierung von katalytisch gecracktem gereinigtem Öl und thermisch gecracktem Vakuumrückstand aus Rücklaufbehälter; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Fraktionierung von katalytisch gecracktem gereinigtem Öl und thermisch gecracktem Vakuumrückstand. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 270-802-5 | 68478-21-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-077-00-8 | Restgas (Erdöl), Stabilisierung von katalytisch gecracktem Naphtha, Absorptionssäule; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Stabilisierung von katalytisch gecracktem Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 270-803-0 | 68478-22-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-078-00-3 | Restgas (Erdöl), kombinierte Fraktionierung der Produkte von katalytischem Cracken, katalytischem Reformieren und Hydrodesulfurierung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Fraktionierung von Produkten aus katalytischem Cracken, katalytischem Reformieren und Hydrodesulfurierung, behandelt zum Entfernen saurer Verunreinigungen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 270-804-6 | 68478-24-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-079-00-9 | Restgas (Erdöl), Fraktionierung von katalytisch reformiertem Naphtha, Stabilisationskolonne; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Fraktionierung und Stabilisierung von katalytisch reformiertem Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 270-806-7 | 68478-26-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-080-00-4 | Restgas (Erdöl), Mischlauf aus Anlage für gesättigte Gase, C4-reich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung und Stabilisierung von Straight-run-Benzin, Destillationsrestgas und Restgas aus der Stabilisationskolonne für katalytisch reformiertes Naphtha. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C3 bis C6, überwiegend Butan und Isobutan.] | 270-813-5 | 68478-32-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-081-00-X | Restgas (Erdöl), Rückgewinnungsanlage gesättigte Gase, C1-2-reich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus Fraktionierung von Destillationsrestgas, Straight-run-Benzin, Restgas aus Stabilisationskolonne für katalytisch reformiertes Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5, überwiegend Methan und Ethan.] | 270-814-0 | 68478-33-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-082-00-5 | Restgas (Erdöl), thermisch gecrackte Vakuumrückstände; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus thermischem Cracken von Vakuumrückständen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 270-815-6 | 68478-34-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-083-00-0 | Kohlenwasserstoffe, C3-4-reich, Erdöldestillat; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation und Kondensation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C3 bis C5, vorwiegend C3 bis C4.] | 270-990-9 | 68512-91-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-084-00-6 | Gase (Erdöl), Abgase aus Hexanabtrennung, schweres Straight-run-Benzin; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung des schweren Straight-run-Benzins. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C6.] | 271-000-8 | 68513-15-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-085-00-1 | Gase (Erdöl), Hydrocracken, Abgase aus Propanabtrennung, kohlenwasserstoffreich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem Hydrocrackverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4. Kann auch geringe Mengen Wasserstoff und Schwefelwasserstoff enthalten.] | 271-001-3 | 68513-16-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-086-00-7 | Gase (Erdöl), Abgase aus Stabilisationskolonne, leichtes Straight-run-Benzin; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung von leichtem Straight-run-Benzin. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C6.] | 271-002-9 | 68513-17-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-087-00-2 | Rückstände (Erdöl), Trennung durch Alkylierung, C4-reich; Gase aus der Erdölverarbeitung; [Komplexer Rückstand aus der Destillation von Läufen aus verschiedenen Raffinerievorgängen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C4 bis C5, überwiegend aus Butan, und siedet im Bereich von etwa -11,7 oC bis 27,8 oC (11 oF bis 82 oF).] | 271-010-2 | 68513-66-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-088-00-8 | Kohlenwasserstoffe, C1-4; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch thermische Crack- und Absorptionsvorgänge und durch Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4 mit einem Siedebereich von etwa -164 oC bis -0,5 oC (-263 oF bis 31 oF).] | 271-032-2 | 68514-31-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-089-00-3 | Kohlenwasserstoffe, C1-4, gesüßt; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Süßung von Kohlenwasserstoffgasen zur Umwandlung von Mercaptanen oder zum Entfernen saurer Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C1 bis C4 mit einem Siedebereich von etwa -164 oC bis -0,5 oC (-263 oF bis 31 oF).] | 271-038-5 | 68514-36-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-090-00-9 | Kohlenwasserstoffe, C1-3; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C3 mit einem Siedebereich von etwa -164 oC bis -42 oC (-263 oF bis -44 oF).] | 271-259-7 | 68527-16-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-091-00-4 | Kohlenwasserstoffe, C1-4, Butanabtrennungsfraktion; Gase aus der Erdölverarbeitung; | 271-261-8 | 68527-19-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-092-00-X | Gase (Erdöl), C1-5, nass; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Rohöl und/oder durch Cracken von Turmgasöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 271-624-0 | 68602-83-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-093-00-5 | Kohlenwasserstoffe, C2-4; Gase aus der Erdölverarbeitung | 271-734-9 | 68606-25-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-094-00-0 | Kohlenwasserstoffe, C3; Gase aus der Erdölverarbeitung | 271-735-4 | 68606-26-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-095-00-6 | Gase (Erdöl), Alkylierungsbeschickung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch katalytisches Cracken von Gasöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C4.] | 271-737-5 | 68606-27-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-096-00-1 | Gase (Erdöl), Abgase aus Fraktionierung der Sumpfprodukte aus Propanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Fraktionierung von Sumpfprodukten aus Propanabtrennung; Besteht vorwiegend aus Butan, Isobutan und Butadien.] | 271-742-2 | 68606-34-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-097-00-7 | Gase (Erdöl), Raffinerieverschnitt; Gase aus der Erdölverarbeitung; [Komplexe Kombination, erhalten aus verschiedenen Verfahren. Besteht aus Wasserstoff, Schwefelwasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 272-183-7 | 68783-07-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-098-00-2 | Gase (Erdöl), katalytisches Cracken; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C5.] | 272-203-4 | 68783-64-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-099-00-8 | Gase (Erdöl), C2-4, gesüßt; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Süßung eines Erdöldestillats zur Umwandlung von Mercaptanen oder zum Entfernen saurer Verunreinigungen. Besteht in erster Linie aus gesättigten und ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C2 bis C4 mit einem Siedebereich von etwa -51 oC bis -34 oC (-60 oF bis -30 oF).] | 272-205-5 | 68783-65-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-100-00-1 | Gase (Erdöl), Abgase aus Rohölfraktionierung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung von Rohöl. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 272-871-7 | 68918-99-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-101-00-7 | Gase (Erdöl), Abgase aus Hexanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung von kombinierten Naphthaläufen. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 272-872-2 | 68919-00-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-102-00-2 | Gase (Erdöl), Abgase aus Fraktionierung von leichtem Straight-run-Benzin, Stabilisationskolonne; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung von leichtem Straight-run-Benzin. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 272-878-5 | 68919-05-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-103-00-8 | Gase (Erdöl), Abgase aus Naphthaentschwefelung durch Unifining, Strippersäule; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Unifining zur Naphthaentschwefelung und vom Naphthaprodukt gestrippt. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 272-879-0 | 68919-06-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-104-00-3 | Gase (Erdöl), Abgase aus katalytischem Reformieren von Straight-run-Benzin; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Reformieren von Straight-run-Benzin und Fraktionieren des gesamten ablaufenden Produkts. Besteht aus Methan, Ethan und Propan.] | 272-882-7 | 68919-09-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-105-00-9 | Gase (Erdöl), Kopfprodukte aus Fließbettverfahren, Splitter; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Fraktionierung der Beschickung für C3-C4-Splitter. Besteht vorwiegend aus C3-Kohlenwasserstoffen.] | 272-893-7 | 68919-20-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-106-00-4 | Gase (Erdöl), Abgase von Straight-run-Benzin, Stabilisationskolonne; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung der Flüssigkeit aus der ersten Kolonne bei der Destillation von Rohöl. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 272-883-2 | 68919-10-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-107-00-X | Gase (Erdöl), katalytisch gecracktes Naphtha, Butanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung von katalytisch gecracktem Naphtha. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 273-169-3 | 68952-76-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-108-00-5 | Restgas (Erdöl), katalytisch gecracktes Destillat und Naphtha, Stabilisationskolonne; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung von katalytisch gecracktem Naphtha und Destillat. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 273-170-9 | 68952-77-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-109-00-0 | Restgas (Erdöl), thermisch gecracktes Destillat, Gasöl und Naphtha, Absorptionssäule; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Trennung von Destillaten, Naphtha und Gasöl nach dem thermischen Cracken. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 273-175-6 | 68952-81-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-110-00-6 | Restgas (Erdöl), Fraktionierung und Stabilisierung thermisch gecrackter Kohlenwasserstoffe aus Coking-Verfahren; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung und Stabilisierung von thermisch gecrackten Kohlenwasserstoffen aus Coking-Verfahren unterzogenem Erdöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 273-176-1 | 68952-82-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-111-00-1 | Gase (Erdöl), leicht, steamcracked, butadienreich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem thermischen Crackverfahren. Besteht aus Kohlenwasserstoffen vorwiegend mit der Kohlenstoffzahl C4.] | 273-265-5 | 68955-28-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-112-00-7 | Gase (Erdöl), katalytisch reformiertes Straight-run-Benzin, Stabilisationskolonne, Kopfprodukt; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Reformieren von Straight-run-Benzin und Fraktionieren des gesamten ablaufenden Produkts. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C4.] | 273-270-2 | 68955-34-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-113-00-2 | Kohlenwasserstoffe, C4; Gase aus der Erdölverarbeitung | 289-339-5 | 87741-01-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-114-00-8 | Alkane, C1-4, C3-reich; Gase aus der Erdölverarbeitung | 292-456-4 | 90622-55-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-115-00-3 | Gase (Erdöl), steamcracked, C3-reich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem Steamcrackverfahren. Besteht vorwiegend aus Propylen und etwas Propan mit einem Siedebereich von etwa -70 oC bis 0 oC (-94 oF bis 32 oF).] | 295-404-9 | 92045-22-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-116-00-9 | Kohlenwasserstoffe, C4, Destillat nach Steamcracken; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation der Produkte aus einem Steamcrackverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit einer Kohlenstoffzahl C4, überwiegend 1-Buten und 2-Buten; enthält auch Butan und Isobuten mit einem Siedebereich von etwa - 12 oC bis 5 oC (10,4 oF bis 41 oF).] | 295-405-4 | 92045-23-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-117-00-4 | Erdölgase, flüssig, gesüßt, C4-Fraktion; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Süßung eines flüssigen Erdölgasgemischs zur Oxidation von Mercaptanen oder zum Entfernen saurer Verunreinigungen. Besteht vorwiegend aus gesättigten und ungesättigten C4-Kohlenwasserstoffen.] | 295-463-0 | 92045-80-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K S U | ||
649-118-00-X | Kohlenwasserstoffe, C4, frei von 1,3-Butadien und Isobuten; Gase aus der Erdölverarbeitung | 306-004-1 | 95465-89-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-119-00-5 | Raffinate (Erdöl), steamcracked C4-Fraktion, Kupferammoniumacetat-Extraktion, C3-5 und C3-5ungesättigt, butadienfrei; Gase aus der Erdölverarbeitung | 307-769-4 | 97722-19-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-120-00-0 | Gase (Erdöl), Beschickung für Aminwäsche; Raffineriegas; [Gas, mit dem die Aminwäsche zur Entfernung von Schwefelwasserstoff beschickt wird. Besteht aus Wasserstoff. Kohlenmonoxid, Kohlendioxid, Schwefelwasserstoff und aliphatische Kohlenwasserstoffe mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5 können ebenfalls enthalten sein.] | 270-746-1 | 68477-65-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-121-00-6 | Gase (Erdöl), Abgase aus Benzolanlage, Hydrodesulfurierung; Raffineriegas; [Abgase aus der Benzolanlage. Besteht in erster Linie aus Wasserstoff. Kohlenmonoxid und Kohlenwasserstoffe mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6 (einschließlich Benzol) können ebenfalls enthalten sein.] | 270-747-7 | 68477-66-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-122-00-1 | Gase (Erdöl), rückgewonnen aus Benzolanlage, wasserstoffreich; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Rückgewinnung von Gasen der Benzolanlage. Besteht in erster Linie aus Wasserstoff sowie geringen Mengen an Kohlenmonoxid und Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C6.] | 270-748-2 | 68477-67-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-123-00-7 | Gase (Erdöl), Mischöl, wasserstoff- und stickstoffreich; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation eines Mischöls. Besteht in erster Linie aus Wasserstoff und Stickstoff sowie geringen Mengen an Kohlenmonoxid, Kohlendioxid und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 270-749-8 | 68477-68-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-124-00-2 | Gase (Erdöl), Kopfprodukte, katalytisch reformiertes Naphtha, Strippersäule; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen aus der Stabilisierung von katalytisch reformiertem Naphtha. Besteht aus Wasserstoff und gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 270-759-2 | 68477-77-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-125-00-8 | Gase (Erdöl), C6-8, katalytisch reformiert und rückgewonnen; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus dem katalytischen Reformieren von C6- bis C8-Beschickung und rückgewonnen zur Erhaltung von Wasserstoff. Besteht in erster Linie aus Wasserstoff. Kann auch geringe Mengen an Kohlenmonoxid, Kohlendioxid, Stickstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6 enthalten.] | 270-761-3 | 68477-80-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-126-00-3 | Gase (Erdöl), C6-8, katalytisch reformiert; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus dem katalytischen Reformieren von C6- bis C8-Beschickung. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C5 und Wasserstoff.] | 270-762-9 | 68477-81-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-127-00-9 | Gase (Erdöl), C6-8, katalytisch reformiert und rückgewonnen, wasserstoffreich; Raffineriegas | 270-763-4 | 68477-82-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-128-00-4 | Gase (Erdöl), C2-Rücklauf; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Extraktion von Wasserstoff aus einem Gaslauf vorwiegend aus Wasserstoff sowie geringen Mengen an Stickstoff, Kohlenmonoxid, Methan, Ethan und Ethylen. Enthält vorwiegend Kohlenwasserstoffe wie Methan, Ethan und Ethylen sowie geringe Mengen an Wasserstoff, Stickstoff und Kohlenmonoxid.] | 270-766-0 | 68477-84-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-129-00-X | Gase (Erdöl), Abgase, trocken, sauer, Gasanreicherung; Raffineriegas; [Komplexe Kombination von trockenen Gasen aus Gasanreicherung. Besteht aus Wasserstoff, Schwefelwasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C3.] | 270-774-4 | 68477-92-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-130-00-5 | Gase (Erdöl), Destillation nach Gasanreicherung, Reabsorptionssäule; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus kombinierten Gasläufen in Reabsorptionssäule für Gasanreicherung. Besteht vorwiegend aus Wasserstoff, Kohlenmonoxid, Kohlendioxid, Stickstoff, Schwefelwasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C3.] | 270-776-5 | 68477-93-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-131-00-0 | Gase (Erdöl), Abgase aus Wasserstoffabsorption; Raffineriegas; [Komplexe Kombination, erhalten durch Wasserstoffabsorption aus einem wasserstoffreichen Lauf. Besteht aus Wasserstoff, Kohlenmonoxid, Stickstoff und Methan sowie geringen Mengen an C2-Kohlenwasserstoffen.] | 270-779-1 | 68477-96-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-132-00-6 | Gase (Erdöl), wasserstoffreich; Raffineriegas; [Komplexe Kombination, durch Kühlen als Gas aus Kohlenwasserstoffgasen abgetrennt. Besteht in erster Linie aus Wasserstoff sowie geringen Mengen an Kohlenmonoxid, Stickstoff, Methan und C2-Kohlenwasserstoffen.] | 270-780-7 | 68477-97-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-133-00-1 | Gase (Erdöl), Mischöl, wasserstoffbehandelt, rückgewonnen, wasserstoff- und stickstoffreich; Raffineriegas; [Komplexe Kombination, erhalten aus rückgewonnenem wasserstoffbehandeltem Mischöl. Besteht in erster Linie aus Wasserstoff und Stickstoff sowie geringen Mengen an Kohlenmonoxid, Kohlendioxid und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 270-781-2 | 68477-98-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-134-00-7 | Gase (Erdöl), rückgewonnen, wasserstoffreich; Raffineriegas; [Komplexe Kombination, erhalten aus rückgewonnenen Reaktorgasen. Besteht in erster Linie aus Wasserstoff sowie geringen Mengen an Kohlenmonoxid, Kohlendioxid, Stickstoff, Schwefelwasserstoff und gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C5.] | 270-783-3 | 68478-00-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-135-00-2 | Gase (Erdöl), Reformer, wasserstoffreich; Raffineriegas; [Komplexe Kombination, erhalten aus den Reformern. Besteht in erster Linie aus Wasserstoff sowie geringen Mengen an Kohlenmonoxid und aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 270-784-9 | 68478-01-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-136-00-8 | Gase (Erdöl), Reformierung durch Wasserstoffbehandlung; Raffineriegas; [Komplexe Kombination, erhalten durch Reformierung durch Wasserstoffbehandlung. Besteht in erster Linie aus Wasserstoff, Methan und Ethan sowie geringen Mengen an Schwefelwasserstoff und aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C5.] | 270-785-4 | 68478-02-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-137-00-3 | Gase (Erdöl), Reformierung durch Wasserstoffbehandlung, wasserstoff- und methanreich; Raffineriegas; [Komplexe Kombination, erhalten durch Reformierung durch Wasserstoffbehandlung. Besteht in erster Linie aus Wasserstoff und Metah sowie geringen Mengen an Kohlenmonoxid, Kohlendioxid und gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C5.] | 270-787-5 | 68478-03-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-138-00-9 | Gase (Erdöl), Reformierung durch Wasserstoffbehandlung, wasserstoffreich; Raffineriegas; [Komplexe Kombination, erhalten durch Reformierung durch Wasserstoffbehandlung. Besteht in erster Linie aus Wasserstoff sowie geringen Mengen an Kohlenmonoxid und aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 270-788-0 | 68478-04-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-139-00-4 | Gase (Erdöl), Destillation nach thermischem Cracken; Raffineriegas; [Komplexe Kombination, hergestellt durch Destillation von Produkten aus einem thermischen Crackverfahren. Besteht aus Wasserstoff, Schwefelwasserstoff, Kohlenmonoxid, Kohlendioxid und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 270-789-6 | 68478-05-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-140-00-X | Restgas (Erdöl), erneute Fraktionierung nach katalytischem Cracken, Absorptionssäule; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen aus der erneuten Fraktionierung von Produkten aus einem katalytischen Crackverfahren. Besteht aus Wasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C3.] | 270-805-1 | 68478-25-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-141-00-5 | Restgas (Erdöl), katalytisch reformiertes Naphtha, Trennsäule; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen aus katalytischem Reformieren von Straight-run-Benzin. Besteht aus Wasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 270-807-2 | 68478-27-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-142-00-0 | Restgas (Erdöl), Stabilisierung von katalytisch reformiertem Naphtha; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen aus der Stabilisierung von katalytisch reformiertem Naphtha. Besteht aus Wasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 270-808-8 | 68478-28-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-143-00-6 | Restgas (Erdöl), Wasserstoffbehandlung gecrackter Destillate, Trennsäule; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung gecrackter Destillate unter Einsatz eines Katalysators. Besteht aus Wasserstoff und gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 270-809-3 | 68478-29-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-144-00-1 | Restgas (Erdöl), hydrodesulfuriertes Straight-run-Benzin, Trennsäule; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Hydrodesulfurierung von Straight-run-Benzin. Besteht aus Wasserstoff und gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 270-810-9 | 68478-30-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-145-00-7 | Gase (Erdöl), Kopfprodukte, katalytisch reformiertes Straight-run-Benzin, Stabilisationskolonne; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus katalytischem Reformieren von Straight-Run-Benzin und anschließender Fraktionierung des gesamten ablaufenden Produkts. Besteht aus Wasserstoff, Methan, Ethan und Propan.] | 270-999-8 | 68513-14-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-146-00-2 | Gase (Erdöl), Abgase, Austreiben des ablaufenden Produkts aus Reformierungsreaktor unter Hochdruck, Auffangbehälter; Raffineriegas; [Komplexe Kombination, hergestellt durch Austreiben des ablaufenden Produkts aus dem Reformierungsreaktor unter Hochdruck. Besteht in erster Linie aus Wasserstoff sowie geringen Mengen an Methan, Ethan und Propan.] | 271-003-4 | 68513-18-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-147-00-8 | Gase (Erdöl), Abgase, Austreiben des ablaufenden Produkts aus Reformierungsreaktor unter Niederdruck, Auffangbehälter; Raffineriegas; [Komplexe Kombination, hergestellt durch Austreiben des ablaufenden Produkts aus dem Reformierungsreaktor unter Niederdruck. Besteht in erster Linie aus Wasserstoff sowie geringen Mengen an Methan, Ethan und Propan.] | 271-005-5 | 68513-19-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-148-00-3 | Gase (Erdöl), Abgase aus Destillation von Erdölraffineriegas; Raffineriegas; [Komplexe Kombination, abgetrennt durch Destillation eines Wasserstoff, Kohlenmonoxid, Kohlendioxid und Kohlenwasserstoffe mit Kohlenstoffzahlen im Bereich von C1 bis C6 enthaltenden Gaslaufs oder erhalten durch Cracken von Ethan und Propan. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 und C2 sowie Wasserstoff, Stickstoff und Kohlenmonoxid.] | 271-258-1 | 68527-15-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-149-00-9 | Gase (Erdöl), Kopfprodukte aus Benzolanlage, Wasserstoffbehandlung und Pentanabtrennung; Raffineriegas; [Komplexe Kombination, hergestellt durch Wasserstoffbehandlung der Benzolanlagenbeschickung unter Einsatz eines Katalysators und anschließende Pentanabtrennung. Besteht in erster Linie aus Wasserstoff, Ethan und Propan sowie geringen Mengen an Stickstoff, Kohlenmonoxid, Kohlendioxid und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] Kann Spuren von Benzol enthalten.] | 271-623-5 | 68602-82-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-150-00-4 | Gase (Erdöl), Abgase aus Fraktionierung der Kopfprodukte aus katalytischem Fließbett-Cracken, sekundäre Absorptionssäule; Raffineriegas; [Komplexe Kombination, erhalten durch Fraktionierung der Kopfprodukte aus dem katalytischen Fließbett-Cracken. Besteht aus Wasserstoff, Stickstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C3.] | 271-625-6 | 68602-84-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-151-00-X | Erdölprodukte, Raffineriegase; Raffineriegas; [Komplexe Kombination, besteht in erster Linie aus Wasserstoff sowie geringen Mengen an Methan, Ethan und Propan.] | 271-750-6 | 68607-11-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-152-00-5 | Gase (Erdöl), Hydrocracken, Niederdruck, Trennsäule; Raffineriegas; [Komplexe Kombination, erhalten durch Flüssigkeit-Dampf-Trennung des beim Hydrocracken aus dem Reaktor ablaufenden Produkts. Besteht vorwiegend aus Wasserstoff und gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C1 bis C3.] | 272-182-1 | 68783-06-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-153-00-0 | Gase (Erdöl), Raffinerie; Raffineriegas; [Komplexe Kombination aus verschiedenen Erdöl-Raffinerievorgängen. Besteht aus Wasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C3.] | 272-338-9 | 68814-67-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-154-00-6 | Gase (Erdöl), Abgase, Platforming-Produkte, Trennsäule; Raffineriegas; [Komplexe Kombination, erhalten aus chemischem Reformieren von Naphthenen zu Aromaten. Besteht aus Wasserstoff und gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C4.] | 272-343-6 | 68814-90-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-155-00-1 | Gase (Erdöl), Abgase, Pentanabtrennung und Stabilisierung von wasserstoffbehandeltem saurem Kerosin. Raffineriegas; [Die komplexe Kombination, erhalten aus Pentanabtrennung und Stabilisierung von wasserstoffbehandeltem Kerosin. Besteht in erster Linie aus Wasserstoff, Methan, Ethan und Propan sowie geringen Mengen an Stickstoff, Schwefelwasserstoff, Kohlenmonoxid und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C5.] | 272-775-5 | 68911-58-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-156-00-7 | Gase (Erdöl), wasserstoffbehandeltes saures Kerosin, Auffangbehälter; Raffineriegas; [Komplexe Kombination, erhalten aus dem Auffangbehälter der Anlage zur Wasserstoffbehandlung von saurem Kerosin unter Einsatz eines Katalysators. Besteht in erster Linie aus Wasserstoff und Methan sowie geringen Mengen an Stickstoff, Kohlenmonoxid und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C5.] | 272-776-0 | 68911-59-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-157-00-2 | Gase (Erdöl), Abgase, Destillat aus Unifining zur Entschwefelung, Strippersäule; Raffineriegas; [Komplexe Kombination, gestrippt aus dem flüssigen Produkt der Entschwefelung durch Unifining. Besteht aus Schwefelwasserstoff, Methan, Ethan und Propan.] | 272-873-8 | 68919-01-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-158-00-8 | Gase (Erdöl), Abgase, Fraktionierung nach katalytischem Fließbett-Cracken; Raffineriegas; [Komplexe Kombination, erhalten durch Fraktionierung des Kopfprodukts aus katalytischem Fließbett-Cracken. Besteht aus Wasserstoff, Schwefelwasserstoff, Stickstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 272-874-3 | 68919-02-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-159-00-3 | Gase (Erdöl), Abgase, Auswaschen nach katalytischem Fließbett-Cracken, sekundäre Absorptionssäule; Raffineriegas; [Komplexe Kombination, hergestellt durch Auswaschen des Kopfprodukts aus dem katalytischen Fließbett-Cracken. Besteht aus Wasserstoff, Stickstoff, Methan, Ethan und Propan.] | 272-875-9 | 68919-03-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-160-00-9 | Gase (Erdöl), Abgase, schweres Destillat, Wasserstoffbehandlung zur Entschwefelung, Strippersäule; Raffineriegas; [Komplexe Kombination, gestrippt vom flüssigen Produkt der Wasserstoffbehandlung zur Entschwefelung des schweren Destillats. Besteht aus Wasserstoff, Schwefelwasserstoff und gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 272-876-4 | 68919-04-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-161-00-4 | Gase (Erdöl), Abgase, Platforming und Stabilisierung, Fraktionierung der Vorläufe; Raffineriegas; [Komplexe Kombination, erhalten durch Fraktionierung der Vorläufe vom Platinkatalysator der Platforming-Anlage. Besteht aus Wasserstoff, Methan, Ethan und Propan.] | 272-880-6 | 68919-07-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-162-00-X | Gase (Erdöl), Abgase, Vorentspannungskolonne, Rohöldestillation; Raffineriegas; [Komplexe Kombination, erhalten aus der ersten Kolonne bei der Rohöldestillation. Besteht aus Stickstoff und gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 272-881-1 | 68919-08-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-163-00-5 | Gase (Erdöl), Abgase, Teer, Strippersäule; Raffineriegas; [Komplexe Kombination, erhalten durch Fraktionierung von reduziertem Rohöl. Besteht aus Wasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 272-884-8 | 68919-11-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-164-00-0 | Gase (Erdöl), Abgase, Unifining, Strippersäule; Raffineriegas; [Kombination von Wasserstoff und Methan, erhalten durch Fraktionierung der Unifining-Produkte.] | 272-885-3 | 68919-12-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-165-00-6 | Restgas (Erdöl), katalytische Hydrodesulfurierung von Naphtha, Trennsäule; Raffineriegas; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Hydrodesulfurierung von Naphtha. Besteht aus Wasserstoff, Methan, Ethan und Propan.] | 273-173-5 | 68952-79-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-166-00-1 | Restgas (Erdöl), Hydrodesulfurierung von Straight-run-Benzin; Raffineriegas; [Komplexe Kombination, erhalten aus der Hydrodesulfurierung von Straight-run-Benzin. Besteht aus Wasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 273-174-0 | 68952-80-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-167-00-7 | Gase (Erdöl), Abgase, Spongeabsorber, Fraktionierung von Kopfprodukten aus katalytischem Fließbett-Cracken und Gasölentschwefelung; Raffineriegas; [Komplexe Kombination, erhalten durch Fraktionierung von Produkten aus dem katalytischen Fließbett-Cracken und der Gasölentschwefelung. Besteht aus Wasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 273-269-7 | 68955-33-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-168-00-2 | Gase (Erdöl), Rohöldestillation und katalytisches Cracken; Raffineriegas; [Komplexe Kombination, hergestellt durch Rohöldestillation und katalytisches Cracken. Besteht aus Wasserstoff, Schwefelwasserstoff, Stickstoff, Kohlenmonoxid sowie Paraffinen und Olefinen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 273-563-5 | 68989-88-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-169-00-8 | Gase (Erdöl), Abgase, Diethanolaminwäsche von Gasöl; Raffineriegas; [Komplexe Kombination, hergestellt durch Entschwefelung von Gasölen mit Diethanolamin. Besteht vorwiegend aus Schwefelwasserstoff, Wasserstoff und aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C1 bis C5.] | 295-397-2 | 92045-15-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-170-00-3 | Gase (Erdöl), Gasöl, ablaufendes Produkt der Hydrodesulfurierung; Raffineriegas; [Komplexe Kombination, erhalten durch Abtrennen der flüssigen Phase vom ablaufenden Produkt aus der Hydrierung. Besteht vorwiegend aus Wasserstoff, Schwefelwasserstoff und aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C3.] | 295-398-8 | 92045-16-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-171-00-9 | Gase (Erdöl), Gasöl, Austreiben nach Hydrodesulfurierung; Raffineriegas; [Komplexe Kombination von Gasen, erhalten aus dem Reforming und dem Austreiben aus dem Hydrierreaktor. Besteht vorwiegend aus Wasserstoff und aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C1 bis C4.] | 295-399-3 | 92045-17-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-172-00-4 | Gase (Erdöl), Abgase, ablaufendes Produkt aus Hydrierreaktor, Auffangbehälter; Raffineriegas; [Komplexe Kombination von Gasen, erhalten aus dem Auffangen der ablaufenden Produkte nach dem Hydrieren. Besteht vorwiegend aus Wasserstoff und aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C1 bis C6.] | 295-400-7 | 92045-18-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-173-00-X | Gase (Erdöl), Rückstände vom Hochdruck-Steamcracken von Naphtha; Raffineriegas; [Komplexe Kombination, erhalten als Gemisch der nichtkondensierbaren Bestandteile des Produkts aus dem Steamcracken von Naphtha sowie als Rückstandsgase aus der Zubereitung von Folgeprodukten. Besteht vorwiegend aus Wasserstoff sowie Paraffinen und Olefinen mit Kohlenstoffzahlen überwiegend im Bereich von C1 bis C5; auch Erdgas kann beigemischt sein.] | 295-401-2 | 92045-19-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-174-00-5 | Gase (Erdöl), Abgase, Visbreaking von Rückständen; Raffineriegas; [Komplexe Kombination, erhalten durch Reduktion der Viskosität von Rückständen in einem Ofen. Besteht vorwiegend aus Schwefelwasserstoff sowie Paraffinen und Olefinen mit Kohlenstoffzahlen überwiegend im Bereich von C1 bis C5.] | 295-402-8 | 92045-20-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-175-00-0 | Klauenöl (Erdöl), säurebehandelt; Weichparaffin; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln von Klauenöl mit Schwefelsäure erhält. Besteht vorwiegend aus Kohlenwasserstoffen mit verzweigter Kette mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50.] | 300-225-7 | 93924-31-3 | Flam. Gas 1 Press. Gas Carc. 1B | H220 H350 H340 | GHS02 GHS04 GHS08 Gef. | H220 H350 H340 | K U | ||
649-176-00-6 | Klauenöl (Erdöl), tonbehandelt; Weichparaffin; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln von Klauenöl mit natürlichem oder modifiziertem Ton in einem Kontakt- oder Perkolationsverfahren zur Beseitigung von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen erhält. Besteht überwiegend aus Kohlenwasserstoffen mit verzweigter Kette mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50.] | 300-226-2 | 93924-32-4 | Flam. Gas 1 Press. Gas Carc. 1B | H220 H350 H340 | GHS02 GHS04 GHS08 Gef. | H220 H350 H340 | K U | ||
649-177-00-1 | Gase (Erdöl), C3-4; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus dem Cracken von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C3 bis C4, vorwiegend aus Propan und Propylen, mit einem Siedebereich von etwa -51 oC bis -1 oC (-60 oF bis 30 oF).] | 268-629-5 | 68131-75-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-178-00-7 | Restgas (Erdöl), Fraktionierung katalytisch gecrackter Destillate und katalytisch gecrackten Naphthas, Absorptionssäule; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus katalytisch gecrackten Destillaten und katalytisch gecracktem Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C4.] | 269-617-2 | 68307-98-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-179-00-2 | Restgas (Erdöl), Fraktionierung und Stabilisierung, katalytische Polymerisation von Naphtha; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus Produkten der Fraktionierung und Stabilisierung nach Polymerisation von Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C1 bis C4.] | 269-618-8 | 68307-99-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-180-00-8 | Restgas (Erdöl), Fraktionierung und Stabilisierung katalytisch reformierten Naphthas, schwefelwasserstofffrei; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus Fraktionierung und Stabilisierung von katalytisch reformiertem Naphtha nach Aminbehandlung zur Entfernung von Schwefelwasserstoff. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 269-619-3 | 68308-00-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-181-00-3 | Restgas (Erdöl), wasserstoffbehandeltes gecracktes Destillat, Strippersäule; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Wasserstoffbehandlung thermisch gecrackter Destillate unter Einsatz eines Katalysators. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 269-620-9 | 68308-01-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-182-00-9 | Restgas (Erdöl), Entschwefelung von Straight-run-Destillat, schwefelwasserstofffrei; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytische Hydrodesulfurierung von Straight-run-Destillaten nach Aminbehandlung zur Entfernung von Schwefelwasserstoff. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 269-630-3 | 68308-10-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-183-00-4 | Restgas (Erdöl), katalytisches Cracken von Gasöl, Absorptionssäule; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus dem katalytischen Cracken von Gasöl. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 269-623-5 | 68308-03-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-184-00-X | Restgas (Erdöl), Gasrückgewinnungsanlage; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus verschiedenen Kohlenwasserstoffläufen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 269-624-0 | 68308-04-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-185-00-5 | Restgas (Erdöl), Gasrückgewinnungsanlage, Ethanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus verschiedenen Kohlenwasserstoffläufen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 269-625-6 | 68308-05-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-186-00-0 | Restgas (Erdöl), Fraktionierung von hydrodesulfuriertem Destillat und hydrodesulfuriertem Naphtha, säurefrei; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Fraktionierung von hydrodesulfurierten Naphtha- und Kohlenwasserstoffdestillatläufen, behandelt zur Beseitigung von sauren Verunreinigungen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 269-626-1 | 68308-06-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-187-00-6 | Restgas (Erdöl), hydrodesulfuriertes Vakuumgasöl, Strippersäule, schwefelwasserstofffrei; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Abtreiben und Stabilisierung von katalytisch hydrodesulfuriertem und durch Aminbehandlung von Schwefelwasserstoff befreitem Vakuumgasöl. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 269-627-7 | 68308-07-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-188-00-1 | Restgas (Erdöl), Stabilisierung von leichtem Straight-run-Benzin, schwefelwasserstofffrei; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung und Stabilisierung von leichtem Straight-run-Benzin nach Entfernung von Schwefelwasserstoff durch Aminbehandlung. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 269-629-8 | 68308-09-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-189-00-7 | Restgas (Erdöl), Alkylierung von Propan mit Propylen, Beschickungsvorbereitung, Ethanabtrennung; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation der Reaktionsprodukte von Propan mit Propylen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 269-631-9 | 68308-11-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-190-00-2 | Restgas (Erdöl), hydrodesulfuriertes Vakuumgasöl, schwefelwasserstofffrei; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Hydrodesulfurieren von durch Aminbehandlung von Schwefelwasserstoff befreitem Vakuumgasöl. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C6.] | 269-632-4 | 68308-12-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-191-00-8 | Gase (Erdöl), katalytisch gecrackte Kopfprodukte; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von Produkten aus dem katalytischen Cracken. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C5 mit einem Siedebereich von etwa (-48 oC bis 32 oC (-54 oF bis 90 oF).] | 270-071-2 | 68409-99-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-193-00-9 | Alkane, C1-2; Gase aus der Erdölverarbeitung | 270-651-5 | 68475-57-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-194-00-4 | Alkane, C2-3; Gase aus der Erdölverarbeitung | 270-652-0 | 68475-58-1 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-195-00-X | Alkane, C3-4; Gase aus der Erdölverarbeitung | 270-653-6 | 68475-59-2 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-196-00-5 | Alkane, C4-5; Gase aus der Erdölverarbeitung | 270-654-1 | 68475-60-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-197-00-0 | Brenngase; Gase aus der Erdölverarbeitung; [Kombination leichter Gase. Besteht vorwiegend aus Wasserstoff und/oder Kohlenwasserstoffen mit niedrigem Molekulargewicht.] | 270-667-2 | 68476-26-6 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-198-00-6 | Brenngase, Rohöldestillate; Gase aus der Erdölverarbeitung; [Komplexe Kombination von leichten Gasen, hergestellt durch Destillation von Rohöl und durch katalytisches Reformieren von Naphtha. Besteht aus Wasserstoff und Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4 mit einem Siedebereich von etwa -217 oC bis -12 oC (-423 oF bis 10 oF).] | 270-670-9 | 68476-29-9 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-199-00-1 | Kohlenwasserstoffe, C3-4; Gase aus der Erdölverarbeitung | 270-681-9 | 68476-40-4 | Press.
Gas Flam. Gas 1 Carc. 1Aa Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-200-00-5 | Kohlenwasserstoffe, C4-5; Gase aus der Erdölverarbeitung | 270-682-4 | 68476-42-6 | Press.
Gas Flam. Gas 1 Carc. 1Aa Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-201-00-0 | Alkane, C2-4, C3-reich; Gase aus der Erdölverarbeitung | 270-689-2 | 68476-49-3 | Press.
Gas Flam. Gas 1 Carc. 1Aa Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-202-00-6 | Erdölgase, flüssig; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C3 bis C7 mit einem Siedebereich von etwa - 40 oC bis 80 oC (-40 oF bis 176 oF).] | 270-704-2 | 68476-85-7 | Press.
Gas Flam. Gas 1 Carc. 1Aa Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K S U | ||
649-203-00-1 | Erdölgase, flüssig, gesüßt; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Einwirkung eines Süßungsverfahrens auf verflüssigtes Erdölgasgemisch zur Umwandlung von Mercaptanen oder zum Entfernen saurer Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C7 mit einem Siedebereich von etwa -40 oC bis 80 oC (-40 oF bis 176 oF).] | 270-705-8 | 68476-86-8 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K S U | ||
649-204-00-7 | Gase (Erdöl), C3-4, isobutanreich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Destillation gesättigter und ungesättigter Kohlenwasserstoffe mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C6, vorwiegend Isobutan. Besteht aus gesättigten und ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C3 bis C4, vorwiegend Isobutan.] | 270-724-1 | 68477-33-8 | Press.
Gas Flam. Gas 1 Carc. 1Aa Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-205-00-2 | Destillate (Erdöl), C3-6, piperylenreich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation gesättigter und ungesättigter aliphatischer Kohlenwasserstoffe mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C6. Besteht aus gesättigten und ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C3 bis C6, vorwiegend Piperylenen.] | 270-726-2 | 68477-35-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-206-00-8 | Gase (Erdöl), Kopfprodukte, Butan, Splitter; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation des Butanlaufs. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C4.] | 270-750-3 | 68477-69-0 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-207-00-3 | Gase (Erdöl), C2-3; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von Produkten aus dem katalytischen Fraktionieren. Enthält vorwiegend Ethan, Ethylen, Propan und Propylen.] | 270-751-9 | 68477-70-3 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-208-00-9 | Gase (Erdöl), Sumpfprodukte, katalytisch gecracktes Gasöl, Propanabtrennung, C4-reich, säurefrei; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen aus der Fraktionierung von katalytisch gecracktem Gasöl und Behandlung zur Beseitigung von Schwefelwasserstoff und anderen sauren Bestandteilen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C3 bis C5, vorwiegend C4.] | 270-752-4 | 68477-71-4 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-209-00-4 | Gase (Erdöl), Sumpfprodukte, katalytisch gecracktes Naphtha, Butanabtrennung, C3-5-reich; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Stabilisierung von katalytisch gecracktem Naphtha. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C5.] | 270-754-5 | 68477-72-5 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-210-00-X | Endgas (Erdöl), Fraktionierung und Stabilisierung von isomerisiertem Naphtha; Gase aus der Erdölverarbeitung; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus Produkten der Stabilisierung und Fraktionierung von isomerisiertem Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C4.] | 269-628-2 | 68308-08-7 | Press.
Gas Flam. Gas 1 Carc. 1A Muta. 1B | H220 H350 H340 | GHS04 GHS02 GHS08 Gef. | H220 H350 H340 | K U | ||
649-211-00-5 | Klauenöl (Erdöl), kohlenstoffbehandelt; Weichparaffin; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Klauenöl mit Aktivkohle erhält, um Spurenbestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 308-126-0 | 97862-76-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-212-00-0 | Destillate (Erdöl), gesüßte mittlere; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten, indem ein Erdöldestillat zur Konvertierung von Mercaptanen oder zum Entfernen saurer Verunreinigungen einem Süßungsverfahren unterzogen wird. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C20 und siedet im Bereich von etwa 150 oC bis 345 oC (302 oF bis 653 oF).] | 265-088-7 | 64741-86-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-213-00-6 | Gasöle (Erdöl), durch Lösungsmittel aufbereitete; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Lösungsmittelextraktionsverfahren. Besteht überwiegend aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11 bis C25 und siedet im Bereich von etwa 205 oC bis 400 oC (401 oF bis 752 oF).] | 265-092-9 | 64741-90-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-214-00-1 | Destillate (Erdöl), durch Lösungsmittel aufbereitete mittlere; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Lösungsmittelextraktionsverfahren. Besteht überwiegend aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C20 und siedet im Bereich von etwa 150 oC bis 345 oC (302 oF bis 653 oF).] | 265-093-4 | 64741-91-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-215-00-7 | Gasöle (Erdöl), säurebehandelte; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Verfahren durch Einwirkung von Schwefelsäure. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C13bis C25 und siedet im Bereich von etwa 230 oC bis 400 oC (446 oF bis 752 oF).] | 265-112-6 | 64742-12-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-216-00-2 | Destillate (Erdöl), säurebehandelte mittlere; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Verfahren durch Einwirkung von Schwefelsäure. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11bis C20 und siedet im Bereich von etwa 205 oC bis 345 oC (401 oF bis 653 oF).] | 265-113-1 | 64742-13-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-217-00-8 | Destillate (Erdöl), säurebehandelte leichte; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Verfahren durch Einwirkung von Schwefelsäure. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C16 und siedet im Bereich von etwa 150 oC bis 290 oC (302 oF bis 554 oF).] | 265-114-7 | 64742-14-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-218-00-3 | Gasöle (Erdöl), chemisch neutralisiert; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandlung zum Entfernen saurer Stoffe. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C13bis C25 und siedet im Bereich von etwa 230 oC bis 400 oC (446 oF bis 752 oF).] | 265-129-9 | 64742-29-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-219-00-9 | Destillate (Erdöl), chemisch neutralisierte mittlere; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandlung zum Entfernen saurer Stoffe. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11bis C20 und siedet im Bereich von etwa 205 oC bis 345 oC (401 oF bis 653 oF).] | 265-130-4 | 64742-30-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-220-00-4 | Destillate (Erdöl), mit Ton behandelte mittlere; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, entsteht durch Behandeln einer Erdölfraktion mit natürlichem oder modifiziertem Ton, gewöhnlich in einem Perkolationsverfahren zum Entfernen von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C20 und siedet im Bereich von etwa 150 oC bis 345 oC (302 oF bis 653 oF).] | 265-139-3 | 64742-38-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-221-00-X | Destillate (Erdöl), mit Wasserstoff behandelte mittlere; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion unter Einsatz eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11 bis C25 mit einem Siedebereich von etwa 205 oC bis 400 oC (401 oF bis 752 oF).] | 265-148-2 | 64742-46-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-222-00-5 | Gasöle (Erdöl), hydrodesulfuriert; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus einem Erdölgrundstoff durch Behandeln mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff umzuwandeln, der entfernt wird. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C13 bis C25 und siedet im Bereich von etwa 230 oC bis 400 oC (446 oF bis 752 oF).] | 265-182-8 | 64742-79-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-223-00-0 | Destillate (Erdöl), hydrodesulfurierte mittlere; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus einem Erdölgrundstoff durch Behandeln mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff umzuwandeln, der entfernt wird. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11bis C25 und siedet im Bereich von etwa 205 oC bis 400 oC (401 oF bis 752 oF).] | 265-183-3 | 64742-80-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-224-00-6 | Brennstoffe, Diesel-; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C20 und siedet im Bereich von etwa 163 oC bis 357 oC (325 oF bis 675 oF).] | 269-822-7 | 68334-30-5 | Carc. 2 | H351 | GHS08 Achtg. | H351 | N | ||
649-225-00-1 | Brennöl, Nr. 2; Gasöl - nicht spezifiziert; [Destillatöl mit einer minimalen Viskosität von 32,6 SUS bei 37,7 oC (100 oF) und einer maximalen Viskosität von 37,9 SUS bei 37,7o C (100 oF).] | 270-671-4 | 68476-30-2 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
649-226-00-7 | Brennöl, Nr. 4; Gasöl - nicht spezifiziert; [Destillatöl mit einer minimalen Viskosität von 45 SUS bei 37,7 oC (100 oF) und einer maximalen Viskosität von 125 SUS bei 37,7o C (100 oF).] | 270-673-5 | 68476-31-3 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
649-227-00-2 | Brenstoffe, Diesel-, Nr. 2; Gasöl - nicht spezifiziert; [Destillatöl mit einer minimalen Viskosität von 32,6 SUS bei 37,7 oC (100 oF).] | 270-676-1 | 68476-34-6 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
649-228-00-8 | Destillate (Erdöl), katalytischer Reformer Fraktionator Rückstand, hochsiedend; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von katalytischem Reformer Faktionator Rückstand. Siedet im Bereich von etwa 343 oC bis 399 oC (650 oF bis 750 oF).] | 270-719-4 | 68477-29-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-229-00-3 | Destillate (Erdöl), katalytischer Reformer Fraktionator Rückstand, intermediär siedend; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von katalytischem Reformer Faktionator Rückstand. Siedet im Bereich von etwa 288 oC bis 371 oC (550 oF bis 700 oF).] | 270-721-5 | 68477-30-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-230-00-9 | Destillate (Erdöl), katalytische Reformer Fraktionator Rückstand, niedrigsiedend; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von katalytischem Reformer Faktionator Rückstand. Siedet etwa unter 288 oC (550 oF).] | 270-722-0 | 68477-31-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-231-00-4 | Destillate (Erdöl), stark raffinierte mittlere; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus einer Erdöl-Fraktion, indem diese mehreren der folgenden Schritte ausgesetzt wird: Filtrieren, Zentrifugieren, atmosphärische Destillation, Vakuumdestillation, Ansäuern, Neutralisieren und Tonbehandlung. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C10 bis C20.] | 292-615-8 | 90640-93-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-232-00-X | Destillate (Erdöl), katalytische Reformer, schwer aromatisch Konzentrat; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Destillation eines katalytisch reformierten Erdölschnittes. Besteht überwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C10 bis C16 und siedet im Bereich von etwa 200 oC bis 300 oC (392 oF bis 572 oF).] | 295-294-2 | 91995-34-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-233-00-5 | Gasöle, paraffinhaltig; Gasöl - nicht spezifiziert; [Destillat aus der Redestillation einer komplexen Kombination von Kohlenwasserstoffen, die man durch Destillation von Ausflüssen aus einer scharfen katalytischen Behandlung von Paraffinen mit Wasserstoff enthält. Siedet im Bereich von etwa 190 oC bis 330 oC (374 oF bis 594 oF).] | 300-227-8 | 93924-33-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-234-00-0 | Naphtha (Erdöl), durch Lösungsmittel aufbereitet hydrodesulfuriert schwer; Gasöl - nicht spezifiziert; | 307-035-3 | 97488-96-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-235-00-6 | Kohlenwasserstoffe, C16-20, mit Wasserstoff behandeltes Mitteldestillat, leichte Destillate; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man als erste Läufe aus der Vakuumdestillation von Ausflüssen aus der Behandlung eines Mitteldestillats mit Wasserstoff erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C16 bis C20 und siedet im Bereich von etwa 290 oC bis 350 oC (554 oF bis 662 oF). Ergibt ein Fertigöl mit einer Viskosität von 2 cSt bei 100 oC (212 oF).] | 307-659-6 | 97675-85-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-236-00-1 | Kohlenwasserstoffe, C12-20, mit Wasserstoff behandelte paraffinhaltige leichte Destillate; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man als erste Läufe aus der Vakuumdestillation von Ausflüssen aus der Behandlung von schweren Paraffinen mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C12 bis C20 und siedet im Bereich von etwa 230 oC bis 350 oC (446 oF bis 662 oF).] Ergibt ein Fertigöl mit einer Viskosität von 2 cSt bei 100 oC (212 oF).] | 307-660-1 | 97675-86-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-237-00-7 | Kohlenwasserstoffe, C11-17, durch Lösungsmittel extrahierte leichte naphthenhaltige; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Extraktion der Aromaten aus einem leichten naphthenhaltigen Destillat mit einer Viskosität von 2,2 cSt bei 40 oC (104 oF) erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11 bis C17 und siedet im Bereich von etwa 200 oC bis 300 oC (392 oF bis 572 oF).] | 307-757-9 | 97722-08-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-238-00-2 | Gasöle, mit Wasserstoff behandelt; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man aus der Redestillation der Ausflüsse aus der Behandlung von Paraffinen mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C17 bis C27 und siedet im Bereich von etwa 330 oC bis 340 oC (626 oF bis 644 oF).] | 308-128-1 | 97862-78-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-239-00-8 | Destillate (Erdöl), mit Kohlenstoff behandelte leichte paraffinhaltige; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung einer Erdölfraktion mit Aktivkohle erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C12 bis C28.] | 309-667-5 | 100683-97-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-240-00-3 | Destillate (Erdöl), intermediäre paraffinhaltige, mit Kohlenstoff behandelt; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Erdöl mit Aktivkohle erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C16 bis C36.] | 309-668-0 | 100683-98-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-241-00-9 | Destillate (Erdöl), intermediäre paraffinhaltige, mit Ton behandelt; Gasöl - nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Erdöl mit Bleicherde erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C16 bis C36.] | 309-669-6 | 100683-99-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-242-00-4 | Alkane, C12-26, verzweigt und linear | 292-454-3 | 90622-53-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-243-00-X | Schmierfette; Fett; [Komplexe Kombination von Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C12 bis C50. Kann organische Salze von Alkalimetallen, Erdalkalimetallen und/oder Aluminiumverbindungen enthalten.] | 278-011-7 | 74869-21-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-244-00-5 | Weichwachs (Erdöl); Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus einer Erdölfraktion durch Lösungsmittelkristallisation (Lösungsmittelentwachsen) oder als Destillationsfraktion aus sehr wächserner Basis. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C20.] | 265-165-5 | 64742-61-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-245-00-0 | Paraffinkuchen (Erdöl), säurebehandelt; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat durch Behandeln einer Erdöl-Paraffinkuchen-Fraktion in einem Schwefelsäureverfahren. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C20.] | 292-659-8 | 90669-77-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-246-00-6 | Paraffinkuchen (Erdöl), mit Ton behandelt; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln einer Erdöl-Paraffinkuchen-Fraktion mit natürlichem oder modifiziertem Ton in einem Kontakt- oder Perkolationsverfahren erhält. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C20.] | 292-660-3 | 90669-78-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-247-00-1 | Paraffinkuchen (Erdöl), mit Wasserstoff behandelt; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln von Paraffinkuchen mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C20.] | 295-523-6 | 92062-09-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-248-00-7 | Paraffinkuchen (Erdöl), niedrig schmelzend; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, die man aus einer Erdöl-Fraktion durch Lösungsmittelentparaffinierung erhält. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 295-524-1 | 92062-10-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-249-00-2 | Paraffinkuchen (Erdöl), niedrig schmelzend, mit Wasserstoff behandelt; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln von niedrig schmelzendem Paraffinkuchen mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 295-525-7 | 92062-11-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-250-00-8 | Paraffinkuchen (Erdöl), niedrig schmelzend, mit Kohlenstoff behandelt; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von niedrig schmelzendem Paraffinkuchen mit Aktivkohle erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 308-155-9 | 97863-04-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-251-00-3 | Paraffinkuchen (Erdöl), niedrig schmelzend, mit Ton behandelt; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von niedrig schmelzendem Paraffinkuchen mit Bentonit erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 308-156-4 | 97863-05-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-252-00-9 | Paraffinkuchen (Erdöl), niedrig schmelzend, mit Kieselsäure behandelt; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von niedrig schmelzendem Paraffinkuchen mit Kieselsäure erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader und verzweigter Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 308-158-5 | 97863-06-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-253-00-4 | Paraffinkuchen (Erdöl), mit Kohlenstoff behandelt; Paraffingatsch; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Erdöl-Paraffinkuchen mit Aktivkohle erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen.] | 309-723-9 | 100684-49-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-254-00-X | Petrolatum; Petrolatum; [Komplexe Kombination von Kohlenwasserstoffen, die als Semifeststoff beim Entwachsen von paraffinhaltigem Rückstandsöl erhalten wird. Besteht überwiegend aus gesättigten, kristallinen und flüssigen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25.] | 232-373-2 | 8009-03-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-255-00-5 | Petrolatum (Erdöl), oxidiertes; Petrolatum; [Komplexe Kombination organischer Verbindungen, überwiegend Carbonsäuren mit hohem Molekulargewicht, erhalten durch Luftoxidation von Petrolatum.] | 265-206-7 | 64743-01-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-256-00-0 | Petrolatum (Erdöl), mit Aluminiumoxid behandelt; Petrolatum; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von Petrolatum mit Al2O3, um polare Bestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten, kristallinen und flüssigen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25.] | 285-098-5 | 85029-74-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-257-00-6 | Petrolatum (Erdöl), mit Wasserstoff behandelt; Petrolatum; [Komplexe Kombination von Kohlenwasserstoffen, die man als Semifeststoff aus entwachstem paraffinhaltigem Rückstandsöl, behandelt mit Wasserstoff unter Einsatz eines Katalysators, erhält. Besteht überwiegend aus gesättigten, mikrokristallinen und flüssigen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20.] | 295-459-9 | 92045-77-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-258-00-1 | Petrolatum (Erdöl), mit Kohlenstoff behandelt; Petrolatum; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Erdöl-Petrolatum mit Aktivkohle erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20.] | 308-149-6 | 97862-97-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-259-00-7 | Petrolatum (Erdöl), mit Kieselsäure behandelt; Petrolatum; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Erdöl-Petrolatum mit Kieselsäure erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C20.] | 308-150-1 | 97862-98-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-260-00-2 | Petrolatum (Erdöl), mit Ton behandelt; Petrolatum; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Petrolatum mit Bleicherde erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25.] | 309-706-6 | 100684-33-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | N | ||
649-261-00-8 | Benzin, natürlich; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, abgetrennt von Naturgas durch Kühl- oder Absorptionsverfahren. Besteht vorwiegend aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C8 mit einem Siedebereich von etwa -20 oC bis 120 oC (-4 oF bis 248 oF).] | 232-349-1 | 8006-61-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-262-00-3 | Naphtha; Naphtha, niedrigsiedend; [Aufbereitete, teilweise aufbereitete oder nicht aufbereitete Erdölprodukte, hergestellt durch Destillation von Naturgas. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C6 mit einem Siedebereich von etwa 100 oC bis 200 oC (212 oF bis 392 oF).] | 232-443-2 | 8030-30-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-263-00-9 | Ligroin; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus der fraktionierten Destillation von Erdöl. Diese Fraktion siedet im Bereich von etwa 20 oC bis 135 oC (58 oF bis 275 oF).] | 232-453-7 | 8032-32-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-264-00-4 | Naphtha (Erdöl), schwer, Straight-run; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Rohöldestillation. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C12 mit einem Siedebereich von etwa 65 oC bis 230 oC (149 oF bis 446 oF).] | 265-041-0 | 64741-41-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-265-00-X | Naphtha (Erdöl), gesamte Straight-run; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Rohöldestillation. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa -20 oC bis 220 oC (-4 oF bis 428 oF).] | 265-042-6 | 64741-42-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-266-00-5 | Naphtha (Erdöl), leicht, Straight-run; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Rohöldestillation. Besteht vorwiegend aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C10 mit einem Siedebereich von etwa -20 oC bis 180 oC (-4 oF bis 356 oF).] | 265-046-8 | 64741-46-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-267-00-0 | Solvent Naphtha (Erdöl), leicht, aliphatisch; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Destillation von Rohöl oder Naturbenzin. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C10 mit einem Siedebereich von etwa 35 oC bis 160 oC (95 oF bis 320 oF).] | 265-192-2 | 64742-89-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-268-00-6 | Destillate (Erdöl), Straight-run leicht,; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C7 mit einem Siedebereich von etwa -88 oC bis 99 oC (-127 oF bis 210 oF).] | 270-077-5 | 68410-05-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-269-00-1 | Benzin, Dampfrückgewinnung; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, abgetrennt durch Kühlen der Gase aus Dampfrückgewinnungssystemen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa -20 oC bis 196 oC (-4 oF bis 384 oF).] | 271-025-4 | 68514-15-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-270-00-7 | Straight-run-Benzin, Topanlage; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt in der Topanlage durch Destillation von Rohöl. Siedet im Bereich von etwa 36,1 oC bis 193,3 oC (97 oF bis 380 oF).] | 271-727-0 | 68606-11-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-271-00-2 | Naphtha (Erdöl), ungesüßt; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Naphthaläufen aus verschiedenen Raffinerieverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C12 mit einem Siedebereich von etwa 0 oC bis 230 oC (25 oF bis 446 oF).] | 272-186-3 | 68783-12-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-272-00-8 | Destillate (Erdöl), Fraktionierung von leichtem Straight-run-Benzin, Stabilisator Kopfbestandteile; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung von leichtem Straight-run-Benzin. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C6.] | 272-931-2 | 68921-08-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-273-00-3 | Naphtha (Erdöl), schwer, Straight-run, aromatenhaltig; Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von rohem Erdöl. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C8 bis C12 mit einem Siedebereich von etwa 130 oC bis 210 oC (266 oF bis 410 oF).] | 309-945-6 | 101631-20-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-274-00-9 | Naphtha (Erdöl), gesamtes Alkylat-; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation der Reaktionsprodukte von Isobutan mit monoolefinischen Kohlenwasserstoffen mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C5. Besteht vorwiegend aus verzweigten gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C12 mit einem Siedebereich von etwa 90 oC bis 220 oC (194 oF bis 428 oF).] | 265-066-7 | 64741-64-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-275-00-4 | Naphtha (Erdöl), schweres Alkylat-; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation der Reaktionsprodukte von Isobutan mit monoolefinischen Kohlenwasserstoffen mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C5. Besteht vorwiegend aus verzweigten gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C9 bis C12 mit einem Siedebereich von etwa 150 oC bis 220 oC (302 oF bis 428 oF).] | 265-067-2 | 64741-65-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-276-00-X | Naphtha (Erdöl), leichtes Alkylat-; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation der Reaktionsprodukte von Isobutan mit monoolefinischen Kohlenwasserstoffen mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C5. Besteht vorwiegend aus verzweigten gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C7 bis C10 mit einem Siedebereich von etwa 90 oC bis 160 oC (194 oF bis 320 oF).] | 265-068-8 | 64741-66-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-277-00-5 | Naphtha (Erdöl), Isomerisation; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus der katalytischen Isomerisierung von geradkettigen paraffinhaltigen C4 bis C6 Kohlenwasserstoffen. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen wie Isobutan, Isopentan, 2,2-Dimethylbutan, 2-Methylpentan und 3-Methylpentan.] | 265-073-5 | 64741-70-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-278-00-0 | Naphtha (Erdöl), durch Lösungsmittel aufbereitet, leicht; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Lösungsmittelextraktionsverfahren. Besteht vorwiegend aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C5 bis C11 mit einem Siedebereich von etwa 35 oC bis 190 oC (95 oF bis 374 oF).] | 265-086-6 | 64741-84-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-279-00-6 | Naphtha (Erdöl), durch Lösungsmittel aufbereitet, schwer; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Lösungsmittelextraktionsverfahren. Besteht vorwiegend aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C7 bis C12 mit einem Siedebereich von etwa 90 oC bis 230 oC (194 oF bis 446 oF).] | 265-095-5 | 64741-92-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-280-00-1 | Raffinate (Erdöl), katalytisches Reformieren, Ethylenglykol-Wasser Gegenstromextrakte; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus dem Udex-Extraktionsverfahren am katalytischen Reformerlauf. Besteht aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C9.] | 270-088-5 | 68410-71-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-281-00-7 | Raffinate (Erdöl), Reformer, in Lurgi-Anlage getrennt; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einer Lurgi-Trennanlage. Besteht vorwiegend aus nichtaromatischen Kohlenwasserstoffen mit variierenden kleinen Mengen an aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C8.] | 270-349-3 | 68425-35-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-282-00-2 | Naphtha (Erdöl), schweres Alkylatbenzin, butanhaltig; Naphtha, niedrigsiedend, modifiziert; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation der Reaktionsprodukte von Isobutan mit monoolefinischen Kohlenwasserstoffen mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C5. Besteht aus vorwiegend verzweigten, gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C12 sowie einigen Butanen mit einem Siedebereich von etwa 35 oC bis 200 oC (95 oF bis 428 oF).] | 271-267-0 | 68527-27-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-283-00-8 | Destillate (Erdöl), aus steamcracked Naphtha, durch Lösungsmittel aufbereitet, leicht, wasserstoffbehandelt; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinate aus der Lösungsmittelextraktion von wasserstoffbehandeltem leichtem Destillat aus steamcracked Naphtha.] | 295-315-5 | 91995-53-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-284-00-3 | Naphtha (Erdöl), C4-12, Butanalkylat, Isooctanreich; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Alkylierung von Butanen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C4 bis C12, reich an Isooctan, siedet im Bereich von etwa 35 oC bis 210 oC (95 oF bis 410 oF).] | 295-430-0 | 92045-49-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-285-00-9 | Kohlenwasserstoffe, wasserstoffbehandelte leichte Naphthadestillate, durch Lösungsmittel aufbereitet; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Destillation von wasserstoffbehandeltem Naphtha, gefolgt von einem Lösungsmittelextraktions- und Destillationsverfahren. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit einem Siedebereich von etwa 94 oC bis 99 oC (201 oF bis 210 oF).] | 295-436-3 | 92045-55-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-286-00-4 | Naphtha (Erdöl), Isomerisierung, C6-Fraktion; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation eines katalytisch isomerisierten Benzins. Besteht vorwiegend aus Hexanisomeren mit einem Siedebereich von etwa 60 oC bis 66 oC (140 oF bis 151 oF).] | 295-440-5 | 92045-58-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-287-00-X | Kohlenwasserstoffe, C6-7, Naphthacracken, durch Lösungsmittel aufbereitet; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Sorption von Benzol aus einem katalytisch voll hydrierten benzolreichen Kohlenwasserstoffschnitt, hergestellt durch Destillation von vorhydriertem gecracktem Naphtha. Besteht vorwiegend aus paraffinhaltigen und napthenhaltigen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C7 mit einem Siedebereich von etwa 70 oC bis 100 oC (158 oF bis 212 oF).] | 295-446-8 | 92045-64-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-288-00-5 | Kohlenwasserstoffe, C6-reich, wasserstoffbehandelte leichte Naphthadestillate, durch Lösungsmittel aufbereitet; Naphtha, niedrigsiedend, modifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von wasserstoffbehandeltem Naphtha mit nachfolgender Lösungsmittelextraktion. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit einem Siedebereich von etwa 65 oC bis 70 oC (149 oF bis 158 oF).] | 309-871-4 | 101316-67-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-289-00-0 | Naphtha (Erdöl), schwer, katalytisch gecrackt; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C12 mit einem Siedebereich von etwa 65 oC bis 230 oC (148 oF bis 446 oF). Enthält eine relativ große Menge an ungesättigten Kohlenwasserstoffen.] | 265-055-7 | 64741-54-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-290-00-6 | Naphtha (Erdöl), leicht, katalytisch gecrackt; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa -20 oC bis 190 oC (-4 oF bis 374 oF). Enthält eine relativ große Menge an ungesättigten Kohlenwasserstoffen.] | 265-056-2 | 64741-55-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-291-00-1 | Kohlenwasserstoffe, C3-11, Destillate nach katalytischem Cracken; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C11 mit einem Siedebereich bis zu etwa 204 oC (400 oF).] | 270-686-6 | 68476-46-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-292-00-7 | Naphtha (Erdöl), katalytisch gecracktes leichtes Destillat; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C1 bis C5.] | 272-185-8 | 68783-09-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-293-00-2 | Destillate (Erdöl), aus steamcracked Naphtha, wasserstoffbehandelt, leicht, aromatisch; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln eines leichten Destillats aus steamcracked Naphtha. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen.] | 295-311-3 | 91995-50-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-294-00-8 | Naphtha (Erdöl), schwer, katalytisch gecrackt, gesüßt; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, die man erhält, wenn man ein katalytisch gekracktes Erdöldestillat einem Süßungsverfahren zur Konvertierung von Mercaptanen oder zum Entfernen saurer Verunreinigungen aussetzt.. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C12 mit einem Siedebereich von etwa 60 oC bis 200 oC (140 oF bis 392 oF).] | 295-431-6 | 92045-50-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-295-00-3 | Naphtha (Erdöl), leicht, katalytisch gecrackt, gesüßt; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, die man erhält, wenn man Naphtha aus einem katalytischen Krackverfahren einem Süßungsverfahren zur Konvertierung von Mercaptanen oder zum Entfernen saurer Verunreinigungen aussetzt. Besteht vorwiegend aus Kohlenwasserstoffen mit einem Siedebereich von etwa 35 oC bis 210 oC (95 oF bis 410 oF).] | 295-441-0 | 92045-59-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-296-00-9 | Kohlenwasserstoffe, C8-12, katalytisches Cracken, chemisch neutralisiert; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation eines Schnitts aus dem katalytischen Cracken, der einer alkalischen Wäsche unterzogen wurde. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C8 bis C12 mit einem Siedebereich von etwa 130 oC bis 210 oC (266 oF bis 410 oF).] | 295-794-0 | 92128-94-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-297-00-4 | Kohlenwasserstoffe, C8-12, Destillate nach katalytischem Cracken; katalytisch gecracktes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C8 bis C12 mit einem Siedebereich von etwa 140 oC bis 210 oC (284 oF bis 410 oF).] | 309-974-4 | 101794-97-2 | Carc. 1B Muta. 1B A Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-298-00-X | Kohlenwasserstoffe, C8-12, katalytisches Cracken, chemisch neutralisiert, gesüßt; katalytisch gecracktes Naphtha, niedrigsiedend; | 309-987-5 | 101896-28-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-299-00-5 | Naphtha (Erdöl), leicht, katalytisch reformiert; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Reformierverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C11 mit einem Siedebereich von etwa 35 oC bis 190 oC (95 oF bis 374 oF). Enthält eine relativ große Menge an aromatischen und verzweigten Kohlenwasserstoffen. Dieser Lauf kann einen Massenanteil von 10 vol% oder mehr Benzol enthalten.] | 265-065-1 | 64741-63-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-300-00-9 | Naphtha (Erdöl), schwer, katalytisch reformiert; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Reformierverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C12mit einem Siedebereich von etwa 90 oC bis 230 oC (194 oF bis 446 oF).] | 265-070-9 | 64741-68-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-301-00-4 | Destillate (Erdöl), katalytisch reformiert, Pentanabtrennung; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem katalytischen Reformierverfahren. Besteht vorwiegend aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C6 mit einem Siedebereich von etwa -49 oC bis 63 oC (-57 oF bis 145 oF).] | 270-660-4 | 68475-79-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-302-00-X | Kohlenwasserstoffe, C2-6, C6-8, katalytisch reformiert; katalytisch reformiertes Naphtha, niedrigsiedend; | 270-687-1 | 68476-47-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-303-00-5 | Rückstände (Erdöl), C6-8, katalytisch reformiert; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexer Rückstand aus dem katalytischen Reformieren von C6-8-Beschickung. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C6.] | 270-794-3 | 68478-15-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-304-00-0 | Naphtha (Erdöl), leicht, katalytisch reformiert, aromatenfrei; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem katalytischen Reformierverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C8 mit einem Siedebereich von etwa 35 oC bis 120 oC (95 oF bis 248 oF). Enthält eine relativ große Menge an, von aromatischen Bestandteilen befreiten, verzweigten Kohlenwasserstoffen.] | 270-993-5 | 68513-03-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-305-00-6 | Destillate (Erdöl), Kopfprodukte, katalytisch reformiertes Straight-run-Naphtha; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus katalytischem Reformieren von Straight-Run-Naphtha mit anschließender Fraktionierung des gesamten ablaufenden Produkts. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C6.] | 271-008-1 | 68513-63-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-306-00-1 | Erdölprodukte, wasserstoffaufbereiter-Katalysereformierer, Reformate; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus einem Hydrofiner-Powerformer-Verfahren mit einem Siedebereich von etwa 27 oC bis 210 oC (80 oF bis 410 oF).] | 271-058-4 | 68514-79-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-307-00-7 | Naphtha (Erdöl), gesamte, reformierte; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Reformierverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C12 mit einem Siedebereich von etwa 35 oC bis 230 oC (95 oF bis 446 oF).] | 272-895-8 | 68919-37-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-308-00-2 | Naphtha (Erdöl), katalytisch reformiert; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Reformierverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C12 mit einem Siedebereich von etwa 30 oC bis 220 oC (90 oF bis 430 oF). Enthält eine relativ große Menge an aromatischen und verzweigten Kohlenwasserstoffen. Dieser Lauf kann einen Massenanteil von 10 vol. % oder mehr Benzol enthalten.] | 273-271-8 | 68955-35-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-309-00-8 | Destillate (Erdöl), katalytisch reformiert, wasserstoffbehandelt, leicht, C8-12, aromatische Fraktion; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Alkylbenzolen, erhalten durch katalytisches Reformieren von Erdölnaphtha. Besteht vorwiegend aus Alkylbenzolen mit Kohlenstoffzahlen überwiegend im Bereich von C8 bis C10 mit einem Siedebereich von etwa 160 oC bis 180 oC (320 oF bis 356 oF).] | 285-509-8 | 85116-58-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-310-00-3 | Aromatische Kohlenwasserstoffe, C8, durch katalytisches Reformieren; katalytisch reformiertes Naphtha, niedrigsiedend; | 295-279-0 | 91995-18-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-311-00-9 | Aromatische Kohlenwasserstoffe, C7-12, C8-reich; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Abtrennen von der das Platformat enthaltenden Fraktion. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C12 (in erster Linie C8) und kann nichtaromatische Kohlenwasserstoffe enthalten, in beiden Fällen mit Siedebereichen von etwa 130 oC bis 200 oC (266 oF bis 392 oF).] | 297-401-8 | 93571-75-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-312-00-4 | Benzin, C5-11, hochoctanig, stabilisiert reformiert; katalytisch reformiertes Naphtha, niedrigsiedend; - [Komplexe, hochoctanige Kombination von Kohlenwasserstoffen, erhalten durch katalytische Dehydrierung von vorwiegend naphthenhaltigem Naphtha. Besteht vorwiegend aus Aromaten und Nichtaromaten mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C11 mit einem Siedebereich von etwa 45 oC bis 185 oC (113 oF bis 365 oF).] | 297-458-9 | 93572-29-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-313-00-X | Kohlenwasserstoffe, C7-12, reich an Aromaten mit C≥9, Reformieren, schwere Fraktion; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Abtrennen von der das Platformat enthaltenden Fraktion. Besteht vorwiegend aus Nichtaromaten mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C12 mit einem Siedebereich von etwa 120 oC bis 210 oC (248 oF bis 380 oF) sowie Aromaten mit C9 und höher.] | 297-465-7 | 93572-35-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-314-00-5 | Kohlenwasserstoffe, C5-11, reich an Nichtaromaten, Reformieren, leichte Fraktion; katalytisch reformiertes Naphtha, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Abtrennen von der das Platformat enthaltenden Fraktion. Besteht vorwiegend aus Nichtaromaten mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C11 mit einem Siedebereich von etwa 35 oC bis 125 oC (94 oF bis 257 oF) sowie Benzol und Toluol.] | 297-466-2 | 93572-36-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-315-00-0 | Klauenöl (Erdöl), kieselsäurebehandelt; Klauenöl; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von Klauenöl mit Kieselsäure erhält, um Spurenbestandteile und Verunreinigungen zu entfernen. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit gerader Kette mit Kohlenstoffzahlen überwiegend größer als C12.] | 308-127-6 | 97862-77-6 | Carc. 1B | H350 H304 | GHS08 Gef. | H350 H304 | L | ||
649-316-00-6 | Naphtha (Erdöl), leicht, thermisch gecrackt; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem thermischen Crackverfahren. Besteht vorwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C4 bis C8 mit einem Siedebereich von etwa -10 oC bis 130 oC (14 oF bis 266 oF).] | 265-075-6 | 64741-74-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-317-00-1 | Naphtha (Erdöl), schwer, thermisch gecrackt Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem thermischen Crackverfahren. Besteht vorwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C12 mit einem Siedebereich von etwa 65 oC bis 220 oC (148 oF bis 428 oF).] | 265-085-0 | 64741-83-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-318-00-7 | Destillate (Erdöl), schwer, aromatisch; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation der Produkte aus dem thermischem Cracken von Ethan und Propan. Diese höhersiedende Fraktion besteht in erster Linie aus aromatischen C5-7-Kohlenwasserstoffen sowie einigen ungesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend von C5. Dieser Lauf kann Benzol enthalten.] | 267-563-4 | 67891-79-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-319-00-2 | Destillate (Erdöl), leicht, aromatisch; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation der Produkte aus dem thermischem Cracken von Ethan und Propan. Diese niedrigsiedende Fraktion besteht in erster Linie aus aromatischen C5-7-Kohlenwasserstoffen sowie einigen ungesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend von C5. Dieser Lauf kann Benzol enthalten.] | 267-565-5 | 67891-80-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | HS08 Gef. | H350 H340 H304 | P | ||
649-320-00-8 | Destillate (Erdöl), Naphtha-Raffinat durch Pyrolyse erhalten, Benzin-Verschnitt; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Pyrolysefraktionierung von Naphtha und Raffinat bei 816 oC (1500 oF). Besteht in erster Linie aus Kohlenwasserstoffen mit einer Kohlenstoffzahl von C9 mit einem Siedepunkt von etwa 204 oC (400 oF).] | 270-344-6 | 68425-29-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-321-00-3 | Aromatische Kohlenwasserstoffe, C6-8, Naphtha-Raffinat durch Pyrolyse erhalten; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch fraktionierte Pyrolyse von Naphtha und Raffinat bei 816 oC (1500 oF). Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C8, einschließlich Benzol.] | 270-658-3 | 68475-70-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-322-00-9 | Destillate (Erdöl), thermisch gecracktes Naphtha und Gasöl; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von thermisch gecracktem Naphtha und/oder Gasöl. Besteht vorwiegend aus olefinischen Kohlenwasserstoffen mit einer Kohlenstoffzahl von C5 mit einem Siedebereich von etwa 33 oC bis 60 oC (91 oF bis 140 oF).] | 271-631-9 | 68603-00-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-323-00-4 | Destillate (Erdöl), thermisch gecracktes Naphtha und Gasöl, C5-Dimere enthaltend; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch extraktive Destillation von thermisch gecracktem Naphtha und/oder Gasöl. Besteht vorwiegend aus Kohlenwasserstoffen mit einer Kohlenstoffzahl von C5 mit einigen dimerisierten C5-Olefinen und einem Siedebereich von etwa 33 oC bis 184 oC (91 oF bis 363 oF).] | 271-632-4 | 68603-01-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-324-00-X | Destillate (Erdöl), thermisch gecracktes Naphtha und Gasöl, extrahiert; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch extraktive Destillation von thermisch gecracktem Naphtha und/oder Gasöl. Besteht aus paraffinhaltigen und olefinhaltigen Kohlenwasserstoffen, vorwiegend aus Isopentenen wie 2-Methyl-1-buten und 2-Methyl-2-buten, mit einem Siedebereich von etwa 31 oC bis 40 oC (88 oF bis 104 oF).] | 271-634-5 | 68603-03-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-325-00-5 | Destillate (Erdöl), leicht, thermisch gecrackt, debutanisiert, aromatisch; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem thermischen Crackverfahren. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen, in erster Linie Benzol.] | 273-266-0 | 68955-29-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-326-00-0 | Naphtha (Erdöl), leicht thermisch gecrackte, gesüßt; Naphtha, thermisch gecrackt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, die man erhält, wenn man ein Erdöldestillat aus dem Hochtemperatur-thermischen Kracken von Schweröl-Fraktionen einem Süßungsverfahren zur Konvertierung von Mercaptanen aussetzt. Besteht vorwiegend aus Aromaten, Olefinen und gesättigten Kohlenwasserstoffen mit einem Siedebereich von etwa 20 oC bis 100 oC (68 oF bis 212 oF).] | 295-447-3 | 92045-65-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-327-00-6 | Naphtha (Erdöl), mit Wasserstoff behandelt, schwere; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion in Gegenwart eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C13 mit einem Siedebereich von etwa 65 oC bis 230 oC (149 oF bis 446 oF).] | 265-150-3 | 64742-48-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-328-00-1 | Naphtha (Erdöl), mit Wasserstoff behandelt, leichte; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion in Gegenwart eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa -20 oC bis 190 oC (-4 oF bis 374 oF).] | 265-151-9 | 64742-49-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-329-00-7 | Naphtha (Erdöl), hydrodesulfurierte leichte; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus einem katalytischen Hydrodesulfurierungsverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa -20 oC bis 190 oC (-4 oF bis 374 oF).] | 265-178-6 | 64742-73-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-330-00-2 | Naphtha (Erdöl), hydrodesulfuriert, schwere; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus einem katalytischen Hydrodesulfurierungsverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C7 bis C12 mit einem Siedebereich von etwa 90 oC bis 230 oC (194 oF bis 446 oF).] | 265-185-4 | 64742-82-1 | Carc. 1B Muta. 1B STOT RE 1 Asp. Tox. 1 | H350 H340 H372 (zentrales Nervensystem) H304 | GHS08 Gef. | H350 H340 H372 (zentrales Nervensystem) H304 | P | ||
649-331-00-8 | Destillate (Erdöl), wasserstoffbehandelt, mittlere, intermediär siedend; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von Produkten aus der Wasserstoffbehandlung von Mitteldestillat. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C10 mit einem Siedebereich von etwa 127 oC bis 188 oC (262 oF bis 370 oF).] | 270-092-7 | 68410-96-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-332-00-3 | Destillate (Erdöl), leichtes Destillat, Wasserstoffbehandlung, niedrig siedend; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von Produkten aus der Wasserstoffbehandlung von Leichtdestillat. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C9 mit einem Siedebereich von etwa 3 oC bis 194 oC (37 oF bis 382 oF).] | 270-093-2 | 68410-97-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-333-00-9 | Destillate (Erdöl), wasserstoffbehandeltes schweres Naphtha, Deisohexanisierer Überschüsse; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation der Produkte aus der Wasserstoffbehandlung von schwerem Naphtha. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C6 mit einem Siedebereich von etwa -49 oC bis 68 oC (-57 oF bis 155 oF).] | 270-094-8 | 68410-98-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-334-00-4 | Lösungsmittelnaphtha (Erdöl), leicht aromatisch, mit Wasserstoff behandelt; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion in Gegenwart eines Katalysators. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C8 bis C10 mit einem Siedebereich von etwa 135 oC bis 210 oC (275 oF bis 410 oF).] | 270-988-8 | 68512-78-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-335-00-X | Naphtha (Erdöl), hydrodesulfuriert, thermisch gecrackte, leichte; Naphtha, wasserstoffbehandelt, niedrigsiedend; [kKomplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung von hydrodesulfuriertem thermisch gecracktem Destillat. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C5 bis C11 mit einem Siedebereich von etwa 23 oC bis 195 oC (73 oF bis 383 oF).] | 285-511-9 | 85116-60-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-336-00-5 | Naphtha (Erdöl), mit Wasserstoff behandelt, leichte, Cycloalkan enthaltend; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation einer Erdölfraktion. Besteht vorwiegend aus Alkanen und Cycloalkanen mit einem Siedebereich von etwa -20 oC bis 190 oC (-4 oF bis 374 oF).] | 285-512-4 | 85116-61-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-337-00-0 | Naphtha (Erdöl), schwer, steamcracked, hydriert; Naphtha, wasserstoffbehandelt, niedrigsiedend; | 295-432-1 | 92045-51-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-338-00-6 | Naphtha (Erdöl), hydrodesulfuriert, gesamte; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus einem katalytischen Hydrodesulfurierungsverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa 30 oC bis 250 oC (86 oF bis 482 oF).] | 295-433-7 | 92045-52-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-339-00-1 | Naphtha (Erdöl), wasserstoffbehandelte, leichte, steamcracked; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln einer Erdöl-Fraktion aus einem Pyrolyseverfahren mit Wasserstoff in Gegenwart eines Katalysators erhält. Besteht vorwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C11 mit einem Siedebereich von etwa 35 oC bis 190 oC (95 oF bis 374 oF).] | 295-438-4 | 92045-57-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-340-00-7 | Kohlenwasserstoffe, C4-12, Naphthacracken, wasserstoffbehandelt; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation des Produkts aus dem Steamcracken von Naphtha und nachfolgender selektiver katalytischer Hydrierung von Gummibildnern. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C12 mit einem Siedebereich von etwa 30 oC bis 230 oC (86 oF bis 446 oF). | 295-443-1 | 92045-61-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-341-00-2 | Solvent Naphtha (Erdöl), wasserstoffbehandelt, leichte, naphthenhaltige; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion in Gegenwart eines Katalysators. Besteht vorwiegend aus cycloparaffinhaltigen Kohlenwasserstoffenmit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C7 mit einem Siedebereich von etwa 73 oC bis 85 oC (163 oF bis 185 oF).] | 295-529-9 | 92062-15-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-342-00-8 | Naphtha (Erdöl), leichte, steamcracked, hydriert; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Abtrennen und nachfolgender Hydrierung der Produkte aus dem Steamcracken zur Ethylenherstellung. Besteht vorwiegend aus gesättigten und ungesättigten Paraffinen, cyclischen Paraffinen und cyclischen aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C4 bis C10 und einem Siedebereich von etwa 50 oC bis 200 oG (122 oF bis 392 oF). Der Anteil der Benzolkohlenwasserstoffe kann bis zu einem Massenanteil von 30 % variieren und der Lauf kann auch geringe Mengen an Schwefel- und oxygenierten Verbindungen enthalten.] | 296-942-7 | 93165-55-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-343-00-3 | Kohlenwasserstoffe, C6-11, mit Wasserstoff behandelt, dearomatisiert; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Lösungsmittel, die mit Wasserstoff behandelt wurden, um Aromaten durch katalytische Hydrierung in Naphthene umzuwandeln.] | 297-852-0 | 93763-33-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-344-00-9 | Kohlenwasserstoffe, C9-12, mit Wasserstoff behandelt, dearomatisiert; Naphtha, wasserstoffbehandelt, niedrigsiedend; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Lösungsmittel, die mit Wasserstoff behandelt wurden, um Aromaten durch katalytische Hydrierung in Naphthene umzuwandeln.] | 297-853-6 | 93763-34-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-345-00-4 | Stoddard Lösungsmittel; Naphtha, niedrigsiedend, nicht spezifiziert; [Farbloses, aufbereitetes Erdöldestillat, frei von ranzigen oder unangenehmen Gerüchen; siedet im Bereich von etwa 148,8 oC bis 204,4 oC (300 oF bis 400 oF).] | 232-489-3 | 8052-41-3 | Carc. 1B Muta. 1B STOT RE 1 Asp. Tox. 1 | H350 H340 H372 (zentrales Nervensystem) H304 | GHS08 Gef. | H350 H340 H372 (zentrales Nervensystem) H304 | P | ||
649-346-00-X | Naturgaskondensate (Erdöl); Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, von Naturgas als Flüssigkeit in einem Oberflächenseparator durch rückstufende Kondensation abgetrennt. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C20. Flüssig bei atmosphärischer Temperatur und atmosphärischem Druck.] | 265-047-3 | 64741-47-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-347-00-5 | Naturgas (Erdöl), rohe flüssige Mischung; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, von Naturgas als Flüssigkeit in einer Gasrecyclinganlage durch Kühlungs- oder Absorptionsverfahren abgetrennt. Besteht hauptsächlich aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C2 bis C8.] | 265-048-9 | 64741-48-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-348-00-0 | Naphtha (Erdöl), leichte, hydrogecrackte; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem Hydrokcrackverfahren. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C10 mit einem Siedebereich von etwa -20 oC bis 180 oC (-4 oF bis 356 oF).] | 265-071-4 | 64741-69-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-349-00-6 | Naphtha (Erdöl), schwer, hydrogecrackt; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem Hydrokcrackverfahren. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C12 mit einem Siedebereich von etwa 65 oC bis 230 oC (148 oF bis 446 oF).] | 265-079-8 | 64741-78-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-350-00-1 | Naphtha (Erdöl), gesüßte; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Aussetzen von Erdöldnaphtha einem Süßungsverfahren zur Konvertierung von Mercaptanen oder zum Entfernen saurer Verunreinigungen . Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C12 mit einem Siedebereich von etwa -10 oC bis 230 oC (14 oF bis 446 oF).] | 265-089-2 | 64741-87-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-351-00-7 | Naphtha (Erdöl), Säure-behandelt-; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Schwefelsäure-Behandlungsverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C7 bis C12 mit einem Siedebereich von etwa 90 oC bis 230 oC (194 oF bis 446 oF).] | 265-115-2 | 64742-15-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-352-00-2 | Naphtha (Erdöl), chemisch neutralisierte, schwere; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch eine Behandlungsmethode zum Entfernen saurer Stoffe. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C12 mit einem Siedebereich von etwa 65 oC bis 230 oC (149 oF bis 446 oF).] | 265-122-0 | 64742-22-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-353-00-8 | Naphtha (Erdöl), chemisch neutralisierte, leichte; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch eine Behandlungsmethode zum Entfernen saurer Stoffe. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa -20 oC bis 190 oC (-4 oF bis 374 oF).] | 265-123-6 | 64742-23-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-354-00-3 | Naphtha (Erdöl), katalytisch entwachst; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Entwachsen einer Erdölfraktion. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C12 mit einem Siedebereich von etwa 35 oC bis 230 oC (95 oF bis 446 oF).] | 265-170-2 | 64742-66-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-355-00-9 | Naphtha (Erdöl), leicht, steamcracked; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation der Produkte aus dem Steamcrackverfahren. Besteht vorwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa -20 oC bis 190 oC (-4 oF bis 374 oF).] Dieser Lauf kann 10 vol.% oder mehr Benzol enthalten.] | 265-187-5 | 64742-83-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-356-00-4 | Lösungsmittelnaphtha (Erdöl), leichte, aromatische; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation aromatischer Läufe. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C8 bis C10 mit einem Siedebereich von etwa 135 oC bis 210 oC (275 oF bis 410 oF).] | 265-199-0 | 64742-95-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-357-00-X | Aromatische Kohlenwasserstoffe, C6-10, säurebehandelt, neutralisiert; Naphtha, niedrigsiedend, nicht spezifiziert; | 268-618-5 | 68131-49-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-358-00-5 | Destillate (Erdöl), C3-5, 2-Methyl-2-buten-reich; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Destillation von Kohlenwasserstoffen mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C5, vorwiegend Isopentan und 3-Methyl-1-buten. Besteht aus gesättigten und ungesättigten Kohlenwasserstoffen im Bereich von C3 bis C5, vorwiegend 2-Methyl-2-buten.] | 270-725-7 | 68477-34-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-359-00-0 | Destillate (Erdöl), polymerisierte steamcracked Erdöldestillate, C5-12-Fraktion; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus der Destillation von polymerisiertem steamcracked Erdöldestillat. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C12.] | 270-735-1 | 68477-50-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-360-00-6 | Destillate (Erdöl), steamcracked, C5-12-Fraktion; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination organischer Verbindungen, erhalten durch Destillation von Produkten aus dem Steamcrackverfahren. Besteht aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C12.] | 270-736-7 | 68477-53-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-361-00-1 | Destillate (Erdöl), steamcracked, C5-10-Fraktion, gemischt mit leichter durch Steam-cracken gewonnener Erdöl-Naphtha-C5-Fraktion; Naphtha, niedrigsiedend, nicht spezifiziert; | 270-738-8 | 68477-55-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-362-00-7 | Extrakte (Erdöl), Kalt-Säure, C4-6; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination organischer Verbindungen, hergestellt durch saure Kaltextraktion gesättigter und ungesättigter aliphatischer Kohlenwasserstoffe mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C6, vorwiegend von Pentanen und Amylenen. Besteht vorwiegend aus gesättigten und ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C4 bis C6, überwiegend C5.] | 270-741-4 | 68477-61-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-363-00-2 | Destillate (Erdöl), Depentanisierer Kopf; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen aus einem katalytisch gecrackten Gaslauf. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C6.] | 270-771-8 | 68477-89-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-364-00-8 | Rückstände (Erdöl), Butan Spalt Boden; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexer Rückstand aus der Destillation des Butanlaufs. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C6.] | 270-791-7 | 68478-12-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-365-00-3 | Rückstandsöle (Erdöl), Isobutanabtrennungskolonne; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexer Rückstand aus der offenen Destillation des Butan-Butylen-Laufs. Besteht aus aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C6.] | 270-795-9 | 68478-16-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-366-00-9 | Naphtha (Erdöl), gesamte Kokerei; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem Flüssigkoker. Besteht vorwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C15 mit einem Siedebereich von etwa 43 oC bis 250 oC (110 oF bis 500 oF).] | 270-991-4 | 68513-02-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-367-00-4 | Naphtha (Erdöl), steamcracked mittlere aromatische Fraktion; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem Steamcrackverfahren. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C7 bis C12 mit einem Siedebereich von etwa 130 oC bis 220 oC (266 oF bis 428 oF).] | 271-138-9 | 68516-20-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-368-00-X | Naphtha (Erdöl), Ton-behandelte gesamte straight-run; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandlung des gesamten Straight-run-Benzins mit natürlichem oder modifizierten Ton, gewöhnlich in einem Perkolationsverfahren zum Entfernen von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa -20 oC bis 220 oC (-4 oF bis 429 oF).] | 271-262-3 | 68527-21-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-369-00-5 | Naphtha (Erdöl), Ton-behandelte leichte straight-run; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandlung von leichtem Straight-run-Benzins mit natürlichem oder modifiziertem Ton, gewöhnlich in einem Perkolationsverfahren zum Entfernen von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C7 bis C10 mit einem Siedebereich von etwa 93 oC bis 180 oC (200 oF bis 356 oF).] | 271-263-9 | 68527-22-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-370-00-0 | Naphtha (Erdöl), leichte, steamcracked, aromatische; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus dem Steamcrackverfahren. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C7 bis C9 mit einem Siedebereich von etwa 110 oC bis 165 oC (230 oF bis 329 oF).] | 271-264-4 | 68527-23-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-371-00-6 | Naphtha (Erdöl), leichte steamcracked, von Benzol befreit; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus dem Steamcrackverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C12 mit einem Siedebereich von etwa 80 oC bis 218 oC (176 oF bis 424 oF).] | 271-266-5 | 68527-26-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-372-00-1 | Naphtha (Erdöl), aromatenhaltig; Naphtha, niedrigsiedend, nicht spezifiziert | 271-635-0 | 68603-08-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-373-00-7 | Benzin, Pyrolyse, Entbutanisierer Boden; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Fraktionierung der Bodenprodukte des Entpropanisierers. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend größer als C5.] | 271-726-5 | 68606-10-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-374-00-2 | Naphtha (Erdöl), leicht, gesüßt; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Aussetzen eines Erdöldestillates einem Süßungsverfahren zur Konvertierung von Mercaptanen oder zum Entfernen saurer Verunreinigungen. Besteht vorwiegend aus gesättigten und ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C3 bis C6 mit einem Siedebereich von etwa -20 oC bis 100 oC (-4 oF bis 212 oF).] | 272-206-0 | 68783-66-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-375-00-8 | Erdgaskondensate; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, abgetrennt und/oder kondensiert aus Erdgas während des Transports und am Bohrlochkopf und/oder während der Produktion, beim Zusammenfügen, beim Übertragen und an Verteilerleitungen von Schächten und Turmwäschern usw gesammelt. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C2 bis C8.] | 272-896-3 | 68919-39-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-376-00-3 | Destillate (Erdöl), Naphtha Unifiner Stripper; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Strippen der Produkte aus dem Naphtha Unifiner. Besteht aus gesättigten aliphatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C2 bis C6.] | 272-932-8 | 68921-09-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-377-00-9 | Naphtha (Erdöl), katalytisch reformierte leichte, aromatenfreie Fraktion; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die nach Entfernen der aromatischen Verbindungen aus katalytisch reformierter leichter Naphtha in einem selektiven Absorptionsverfahren zurückbleibt. Besteht vorwiegend aus paraffinischen und cyclischen Verbindungen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C8 mit einem Siedebereich von etwa 66 oC bis 121 oC (151 oF bis 320 oF).] | 285-510-3 | 85116-59-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-378-00-4 | Benzin; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen; besteht in erster Linie aus Paraffinen, Cycloparaffinen, aromatischen und olefinhaltigen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend größer als C3 mit einem Siedebereich von 30 oC bis 260 oC (86 oF bis 500 oF).] | 289-220-8 | 86290-81-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-379-00-X | Aromatische Kohlenwasserstoffe, C7-8, Dealkylierungsprodukte, Destillationsrückstände; Naphtha, niedrigsiedend, nicht spezifiziert; | 292-698-0 | 90989-42-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-380-00-5 | Kohlenwasserstoffe, C4-6, leichte, Depentanisierer leichte, aromatisch mit Wasserstoff behandelt; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als erste Läufe aus der Säule zur Pentanabtrennung vor der Wasserstoffbehandlung der aromatischen Beschickungen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C4 bis C6, hauptsächlich Pentanen und Pentenen, mit einem Siedebereich von etwa 25 oC bis 40 oC (77 oF bis 104 oF).] | 295-298-4 | 91995-38-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-381-00-0 | Destillate (Erdöl), Wärme-Soaker steamcracked Naphtha, C5-reich; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von steamcracked Naphtha aus dem Wärme-Soaker. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C4 bis C6, vorwiegend C5.] | 295-302-4 | 91995-41-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-382-00-6 | Extrakte (Erdöl), katalytisch reformierte, leichte, Naphtha lösungsmittel; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten als Extrakt durch Lösungsmittelextraktion eines katalytisch reformierten Erdölschnitts. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C7 bis C8 mit einem Siedebereich von etwa 100 oC bis 200 oC (212 oF bis 392 oF).] | 295-331-2 | 91995-68-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-383-00-1 | Naphtha (Erdöl), hydrodesulfuriert, leichte, dearomatisiert; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von hydrodesulfurierten und dearomatisierten leichten Erdöl-Fraktionen. Besteht vorwiegend aus C7-Paraffinen und Cycloparaffinen mit einem Siedebereich von etwa 90 oC bis 100 oC (194 oF bis 212 oF).] | 295-434-2 | 92045-53-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-384-00-7 | Naphtha (Erdöl), leicht, C5-reich, gesüßt; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man erhält, wenn man Erdölnaphtha einem Süßungsverfahren zur Konvertierung von Mercaptanen oder zum Entfernen saurer Verunreinigungen aussetzt. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C5, hauptsächlich C5, mit einem Siedebereich von etwa -10 oC bis 35 oC (14 oF bis 95 oF).] | 295-442-6 | 92045-60-8 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-385-00-2 | Kohlenwasserstoffe, C8-11, Naphthacracken, Toluolschnitt; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von vorhydriertem gecracktem Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C8 bis C11 mit einem Siedebereich von etwa 130 oC bis 205 oC (266 oF bis 401 oF).] | 295-444-7 | 92045-62-0 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-386-00-8 | Kohlenwasserstoffe, C4-11, Naphthacracken, aromatenfrei; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten aus vorhydriertem gecracktem Naphtha nach destillativer Abtrennung von benzol- und toluolhaltigen Kohlenwasserstoffschnitten und einer höhersiedenden Fraktion. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C11 mit einem Siedebereich von etwa 30 oC bis 205 oC (86 oF bis 401 oF).] | 295-445-2 | 92045-63-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-387-00-3 | Naphtha (Erdöl), leichte, aus dem Wärme-Soaker, steamcracked; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionieren von steamcracked Naphtha nach Rückgewinnung aus einem Wärme-Soakverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C4 bis C6 mit einem Siedebereich von etwa 0 oC bis 80 oC (32 oF bis 176 oF).] | 296-028-8 | 92201-97-3 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-388-00-9 | Destillate (Erdöl), C6-reich; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von Erdölausgangsstoffen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C5 bis C7, reich an C6, mit einem Siedebereich von etwa 60 oC bis 70 oC (140 oF bis 158 oF).] | 296-903-4 | 93165-19-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-389-00-4 | Benzin, Pyrolyse, hydriert; Naphtha, niedrigsiedend, nicht spezifiziert; [Destillations-Fraktion aus der Hydrierung von Pyrolysebenzin mit einem Siedebereich von etwa 20 oC bis 200 oC (68 oF bis 392 oF).] | 302-639-3 | 94114-03-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-390-00-X | Destillate (Erdöl), steamcracked, C8-12-Fraktion; polymerisiert, leichte Destillate; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation der polymerisierten C8-12-Fraktion aus steamcracked Erdöldestillaten. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C8 bis C12.] | 305-750-5 | 95009-23-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-391-00-5 | Extrakte (Erdöl), schwer, Naphtha, Lösungsmittelextraktion, mit Ton behandelt; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Bleicherdebehandlung eines schweren naphthahaltigen Lösungsmittel-Erdölextraktes. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C10 mit einem Siedebereich von etwa 80 oC bis 180 oC (175 oF bis 356 oF).] | 308-261-5 | 97926-43-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-392-00-0 | Naphtha (Erdöl), leichte steamcracked, von Benzol befreit, thermisch behandelt; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandlung und Destillation von Benzol befreitem leichtem steamcracked Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C7 bis C12 mit einem Siedebereich von etwa 95 oC bis 200 oC (203 oF bis 392 oF).] | 308-713-1 | 98219-46-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-393-00-6 | Naphtha (Erdöl), leichte, steamcracked, thermisch behandelt; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandlung und Destillation von leichtem steamcracked Erdöl-Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C6 mit einem Siedebereich von etwa 35 oC bis 80 oC (95 oF bis 176 oF).] | 308-714-7 | 98219-47-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-394-00-1 | Destillate (Erdöl), C7-9, C8-reich, hydrodesulfuriert, dearomatisiert; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation einer Erdöl- leichten Fraktion, hydrodesulfuriert und dearomatisiert. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C7 bis C9, überwiegend C8-Paraffinen und Cycloparaffinen und siedet im Bereich von etwa 120 oC bis 130 oC (248 oF bis 266 oF).] | 309-862-5 | 101316-56-7 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-395-00-7 | Kohlenwasserstoffe, C6-8, hydriert, durch Sorption dearomatisiert, Toluol-Raffination; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten bei den Sorptionen von Toluol aus einer Kohlenwasserstoff-Fraktion von gecracktem Benzin, das unter Einsatz eines Katalysators wasserstoffbehandelt wurde. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C6 bis C8 mit einem Siedebereich von etwa 80 oC bis 135 oC (176 oF bis 275 oF).] | 309-870-9 | 101316-66-9 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-396-00-2 | Naphtha (Erdöl), hydrodesulfuriert, gesamte Verkoker; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung aus hydrodesulfuriertem Verkokerdestillat. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C5 bis C11 mit einem Siedebereich von etwa 23 oC bis 196 oC (73 oF bis 385 oF).] | 309-879-8 | 101316-76-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-397-00-8 | Naphtha (Erdöl), gesüßt, leicht; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, die man erhält, wenn man eine Erdöl-Naphtha einem Süßungsverfahren zur Konvertierung von Mercaptanen oder zum Entfernen saurer Verunreinigungen aussetzt. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C5 bis C8 mit einem Siedebereich von etwa 20 oC bis 130 oC (68 oF bis 266 oF).] | 309-976-5 | 101795-01-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-398-00-3 | Kohlenwasserstoffe, C3-6, C5-reich, steamcracked Naphtha; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von steamcracked Naphtha. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C3 bis C6, vorwiegend C5.] | 310-012-0 | 102110-14-5 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-399-00-9 | Kohlenwasserstoffe, C5-reich, Dicyclopentadien enthaltend; Naphtha, niedrigsiedend, nicht spezifiziert; [Komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation der Produkte aus dem Steamcrackeverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen von C5und Dicyclopentadien und einem Siedebereich von etwa 30 oC bis 170 oC (86 oF bis 338 oF).] | 310-013-6 | 102110-15-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-400-00-2 | Rückstände (Erdöl), steamcracked, leicht, aromatisch; Naphtha, niedrigsiedend, nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation der Produkte des Steamcrackens oder eines ähnlichen Verfahrens nach Abscheiden der sehr leichten Produkte, woraus ein Rückstand aus Kohlenwasserstoffen mit Kohlenstoffzahlen größer als C5 entsteht. Besteht aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen größer als C5 und einem Siedebereich über etwa 40 oC (104 oF).] | 310-057-6 | 102110-55-4 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-401-00-8 | Kohlenwasserstoffe, C≥5, C5-6-reich; Naphtha, niedrigsiedend, nicht spezifiziert; | 270-690-8 | 68476-50-6 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-402-00-3 | Kohlenwasserstoffe, C5-reich; Naphtha, niedrigsiedend, nicht spezifiziert; | 270-695-5 | 68476-55-1 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-403-00-9 | Aromatische Kohlenwasserstoffe, C8-10; Naphtha, niedrigsiedend, nicht spezifiziert; | 292-695-4 | 90989-39-2 | Carc. 1B Muta. 1B Asp. Tox. 1 | H350 H340 H304 | GHS08 Gef. | H350 H340 H304 | P | ||
649-404-00-4 | Kerosin (Erdöl); Straight-run Kerosin; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Rohöl. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C16 und siedet im Bereich von etwa 150 oC bis 290 oC (320 oF bis 554 oF).] | 232-366-4 | 8008-20-6 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-405-00-X | Lösungsmittelnaphtha (Erdöl), mittlere aliphatische; Straight-run Kerosin; [komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Destillation von Rohöl oder natürlichem Benzin. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C12 und siedet im Bereich von etwa 140 oC bis 220 oC (284 oF bis 428 oF).] | 265-191-7 | 64742-88-7 | STOT RE 1 Asp. Tox. 1 | H372 (zentrales Nervensystem) H304 | GHS08 Gef. | H372 (zentrales Nervensystem) H304 | |||
649-406-00-5 | Lösungsmittelnaphtha (Erdöl), schwere aliphatische; Straight-runKerosin; [komplexe Kombination von Kohlenwasserstoffen, erhalten aus der Destillation von Rohöl oder natürlichem Benzin. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11 bis C16 und siedet im Bereich von etwa 190 oC bis 290 oC (374 oF bis 554 oF).] | 265-200-4 | 64742-96-7 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-407-00-0 | Kerosin (Erdöl), Straight-run breite Fraktion; Straight-run-Kerosin; [komplexe Kombination von Kohlenwasserstoffen, die man als breite Fraktion der Kohlenwasserstoff-Brennstoff-Fraktion aus atmosphärischer Destillation erhält. Siedet im Bereich von etwa 70 oC bis 220 oC (158 oF bis 428 oF).] | 295-418-5 | 92045-37-9 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-408-00-6 | Destillate (Erdöl), steamcracked; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation der Produkte aus dem Steamcracken. Besteht überwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C16 und siedet im Bereich von etwa 90 oC bis 290 oC (190 oF bis 554 oF).] | 265-194-3 | 64742-91-2 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-409-00-1 | Destillate (Erdöl), gecrackte gestrippte steamcracked Erdöldestillate, C8-10-Fraktion; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation gecrackter gestrippter steamcracked Destillate. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C8 bis C10 und siedet im Bereich von etwa 129 oC bis 194 oC (264 oF bis 382 oF).] | 270-728-3 | 68477-39-4 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-410-00-7 | Destillate (Erdöl), gecrackte gestrippte steamcracked Erdöldestillate, C10-12-Fraktion; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation gecrackter gestrippter steamcracked Destillate. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C10 bis C12.] | 270-729-9 | 68477-40-7 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-411-00-2 | Destillate (Erdöl), steamcracked, C8-12-Fraktion; gecracktes Kerosin; [komplexe Kombination organischer Verbindungen, erhalten durch Destillation von Produkten aus dem Steamcracken. Besteht vorwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C8 bis C12.] | 270-737-2 | 68477-54-3 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-412-00-8 | Kerosin (Erdöl), hydrodesulfuriert, thermisch gecrackt; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung aus hydrodesulfuriertem thermisch gecracktem Destillat. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C8 bis C16 und siedet im Bereich von etwa 120 oC bis 283 oC (284 oF bis 541 oF).] | 285-507-7 | 85116-55-8 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-413-00-3 | Aromatische Kohlenwasserstoffe, C≥10, Steamcracken, mit Wasserstoff behandelt; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation der Produkte aus einem Steamcrackverfahren, mit Wasserstoff unter Einsatz eines Katalysators behandelt. Besteht überwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C10 und siedet im Bereich von etwa 150 oC bis 320 oC (302 oF bis 608 oF).] | 292-621-0 | 90640-98-5 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-414-00-9 | Naphtha (Erdöl), steamcracked, mit Wasserstoff behandelt, C9-10-Aromaten-reich; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, die durch Destillation der Produkte aus einem Steamcrackverfahren mit nachfolgender Wasserstoffbehandlung unter Einsatz eines Katalysators entsteht. Besteht überwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C9 bis C10 und siedet im Bereich von etwa 140 oC bis 200 oC (284 oF bis 392 oF).] | 292-637-8 | 90641-13-7 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-415-00-4 | Destillate (Erdöl), thermisch gecrackt, alkylaromatisch kohlenwasserstoffreich; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, die man durch Destillation von thermisch gecrackten schweren Teeren erhält. Besteht überwiegend aus hoch alkylierten aromatischen Kohlenwasserstoffen und siedet im Bereich von etwa 100 oC bis 250 oC (212 oF bis 482 oF).] | 309-866-7 | 101316-61-4 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-416-00-X | Destillate (Erdöl), katalytisch gecrackter schwerer Teer, leicht; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, die man durch Destillation von katalytisch gecrackten schweren Teeren erhält. Besteht überwiegend aus hoch alkylierten aromatischen Kohlenwasserstoffen und siedet im Bereich von etwa 100 oC bis 250 oC (212 oF bis 482 oF).] | 309-938-8 | 101631-13-4 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-417-00-5 | Lösungsmittelnaphtha (Erdöl), hydrogecrackte schwere aromatische; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation von hydrogecracktem Erdöldestillat. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C16 und siedet im Bereich von etwa 235 oC bis 290 oC (455 oF bis 554 oF).] | 309-881-9 | 101316-80-7 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-418-00-0 | Destillate (Erdöl), steamcracked schwerer Teer, leicht; gecracktes Kerosin; [komplexe Kombination von Kohlenwasserstoffen, die man durch Destillation von steamcracked schweren Teeren erhält. Besteht überwiegend aus hoch alkylierten aromatischen Kohlenwasserstoffen und siedet im Bereich von etwa 100 oC bis 250 oC (212 oF bis 482 oF).] | 309-940-9 | 101631-15-6 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-419-00-6 | Destillate (Erdöl), Alkylat; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation der Reaktionsprodukte von Isobutan mit monoolefinischen Kohlenwasserstoffen mit Kohlenstoffzahlen gewöhnlich im Bereich von C3 bis C5. Besteht aus gesättigten Kohlenwasserstoffen mit überwiegend verzweigter Kette und Kohlenstoffzahlen überwiegend im Bereich von C11bis C17 und siedet im Bereich von etwa 205 oC bis 320 oC (401 oF bis 608 oF).] | 265-074-0 | 64741-73-7 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-420-00-1 | Extrakte (Erdöl), schwere Naphtha-Lösungsmittel-; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten als Extrakt aus einem Lösungsmittelextraktionsverfahren. Besteht überwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C12 und siedet im Bereich von etwa 90 oC bis 220 oC (194 oF bis 428 oF).] | 265-099-7 | 64741-98-6 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-421-00-7 | Destillate (Erdöl), chemisch neutralisierte leichte; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandlung zum Entfernen saurer Stoffe. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C16 und siedet im Bereich von etwa 150 oC bis 290 oC (302 oF bis 554 oF).] | 265-132-5 | 64742-31-0 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-422-00-2 | Destillate (Erdöl), mit Wasserstoff behandelte leichte; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion unter Einsatz eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C16 und siedet im Bereich von etwa 150 oC bis 290 oC (302 oF bis 554 oF).] | 265-149-8 | 64742-47-8 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-423-00-8 | Kerosin (Erdöl), hydrodesulfuriertes; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten aus einem Erdölgrundstoff durch Behandeln mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff umzuwandeln, der entfernt wird. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C16 und siedet im Bereich von etwa 150 oC bis 290 oC (302 oF bis 554 oF).] | 265-184-9 | 64742-81-0 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-424-00-3 | Lösungsmittelnaphtha (Erdöl), schwer, aromatisch; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation aromatischer Läufe. Besteht überwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C16 und siedet im Bereich von etwa 165 oC bis 290 oC (330 oF bis 554 oF).] | 265-198-5 | 64742-94-5 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-425-00-9 | Naphtha (Erdöl), schwere Kokerei; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem Flüssig-Verkoker. Besteht vorwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C6 bis C15 und siedet im Bereich von etwa 157 oC bis 288 oC (315 oF bis 550 oF).] | 269-778-9 | 68333-23-3 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-426-00-4 | Naphtha (Erdöl), katalytisch reformierte hydrodesulfurierte schwere, aromatische Fraktion; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung aus katalytisch reformierter hydrodesulfurierter Naphtha. Besteht überwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C7 bis C13 und siedet im Bereich von etwa 98 oC bis 218 oC (208 oF bis 424 oF).] | 285-508-2 | 85116-57-0 | Asp. Tox. 1 | H304 | GHS08-Gef. | H304 | |||
649-427-00-X | Kerosin (Erdöl), gesüßt; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Süßung eines Erdöldestillats zur Umwandlung von Mercaptanen oder zum Entfernen saurer Verunreinigungen. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9 bis C16 und siedet im Bereich von etwa 130 oC bis 290 oC (266 oF bis 554 oF).] | 294-799-5 | 91770-15-9 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-428-00-5 | Kerosin (Erdöl), durch Lösungsmittel aufbereitet gesüßt; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man aus einem Erdölausgangsstoff durch Lösungsmittelaufbereitung und Süßen erhält. Siedet im Bereich von etwa 150 oC bis 260 oC (302 oF bis 500 oF).] | 295-416-4 | 92045-36-8 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-429-00-0 | Kohlenwasserstoffe, C9-16, mit Wasserstoff behandelt, dearomatisiert; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten als Lösungsmittel, die mit Wasserstoff behandelt wurden, um Aromaten durch katalytische Hydrierung in Naphthene umzuwandeln.] | 297-854-1 | 93763-35-0 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-430-00-6 | Kerosin (Erdöl), durch Lösungsmittel aufbereitet hydrodesulfuriert; Kerosin - nicht spezifiziert | 307-033-2 | 97488-94-3 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-431-00-1 | Destillate (Erdöl), hydrodesulfurierte gesamte mittlere Verkoker; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung aus hydrodesulfuriertem Verkokerdestillat. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C8 bis C16 und siedet im Bereich von etwa 120 oC bis 283 oC (248 oF bis 541 oF).] | 309-864-6 | 101316-58-9 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-432-00-7 | Lösungsmittelnaphtha (Erdöl), hydrodesulfurierte schwere aromatische; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten aus katalytischer Hydrodesulfurierung einer Erdölfraktion. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C10 bis C13 und siedet im Bereich von etwa 180 oC bis 240 oC (356 oF bis 464 oF).] | 309-882-4 | 101316-81-8 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-433-00-2 | Lösungsmittelnaphtha (Erdöl), hydrodesulfurierte mittlere; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten aus katalytischer Hydrodesulfurierung einer Erdölfraktion. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C10 bis C13 und siedet im Bereich von etwa 175 oC bis 220 oC (347 oF bis 428 oF).] | 309-884-5 | 101316-82-9 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-434-00-8 | Kerosin (Erdöl), mit Wasserstoff behandelt; Kerosin - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Destillation von Erdöl und nachfolgender Behandlung mit Wasserstoff erhält. Besteht überwiegend aus Alkanen, Cycloalkanen und Alkylbenzolen mit Kohlenstoffzahlen überwiegend im Bereich von C12 bis C16 und siedet im Bereich von etwa 230 oC bis 270 oC (446 oF bis 518 oF).] | 309-944-0 | 101631-19-0 | Asp. Tox. 1 | H304 | GHS08 Gef. | H304 | |||
649-435-00-3 | Destillate (Erdöl), leichte katalytisch gecrackte; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9bis C25 und siedet im Bereich von etwa 150 oC bis 400 oC (302 oF bis 752 oF). Enthält eine relativ große Menge bicyclischer aromatischer Kohlenwasserstoffe.] | 265-060-4 | 64741-59-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-436-00-9 | Destillate (Erdöl), mittlere katalytisch gecrackte; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11bis C30 und siedet im Bereich von etwa 205 oC bis 450 oC (401 oF bis 842 oF). Enthält eine relativ große Menge tricyclischer aromatischer Kohlenwasserstoffe.] | 265-062-5 | 64741-60-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-437-00-4 | Destillate (Erdöl), leichte hydrogecrackte; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten des Hydrocrackens. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C10 bis C18 und siedet im Bereich von etwa 160 oC bis 320 oC (320 oF bis 608 oF).] | 265-078-2 | 64741-77-1 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
649-438-00-X | Destillate (Erdöl), leichte thermisch gecrackte; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem thermischen Crackverfahren. Besteht überwiegend aus ungesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C10 bis C22 und siedet im Bereich von etwa 160 oC bis 370 oC (320 oF bis 698 oF).] | 265-084-5 | 64741-82-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-439-00-5 | Destillate (Erdöl), hydrodesulfurierte leichte katalytisch gecrackte; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von leichten katalytisch gecrackten Destillaten mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff zu überführen, der entfernt wird. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C9bis C25 und siedet im Bereich von etwa 150 oC bis 400 oC (302 oF bis 752 oF). Enthält eine relativ große Menge bicyclischer aromatischer Kohlenwasserstoffe.] | 269-781-5 | 68333-25-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-440-00-0 | Destillate (Erdöl), leichte steamcracked Naphtha; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen aus der multiplen Destillation von Produkten aus einem Steamcrackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C10 bis C18.] | 270-662-5 | 68475-80-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-441-00-6 | Destillate (Erdöl), gecrackte steamcracked Erdöldestillate; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Destillation gecrackten steamcracked Destillates und/oder seiner Fraktionierungsprodukte. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C10 bis zu Polymeren mit niedrigem Molekulargewicht.] | 270-727-8 | 68477-38-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-442-00-1 | Gasöle (Erdöl), steamcracked; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten aus einem Steamcrackverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C9 und siedet im Bereich von etwa 205 oC bis 400 oC (400 oF bis 752 oF).] | 271-260-2 | 68527-18-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-443-00-7 | Destillate (Erdöl), hydrodesulfurierte thermisch gecrackte mittlere; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung aus hydrodesulfurierten thermisch gecrackten Destillatausgangsstoffen. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C11 bis C25 und siedet im Bereich von etwa 205 oC bis 400 oC (401 oF bis 752 oF).] | 285-505-6 | 85116-53-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-444-00-2 | Gasöle (Erdöl), thermisch gecrackt, hydrodesulfuriert; Crackgasöl | 295-411-7 | 92045-29-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-445-00-8 | Rückstände (Erdöl), hydrierte steamcracked Naphtha; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, die man als Rückstandsfraktion aus der Destillation von mit Wasserstoff behandelter steamcracked Naphtha erhält. Besteht überwiegend aus Kohlenwasserstoffen und siedet im Bereich von etwa 200 oC bis 350 oC (32 oF bis 662 oF).] | 295-514-7 | 92062-00-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-446-00-3 | Rückstände (Erdöl), steamcracked Naphthadestillation; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, die man als Kolonnenbodenlauf aus der Abtrennung von Ausflüssen aus steamcracked Naphtha bei einer hohen Temperatur erhält. Siedet im Bereich von etwa 147 oC bis 300 oC (297 oF bis 572 oF) und ergibt ein Fertigöl mit einer Viskosität von 18 cSt bei 50 oC.] | 295-517-3 | 92062-04-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-447-00-9 | Destillate (Erdöl), leichte katalytisch gecrackte, thermisch abgebaut; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Destillation von Produkten aus einem katalytischen Crackverfahren, das als Wärmetransfer-Flüssigkeit benutzt wurde. Besteht überwiegend aus Kohlenwasserstoffen und siedet im Bereich von etwa 190 oC bis 340 oC (374 oF bis 644 oF). Dieser Lauf enthält wahrscheinlich organische Schwefelverbindungen.] | 295-991-1 | 92201-60-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-448-00-4 | Rückstände (Erdöl), steamcracked Wärme-Soaker Naphtha; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, die man als Rückstand aus der Destillation von steamcracked Naphtha aus dem Wärme-Soaker erhält. Siedet im Bereich von etwa 150 oC bis 350 oC (302 oF bis 662 oF).] | 297-905-8 | 93763-85-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-449-00-X | Kohlenwasserstoffe, C16-20, durch Lösungsmittel entwachst hydrogecrackt paraffinhaltig Destillationsrückstand; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, die man durch Entwachsen eines Destillationsrückstandes aus hydrogecracktem paraffinhaltigen Destillat durch Lösungsmittel erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C16 bis C20 und siedet im Bereich von etwa 360 oC bis 500 oC (680 oF bis 932 oF). Ergibt ein Fertigöl mit einer Viskosität von 4,5 cSt bei etwa 100 oC (212 oF).] | 307-662-2 | 97675-88-2 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
649-450-00-5 | Gasöle (Erdöl), leichte Vakuum, thermisch gecrackt hydrodesulfuriert; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, die man durch katalytische Hydrodesulfurierung von thermisch gecracktem leichten Vakuum-Erdöl erhält. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C14 bis C20 und siedet im Bereich von etwa 270 oC bis 370 oC (518 oF bis 698 oF).] | 308-278-8 | 97926-59-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-451-00-0 | Destillate (Erdöl), hydrodesulfurierte mittlere Verkoker; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Fraktionierung aus hydrodesulfurierten Verkokerdestillatausgangsstoffen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C12bis C21 und siedet im Bereich von etwa 200 oC bis 360 oC (392 oF bis 680 oF).] | 309-865-1 | 101316-59-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-452-00-6 | Destillate (Erdöl), schwere steamcracked; gecracktes Gasöl; [komplexe Kombination von Kohlenwasserstoffen, die man durch Destillation von steamcracked schweren Rückständen erhält. Besteht überwiegend aus hoch alkylierten aromatischen Kohlenwasserstoffen und siedet im Bereich von etwa 250 oC bis 400 oC (482 oF bis 752 oF).] | 309-939-3 | 101631-14-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | |||
649-453-00-1 | Destillate (Erdöl), schwere hydrogecrackte; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen aus der Destillation von Produkten des Hydrocrackens. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C15 bis C39 und siedet im Bereich von etwa 260 oC bis 600 oC (500 oF bis 1112 oF).] | 265-077-7 | 64741-76-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-454-00-7 | Destillate (Erdöl), durch Lösungsmittel aufbereitete schwere paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Lösungsmittelextraktionsverfahren. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF).] | 265-090-8 | 64741-88-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-455-00-2 | Destillate (Erdöl), durch Lösungsmittel aufbereitete leichte paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Lösungsmittelextraktionsverfahren. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF).] | 265-091-3 | 64741-89-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-456-00-8 | Rückstandsöle (Erdöl), durch Lösungsmittel entasphaltierte; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten als lösungsmittellösliche Fraktion aus C3-C4 Lösungsmittel-Deasphaltieren eines Rückstandes. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25 und siedet bei über etwa 400 oC (752 oF).] | 265-096-0 | 64741-95-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-457-00-3 | Destillate (Erdöl), durch Lösungsmittel aufbereitete schwere naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Lösungsmittelextraktionsverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-097-6 | 64741-96-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-458-00-9 | Destillate (Erdöl), durch Lösungsmittel aufbereitete leichte naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten als Raffinat aus einem Lösungsmittelextraktionsverfahren. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-098-1 | 64741-97-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-459-00-4 | Rückstandsöle (Erdöl), durch Lösungsmittel aufbereitet; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten als lösungsmittelunlösliche Fraktion aus Lösungsmittel-Aufbereiten eines Rückstandes mit einem polaren organischen Lösungsmittel wie Phenol oder Furfural. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25 und siedet bei über etwa 400 oC (752 oF).] | 265-101-6 | 64742-01-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-460-00-X | Destillate (Erdöl), tonbehandelte paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, entsteht durch Behandeln einer Erdölfraktion mit natürlichem oder modifiziertem Ton in einem Kontakt- oder einem Perkolationsverfahren zum Entfernen von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält eine relativ große Menge an gesättigten Kohlenwasserstoffen.] | 265-137-2 | 64742-36-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-461-00-5 | Destillate (Erdöl), tonbehandelte leichte paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, entsteht durch Behandeln einer Erdölfraktion mit natürlichem oder modifiziertem Ton in einem Kontakt- oder einem Perkolationsverfahren zum Entfernen von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält eine relativ große Menge an gesättigten Kohlenwasserstoffen.] | 265-138-8 | 64742-37-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-462-00-0 | Rückstandsöle (Erdöl), tonbehandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln eines Rückstandöles mit natürlichem oder modifiziertem Ton in einem Kontakt- oder einem Perkolationsverfahren zum Entfernen der Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25 und siedet bei über etwa 400 oC (752 oF).] | 265-143-5 | 64742-41-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-463-00-6 | Destillate (Erdöl), tonbehandelte schwere naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, entsteht durch Behandeln einer Erdölfraktion mit natürlichem oder modifiziertem Ton in einem Kontakt- oder einem Perkolationsverfahren zum Entfernen von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-146-1 | 64742-44-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-464-00-1 | Destillate (Erdöl), tonbehandelte leichte naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, entsteht durch Behandeln einer Erdölfraktion mit natürlichem oder modifiziertem Ton in einem Kontakt- oder einem Perkolationsverfahren zum Entfernen von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-147-7 | 64742-45-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-465-00-7 | Destillate (Erdöl), mit Wasserstoff behandelte schwere naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion unter Einsatz eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-155-0 | 64742-52-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-466-00-2 | Destillate (Erdöl), mit Wasserstoff behandelte leichte naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion unter Einsatz eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-156-6 | 64742-53-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-467-00-8 | Destillate (Erdöl), mit Wasserstoff behandelte schwere paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion unter Einsatz eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält eine relativ große Menge an gesättigten Kohlenwasserstoffen.] | 265-157-1 | 64742-54-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-468-00-3 | Destillate (Erdöl), mit Wasserstoff behandelte leichte paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion unter Einsatz eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält eine relativ große Menge an gesättigten Kohlenwasserstoffen.] | 265-158-7 | 64742-55-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-469-00-9 | Destillate (Erdöl), lösungsmittelentwachste leichte paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Entfernen von normalen Paraffinen aus einer Erdölfraktion durch Lösungsmittelkristallisation. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF).] | 265-159-2 | 64742-56-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-470-00-4 | Rückstandsöle (Erdöl), mit Wasserstoff behandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Wasserstoffbehandlung einer Erdölfraktion unter Einsatz eines Katalysators. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25 und siedet bei über etwa 400 oC (752 oF).] | 265-160-8 | 64742-57-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-471-00-X | Rückstandsöle (Erdöl), lösungsmittel-entwachste; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Entfernen von Kohlenwasserstoffen mit langer, verzweigter Kette aus einem Rückstandsöl durch Lösungsmittelkristallisation. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25 und siedet bei über etwa 400 oC (752 oF).] | 265-166-0 | 64742-62-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-472-00-5 | Destillate (Erdöl), lösungsmittel-entwachste schwere naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Entfernen von normalen Paraffinen aus einer Erdölfraktion durch Lösungsmittelkristallisation. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-167-6 | 64742-63-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-473-00-0 | Destillate (Erdöl), lösungsmittel-entwachste leichte naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Entfernen von normalen Paraffinen aus einer Erdölfraktion durch Lösungsmittelkristallisation. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-168-1 | 64742-64-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-474-00-6 | Destillate (Erdöl), lösungsmittel-entwachste schwere paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Entfernen von normalen Paraffinen aus einer Erdölfraktion durch Lösungsmittelkristallisation. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF).] | 265-169-7 | 64742-65-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-475-00-1 | Naphthenhaltige Öle (Erdöl), katalytisch entwachste schwere; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Entwachsen. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-172-3 | 64742-68-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-476-00-7 | Naphthenhaltige Öle (Erdöl), katalytisch entwachste leichte; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Entwachsen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C30und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-173-9 | 64742-69-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-477-00-2 | Paraffinöle (Erdöl), katalytisch entwachste schwere; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Entwachsen. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF).] | 265-174-4 | 64742-70-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-478-00-8 | Paraffinöle (Erdöl), katalytisch entwachste leichte; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Entwachsen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF).] | 265-176-5 | 64742-71-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-479-00-3 | Naphthenhaltige Öle (Erdöl), komplexe entwachste schwere; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Entfernen von Paraffinkohlenwasserstoffen mit gerader Kette als Feststoff durch Behandeln mit einem Mittel wie Harnstoff. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-179-1 | 64742-75-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-480-00-9 | Naphthenhaltige Öle (Erdöl), komplexe entwachste leichte; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch katalytisches Entwachsen. Besteht aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 265-180-7 | 64742-76-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-481-00-4 | Schmieröle (Erdöl), C20-50-, mit Wasserstoff behandelte neutrale aus Öl, hohe Viskosität; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von leichtem Vakuumgasöl, schwerem Vakuumgasöl und durch Lösungsmittel deasphaltiertem Rückstandsöl mit Wasserstoff unter Einsatz eines Katalysators in zwei Stufen, mit Entwachsen zwischen beiden Stufen. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von etwa 112 cSt bei 40 oC. Enthält eine relativ große Menge an gesättigten Kohlenwasserstoffen.] | 276-736-3 | 72623-85-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-482-00-X | Schmieröle (Erdöl), C15-30-, mit Wasserstoff behandelte neutrale aus Öl; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von leichtem Vakuumgasöl und schwerem Vakuumgasöl mit Wasserstoff unter Einsatz eines Katalysators in einem Zweistufenverfahren, mit Entwachsen zwischen beiden Stufen. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C30 und ergibt Fertigöl mit einer Viskosität von etwa 15 cSt bei 40 oC. Enthält eine relativ große Menge an gesättigten Kohlenwasserstoffen.] | 276-737-9 | 72623-86-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-483-00-5 | Schmieröle (Erdöl), C20-50-, mit Wasserstoff behandelte neutrale aus Öl; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von leichtem Vakuumgasöl, schwerem Vakuumgasöl und durch Lösungsmittel deasphaltiertem Rückstandsöl mit Wasserstoff unter Einsatz eines Katalysators in einem Zweistufenverfahren, mit Entwachsen zwischen beiden Stufen. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von etwa 32 cSt bei 40 oC. Enthält eine relativ große Menge an gesättigten Kohlenwasserstoffen.] | 276-738-4 | 72623-87-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-484-00-0 | Schmieröle; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten aus Lösungsmittelextraktion und Entwachsungsverfahren. Besteht vorwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen im Bereich von C15 bis C50.] | 278-012-2 | 74869-22-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-485-00-6 | Destillate (Erdöl), komplexe entwachste schwere paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Entwachsen von schwerem paraffinhaltigen Destillat. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20bis C50 und ergibt Fertigöl mit einer Viskosität von oder größer als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 292-613-7 | 90640-91-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-486-00-1 | Destillate (Erdöl), komplexe entwachste leichte paraffinhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Entwachsen von leichtem paraffinhaltigen Destillat. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C12 bis C30 und ergibt Fertigöl mit einer Viskosität von weniger als 19 cSt bei 40 oC (100 SUS bei 100 oF). Enthält relativ wenige normale Paraffine.] | 292-614-2 | 90640-92-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-487-00-7 | Destillate (Erdöl), durch Lösungsmittel entwachste schwere paraffinhaltige, mit Ton behandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von entwachstem schwerem paraffinhaltigen Destillat mit neutralem oder modifiziertem Ton in einem Kontakt- oder einem Perkolationsverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50.] | 292-616-3 | 90640-94-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-488-00-2 | Kohlenwasserstoffe, C20-50, durch Lösungsmittel entwachste schwere paraffinhaltige, mit Wasserstoff behandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von entwachstem schwerem paraffinhaltigen Destillat mit Wasserstoff unter Einsatz eines Katalysators. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50.] | 292-617-9 | 90640-95-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-489-00-8 | Destillate (Erdöl), durch Lösungsmittel entwachste leichte paraffinhaltige, mit Ton behandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von entwachstem leichtem paraffinhaltigen Destillat mit neutralem oder modifiziertem Ton in einem Kontakt- oder einem Perkolationsverfahren. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C15 bis C30.] | 292-618-4 | 90640-96-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-490-00-3 | Destillate (Erdöl), durch Lösungsmittel entwachste leichte paraffinhaltige, mit Wasserstoff behandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Behandeln von entwachstem leichtem paraffinhaltigen Destillat mit Wasserstoff unter Einsatz eines Katalysators. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C15 bis C30.] | 292-620-5 | 90640-97-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-491-00-9 | Rückstandsöle (Erdöl), mit Wasserstoff behandelt, durch Lösungsmittel entwachst; Basisöl - nicht spezifiziert; | 292-656-1 | 90669-74-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-492-00-4 | Restöle (Erdöl), katalytisch entwachst; Basisöl - nicht spezifiziert; | 294-843-3 | 91770-57-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-493-00-X | Destillate (Erdöl), entwachste schwere paraffinhaltige, mit Wasserstoff behandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man aus intensiver Behandlung von entwachstem Destillat durch Hydrierung unter Einsatz eines Katalysators erhält. Besteht überwiegend aus gesättigten Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C25 bis C39 und ergibt Fertigöl mit einer Viskosität von etwa 44 cSt bei 50 oC.] | 295-300-3 | 91995-39-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-494-00-5 | Destillate (Erdöl), entwachste leichte paraffinhaltige, mit Wasserstoff behandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man aus intensiver Behandlung von entwachstem Destillat durch Hydrierung unter Einsatz eines Katalysators erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C21 bis C29 und ergibt Fertigöl mit einer Viskosität von etwa 13 cSt bei 50 oC.] | 295-301-9 | 91995-40-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-495-00-0 | Destillate (Erdöl), hydrogecrackte durch Lösungsmittel aufbereitete, entwachst; Basisöl - nicht spezifiziert; [komplexe Kombination von flüssigen Kohlenwasserstoffen, die man durch Rekristallisation von entwachsten hydrogecrackten durch Lösungsmittel aufbereiteten Erdöldestillaten erhält.] | 295-306-6 | 91995-45-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-496-00-6 | Destillate (Erdöl), durch Lösungsmittel aufbereitete leichte naphthenhaltige, mit Wasserstoff behandelt; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln einer Erdöl-Fraktion mit Wasserstoff unter Einsatz eines Katalysators und Entfernen der aromatischen Kohlenwasserstoffe durch Lösungsmittelextraktion erhält. Besteht überwiegend aus naphthenhaltigen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C30 und ergibt Fertigöl mit einer Viskosität von 13 bis 15 cSt bei 40 oC.] | 295-316-0 | 91995-54-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-497-00-1 | Schmieröle (Erdöl), C17-35, durch Lösungsmittel extrahiert, entwachst, mit Wasserstoff behandelt; Basisöl - nicht spezifiziert | 295-423-2 | 92045-42-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-498-00-7 | Schmieröle (Erdöl), hydrogecrackt durch nichtaromatisches Lösungsmittel entparaffiniert; Basisöl - nicht spezifiziert | 295-424-8 | 92045-43-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-499-00-2 | Rückstandsöle (Erdöl), hydrogecrackte mit Säure behandelte durch Lösungsmittel entwachste; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, hergestellt durch Entfernen von Lösungsmittel aus Paraffinen aus dem Destillationsrückstand von mit Säure behandelten, hydrogecrackten schweren Paraffinen und siedet etwa über 380 oC (716 oF).] | 295-499-7 | 92061-86-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-500-00-6 | Paraffinöle (Erdöl), durch Lösungsmittel aufbereitete entwachste schwere; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man aus Schwefel enthaltendem paraffinhaltigem Rohöl erhält. Besteht überwiegend aus einem durch Lösungsmittel aufbereiteten entparaffinierten Schmieröl mit einer Viskosität von 65 cSt bei 50 oC.] | 295-810-6 | 92129-09-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-501-00-1 | Schmieröle (Erdöl), Basisöle, paraffinhaltig; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Aufbereiten von Rohöl erhält. Besteht überwiegend aus Aromaten, Naphthenen und Paraffinen und ergibt Fertigöl mit einer Viskosität von 23 cSt bei 40 oC (120 SUS bei 100 oF).] | 297-474-6 | 93572-43-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-502-00-7 | Kohlenwasserstoffe, hydrogecrackte paraffinhaltige Destillationsrückstände, durch Lösungsmittel entwachst; Basisöl - nicht spezifiziert | 297-857-8 | 93763-38-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-503-00-2 | Kohlenwasserstoffe, C20-50, Restöl-Hydrierung Vakuumdestillat; Basisöl - nicht spezifiziert | 300-257-1 | 93924-61-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-504-00-8 | Destillate (Erdöl), durch Lösungsmittel aufbereitete mit Wasserstoff behandelte schwere, hydriert; Basisöl - nicht spezifiziert | 305-588-5 | 94733-08-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-505-00-3 | Destillate (Erdöl), durch Lösungsmittel aufbereitete hydrogecrackte leichte; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittel-Dearomatisierung des Rückstandes von hydrogecracktem Erdöl erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C18 bis C27 und siedet im Bereich von etwa 370 oC bis 450 oC (698 oF bis 842 oF).] | 305-589-0 | 94733-09-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-506-00-9 | Schmieröle (Erdöl), C18-40, durch Lösungsmittel entwachste hydrogecrackte aus Destillatbasis; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelentparaffinierung des Rückstandes von hydrogecracktem Erdöl erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C18 bis C40 und siedet im Bereich von etwa 370 oC bis 550 oC (698 oF bis 1022 oF).] | 305-594-8 | 94733-15-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-507-00-4 | Schmieröle (Erdöl), C18-40, durch Lösungsmittel entwachste hydrierte aus Raffinatbasis; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelentparaffinierung des hydrierten Raffinates aus der Lösungsmittelextraktion eines mit Wasserstoff behandelten Erdöldestillates erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C18 bis C40 und siedet im Bereich von etwa 370 oC bis 550 oC (698 oF bis 1022 oF).] | 305-595-3 | 94733-16-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-508-00-X | Kohlenwasserstoffe, C13-30, aromatenreich, durch Lösungsmittel extrahierte naphthenhaltige Destillate; Basisöl - nicht spezifiziert | 305-971-7 | 95371-04-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-509-00-5 | Kohlenwasserstoffe, C16-32, aromatenreich, durch Lösungsmittel extrahierte naphthenhaltige Destillate; Basisöl - nicht spezifiziert | 305-972-2 | 95371-05-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-510-00-0 | Kohlenwasserstoffe, C37-68, entwachste deasphaltierte mit Wasserstoff behandelte Vakuumdestillationsrückstände; Basisöl - nicht spezifiziert | 305-974-3 | 95371-07-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-511-00-6 | Kohlenwasserstoffe, C37-65, mit Wasserstoff behandelte deasphaltierte Vakuumdestillationsrückstände; Basisöl - nicht spezifiziert | 305-975-9 | 95371-08-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-512-00-1 | Destillate (Erdöl), hydrogecrackte durch Lösungsmittel aufbereitete leichte; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelbehandlung eines Destillates aus hydrogecrackten Erdöldestillaten erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C18 bis C27 und siedet im Bereich von etwa 370 oC bis 450 oC (698 oF bis 842 oF).] | 307-010-7 | 97488-73-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-513-00-7 | Destillate (Erdöl), durch Lösungsmittel aufbereitete hydrierte schwere, Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelbehandlung eines hydrierten Erdöldestillates erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C19 bis C40 und siedet im Bereich von etwa 390 oC bis 550 oC (734 oF bis 1022 oF).] | 307-011-2 | 97488-74-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-514-00-2 | Schmieröle (Erdöl), C18-27, hydrogecrackte durch Lösungsmittel entwachste; Basisöl - nicht spezifiziert | 307-034-8 | 97488-95-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-515-00-8 | Kohlenwasserstoffe, C17-30, mit Wasserstoff behandelt durch Lösungsmittel deasphaltiert offene Destillation Rückstand leichte Destillate; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man als erste Läufe aus der Vakuumdestillation von Ausflüssen aus der Behandlung eines durch Lösungsmittel deasphaltierten Vakuumrückstandes mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C17 bis C30 und siedet im Bereich von etwa 300 oC bis 400 oC (572 oF bis 752 oF). Ergibt ein Fertigöl mit einer Viskosität von 4 cSt bei etwa 100 oC (212 oF).] | 307-661-7 | 97675-87-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-516-00-3 | Kohlenwasserstoffe, C17-40, mit Wasserstoff behandelter durch Lösungsmittel deasphaltierter Destillationsrückstand, leichte Vakuumdestillate; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man als erste Läufe aus der Vakuumdestillation von Ausflüssen aus der katalytischen Behandlung mit Wasserstoff eines durch Lösungsmittel deasphaltierten Vakuumrückstandes mit einer Viskosität von 8 cSt bei etwa 100o oC (212 oF) erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C17 bis C40 und siedet im Bereich von etwa 300 oC bis 500 oC (592 oF bis 932 oF).] | 307-755-8 | 97722-06-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-517-00-9 | Kohlenwasserstoffe, C13-27, durch Lösungsmittel extrahierte leichte naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Extraktion der Aromaten aus einem leichten naphthenhaltigen Destillat mit einer Viskosität von 9,5 cSt bei 40 oC (104 oF) erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C13 bis C27 und siedet im Bereich von etwa 240 oC bis 400 oC (464 oF bis 752 oF).] | 307-758-4 | 97722-09-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-518-00-4 | Kohlenwasserstoffe, C14-29, durch Lösungsmittel extrahierte leichte naphthenhaltige; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Extraktion der Aromaten aus einem leichten naphthenhaltigen Destillat mit einer Viskosität von 16 cSt bei 40 oC (104 oF) erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C14 bis C29 und siedet im Bereich von etwa 250 oC bis 425 oC (482 oF bis 797 oF).] | 307-760-5 | 97722-10-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-519-00-X | Kohlenwasserstoffe, C27-42, dearomatisiert; Basisöl - nicht spezifiziert | 308-131-8 | 97862-81-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-520-00-5 | Kohlenwasserstoffe, C17-30, mit Wasserstoff behandelte Destillate, Leichtdestillate; Basisöl - nicht spezifiziert | 308-132-3 | 97862-82-3 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-521-00-0 | Kohlenwasserstoffe, C27-45, naphthenhaltige, Vakuumdestillation; Basisöl - nicht spezifiziert | 308-133-9 | 97862-83-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-522-00-6 | Kohlenwasserstoffe, C27-45, dearomatisiert; Basisöl - nicht spezifiziert | 308-287-7 | 97926-68-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-523-00-1 | Kohlenwasserstoffe, C20-58, mit Wasserstoff behandelt; Basisöl - nicht spezifiziert | 308-289-8 | 97926-70-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-524-00-7 | Kohlenwasserstoffe, C27-42, naphthenhaltig; Basisöl - nicht spezifiziert | 308-290-3 | 97926-71-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-525-00-2 | Rückstandsöle (Erdöl), mit Kohlenstoff behandelt, durch Lösungsmittel entwachst; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von durch Lösungsmittel entwachsten Erdölrückstandsölen mit Aktivkohle erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen.] | 309-710-8 | 100684-37-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-526-00-8 | Rückstandsöle (Erdöl), mit Ton behandelt, durch Lösungsmittel entwachst; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandlung von durch Lösungsmittel entwachsten Erdölrückstandsölen mit Bleicherde erhält, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen.] | 309-711-3 | 100684-38-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-527-00-3 | Schmieröle (Erdöl), C>25, durch Lösungsmittel extrahiert, deasphaltiert, entwachst, hydriert; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelextraktion und Hydrierung von Vakuumdestillationsrückständen erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend größer als C25 und ergibt Fertigöl mit einer Viskosität im Bereich von 32 cSt bis 37 cSt bei 100 oC (212 oF).] | 309-874-0 | 101316-69-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-528-00-9 | Schmieröle (Erdöl), C17-32, durch Lösungsmittel extrahiert, entwachst, hydriert; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelextraktion und Hydrierung von Rückständen aus der offenen Destillation erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C17 bis C32 und ergibt Fertigöl mit einer Viskosität im Bereich von 17 cSt bis 23 cSt bei 40 oC (104 oF).] | 309-875-6 | 101316-70-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-529-00-4 | Schmieröle (Erdöl), C20-35, durch Lösungsmittel extrahiert, entwachst, hydriert; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelextraktion und Hydrierung von Rückständen aus der offenen Destillation erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C35 und ergibt Fertigöl mit einer Viskosität im Bereich von 37 cSt bis 44 cSt bei 40 oC (104 oF).] | 309-876-1 | 101316-71-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-530-00-X | Schmieröle (Erdöl), C24-50, durch Lösungsmittel extrahiert, entwachst, hydriert; Basisöl - nicht spezifiziert; [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelextraktion und Hydrierung von Rückständen aus der offenen Destillation erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C24 bis C50 und ergibt Fertigöl mit einer Viskosität im Bereich von 16 cSt bis 75 cSt bei 40 oC (104 oF).] | 309-877-7 | 101316-72-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-531-00-5 | Extrakte (Erdöl), schweres naphthenhaltiges Destillat Lösungsmittel, aromatisch konzentriert; Aromatenextrakt aus Destillat (behandelt); [aromatisches Konzentrat, hergestellt durch Zusatz von Wasser zu schwerem naphthenhaltigen Destillatlösungsmittelextrakt und Extraktionslösungsmittel.] | 272-175-3 | 68783-00-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-532-00-0 | Extrakte (Erdöl), durch Lösungsmittel aufbereitetes schweres paraffinhaltiges Destillat Lösungsmittel, Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, erhalten als Extrakt aus der Re-Extraktion von durch Lösungsmittel aufbereitetem schweren paraffinhaltigen Destillat. Besteht aus gesättigten und aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50.] | 272-180-0 | 68783-04-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-533-00-6 | Extrakte (Erdöl), schwere paraffinhaltige Destillate, durch Lösungsmittel deasphaltiert; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, erhalten als Extrakt aus einer Lösungsmittelextraktion von schwerem paraffinhaltigem Destillat.] | 272-342-0 | 68814-89-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-534-00-1 | Extrakte (Erdöl), schweres naphthenhaltiges Destillat Lösungsmittel, mit Wasserstoff behandelt; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln eines schweren naphthenhaltigen Destillatlösungsmittelextrakts mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C20 bis C50 und ergibt Fertigöl mit einer Viskosität von mindestens 19 cSt bei 40 oC (100 SUS bei 100 oF).] | 292-631-5 | 90641-07-9 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-535-00-7 | Extrakte (Erdöl), schweres paraffinhaltiges Destillat Lösungsmittel, mit Wasserstoff behandelt; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln eines schweren paraffinhaltigen Destillatlösungsmittelextrakts mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C21 bis C33 und siedet im Bereich von etwa 350 oC bis 480 oC (662 oF bis 896 oF).] | 292-632-0 | 90641-08-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-536-00-2 | Extrakte (Erdöl), leichtes paraffinhaltiges Destillat Lösungsmittel, mit Wasserstoff behandelt; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln eines leichten paraffinhaltigen Destillatlösungsmittelextrakts mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C17 bis C26 und siedet im Bereich von etwa 280 oC bis 400 oC (536 oF bis 752 oF).] | 292-633-6 | 90641-09-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-537-00-8 | Extrakte (Erdöl), mit Wasserstoff behandeltes leichtes paraffinhaltiges Destillat Lösungsmittel; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man als Extrakt aus der Lösungsmittelextration von intermediärem paraffinhaltigen Kopf-Lösungsmittel-Destillat erhält, das mit Wasserstoff unter Einsatz eines Katalysators behandelt wird. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C16 bis C36.] | 295-335-4 | 91995-73-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-538-00-3 | Extrakte (Erdöl), leichtes naphthenhaltiges Destillat Lösungsmittel, hydrodesulfuriert; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man durch Behandeln eines Extraktes aus einem Lösungsmittelextraktionsverfahren mit Wasserstoff unter Einsatz eines Katalysators unter Bedingungen in erster Linie zur Beseitigung von Schwefelverbindungen erhält. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C15 bis C30. Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis 6-gliedrigen kondensierten Ringsystemen.] | 295-338-0 | 91995-75-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-539-00-9 | Extrakte (Erdöl), leichtes paraffinhaltiges Destillat Lösungsmittel, mit Säure behandelt; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man als Fraktion der Destillation eines Extraktes aus der Lösungsmittelextraktion von leichten paraffinhaltigen Kopf-Erdöldestillaten erhält, die einer schwefelsauren Aufbereitung ausgesetzt werden. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C16 bis C32.] | 295-339-6 | 91995-76-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-540-00-4 | Extrakte (Erdöl), leichtes paraffinhaltiges Destillat Lösungsmittel, hydrodesulfuriert; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, erhalten durch Lösungsmittelextraktion eines leichten paraffinhaltigen Destillates und Behandeln mit Wasserstoff zur Umwandlung von organischem Schwefel in Schwefelwasserstoff, der entfernt wird Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C40 und ergibt Fertigöl mit einer Viskosität größer als 10 cSt bei 40 oC.] | 295-340-1 | 91995-77-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-541-00-X | Extrakte (Erdöl), leichtes Vakuum Gasöl Lösungsmittel, mit Wasserstoff behandelt, Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelextraktion aus leichten Vakuum-Erdöl-Gasölen und Behandeln mit Wasserstoff unter Einsatz eines Katalysators erhält. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C13 bis C30.] | 295-342-2 | 91995-79-8 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-542-00-5 | Extrakte (Erdöl), schweres paraffinhaltiges Destillat Lösungsmittel, mit Ton behandelt; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, entsteht durch Behandeln einer Erdölfraktion mit natürlichem oder modifiziertem Ton in einem Kontakt- oder einem Perkolationsverfahren zum Entfernen von Spuren polarer Verbindungen und von vorhandenen Verunreinigungen. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50. Dieser Lauf enthält wahrscheinlich 5 Gewichtsprozent oder mehr aromatische Kohlenwasserstoffe mit 4- bis - 6-gliedrigen kondensierten Ringsystemen.] | 296-437-1 | 92704-08-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-543-00-0 | Extrakte (Erdöl), schweres naphthenhaltiges Destillat Lösungsmittel, hydrodesulfuriert; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, erhalten aus einem Erdölgrundstoff durch Behandeln mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff umzuwandeln, der entfernt wird. Besteht vorwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C15 bis C50 und ergibt Fertigöl mit einer Viskosität größer als 19 cSt bei 40 oC.] | 297-827-4 | 93763-10-1 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-544-00-6 | Extrakte (Erdöl), durch Lösungsmittel entwachstes schweres paraffinhaltiges Destillat Lösungsmittel, hydrodesulfuriert; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, erhalten aus einem durch Lösungsmittel entwachsten Erdölgrundstoff durch Behandeln mit Wasserstoff, um organischen Schwefel in Schwefelwasserstoff umzuwandeln, der entfernt wird. Besteht überwiegend aus Kohlenwasserstoffen mit Kohlenstoffzahlen überwiegend im Bereich von C15 bis C50 und ergibt Fertigöl mit einer Viskosität größer als 19 cSt bei 40 oC.] | 297-829-5 | 93763-11-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-545-00-1 | Extrakte (Erdöl), leichtes paraffinhaltiges Destillat Lösungsmittel, mit Kohlenstoff behandelt; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man als eine Fraktion aus der Destillation eines Extraktes erhält, den man durch Lösungsmittelextraktion von leichtem paraffinhaltigen Kopf-Erdöldestillat wiedergewinnt, mit Aktivkohle behandelt, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C16 bis C32.] | 309-672-2 | 100684-02-4 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-546-00-7 | Extrakte (Erdöl), leichtes paraffinhaltiges Destillat Lösungsmittel, mit Ton behandelt; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man als eine Fraktion aus der Destillation eines Extraktes erhält, den man durch Lösungsmittelextraktion von leichten paraffinhaltigen Kopf-Erdöldestillaten wiedergewinnt, mit Bleicherde behandelt, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C16 bis C32.] | 309-673-8 | 100684-03-5 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-547-00-2 | Extrakte (Erdöl), leichte Vakuum, Gasöl Lösungsmittel, mit Kohlenstoff behandelt; Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelextraktion von leichtem Vakuumerdölgas erhält, mit Aktivkohle behandelt, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C13 bis C30.] | 309-674-3 | 100684-04-6 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-548-00-8 | Extrakte (Erdöl), leichte Vakuum Gasöl Lösungsmittel, mit Ton behandelt, Aromatenextrakt aus Destillat (behandelt); [komplexe Kombination von Kohlenwasserstoffen, die man durch Lösungsmittelextraktion von leichtem Vakuumerdölgas erhält, mit Bleicherde behandelt, um Spuren polarer Bestandteile und Verunreinigungen zu entfernen. Besteht vorwiegend aus aromatischen Kohlenwasserstoffen mit Kohlenstoffzahlen vorwiegend im Bereich von C13 bis C30.] | 309-675-9 | 100684-05-7 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-549-00-3 | Klauenöl (Erdöl); Klauenöl; [komplexe Kombination von Kohlenwasserstoffen, erhalten als Ölfraktion aus einem Lösungsmittelentöl- oder Wachsschmelzverfahren. Besteht überwiegend aus Kohlenwasserstoffen mit verzweigter Kette mit Kohlenstoffzahlen vorwiegend im Bereich von C20 bis C50.] | 265-171-8 | 64742-67-2 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
649-550-00-9 | Klauenöl (Erdöl), mit Wasserstoff behandelt; Klauenöl | 295-394-6 | 92045-12-0 | Carc. 1B | H350 | GHS08 Gef. | H350 | L | ||
650-002-00-6 | Terpentin, Öl | 232-350-7 | 8006-64-2 | Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Asp. Tox. 1 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 | H226 H332 H312 H302 H304 H319 H315 H317 H411 | GHS02 GHS08 GHS07 GHS09 Gef. | H226 H332 H312 H302 H304 H319 H315 H317 H411 | |||
650-003-00-1 | Fenson (ISO); (4-Chlor-phenyl)-benzyl-sulfonat; | 201-274-6 | 80-38-6 | Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 2 | H302 H319 H411 | GHS07 GHS09 Achtg. | H302 H319 H411 | |||
650-004-00-7 | Norbormid (ISO); 5-(α-Hydroxy-α-2-pyridylbenzyl)-7-(α -2-pyridylbenzyliden)bicyclo[2.2.1]hept-5-en-2,3-dicarboximid | 213-589-6 | 991-42-4 | Acute Tox. 4 * | H302 | GHS07 Achtg. | H302 | |||
650-005-00-2 | (2 R,6a S,12a S)-1,2,6,6a,12,12a-Hexahydro-2-isopropenyl-8,9-dimethoxychromeno[3,4-b]furo[2,3-h]chromen-6-on, rotenon | 201-501-9 | 83-79-4 | Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H301 H319 H335 H315 H400 H410 | GHS06 GHS09 Gef. | H301 H319 H335 H315 H410 | |||
650-006-00-8 | Benchinox (ISO); p-Benzoquinon-1-benzoylhydrazon-4-oxim | 207-807-9 | 495-73-8 | Acute Tox. 3 * Acute Tox. 4 * | H301 H312 | GHS06 Gef. | H301 H312 | |||
650-007-00-3 | Chlordimeform (ISO); N2-(4-Chlor- o-tolyl)- N1, N1-dimethylformamidin | 228-200-5 | 6164-98-3 | Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H312 H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H312 H302 H410 | |||
650-008-00-9 | Drazoxolon (ISO); 4-(2-Chlorphenylhydrazon)-3-methyl-5-isoxazolon | 227-197-8 | 5707-69-7 | Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 | H301 H400 H410 | GHS06 GHS09 Gef. | H301 H410 | |||
650-009-00-4 | Chlordimeformhydrochlorid; N"-(4-Chlor- o-tolyl)- N, N-dimethylformamidinmonohydrochlorid; N2-(4-Chlor- o-tolyl)- N1, N1-dimethylformamidinhydrochlorid | 243-269-1 | 19750-95-9 | Carc. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H351 H302 H410 | |||
650-010-00-X | Benzyl violet 4B; (4-((4-(Dimethylamino)phenyl)(4-(ethyl(3-sulfonatobenzyl)amino)phenyl)methylen)cyclohexa-2,5-dien-1-yliden)(ethyl)(3-sulfonatobenzyl)ammonium, Natriumsalz | 216-901-9 | 1694-09-3 | Carc. 2 | H351 | GHS08 Achtg. | H351 | |||
650-012-00-0 | Erionit | - | 12510-42-8 | Carc. 1A | H350 | GHS08 Gef. | H350 | |||
650-013-00-6 | Asbest | - - - - - - - | 12001-28-4 132207-32-0 12172-73-5 77536-66-4 77536-68-6 77536-67-5 12001-29-5 | Carc. 1A STOT RE 1 | H350 H372 ** | GHS08 Gef. | H350 H372 ** | |||
650-014-00-1 | Diethyl-2,4-dihydroxycyclodisiloxan-2,4-diylbis(trimethylen)diphosphonat, Tetranatriumsalz, Reaktionsprodukte mit Dinatriummetasilicat | 401-770-4 | - | Skin Corr. 1B Acute Tox. 4 * | H314 H302 | GHS05 GHS07 Gef. | H314 H302 | |||
650-015-00-7 | Kolophonium | 232-475-7 232-484-6 277-299-1 | 8050-09-7 8052-10-6 73138-82-6 | Skin Sens. 1 | H317 | GHS07 Achtg. | H317 | |||
650-016-00-2 | Mineralwolle, soweit in diesem Anhang nicht gesondert aufgeführt; [künstlich hergestellte ungerichtete glasartige (Silikat-)Fasern mit einem Anteil an Alkali- und Erdalkalimetalloxiden (Na2O+K2O+CaO+MgO+BaO) von mehr als 18 Gew.- %] | - | - | Carc. 2 | H351 | GHS08 Achtg. | H351 | AQR | ||
650-017-00-8 | Feuerfeste Keramikfasern, Fasern für besondere Verwendungszwecke, soweit in diesem Anhang nicht gesondert aufgeführt; [künstlich hergestellte ungerichtete glasartige (Silikat-)Fasern mit einem Anteil an Alkali- und Erdalkalimetalloxiden (Na2O+K2O+CaO+MgO+BaO) von bis zu 18 Gew.- %] | - | - | Carc. 1B | H350i | GHS08 Gef. | H350i | AR | ||
650-018-00-3 | Reaktionsprodukt von: Acetophenon, Formaldehyd, Cyclohexylamin, Methanol und Essigsäure | 406-230-1 | - | Flam. Liq. 3 Carc. 2 Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H226 H351 H314 H332 H317 H400 H410 | GHS02 GHS08 GHS05 GHS07 GHS09 Gef. | H226 H351 H314 H332 H317 H410 | |||
650-031-00-4 | Bis(4-hydroxy- N-methylanilinium)sulfat; Metol | 200-237-1 | 55-55-0 | Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 ** H317 H400 H410 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H317 H410 | |||
650-032-00-X | Cyproconazol (ISO); (2 RS,3 RS;2 RS,3 SR)-2-(4-Chlorphenyl)-3-cyclopropyl-1-(1 H-1,2,4-triazol-1-yl)butan-2-ol | 94361-06-5 | Repr. 1B Acute Tox. 3 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H360D H301 H373 (Leber) H400 H410 | GHS08 GHS06 GHS09 Gef. | H360D H301 H373 (Leber) H410 | M = 10 M = 1 | |||
650-041-00-9 | Triasulfuron (ISO); 1-[2-(2-Chlorethoxy)phenylsulfonyl]-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)harnstoff | - | 82097-50-5 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
650-042-00-4 | Reaktionsprodukt aus Polyethylen-polyamin-(C16-C18)-alkylamiden mit Monothio-(C2)-alkylphosphonaten | 417-450-2 | - | Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H319 H315 H317 H412 | GHS07 Achtg. | H319 H315 H317 H412 | |||
650-043-00-X | Reaktionsprodukt aus 3,5-Bis- tert-butylsalicylsäure und Aluminiumsulfat | 420-310-3 | - | Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Achtg. | H302 H410 | |||
650-044-00-5 | gemischte lineare und verzweigte C14-15-Alkohole ethoxyliert, Reaktionsprodukt mit Epichlorhydrin | 420-480-9 | 158570-99-1 | Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H317 H400 H410 | GHS07 GHS09 Achtg. | H315 H317 H410 | |||
650-045-00-0 | Reaktionsprodukt aus: 1,2,3-Propantricarbonsäure, 2-hydroxy, Diethylester, 1-Propanol und Zirkonium-tetra-n-propanolat | 417-110-3 | - | Flam. Liq. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H225 H315 H318 H411 | GHS02 GHS05 GHS09 Gef. | H225 H315 H318 H411 | |||
650-046-00-6 | Di(tetramethylammonium)(29 H,31 H-phthalocyanin- N29, N30, N31, N32)disulfonamiddisulfonat, cuprat(2-)komplex, derivate | 416-180-2 | 12222-04-7 | Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 | H302 H373 ** H411 | GHS08 GHS07 GHS09 Achtg. | H302 H373 ** H411 | |||
650-047-00-1 | Dibenzylphenylsulfonium hexafluorantimonat | 417-760-8 | 134164-24-2 | STOT RE 1 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H372 ** H302 H318 H317 H411 | GHS08 GHS05 GHS07 GHS09 Gef. | H372 ** H302 H318 H317 H411 | |||
650-048-00-7 | Reaktionsprodukt aus: Borax, Wasserstoffperoxid, Acetanhydrid und Essigsäure | 420-070-1 | - | Org. Perox.
D **** Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 | H242 H332 H312 H302 H314 H400 | GHS02 GHS05 GHS07 GHS09 Gef. | H242 H332 H312 H302 H314 H400 | |||
650-049-00-2 | 2-Alkoyloxyethylhydrogenmaleat, wobei Alkoyl (gewichtsmäßig) zu 70 bis 85 % aus ungesättigtem Octadecoyl, zu 0,5 bis 10 % aus gesättigtem Octadecoyl und zu 2 bis 18 % aus gesättigtem Hexadecoyl besteht | 417-960-5 | - | Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H315 H318 H317 H400 H410 | GHS05 GHS07 GHS09 Gef. | H315 H318 H317 H410 | |||
650-050-00-8 | Reaktionsmasse aus: 1-Methyl-3-hydroxypropyl 3,5-[1,1-dimethylethyl]-4-hydroxydihydrocinnamat und/oder 3-hydroxybutyl 3,5-[1,1-dimethylethyl]-4-hydroxydihydrocinnamat; 1,3-Butandiol bis[3-(3"-(1,1-dimethylethyl)4"-hydroxy-phenyl)propionat] isomere; 1,3-Butandiol bis[3-(3",5"-(1,1-dimethylethyl)-4"-hydroxyphenyl)propionat] isomere | 423-600-8 | - | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
650-055-00-5 | Silbernatriumzirkoniumhydrogenphosphat | 422-570-3 | 155925-27-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Achtg. | H410 | |||
650-056-00-0 | Dibutylbis(pentan-2,4-dionato- O,O")tin | 245-152-0 | 22673-19-4 | Repr. 1B STOT RE 1 | H360FD H372 (Immunsystem) | GHS08 Dgr | H360FD H372 (Immunsystem)" | |||
650-057-00-6 | Margosa, Extrakt [kaltgepresstes Öl aus den geschälten Kernen von Azadirachta indica, mit überkritischem Kohlendioxid extrahiert] | 283-644-7 | 84696-25-3 | Aquatic Chronic 3 | H412 | H412 | ||||
"650-058-00-1 | Margosa, Extrakt [aus den Kernen von Azadirachta indica, mit Wasser extrahiert und mit organischen Lösungsmitteln weiter verarbeitet] | 283-644-7 | 84696-25-3 | Repr. 2 Skin Sens. 1 Aquatic Chronic 1 | H361d H317 H410 | GHS08 GHS07 GHS09 Wng | H361d H317 H410 | M = 10" | ||
*) ATE für orale und dermale Exposition werden in mg/kg KG ausgedrückt, was für Milligramm pro Kilogramm Körpergewicht steht. |
weiter |